{"PMID":10082498,"re_id":0,"annotated sentence":"At 4 hours, losartan blocked 43% of the <e2>Ang II<\\e2> induced systolic blood pressure increase; <e1>valsartan<\\e1>  51%; and irbesartan, 88% (P<0.01 between drugs)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"valsartan","object":"Ang II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"At 4 hours, losartan blocked 43% of the <e2>GENE-Y<\\e2> induced systolic blood pressure increase; <e1>CHEMICAL<\\e1>  51%; and irbesartan, 88% (P<0.01 between drugs)","sentence":"At 4 hours, losartan blocked 43% of the Ang II induced systolic blood pressure increase; valsartan  51%; and irbesartan, 88% (P<0.01 between drugs)"}
{"PMID":10082498,"re_id":1,"annotated sentence":"At 4 hours, losartan blocked 43% of the <e2>Ang II<\\e2> induced systolic blood pressure increase; valsartan, 51%; and <e1>irbesartan<\\e1>  88% (P<0.01 between drugs)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"irbesartan","object":"Ang II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"At 4 hours, losartan blocked 43% of the <e2>GENE-Y<\\e2> induced systolic blood pressure increase; valsartan, 51%; and <e1>CHEMICAL<\\e1>  88% (P<0.01 between drugs)","sentence":"At 4 hours, losartan blocked 43% of the Ang II induced systolic blood pressure increase; valsartan, 51%; and irbesartan  88% (P<0.01 between drugs)"}
{"PMID":10082498,"re_id":2,"annotated sentence":"This study thus demonstrates that the first administration of the recommended starting dose of <e1>irbesartan<\\e1> induces a greater and longer lasting <e2>Ang II receptor<\\e2> blockade than that of valsartan and losartan in normotensive subjects.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"irbesartan","object":"Ang II receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This study thus demonstrates that the first administration of the recommended starting dose of <e1>CHEMICAL<\\e1> induces a greater and longer lasting <e2>GENE-N<\\e2> blockade than that of valsartan and losartan in normotensive subjects.","sentence":"This study thus demonstrates that the first administration of the recommended starting dose of irbesartan induces a greater and longer lasting Ang II receptor blockade than that of valsartan and losartan in normotensive subjects."}
{"PMID":10082498,"re_id":3,"annotated sentence":"This study thus demonstrates that the first administration of the recommended starting dose of irbesartan induces a greater and longer lasting <e2>Ang II receptor<\\e2> blockade than that of <e1>valsartan<\\e1> and losartan in normotensive subjects.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"valsartan","object":"Ang II receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This study thus demonstrates that the first administration of the recommended starting dose of irbesartan induces a greater and longer lasting <e2>GENE-N<\\e2> blockade than that of <e1>CHEMICAL<\\e1> and losartan in normotensive subjects.","sentence":"This study thus demonstrates that the first administration of the recommended starting dose of irbesartan induces a greater and longer lasting Ang II receptor blockade than that of valsartan and losartan in normotensive subjects."}
{"PMID":10082498,"re_id":4,"annotated sentence":"This study thus demonstrates that the first administration of the recommended starting dose of irbesartan induces a greater and longer lasting <e2>Ang II receptor<\\e2> blockade than that of valsartan and <e1>losartan<\\e1> in normotensive subjects.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"losartan","object":"Ang II receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This study thus demonstrates that the first administration of the recommended starting dose of irbesartan induces a greater and longer lasting <e2>GENE-N<\\e2> blockade than that of valsartan and <e1>CHEMICAL<\\e1> in normotensive subjects.","sentence":"This study thus demonstrates that the first administration of the recommended starting dose of irbesartan induces a greater and longer lasting Ang II receptor blockade than that of valsartan and losartan in normotensive subjects."}
{"PMID":10226872,"re_id":0,"annotated sentence":"In humans, prolonged administration of the <e2>beta 2-adrenoceptor<\\e2> agonist <e1>terbutaline<\\e1> leads to a desensitization of beta 2-adrenoceptor-mediated cardiovascular responses, which can be blunted by concomitant administration of the antianaphylactic drug ketotifen","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"terbutaline","object":"beta 2-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In humans, prolonged administration of the <e2>GENE-Y<\\e2> agonist <e1>CHEMICAL<\\e1> leads to a desensitization of GENE-Y-mediated cardiovascular responses, which can be blunted by concomitant administration of the antianaphylactic drug ketotifen","sentence":"In humans, prolonged administration of the beta 2-adrenoceptor agonist terbutaline leads to a desensitization of beta 2-adrenoceptor-mediated cardiovascular responses, which can be blunted by concomitant administration of the antianaphylactic drug ketotifen"}
{"PMID":10226872,"re_id":1,"annotated sentence":"beta 2-Adrenoceptor cardiovascular function was assessed by the increase in heart rate and reduction of diastolic blood pressure induced by an incremental intravenous infusion of the unselective <e2>beta-adrenoceptor<\\e2> agonist <e1>isoprenaline<\\e1>  beta 1-adrenoceptor cardiovascular function was assessed by exercise-induced tachycardia","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"isoprenaline","object":"beta-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"beta 2-Adrenoceptor cardiovascular function was assessed by the increase in heart rate and reduction of diastolic blood pressure induced by an incremental intravenous infusion of the unselective <e2>GENE-N<\\e2> agonist <e1>CHEMICAL<\\e1>  beta 1-adrenoceptor cardiovascular function was assessed by exercise-induced tachycardia","sentence":"beta 2-Adrenoceptor cardiovascular function was assessed by the increase in heart rate and reduction of diastolic blood pressure induced by an incremental intravenous infusion of the unselective beta-adrenoceptor agonist isoprenaline  beta 1-adrenoceptor cardiovascular function was assessed by exercise-induced tachycardia"}
{"PMID":10362188,"re_id":0,"annotated sentence":"OBJECTIVES: This study examined the effect of a small-molecule, direct <e2>thrombin<\\e2> inhibitor, <e1>argatroban<\\e1>  on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"argatroban","object":"thrombin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"OBJECTIVES: This study examined the effect of a small-molecule, direct <e2>GENE-Y<\\e2> inhibitor, <e1>CHEMICAL<\\e1>  on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI)","sentence":"OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, argatroban  on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI)"}
{"PMID":10362188,"re_id":1,"annotated sentence":"In vitro and in vivo studies have shown that <e1>argatroban<\\e1> has advantages over heparin for the inhibition of clot-bound <e2>thrombin<\\e2> and for the enhancement of thrombolysis with TPA","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"argatroban","object":"thrombin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In vitro and in vivo studies have shown that <e1>CHEMICAL<\\e1> has advantages over heparin for the inhibition of clot-bound <e2>GENE-Y<\\e2> and for the enhancement of thrombolysis with TPA","sentence":"In vitro and in vivo studies have shown that argatroban has advantages over heparin for the inhibition of clot-bound thrombin and for the enhancement of thrombolysis with TPA"}
{"PMID":10373224,"re_id":0,"annotated sentence":"At clinically relevant concentrations, <e1>candesartan<\\e1> is an insurmountable and long-lasting antagonist of the vascular contractile responses to <e2>Ang II<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"candesartan","object":"Ang II","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"At clinically relevant concentrations, <e1>CHEMICAL<\\e1> is an insurmountable and long-lasting antagonist of the vascular contractile responses to <e2>GENE-N<\\e2> ","sentence":"At clinically relevant concentrations, candesartan is an insurmountable and long-lasting antagonist of the vascular contractile responses to Ang II "}
{"PMID":10373224,"re_id":1,"annotated sentence":"In both vascular preparations, <e1>candesartan<\\e1> caused a marked decrease in the maximal contractile response of the <e2>angiotensin II<\\e2> (Ang II) concentration-response curve","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"candesartan","object":"angiotensin II","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In both vascular preparations, <e1>CHEMICAL<\\e1> caused a marked decrease in the maximal contractile response of the <e2>GENE-N<\\e2> (Ang II) concentration-response curve","sentence":"In both vascular preparations, candesartan caused a marked decrease in the maximal contractile response of the angiotensin II (Ang II) concentration-response curve"}
{"PMID":10373224,"re_id":2,"annotated sentence":"In both vascular preparations, <e1>candesartan<\\e1> caused a marked decrease in the maximal contractile response of the angiotensin II (<e2>Ang II<\\e2>  concentration-response curve","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"candesartan","object":"Ang II","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In both vascular preparations, <e1>CHEMICAL<\\e1> caused a marked decrease in the maximal contractile response of the angiotensin II (<e2>GENE-N<\\e2>  concentration-response curve","sentence":"In both vascular preparations, candesartan caused a marked decrease in the maximal contractile response of the angiotensin II (Ang II  concentration-response curve"}
{"PMID":10373224,"re_id":3,"annotated sentence":"The functional inhibitory characteristics of the <e2>angiotensin II type 1 receptor<\\e2> blockers (ARB) candesartan; <e1>irbesartan<\\e1>  and losartan and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"irbesartan","object":"angiotensin II type 1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The functional inhibitory characteristics of the <e2>GENE-N<\\e2> blockers (ARB) candesartan; <e1>CHEMICAL<\\e1>  and losartan and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro","sentence":"The functional inhibitory characteristics of the angiotensin II type 1 receptor blockers (ARB) candesartan; irbesartan  and losartan and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro"}
{"PMID":10373224,"re_id":4,"annotated sentence":"The functional inhibitory characteristics of the <e2>angiotensin II type 1 receptor<\\e2> blockers (ARB) <e1>candesartan<\\e1>  irbesartan; and losartan and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"candesartan","object":"angiotensin II type 1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The functional inhibitory characteristics of the <e2>GENE-N<\\e2> blockers (ARB) <e1>CHEMICAL<\\e1>  irbesartan; and losartan and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro","sentence":"The functional inhibitory characteristics of the angiotensin II type 1 receptor blockers (ARB) candesartan  irbesartan; and losartan and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro"}
{"PMID":10373224,"re_id":5,"annotated sentence":"The functional inhibitory characteristics of the <e2>angiotensin II type 1 receptor<\\e2> blockers (ARB) candesartan; irbesartan; and <e1>losartan<\\e1> and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"losartan","object":"angiotensin II type 1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The functional inhibitory characteristics of the <e2>GENE-N<\\e2> blockers (ARB) candesartan; irbesartan; and <e1>CHEMICAL<\\e1> and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro","sentence":"The functional inhibitory characteristics of the angiotensin II type 1 receptor blockers (ARB) candesartan; irbesartan; and losartan and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro"}
{"PMID":10373224,"re_id":6,"annotated sentence":"In addition, when <e1>candesartan<\\e1> was given to conscious rats, the inhibitory effect on <e2>Ang II<\\e2> induced blood pressure responses persisted during the 24-hour period despite nondetectable plasma concentrations of candesartan at 24 hours","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"candesartan","object":"Ang II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, when <e1>CHEMICAL<\\e1> was given to conscious rats, the inhibitory effect on <e2>GENE-Y<\\e2> induced blood pressure responses persisted during the 24-hour period despite nondetectable plasma concentrations of CHEMICAL at 24 hours","sentence":"In addition, when candesartan was given to conscious rats, the inhibitory effect on Ang II induced blood pressure responses persisted during the 24-hour period despite nondetectable plasma concentrations of candesartan at 24 hours"}
{"PMID":10373224,"re_id":7,"annotated sentence":"The functional inhibitory characteristics of the <e2>angiotensin II type 1 receptor<\\e2> blockers (ARB) candesartan; irbesartan; and losartan and its active metabolite <e1>EXP 3174<\\e1> (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"EXP 3174","object":"angiotensin II type 1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The functional inhibitory characteristics of the <e2>GENE-N<\\e2> blockers (ARB) candesartan; irbesartan; and losartan and its active metabolite <e1>CHEMICAL<\\e1> (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro","sentence":"The functional inhibitory characteristics of the angiotensin II type 1 receptor blockers (ARB) candesartan; irbesartan; and losartan and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro"}
{"PMID":10373224,"re_id":8,"annotated sentence":"The functional inhibitory characteristics of the <e2>angiotensin II type 1 receptor<\\e2> blockers (ARB) candesartan; irbesartan; and losartan and its active metabolite EXP 3174 (<e1>EXP<\\e1>  were studied in rabbit aortic strips and rat portal vein preparations in vitro","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"EXP","object":"angiotensin II type 1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The functional inhibitory characteristics of the <e2>GENE-N<\\e2> blockers (ARB) candesartan; irbesartan; and losartan and its active metabolite CHEMICAL 3174 (<e1>CHEMICAL<\\e1>  were studied in rabbit aortic strips and rat portal vein preparations in vitro","sentence":"The functional inhibitory characteristics of the angiotensin II type 1 receptor blockers (ARB) candesartan; irbesartan; and losartan and its active metabolite EXP 3174 (EXP  were studied in rabbit aortic strips and rat portal vein preparations in vitro"}
{"PMID":10381787,"re_id":0,"annotated sentence":"Dose-dependent inhibition of platelet <e2>cyclooxygenase-1<\\e2> and monocyte cyclooxygenase-2 by <e1>meloxicam<\\e1> in healthy subjects","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"meloxicam","object":"cyclooxygenase-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Dose-dependent inhibition of platelet <e2>GENE-Y<\\e2> and monocyte cyclooxygenase-2 by <e1>CHEMICAL<\\e1> in healthy subjects","sentence":"Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects"}
{"PMID":10381787,"re_id":1,"annotated sentence":"Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte <e2>cyclooxygenase-2<\\e2> by <e1>meloxicam<\\e1> in healthy subjects","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"meloxicam","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte <e2>GENE-Y<\\e2> by <e1>CHEMICAL<\\e1> in healthy subjects","sentence":"Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects"}
{"PMID":10381787,"re_id":2,"annotated sentence":"In contrast, the administration of 7.5 and 15 mg of <e1>meloxicam<\\e1> caused dose-dependent reductions in monocyte <e2>COX-2<\\e2> activity by 51% and 70%, respectively, and in platelet COX-1 activity by 25% and 35%, respectively","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"meloxicam","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, the administration of 7.5 and 15 mg of <e1>CHEMICAL<\\e1> caused dose-dependent reductions in monocyte <e2>GENE-Y<\\e2> activity by 51% and 70%, respectively, and in platelet COX-1 activity by 25% and 35%, respectively","sentence":"In contrast, the administration of 7.5 and 15 mg of meloxicam caused dose-dependent reductions in monocyte COX-2 activity by 51% and 70%, respectively, and in platelet COX-1 activity by 25% and 35%, respectively"}
{"PMID":10381787,"re_id":3,"annotated sentence":"In contrast, the administration of 7.5 and 15 mg of <e1>meloxicam<\\e1> caused dose-dependent reductions in monocyte COX-2 activity by 51% and 70%, respectively, and in platelet <e2>COX-1<\\e2> activity by 25% and 35%, respectively","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"meloxicam","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, the administration of 7.5 and 15 mg of <e1>CHEMICAL<\\e1> caused dose-dependent reductions in monocyte COX-2 activity by 51% and 70%, respectively, and in platelet <e2>GENE-Y<\\e2> activity by 25% and 35%, respectively","sentence":"In contrast, the administration of 7.5 and 15 mg of meloxicam caused dose-dependent reductions in monocyte COX-2 activity by 51% and 70%, respectively, and in platelet COX-1 activity by 25% and 35%, respectively"}
{"PMID":10381787,"re_id":4,"annotated sentence":"Although the IC50 value of <e1>meloxicam<\\e1> for inhibition of <e2>COX-1<\\e2> was 10-fold higher than the IC50 value of COX-2 in vitro, this biochemical selectivity was inadequate to clearly separate the effects of meloxicam on the two isozymes after oral dosing as a function of the daily dose and interindividual variation in steady-state plasma levels.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"meloxicam","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although the IC50 value of <e1>CHEMICAL<\\e1> for inhibition of <e2>GENE-Y<\\e2> was 10-fold higher than the IC50 value of COX-2 in vitro, this biochemical selectivity was inadequate to clearly separate the effects of CHEMICAL on the two isozymes after oral dosing as a function of the daily dose and interindividual variation in steady-state plasma levels.","sentence":"Although the IC50 value of meloxicam for inhibition of COX-1 was 10-fold higher than the IC50 value of COX-2 in vitro, this biochemical selectivity was inadequate to clearly separate the effects of meloxicam on the two isozymes after oral dosing as a function of the daily dose and interindividual variation in steady-state plasma levels."}
{"PMID":10381787,"re_id":5,"annotated sentence":"Although the IC50 value of <e1>meloxicam<\\e1> for inhibition of COX-1 was 10-fold higher than the IC50 value of <e2>COX-2<\\e2> in vitro, this biochemical selectivity was inadequate to clearly separate the effects of meloxicam on the two isozymes after oral dosing as a function of the daily dose and interindividual variation in steady-state plasma levels.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"meloxicam","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although the IC50 value of <e1>CHEMICAL<\\e1> for inhibition of COX-1 was 10-fold higher than the IC50 value of <e2>GENE-Y<\\e2> in vitro, this biochemical selectivity was inadequate to clearly separate the effects of CHEMICAL on the two isozymes after oral dosing as a function of the daily dose and interindividual variation in steady-state plasma levels.","sentence":"Although the IC50 value of meloxicam for inhibition of COX-1 was 10-fold higher than the IC50 value of COX-2 in vitro, this biochemical selectivity was inadequate to clearly separate the effects of meloxicam on the two isozymes after oral dosing as a function of the daily dose and interindividual variation in steady-state plasma levels."}
{"PMID":10381787,"re_id":6,"annotated sentence":"Concentration-response curves for the inhibition of monocyte <e2>COX-2<\\e2> and platelet COX-1 were obtained in vitro after the incubation of <e1>meloxicam<\\e1> with whole blood samples","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"meloxicam","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Concentration-response curves for the inhibition of monocyte <e2>GENE-Y<\\e2> and platelet COX-1 were obtained in vitro after the incubation of <e1>CHEMICAL<\\e1> with whole blood samples","sentence":"Concentration-response curves for the inhibition of monocyte COX-2 and platelet COX-1 were obtained in vitro after the incubation of meloxicam with whole blood samples"}
{"PMID":10381787,"re_id":7,"annotated sentence":"Concentration-response curves for the inhibition of monocyte COX-2 and platelet <e2>COX-1<\\e2> were obtained in vitro after the incubation of <e1>meloxicam<\\e1> with whole blood samples","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"meloxicam","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Concentration-response curves for the inhibition of monocyte COX-2 and platelet <e2>GENE-Y<\\e2> were obtained in vitro after the incubation of <e1>CHEMICAL<\\e1> with whole blood samples","sentence":"Concentration-response curves for the inhibition of monocyte COX-2 and platelet COX-1 were obtained in vitro after the incubation of meloxicam with whole blood samples"}
{"PMID":10381787,"re_id":8,"annotated sentence":"Before dosing and 24 h after the seventh dose of each regimen, heparinized whole blood samples were incubated with lipopolysaccharide (10 microgram\/ml) for 24 h at 37 degrees C, and <e1>prostaglandin E2<\\e1> was measured in plasma as an index of monocyte <e2>COX-2<\\e2> activity","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"prostaglandin E2","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Before dosing and 24 h after the seventh dose of each regimen, heparinized whole blood samples were incubated with lipopolysaccharide (10 microgram\/ml) for 24 h at 37 degrees C, and <e1>CHEMICAL<\\e1> was measured in plasma as an index of monocyte <e2>GENE-Y<\\e2> activity","sentence":"Before dosing and 24 h after the seventh dose of each regimen, heparinized whole blood samples were incubated with lipopolysaccharide (10 microgram\/ml) for 24 h at 37 degrees C, and prostaglandin E2 was measured in plasma as an index of monocyte COX-2 activity"}
{"PMID":10381787,"re_id":9,"annotated sentence":"The production of <e1>thromboxane B2<\\e1> in whole blood allowed to clot at 37 degrees C for 60 min was assessed as an index of platelet <e2>COX-1<\\e2> activity","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"thromboxane B2","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The production of <e1>CHEMICAL<\\e1> in whole blood allowed to clot at 37 degrees C for 60 min was assessed as an index of platelet <e2>GENE-Y<\\e2> activity","sentence":"The production of thromboxane B2 in whole blood allowed to clot at 37 degrees C for 60 min was assessed as an index of platelet COX-1 activity"}
{"PMID":10432475,"re_id":0,"annotated sentence":"In distinction, the preferential <e2>beta 1-AR<\\e2> antagonist, <e1>betaxolol<\\e1>  and the preferential beta 2-AR antagonist, ICI118,551, did not increase basal levels of DA, NAD, or 5-HT","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"betaxolol","object":"beta 1-AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In distinction, the preferential <e2>GENE-Y<\\e2> antagonist, <e1>CHEMICAL<\\e1>  and the preferential beta 2-AR antagonist, ICI118,551, did not increase basal levels of DA, NAD, or 5-HT","sentence":"In distinction, the preferential beta 1-AR antagonist, betaxolol  and the preferential beta 2-AR antagonist, ICI118,551, did not increase basal levels of DA, NAD, or 5-HT"}
{"PMID":10432475,"re_id":1,"annotated sentence":"In distinction, the preferential beta 1-AR antagonist, betaxolol, and the preferential <e2>beta 2-AR<\\e2> antagonist, <e1>ICI118,551<\\e1>  did not increase basal levels of DA, NAD, or 5-HT","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"ICI118,551","object":"beta 2-AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In distinction, the preferential beta 1-AR antagonist, betaxolol, and the preferential <e2>GENE-Y<\\e2> antagonist, <e1>CHEMICAL<\\e1>  did not increase basal levels of DA, NAD, or 5-HT","sentence":"In distinction, the preferential beta 1-AR antagonist, betaxolol, and the preferential beta 2-AR antagonist, ICI118,551  did not increase basal levels of DA, NAD, or 5-HT"}
{"PMID":10432475,"re_id":2,"annotated sentence":"The selective <e2>5-HT1A<\\e2> receptor antagonist, <e1>WAY100,635<\\e1>  slightly attenuated the (-)-pindolol-induced increase in DA and NAD levels, while the selective 5-HT1B antagonist, SB224,289, was ineffective","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"WAY100,635","object":"5-HT1A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The selective <e2>GENE-Y<\\e2> receptor antagonist, <e1>CHEMICAL<\\e1>  slightly attenuated the (-)-pindolol-induced increase in DA and NAD levels, while the selective 5-HT1B antagonist, SB224,289, was ineffective","sentence":"The selective 5-HT1A receptor antagonist, WAY100,635  slightly attenuated the (-)-pindolol-induced increase in DA and NAD levels, while the selective 5-HT1B antagonist, SB224,289, was ineffective"}
{"PMID":10432475,"re_id":3,"annotated sentence":"The selective 5-HT1A receptor antagonist, WAY100,635, slightly attenuated the (-)-pindolol-induced increase in DA and NAD levels, while the selective <e2>5-HT1B<\\e2> antagonist, <e1>SB224,289<\\e1>  was ineffective","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"SB224,289","object":"5-HT1B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The selective 5-HT1A receptor antagonist, WAY100,635, slightly attenuated the (-)-pindolol-induced increase in DA and NAD levels, while the selective <e2>GENE-Y<\\e2> antagonist, <e1>CHEMICAL<\\e1>  was ineffective","sentence":"The selective 5-HT1A receptor antagonist, WAY100,635, slightly attenuated the (-)-pindolol-induced increase in DA and NAD levels, while the selective 5-HT1B antagonist, SB224,289  was ineffective"}
{"PMID":10439935,"re_id":0,"annotated sentence":"UNLABELLED: <e1>Entacapone<\\e1> is a potent and specific peripheral <e2>catechol-O-methyltransferase<\\e2> (COMT) inhibitor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Entacapone","object":"catechol-O-methyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"UNLABELLED: <e1>CHEMICAL<\\e1> is a potent and specific peripheral <e2>GENE-Y<\\e2> (COMT) inhibitor","sentence":"UNLABELLED: Entacapone is a potent and specific peripheral catechol-O-methyltransferase (COMT) inhibitor"}
{"PMID":10439935,"re_id":1,"annotated sentence":"UNLABELLED: <e1>Entacapone<\\e1> is a potent and specific peripheral catechol-O-methyltransferase (<e2>COMT<\\e2>  inhibitor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Entacapone","object":"COMT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"UNLABELLED: <e1>CHEMICAL<\\e1> is a potent and specific peripheral catechol-O-methyltransferase (<e2>GENE-Y<\\e2>  inhibitor","sentence":"UNLABELLED: Entacapone is a potent and specific peripheral catechol-O-methyltransferase (COMT  inhibitor"}
{"PMID":10460702,"re_id":0,"annotated sentence":"We found that <e1>5-HT<\\e1> stimulated the conversion of [3H]L-arginine ([3H]L-Arg) to [3H]L-Cit, indicating <e2>eNOS<\\e2> activation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"5-HT","object":"eNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that <e1>CHEMICAL<\\e1> stimulated the conversion of [3H]L-arginine ([3H]L-Arg) to [3H]L-Cit, indicating <e2>GENE-Y<\\e2> activation","sentence":"We found that 5-HT stimulated the conversion of [3H]L-arginine ([3H]L-Arg) to [3H]L-Cit, indicating eNOS activation"}
{"PMID":10460702,"re_id":1,"annotated sentence":"<e1>5-hydroxytryptamine<\\e1> evokes <e2>endothelial nitric oxide synthase<\\e2> activation in bovine aortic endothelial cell cultures","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"5-hydroxytryptamine","object":"endothelial nitric oxide synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> evokes <e2>GENE-Y<\\e2> activation in bovine aortic endothelial cell cultures","sentence":"5-hydroxytryptamine evokes endothelial nitric oxide synthase activation in bovine aortic endothelial cell cultures"}
{"PMID":10460702,"re_id":2,"annotated sentence":"These findings lend evidence of a 5-HT1B receptor\/eNOS pathway, accounting in part for the activation of <e2>eNOS<\\e2> by <e1>5-HT<\\e1>  Further investigation is needed to determine the role of other vascular 5-HT receptors in the stimulation of eNOS activity.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"5-HT","object":"eNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These findings lend evidence of a CHEMICAL1B receptor\/GENE-Y pathway, accounting in part for the activation of <e2>GENE-Y<\\e2> by <e1>CHEMICAL<\\e1>  Further investigation is needed to determine the role of other vascular CHEMICAL receptors in the stimulation of GENE-Y activity.","sentence":"These findings lend evidence of a 5-HT1B receptor\/eNOS pathway, accounting in part for the activation of eNOS by 5-HT  Further investigation is needed to determine the role of other vascular 5-HT receptors in the stimulation of eNOS activity."}
{"PMID":10460702,"re_id":3,"annotated sentence":"The high affinity <e2>5-HT1B<\\e2> receptor agonist, <e1>5-nonyloxytryptamine<\\e1> (5-NOT)-stimulated [3H]L-Cit turnover responses were concentration-(0.01 nM to 100 microM) and time-dependent","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"5-nonyloxytryptamine","object":"5-HT1B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The high affinity <e2>GENE-Y<\\e2> receptor agonist, <e1>CHEMICAL<\\e1> (5-NOT)-stimulated [3H]L-Cit turnover responses were concentration-(0.01 nM to 100 microM) and time-dependent","sentence":"The high affinity 5-HT1B receptor agonist, 5-nonyloxytryptamine (5-NOT)-stimulated [3H]L-Cit turnover responses were concentration-(0.01 nM to 100 microM) and time-dependent"}
{"PMID":10460702,"re_id":4,"annotated sentence":"These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B\/5-HT2 receptor antagonist, methiothepin, and the <e2>eNOS<\\e2> selective antagonists (0.01-10 microM): <e1>L-Nomega -monomethyl-L-arginine<\\e1> (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"L-Nomega -monomethyl-L-arginine","object":"eNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B\/5-HT2 receptor antagonist, methiothepin, and the <e2>GENE-Y<\\e2> selective antagonists (0.01-10 microM): <e1>CHEMICAL<\\e1> (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO)","sentence":"These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B\/5-HT2 receptor antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO)"}
{"PMID":10460702,"re_id":5,"annotated sentence":"These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the <e2>5-HT1B<\\e2> 5-HT2 receptor antagonist, <e1>methiothepin<\\e1>  and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"methiothepin","object":"5-HT1B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These responses were effectively blocked by the GENE-Y receptor antagonist, isamoltane, the <e2>GENE-Y<\\e2> 5-HT2 receptor antagonist, <e1>CHEMICAL<\\e1>  and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO)","sentence":"These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B 5-HT2 receptor antagonist, methiothepin  and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO)"}
{"PMID":10460702,"re_id":6,"annotated sentence":"These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B\/<e2>5-HT2 receptor<\\e2> antagonist, <e1>methiothepin<\\e1>  and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"methiothepin","object":"5-HT2 receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B\/<e2>GENE-N<\\e2> antagonist, <e1>CHEMICAL<\\e1>  and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO)","sentence":"These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B\/5-HT2 receptor antagonist, methiothepin  and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO)"}
{"PMID":10460702,"re_id":7,"annotated sentence":"These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B\/5-HT2 receptor antagonist, methiothepin, and the <e2>eNOS<\\e2> selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (<e1>L-NMMA<\\e1>  and L-N omega-iminoethyl-L-ornithine (L-NIO)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"L-NMMA","object":"eNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B\/5-HT2 receptor antagonist, methiothepin, and the <e2>GENE-Y<\\e2> selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (<e1>CHEMICAL<\\e1>  and L-N omega-iminoethyl-L-ornithine (L-NIO)","sentence":"These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B\/5-HT2 receptor antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA  and L-N omega-iminoethyl-L-ornithine (L-NIO)"}
{"PMID":10460702,"re_id":8,"annotated sentence":"These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B\/5-HT2 receptor antagonist, methiothepin, and the <e2>eNOS<\\e2> selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and <e1>L-N omega-iminoethyl-L-ornithine<\\e1> (L-NIO)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"L-N omega-iminoethyl-L-ornithine","object":"eNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B\/5-HT2 receptor antagonist, methiothepin, and the <e2>GENE-Y<\\e2> selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and <e1>CHEMICAL<\\e1> (L-NIO)","sentence":"These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B\/5-HT2 receptor antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO)"}
{"PMID":10460702,"re_id":9,"annotated sentence":"These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B\/5-HT2 receptor antagonist, methiothepin, and the <e2>eNOS<\\e2> selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (<e1>L-NIO<\\e1> ","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"L-NIO","object":"eNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B\/5-HT2 receptor antagonist, methiothepin, and the <e2>GENE-Y<\\e2> selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (<e1>CHEMICAL<\\e1> ","sentence":"These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B\/5-HT2 receptor antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO "}
{"PMID":10460702,"re_id":10,"annotated sentence":"Here, we tested the hypothesis that 5-HT receptors mediate <e2>eNOS<\\e2> activation by measuring agonist-stimulated <e1>[3H]L-citrulline<\\e1> ([3H]L-Cit) formation in BAEC cultures","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"[3H]L-citrulline","object":"eNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we tested the hypothesis that 5-HT receptors mediate <e2>GENE-Y<\\e2> activation by measuring agonist-stimulated <e1>CHEMICAL<\\e1> ([3H]L-Cit) formation in BAEC cultures","sentence":"Here, we tested the hypothesis that 5-HT receptors mediate eNOS activation by measuring agonist-stimulated [3H]L-citrulline ([3H]L-Cit) formation in BAEC cultures"}
{"PMID":10460702,"re_id":11,"annotated sentence":"Here, we tested the hypothesis that 5-HT receptors mediate <e2>eNOS<\\e2> activation by measuring agonist-stimulated [3H]L-citrulline (<e1>[3H]L-Cit<\\e1>  formation in BAEC cultures","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"[3H]L-Cit","object":"eNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we tested the hypothesis that 5-HT receptors mediate <e2>GENE-Y<\\e2> activation by measuring agonist-stimulated [3H]L-citrulline (<e1>CHEMICAL<\\e1>  formation in BAEC cultures","sentence":"Here, we tested the hypothesis that 5-HT receptors mediate eNOS activation by measuring agonist-stimulated [3H]L-citrulline ([3H]L-Cit  formation in BAEC cultures"}
{"PMID":10460702,"re_id":12,"annotated sentence":"We found that 5-HT stimulated the conversion of <e1>[3H]L-arginine<\\e1> ([3H]L-Arg) to [3H]L-Cit, indicating <e2>eNOS<\\e2> activation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"[3H]L-arginine","object":"eNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that 5-HT stimulated the conversion of <e1>CHEMICAL<\\e1> ([3H]L-Arg) to [3H]L-Cit, indicating <e2>GENE-Y<\\e2> activation","sentence":"We found that 5-HT stimulated the conversion of [3H]L-arginine ([3H]L-Arg) to [3H]L-Cit, indicating eNOS activation"}
{"PMID":10460702,"re_id":13,"annotated sentence":"We found that 5-HT stimulated the conversion of [3H]L-arginine (<e1>[3H]L-Arg<\\e1>  to [3H]L-Cit, indicating <e2>eNOS<\\e2> activation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"[3H]L-Arg","object":"eNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that 5-HT stimulated the conversion of [3H]L-arginine (<e1>CHEMICAL<\\e1>  to [3H]L-Cit, indicating <e2>GENE-Y<\\e2> activation","sentence":"We found that 5-HT stimulated the conversion of [3H]L-arginine ([3H]L-Arg  to [3H]L-Cit, indicating eNOS activation"}
{"PMID":10460702,"re_id":14,"annotated sentence":"We found that 5-HT stimulated the conversion of [3H]L-arginine ([3H]L-Arg) to <e1>[3H]L-Cit<\\e1>  indicating <e2>eNOS<\\e2> activation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"[3H]L-Cit","object":"eNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that 5-HT stimulated the conversion of [3H]L-arginine ([3H]L-Arg) to <e1>CHEMICAL<\\e1>  indicating <e2>GENE-Y<\\e2> activation","sentence":"We found that 5-HT stimulated the conversion of [3H]L-arginine ([3H]L-Arg) to [3H]L-Cit  indicating eNOS activation"}
{"PMID":10460702,"re_id":15,"annotated sentence":"Activation of <e2>endothelial nitric oxide synthase<\\e2> (eNOS) results in the production of <e1>nitric oxide<\\e1> (NO) that mediates the vasorelaxing properties of endothelial cells","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"nitric oxide","object":"endothelial nitric oxide synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Activation of <e2>endothelial CHEMICAL synthase<\\e2> (eNOS) results in the production of <e1>CHEMICAL<\\e1> (NO) that mediates the vasorelaxing properties of endothelial cells","sentence":"Activation of endothelial nitric oxide synthase (eNOS) results in the production of nitric oxide (NO) that mediates the vasorelaxing properties of endothelial cells"}
{"PMID":10460702,"re_id":16,"annotated sentence":"Activation of endothelial nitric oxide synthase (<e2>eNOS<\\e2>  results in the production of <e1>nitric oxide<\\e1> (NO) that mediates the vasorelaxing properties of endothelial cells","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"nitric oxide","object":"eNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Activation of endothelial CHEMICAL synthase (<e2>GENE-Y<\\e2>  results in the production of <e1>CHEMICAL<\\e1> (NO) that mediates the vasorelaxing properties of endothelial cells","sentence":"Activation of endothelial nitric oxide synthase (eNOS  results in the production of nitric oxide (NO) that mediates the vasorelaxing properties of endothelial cells"}
{"PMID":10460702,"re_id":17,"annotated sentence":"Activation of <e2>endothelial nitric oxide synthase<\\e2> (eNOS) results in the production of nitric oxide (<e1>NO<\\e1>  that mediates the vasorelaxing properties of endothelial cells","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"NO","object":"endothelial nitric oxide synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Activation of <e2>GENE-Y<\\e2> (eCHEMICALS) results in the production of nitric oxide (<e1>CHEMICAL<\\e1>  that mediates the vasorelaxing properties of endothelial cells","sentence":"Activation of endothelial nitric oxide synthase (eNOS) results in the production of nitric oxide (NO  that mediates the vasorelaxing properties of endothelial cells"}
{"PMID":10460702,"re_id":18,"annotated sentence":"Activation of endothelial nitric oxide synthase (<e2>eNOS<\\e2>  results in the production of nitric oxide (<e1>NO<\\e1>  that mediates the vasorelaxing properties of endothelial cells","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"NO","object":"eNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Activation of endothelial nitric oxide synthase (<e2>eCHEMICALS<\\e2>  results in the production of nitric oxide (<e1>CHEMICAL<\\e1>  that mediates the vasorelaxing properties of endothelial cells","sentence":"Activation of endothelial nitric oxide synthase (eNOS  results in the production of nitric oxide (NO  that mediates the vasorelaxing properties of endothelial cells"}
{"PMID":10531013,"re_id":0,"annotated sentence":"We report that the radiation-induced activation of the kinase Cds1 [4] (also known as Chk2 [5]) is inhibited by caffeine in vivo and that <e2>ATM<\\e2> kinase activity is directly inhibited by <e1>caffeine<\\e1> in vitro","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"caffeine","object":"ATM","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We report that the radiation-induced activation of the kinase Cds1 [4] (also known as Chk2 [5]) is inhibited by CHEMICAL in vivo and that <e2>GENE-Y<\\e2> kinase activity is directly inhibited by <e1>CHEMICAL<\\e1> in vitro","sentence":"We report that the radiation-induced activation of the kinase Cds1 [4] (also known as Chk2 [5]) is inhibited by caffeine in vivo and that ATM kinase activity is directly inhibited by caffeine in vitro"}
{"PMID":10531013,"re_id":1,"annotated sentence":"We report that the radiation-induced activation of the kinase Cds1 [4] (also known as Chk2 [5]) is inhibited by caffeine in vivo and that ATM <e2>kinase<\\e2> activity is directly inhibited by <e1>caffeine<\\e1> in vitro","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"caffeine","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We report that the radiation-induced activation of the GENE-N Cds1 [4] (also known as Chk2 [5]) is inhibited by CHEMICAL in vivo and that ATM <e2>GENE-N<\\e2> activity is directly inhibited by <e1>CHEMICAL<\\e1> in vitro","sentence":"We report that the radiation-induced activation of the kinase Cds1 [4] (also known as Chk2 [5]) is inhibited by caffeine in vivo and that ATM kinase activity is directly inhibited by caffeine in vitro"}
{"PMID":10531013,"re_id":2,"annotated sentence":"Inhibition of <e2>ATM<\\e2> provides a molecular explanation of the attenuation of DNA-damage checkpoint responses and for the increased radiosensitivity of <e1>caffeine<\\e1> treated cells [6] [7] [8].","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"caffeine","object":"ATM","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of <e2>GENE-Y<\\e2> provides a molecular explanation of the attenuation of DNA-damage checkpoint responses and for the increased radiosensitivity of <e1>CHEMICAL<\\e1> treated cells [6] [7] [8].","sentence":"Inhibition of ATM provides a molecular explanation of the attenuation of DNA-damage checkpoint responses and for the increased radiosensitivity of caffeine treated cells [6] [7] [8]."}
{"PMID":10531013,"re_id":3,"annotated sentence":"We report that the radiation-induced activation of the <e2>kinase<\\e2> Cds1 [4] (also known as Chk2 [5]) is inhibited by <e1>caffeine<\\e1> in vivo and that ATM kinase activity is directly inhibited by caffeine in vitro","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"caffeine","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We report that the radiation-induced activation of the <e2>GENE-N<\\e2> Cds1 [4] (also known as Chk2 [5]) is inhibited by <e1>CHEMICAL<\\e1> in vivo and that ATM GENE-N activity is directly inhibited by CHEMICAL in vitro","sentence":"We report that the radiation-induced activation of the kinase Cds1 [4] (also known as Chk2 [5]) is inhibited by caffeine in vivo and that ATM kinase activity is directly inhibited by caffeine in vitro"}
{"PMID":10531013,"re_id":4,"annotated sentence":"We report that the radiation-induced activation of the kinase <e2>Cds1<\\e2> [4] (also known as Chk2 [5]) is inhibited by <e1>caffeine<\\e1> in vivo and that ATM kinase activity is directly inhibited by caffeine in vitro","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"caffeine","object":"Cds1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We report that the radiation-induced activation of the kinase <e2>GENE-Y<\\e2> [4] (also known as Chk2 [5]) is inhibited by <e1>CHEMICAL<\\e1> in vivo and that ATM kinase activity is directly inhibited by CHEMICAL in vitro","sentence":"We report that the radiation-induced activation of the kinase Cds1 [4] (also known as Chk2 [5]) is inhibited by caffeine in vivo and that ATM kinase activity is directly inhibited by caffeine in vitro"}
{"PMID":10531013,"re_id":5,"annotated sentence":"We report that the radiation-induced activation of the kinase Cds1 [4] (also known as <e2>Chk2<\\e2> [5]) is inhibited by <e1>caffeine<\\e1> in vivo and that ATM kinase activity is directly inhibited by caffeine in vitro","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"caffeine","object":"Chk2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We report that the radiation-induced activation of the kinase Cds1 [4] (also known as <e2>GENE-Y<\\e2> [5]) is inhibited by <e1>CHEMICAL<\\e1> in vivo and that ATM kinase activity is directly inhibited by CHEMICAL in vitro","sentence":"We report that the radiation-induced activation of the kinase Cds1 [4] (also known as Chk2 [5]) is inhibited by caffeine in vivo and that ATM kinase activity is directly inhibited by caffeine in vitro"}
{"PMID":10531013,"re_id":6,"annotated sentence":"<e1>Caffeine<\\e1> inhibits the checkpoint <e2>kinase<\\e2> ATM","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Caffeine","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> inhibits the checkpoint <e2>GENE-N<\\e2> ATM","sentence":"Caffeine inhibits the checkpoint kinase ATM"}
{"PMID":10531013,"re_id":7,"annotated sentence":"<e1>Caffeine<\\e1> inhibits the checkpoint kinase <e2>ATM<\\e2>  The basis of many anti-cancer therapies is the use of genotoxic agents that damage DNA and thus kill dividing cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Caffeine","object":"ATM","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits the checkpoint kinase <e2>GENE-Y<\\e2>  The basis of many anti-cancer therapies is the use of genotoxic agents that damage DNA and thus kill dividing cells","sentence":"Caffeine inhibits the checkpoint kinase ATM  The basis of many anti-cancer therapies is the use of genotoxic agents that damage DNA and thus kill dividing cells"}
{"PMID":10546982,"re_id":0,"annotated sentence":"The turnover of <e2>SERT<\\e2> was determined from the rate of recovery of binding after administration of <e1>RTI-76<\\e1>  an irreversible inhibitor of ligand binding","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"RTI-76","object":"SERT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The turnover of <e2>GENE-Y<\\e2> was determined from the rate of recovery of binding after administration of <e1>CHEMICAL<\\e1>  an irreversible inhibitor of ligand binding","sentence":"The turnover of SERT was determined from the rate of recovery of binding after administration of RTI-76  an irreversible inhibitor of ligand binding"}
{"PMID":10546982,"re_id":1,"annotated sentence":"In preliminary studies, in vitro incubation of rat cerebral cortex with <e1>RTI-76<\\e1> produced a wash and temperature resistant inhibition of <e2>SERT<\\e2> binding densities (Bmax)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"RTI-76","object":"SERT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In preliminary studies, in vitro incubation of rat cerebral cortex with <e1>CHEMICAL<\\e1> produced a wash and temperature resistant inhibition of <e2>GENE-Y<\\e2> binding densities (Bmax)","sentence":"In preliminary studies, in vitro incubation of rat cerebral cortex with RTI-76 produced a wash and temperature resistant inhibition of SERT binding densities (Bmax)"}
{"PMID":10546982,"re_id":2,"annotated sentence":"Citalopram protected against the <e1>RTI-76<\\e1> induced inhibition of <e2>SERT<\\e2> binding","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"RTI-76","object":"SERT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Citalopram protected against the <e1>CHEMICAL<\\e1> induced inhibition of <e2>GENE-Y<\\e2> binding","sentence":"Citalopram protected against the RTI-76 induced inhibition of SERT binding"}
{"PMID":10546982,"re_id":3,"annotated sentence":"The decrease and recovery of <e1>[3H]-5-HT<\\e1> uptake correlated highly (r = 0.93) with the recovery of <e2>SERT<\\e2> binding.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"[3H]-5-HT","object":"SERT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The decrease and recovery of <e1>CHEMICAL<\\e1> uptake correlated highly (r = 0.93) with the recovery of <e2>GENE-Y<\\e2> binding.","sentence":"The decrease and recovery of [3H]-5-HT uptake correlated highly (r = 0.93) with the recovery of SERT binding."}
{"PMID":10579749,"re_id":0,"annotated sentence":"The mode of (functional) <e2>AT1<\\e2> receptor antagonism has been characterized as surmountable\/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable\/noncompetitive (candesartan, <e1>saprisartan<\\e1>  zolasartan, irbesartan, valsartan, telmisartan, E3174)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"saprisartan","object":"AT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mode of (functional) <e2>GENE-Y<\\e2> receptor antagonism has been characterized as surmountable\/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable\/noncompetitive (candesartan, <e1>CHEMICAL<\\e1>  zolasartan, irbesartan, valsartan, telmisartan, E3174)","sentence":"The mode of (functional) AT1 receptor antagonism has been characterized as surmountable\/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable\/noncompetitive (candesartan, saprisartan  zolasartan, irbesartan, valsartan, telmisartan, E3174)"}
{"PMID":10579749,"re_id":1,"annotated sentence":"The mode of (functional) <e2>AT1<\\e2> receptor antagonism has been characterized as surmountable\/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable\/noncompetitive (candesartan, saprisartan, <e1>zolasartan<\\e1>  irbesartan, valsartan, telmisartan, E3174)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"zolasartan","object":"AT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mode of (functional) <e2>GENE-Y<\\e2> receptor antagonism has been characterized as surmountable\/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable\/noncompetitive (candesartan, saprisartan, <e1>CHEMICAL<\\e1>  irbesartan, valsartan, telmisartan, E3174)","sentence":"The mode of (functional) AT1 receptor antagonism has been characterized as surmountable\/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable\/noncompetitive (candesartan, saprisartan, zolasartan  irbesartan, valsartan, telmisartan, E3174)"}
{"PMID":10579749,"re_id":2,"annotated sentence":"The mode of (functional) <e2>AT1<\\e2> receptor antagonism has been characterized as surmountable\/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable\/noncompetitive (candesartan, saprisartan, zolasartan, <e1>irbesartan<\\e1>  valsartan, telmisartan, E3174)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"irbesartan","object":"AT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mode of (functional) <e2>GENE-Y<\\e2> receptor antagonism has been characterized as surmountable\/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable\/noncompetitive (candesartan, saprisartan, zolasartan, <e1>CHEMICAL<\\e1>  valsartan, telmisartan, E3174)","sentence":"The mode of (functional) AT1 receptor antagonism has been characterized as surmountable\/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable\/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan  valsartan, telmisartan, E3174)"}
{"PMID":10579749,"re_id":3,"annotated sentence":"The mode of (functional) <e2>AT1<\\e2> receptor antagonism has been characterized as surmountable\/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable\/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, <e1>valsartan<\\e1>  telmisartan, E3174)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"valsartan","object":"AT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mode of (functional) <e2>GENE-Y<\\e2> receptor antagonism has been characterized as surmountable\/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable\/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, <e1>CHEMICAL<\\e1>  telmisartan, E3174)","sentence":"The mode of (functional) AT1 receptor antagonism has been characterized as surmountable\/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable\/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan  telmisartan, E3174)"}
{"PMID":10579749,"re_id":4,"annotated sentence":"The mode of (functional) <e2>AT1<\\e2> receptor antagonism has been characterized as surmountable\/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable\/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, <e1>telmisartan<\\e1>  E3174)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"telmisartan","object":"AT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mode of (functional) <e2>GENE-Y<\\e2> receptor antagonism has been characterized as surmountable\/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable\/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, <e1>CHEMICAL<\\e1>  E3174)","sentence":"The mode of (functional) AT1 receptor antagonism has been characterized as surmountable\/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable\/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan  E3174)"}
{"PMID":10579749,"re_id":5,"annotated sentence":"The mode of (functional) <e2>AT1<\\e2> receptor antagonism has been characterized as surmountable\/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable\/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, <e1>E3174<\\e1> ","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"E3174","object":"AT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mode of (functional) <e2>GENE-Y<\\e2> receptor antagonism has been characterized as surmountable\/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable\/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, <e1>CHEMICAL<\\e1> ","sentence":"The mode of (functional) AT1 receptor antagonism has been characterized as surmountable\/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable\/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174 "}
{"PMID":10579749,"re_id":6,"annotated sentence":"Among the current <e2>AT1<\\e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of <e1>losartan<\\e1>  10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"losartan","object":"AT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Among the current <e2>GENE-Y<\\e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of <e1>CHEMICAL<\\e1>  10, tasosartan 20, CHEMICAL 50, eprosartan 100 and the prodrug candesartan cilexetil 280","sentence":"Among the current AT1 receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan  10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280"}
{"PMID":10579749,"re_id":7,"annotated sentence":"<e1>Losartan<\\e1> was the first, but by no means remained the only, <e2>AT1<\\e2> receptor antagonist","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Losartan","object":"AT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> was the first, but by no means remained the only, <e2>GENE-Y<\\e2> receptor antagonist","sentence":"Losartan was the first, but by no means remained the only, AT1 receptor antagonist"}
{"PMID":10579749,"re_id":8,"annotated sentence":"Among the current <e2>AT1<\\e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, <e1>tasosartan<\\e1> 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"tasosartan","object":"AT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Among the current <e2>GENE-Y<\\e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, <e1>CHEMICAL<\\e1> 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280","sentence":"Among the current AT1 receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280"}
{"PMID":10579749,"re_id":9,"annotated sentence":"Among the current <e2>AT1<\\e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: <e1>candesartan<\\e1> 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"candesartan","object":"AT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Among the current <e2>GENE-Y<\\e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: <e1>CHEMICAL<\\e1> 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug CHEMICAL cilexetil 280","sentence":"Among the current AT1 receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280"}
{"PMID":10579749,"re_id":10,"annotated sentence":"Among the current <e2>AT1<\\e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, <e1>telmisartan<\\e1> 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"telmisartan","object":"AT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Among the current <e2>GENE-Y<\\e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, <e1>CHEMICAL<\\e1> 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280","sentence":"Among the current AT1 receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280"}
{"PMID":10579749,"re_id":11,"annotated sentence":"Among the current <e2>AT1<\\e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, <e1>E3174<\\e1> (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"E3174","object":"AT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Among the current <e2>GENE-Y<\\e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, <e1>CHEMICAL<\\e1> (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280","sentence":"Among the current AT1 receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280"}
{"PMID":10579749,"re_id":12,"annotated sentence":"Among the current <e2>AT1<\\e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, <e1>losartan<\\e1> 50, eprosartan 100 and the prodrug candesartan cilexetil 280","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"losartan","object":"AT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Among the current <e2>GENE-Y<\\e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of CHEMICAL) 10, tasosartan 20, <e1>CHEMICAL<\\e1> 50, eprosartan 100 and the prodrug candesartan cilexetil 280","sentence":"Among the current AT1 receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280"}
{"PMID":10579749,"re_id":13,"annotated sentence":"Among the current <e2>AT1<\\e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, <e1>eprosartan<\\e1> 100 and the prodrug candesartan cilexetil 280","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"eprosartan","object":"AT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Among the current <e2>GENE-Y<\\e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, <e1>CHEMICAL<\\e1> 100 and the prodrug candesartan cilexetil 280","sentence":"Among the current AT1 receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280"}
{"PMID":10579749,"re_id":14,"annotated sentence":"Among the current <e2>AT1<\\e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug <e1>candesartan cilexetil<\\e1> 280","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"candesartan cilexetil","object":"AT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Among the current <e2>GENE-Y<\\e2> receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug <e1>CHEMICAL<\\e1> 280","sentence":"Among the current AT1 receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280"}
{"PMID":10579749,"re_id":15,"annotated sentence":"The mode of (functional) <e2>AT1<\\e2> receptor antagonism has been characterized as surmountable\/noncompetitive (<e1>losartan<\\e1>  tasosartan, eprosartan) or insurmountable\/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"losartan","object":"AT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mode of (functional) <e2>GENE-Y<\\e2> receptor antagonism has been characterized as surmountable\/noncompetitive (<e1>CHEMICAL<\\e1>  tasosartan, eprosartan) or insurmountable\/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174)","sentence":"The mode of (functional) AT1 receptor antagonism has been characterized as surmountable\/noncompetitive (losartan  tasosartan, eprosartan) or insurmountable\/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174)"}
{"PMID":10579749,"re_id":16,"annotated sentence":"The mode of (functional) <e2>AT1<\\e2> receptor antagonism has been characterized as surmountable\/noncompetitive (losartan, <e1>tasosartan<\\e1>  eprosartan) or insurmountable\/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"tasosartan","object":"AT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mode of (functional) <e2>GENE-Y<\\e2> receptor antagonism has been characterized as surmountable\/noncompetitive (losartan, <e1>CHEMICAL<\\e1>  eprosartan) or insurmountable\/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174)","sentence":"The mode of (functional) AT1 receptor antagonism has been characterized as surmountable\/noncompetitive (losartan, tasosartan  eprosartan) or insurmountable\/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174)"}
{"PMID":10579749,"re_id":17,"annotated sentence":"The mode of (functional) <e2>AT1<\\e2> receptor antagonism has been characterized as surmountable\/noncompetitive (losartan, tasosartan, <e1>eprosartan<\\e1>  or insurmountable\/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"eprosartan","object":"AT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mode of (functional) <e2>GENE-Y<\\e2> receptor antagonism has been characterized as surmountable\/noncompetitive (losartan, tasosartan, <e1>CHEMICAL<\\e1>  or insurmountable\/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174)","sentence":"The mode of (functional) AT1 receptor antagonism has been characterized as surmountable\/noncompetitive (losartan, tasosartan, eprosartan  or insurmountable\/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174)"}
{"PMID":10579749,"re_id":18,"annotated sentence":"The mode of (functional) <e2>AT1<\\e2> receptor antagonism has been characterized as surmountable\/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable\/noncompetitive (<e1>candesartan<\\e1>  saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"candesartan","object":"AT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mode of (functional) <e2>GENE-Y<\\e2> receptor antagonism has been characterized as surmountable\/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable\/noncompetitive (<e1>CHEMICAL<\\e1>  saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174)","sentence":"The mode of (functional) AT1 receptor antagonism has been characterized as surmountable\/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable\/noncompetitive (candesartan  saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174)"}
{"PMID":10683249,"re_id":0,"annotated sentence":"The mNQO activity was insensitive to <e1>dicoumarol<\\e1>  a potent inhibitor of cytosolic <e2>NQO1<\\e2>  Western analysis of microsomal proteins revealed 29- and 18-kDa bands that cross-reacted with polyclonal antibodies raised against cytosolic NQO1","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dicoumarol","object":"NQO1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mNQO activity was insensitive to <e1>CHEMICAL<\\e1>  a potent inhibitor of cytosolic <e2>GENE-Y<\\e2>  Western analysis of microsomal proteins revealed 29- and 18-kDa bands that cross-reacted with polyclonal antibodies raised against cytosolic GENE-Y","sentence":"The mNQO activity was insensitive to dicoumarol  a potent inhibitor of cytosolic NQO1  Western analysis of microsomal proteins revealed 29- and 18-kDa bands that cross-reacted with polyclonal antibodies raised against cytosolic NQO1"}
{"PMID":10683249,"re_id":1,"annotated sentence":"A role of cytosolic <e2>NQO1<\\e2> in protection of cells from oxidative stress, cytotoxicity, and mutagenicity of <e1>quinones<\\e1> was established","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"quinones","object":"NQO1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A role of cytosolic <e2>GENE-Y<\\e2> in protection of cells from oxidative stress, cytotoxicity, and mutagenicity of <e1>CHEMICAL<\\e1> was established","sentence":"A role of cytosolic NQO1 in protection of cells from oxidative stress, cytotoxicity, and mutagenicity of quinones was established"}
{"PMID":10683249,"re_id":2,"annotated sentence":"The <e2>mNQO<\\e2> activity showed significantly higher affinity for NADH than NADPH as electron donors and catalyzed reduction of <e1>2,6-dichlorophenolindophenol<\\e1> and menadione","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"2,6-dichlorophenolindophenol","object":"mNQO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e2>GENE-N<\\e2> activity showed significantly higher affinity for NADH than NADPH as electron donors and catalyzed reduction of <e1>CHEMICAL<\\e1> and menadione","sentence":"The mNQO activity showed significantly higher affinity for NADH than NADPH as electron donors and catalyzed reduction of 2,6-dichlorophenolindophenol and menadione"}
{"PMID":10683249,"re_id":3,"annotated sentence":"The <e2>mNQO<\\e2> activity showed significantly higher affinity for NADH than NADPH as electron donors and catalyzed reduction of 2,6-dichlorophenolindophenol and <e1>menadione<\\e1>  The mNQO activity was insensitive to dicoumarol, a potent inhibitor of cytosolic NQO1","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"menadione","object":"mNQO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e2>GENE-N<\\e2> activity showed significantly higher affinity for NADH than NADPH as electron donors and catalyzed reduction of 2,6-dichlorophenolindophenol and <e1>CHEMICAL<\\e1>  The GENE-N activity was insensitive to dicoumarol, a potent inhibitor of cytosolic NQO1","sentence":"The mNQO activity showed significantly higher affinity for NADH than NADPH as electron donors and catalyzed reduction of 2,6-dichlorophenolindophenol and menadione  The mNQO activity was insensitive to dicoumarol, a potent inhibitor of cytosolic NQO1"}
{"PMID":10683249,"re_id":4,"annotated sentence":"<e2>Quinone oxidoreductases<\\e2> are flavoproteins that catalyze two-electron reduction and detoxification of <e1>quinones<\\e1>  This leads to the protection of cells against toxicity, mutagenicity, and cancer due to exposure to environmental and synthetic quinones and its precursors","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"quinones","object":"Quinone oxidoreductases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> are flavoproteins that catalyze two-electron reduction and detoxification of <e1>CHEMICAL<\\e1>  This leads to the protection of cells against toxicity, mutagenicity, and cancer due to exposure to environmental and synthetic CHEMICAL and its precursors","sentence":"Quinone oxidoreductases are flavoproteins that catalyze two-electron reduction and detoxification of quinones  This leads to the protection of cells against toxicity, mutagenicity, and cancer due to exposure to environmental and synthetic quinones and its precursors"}
{"PMID":10688973,"re_id":0,"annotated sentence":"The related piperidines ohmefentanyl and <e1>sufentanil<\\e1> and the nonselective opioid receptor agonist etorphine were less potent <e2>nociceptin receptor<\\e2> agonists","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"sufentanil","object":"nociceptin receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The related piperidines ohmefentanyl and <e1>CHEMICAL<\\e1> and the nonselective opioid receptor agonist etorphine were less potent <e2>GENE-Y<\\e2> agonists","sentence":"The related piperidines ohmefentanyl and sufentanil and the nonselective opioid receptor agonist etorphine were less potent nociceptin receptor agonists"}
{"PMID":10688973,"re_id":1,"annotated sentence":"The related piperidines ohmefentanyl and sufentanil and the nonselective <e2>opioid receptor<\\e2> agonist <e1>etorphine<\\e1> were less potent nociceptin receptor agonists","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"etorphine","object":"opioid receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The related piperidines ohmefentanyl and sufentanil and the nonselective <e2>GENE-N<\\e2> agonist <e1>CHEMICAL<\\e1> were less potent nociceptin receptor agonists","sentence":"The related piperidines ohmefentanyl and sufentanil and the nonselective opioid receptor agonist etorphine were less potent nociceptin receptor agonists"}
{"PMID":10688973,"re_id":2,"annotated sentence":"The related piperidines ohmefentanyl and sufentanil and the nonselective opioid receptor agonist <e1>etorphine<\\e1> were less potent <e2>nociceptin receptor<\\e2> agonists","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"etorphine","object":"nociceptin receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The related piperidines ohmefentanyl and sufentanil and the nonselective opioid receptor agonist <e1>CHEMICAL<\\e1> were less potent <e2>GENE-Y<\\e2> agonists","sentence":"The related piperidines ohmefentanyl and sufentanil and the nonselective opioid receptor agonist etorphine were less potent nociceptin receptor agonists"}
{"PMID":10688973,"re_id":3,"annotated sentence":"The nonselective <e2>opioid receptor<\\e2> partial agonist <e1>buprenorphine<\\e1> and the nonselective opioid receptor antagonist (-)-quadazocine exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"buprenorphine","object":"opioid receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The nonselective <e2>GENE-N<\\e2> partial agonist <e1>CHEMICAL<\\e1> and the nonselective GENE-N antagonist (-)-quadazocine exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors","sentence":"The nonselective opioid receptor partial agonist buprenorphine and the nonselective opioid receptor antagonist (-)-quadazocine exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors"}
{"PMID":10688973,"re_id":4,"annotated sentence":"The nonselective opioid receptor partial agonist buprenorphine and the nonselective opioid receptor antagonist <e1>(-)-quadazocine<\\e1> exhibited pure antagonism at rat brain receptors, but displayed partial agonism at <e2>human ORL1<\\e2> receptors","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"(-)-quadazocine","object":"human ORL1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The nonselective opioid receptor partial agonist buprenorphine and the nonselective opioid receptor antagonist <e1>CHEMICAL<\\e1> exhibited pure antagonism at rat brain receptors, but displayed partial agonism at <e2>GENE-Y<\\e2> receptors","sentence":"The nonselective opioid receptor partial agonist buprenorphine and the nonselective opioid receptor antagonist (-)-quadazocine exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors"}
{"PMID":10688973,"re_id":5,"annotated sentence":"The <e2>mu-opioid receptor<\\e2> selective agonist <e1>lofentanil<\\e1> potently and competitively displaced [3H]nociceptin at rat brain receptors (IC(50) 62 nM)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"lofentanil","object":"mu-opioid receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> selective agonist <e1>CHEMICAL<\\e1> potently and competitively displaced [3H]nociceptin at rat brain receptors (IC(50) 62 nM)","sentence":"The mu-opioid receptor selective agonist lofentanil potently and competitively displaced [3H]nociceptin at rat brain receptors (IC(50) 62 nM)"}
{"PMID":10688973,"re_id":6,"annotated sentence":"<e1>Lofentanil<\\e1> exhibited full agonism for enhancement of [35S]GTPgammaS binding to human recombinant <e2>ORL1<\\e2> receptors (EC(50) 50 nM)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"Lofentanil","object":"ORL1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> exhibited full agonism for enhancement of [35S]GTPgammaS binding to human recombinant <e2>GENE-Y<\\e2> receptors (EC(50) 50 nM)","sentence":"Lofentanil exhibited full agonism for enhancement of [35S]GTPgammaS binding to human recombinant ORL1 receptors (EC(50) 50 nM)"}
{"PMID":10688973,"re_id":7,"annotated sentence":"The related <e1>piperidines<\\e1> ohmefentanyl and sufentanil and the nonselective opioid receptor agonist etorphine were less potent <e2>nociceptin receptor<\\e2> agonists","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"piperidines","object":"nociceptin receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The related <e1>CHEMICAL<\\e1> ohmefentanyl and sufentanil and the nonselective opioid receptor agonist etorphine were less potent <e2>GENE-Y<\\e2> agonists","sentence":"The related piperidines ohmefentanyl and sufentanil and the nonselective opioid receptor agonist etorphine were less potent nociceptin receptor agonists"}
{"PMID":10688973,"re_id":8,"annotated sentence":"The related piperidines <e1>ohmefentanyl<\\e1> and sufentanil and the nonselective opioid receptor agonist etorphine were less potent <e2>nociceptin receptor<\\e2> agonists","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"ohmefentanyl","object":"nociceptin receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The related piperidines <e1>CHEMICAL<\\e1> and sufentanil and the nonselective opioid receptor agonist etorphine were less potent <e2>GENE-Y<\\e2> agonists","sentence":"The related piperidines ohmefentanyl and sufentanil and the nonselective opioid receptor agonist etorphine were less potent nociceptin receptor agonists"}
{"PMID":10688973,"re_id":9,"annotated sentence":"The kappa(1)+kappa(3)-opioid receptor agonist\/mu-opioid receptor antagonist <e1>naloxone benzoylhydrazone<\\e1> was a pure antagonist at both rat brain and human <e2>ORL1<\\e2> receptors","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"naloxone benzoylhydrazone","object":"ORL1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The kappa(1)+kappa(3)-opioid receptor agonist\/mu-opioid receptor antagonist <e1>CHEMICAL<\\e1> was a pure antagonist at both rat brain and human <e2>GENE-N<\\e2> receptors","sentence":"The kappa(1)+kappa(3)-opioid receptor agonist\/mu-opioid receptor antagonist naloxone benzoylhydrazone was a pure antagonist at both rat brain and human ORL1 receptors"}
{"PMID":10688973,"re_id":10,"annotated sentence":"The kappa(1)+kappa(3)-opioid receptor agonist\/<e2>mu-opioid receptor<\\e2> antagonist <e1>naloxone benzoylhydrazone<\\e1> was a pure antagonist at both rat brain and human ORL1 receptors","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"naloxone benzoylhydrazone","object":"mu-opioid receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The kappa(1)+kappa(3)-opioid receptor agonist\/<e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> was a pure antagonist at both rat brain and human ORL1 receptors","sentence":"The kappa(1)+kappa(3)-opioid receptor agonist\/mu-opioid receptor antagonist naloxone benzoylhydrazone was a pure antagonist at both rat brain and human ORL1 receptors"}
{"PMID":10688973,"re_id":11,"annotated sentence":"The nonselective opioid receptor partial agonist buprenorphine and the nonselective <e2>opioid receptor<\\e2> antagonist <e1>(-)-quadazocine<\\e1> exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"(-)-quadazocine","object":"opioid receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The nonselective GENE-N partial agonist buprenorphine and the nonselective <e2>GENE-N<\\e2> antagonist <e1>CHEMICAL<\\e1> exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors","sentence":"The nonselective opioid receptor partial agonist buprenorphine and the nonselective opioid receptor antagonist (-)-quadazocine exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors"}
{"PMID":10697523,"re_id":0,"annotated sentence":"Thirty-week administration of <e1>UFT<\\e1> with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of <e2>thymidylate synthase<\\e2> inhibition and the decrease of thymidine kinase activity in the tumor cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"UFT","object":"thymidylate synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thirty-week administration of <e1>CHEMICAL<\\e1> with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of <e2>GENE-Y<\\e2> inhibition and the decrease of thymidine kinase activity in the tumor cells","sentence":"Thirty-week administration of UFT with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of thymidylate synthase inhibition and the decrease of thymidine kinase activity in the tumor cells"}
{"PMID":10697523,"re_id":1,"annotated sentence":"Thirty-week administration of <e1>UFT<\\e1> with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of thymidylate synthase inhibition and the decrease of <e2>thymidine kinase<\\e2> activity in the tumor cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"UFT","object":"thymidine kinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thirty-week administration of <e1>CHEMICAL<\\e1> with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of thymidylate synthase inhibition and the decrease of <e2>GENE-Y<\\e2> activity in the tumor cells","sentence":"Thirty-week administration of UFT with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of thymidylate synthase inhibition and the decrease of thymidine kinase activity in the tumor cells"}
{"PMID":10697523,"re_id":2,"annotated sentence":"Thirty-week administration of UFT with or without <e1>leucovorin<\\e1> markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of <e2>thymidylate synthase<\\e2> inhibition and the decrease of thymidine kinase activity in the tumor cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"leucovorin","object":"thymidylate synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thirty-week administration of UFT with or without <e1>CHEMICAL<\\e1> markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of <e2>GENE-Y<\\e2> inhibition and the decrease of thymidine kinase activity in the tumor cells","sentence":"Thirty-week administration of UFT with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of thymidylate synthase inhibition and the decrease of thymidine kinase activity in the tumor cells"}
{"PMID":10697523,"re_id":3,"annotated sentence":"Thirty-week administration of UFT with or without <e1>leucovorin<\\e1> markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of thymidylate synthase inhibition and the decrease of <e2>thymidine kinase<\\e2> activity in the tumor cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"leucovorin","object":"thymidine kinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thirty-week administration of UFT with or without <e1>CHEMICAL<\\e1> markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of thymidylate synthase inhibition and the decrease of <e2>GENE-Y<\\e2> activity in the tumor cells","sentence":"Thirty-week administration of UFT with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of thymidylate synthase inhibition and the decrease of thymidine kinase activity in the tumor cells"}
{"PMID":10697523,"re_id":4,"annotated sentence":"<e2>Thymidylate synthase<\\e2> is inhibited by <e1>5-fluorodeoxyuridine monophosphate<\\e1>  forming an inactive ternary complex with intracellular folate","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-fluorodeoxyuridine monophosphate","object":"Thymidylate synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> is inhibited by <e1>CHEMICAL<\\e1>  forming an inactive ternary complex with intracellular folate","sentence":"Thymidylate synthase is inhibited by 5-fluorodeoxyuridine monophosphate  forming an inactive ternary complex with intracellular folate"}
{"PMID":10697523,"re_id":5,"annotated sentence":"<e2>Thymidylate synthase<\\e2> and thymidine kinase are key enzymes involved in the de novo and salvage pathways for <e1>pyrimidine nucleotide<\\e1> synthesis, respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"pyrimidine nucleotide","object":"Thymidylate synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> and thymidine kinase are key enzymes involved in the de novo and salvage pathways for <e1>CHEMICAL<\\e1> synthesis, respectively","sentence":"Thymidylate synthase and thymidine kinase are key enzymes involved in the de novo and salvage pathways for pyrimidine nucleotide synthesis, respectively"}
{"PMID":10697523,"re_id":6,"annotated sentence":"Thymidylate synthase and <e2>thymidine kinase<\\e2> are key enzymes involved in the de novo and salvage pathways for <e1>pyrimidine nucleotide<\\e1> synthesis, respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"pyrimidine nucleotide","object":"thymidine kinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thymidylate synthase and <e2>GENE-Y<\\e2> are key enzymes involved in the de novo and salvage pathways for <e1>CHEMICAL<\\e1> synthesis, respectively","sentence":"Thymidylate synthase and thymidine kinase are key enzymes involved in the de novo and salvage pathways for pyrimidine nucleotide synthesis, respectively"}
{"PMID":10698696,"re_id":0,"annotated sentence":"Ornithine decarboxylase (<e2>ODC<\\e2>  catalyses the first step in the synthesis of the polyamines putrescine, <e1>spermidine<\\e1> and spermine","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"spermidine","object":"ODC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ornithine decarboxylase (<e2>GENE-Y<\\e2>  catalyses the first step in the synthesis of the polyamines putrescine, <e1>CHEMICAL<\\e1> and spermine","sentence":"Ornithine decarboxylase (ODC  catalyses the first step in the synthesis of the polyamines putrescine, spermidine and spermine"}
{"PMID":10698696,"re_id":1,"annotated sentence":"<e2>Ornithine decarboxylase<\\e2> (ODC) catalyses the first step in the synthesis of the polyamines putrescine, <e1>spermidine<\\e1> and spermine","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"spermidine","object":"Ornithine decarboxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (ODC) catalyses the first step in the synthesis of the polyamines putrescine, <e1>CHEMICAL<\\e1> and spermine","sentence":"Ornithine decarboxylase (ODC) catalyses the first step in the synthesis of the polyamines putrescine, spermidine and spermine"}
{"PMID":10698696,"re_id":2,"annotated sentence":"Ornithine decarboxylase (<e2>ODC<\\e2>  catalyses the first step in the synthesis of the polyamines putrescine, spermidine and <e1>spermine<\\e1>  The polyamines are essential for cell growth, but at elevated levels they may be tumorigenic, toxic, or may induce apoptosis","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"spermine","object":"ODC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ornithine decarboxylase (<e2>GENE-Y<\\e2>  catalyses the first step in the synthesis of the polyamines putrescine, spermidine and <e1>CHEMICAL<\\e1>  The polyamines are essential for cell growth, but at elevated levels they may be tumorigenic, toxic, or may induce apoptosis","sentence":"Ornithine decarboxylase (ODC  catalyses the first step in the synthesis of the polyamines putrescine, spermidine and spermine  The polyamines are essential for cell growth, but at elevated levels they may be tumorigenic, toxic, or may induce apoptosis"}
{"PMID":10698696,"re_id":3,"annotated sentence":"<e2>Ornithine decarboxylase<\\e2> (ODC) catalyses the first step in the synthesis of the polyamines putrescine, spermidine and <e1>spermine<\\e1>  The polyamines are essential for cell growth, but at elevated levels they may be tumorigenic, toxic, or may induce apoptosis","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"spermine","object":"Ornithine decarboxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (ODC) catalyses the first step in the synthesis of the polyamines putrescine, spermidine and <e1>CHEMICAL<\\e1>  The polyamines are essential for cell growth, but at elevated levels they may be tumorigenic, toxic, or may induce apoptosis","sentence":"Ornithine decarboxylase (ODC) catalyses the first step in the synthesis of the polyamines putrescine, spermidine and spermine  The polyamines are essential for cell growth, but at elevated levels they may be tumorigenic, toxic, or may induce apoptosis"}
{"PMID":10698696,"re_id":4,"annotated sentence":"Ornithine decarboxylase (<e2>ODC<\\e2>  catalyses the first step in the synthesis of the polyamines <e1>putrescine<\\e1>  spermidine and spermine","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"putrescine","object":"ODC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ornithine decarboxylase (<e2>GENE-Y<\\e2>  catalyses the first step in the synthesis of the polyamines <e1>CHEMICAL<\\e1>  spermidine and spermine","sentence":"Ornithine decarboxylase (ODC  catalyses the first step in the synthesis of the polyamines putrescine  spermidine and spermine"}
{"PMID":10698696,"re_id":5,"annotated sentence":"<e2>Ornithine decarboxylase<\\e2> (ODC) catalyses the first step in the synthesis of the polyamines <e1>putrescine<\\e1>  spermidine and spermine","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"putrescine","object":"Ornithine decarboxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (ODC) catalyses the first step in the synthesis of the polyamines <e1>CHEMICAL<\\e1>  spermidine and spermine","sentence":"Ornithine decarboxylase (ODC) catalyses the first step in the synthesis of the polyamines putrescine  spermidine and spermine"}
{"PMID":10742288,"re_id":0,"annotated sentence":"In <e2>alpha(2A)-adrenoceptor<\\e2> transfected cells the rank order of agonist potency was <e1>A-54741<\\e1> (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)>noradrenaline (6.92)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"A-54741","object":"alpha(2A)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In <e2>GENE-Y<\\e2> transfected cells the rank order of agonist potency was <e1>CHEMICAL<\\e1> (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)>noradrenaline (6.92)","sentence":"In alpha(2A)-adrenoceptor transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)>noradrenaline (6.92)"}
{"PMID":10742288,"re_id":1,"annotated sentence":"In <e2>alpha(2A)-adrenoceptor<\\e2> transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)><e1>dexmedetomidine<\\e1> (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)>noradrenaline (6.92)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"dexmedetomidine","object":"alpha(2A)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In <e2>GENE-Y<\\e2> transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)><e1>CHEMICAL<\\e1> (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)>noradrenaline (6.92)","sentence":"In alpha(2A)-adrenoceptor transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)>noradrenaline (6.92)"}
{"PMID":10742288,"re_id":2,"annotated sentence":"In <e2>alpha(2A)-adrenoceptor<\\e2> transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>dexmedetomidine (8.88)><e1>UK-14304<\\e1> (8.42)>B-HT 920 (7.05)>noradrenaline (6.92)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"UK-14304","object":"alpha(2A)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In <e2>GENE-Y<\\e2> transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>dexmedetomidine (8.88)><e1>CHEMICAL<\\e1> (8.42)>B-HT 920 (7.05)>noradrenaline (6.92)","sentence":"In alpha(2A)-adrenoceptor transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)>noradrenaline (6.92)"}
{"PMID":10742288,"re_id":3,"annotated sentence":"In <e2>alpha(2A)-adrenoceptor<\\e2> transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)><e1>B-HT 920<\\e1> (7.05)>noradrenaline (6.92)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"B-HT 920","object":"alpha(2A)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In <e2>GENE-Y<\\e2> transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)><e1>CHEMICAL<\\e1> (7.05)>noradrenaline (6.92)","sentence":"In alpha(2A)-adrenoceptor transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)>noradrenaline (6.92)"}
{"PMID":10742288,"re_id":4,"annotated sentence":"In <e2>alpha(2A)-adrenoceptor<\\e2> transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)><e1>noradrenaline<\\e1> (6.92)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"noradrenaline","object":"alpha(2A)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In <e2>GENE-Y<\\e2> transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)><e1>CHEMICAL<\\e1> (6.92)","sentence":"In alpha(2A)-adrenoceptor transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)>noradrenaline (6.92)"}
{"PMID":10796070,"re_id":0,"annotated sentence":"<e2>Glucocorticoid receptors<\\e2> were activated by <e1>dexamethasone<\\e1> as assessed using a glucocorticoid-responsive reporter plasmid, pTAT3-CAT","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"dexamethasone","object":"Glucocorticoid receptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> were activated by <e1>CHEMICAL<\\e1> as assessed using a glucocorticoid-responsive reporter plasmid, pTAT3-CAT","sentence":"Glucocorticoid receptors were activated by dexamethasone as assessed using a glucocorticoid-responsive reporter plasmid, pTAT3-CAT"}
{"PMID":10796070,"re_id":1,"annotated sentence":"The <e2>glucocorticoid receptor<\\e2> antagonist <e1>RU-486<\\e1> (mifepristone) significantly counteracted the effect of dexamethasone on glucocorticoid receptor activation, indicating that the dexamethasone effect is specific and is mediated through the glucocorticoid receptor","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"RU-486","object":"glucocorticoid receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> (mifepristone) significantly counteracted the effect of dexamethasone on GENE-Y activation, indicating that the dexamethasone effect is specific and is mediated through the GENE-Y","sentence":"The glucocorticoid receptor antagonist RU-486 (mifepristone) significantly counteracted the effect of dexamethasone on glucocorticoid receptor activation, indicating that the dexamethasone effect is specific and is mediated through the glucocorticoid receptor"}
{"PMID":10796070,"re_id":2,"annotated sentence":"The <e2>glucocorticoid receptor<\\e2> antagonist RU-486 (<e1>mifepristone<\\e1>  significantly counteracted the effect of dexamethasone on glucocorticoid receptor activation, indicating that the dexamethasone effect is specific and is mediated through the glucocorticoid receptor","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"mifepristone","object":"glucocorticoid receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> antagonist RU-486 (<e1>CHEMICAL<\\e1>  significantly counteracted the effect of dexamethasone on GENE-Y activation, indicating that the dexamethasone effect is specific and is mediated through the GENE-Y","sentence":"The glucocorticoid receptor antagonist RU-486 (mifepristone  significantly counteracted the effect of dexamethasone on glucocorticoid receptor activation, indicating that the dexamethasone effect is specific and is mediated through the glucocorticoid receptor"}
{"PMID":10839333,"re_id":0,"annotated sentence":"RESULTS: <e1>Quetiapine<\\e1> was an effective antipsychotic and improved the extrapyramidal symptoms and <e2>prolactin<\\e2> level elevation noted at baseline","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Quetiapine","object":"prolactin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: <e1>CHEMICAL<\\e1> was an effective antipsychotic and improved the extrapyramidal symptoms and <e2>GENE-Y<\\e2> level elevation noted at baseline","sentence":"RESULTS: Quetiapine was an effective antipsychotic and improved the extrapyramidal symptoms and prolactin level elevation noted at baseline"}
{"PMID":10887187,"re_id":0,"annotated sentence":"In a physiological K(+) gradient, <e2>TWIK-2<\\e2> is half inhibited by 0.1 mm <e1>Ba(2+)<\\e1>  quinine, and quinidine","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Ba(2+)","object":"TWIK-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In a physiological K(+) gradient, <e2>GENE-Y<\\e2> is half inhibited by 0.1 mm <e1>CHEMICAL<\\e1>  quinine, and quinidine","sentence":"In a physiological K(+) gradient, TWIK-2 is half inhibited by 0.1 mm Ba(2+)  quinine, and quinidine"}
{"PMID":10887187,"re_id":1,"annotated sentence":"In a physiological K(+) gradient, <e2>TWIK-2<\\e2> is half inhibited by 0.1 mm Ba(2+), <e1>quinine<\\e1>  and quinidine","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"quinine","object":"TWIK-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In a physiological K(+) gradient, <e2>GENE-Y<\\e2> is half inhibited by 0.1 mm Ba(2+), <e1>CHEMICAL<\\e1>  and quinidine","sentence":"In a physiological K(+) gradient, TWIK-2 is half inhibited by 0.1 mm Ba(2+), quinine  and quinidine"}
{"PMID":10887187,"re_id":2,"annotated sentence":"In a physiological K(+) gradient, <e2>TWIK-2<\\e2> is half inhibited by 0.1 mm Ba(2+), quinine, and <e1>quinidine<\\e1>  Finally, cysteine 53 in the M1P1 external loop is required for functional expression of TWIK-2 but is not critical for subunit self-assembly","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"quinidine","object":"TWIK-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In a physiological K(+) gradient, <e2>GENE-Y<\\e2> is half inhibited by 0.1 mm Ba(2+), quinine, and <e1>CHEMICAL<\\e1>  Finally, cysteine 53 in the M1P1 external loop is required for functional expression of GENE-Y but is not critical for subunit self-assembly","sentence":"In a physiological K(+) gradient, TWIK-2 is half inhibited by 0.1 mm Ba(2+), quinine, and quinidine  Finally, cysteine 53 in the M1P1 external loop is required for functional expression of TWIK-2 but is not critical for subunit self-assembly"}
{"PMID":10917903,"re_id":0,"annotated sentence":"Initial in vitro studies utilizing HEP-G2 liver cells revealed that addition of <e1>eicosapentaenoic acid<\\e1> (EPA) blocked <e2>Delta-5-desaturase<\\e2> activity, the terminal enzymatic step in AA synthesis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"eicosapentaenoic acid","object":"Delta-5-desaturase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Initial in vitro studies utilizing HEP-G2 liver cells revealed that addition of <e1>CHEMICAL<\\e1> (EPA) blocked <e2>GENE-Y<\\e2> activity, the terminal enzymatic step in AA synthesis","sentence":"Initial in vitro studies utilizing HEP-G2 liver cells revealed that addition of eicosapentaenoic acid (EPA) blocked Delta-5-desaturase activity, the terminal enzymatic step in AA synthesis"}
{"PMID":10917903,"re_id":1,"annotated sentence":"Initial in vitro studies utilizing HEP-G2 liver cells revealed that addition of eicosapentaenoic acid (<e1>EPA<\\e1>  blocked <e2>Delta-5-desaturase<\\e2> activity, the terminal enzymatic step in AA synthesis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"EPA","object":"Delta-5-desaturase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Initial in vitro studies utilizing HEP-G2 liver cells revealed that addition of eicosapentaenoic acid (<e1>CHEMICAL<\\e1>  blocked <e2>GENE-Y<\\e2> activity, the terminal enzymatic step in AA synthesis","sentence":"Initial in vitro studies utilizing HEP-G2 liver cells revealed that addition of eicosapentaenoic acid (EPA  blocked Delta-5-desaturase activity, the terminal enzymatic step in AA synthesis"}
{"PMID":10931813,"re_id":0,"annotated sentence":"BACKGROUND: This study examines the effects of <e1>nicorandil<\\e1>  a <e2>K(+) channel<\\e2> opener, on transmural dispersion of repolarization (TDR) and induction of torsade de pointes (TdP) under conditions mimicking the LQT1, LQT2, and LQT3 forms of the congenital long-QT syndrome (LQTS)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"nicorandil","object":"K(+) channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"BACKGROUND: This study examines the effects of <e1>CHEMICAL<\\e1>  a <e2>GENE-N<\\e2> opener, on transmural dispersion of repolarization (TDR) and induction of torsade de pointes (TdP) under conditions mimicking the LQT1, LQT2, and LQT3 forms of the congenital long-QT syndrome (LQTS)","sentence":"BACKGROUND: This study examines the effects of nicorandil  a K(+) channel opener, on transmural dispersion of repolarization (TDR) and induction of torsade de pointes (TdP) under conditions mimicking the LQT1, LQT2, and LQT3 forms of the congenital long-QT syndrome (LQTS)"}
{"PMID":10931813,"re_id":1,"annotated sentence":"Isoproterenol (50 to 100 nmol\/L) was used to mimic an increase in beta-adrenergic tone, <e1>d-sotalol<\\e1> (100 micromol\/L) to block <e2>I(Kr)<\\e2> (LQT2 model), and ATX-II (20 nmol\/L) to augment late I(Na) (LQT3 model)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"d-sotalol","object":"I(Kr)","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Isoproterenol (50 to 100 nmol\/L) was used to mimic an increase in beta-adrenergic tone, <e1>CHEMICAL<\\e1> (100 micromol\/L) to block <e2>GENE-N<\\e2> (LQT2 model), and ATX-II (20 nmol\/L) to augment late I(Na) (LQT3 model)","sentence":"Isoproterenol (50 to 100 nmol\/L) was used to mimic an increase in beta-adrenergic tone, d-sotalol (100 micromol\/L) to block I(Kr) (LQT2 model), and ATX-II (20 nmol\/L) to augment late I(Na) (LQT3 model)"}
{"PMID":10931813,"re_id":2,"annotated sentence":"Isoproterenol (50 to 100 nmol\/L) was used to mimic an increase in beta-adrenergic tone, <e1>d-sotalol<\\e1> (100 micromol\/L) to block I(Kr) (LQT2 model), and <e2>ATX-II<\\e2> (20 nmol\/L) to augment late I(Na) (LQT3 model)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"d-sotalol","object":"ATX-II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Isoproterenol (50 to 100 nmol\/L) was used to mimic an increase in beta-adrenergic tone, <e1>CHEMICAL<\\e1> (100 micromol\/L) to block I(Kr) (LQT2 model), and <e2>GENE-Y<\\e2> (20 nmol\/L) to augment late I(Na) (LQT3 model)","sentence":"Isoproterenol (50 to 100 nmol\/L) was used to mimic an increase in beta-adrenergic tone, d-sotalol (100 micromol\/L) to block I(Kr) (LQT2 model), and ATX-II (20 nmol\/L) to augment late I(Na) (LQT3 model)"}
{"PMID":10931813,"re_id":3,"annotated sentence":"<e1>Isoproterenol<\\e1> (50 to 100 nmol\/L) was used to mimic an increase in beta-adrenergic tone, d-sotalol (100 micromol\/L) to block <e2>I(Kr)<\\e2> (LQT2 model), and ATX-II (20 nmol\/L) to augment late I(Na) (LQT3 model)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Isoproterenol","object":"I(Kr)","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (50 to 100 nmol\/L) was used to mimic an increase in beta-adrenergic tone, d-sotalol (100 micromol\/L) to block <e2>GENE-N<\\e2> (LQT2 model), and ATX-II (20 nmol\/L) to augment late I(Na) (LQT3 model)","sentence":"Isoproterenol (50 to 100 nmol\/L) was used to mimic an increase in beta-adrenergic tone, d-sotalol (100 micromol\/L) to block I(Kr) (LQT2 model), and ATX-II (20 nmol\/L) to augment late I(Na) (LQT3 model)"}
{"PMID":10931813,"re_id":4,"annotated sentence":"<e1>Isoproterenol<\\e1> (50 to 100 nmol\/L) was used to mimic an increase in beta-adrenergic tone, d-sotalol (100 micromol\/L) to block I(Kr) (LQT2 model), and <e2>ATX-II<\\e2> (20 nmol\/L) to augment late I(Na) (LQT3 model)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Isoproterenol","object":"ATX-II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (50 to 100 nmol\/L) was used to mimic an increase in beta-adrenergic tone, d-sotalol (100 micromol\/L) to block I(Kr) (LQT2 model), and <e2>GENE-Y<\\e2> (20 nmol\/L) to augment late I(Na) (LQT3 model)","sentence":"Isoproterenol (50 to 100 nmol\/L) was used to mimic an increase in beta-adrenergic tone, d-sotalol (100 micromol\/L) to block I(Kr) (LQT2 model), and ATX-II (20 nmol\/L) to augment late I(Na) (LQT3 model)"}
{"PMID":10933891,"re_id":0,"annotated sentence":"<e2>Peroxisome proliferator-activated receptor alpha<\\e2> (PPARalpha) activators, <e1>bezafibrate<\\e1> and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"bezafibrate","object":"Peroxisome proliferator-activated receptor alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (PPARalpha) activators, <e1>CHEMICAL<\\e1> and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes","sentence":"Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, bezafibrate and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes"}
{"PMID":10933891,"re_id":1,"annotated sentence":"Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, <e1>bezafibrate<\\e1> and Wy-14,643, increase <e2>uncoupling protein-3<\\e2> mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"bezafibrate","object":"uncoupling protein-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, <e1>CHEMICAL<\\e1> and Wy-14,643, increase <e2>GENE-Y<\\e2> mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes","sentence":"Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, bezafibrate and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes"}
{"PMID":10933891,"re_id":2,"annotated sentence":"Peroxisome proliferator-activated receptor alpha (<e2>PPARalpha<\\e2>  activators, <e1>bezafibrate<\\e1> and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"bezafibrate","object":"PPARalpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Peroxisome proliferator-activated receptor alpha (<e2>GENE-Y<\\e2>  activators, <e1>CHEMICAL<\\e1> and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes","sentence":"Peroxisome proliferator-activated receptor alpha (PPARalpha  activators, bezafibrate and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes"}
{"PMID":10933891,"re_id":3,"annotated sentence":"<e2>Peroxisome proliferator-activated receptor alpha<\\e2> (PPARalpha) activators, bezafibrate and <e1>Wy-14,643<\\e1>  increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Wy-14,643","object":"Peroxisome proliferator-activated receptor alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (PPARalpha) activators, bezafibrate and <e1>CHEMICAL<\\e1>  increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes","sentence":"Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, bezafibrate and Wy-14,643  increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes"}
{"PMID":10933891,"re_id":4,"annotated sentence":"Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, bezafibrate and <e1>Wy-14,643<\\e1>  increase <e2>uncoupling protein-3<\\e2> mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Wy-14,643","object":"uncoupling protein-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, bezafibrate and <e1>CHEMICAL<\\e1>  increase <e2>GENE-Y<\\e2> mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes","sentence":"Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, bezafibrate and Wy-14,643  increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes"}
{"PMID":10933891,"re_id":5,"annotated sentence":"Peroxisome proliferator-activated receptor alpha (<e2>PPARalpha<\\e2>  activators, bezafibrate and <e1>Wy-14,643<\\e1>  increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Wy-14,643","object":"PPARalpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Peroxisome proliferator-activated receptor alpha (<e2>GENE-Y<\\e2>  activators, bezafibrate and <e1>CHEMICAL<\\e1>  increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes","sentence":"Peroxisome proliferator-activated receptor alpha (PPARalpha  activators, bezafibrate and Wy-14,643  increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes"}
{"PMID":10933891,"re_id":6,"annotated sentence":"The induction in <e2>UCP-3<\\e2> expression was not accompanied by changes in the mitochondrial membrane potential of rat primary preadipocytes after <e1>bezafibrate<\\e1> or Wy-14,643 treatment","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"bezafibrate","object":"UCP-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The induction in <e2>GENE-Y<\\e2> expression was not accompanied by changes in the mitochondrial membrane potential of rat primary preadipocytes after <e1>CHEMICAL<\\e1> or Wy-14,643 treatment","sentence":"The induction in UCP-3 expression was not accompanied by changes in the mitochondrial membrane potential of rat primary preadipocytes after bezafibrate or Wy-14,643 treatment"}
{"PMID":10933891,"re_id":7,"annotated sentence":"The induction in <e2>UCP-3<\\e2> expression was not accompanied by changes in the mitochondrial membrane potential of rat primary preadipocytes after bezafibrate or <e1>Wy-14,643<\\e1> treatment","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Wy-14,643","object":"UCP-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The induction in <e2>GENE-Y<\\e2> expression was not accompanied by changes in the mitochondrial membrane potential of rat primary preadipocytes after bezafibrate or <e1>CHEMICAL<\\e1> treatment","sentence":"The induction in UCP-3 expression was not accompanied by changes in the mitochondrial membrane potential of rat primary preadipocytes after bezafibrate or Wy-14,643 treatment"}
{"PMID":10933891,"re_id":8,"annotated sentence":"Since it has been proposed that UCP-3 could be involved in the regulation of the use of fatty acids as fuel substrates, the <e2>UCP-3<\\e2> induction achieved after <e1>bezafibrate<\\e1> and Wy-14, 643 treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as triglycerides","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"bezafibrate","object":"UCP-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Since it has been proposed that GENE-Y could be involved in the regulation of the use of fatty acids as fuel substrates, the <e2>GENE-Y<\\e2> induction achieved after <e1>CHEMICAL<\\e1> and Wy-14, 643 treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as triglycerides","sentence":"Since it has been proposed that UCP-3 could be involved in the regulation of the use of fatty acids as fuel substrates, the UCP-3 induction achieved after bezafibrate and Wy-14, 643 treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as triglycerides"}
{"PMID":10933891,"re_id":9,"annotated sentence":"Since it has been proposed that UCP-3 could be involved in the regulation of the use of fatty acids as fuel substrates, the <e2>UCP-3<\\e2> induction achieved after bezafibrate and <e1>Wy-14, 643<\\e1> treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as triglycerides","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Wy-14, 643","object":"UCP-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Since it has been proposed that GENE-Y could be involved in the regulation of the use of fatty acids as fuel substrates, the <e2>GENE-Y<\\e2> induction achieved after bezafibrate and <e1>CHEMICAL<\\e1> treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as triglycerides","sentence":"Since it has been proposed that UCP-3 could be involved in the regulation of the use of fatty acids as fuel substrates, the UCP-3 induction achieved after bezafibrate and Wy-14, 643 treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as triglycerides"}
{"PMID":10933891,"re_id":10,"annotated sentence":"Thus, <e1>bezafibrate<\\e1> treatment resulted in an 8-fold induction in <e2>UCP-3<\\e2> mRNA levels in preadipocytes compared with the 3.5-fold induction observed in adipocytes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"bezafibrate","object":"UCP-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, <e1>CHEMICAL<\\e1> treatment resulted in an 8-fold induction in <e2>GENE-Y<\\e2> mRNA levels in preadipocytes compared with the 3.5-fold induction observed in adipocytes","sentence":"Thus, bezafibrate treatment resulted in an 8-fold induction in UCP-3 mRNA levels in preadipocytes compared with the 3.5-fold induction observed in adipocytes"}
{"PMID":10933891,"re_id":11,"annotated sentence":"<e2>Uncoupling proteins<\\e2> (UCPs) are inner mitochondrial membrane transporters which act as pores for <e1>H(+)<\\e1> ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"H(+)","object":"Uncoupling proteins","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> (UCPs) are inner mitochondrial membrane transporters which act as pores for <e1>CHEMICAL<\\e1> ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis","sentence":"Uncoupling proteins (UCPs) are inner mitochondrial membrane transporters which act as pores for H(+) ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis"}
{"PMID":10933891,"re_id":12,"annotated sentence":"Uncoupling proteins (<e2>UCPs<\\e2>  are inner mitochondrial membrane transporters which act as pores for <e1>H(+)<\\e1> ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"H(+)","object":"UCPs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Uncoupling proteins (<e2>GENE-N<\\e2>  are inner mitochondrial membrane transporters which act as pores for <e1>CHEMICAL<\\e1> ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis","sentence":"Uncoupling proteins (UCPs  are inner mitochondrial membrane transporters which act as pores for H(+) ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis"}
{"PMID":10939639,"re_id":0,"annotated sentence":"The ensemble of results suggests that the ability of <e1>Sch B<\\e1> pretreatment to enhance hepatocellular <e2>DTD<\\e2> activity may at least in part be attributed to the protection against menadione hepatotoxicity.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Sch B","object":"DTD","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The ensemble of results suggests that the ability of <e1>CHEMICAL<\\e1> pretreatment to enhance hepatocellular <e2>GENE-Y<\\e2> activity may at least in part be attributed to the protection against menadione hepatotoxicity.","sentence":"The ensemble of results suggests that the ability of Sch B pretreatment to enhance hepatocellular DTD activity may at least in part be attributed to the protection against menadione hepatotoxicity."}
{"PMID":10939639,"re_id":1,"annotated sentence":"<e1>Schisandrin B<\\e1> protects against menadione-induced hepatotoxicity by enhancing <e2>DT-diaphorase<\\e2> activity","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Schisandrin B","object":"DT-diaphorase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> protects against menadione-induced hepatotoxicity by enhancing <e2>GENE-Y<\\e2> activity","sentence":"Schisandrin B protects against menadione-induced hepatotoxicity by enhancing DT-diaphorase activity"}
{"PMID":10939639,"re_id":2,"annotated sentence":"Hepatocytes isolated from <e1>Sch B<\\e1> pretreated (a daily dose of 1 mmol\/kg for 3 days) rats showed a significant increase (25%) in <e2>DTD<\\e2> activity","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Sch B","object":"DTD","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Hepatocytes isolated from <e1>CHEMICAL<\\e1> pretreated (a daily dose of 1 mmol\/kg for 3 days) rats showed a significant increase (25%) in <e2>GENE-Y<\\e2> activity","sentence":"Hepatocytes isolated from Sch B pretreated (a daily dose of 1 mmol\/kg for 3 days) rats showed a significant increase (25%) in DTD activity"}
{"PMID":10939639,"re_id":3,"annotated sentence":"Pretreating mice with schisandrin B (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol\/kg for 3 days protected against <e1>menadione<\\e1> induced hepatic oxidative damage in mice, as evidenced by decreases in plasma <e2>alanine aminotransferase<\\e2> activity (78%) and hepatic malondialdehyde level (70%), when compared with the menadione intoxicated control","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"menadione","object":"alanine aminotransferase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Pretreating mice with schisandrin B (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol\/kg for 3 days protected against <e1>CHEMICAL<\\e1> induced hepatic oxidative damage in mice, as evidenced by decreases in plasma <e2>GENE-N<\\e2> activity (78%) and hepatic malondialdehyde level (70%), when compared with the CHEMICAL intoxicated control","sentence":"Pretreating mice with schisandrin B (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol\/kg for 3 days protected against menadione induced hepatic oxidative damage in mice, as evidenced by decreases in plasma alanine aminotransferase activity (78%) and hepatic malondialdehyde level (70%), when compared with the menadione intoxicated control"}
{"PMID":10942908,"re_id":0,"annotated sentence":"<e2>Creatine phosphokinase<\\e2> activity in plasma increased slightly (compared to control, <e1>pyridostigmine<\\e1> or exercise group) in mice treated with pyridostigmine plus exercise, which may be indicative of perturbation in the integrity of the skeletal muscle due to combination","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"pyridostigmine","object":"Creatine phosphokinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> activity in plasma increased slightly (compared to control, <e1>CHEMICAL<\\e1> or exercise group) in mice treated with CHEMICAL plus exercise, which may be indicative of perturbation in the integrity of the skeletal muscle due to combination","sentence":"Creatine phosphokinase activity in plasma increased slightly (compared to control, pyridostigmine or exercise group) in mice treated with pyridostigmine plus exercise, which may be indicative of perturbation in the integrity of the skeletal muscle due to combination"}
{"PMID":10942908,"re_id":1,"annotated sentence":"<e2>Creatine phosphokinase<\\e2> activity in plasma increased slightly (compared to control, pyridostigmine or exercise group) in mice treated with <e1>pyridostigmine<\\e1> plus exercise, which may be indicative of perturbation in the integrity of the skeletal muscle due to combination","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"pyridostigmine","object":"Creatine phosphokinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> activity in plasma increased slightly (compared to control, CHEMICAL or exercise group) in mice treated with <e1>CHEMICAL<\\e1> plus exercise, which may be indicative of perturbation in the integrity of the skeletal muscle due to combination","sentence":"Creatine phosphokinase activity in plasma increased slightly (compared to control, pyridostigmine or exercise group) in mice treated with pyridostigmine plus exercise, which may be indicative of perturbation in the integrity of the skeletal muscle due to combination"}
{"PMID":10942908,"re_id":2,"annotated sentence":"The group treated with <e1>pyridostigmine<\\e1> alone showed decreased plasma <e2>butyrylcholinesterase<\\e2> (BChE) activity (87% of control), whereas pyridostigmine plus exercise significantly decreased the BChE activity (79% of control), indicating an interactive effect of the combination","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pyridostigmine","object":"butyrylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The group treated with <e1>CHEMICAL<\\e1> alone showed decreased plasma <e2>GENE-Y<\\e2> (BChE) activity (87% of control), whereas CHEMICAL plus exercise significantly decreased the BChE activity (79% of control), indicating an interactive effect of the combination","sentence":"The group treated with pyridostigmine alone showed decreased plasma butyrylcholinesterase (BChE) activity (87% of control), whereas pyridostigmine plus exercise significantly decreased the BChE activity (79% of control), indicating an interactive effect of the combination"}
{"PMID":10942908,"re_id":3,"annotated sentence":"The group treated with <e1>pyridostigmine<\\e1> alone showed decreased plasma butyrylcholinesterase (<e2>BChE<\\e2>  activity (87% of control), whereas pyridostigmine plus exercise significantly decreased the BChE activity (79% of control), indicating an interactive effect of the combination","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pyridostigmine","object":"BChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The group treated with <e1>CHEMICAL<\\e1> alone showed decreased plasma butyrylcholinesterase (<e2>GENE-Y<\\e2>  activity (87% of control), whereas CHEMICAL plus exercise significantly decreased the GENE-Y activity (79% of control), indicating an interactive effect of the combination","sentence":"The group treated with pyridostigmine alone showed decreased plasma butyrylcholinesterase (BChE  activity (87% of control), whereas pyridostigmine plus exercise significantly decreased the BChE activity (79% of control), indicating an interactive effect of the combination"}
{"PMID":10942908,"re_id":4,"annotated sentence":"The group treated with pyridostigmine alone showed decreased plasma butyrylcholinesterase (BChE) activity (87% of control), whereas <e1>pyridostigmine<\\e1> plus exercise significantly decreased the <e2>BChE<\\e2> activity (79% of control), indicating an interactive effect of the combination","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pyridostigmine","object":"BChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The group treated with CHEMICAL alone showed decreased plasma butyrylcholinesterase (GENE-Y) activity (87% of control), whereas <e1>CHEMICAL<\\e1> plus exercise significantly decreased the <e2>GENE-Y<\\e2> activity (79% of control), indicating an interactive effect of the combination","sentence":"The group treated with pyridostigmine alone showed decreased plasma butyrylcholinesterase (BChE) activity (87% of control), whereas pyridostigmine plus exercise significantly decreased the BChE activity (79% of control), indicating an interactive effect of the combination"}
{"PMID":10942908,"re_id":5,"annotated sentence":"However, <e2>AChE<\\e2> activity in triceps muscle decreased significantly (78% of control) in the group treated with <e1>pyridostigmine<\\e1> plus exercise","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pyridostigmine","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, <e2>GENE-Y<\\e2> activity in triceps muscle decreased significantly (78% of control) in the group treated with <e1>CHEMICAL<\\e1> plus exercise","sentence":"However, AChE activity in triceps muscle decreased significantly (78% of control) in the group treated with pyridostigmine plus exercise"}
{"PMID":11056242,"re_id":0,"annotated sentence":"RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng\/mL), had no significant effect on MCP-1 expression, whereas <e1>danazol<\\e1> (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on <e2>MCP-1<\\e2> expression","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"danazol","object":"MCP-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng\/mL), had no significant effect on GENE-Y expression, whereas <e1>CHEMICAL<\\e1> (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on <e2>GENE-Y<\\e2> expression","sentence":"RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng\/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression"}
{"PMID":11056242,"re_id":1,"annotated sentence":"RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng\/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a <e1>testosterone<\\e1> analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on <e2>MCP-1<\\e2> expression","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"testosterone","object":"MCP-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng\/mL), had no significant effect on GENE-Y expression, whereas danazol (10(-7)-10(-5) M), a <e1>CHEMICAL<\\e1> analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on <e2>GENE-Y<\\e2> expression","sentence":"RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng\/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression"}
{"PMID":11056242,"re_id":2,"annotated sentence":"RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng\/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and <e1>dexamethasone<\\e1>  an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on <e2>MCP-1<\\e2> expression","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dexamethasone","object":"MCP-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng\/mL), had no significant effect on GENE-Y expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and <e1>CHEMICAL<\\e1>  an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on <e2>GENE-Y<\\e2> expression","sentence":"RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng\/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and dexamethasone  an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression"}
{"PMID":11056242,"re_id":3,"annotated sentence":"RESULT(S): <e1>Buserelin acetate<\\e1>  a <e2>GnRH<\\e2> agonist (0.1-10 ng\/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"Buserelin acetate","object":"GnRH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULT(S): <e1>CHEMICAL<\\e1>  a <e2>GENE-Y<\\e2> agonist (0.1-10 ng\/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression","sentence":"RESULT(S): Buserelin acetate  a GnRH agonist (0.1-10 ng\/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression"}
{"PMID":11146120,"re_id":0,"annotated sentence":"Mobility shift assays on whole cell extracts showed that <e1>clenbuterol<\\e1> increased AP1 binding in 3T3 cells prior to increasing <e2>NGF<\\e2> synthesis","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"clenbuterol","object":"NGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Mobility shift assays on whole cell extracts showed that <e1>CHEMICAL<\\e1> increased AP1 binding in 3T3 cells prior to increasing <e2>GENE-Y<\\e2> synthesis","sentence":"Mobility shift assays on whole cell extracts showed that clenbuterol increased AP1 binding in 3T3 cells prior to increasing NGF synthesis"}
{"PMID":11146120,"re_id":1,"annotated sentence":"Clenbuterol was without effect on NGF mRNA levels in L929 cells, whereas <e1>CB1093<\\e1> caused significant increases in both <e2>NGF<\\e2> mRNA and protein levels in both 3T3 and L929 cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CB1093","object":"NGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Clenbuterol was without effect on GENE-Y mRNA levels in L929 cells, whereas <e1>CHEMICAL<\\e1> caused significant increases in both <e2>GENE-Y<\\e2> mRNA and protein levels in both 3T3 and L929 cells","sentence":"Clenbuterol was without effect on NGF mRNA levels in L929 cells, whereas CB1093 caused significant increases in both NGF mRNA and protein levels in both 3T3 and L929 cells"}
{"PMID":11146120,"re_id":2,"annotated sentence":"This study demonstrates that <e1>CB1093<\\e1> and clenbuterol stimulate <e2>NGF<\\e2> levels in vitro and that AP-1 binding could be a commonality between the mechanism of NGF induction of these two compounds.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CB1093","object":"NGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This study demonstrates that <e1>CHEMICAL<\\e1> and clenbuterol stimulate <e2>GENE-Y<\\e2> levels in vitro and that AP-1 binding could be a commonality between the mechanism of GENE-Y induction of these two compounds.","sentence":"This study demonstrates that CB1093 and clenbuterol stimulate NGF levels in vitro and that AP-1 binding could be a commonality between the mechanism of NGF induction of these two compounds."}
{"PMID":11146120,"re_id":3,"annotated sentence":"This study demonstrates that <e1>CB1093<\\e1> and clenbuterol stimulate NGF levels in vitro and that AP-1 binding could be a commonality between the mechanism of <e2>NGF<\\e2> induction of these two compounds.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CB1093","object":"NGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This study demonstrates that <e1>CHEMICAL<\\e1> and clenbuterol stimulate GENE-Y levels in vitro and that AP-1 binding could be a commonality between the mechanism of <e2>GENE-Y<\\e2> induction of these two compounds.","sentence":"This study demonstrates that CB1093 and clenbuterol stimulate NGF levels in vitro and that AP-1 binding could be a commonality between the mechanism of NGF induction of these two compounds."}
{"PMID":11146120,"re_id":4,"annotated sentence":"This study demonstrates that CB1093 and <e1>clenbuterol<\\e1> stimulate <e2>NGF<\\e2> levels in vitro and that AP-1 binding could be a commonality between the mechanism of NGF induction of these two compounds.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"clenbuterol","object":"NGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This study demonstrates that CB1093 and <e1>CHEMICAL<\\e1> stimulate <e2>GENE-Y<\\e2> levels in vitro and that AP-1 binding could be a commonality between the mechanism of GENE-Y induction of these two compounds.","sentence":"This study demonstrates that CB1093 and clenbuterol stimulate NGF levels in vitro and that AP-1 binding could be a commonality between the mechanism of NGF induction of these two compounds."}
{"PMID":11146120,"re_id":5,"annotated sentence":"This study demonstrates that CB1093 and <e1>clenbuterol<\\e1> stimulate NGF levels in vitro and that AP-1 binding could be a commonality between the mechanism of <e2>NGF<\\e2> induction of these two compounds.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"clenbuterol","object":"NGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This study demonstrates that CB1093 and <e1>CHEMICAL<\\e1> stimulate GENE-Y levels in vitro and that AP-1 binding could be a commonality between the mechanism of <e2>GENE-Y<\\e2> induction of these two compounds.","sentence":"This study demonstrates that CB1093 and clenbuterol stimulate NGF levels in vitro and that AP-1 binding could be a commonality between the mechanism of NGF induction of these two compounds."}
{"PMID":11146120,"re_id":6,"annotated sentence":"The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (<e1>CB1093<\\e1>  with minimal calcaemic effects, and clenbuterol, a long-acting beta(2)-adrenoceptor agonist, both of which induce <e2>NGF<\\e2> synthesis in vivo","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CB1093","object":"NGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (<e1>CHEMICAL<\\e1>  with minimal calcaemic effects, and clenbuterol, a long-acting beta(2)-adrenoceptor agonist, both of which induce <e2>GENE-Y<\\e2> synthesis in vivo","sentence":"The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (CB1093  with minimal calcaemic effects, and clenbuterol, a long-acting beta(2)-adrenoceptor agonist, both of which induce NGF synthesis in vivo"}
{"PMID":11146120,"re_id":7,"annotated sentence":"The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (CB1093) with minimal calcaemic effects, and <e1>clenbuterol<\\e1>  a long-acting beta(2)-adrenoceptor agonist, both of which induce <e2>NGF<\\e2> synthesis in vivo","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"clenbuterol","object":"NGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (CB1093) with minimal calcaemic effects, and <e1>CHEMICAL<\\e1>  a long-acting beta(2)-adrenoceptor agonist, both of which induce <e2>GENE-Y<\\e2> synthesis in vivo","sentence":"The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (CB1093) with minimal calcaemic effects, and clenbuterol  a long-acting beta(2)-adrenoceptor agonist, both of which induce NGF synthesis in vivo"}
{"PMID":11146120,"re_id":8,"annotated sentence":"<e1>Clenbuterol<\\e1> caused significant increases in both <e2>NGF<\\e2> mRNA and protein in 3T3 cells; with maxima at 10 nM and at 8-12 h exposure","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Clenbuterol","object":"NGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> caused significant increases in both <e2>GENE-Y<\\e2> mRNA and protein in 3T3 cells; with maxima at 10 nM and at 8-12 h exposure","sentence":"Clenbuterol caused significant increases in both NGF mRNA and protein in 3T3 cells; with maxima at 10 nM and at 8-12 h exposure"}
{"PMID":11146120,"re_id":9,"annotated sentence":"The present studies were undertaken to compare two compounds, a <e1>vitamin D(3)<\\e1> analogue (CB1093) with minimal calcaemic effects, and clenbuterol, a long-acting beta(2)-adrenoceptor agonist, both of which induce <e2>NGF<\\e2> synthesis in vivo","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"vitamin D(3)","object":"NGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The present studies were undertaken to compare two compounds, a <e1>CHEMICAL<\\e1> analogue (CB1093) with minimal calcaemic effects, and clenbuterol, a long-acting beta(2)-adrenoceptor agonist, both of which induce <e2>GENE-Y<\\e2> synthesis in vivo","sentence":"The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (CB1093) with minimal calcaemic effects, and clenbuterol, a long-acting beta(2)-adrenoceptor agonist, both of which induce NGF synthesis in vivo"}
{"PMID":11146120,"re_id":10,"annotated sentence":"The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (CB1093) with minimal calcaemic effects, and <e1>clenbuterol<\\e1>  a long-acting <e2>beta(2)-adrenoceptor<\\e2> agonist, both of which induce NGF synthesis in vivo","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"clenbuterol","object":"beta(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (CB1093) with minimal calcaemic effects, and <e1>CHEMICAL<\\e1>  a long-acting <e2>GENE-Y<\\e2> agonist, both of which induce NGF synthesis in vivo","sentence":"The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (CB1093) with minimal calcaemic effects, and clenbuterol  a long-acting beta(2)-adrenoceptor agonist, both of which induce NGF synthesis in vivo"}
{"PMID":11157886,"re_id":0,"annotated sentence":"CONCLUSIONS: After the initial bleach, <e1>halothane<\\e1> impeded photon absorption by rhodopsin by inhibiting metabolic <e2>rhodopsin<\\e2> regeneration","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"halothane","object":"rhodopsin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"CONCLUSIONS: After the initial bleach, <e1>CHEMICAL<\\e1> impeded photon absorption by GENE-N by inhibiting metabolic <e2>GENE-N<\\e2> regeneration","sentence":"CONCLUSIONS: After the initial bleach, halothane impeded photon absorption by rhodopsin by inhibiting metabolic rhodopsin regeneration"}
{"PMID":11157886,"re_id":1,"annotated sentence":"RESULTS: <e1>Halothane<\\e1> anesthesia reversibly inhibited metabolic <e2>rhodopsin<\\e2> regeneration and thus prevented rhodopsin from absorbing high numbers of photons during light exposure","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Halothane","object":"rhodopsin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"RESULTS: <e1>CHEMICAL<\\e1> anesthesia reversibly inhibited metabolic <e2>GENE-N<\\e2> regeneration and thus prevented GENE-N from absorbing high numbers of photons during light exposure","sentence":"RESULTS: Halothane anesthesia reversibly inhibited metabolic rhodopsin regeneration and thus prevented rhodopsin from absorbing high numbers of photons during light exposure"}
{"PMID":11157886,"re_id":2,"annotated sentence":"RESULTS: <e1>Halothane<\\e1> anesthesia reversibly inhibited metabolic rhodopsin regeneration and thus prevented <e2>rhodopsin<\\e2> from absorbing high numbers of photons during light exposure","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Halothane","object":"rhodopsin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"RESULTS: <e1>CHEMICAL<\\e1> anesthesia reversibly inhibited metabolic GENE-N regeneration and thus prevented <e2>GENE-N<\\e2> from absorbing high numbers of photons during light exposure","sentence":"RESULTS: Halothane anesthesia reversibly inhibited metabolic rhodopsin regeneration and thus prevented rhodopsin from absorbing high numbers of photons during light exposure"}
{"PMID":11157886,"re_id":3,"annotated sentence":"Protective effect of <e1>halothane<\\e1> anesthesia on retinal light damage: inhibition of metabolic <e2>rhodopsin<\\e2> regeneration","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"halothane","object":"rhodopsin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Protective effect of <e1>CHEMICAL<\\e1> anesthesia on retinal light damage: inhibition of metabolic <e2>GENE-N<\\e2> regeneration","sentence":"Protective effect of halothane anesthesia on retinal light damage: inhibition of metabolic rhodopsin regeneration"}
{"PMID":11243491,"re_id":0,"annotated sentence":"METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [<e1>buspirone<\\e1> (partial <e2>5-HT1A<\\e2> agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"buspirone","object":"5-HT1A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with GENE-Y and 5-HT1B receptor agonists [<e1>CHEMICAL<\\e1> (partial <e2>GENE-Y<\\e2> agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test","sentence":"METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test"}
{"PMID":11243491,"re_id":1,"annotated sentence":"METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), <e1>anpirtoline<\\e1> (<e2>5-HT1B<\\e2> agonist)] in the mouse forced swimming test","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"anpirtoline","object":"5-HT1B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and GENE-Y receptor agonists [buspirone (partial 5-HT1A agonist), <e1>CHEMICAL<\\e1> (<e2>GENE-Y<\\e2> agonist)] in the mouse forced swimming test","sentence":"METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test"}
{"PMID":11252887,"re_id":0,"annotated sentence":"<e1>Pemetrexed disodium<\\e1> (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, <e2>dihydrofolate reductase<\\e2>  and glycinamide ribonucleotide formyl transferase","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pemetrexed disodium","object":"dihydrofolate reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, <e2>GENE-Y<\\e2>  and glycinamide ribonucleotide formyl transferase","sentence":"Pemetrexed disodium (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase  and glycinamide ribonucleotide formyl transferase"}
{"PMID":11252887,"re_id":1,"annotated sentence":"<e1>Pemetrexed disodium<\\e1> (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and <e2>glycinamide ribonucleotide formyl transferase<\\e2>  This agent is broadly active in a wide variety of solid tumors, including breast cancer","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pemetrexed disodium","object":"glycinamide ribonucleotide formyl transferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and <e2>GENE-Y<\\e2>  This agent is broadly active in a wide variety of solid tumors, including breast cancer","sentence":"Pemetrexed disodium (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase  This agent is broadly active in a wide variety of solid tumors, including breast cancer"}
{"PMID":11252887,"re_id":2,"annotated sentence":"<e1>Pemetrexed disodium<\\e1> (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits <e2>thymidylate synthase<\\e2>  dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pemetrexed disodium","object":"thymidylate synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits <e2>GENE-Y<\\e2>  dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase","sentence":"Pemetrexed disodium (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase  dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase"}
{"PMID":11252887,"re_id":3,"annotated sentence":"Pemetrexed disodium (<e1>Alimta<\\e1>  LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, <e2>dihydrofolate reductase<\\e2>  and glycinamide ribonucleotide formyl transferase","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Alimta","object":"dihydrofolate reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pemetrexed disodium (<e1>CHEMICAL<\\e1>  LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, <e2>GENE-Y<\\e2>  and glycinamide ribonucleotide formyl transferase","sentence":"Pemetrexed disodium (Alimta  LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase  and glycinamide ribonucleotide formyl transferase"}
{"PMID":11252887,"re_id":4,"annotated sentence":"Pemetrexed disodium (<e1>Alimta<\\e1>  LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and <e2>glycinamide ribonucleotide formyl transferase<\\e2>  This agent is broadly active in a wide variety of solid tumors, including breast cancer","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Alimta","object":"glycinamide ribonucleotide formyl transferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pemetrexed disodium (<e1>CHEMICAL<\\e1>  LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and <e2>GENE-Y<\\e2>  This agent is broadly active in a wide variety of solid tumors, including breast cancer","sentence":"Pemetrexed disodium (Alimta  LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase  This agent is broadly active in a wide variety of solid tumors, including breast cancer"}
{"PMID":11252887,"re_id":5,"annotated sentence":"Pemetrexed disodium (<e1>Alimta<\\e1>  LY231514) is a novel, multitargeted antifolate that inhibits <e2>thymidylate synthase<\\e2>  dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Alimta","object":"thymidylate synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pemetrexed disodium (<e1>CHEMICAL<\\e1>  LY231514) is a novel, multitargeted antifolate that inhibits <e2>GENE-Y<\\e2>  dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase","sentence":"Pemetrexed disodium (Alimta  LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase  dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase"}
{"PMID":11252887,"re_id":6,"annotated sentence":"Pemetrexed disodium (Alimta, <e1>LY231514<\\e1>  is a novel, multitargeted antifolate that inhibits thymidylate synthase, <e2>dihydrofolate reductase<\\e2>  and glycinamide ribonucleotide formyl transferase","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"LY231514","object":"dihydrofolate reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pemetrexed disodium (Alimta, <e1>CHEMICAL<\\e1>  is a novel, multitargeted antifolate that inhibits thymidylate synthase, <e2>GENE-Y<\\e2>  and glycinamide ribonucleotide formyl transferase","sentence":"Pemetrexed disodium (Alimta, LY231514  is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase  and glycinamide ribonucleotide formyl transferase"}
{"PMID":11252887,"re_id":7,"annotated sentence":"Pemetrexed disodium (Alimta, <e1>LY231514<\\e1>  is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and <e2>glycinamide ribonucleotide formyl transferase<\\e2>  This agent is broadly active in a wide variety of solid tumors, including breast cancer","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"LY231514","object":"glycinamide ribonucleotide formyl transferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pemetrexed disodium (Alimta, <e1>CHEMICAL<\\e1>  is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and <e2>GENE-Y<\\e2>  This agent is broadly active in a wide variety of solid tumors, including breast cancer","sentence":"Pemetrexed disodium (Alimta, LY231514  is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase  This agent is broadly active in a wide variety of solid tumors, including breast cancer"}
{"PMID":11252887,"re_id":8,"annotated sentence":"Pemetrexed disodium (Alimta, <e1>LY231514<\\e1>  is a novel, multitargeted antifolate that inhibits <e2>thymidylate synthase<\\e2>  dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"LY231514","object":"thymidylate synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pemetrexed disodium (Alimta, <e1>CHEMICAL<\\e1>  is a novel, multitargeted antifolate that inhibits <e2>GENE-Y<\\e2>  dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase","sentence":"Pemetrexed disodium (Alimta, LY231514  is a novel, multitargeted antifolate that inhibits thymidylate synthase  dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase"}
{"PMID":11304699,"re_id":0,"annotated sentence":"To mechanistically evaluate this regional selectivity, we assessed <e2>cyclo-oxygenase-2<\\e2> (COX-2) expression in the uninvolved mucosa and demonstrated a 3- to 4-fold excess in the distal relative to the proximal bowel in both MIN mice and <e1>AOM<\\e1> treated rats","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"AOM","object":"cyclo-oxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"To mechanistically evaluate this regional selectivity, we assessed <e2>GENE-N<\\e2> (COX-2) expression in the uninvolved mucosa and demonstrated a 3- to 4-fold excess in the distal relative to the proximal bowel in both MIN mice and <e1>CHEMICAL<\\e1> treated rats","sentence":"To mechanistically evaluate this regional selectivity, we assessed cyclo-oxygenase-2 (COX-2) expression in the uninvolved mucosa and demonstrated a 3- to 4-fold excess in the distal relative to the proximal bowel in both MIN mice and AOM treated rats"}
{"PMID":11304699,"re_id":1,"annotated sentence":"To mechanistically evaluate this regional selectivity, we assessed cyclo-oxygenase-2 (<e2>COX-2<\\e2>  expression in the uninvolved mucosa and demonstrated a 3- to 4-fold excess in the distal relative to the proximal bowel in both MIN mice and <e1>AOM<\\e1> treated rats","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"AOM","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"To mechanistically evaluate this regional selectivity, we assessed cyclo-oxygenase-2 (<e2>GENE-N<\\e2>  expression in the uninvolved mucosa and demonstrated a 3- to 4-fold excess in the distal relative to the proximal bowel in both MIN mice and <e1>CHEMICAL<\\e1> treated rats","sentence":"To mechanistically evaluate this regional selectivity, we assessed cyclo-oxygenase-2 (COX-2  expression in the uninvolved mucosa and demonstrated a 3- to 4-fold excess in the distal relative to the proximal bowel in both MIN mice and AOM treated rats"}
{"PMID":11309392,"re_id":0,"annotated sentence":"We took advantage of the previous observations that <e1>phosphatidylserine<\\e1> inhibits <e2>DGK-delta<\\e2> (reviewed by Sakane, F., Imai, S., Kai, M., Wada, I., and Kanoh, H","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phosphatidylserine","object":"DGK-delta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We took advantage of the previous observations that <e1>CHEMICAL<\\e1> inhibits <e2>GENE-Y<\\e2> (reviewed by Sakane, F., Imai, S., Kai, M., Wada, I., and Kanoh, H","sentence":"We took advantage of the previous observations that phosphatidylserine inhibits DGK-delta (reviewed by Sakane, F., Imai, S., Kai, M., Wada, I., and Kanoh, H"}
{"PMID":11309392,"re_id":1,"annotated sentence":"<e2>Diacylglycerol kinase<\\e2> (DGK) catalyzes the conversion of <e1>diacylglycerol<\\e1> to phosphatidic acid, making it an attractive candidate for a signal transduction component","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"diacylglycerol","object":"Diacylglycerol kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> (DGK) catalyzes the conversion of <e1>CHEMICAL<\\e1> to phosphatidic acid, making it an attractive candidate for a signal transduction component","sentence":"Diacylglycerol kinase (DGK) catalyzes the conversion of diacylglycerol to phosphatidic acid, making it an attractive candidate for a signal transduction component"}
{"PMID":11309392,"re_id":2,"annotated sentence":"Diacylglycerol kinase (<e2>DGK<\\e2>  catalyzes the conversion of <e1>diacylglycerol<\\e1> to phosphatidic acid, making it an attractive candidate for a signal transduction component","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"diacylglycerol","object":"DGK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Diacylglycerol kinase (<e2>GENE-N<\\e2>  catalyzes the conversion of <e1>CHEMICAL<\\e1> to phosphatidic acid, making it an attractive candidate for a signal transduction component","sentence":"Diacylglycerol kinase (DGK  catalyzes the conversion of diacylglycerol to phosphatidic acid, making it an attractive candidate for a signal transduction component"}
{"PMID":11309392,"re_id":3,"annotated sentence":"<e2>Diacylglycerol kinase<\\e2> (DGK) catalyzes the conversion of diacylglycerol to <e1>phosphatidic acid<\\e1>  making it an attractive candidate for a signal transduction component","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"phosphatidic acid","object":"Diacylglycerol kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> (DGK) catalyzes the conversion of diacylglycerol to <e1>CHEMICAL<\\e1>  making it an attractive candidate for a signal transduction component","sentence":"Diacylglycerol kinase (DGK) catalyzes the conversion of diacylglycerol to phosphatidic acid  making it an attractive candidate for a signal transduction component"}
{"PMID":11309392,"re_id":4,"annotated sentence":"Diacylglycerol kinase (<e2>DGK<\\e2>  catalyzes the conversion of diacylglycerol to <e1>phosphatidic acid<\\e1>  making it an attractive candidate for a signal transduction component","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"phosphatidic acid","object":"DGK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Diacylglycerol kinase (<e2>GENE-N<\\e2>  catalyzes the conversion of diacylglycerol to <e1>CHEMICAL<\\e1>  making it an attractive candidate for a signal transduction component","sentence":"Diacylglycerol kinase (DGK  catalyzes the conversion of diacylglycerol to phosphatidic acid  making it an attractive candidate for a signal transduction component"}
{"PMID":11318430,"re_id":0,"annotated sentence":"<e1>Nordihydroguaiaretic acid<\\e1> (NDGA) has been shown to inhibit both 5-lipoxygenase and <e2>ornithine decarboxylase<\\e2> and is active against several cancer cell lines and at least one mouse tumor model","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Nordihydroguaiaretic acid","object":"ornithine decarboxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (NDGA) has been shown to inhibit both 5-lipoxygenase and <e2>GENE-Y<\\e2> and is active against several cancer cell lines and at least one mouse tumor model","sentence":"Nordihydroguaiaretic acid (NDGA) has been shown to inhibit both 5-lipoxygenase and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model"}
{"PMID":11318430,"re_id":1,"annotated sentence":"<e1>Nordihydroguaiaretic acid<\\e1> (NDGA) has been shown to inhibit both <e2>5-lipoxygenase<\\e2> and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Nordihydroguaiaretic acid","object":"5-lipoxygenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (NDGA) has been shown to inhibit both <e2>GENE-Y<\\e2> and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model","sentence":"Nordihydroguaiaretic acid (NDGA) has been shown to inhibit both 5-lipoxygenase and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model"}
{"PMID":11318430,"re_id":2,"annotated sentence":"Nordihydroguaiaretic acid (<e1>NDGA<\\e1>  has been shown to inhibit both 5-lipoxygenase and <e2>ornithine decarboxylase<\\e2> and is active against several cancer cell lines and at least one mouse tumor model","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NDGA","object":"ornithine decarboxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Nordihydroguaiaretic acid (<e1>CHEMICAL<\\e1>  has been shown to inhibit both 5-lipoxygenase and <e2>GENE-Y<\\e2> and is active against several cancer cell lines and at least one mouse tumor model","sentence":"Nordihydroguaiaretic acid (NDGA  has been shown to inhibit both 5-lipoxygenase and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model"}
{"PMID":11318430,"re_id":3,"annotated sentence":"Nordihydroguaiaretic acid (<e1>NDGA<\\e1>  has been shown to inhibit both <e2>5-lipoxygenase<\\e2> and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NDGA","object":"5-lipoxygenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Nordihydroguaiaretic acid (<e1>CHEMICAL<\\e1>  has been shown to inhibit both <e2>GENE-Y<\\e2> and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model","sentence":"Nordihydroguaiaretic acid (NDGA  has been shown to inhibit both 5-lipoxygenase and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model"}
{"PMID":11392054,"re_id":0,"annotated sentence":"<e2>Carbonic anhydrase<\\e2> (CA) is a zinc enzyme that catalyses the reversible hydration reaction of <e1>CO2<\\e1> and plays a major role in the acid-base balance","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"CO2","object":"Carbonic anhydrase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> (CA) is a zinc enzyme that catalyses the reversible hydration reaction of <e1>CHEMICAL<\\e1> and plays a major role in the acid-base balance","sentence":"Carbonic anhydrase (CA) is a zinc enzyme that catalyses the reversible hydration reaction of CO2 and plays a major role in the acid-base balance"}
{"PMID":11392054,"re_id":1,"annotated sentence":"Carbonic anhydrase (<e2>CA<\\e2>  is a zinc enzyme that catalyses the reversible hydration reaction of <e1>CO2<\\e1> and plays a major role in the acid-base balance","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"CO2","object":"CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Carbonic anhydrase (<e2>GENE-N<\\e2>  is a zinc enzyme that catalyses the reversible hydration reaction of <e1>CHEMIGENE-NL<\\e1> and plays a major role in the acid-base balance","sentence":"Carbonic anhydrase (CA  is a zinc enzyme that catalyses the reversible hydration reaction of CO2 and plays a major role in the acid-base balance"}
{"PMID":11393267,"re_id":0,"annotated sentence":"The temporal profile of butyrylcholinesterase (BuChE) and in vitro <e1>pralidoxime<\\e1> reactivated <e2>BuChE<\\e2> was studied in a cohort of 25 organophosphate-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of oxime treatment","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"pralidoxime","object":"BuChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The temporal profile of butyrylcholinesterase (GENE-Y) and in vitro <e1>CHEMICAL<\\e1> reactivated <e2>GENE-Y<\\e2> was studied in a cohort of 25 organophosphate-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of oxime treatment","sentence":"The temporal profile of butyrylcholinesterase (BuChE) and in vitro pralidoxime reactivated BuChE was studied in a cohort of 25 organophosphate-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of oxime treatment"}
{"PMID":11393267,"re_id":1,"annotated sentence":"Reactivation potentials of <e2>BuChE<\\e2> (the difference between <e1>oxime<\\e1> reactivated and -unreactivated enzyme activity) declined significantly with time after organophosphate ingestion","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"oxime","object":"BuChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reactivation potentials of <e2>GENE-Y<\\e2> (the difference between <e1>CHEMICAL<\\e1> reactivated and -unreactivated enzyme activity) declined significantly with time after organophosphate ingestion","sentence":"Reactivation potentials of BuChE (the difference between oxime reactivated and -unreactivated enzyme activity) declined significantly with time after organophosphate ingestion"}
{"PMID":11393267,"re_id":2,"annotated sentence":"Patients who received <e1>oxime<\\e1> prior to hospitalization had a higher rate of intermediate syndrome and lower levels of <e2>BuChE<\\e2> at admission than those who had not","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"oxime","object":"BuChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Patients who received <e1>CHEMICAL<\\e1> prior to hospitalization had a higher rate of intermediate syndrome and lower levels of <e2>GENE-Y<\\e2> at admission than those who had not","sentence":"Patients who received oxime prior to hospitalization had a higher rate of intermediate syndrome and lower levels of BuChE at admission than those who had not"}
{"PMID":11393267,"re_id":3,"annotated sentence":"Reactivation potentials of <e2>BuChE<\\e2> (the difference between oxime-reactivated and -unreactivated enzyme activity) declined significantly with time after <e1>organophosphate<\\e1> ingestion","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"organophosphate","object":"BuChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reactivation potentials of <e2>GENE-Y<\\e2> (the difference between oxime-reactivated and -unreactivated enzyme activity) declined significantly with time after <e1>CHEMICAL<\\e1> ingestion","sentence":"Reactivation potentials of BuChE (the difference between oxime-reactivated and -unreactivated enzyme activity) declined significantly with time after organophosphate ingestion"}
{"PMID":11481271,"re_id":0,"annotated sentence":"CONCLUSIONS: The <e2>alpha(2)-adrenoceptor<\\e2> agonists <e1>brimonidine<\\e1>  apraclonidine, and oxymetazoline are potent vasoconstrictors in the porcine ciliary artery","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"brimonidine","object":"alpha(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"CONCLUSIONS: The <e2>GENE-N<\\e2> agonists <e1>CHEMICAL<\\e1>  apraclonidine, and oxymetazoline are potent vasoconstrictors in the porcine ciliary artery","sentence":"CONCLUSIONS: The alpha(2)-adrenoceptor agonists brimonidine  apraclonidine, and oxymetazoline are potent vasoconstrictors in the porcine ciliary artery"}
{"PMID":11481271,"re_id":1,"annotated sentence":"CONCLUSIONS: The <e2>alpha(2)-adrenoceptor<\\e2> agonists brimonidine, <e1>apraclonidine<\\e1>  and oxymetazoline are potent vasoconstrictors in the porcine ciliary artery","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"apraclonidine","object":"alpha(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"CONCLUSIONS: The <e2>GENE-N<\\e2> agonists brimonidine, <e1>CHEMICAL<\\e1>  and oxymetazoline are potent vasoconstrictors in the porcine ciliary artery","sentence":"CONCLUSIONS: The alpha(2)-adrenoceptor agonists brimonidine, apraclonidine  and oxymetazoline are potent vasoconstrictors in the porcine ciliary artery"}
{"PMID":11481271,"re_id":2,"annotated sentence":"CONCLUSIONS: The <e2>alpha(2)-adrenoceptor<\\e2> agonists brimonidine, apraclonidine, and <e1>oxymetazoline<\\e1> are potent vasoconstrictors in the porcine ciliary artery","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"oxymetazoline","object":"alpha(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"CONCLUSIONS: The <e2>GENE-N<\\e2> agonists brimonidine, apraclonidine, and <e1>CHEMICAL<\\e1> are potent vasoconstrictors in the porcine ciliary artery","sentence":"CONCLUSIONS: The alpha(2)-adrenoceptor agonists brimonidine, apraclonidine, and oxymetazoline are potent vasoconstrictors in the porcine ciliary artery"}
{"PMID":11481271,"re_id":3,"annotated sentence":"The segments were contracted with the <e2>alpha(2)-adrenoceptor<\\e2> agonists <e1>brimonidine<\\e1>  apraclonidine, and oxymetazoline","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"brimonidine","object":"alpha(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The segments were contracted with the <e2>GENE-N<\\e2> agonists <e1>CHEMICAL<\\e1>  apraclonidine, and oxymetazoline","sentence":"The segments were contracted with the alpha(2)-adrenoceptor agonists brimonidine  apraclonidine, and oxymetazoline"}
{"PMID":11481271,"re_id":4,"annotated sentence":"The segments were contracted with the <e2>alpha(2)-adrenoceptor<\\e2> agonists brimonidine, <e1>apraclonidine<\\e1>  and oxymetazoline","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"apraclonidine","object":"alpha(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The segments were contracted with the <e2>GENE-N<\\e2> agonists brimonidine, <e1>CHEMICAL<\\e1>  and oxymetazoline","sentence":"The segments were contracted with the alpha(2)-adrenoceptor agonists brimonidine, apraclonidine  and oxymetazoline"}
{"PMID":11481271,"re_id":5,"annotated sentence":"The segments were contracted with the <e2>alpha(2)-adrenoceptor<\\e2> agonists brimonidine, apraclonidine, and <e1>oxymetazoline<\\e1>  To determine which subtypes of the alpha(2)-adrenoceptor mediate this contraction, antagonists subselective for the different alpha(2)-adrenoceptors were added to the vessel bath before concentration-response curves for brimonidine were obtained","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"oxymetazoline","object":"alpha(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The segments were contracted with the <e2>GENE-N<\\e2> agonists brimonidine, apraclonidine, and <e1>CHEMICAL<\\e1>  To determine which subtypes of the GENE-N mediate this contraction, antagonists subselective for the different GENE-Ns were added to the vessel bath before concentration-response curves for brimonidine were obtained","sentence":"The segments were contracted with the alpha(2)-adrenoceptor agonists brimonidine, apraclonidine, and oxymetazoline  To determine which subtypes of the alpha(2)-adrenoceptor mediate this contraction, antagonists subselective for the different alpha(2)-adrenoceptors were added to the vessel bath before concentration-response curves for brimonidine were obtained"}
{"PMID":11481271,"re_id":6,"annotated sentence":"RESULTS: The <e2>alpha(2)-adrenoceptor<\\e2> agonists induced vasoconstriction in the porcine ciliary artery with the following potency order (EC(50)) expressed in nanomolar: <e1>brimonidine<\\e1> 2.11, oxymetazoline 5.26, and apraclonidine 13.0","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"brimonidine","object":"alpha(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"RESULTS: The <e2>GENE-N<\\e2> agonists induced vasoconstriction in the porcine ciliary artery with the following potency order (EC(50)) expressed in nanomolar: <e1>CHEMICAL<\\e1> 2.11, oxymetazoline 5.26, and apraclonidine 13.0","sentence":"RESULTS: The alpha(2)-adrenoceptor agonists induced vasoconstriction in the porcine ciliary artery with the following potency order (EC(50)) expressed in nanomolar: brimonidine 2.11, oxymetazoline 5.26, and apraclonidine 13.0"}
{"PMID":11481271,"re_id":7,"annotated sentence":"RESULTS: The <e2>alpha(2)-adrenoceptor<\\e2> agonists induced vasoconstriction in the porcine ciliary artery with the following potency order (EC(50)) expressed in nanomolar: brimonidine 2.11, <e1>oxymetazoline<\\e1> 5.26, and apraclonidine 13.0","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"oxymetazoline","object":"alpha(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"RESULTS: The <e2>GENE-N<\\e2> agonists induced vasoconstriction in the porcine ciliary artery with the following potency order (EC(50)) expressed in nanomolar: brimonidine 2.11, <e1>CHEMICAL<\\e1> 5.26, and apraclonidine 13.0","sentence":"RESULTS: The alpha(2)-adrenoceptor agonists induced vasoconstriction in the porcine ciliary artery with the following potency order (EC(50)) expressed in nanomolar: brimonidine 2.11, oxymetazoline 5.26, and apraclonidine 13.0"}
{"PMID":11481271,"re_id":8,"annotated sentence":"RESULTS: The <e2>alpha(2)-adrenoceptor<\\e2> agonists induced vasoconstriction in the porcine ciliary artery with the following potency order (EC(50)) expressed in nanomolar: brimonidine 2.11, oxymetazoline 5.26, and <e1>apraclonidine<\\e1> 13.0","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"apraclonidine","object":"alpha(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"RESULTS: The <e2>GENE-N<\\e2> agonists induced vasoconstriction in the porcine ciliary artery with the following potency order (EC(50)) expressed in nanomolar: brimonidine 2.11, oxymetazoline 5.26, and <e1>CHEMICAL<\\e1> 13.0","sentence":"RESULTS: The alpha(2)-adrenoceptor agonists induced vasoconstriction in the porcine ciliary artery with the following potency order (EC(50)) expressed in nanomolar: brimonidine 2.11, oxymetazoline 5.26, and apraclonidine 13.0"}
{"PMID":11481271,"re_id":9,"annotated sentence":"Schild analyses for the antagonists against brimonidine yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for <e1>BRL44408<\\e1> (7.8), ARC 239 (5.8) and for prazosin (6.0) suggesting the presence of functional <e2>alpha(2A)-adrenoceptors<\\e2>  Moreover, there was a good correlation of pK(B) with ligand-binding affinity (pK(i)) of the alpha(2A)-adrenoceptor in the porcine eye tissue","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"BRL44408","object":"alpha(2A)-adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Schild analyses for the antagonists against brimonidine yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for <e1>CHEMICAL<\\e1> (7.8), ARC 239 (5.8) and for prazosin (6.0) suggesting the presence of functional <e2>GENE-Y<\\e2>  Moreover, there was a good correlation of pK(B) with ligand-binding affinity (pK(i)) of the alpha(2A)-adrenoceptor in the porcine eye tissue","sentence":"Schild analyses for the antagonists against brimonidine yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for BRL44408 (7.8), ARC 239 (5.8) and for prazosin (6.0) suggesting the presence of functional alpha(2A)-adrenoceptors  Moreover, there was a good correlation of pK(B) with ligand-binding affinity (pK(i)) of the alpha(2A)-adrenoceptor in the porcine eye tissue"}
{"PMID":11481271,"re_id":10,"annotated sentence":"Schild analyses for the antagonists against brimonidine yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for BRL44408 (7.8), <e1>ARC 239<\\e1> (5.8) and for prazosin (6.0) suggesting the presence of functional <e2>alpha(2A)-adrenoceptors<\\e2>  Moreover, there was a good correlation of pK(B) with ligand-binding affinity (pK(i)) of the alpha(2A)-adrenoceptor in the porcine eye tissue","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"ARC 239","object":"alpha(2A)-adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Schild analyses for the antagonists against brimonidine yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for BRL44408 (7.8), <e1>CHEMICAL<\\e1> (5.8) and for prazosin (6.0) suggesting the presence of functional <e2>GENE-Y<\\e2>  Moreover, there was a good correlation of pK(B) with ligand-binding affinity (pK(i)) of the alpha(2A)-adrenoceptor in the porcine eye tissue","sentence":"Schild analyses for the antagonists against brimonidine yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for BRL44408 (7.8), ARC 239 (5.8) and for prazosin (6.0) suggesting the presence of functional alpha(2A)-adrenoceptors  Moreover, there was a good correlation of pK(B) with ligand-binding affinity (pK(i)) of the alpha(2A)-adrenoceptor in the porcine eye tissue"}
{"PMID":11481271,"re_id":11,"annotated sentence":"Schild analyses for the antagonists against brimonidine yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for BRL44408 (7.8), ARC 239 (5.8) and for <e1>prazosin<\\e1> (6.0) suggesting the presence of functional <e2>alpha(2A)-adrenoceptors<\\e2>  Moreover, there was a good correlation of pK(B) with ligand-binding affinity (pK(i)) of the alpha(2A)-adrenoceptor in the porcine eye tissue","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"prazosin","object":"alpha(2A)-adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Schild analyses for the antagonists against brimonidine yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for BRL44408 (7.8), ARC 239 (5.8) and for <e1>CHEMICAL<\\e1> (6.0) suggesting the presence of functional <e2>GENE-Y<\\e2>  Moreover, there was a good correlation of pK(B) with ligand-binding affinity (pK(i)) of the alpha(2A)-adrenoceptor in the porcine eye tissue","sentence":"Schild analyses for the antagonists against brimonidine yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for BRL44408 (7.8), ARC 239 (5.8) and for prazosin (6.0) suggesting the presence of functional alpha(2A)-adrenoceptors  Moreover, there was a good correlation of pK(B) with ligand-binding affinity (pK(i)) of the alpha(2A)-adrenoceptor in the porcine eye tissue"}
{"PMID":11481271,"re_id":12,"annotated sentence":"The following alpha(2)-adrenoceptor antagonists were applied: <e1>BRL44408<\\e1> (<e2>alpha(2A)<\\e2> selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and prazosin (alpha(2B)- and alpha(2C)-selective)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"BRL44408","object":"alpha(2A)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The following alpha(2)-adrenoceptor antagonists were applied: <e1>CHEMICAL<\\e1> (<e2>GENE-Y<\\e2> selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and prazosin (alpha(2B)- and alpha(2C)-selective)","sentence":"The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A) selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and prazosin (alpha(2B)- and alpha(2C)-selective)"}
{"PMID":11481271,"re_id":13,"annotated sentence":"The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), <e1>ARC239<\\e1> (<e2>alpha(2B)<\\e2>  and alpha(2C)-selective), and prazosin (alpha(2B)- and alpha(2C)-selective)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"ARC239","object":"alpha(2B)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), <e1>CHEMICAL<\\e1> (<e2>GENE-Y<\\e2>  and alpha(2C)-selective), and prazosin (GENE-Y- and alpha(2C)-selective)","sentence":"The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), ARC239 (alpha(2B)  and alpha(2C)-selective), and prazosin (alpha(2B)- and alpha(2C)-selective)"}
{"PMID":11481271,"re_id":14,"annotated sentence":"The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), <e1>ARC239<\\e1> (alpha(2B)- and <e2>alpha(2C)<\\e2> selective), and prazosin (alpha(2B)- and alpha(2C)-selective)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"ARC239","object":"alpha(2C)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), <e1>CHEMICAL<\\e1> (alpha(2B)- and <e2>GENE-Y<\\e2> selective), and prazosin (alpha(2B)- and GENE-Y-selective)","sentence":"The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), ARC239 (alpha(2B)- and alpha(2C) selective), and prazosin (alpha(2B)- and alpha(2C)-selective)"}
{"PMID":11481271,"re_id":15,"annotated sentence":"The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and <e1>prazosin<\\e1> (<e2>alpha(2B)<\\e2>  and alpha(2C)-selective)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"prazosin","object":"alpha(2B)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), ARC239 (GENE-Y- and alpha(2C)-selective), and <e1>CHEMICAL<\\e1> (<e2>GENE-Y<\\e2>  and alpha(2C)-selective)","sentence":"The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and prazosin (alpha(2B)  and alpha(2C)-selective)"}
{"PMID":11481271,"re_id":16,"annotated sentence":"The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and <e1>prazosin<\\e1> (alpha(2B)- and <e2>alpha(2C)<\\e2> selective)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"prazosin","object":"alpha(2C)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), ARC239 (alpha(2B)- and GENE-Y-selective), and <e1>CHEMICAL<\\e1> (alpha(2B)- and <e2>GENE-Y<\\e2> selective)","sentence":"The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and prazosin (alpha(2B)- and alpha(2C) selective)"}
{"PMID":11742712,"re_id":0,"annotated sentence":"<e1>Pemetrexed disodium<\\e1> (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, <e2>thymidylate synthase<\\e2>  dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pemetrexed disodium","object":"thymidylate synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, <e2>GENE-Y<\\e2>  dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase","sentence":"Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase  dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase"}
{"PMID":11742712,"re_id":1,"annotated sentence":"<e1>Pemetrexed disodium<\\e1> (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, <e2>dihydrofolate reductase<\\e2>  and glycinamide ribonucleotide formyltransferase","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pemetrexed disodium","object":"dihydrofolate reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, <e2>GENE-Y<\\e2>  and glycinamide ribonucleotide formyltransferase","sentence":"Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, dihydrofolate reductase  and glycinamide ribonucleotide formyltransferase"}
{"PMID":11742712,"re_id":2,"annotated sentence":"<e1>Pemetrexed disodium<\\e1> (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, dihydrofolate reductase, and <e2>glycinamide ribonucleotide formyltransferase<\\e2>  Pemetrexed disodium is broadly active in a wide variety of solid tumours, including non-small cell lung, breast, bladder, head and neck and ovarian cancers","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pemetrexed disodium","object":"glycinamide ribonucleotide formyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, dihydrofolate reductase, and <e2>GENE-Y<\\e2>  CHEMICAL is broadly active in a wide variety of solid tumours, including non-small cell lung, breast, bladder, head and neck and ovarian cancers","sentence":"Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase  Pemetrexed disodium is broadly active in a wide variety of solid tumours, including non-small cell lung, breast, bladder, head and neck and ovarian cancers"}
{"PMID":11742712,"re_id":3,"annotated sentence":"Pemetrexed disodium (<e1>ALIMTA<\\e1>  is a novel antimetabolite that inhibits at least three folate-dependent enzymes, <e2>thymidylate synthase<\\e2>  dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ALIMTA","object":"thymidylate synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pemetrexed disodium (<e1>CHEMICAL<\\e1>  is a novel antimetabolite that inhibits at least three folate-dependent enzymes, <e2>GENE-Y<\\e2>  dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase","sentence":"Pemetrexed disodium (ALIMTA  is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase  dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase"}
{"PMID":11742712,"re_id":4,"annotated sentence":"Pemetrexed disodium (<e1>ALIMTA<\\e1>  is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, <e2>dihydrofolate reductase<\\e2>  and glycinamide ribonucleotide formyltransferase","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ALIMTA","object":"dihydrofolate reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pemetrexed disodium (<e1>CHEMICAL<\\e1>  is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, <e2>GENE-Y<\\e2>  and glycinamide ribonucleotide formyltransferase","sentence":"Pemetrexed disodium (ALIMTA  is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, dihydrofolate reductase  and glycinamide ribonucleotide formyltransferase"}
{"PMID":11742712,"re_id":5,"annotated sentence":"Pemetrexed disodium (<e1>ALIMTA<\\e1>  is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, dihydrofolate reductase, and <e2>glycinamide ribonucleotide formyltransferase<\\e2>  Pemetrexed disodium is broadly active in a wide variety of solid tumours, including non-small cell lung, breast, bladder, head and neck and ovarian cancers","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ALIMTA","object":"glycinamide ribonucleotide formyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pemetrexed disodium (<e1>CHEMICAL<\\e1>  is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, dihydrofolate reductase, and <e2>GENE-Y<\\e2>  Pemetrexed disodium is broadly active in a wide variety of solid tumours, including non-small cell lung, breast, bladder, head and neck and ovarian cancers","sentence":"Pemetrexed disodium (ALIMTA  is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase  Pemetrexed disodium is broadly active in a wide variety of solid tumours, including non-small cell lung, breast, bladder, head and neck and ovarian cancers"}
{"PMID":11752472,"re_id":0,"annotated sentence":"<e2>DHFS<\\e2> is present exclusively in the mitochondria, making this compartment the sole site of synthesis of <e1>dihydrofolate<\\e1> in the plant cell","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"dihydrofolate","object":"DHFS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> is present exclusively in the mitochondria, making this compartment the sole site of synthesis of <e1>CHEMICAL<\\e1> in the plant cell","sentence":"DHFS is present exclusively in the mitochondria, making this compartment the sole site of synthesis of dihydrofolate in the plant cell"}
{"PMID":11772142,"re_id":0,"annotated sentence":"CONCLUSION: <e1>Rabeprazole<\\e1> is a well tolerated <e2>proton pump<\\e2> inhibitor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Rabeprazole","object":"proton pump","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"CONCLUSION: <e1>CHEMICAL<\\e1> is a well tolerated <e2>GENE-N<\\e2> inhibitor","sentence":"CONCLUSION: Rabeprazole is a well tolerated proton pump inhibitor"}
{"PMID":11772142,"re_id":1,"annotated sentence":"UNLABELLED: <e1>Rabeprazole<\\e1> is an inhibitor of the <e2>gastric proton pump<\\e2>  It causes dose-dependent inhibition of acid secretion","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Rabeprazole","object":"gastric proton pump","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"UNLABELLED: <e1>CHEMICAL<\\e1> is an inhibitor of the <e2>GENE-N<\\e2>  It causes dose-dependent inhibition of acid secretion","sentence":"UNLABELLED: Rabeprazole is an inhibitor of the gastric proton pump  It causes dose-dependent inhibition of acid secretion"}
{"PMID":11799102,"re_id":0,"annotated sentence":"At the same time, mean plasma active <e2>renin<\\e2> was increased 16- and 34-fold at the highest dose of <e1>Aliskiren<\\e1>  Plasma drug levels of Aliskiren were dose-dependent with maximal concentrations reached between 3 to 6 hours after administration; steady state was reached between 5 and 8 days after multiple dosing","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Aliskiren","object":"renin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"At the same time, mean plasma active <e2>GENE-Y<\\e2> was increased 16- and 34-fold at the highest dose of <e1>CHEMICAL<\\e1>  Plasma drug levels of CHEMICAL were dose-dependent with maximal concentrations reached between 3 to 6 hours after administration; steady state was reached between 5 and 8 days after multiple dosing","sentence":"At the same time, mean plasma active renin was increased 16- and 34-fold at the highest dose of Aliskiren  Plasma drug levels of Aliskiren were dose-dependent with maximal concentrations reached between 3 to 6 hours after administration; steady state was reached between 5 and 8 days after multiple dosing"}
{"PMID":11799102,"re_id":1,"annotated sentence":"In conclusion, the <e2>renin<\\e2> inhibitor <e1>Aliskiren<\\e1> dose-dependently decreases Ang II levels in humans following oral administration","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Aliskiren","object":"renin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, the <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1> dose-dependently decreases Ang II levels in humans following oral administration","sentence":"In conclusion, the renin inhibitor Aliskiren dose-dependently decreases Ang II levels in humans following oral administration"}
{"PMID":11799102,"re_id":2,"annotated sentence":"In conclusion, the renin inhibitor <e1>Aliskiren<\\e1> dose-dependently decreases <e2>Ang II<\\e2> levels in humans following oral administration","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Aliskiren","object":"Ang II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, the renin inhibitor <e1>CHEMICAL<\\e1> dose-dependently decreases <e2>GENE-Y<\\e2> levels in humans following oral administration","sentence":"In conclusion, the renin inhibitor Aliskiren dose-dependently decreases Ang II levels in humans following oral administration"}
{"PMID":11799102,"re_id":3,"annotated sentence":"<e1>Aliskiren<\\e1> has the potential to become the first orally active <e2>renin<\\e2> inhibitor that provides a true alternative to ACE-inhibitors and Ang II receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Aliskiren","object":"renin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> has the potential to become the first orally active <e2>GENE-Y<\\e2> inhibitor that provides a true alternative to ACE-inhibitors and Ang II receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases.","sentence":"Aliskiren has the potential to become the first orally active renin inhibitor that provides a true alternative to ACE-inhibitors and Ang II receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases."}
{"PMID":11799102,"re_id":4,"annotated sentence":"<e1>Aliskiren<\\e1> has the potential to become the first orally active renin inhibitor that provides a true alternative to <e2>ACE<\\e2> inhibitors and Ang II receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Aliskiren","object":"ACE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> has the potential to become the first orally active renin inhibitor that provides a true alternative to <e2>GENE-Y<\\e2> inhibitors and Ang II receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases.","sentence":"Aliskiren has the potential to become the first orally active renin inhibitor that provides a true alternative to ACE inhibitors and Ang II receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases."}
{"PMID":11799102,"re_id":5,"annotated sentence":"We tested the new orally active nonpeptidic <e2>renin<\\e2> inhibitor <e1>SPP100<\\e1> (Aliskiren, an octanamide with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol\/d sodium diet using a double-blind, 3-way crossover protocol","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SPP100","object":"renin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We tested the new orally active nonpeptidic <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1> (Aliskiren, an octanamide with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol\/d sodium diet using a double-blind, 3-way crossover protocol","sentence":"We tested the new orally active nonpeptidic renin inhibitor SPP100 (Aliskiren, an octanamide with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol\/d sodium diet using a double-blind, 3-way crossover protocol"}
{"PMID":11799102,"re_id":6,"annotated sentence":"We tested the new orally active nonpeptidic <e2>renin<\\e2> inhibitor SPP100 (<e1>Aliskiren<\\e1>  an octanamide with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol\/d sodium diet using a double-blind, 3-way crossover protocol","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Aliskiren","object":"renin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We tested the new orally active nonpeptidic <e2>GENE-Y<\\e2> inhibitor SPP100 (<e1>CHEMICAL<\\e1>  an octanamide with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol\/d sodium diet using a double-blind, 3-way crossover protocol","sentence":"We tested the new orally active nonpeptidic renin inhibitor SPP100 (Aliskiren  an octanamide with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol\/d sodium diet using a double-blind, 3-way crossover protocol"}
{"PMID":11799102,"re_id":7,"annotated sentence":"We tested the new orally active nonpeptidic <e2>renin<\\e2> inhibitor SPP100 (Aliskiren, an <e1>octanamide<\\e1> with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol\/d sodium diet using a double-blind, 3-way crossover protocol","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"octanamide","object":"renin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We tested the new orally active nonpeptidic <e2>GENE-Y<\\e2> inhibitor SPP100 (Aliskiren, an <e1>CHEMICAL<\\e1> with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol\/d sodium diet using a double-blind, 3-way crossover protocol","sentence":"We tested the new orally active nonpeptidic renin inhibitor SPP100 (Aliskiren, an octanamide with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol\/d sodium diet using a double-blind, 3-way crossover protocol"}
{"PMID":11799102,"re_id":8,"annotated sentence":"There was a dose-dependent decrease in plasma <e2>renin<\\e2> activity, Ang I, and Ang II following single doses of <e1>Aliskiren<\\e1> starting with 40 mg","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Aliskiren","object":"renin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"There was a dose-dependent decrease in plasma <e2>GENE-Y<\\e2> activity, Ang I, and Ang II following single doses of <e1>CHEMICAL<\\e1> starting with 40 mg","sentence":"There was a dose-dependent decrease in plasma renin activity, Ang I, and Ang II following single doses of Aliskiren starting with 40 mg"}
{"PMID":11799102,"re_id":9,"annotated sentence":"There was a dose-dependent decrease in plasma renin activity, <e2>Ang I<\\e2>  and Ang II following single doses of <e1>Aliskiren<\\e1> starting with 40 mg","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Aliskiren","object":"Ang I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"There was a dose-dependent decrease in plasma renin activity, <e2>GENE-Y<\\e2>  and GENE-YI following single doses of <e1>CHEMICAL<\\e1> starting with 40 mg","sentence":"There was a dose-dependent decrease in plasma renin activity, Ang I  and Ang II following single doses of Aliskiren starting with 40 mg"}
{"PMID":11799102,"re_id":10,"annotated sentence":"There was a dose-dependent decrease in plasma renin activity, Ang I, and <e2>Ang II<\\e2> following single doses of <e1>Aliskiren<\\e1> starting with 40 mg","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Aliskiren","object":"Ang II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"There was a dose-dependent decrease in plasma renin activity, Ang I, and <e2>GENE-Y<\\e2> following single doses of <e1>CHEMICAL<\\e1> starting with 40 mg","sentence":"There was a dose-dependent decrease in plasma renin activity, Ang I, and Ang II following single doses of Aliskiren starting with 40 mg"}
{"PMID":11799102,"re_id":11,"annotated sentence":"<e2>Angiotensin II<\\e2> suppression in humans by the orally active renin inhibitor <e1>Aliskiren<\\e1> (SPP100): comparison with enalapril","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Aliskiren","object":"Angiotensin II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> suppression in humans by the orally active renin inhibitor <e1>CHEMICAL<\\e1> (SPP100): comparison with enalapril","sentence":"Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril"}
{"PMID":11799102,"re_id":12,"annotated sentence":"Angiotensin II suppression in humans by the orally active <e2>renin<\\e2> inhibitor <e1>Aliskiren<\\e1> (SPP100): comparison with enalapril","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Aliskiren","object":"renin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Angiotensin II suppression in humans by the orally active <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1> (SPP100): comparison with enalapril","sentence":"Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril"}
{"PMID":11799102,"re_id":13,"annotated sentence":"<e2>Angiotensin II<\\e2> suppression in humans by the orally active renin inhibitor Aliskiren (<e1>SPP100<\\e1> : comparison with enalapril","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SPP100","object":"Angiotensin II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> suppression in humans by the orally active renin inhibitor Aliskiren (<e1>CHEMICAL<\\e1> : comparison with enalapril","sentence":"Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100 : comparison with enalapril"}
{"PMID":11799102,"re_id":14,"annotated sentence":"Angiotensin II suppression in humans by the orally active <e2>renin<\\e2> inhibitor Aliskiren (<e1>SPP100<\\e1> : comparison with enalapril","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SPP100","object":"renin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Angiotensin II suppression in humans by the orally active <e2>GENE-Y<\\e2> inhibitor Aliskiren (<e1>CHEMICAL<\\e1> : comparison with enalapril","sentence":"Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100 : comparison with enalapril"}
{"PMID":11799102,"re_id":15,"annotated sentence":"Inhibition was still marked and significant after repeated dosing with maximal decreases in <e2>Ang II<\\e2> levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of <e1>Aliskiren<\\e1> was compared with placebo","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Aliskiren","object":"Ang II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition was still marked and significant after repeated dosing with maximal decreases in <e2>GENE-Y<\\e2> levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of <e1>CHEMICAL<\\e1> was compared with placebo","sentence":"Inhibition was still marked and significant after repeated dosing with maximal decreases in Ang II levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of Aliskiren was compared with placebo"}
{"PMID":11799102,"re_id":16,"annotated sentence":"<e1>Aliskiren<\\e1> has the potential to become the first orally active renin inhibitor that provides a true alternative to ACE-inhibitors and <e2>Ang II receptor<\\e2> antagonists in therapy for hypertension and other cardiovascular and renal diseases.","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Aliskiren","object":"Ang II receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> has the potential to become the first orally active renin inhibitor that provides a true alternative to ACE-inhibitors and <e2>GENE-N<\\e2> antagonists in therapy for hypertension and other cardiovascular and renal diseases.","sentence":"Aliskiren has the potential to become the first orally active renin inhibitor that provides a true alternative to ACE-inhibitors and Ang II receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases."}
{"PMID":11893059,"re_id":0,"annotated sentence":"The earliest known <e2>AChE<\\e2> inhibitors, namely, <e1>physostigmine<\\e1> and tacrine, performed poorly in clinical trials (e.g., poor oral activity, brain penetration, and hepatotoxic liability)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"physostigmine","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The earliest known <e2>GENE-Y<\\e2> inhibitors, namely, <e1>CHEMICAL<\\e1> and tacrine, performed poorly in clinical trials (e.g., poor oral activity, brain penetration, and hepatotoxic liability)","sentence":"The earliest known AChE inhibitors, namely, physostigmine and tacrine, performed poorly in clinical trials (e.g., poor oral activity, brain penetration, and hepatotoxic liability)"}
{"PMID":11893059,"re_id":1,"annotated sentence":"The earliest known <e2>AChE<\\e2> inhibitors, namely, physostigmine and <e1>tacrine<\\e1>  performed poorly in clinical trials (e.g., poor oral activity, brain penetration, and hepatotoxic liability)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tacrine","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The earliest known <e2>GENE-Y<\\e2> inhibitors, namely, physostigmine and <e1>CHEMICAL<\\e1>  performed poorly in clinical trials (e.g., poor oral activity, brain penetration, and hepatotoxic liability)","sentence":"The earliest known AChE inhibitors, namely, physostigmine and tacrine  performed poorly in clinical trials (e.g., poor oral activity, brain penetration, and hepatotoxic liability)"}
{"PMID":11893059,"re_id":2,"annotated sentence":"<e1>Donepezil hydrochloride<\\e1> inaugurates a new class of <e2>AChE<\\e2> inhibitors with longer and more selective action and with manageable adverse effects.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Donepezil hydrochloride","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inaugurates a new class of <e2>GENE-Y<\\e2> inhibitors with longer and more selective action and with manageable adverse effects.","sentence":"Donepezil hydrochloride inaugurates a new class of AChE inhibitors with longer and more selective action and with manageable adverse effects."}
{"PMID":12046682,"re_id":0,"annotated sentence":"<e1>Thalidomide<\\e1> -removed from widespread clinical use by 1962 because of severe teratogenicity--has anti-angiogenic and immunomodulatory effects, including the inhibition of <e2>TNF alpha<\\e2>  It has returned to practice as an effective oral agent in the management of various disease states including erythema nodosum leprosum, for which it was FDA-approved in 1998, and more recently certain malignancies, including multiple myeloma","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Thalidomide","object":"TNF alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> -removed from widespread clinical use by 1962 because of severe teratogenicity--has anti-angiogenic and immunomodulatory effects, including the inhibition of <e2>GENE-Y<\\e2>  It has returned to practice as an effective oral agent in the management of various disease states including erythema nodosum leprosum, for which it was FDA-approved in 1998, and more recently certain malignancies, including multiple myeloma","sentence":"Thalidomide -removed from widespread clinical use by 1962 because of severe teratogenicity--has anti-angiogenic and immunomodulatory effects, including the inhibition of TNF alpha  It has returned to practice as an effective oral agent in the management of various disease states including erythema nodosum leprosum, for which it was FDA-approved in 1998, and more recently certain malignancies, including multiple myeloma"}
{"PMID":12063741,"re_id":0,"annotated sentence":"As a prodrug <e1>leflunomide<\\e1> is completely converted to its active metabolite A 77 1726 (M1) which blocks the <e2>dihydroorotate dehydrogenase<\\e2>  a key enzyme of the pyrimidine de novo synthesis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"leflunomide","object":"dihydroorotate dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"As a prodrug <e1>CHEMICAL<\\e1> is completely converted to its active metabolite A 77 1726 (M1) which blocks the <e2>GENE-Y<\\e2>  a key enzyme of the pyrimidine de novo synthesis","sentence":"As a prodrug leflunomide is completely converted to its active metabolite A 77 1726 (M1) which blocks the dihydroorotate dehydrogenase  a key enzyme of the pyrimidine de novo synthesis"}
{"PMID":12063741,"re_id":1,"annotated sentence":"As a prodrug leflunomide is completely converted to its active metabolite <e1>A 77 1726<\\e1> (M1) which blocks the <e2>dihydroorotate dehydrogenase<\\e2>  a key enzyme of the pyrimidine de novo synthesis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"A 77 1726","object":"dihydroorotate dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"As a prodrug leflunomide is completely converted to its active metabolite <e1>CHEMICAL<\\e1> (M1) which blocks the <e2>GENE-Y<\\e2>  a key enzyme of the pyrimidine de novo synthesis","sentence":"As a prodrug leflunomide is completely converted to its active metabolite A 77 1726 (M1) which blocks the dihydroorotate dehydrogenase  a key enzyme of the pyrimidine de novo synthesis"}
{"PMID":12080538,"re_id":0,"annotated sentence":"A recent study showed that <e1>anastrozole<\\e1>  an <e2>aromatase<\\e2> inhibitor, is as effective or even superior to tamoxifen when used as a first-line therapy","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"anastrozole","object":"aromatase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A recent study showed that <e1>CHEMICAL<\\e1>  an <e2>GENE-Y<\\e2> inhibitor, is as effective or even superior to tamoxifen when used as a first-line therapy","sentence":"A recent study showed that anastrozole  an aromatase inhibitor, is as effective or even superior to tamoxifen when used as a first-line therapy"}
{"PMID":12080538,"re_id":1,"annotated sentence":"<e1>Fulvestrant<\\e1>  the first agent in this new class, not only induces the degradation of the <e2>estrogen receptor<\\e2> but also is an estrogen antagonist; further, its lack of agonist activity provides a better safety profile","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Fulvestrant","object":"estrogen receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  the first agent in this new class, not only induces the degradation of the <e2>GENE-Y<\\e2> but also is an estrogen antagonist; further, its lack of agonist activity provides a better safety profile","sentence":"Fulvestrant  the first agent in this new class, not only induces the degradation of the estrogen receptor but also is an estrogen antagonist; further, its lack of agonist activity provides a better safety profile"}
{"PMID":12082550,"re_id":0,"annotated sentence":"<e1>Lovastatin<\\e1>  a specific inhibitor of <e2>HMG-CoA reductase<\\e2>  induces a pronounced apoptotic response in a specific subset of tumor types, including HNSCC and CC","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Lovastatin","object":"HMG-CoA reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a specific inhibitor of <e2>GENE-Y<\\e2>  induces a pronounced apoptotic response in a specific subset of tumor types, including HNSCC and CC","sentence":"Lovastatin  a specific inhibitor of HMG-CoA reductase  induces a pronounced apoptotic response in a specific subset of tumor types, including HNSCC and CC"}
{"PMID":12137927,"re_id":0,"annotated sentence":"Chronic treatment with the <e2>NET<\\e2> inhibitor, <e1>desipramine<\\e1> (DMI), reduced NET levels in both control and Dbh -\/- mice, demonstrating that NE is not required for the regulation of NET by antidepressant drugs","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"desipramine","object":"NET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Chronic treatment with the <e2>GENE-Y<\\e2> inhibitor, <e1>CHEMICAL<\\e1> (DMI), reduced GENE-Y levels in both control and Dbh -\/- mice, demonstrating that NE is not required for the regulation of GENE-Y by antidepressant drugs","sentence":"Chronic treatment with the NET inhibitor, desipramine (DMI), reduced NET levels in both control and Dbh -\/- mice, demonstrating that NE is not required for the regulation of NET by antidepressant drugs"}
{"PMID":12137927,"re_id":1,"annotated sentence":"Chronic treatment with the NET inhibitor, <e1>desipramine<\\e1> (DMI), reduced <e2>NET<\\e2> levels in both control and Dbh -\/- mice, demonstrating that NE is not required for the regulation of NET by antidepressant drugs","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"desipramine","object":"NET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Chronic treatment with the GENE-Y inhibitor, <e1>CHEMICAL<\\e1> (DMI), reduced <e2>GENE-Y<\\e2> levels in both control and Dbh -\/- mice, demonstrating that NE is not required for the regulation of GENE-Y by antidepressant drugs","sentence":"Chronic treatment with the NET inhibitor, desipramine (DMI), reduced NET levels in both control and Dbh -\/- mice, demonstrating that NE is not required for the regulation of NET by antidepressant drugs"}
{"PMID":12170059,"re_id":0,"annotated sentence":"Probes were perfused with artificial cerebrospinal fluid containing nicotine, the specific <e2>alpha(4)beta(2*) nAChR<\\e2> agonist <e1>metanicotine<\\e1>  or nicotine plus nAChR antagonists and norepinephrine measured in the microdialysates","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"metanicotine","object":"alpha(4)beta(2*) nAChR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Probes were perfused with artificial cerebrospinal fluid containing nicotine, the specific <e2>GENE-Y<\\e2> agonist <e1>CHEMICAL<\\e1>  or nicotine plus nAChR antagonists and norepinephrine measured in the microdialysates","sentence":"Probes were perfused with artificial cerebrospinal fluid containing nicotine, the specific alpha(4)beta(2*) nAChR agonist metanicotine  or nicotine plus nAChR antagonists and norepinephrine measured in the microdialysates"}
{"PMID":12170059,"re_id":1,"annotated sentence":"Probes were perfused with artificial cerebrospinal fluid containing nicotine, the specific <e2>alpha(4)beta(2*) nAChR<\\e2> agonist metanicotine, or <e1>nicotine<\\e1> plus nAChR antagonists and norepinephrine measured in the microdialysates","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"nicotine","object":"alpha(4)beta(2*) nAChR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Probes were perfused with artificial cerebrospinal fluid containing CHEMICAL, the specific <e2>GENE-Y<\\e2> agonist metaCHEMICAL, or <e1>CHEMICAL<\\e1> plus nAChR antagonists and norepinephrine measured in the microdialysates","sentence":"Probes were perfused with artificial cerebrospinal fluid containing nicotine, the specific alpha(4)beta(2*) nAChR agonist metanicotine, or nicotine plus nAChR antagonists and norepinephrine measured in the microdialysates"}
{"PMID":12180353,"re_id":0,"annotated sentence":"<e1>Cilostazol<\\e1> decreases levels of serum triglycerides and causes some increase in <e2>HDL<\\e2> cholesterol levels","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Cilostazol","object":"HDL","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> decreases levels of serum triglycerides and causes some increase in <e2>GENE-N<\\e2> cholesterol levels","sentence":"Cilostazol decreases levels of serum triglycerides and causes some increase in HDL cholesterol levels"}
{"PMID":12180353,"re_id":1,"annotated sentence":"<e1>Cilostazol<\\e1> undergoes intensive and finally complete hepatic metabolism via the <e2>cytochrome P450<\\e2> systems","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Cilostazol","object":"cytochrome P450","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> undergoes intensive and finally complete hepatic metabolism via the <e2>GENE-N<\\e2> systems","sentence":"Cilostazol undergoes intensive and finally complete hepatic metabolism via the cytochrome P450 systems"}
{"PMID":12181427,"re_id":0,"annotated sentence":"In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for <e1>cilostazol<\\e1> but no difference for milrinone from the recombinant <e2>PDE3A<\\e2>  Molecular models show that the PDE3 inhibitors cilostazol and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cilostazol","object":"PDE3A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for <e1>CHEMICAL<\\e1> but no difference for milrinone from the recombinant <e2>GENE-Y<\\e2>  Molecular models show that the PDE3 inhibitors CHEMICAL and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site","sentence":"In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for cilostazol but no difference for milrinone from the recombinant PDE3A  Molecular models show that the PDE3 inhibitors cilostazol and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site"}
{"PMID":12181427,"re_id":1,"annotated sentence":"In contrast, the mutants <e2>T844A<\\e2>  F972A and Q975A showed increased K(i) for <e1>cilostazol<\\e1> but no difference for milrinone from the recombinant PDE3A","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cilostazol","object":"T844A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In contrast, the mutants <e2>GENE-N<\\e2>  F972A and Q975A showed increased K(i) for <e1>CHEMICAL<\\e1> but no difference for milrinone from the recombinant PDE3A","sentence":"In contrast, the mutants T844A  F972A and Q975A showed increased K(i) for cilostazol but no difference for milrinone from the recombinant PDE3A"}
{"PMID":12181427,"re_id":2,"annotated sentence":"In contrast, the mutants T844A, <e2>F972A<\\e2> and Q975A showed increased K(i) for <e1>cilostazol<\\e1> but no difference for milrinone from the recombinant PDE3A","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cilostazol","object":"F972A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In contrast, the mutants T844A, <e2>GENE-N<\\e2> and Q975A showed increased K(i) for <e1>CHEMICAL<\\e1> but no difference for milrinone from the recombinant PDE3A","sentence":"In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for cilostazol but no difference for milrinone from the recombinant PDE3A"}
{"PMID":12181427,"re_id":3,"annotated sentence":"In contrast, the mutants T844A, F972A and <e2>Q975A<\\e2> showed increased K(i) for <e1>cilostazol<\\e1> but no difference for milrinone from the recombinant PDE3A","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cilostazol","object":"Q975A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In contrast, the mutants T844A, F972A and <e2>GENE-N<\\e2> showed increased K(i) for <e1>CHEMICAL<\\e1> but no difference for milrinone from the recombinant PDE3A","sentence":"In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for cilostazol but no difference for milrinone from the recombinant PDE3A"}
{"PMID":12181427,"re_id":4,"annotated sentence":"In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for cilostazol but no difference for <e1>milrinone<\\e1> from the recombinant <e2>PDE3A<\\e2>  Molecular models show that the PDE3 inhibitors cilostazol and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"milrinone","object":"PDE3A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for cilostazol but no difference for <e1>CHEMICAL<\\e1> from the recombinant <e2>GENE-Y<\\e2>  Molecular models show that the PDE3 inhibitors cilostazol and CHEMICAL share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site","sentence":"In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for cilostazol but no difference for milrinone from the recombinant PDE3A  Molecular models show that the PDE3 inhibitors cilostazol and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site"}
{"PMID":12181427,"re_id":5,"annotated sentence":"In contrast, the mutants <e2>T844A<\\e2>  F972A and Q975A showed increased K(i) for cilostazol but no difference for <e1>milrinone<\\e1> from the recombinant PDE3A","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"milrinone","object":"T844A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In contrast, the mutants <e2>GENE-N<\\e2>  F972A and Q975A showed increased K(i) for cilostazol but no difference for <e1>CHEMICAL<\\e1> from the recombinant PDE3A","sentence":"In contrast, the mutants T844A  F972A and Q975A showed increased K(i) for cilostazol but no difference for milrinone from the recombinant PDE3A"}
{"PMID":12181427,"re_id":6,"annotated sentence":"In contrast, the mutants T844A, <e2>F972A<\\e2> and Q975A showed increased K(i) for cilostazol but no difference for <e1>milrinone<\\e1> from the recombinant PDE3A","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"milrinone","object":"F972A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In contrast, the mutants T844A, <e2>GENE-N<\\e2> and Q975A showed increased K(i) for cilostazol but no difference for <e1>CHEMICAL<\\e1> from the recombinant PDE3A","sentence":"In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for cilostazol but no difference for milrinone from the recombinant PDE3A"}
{"PMID":12181427,"re_id":7,"annotated sentence":"In contrast, the mutants T844A, F972A and <e2>Q975A<\\e2> showed increased K(i) for cilostazol but no difference for <e1>milrinone<\\e1> from the recombinant PDE3A","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"milrinone","object":"Q975A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In contrast, the mutants T844A, F972A and <e2>GENE-N<\\e2> showed increased K(i) for cilostazol but no difference for <e1>CHEMICAL<\\e1> from the recombinant PDE3A","sentence":"In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for cilostazol but no difference for milrinone from the recombinant PDE3A"}
{"PMID":12181427,"re_id":8,"annotated sentence":"Molecular models show that the <e2>PDE3<\\e2> inhibitors <e1>cilostazol<\\e1> and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cilostazol","object":"PDE3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Molecular models show that the <e2>GENE-Y<\\e2> inhibitors <e1>CHEMICAL<\\e1> and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against GENE-Y active site","sentence":"Molecular models show that the PDE3 inhibitors cilostazol and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site"}
{"PMID":12181427,"re_id":9,"annotated sentence":"Molecular models show that the <e2>PDE3<\\e2> inhibitors cilostazol and <e1>milrinone<\\e1> share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"milrinone","object":"PDE3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Molecular models show that the <e2>GENE-Y<\\e2> inhibitors cilostazol and <e1>CHEMICAL<\\e1> share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against GENE-Y active site","sentence":"Molecular models show that the PDE3 inhibitors cilostazol and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site"}
{"PMID":12181427,"re_id":10,"annotated sentence":"Our study implies that highly conserved residuals Y751, D950 and F1004 in the <e2>PDE<\\e2> families are key residues for binding of both substrate and inhibitors, and nonconserved T844 may be responsible for the <e1>cilostazol<\\e1> selectivity of PDE3A","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cilostazol","object":"PDE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our study implies that highly conserved residuals Y751, D950 and F1004 in the <e2>GENE-Y<\\e2> families are key residues for binding of both substrate and inhibitors, and nonconserved T844 may be responsible for the <e1>CHEMICAL<\\e1> selectivity of GENE-Y3A","sentence":"Our study implies that highly conserved residuals Y751, D950 and F1004 in the PDE families are key residues for binding of both substrate and inhibitors, and nonconserved T844 may be responsible for the cilostazol selectivity of PDE3A"}
{"PMID":12181427,"re_id":11,"annotated sentence":"Our study implies that highly conserved residuals Y751, D950 and F1004 in the PDE families are key residues for binding of both substrate and inhibitors, and nonconserved T844 may be responsible for the <e1>cilostazol<\\e1> selectivity of <e2>PDE3A<\\e2>  Detailed knowledge of the structure of inhibitory sites should contribute to development of more potent and specific inhibitory drugs.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cilostazol","object":"PDE3A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our study implies that highly conserved residuals Y751, D950 and F1004 in the PDE families are key residues for binding of both substrate and inhibitors, and nonconserved T844 may be responsible for the <e1>CHEMICAL<\\e1> selectivity of <e2>GENE-Y<\\e2>  Detailed knowledge of the structure of inhibitory sites should contribute to development of more potent and specific inhibitory drugs.","sentence":"Our study implies that highly conserved residuals Y751, D950 and F1004 in the PDE families are key residues for binding of both substrate and inhibitors, and nonconserved T844 may be responsible for the cilostazol selectivity of PDE3A  Detailed knowledge of the structure of inhibitory sites should contribute to development of more potent and specific inhibitory drugs."}
{"PMID":12181427,"re_id":12,"annotated sentence":"We changed the residues to alanine using site-directed mutagenesis technique, expressed the mutants in a baculovirus\/Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by <e1>milrinone<\\e1> and cilostazol, specific inhibitors of <e2>PDE3<\\e2>  The mutants displayed differential sensitivity to the inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"milrinone","object":"PDE3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We changed the residues to alanine using site-directed mutagenesis technique, expressed the mutants in a baculovirus\/Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by <e1>CHEMICAL<\\e1> and cilostazol, specific inhibitors of <e2>GENE-Y<\\e2>  The mutants displayed differential sensitivity to the inhibitors","sentence":"We changed the residues to alanine using site-directed mutagenesis technique, expressed the mutants in a baculovirus\/Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by milrinone and cilostazol, specific inhibitors of PDE3  The mutants displayed differential sensitivity to the inhibitors"}
{"PMID":12181427,"re_id":13,"annotated sentence":"We changed the residues to alanine using site-directed mutagenesis technique, expressed the mutants in a baculovirus\/Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by milrinone and <e1>cilostazol<\\e1>  specific inhibitors of <e2>PDE3<\\e2>  The mutants displayed differential sensitivity to the inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cilostazol","object":"PDE3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We changed the residues to alanine using site-directed mutagenesis technique, expressed the mutants in a baculovirus\/Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by milrinone and <e1>CHEMICAL<\\e1>  specific inhibitors of <e2>GENE-Y<\\e2>  The mutants displayed differential sensitivity to the inhibitors","sentence":"We changed the residues to alanine using site-directed mutagenesis technique, expressed the mutants in a baculovirus\/Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by milrinone and cilostazol  specific inhibitors of PDE3  The mutants displayed differential sensitivity to the inhibitors"}
{"PMID":12181427,"re_id":14,"annotated sentence":"Mutants <e2>Y751A<\\e2>  D950A, and F1004A had reduced sensitivity to <e1>milrinone<\\e1> (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"milrinone","object":"Y751A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Mutants <e2>GENE-N<\\e2>  D950A, and F1004A had reduced sensitivity to <e1>CHEMICAL<\\e1> (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A)","sentence":"Mutants Y751A  D950A, and F1004A had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A)"}
{"PMID":12181427,"re_id":15,"annotated sentence":"Mutants Y751A, <e2>D950A<\\e2>  and F1004A had reduced sensitivity to <e1>milrinone<\\e1> (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"milrinone","object":"D950A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Mutants Y751A, <e2>GENE-N<\\e2>  and F1004A had reduced sensitivity to <e1>CHEMICAL<\\e1> (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A)","sentence":"Mutants Y751A, D950A  and F1004A had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A)"}
{"PMID":12181427,"re_id":16,"annotated sentence":"Mutants Y751A, D950A, and <e2>F1004A<\\e2> had reduced sensitivity to <e1>milrinone<\\e1> (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"milrinone","object":"F1004A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Mutants Y751A, D950A, and <e2>GENE-N<\\e2> had reduced sensitivity to <e1>CHEMICAL<\\e1> (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A)","sentence":"Mutants Y751A, D950A, and F1004A had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A)"}
{"PMID":12181427,"re_id":17,"annotated sentence":"Mutants Y751A, D950A, and F1004A had reduced sensitivity to <e1>milrinone<\\e1> (K(i) changed from 0.66 microM for the recombinant <e2>PDE3A<\\e2> to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"milrinone","object":"PDE3A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Mutants Y751A, D950A, and F1004A had reduced sensitivity to <e1>CHEMICAL<\\e1> (K(i) changed from 0.66 microM for the recombinant <e2>GENE-Y<\\e2> to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant GENE-Y)","sentence":"Mutants Y751A, D950A, and F1004A had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A)"}
{"PMID":12181427,"re_id":18,"annotated sentence":"Mutants Y751A, D950A, and F1004A had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to <e1>cilostazol<\\e1> (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant <e2>PDE3A<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cilostazol","object":"PDE3A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Mutants Y751A, D950A, and F1004A had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant GENE-Y to 7.5 to 156 microM for the mutants), and diminished sensitivity to <e1>CHEMICAL<\\e1> (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant <e2>GENE-Y<\\e2> ","sentence":"Mutants Y751A, D950A, and F1004A had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A "}
{"PMID":12217700,"re_id":0,"annotated sentence":"The bacterial enzyme <e2>maltodextrin phosphorylase<\\e2> (MalP) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as <e1>glucose-1-phosphate<\\e1> (Glc1P)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glucose-1-phosphate","object":"maltodextrin phosphorylase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The bacterial enzyme <e2>GENE-N<\\e2> (MalP) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as <e1>CHEMICAL<\\e1> (Glc1P)","sentence":"The bacterial enzyme maltodextrin phosphorylase (MalP) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as glucose-1-phosphate (Glc1P)"}
{"PMID":12217700,"re_id":1,"annotated sentence":"The bacterial enzyme maltodextrin phosphorylase (<e2>MalP<\\e2>  catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as <e1>glucose-1-phosphate<\\e1> (Glc1P)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glucose-1-phosphate","object":"MalP","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The bacterial enzyme maltodextrin phosphorylase (<e2>GENE-N<\\e2>  catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as <e1>CHEMICAL<\\e1> (Glc1P)","sentence":"The bacterial enzyme maltodextrin phosphorylase (MalP  catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as glucose-1-phosphate (Glc1P)"}
{"PMID":12217700,"re_id":2,"annotated sentence":"The bacterial enzyme <e2>maltodextrin phosphorylase<\\e2> (MalP) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as glucose-1-phosphate (<e1>Glc1P<\\e1> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Glc1P","object":"maltodextrin phosphorylase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The bacterial enzyme <e2>GENE-N<\\e2> (MalP) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as glucose-1-phosphate (<e1>CHEMICAL<\\e1> ","sentence":"The bacterial enzyme maltodextrin phosphorylase (MalP) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as glucose-1-phosphate (Glc1P "}
{"PMID":12217700,"re_id":3,"annotated sentence":"The bacterial enzyme maltodextrin phosphorylase (<e2>MalP<\\e2>  catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as glucose-1-phosphate (<e1>Glc1P<\\e1> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Glc1P","object":"MalP","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The bacterial enzyme maltodextrin phosphorylase (<e2>GENE-N<\\e2>  catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as glucose-1-phosphate (<e1>CHEMICAL<\\e1> ","sentence":"The bacterial enzyme maltodextrin phosphorylase (MalP  catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as glucose-1-phosphate (Glc1P "}
{"PMID":12383039,"re_id":0,"annotated sentence":"OBJECTIVE: <e1>Fondaparinux sodium<\\e1> is the first in a new class of synthetic <e2>factor Xa<\\e2> inhibitors that binds reversibly with high affinity to antithrombin III","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Fondaparinux sodium","object":"factor Xa","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"OBJECTIVE: <e1>CHEMICAL<\\e1> is the first in a new class of synthetic <e2>GENE-Y<\\e2> inhibitors that binds reversibly with high affinity to antithrombin III","sentence":"OBJECTIVE: Fondaparinux sodium is the first in a new class of synthetic factor Xa inhibitors that binds reversibly with high affinity to antithrombin III"}
{"PMID":12409268,"re_id":0,"annotated sentence":"It is caused by a deficiency of <e2>propionyl-CoA carboxylase<\\e2> (PCC, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of <e1>propionyl-CoA<\\e1> to D-methylmalonyl-CoA","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"propionyl-CoA","object":"propionyl-CoA carboxylase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"It is caused by a deficiency of <e2>CHEMICAL carboxylase<\\e2> (PCC, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of <e1>CHEMICAL<\\e1> to D-methylmalonyl-CoA","sentence":"It is caused by a deficiency of propionyl-CoA carboxylase (PCC, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA"}
{"PMID":12409268,"re_id":1,"annotated sentence":"It is caused by a deficiency of propionyl-CoA carboxylase (<e2>PCC<\\e2>  EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of <e1>propionyl-CoA<\\e1> to D-methylmalonyl-CoA","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"propionyl-CoA","object":"PCC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"It is caused by a deficiency of CHEMICAL carboxylase (<e2>GENE-N<\\e2>  EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of <e1>CHEMICAL<\\e1> to D-methylmalonyl-CoA","sentence":"It is caused by a deficiency of propionyl-CoA carboxylase (PCC  EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA"}
{"PMID":12409268,"re_id":2,"annotated sentence":"It is caused by a deficiency of propionyl-CoA carboxylase (PCC, <e2>EC 6.4.1.3<\\e2> , a biotin-dependent enzyme that catalyzes the carboxylation of <e1>propionyl-CoA<\\e1> to D-methylmalonyl-CoA","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"propionyl-CoA","object":"EC 6.4.1.3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"It is caused by a deficiency of CHEMICAL carboxylase (PCC, <e2>GENE-Y<\\e2> , a biotin-dependent enzyme that catalyzes the carboxylation of <e1>CHEMICAL<\\e1> to D-methylmalonyl-CoA","sentence":"It is caused by a deficiency of propionyl-CoA carboxylase (PCC, EC 6.4.1.3 , a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA"}
{"PMID":12409268,"re_id":3,"annotated sentence":"It is caused by a deficiency of <e2>propionyl-CoA carboxylase<\\e2> (PCC, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to <e1>D-methylmalonyl-CoA<\\e1>  PCC is a heteropolymeric enzyme composed of alpha- and beta-subunits","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"D-methylmalonyl-CoA","object":"propionyl-CoA carboxylase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"It is caused by a deficiency of <e2>GENE-N<\\e2> (PCC, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to <e1>CHEMICAL<\\e1>  PCC is a heteropolymeric enzyme composed of alpha- and beta-subunits","sentence":"It is caused by a deficiency of propionyl-CoA carboxylase (PCC, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA  PCC is a heteropolymeric enzyme composed of alpha- and beta-subunits"}
{"PMID":12409268,"re_id":4,"annotated sentence":"It is caused by a deficiency of propionyl-CoA carboxylase (<e2>PCC<\\e2>  EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to <e1>D-methylmalonyl-CoA<\\e1>  PCC is a heteropolymeric enzyme composed of alpha- and beta-subunits","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"D-methylmalonyl-CoA","object":"PCC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"It is caused by a deficiency of propionyl-CoA carboxylase (<e2>GENE-N<\\e2>  EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to <e1>CHEMICAL<\\e1>  GENE-N is a heteropolymeric enzyme composed of alpha- and beta-subunits","sentence":"It is caused by a deficiency of propionyl-CoA carboxylase (PCC  EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA  PCC is a heteropolymeric enzyme composed of alpha- and beta-subunits"}
{"PMID":12409268,"re_id":5,"annotated sentence":"It is caused by a deficiency of propionyl-CoA carboxylase (PCC, <e2>EC 6.4.1.3<\\e2> , a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to <e1>D-methylmalonyl-CoA<\\e1>  PCC is a heteropolymeric enzyme composed of alpha- and beta-subunits","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"D-methylmalonyl-CoA","object":"EC 6.4.1.3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"It is caused by a deficiency of propionyl-CoA carboxylase (PCC, <e2>GENE-Y<\\e2> , a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to <e1>CHEMICAL<\\e1>  PCC is a heteropolymeric enzyme composed of alpha- and beta-subunits","sentence":"It is caused by a deficiency of propionyl-CoA carboxylase (PCC, EC 6.4.1.3 , a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA  PCC is a heteropolymeric enzyme composed of alpha- and beta-subunits"}
{"PMID":12445705,"re_id":0,"annotated sentence":"Although only <e1>clozapine<\\e1> and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined <e2>5-HT(2A)<\\e2> and D(2) blockade","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"clozapine","object":"5-HT(2A)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although only <e1>CHEMICAL<\\e1> and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined <e2>GENE-Y<\\e2> and D(2) blockade","sentence":"Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade"}
{"PMID":12445705,"re_id":1,"annotated sentence":"Although only <e1>clozapine<\\e1> and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and <e2>D(2)<\\e2> blockade","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"clozapine","object":"D(2)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although only <e1>CHEMICAL<\\e1> and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and <e2>GENE-Y<\\e2> blockade","sentence":"Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade"}
{"PMID":12445705,"re_id":2,"annotated sentence":"Although only clozapine and <e1>ziprasidone<\\e1> are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined <e2>5-HT(2A)<\\e2> and D(2) blockade","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ziprasidone","object":"5-HT(2A)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although only clozapine and <e1>CHEMICAL<\\e1> are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined <e2>GENE-Y<\\e2> and D(2) blockade","sentence":"Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade"}
{"PMID":12445705,"re_id":3,"annotated sentence":"Although only clozapine and <e1>ziprasidone<\\e1> are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and <e2>D(2)<\\e2> blockade","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ziprasidone","object":"D(2)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although only clozapine and <e1>CHEMICAL<\\e1> are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and <e2>GENE-Y<\\e2> blockade","sentence":"Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade"}
{"PMID":12445705,"re_id":4,"annotated sentence":"Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, <e1>WAY100635<\\e1>  a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined <e2>5-HT(2A)<\\e2> and D(2) blockade","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"WAY100635","object":"5-HT(2A)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, <e1>CHEMICAL<\\e1>  a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined <e2>GENE-Y<\\e2> and D(2) blockade","sentence":"Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635  a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade"}
{"PMID":12445705,"re_id":5,"annotated sentence":"Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, <e1>WAY100635<\\e1>  a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and <e2>D(2)<\\e2> blockade","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"WAY100635","object":"D(2)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, <e1>CHEMICAL<\\e1>  a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and <e2>GENE-Y<\\e2> blockade","sentence":"Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635  a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade"}
{"PMID":12445705,"re_id":6,"annotated sentence":"However, <e2>5-HT(1A)<\\e2> agonism may be important only for <e1>quetiapine<\\e1> induced ACh release.","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"quetiapine","object":"5-HT(1A)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, <e2>GENE-Y<\\e2> agonism may be important only for <e1>CHEMICAL<\\e1> induced ACh release.","sentence":"However, 5-HT(1A) agonism may be important only for quetiapine induced ACh release."}
{"PMID":12445705,"re_id":7,"annotated sentence":"Although only <e1>clozapine<\\e1> and ziprasidone are directly acting <e2>5-HT(1A)<\\e2> agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"clozapine","object":"5-HT(1A)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although only <e1>CHEMICAL<\\e1> and ziprasidone are directly acting <e2>GENE-Y<\\e2> agonists, WAY100635, a selective GENE-Y antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade","sentence":"Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade"}
{"PMID":12445705,"re_id":8,"annotated sentence":"Although only clozapine and <e1>ziprasidone<\\e1> are directly acting <e2>5-HT(1A)<\\e2> agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"ziprasidone","object":"5-HT(1A)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although only clozapine and <e1>CHEMICAL<\\e1> are directly acting <e2>GENE-Y<\\e2> agonists, WAY100635, a selective GENE-Y antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade","sentence":"Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade"}
{"PMID":12445705,"re_id":9,"annotated sentence":"Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, <e1>WAY100635<\\e1>  a selective <e2>5-HT(1A)<\\e2> antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"WAY100635","object":"5-HT(1A)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although only clozapine and ziprasidone are directly acting GENE-Y agonists, <e1>CHEMICAL<\\e1>  a selective <e2>GENE-Y<\\e2> antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade","sentence":"Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635  a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade"}
{"PMID":12545144,"re_id":0,"annotated sentence":"BACKGROUND: The novel antiepileptic drug <e1>retigabine<\\e1> is the first selective M-current potassium channel opener for <e2>KCNQ2\/3<\\e2> and KCNQ3\/5 channels","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"retigabine","object":"KCNQ2\/3","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"BACKGROUND: The novel antiepileptic drug <e1>CHEMICAL<\\e1> is the first selective M-current potassium channel opener for <e2>GENE-N<\\e2> and KCNQ3\/5 channels","sentence":"BACKGROUND: The novel antiepileptic drug retigabine is the first selective M-current potassium channel opener for KCNQ2\/3 and KCNQ3\/5 channels"}
{"PMID":12545144,"re_id":1,"annotated sentence":"BACKGROUND: The novel antiepileptic drug <e1>retigabine<\\e1> is the first selective M-current potassium channel opener for KCNQ2\/3 and <e2>KCNQ3\/5<\\e2> channels","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"retigabine","object":"KCNQ3\/5","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"BACKGROUND: The novel antiepileptic drug <e1>CHEMICAL<\\e1> is the first selective M-current potassium channel opener for KCNQ2\/3 and <e2>GENE-N<\\e2> channels","sentence":"BACKGROUND: The novel antiepileptic drug retigabine is the first selective M-current potassium channel opener for KCNQ2\/3 and KCNQ3\/5 channels"}
{"PMID":12545144,"re_id":2,"annotated sentence":"BACKGROUND: The novel antiepileptic drug <e1>retigabine<\\e1> is the first selective <e2>M-current potassium channel<\\e2> opener for KCNQ2\/3 and KCNQ3\/5 channels","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"retigabine","object":"M-current potassium channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"BACKGROUND: The novel antiepileptic drug <e1>CHEMICAL<\\e1> is the first selective <e2>GENE-N<\\e2> opener for KCNQ2\/3 and KCNQ3\/5 channels","sentence":"BACKGROUND: The novel antiepileptic drug retigabine is the first selective M-current potassium channel opener for KCNQ2\/3 and KCNQ3\/5 channels"}
{"PMID":12588370,"re_id":0,"annotated sentence":"OBJECTIVE: Because of these physiological effects and the widespread use of the selective <e2>COX-2<\\e2> inhibitor, <e1>celecoxib<\\e1>  we wanted to determine if inhibition of COX-2 would affect incisional skin wound healing","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"celecoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"OBJECTIVE: Because of these physiological effects and the widespread use of the selective <e2>GENE-Y<\\e2> inhibitor, <e1>CHEMICAL<\\e1>  we wanted to determine if inhibition of GENE-Y would affect incisional skin wound healing","sentence":"OBJECTIVE: Because of these physiological effects and the widespread use of the selective COX-2 inhibitor, celecoxib  we wanted to determine if inhibition of COX-2 would affect incisional skin wound healing"}
{"PMID":12588370,"re_id":1,"annotated sentence":"METHODS: Using a cutaneous full-thickness, sutured, incisional wound model in hairless SKH-1 mice, we evaluated the role of COX-2 in the wound healing process by comparing the effects of a nonselective <e2>COX<\\e2> inhibitor, <e1>diclofenac<\\e1>  with a selective COX-2 inhibitor, SC-791","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"diclofenac","object":"COX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"METHODS: Using a cutaneous full-thickness, sutured, incisional wound model in hairless SKH-1 mice, we evaluated the role of GENE-N-2 in the wound healing process by comparing the effects of a nonselective <e2>GENE-N<\\e2> inhibitor, <e1>CHEMICAL<\\e1>  with a selective GENE-N-2 inhibitor, SC-791","sentence":"METHODS: Using a cutaneous full-thickness, sutured, incisional wound model in hairless SKH-1 mice, we evaluated the role of COX-2 in the wound healing process by comparing the effects of a nonselective COX inhibitor, diclofenac  with a selective COX-2 inhibitor, SC-791"}
{"PMID":12657913,"re_id":0,"annotated sentence":"The effects of histamine H1-receptor antagonists, <e1>promethazine<\\e1> and homochlorcyclizine, both of which are inhibitors of <e2>CYP2D6<\\e2>  on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg\/d, for 2 to 29 weeks","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"promethazine","object":"CYP2D6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The effects of histamine H1-receptor antagonists, <e1>CHEMICAL<\\e1> and homochlorcyclizine, both of which are inhibitors of <e2>GENE-Y<\\e2>  on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg\/d, for 2 to 29 weeks","sentence":"The effects of histamine H1-receptor antagonists, promethazine and homochlorcyclizine, both of which are inhibitors of CYP2D6  on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg\/d, for 2 to 29 weeks"}
{"PMID":12657913,"re_id":1,"annotated sentence":"The effects of histamine H1-receptor antagonists, promethazine and <e1>homochlorcyclizine<\\e1>  both of which are inhibitors of <e2>CYP2D6<\\e2>  on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg\/d, for 2 to 29 weeks","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"homochlorcyclizine","object":"CYP2D6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The effects of histamine H1-receptor antagonists, promethazine and <e1>CHEMICAL<\\e1>  both of which are inhibitors of <e2>GENE-Y<\\e2>  on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg\/d, for 2 to 29 weeks","sentence":"The effects of histamine H1-receptor antagonists, promethazine and homochlorcyclizine  both of which are inhibitors of CYP2D6  on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg\/d, for 2 to 29 weeks"}
{"PMID":12657913,"re_id":2,"annotated sentence":"Thus, the current study suggests that coadministration of clinical doses of <e1>promethazine<\\e1> and homochlorcyclizine increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the <e2>CYP2D6<\\e2> catalyzed metabolism of haloperidol and reduced haloperidol.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"promethazine","object":"CYP2D6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, the current study suggests that coadministration of clinical doses of <e1>CHEMICAL<\\e1> and homochlorcyclizine increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the <e2>GENE-Y<\\e2> catalyzed metabolism of haloperidol and reduced haloperidol.","sentence":"Thus, the current study suggests that coadministration of clinical doses of promethazine and homochlorcyclizine increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the CYP2D6 catalyzed metabolism of haloperidol and reduced haloperidol."}
{"PMID":12657913,"re_id":3,"annotated sentence":"Thus, the current study suggests that coadministration of clinical doses of promethazine and <e1>homochlorcyclizine<\\e1> increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the <e2>CYP2D6<\\e2> catalyzed metabolism of haloperidol and reduced haloperidol.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"homochlorcyclizine","object":"CYP2D6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, the current study suggests that coadministration of clinical doses of promethazine and <e1>CHEMICAL<\\e1> increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the <e2>GENE-Y<\\e2> catalyzed metabolism of haloperidol and reduced haloperidol.","sentence":"Thus, the current study suggests that coadministration of clinical doses of promethazine and homochlorcyclizine increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the CYP2D6 catalyzed metabolism of haloperidol and reduced haloperidol."}
{"PMID":12657913,"re_id":4,"annotated sentence":"The effects of <e2>histamine H1-receptor<\\e2> antagonists, <e1>promethazine<\\e1> and homochlorcyclizine, both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg\/d, for 2 to 29 weeks","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"promethazine","object":"histamine H1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The effects of <e2>GENE-Y<\\e2> antagonists, <e1>CHEMICAL<\\e1> and homochlorcyclizine, both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg\/d, for 2 to 29 weeks","sentence":"The effects of histamine H1-receptor antagonists, promethazine and homochlorcyclizine, both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg\/d, for 2 to 29 weeks"}
{"PMID":12657913,"re_id":5,"annotated sentence":"The effects of <e2>histamine H1-receptor<\\e2> antagonists, promethazine and <e1>homochlorcyclizine<\\e1>  both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg\/d, for 2 to 29 weeks","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"homochlorcyclizine","object":"histamine H1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The effects of <e2>GENE-Y<\\e2> antagonists, promethazine and <e1>CHEMICAL<\\e1>  both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg\/d, for 2 to 29 weeks","sentence":"The effects of histamine H1-receptor antagonists, promethazine and homochlorcyclizine  both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg\/d, for 2 to 29 weeks"}
{"PMID":12657913,"re_id":6,"annotated sentence":"<e2>Histamine H1-receptor<\\e2> antagonists, <e1>promethazine<\\e1> and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"promethazine","object":"Histamine H1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> antagonists, <e1>CHEMICAL<\\e1> and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol","sentence":"Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol"}
{"PMID":12657913,"re_id":7,"annotated sentence":"<e2>Histamine H1-receptor<\\e2> antagonists, promethazine and <e1>homochlorcyclizine<\\e1>  increase the steady-state plasma concentrations of haloperidol and reduced haloperidol","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"homochlorcyclizine","object":"Histamine H1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> antagonists, promethazine and <e1>CHEMICAL<\\e1>  increase the steady-state plasma concentrations of haloperidol and reduced haloperidol","sentence":"Histamine H1-receptor antagonists, promethazine and homochlorcyclizine  increase the steady-state plasma concentrations of haloperidol and reduced haloperidol"}
{"PMID":12657913,"re_id":8,"annotated sentence":"Thus, the current study suggests that coadministration of clinical doses of promethazine and homochlorcyclizine increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the <e2>CYP2D6<\\e2> catalyzed metabolism of haloperidol and reduced <e1>haloperidol<\\e1> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"haloperidol","object":"CYP2D6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, the current study suggests that coadministration of clinical doses of promethazine and homochlorcyclizine increases the Css of CHEMICAL and reduced CHEMICAL via the inhibitory effects on the <e2>GENE-Y<\\e2> catalyzed metabolism of CHEMICAL and reduced <e1>CHEMICAL<\\e1> ","sentence":"Thus, the current study suggests that coadministration of clinical doses of promethazine and homochlorcyclizine increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the CYP2D6 catalyzed metabolism of haloperidol and reduced haloperidol "}
{"PMID":12657913,"re_id":9,"annotated sentence":"Thus, the current study suggests that coadministration of clinical doses of promethazine and homochlorcyclizine increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the <e2>CYP2D6<\\e2> catalyzed metabolism of <e1>haloperidol<\\e1> and reduced haloperidol.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"haloperidol","object":"CYP2D6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, the current study suggests that coadministration of clinical doses of promethazine and homochlorcyclizine increases the Css of CHEMICAL and reduced CHEMICAL via the inhibitory effects on the <e2>GENE-Y<\\e2> catalyzed metabolism of <e1>CHEMICAL<\\e1> and reduced CHEMICAL.","sentence":"Thus, the current study suggests that coadministration of clinical doses of promethazine and homochlorcyclizine increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the CYP2D6 catalyzed metabolism of haloperidol and reduced haloperidol."}
{"PMID":12679340,"re_id":0,"annotated sentence":"The four lysine residues located in the SMG loop, Lys-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of <e2>OTCase<\\e2> to <e1>ornithine<\\e1> and to arginase and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ornithine","object":"OTCase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The four lysine residues located in the SMG loop, Lys-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of <e2>GENE-Y<\\e2> to <e1>CHEMICAL<\\e1> and to arginase and appear to be involved in transducing and enhancing the signal given by CHEMICAL for the closure of the catalytic domain.","sentence":"The four lysine residues located in the SMG loop, Lys-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of OTCase to ornithine and to arginase and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain."}
{"PMID":1280065,"re_id":0,"annotated sentence":"Inhibition of binding of both <e2>plasminogen<\\e2> and plasmin to gp330 by <e1>benzamidine<\\e1> was similar, although EACA inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to gp330","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"benzamidine","object":"plasminogen","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of binding of both <e2>GENE-Y<\\e2> and plasmin to gp330 by <e1>CHEMICAL<\\e1> was similar, although EACA inhibited the binding of plasmin to gp330 slightly more than the binding of GENE-Y to gp330","sentence":"Inhibition of binding of both plasminogen and plasmin to gp330 by benzamidine was similar, although EACA inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to gp330"}
{"PMID":1280065,"re_id":1,"annotated sentence":"Inhibition of binding of both plasminogen and <e2>plasmin<\\e2> to gp330 by <e1>benzamidine<\\e1> was similar, although EACA inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to gp330","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"benzamidine","object":"plasmin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of binding of both GENE-Yogen and <e2>GENE-Y<\\e2> to gp330 by <e1>CHEMICAL<\\e1> was similar, although EACA inhibited the binding of GENE-Y to gp330 slightly more than the binding of GENE-Yogen to gp330","sentence":"Inhibition of binding of both plasminogen and plasmin to gp330 by benzamidine was similar, although EACA inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to gp330"}
{"PMID":1280065,"re_id":2,"annotated sentence":"Inhibition of binding of both plasminogen and plasmin to gp330 by benzamidine was similar, although <e1>EACA<\\e1> inhibited the binding of <e2>plasmin<\\e2> to gp330 slightly more than the binding of plasminogen to gp330","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"EACA","object":"plasmin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of binding of both GENE-Yogen and GENE-Y to gp330 by benzamidine was similar, although <e1>CHEMICAL<\\e1> inhibited the binding of <e2>GENE-Y<\\e2> to gp330 slightly more than the binding of GENE-Yogen to gp330","sentence":"Inhibition of binding of both plasminogen and plasmin to gp330 by benzamidine was similar, although EACA inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to gp330"}
{"PMID":1280065,"re_id":3,"annotated sentence":"Inhibition of binding of both plasminogen and plasmin to gp330 by benzamidine was similar, although <e1>EACA<\\e1> inhibited the binding of plasmin to gp330 slightly more than the binding of <e2>plasminogen<\\e2> to gp330","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"EACA","object":"plasminogen","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of binding of both GENE-Y and plasmin to gp330 by benzamidine was similar, although <e1>CHEMICAL<\\e1> inhibited the binding of plasmin to gp330 slightly more than the binding of <e2>GENE-Y<\\e2> to gp330","sentence":"Inhibition of binding of both plasminogen and plasmin to gp330 by benzamidine was similar, although EACA inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to gp330"}
{"PMID":12818701,"re_id":0,"annotated sentence":"Involvement of alpha(1)-adrenoceptors was established as mydriatic responses were inhibited by systemic administration of nonselective <e2>alpha-adrenoceptor<\\e2> antagonists, <e1>phentolamine<\\e1> (0.3-3 mg\/kg) and phenoxybenzamine (0.03-0.3 mg\/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, prazosin (0.3 mg\/kg)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"phentolamine","object":"alpha-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Involvement of alpha(1)-adrenoceptors was established as mydriatic responses were inhibited by systemic administration of nonselective <e2>GENE-N<\\e2> antagonists, <e1>CHEMICAL<\\e1> (0.3-3 mg\/kg) and phenoxybenzamine (0.03-0.3 mg\/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, prazosin (0.3 mg\/kg)","sentence":"Involvement of alpha(1)-adrenoceptors was established as mydriatic responses were inhibited by systemic administration of nonselective alpha-adrenoceptor antagonists, phentolamine (0.3-3 mg\/kg) and phenoxybenzamine (0.03-0.3 mg\/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, prazosin (0.3 mg\/kg)"}
{"PMID":12818701,"re_id":1,"annotated sentence":"Involvement of alpha(1)-adrenoceptors was established as mydriatic responses were inhibited by systemic administration of nonselective <e2>alpha-adrenoceptor<\\e2> antagonists, phentolamine (0.3-3 mg\/kg) and <e1>phenoxybenzamine<\\e1> (0.03-0.3 mg\/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, prazosin (0.3 mg\/kg)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"phenoxybenzamine","object":"alpha-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Involvement of alpha(1)-adrenoceptors was established as mydriatic responses were inhibited by systemic administration of nonselective <e2>GENE-N<\\e2> antagonists, phentolamine (0.3-3 mg\/kg) and <e1>CHEMICAL<\\e1> (0.03-0.3 mg\/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, prazosin (0.3 mg\/kg)","sentence":"Involvement of alpha(1)-adrenoceptors was established as mydriatic responses were inhibited by systemic administration of nonselective alpha-adrenoceptor antagonists, phentolamine (0.3-3 mg\/kg) and phenoxybenzamine (0.03-0.3 mg\/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, prazosin (0.3 mg\/kg)"}
{"PMID":12818701,"re_id":2,"annotated sentence":"Involvement of alpha(1)-adrenoceptors was established as mydriatic responses were inhibited by systemic administration of nonselective alpha-adrenoceptor antagonists, phentolamine (0.3-3 mg\/kg) and phenoxybenzamine (0.03-0.3 mg\/kg), as well as by the selective <e2>alpha(1)-adrenoceptor<\\e2> antagonist, <e1>prazosin<\\e1> (0.3 mg\/kg)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"prazosin","object":"alpha(1)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Involvement of GENE-Ns was established as mydriatic responses were inhibited by systemic administration of nonselective alpha-adrenoceptor antagonists, phentolamine (0.3-3 mg\/kg) and phenoxybenzamine (0.03-0.3 mg\/kg), as well as by the selective <e2>GENE-N<\\e2> antagonist, <e1>CHEMICAL<\\e1> (0.3 mg\/kg)","sentence":"Involvement of alpha(1)-adrenoceptors was established as mydriatic responses were inhibited by systemic administration of nonselective alpha-adrenoceptor antagonists, phentolamine (0.3-3 mg\/kg) and phenoxybenzamine (0.03-0.3 mg\/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, prazosin (0.3 mg\/kg)"}
{"PMID":12818701,"re_id":3,"annotated sentence":"The <e2>alpha(2)-adrenoceptor<\\e2> antagonist, <e1>rauwolscine<\\e1> (0.5 mg\/kg), was without antagonistic effects","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"rauwolscine","object":"alpha(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e2>GENE-N<\\e2> antagonist, <e1>CHEMICAL<\\e1> (0.5 mg\/kg), was without antagonistic effects","sentence":"The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg\/kg), was without antagonistic effects"}
{"PMID":12818701,"re_id":4,"annotated sentence":"<e2>alpha(1A)-Adrenoceptor<\\e2> selective antagonists, <e1>2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane<\\e1> (WB-4101; 0.1-1 mg\/kg) and 5-methylurapidil (0.1-1 mg\/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg\/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg\/kg), were used to delineate the adrenoceptor subtypes involved","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane","object":"alpha(1A)-Adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> selective antagonists, <e1>CHEMICAL<\\e1> (WB-4101; 0.1-1 mg\/kg) and 5-methylurapidil (0.1-1 mg\/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg\/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg\/kg), were used to delineate the adrenoceptor subtypes involved","sentence":"alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg\/kg) and 5-methylurapidil (0.1-1 mg\/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg\/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg\/kg), were used to delineate the adrenoceptor subtypes involved"}
{"PMID":12818701,"re_id":5,"annotated sentence":"<e2>alpha(1A)-Adrenoceptor<\\e2> selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (<e1>WB-4101<\\e1>  0.1-1 mg\/kg) and 5-methylurapidil (0.1-1 mg\/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg\/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg\/kg), were used to delineate the adrenoceptor subtypes involved","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"WB-4101","object":"alpha(1A)-Adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (<e1>CHEMICAL<\\e1>  0.1-1 mg\/kg) and 5-methylurapidil (0.1-1 mg\/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg\/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg\/kg), were used to delineate the adrenoceptor subtypes involved","sentence":"alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101  0.1-1 mg\/kg) and 5-methylurapidil (0.1-1 mg\/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg\/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg\/kg), were used to delineate the adrenoceptor subtypes involved"}
{"PMID":12818701,"re_id":6,"annotated sentence":"<e2>alpha(1A)-Adrenoceptor<\\e2> selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg\/kg) and <e1>5-methylurapidil<\\e1> (0.1-1 mg\/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg\/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg\/kg), were used to delineate the adrenoceptor subtypes involved","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"5-methylurapidil","object":"alpha(1A)-Adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg\/kg) and <e1>CHEMICAL<\\e1> (0.1-1 mg\/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg\/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg\/kg), were used to delineate the adrenoceptor subtypes involved","sentence":"alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg\/kg) and 5-methylurapidil (0.1-1 mg\/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg\/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg\/kg), were used to delineate the adrenoceptor subtypes involved"}
{"PMID":12818701,"re_id":7,"annotated sentence":"alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg\/kg) and 5-methylurapidil (0.1-1 mg\/kg), the <e2>alpha(1B)-adrenoceptor<\\e2> selective antagonist, <e1>4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline<\\e1> (L-765314; 0.3-1 mg\/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg\/kg), were used to delineate the adrenoceptor subtypes involved","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline","object":"alpha(1B)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg\/kg) and 5-methylurapidil (0.1-1 mg\/kg), the <e2>GENE-Y<\\e2> selective antagonist, <e1>CHEMICAL<\\e1> (L-765314; 0.3-1 mg\/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg\/kg), were used to delineate the adrenoceptor subtypes involved","sentence":"alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg\/kg) and 5-methylurapidil (0.1-1 mg\/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg\/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg\/kg), were used to delineate the adrenoceptor subtypes involved"}
{"PMID":12818701,"re_id":8,"annotated sentence":"alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg\/kg) and 5-methylurapidil (0.1-1 mg\/kg), the <e2>alpha(1B)-adrenoceptor<\\e2> selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (<e1>L-765314<\\e1>  0.3-1 mg\/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg\/kg), were used to delineate the adrenoceptor subtypes involved","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"L-765314","object":"alpha(1B)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg\/kg) and 5-methylurapidil (0.1-1 mg\/kg), the <e2>GENE-Y<\\e2> selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (<e1>CHEMICAL<\\e1>  0.3-1 mg\/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg\/kg), were used to delineate the adrenoceptor subtypes involved","sentence":"alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg\/kg) and 5-methylurapidil (0.1-1 mg\/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314  0.3-1 mg\/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg\/kg), were used to delineate the adrenoceptor subtypes involved"}
{"PMID":12818701,"re_id":9,"annotated sentence":"alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg\/kg) and 5-methylurapidil (0.1-1 mg\/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg\/kg), as well as the <e2>alpha(1D)-adrenoceptor<\\e2> selective antagonist, <e1>8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione<\\e1> (BMY-7378; 1 mg\/kg), were used to delineate the adrenoceptor subtypes involved","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione","object":"alpha(1D)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg\/kg) and 5-methylurapidil (0.1-1 mg\/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg\/kg), as well as the <e2>GENE-Y<\\e2> selective antagonist, <e1>CHEMICAL<\\e1> (BMY-7378; 1 mg\/kg), were used to delineate the adrenoceptor subtypes involved","sentence":"alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg\/kg) and 5-methylurapidil (0.1-1 mg\/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg\/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg\/kg), were used to delineate the adrenoceptor subtypes involved"}
{"PMID":12818701,"re_id":10,"annotated sentence":"alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg\/kg) and 5-methylurapidil (0.1-1 mg\/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg\/kg), as well as the <e2>alpha(1D)-adrenoceptor<\\e2> selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (<e1>BMY-7378<\\e1>  1 mg\/kg), were used to delineate the adrenoceptor subtypes involved","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"BMY-7378","object":"alpha(1D)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg\/kg) and 5-methylurapidil (0.1-1 mg\/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg\/kg), as well as the <e2>GENE-Y<\\e2> selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (<e1>CHEMICAL<\\e1>  1 mg\/kg), were used to delineate the adrenoceptor subtypes involved","sentence":"alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg\/kg) and 5-methylurapidil (0.1-1 mg\/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg\/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378  1 mg\/kg), were used to delineate the adrenoceptor subtypes involved"}
{"PMID":12824918,"re_id":0,"annotated sentence":"To further investigate this positive correlation and its possible therapeutic implications, a selective <e2>COX-2<\\e2> inhibitor, <e1>etodolac<\\e1>  was tested on three variants of HT-29 colon cancer cell lines, HT-29\/Inv1, HT-29\/Inv2 and HT-29\/Inv3, with graded increases of in vitro Matrigel invasive potential and COX-2 expression levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"etodolac","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To further investigate this positive correlation and its possible therapeutic implications, a selective <e2>GENE-Y<\\e2> inhibitor, <e1>CHEMICAL<\\e1>  was tested on three variants of HT-29 colon cancer cell lines, HT-29\/Inv1, HT-29\/Inv2 and HT-29\/Inv3, with graded increases of in vitro Matrigel invasive potential and GENE-Y expression levels","sentence":"To further investigate this positive correlation and its possible therapeutic implications, a selective COX-2 inhibitor, etodolac  was tested on three variants of HT-29 colon cancer cell lines, HT-29\/Inv1, HT-29\/Inv2 and HT-29\/Inv3, with graded increases of in vitro Matrigel invasive potential and COX-2 expression levels"}
{"PMID":12827214,"re_id":0,"annotated sentence":"However, other <e2>alpha(1)-adrenoceptor<\\e2> antagonists (<e1>tamsulosin<\\e1>  WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit alpha(1)-adrenoceptor antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"tamsulosin","object":"alpha(1)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, other <e2>GENE-N<\\e2> antagonists (<e1>CHEMICAL<\\e1>  WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit GENE-N antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding","sentence":"However, other alpha(1)-adrenoceptor antagonists (tamsulosin  WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit alpha(1)-adrenoceptor antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding"}
{"PMID":12827214,"re_id":1,"annotated sentence":"However, other <e2>alpha(1)-adrenoceptor<\\e2> antagonists (tamsulosin, <e1>WB4101<\\e1> and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit alpha(1)-adrenoceptor antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"WB4101","object":"alpha(1)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, other <e2>GENE-N<\\e2> antagonists (tamsulosin, <e1>CHEMICAL<\\e1> and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit GENE-N antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding","sentence":"However, other alpha(1)-adrenoceptor antagonists (tamsulosin, WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit alpha(1)-adrenoceptor antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding"}
{"PMID":12827214,"re_id":2,"annotated sentence":"However, other <e2>alpha(1)-adrenoceptor<\\e2> antagonists (tamsulosin, WB4101 and <e1>corynanthine<\\e1>  did not inhibit the binding at a range of concentrations that generally exhibit alpha(1)-adrenoceptor antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"corynanthine","object":"alpha(1)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, other <e2>GENE-N<\\e2> antagonists (tamsulosin, WB4101 and <e1>CHEMICAL<\\e1>  did not inhibit the binding at a range of concentrations that generally exhibit GENE-N antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding","sentence":"However, other alpha(1)-adrenoceptor antagonists (tamsulosin, WB4101 and corynanthine  did not inhibit the binding at a range of concentrations that generally exhibit alpha(1)-adrenoceptor antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding"}
{"PMID":12837768,"re_id":0,"annotated sentence":"A comparison of the results with previous data for desipramine and cocaine inhibition of <e1>norepinephrine<\\e1> uptake by the mutant <e2>hNETs<\\e2> reveals that MrIA binding to hNET occurs at a site that is distinct from but overlaps with the binding sites for tricyclic antidepressants and cocaine.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"norepinephrine","object":"hNETs","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A comparison of the results with previous data for desipramine and cocaine inhibition of <e1>CHEMICAL<\\e1> uptake by the mutant <e2>GENE-Y<\\e2> reveals that MrIA binding to hNET occurs at a site that is distinct from but overlaps with the binding sites for tricyclic antidepressants and cocaine.","sentence":"A comparison of the results with previous data for desipramine and cocaine inhibition of norepinephrine uptake by the mutant hNETs reveals that MrIA binding to hNET occurs at a site that is distinct from but overlaps with the binding sites for tricyclic antidepressants and cocaine."}
{"PMID":12837768,"re_id":1,"annotated sentence":"The potency of MrIA was greater for inhibition of uptake by <e2>hNET<\\e2> of <e1>[3H]norepinephrine<\\e1> (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the human dopamine transporter and serotonin transporter were not inhibited by MrIA (to 7 microM)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"[3H]norepinephrine","object":"hNET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The potency of MrIA was greater for inhibition of uptake by <e2>GENE-Y<\\e2> of <e1>CHEMICAL<\\e1> (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the human dopamine transporter and serotonin transporter were not inhibited by MrIA (to 7 microM)","sentence":"The potency of MrIA was greater for inhibition of uptake by hNET of [3H]norepinephrine (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the human dopamine transporter and serotonin transporter were not inhibited by MrIA (to 7 microM)"}
{"PMID":12837768,"re_id":2,"annotated sentence":"The potency of MrIA was greater for inhibition of uptake by <e2>hNET<\\e2> of [3H]norepinephrine (Ki 1.89 microM) than <e1>[3H]dopamine<\\e1> (Ki 4.33 microM), and the human dopamine transporter and serotonin transporter were not inhibited by MrIA (to 7 microM)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"[3H]dopamine","object":"hNET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The potency of MrIA was greater for inhibition of uptake by <e2>GENE-Y<\\e2> of [3H]norepinephrine (Ki 1.89 microM) than <e1>CHEMICAL<\\e1> (Ki 4.33 microM), and the human dopamine transporter and serotonin transporter were not inhibited by MrIA (to 7 microM)","sentence":"The potency of MrIA was greater for inhibition of uptake by hNET of [3H]norepinephrine (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the human dopamine transporter and serotonin transporter were not inhibited by MrIA (to 7 microM)"}
{"PMID":1284246,"re_id":0,"annotated sentence":"A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, <e2>ACY-1<\\e2>  [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of <e1>N-acylated L-amino acids<\\e1> except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"N-acylated L-amino acids","object":"ACY-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, <e2>GENE-Y<\\e2>  [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of <e1>CHEMICAL<\\e1> except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced","sentence":"A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1  [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced"}
{"PMID":1284246,"re_id":1,"annotated sentence":"A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [<e2>EC 3.5.1.14<\\e2> , a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of <e1>N-acylated L-amino acids<\\e1> except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"N-acylated L-amino acids","object":"EC 3.5.1.14","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [<e2>GENE-Y<\\e2> , a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of <e1>CHEMICAL<\\e1> except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced","sentence":"A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14 , a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced"}
{"PMID":1284246,"re_id":2,"annotated sentence":"A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric <e2>metalloprotein<\\e2> having two Zn2+ in the molecule, which catalyzes the deacylation of <e1>N-acylated L-amino acids<\\e1> except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"N-acylated L-amino acids","object":"metalloprotein","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric <e2>GENE-N<\\e2> having two Zn2+ in the molecule, which catalyzes the deacylation of <e1>CHEMICAL<\\e1> except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced","sentence":"A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced"}
{"PMID":1284246,"re_id":3,"annotated sentence":"A cDNA encoding the complete amino acid sequence of <e2>aminoacylase 1<\\e2> (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of <e1>N-acylated L-amino acids<\\e1> except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"N-acylated L-amino acids","object":"aminoacylase 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A cDNA encoding the complete amino acid sequence of <e2>GENE-Y<\\e2> (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of <e1>CHEMICAL<\\e1> except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced","sentence":"A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced"}
{"PMID":1284246,"re_id":4,"annotated sentence":"A cDNA encoding the complete amino acid sequence of aminoacylase 1 (<e2>N-acylamino acid aminohydrolase<\\e2>  ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of <e1>N-acylated L-amino acids<\\e1> except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"N-acylated L-amino acids","object":"N-acylamino acid aminohydrolase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A cDNA encoding the complete amino acid sequence of aminoacylase 1 (<e2>GENE-Y<\\e2>  ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of <e1>CHEMICAL<\\e1> except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced","sentence":"A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase  ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced"}
{"PMID":12901032,"re_id":0,"annotated sentence":"Patients stable on warfarin therapy and concurrently taking a <e2>cyclooxygenase-2<\\e2> (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, <e1>salsalate<\\e1>  or acetaminophen) randomly received celecoxib 200 mg\/day or rofecoxib 25 mg\/day for three weeks","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"salsalate","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Patients stable on warfarin therapy and concurrently taking a <e2>GENE-Y<\\e2> (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, <e1>CHEMICAL<\\e1>  or acetaminophen) randomly received celecoxib 200 mg\/day or rofecoxib 25 mg\/day for three weeks","sentence":"Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate  or acetaminophen) randomly received celecoxib 200 mg\/day or rofecoxib 25 mg\/day for three weeks"}
{"PMID":12901032,"re_id":1,"annotated sentence":"Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (<e2>COX-2<\\e2>  inhibitor comparator (traditional nonsteroidal antiinflammatory medications, <e1>salsalate<\\e1>  or acetaminophen) randomly received celecoxib 200 mg\/day or rofecoxib 25 mg\/day for three weeks","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"salsalate","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (<e2>GENE-Y<\\e2>  inhibitor comparator (traditional nonsteroidal antiinflammatory medications, <e1>CHEMICAL<\\e1>  or acetaminophen) randomly received celecoxib 200 mg\/day or rofecoxib 25 mg\/day for three weeks","sentence":"Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (COX-2  inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate  or acetaminophen) randomly received celecoxib 200 mg\/day or rofecoxib 25 mg\/day for three weeks"}
{"PMID":12901032,"re_id":2,"annotated sentence":"Patients stable on warfarin therapy and concurrently taking a <e2>cyclooxygenase-2<\\e2> (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or <e1>acetaminophen<\\e1>  randomly received celecoxib 200 mg\/day or rofecoxib 25 mg\/day for three weeks","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acetaminophen","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Patients stable on warfarin therapy and concurrently taking a <e2>GENE-Y<\\e2> (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or <e1>CHEMICAL<\\e1>  randomly received celecoxib 200 mg\/day or rofecoxib 25 mg\/day for three weeks","sentence":"Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen  randomly received celecoxib 200 mg\/day or rofecoxib 25 mg\/day for three weeks"}
{"PMID":12901032,"re_id":3,"annotated sentence":"Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (<e2>COX-2<\\e2>  inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or <e1>acetaminophen<\\e1>  randomly received celecoxib 200 mg\/day or rofecoxib 25 mg\/day for three weeks","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acetaminophen","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (<e2>GENE-Y<\\e2>  inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or <e1>CHEMICAL<\\e1>  randomly received celecoxib 200 mg\/day or rofecoxib 25 mg\/day for three weeks","sentence":"Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (COX-2  inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen  randomly received celecoxib 200 mg\/day or rofecoxib 25 mg\/day for three weeks"}
{"PMID":12901032,"re_id":4,"annotated sentence":"Patients stable on warfarin therapy and concurrently taking a <e2>cyclooxygenase-2<\\e2> (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received <e1>celecoxib<\\e1> 200 mg\/day or rofecoxib 25 mg\/day for three weeks","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"celecoxib","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Patients stable on warfarin therapy and concurrently taking a <e2>GENE-Y<\\e2> (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received <e1>CHEMICAL<\\e1> 200 mg\/day or rofecoxib 25 mg\/day for three weeks","sentence":"Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received celecoxib 200 mg\/day or rofecoxib 25 mg\/day for three weeks"}
{"PMID":12901032,"re_id":5,"annotated sentence":"Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (<e2>COX-2<\\e2>  inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received <e1>celecoxib<\\e1> 200 mg\/day or rofecoxib 25 mg\/day for three weeks","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"celecoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (<e2>GENE-Y<\\e2>  inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received <e1>CHEMICAL<\\e1> 200 mg\/day or rofecoxib 25 mg\/day for three weeks","sentence":"Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (COX-2  inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received celecoxib 200 mg\/day or rofecoxib 25 mg\/day for three weeks"}
{"PMID":12901032,"re_id":6,"annotated sentence":"Patients stable on warfarin therapy and concurrently taking a <e2>cyclooxygenase-2<\\e2> (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received celecoxib 200 mg\/day or <e1>rofecoxib<\\e1> 25 mg\/day for three weeks","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"rofecoxib","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Patients stable on warfarin therapy and concurrently taking a <e2>GENE-Y<\\e2> (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received celecoxib 200 mg\/day or <e1>CHEMICAL<\\e1> 25 mg\/day for three weeks","sentence":"Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received celecoxib 200 mg\/day or rofecoxib 25 mg\/day for three weeks"}
{"PMID":12901032,"re_id":7,"annotated sentence":"Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (<e2>COX-2<\\e2>  inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received celecoxib 200 mg\/day or <e1>rofecoxib<\\e1> 25 mg\/day for three weeks","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"rofecoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (<e2>GENE-Y<\\e2>  inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received celecoxib 200 mg\/day or <e1>CHEMICAL<\\e1> 25 mg\/day for three weeks","sentence":"Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (COX-2  inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received celecoxib 200 mg\/day or rofecoxib 25 mg\/day for three weeks"}
{"PMID":12927226,"re_id":0,"annotated sentence":"RESULTS: <e1>Eprosartan<\\e1> tended to lower mean AP, it slightly increased heart rate (HR) (p<0.05), and markedly increased circulating <e2>Ang-II<\\e2> levels (p<0.01)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Eprosartan","object":"Ang-II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: <e1>CHEMICAL<\\e1> tended to lower mean AP, it slightly increased heart rate (HR) (p<0.05), and markedly increased circulating <e2>GENE-Y<\\e2> levels (p<0.01)","sentence":"RESULTS: Eprosartan tended to lower mean AP, it slightly increased heart rate (HR) (p<0.05), and markedly increased circulating Ang-II levels (p<0.01)"}
{"PMID":12927226,"re_id":1,"annotated sentence":"We sought to assess the effects of the <e2>angiotensin type 1 (AT1) receptor<\\e2> blocker <e1>eprosartan<\\e1> on HRV and BRG","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"eprosartan","object":"angiotensin type 1 (AT1) receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We sought to assess the effects of the <e2>GENE-Y<\\e2> blocker <e1>CHEMICAL<\\e1> on HRV and BRG","sentence":"We sought to assess the effects of the angiotensin type 1 (AT1) receptor blocker eprosartan on HRV and BRG"}
{"PMID":12927226,"re_id":2,"annotated sentence":"<e2>AT1<\\e2> antagonism by <e1>eprosartan<\\e1> lowers heart rate variability and baroreflex gain","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"eprosartan","object":"AT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> antagonism by <e1>CHEMICAL<\\e1> lowers heart rate variability and baroreflex gain","sentence":"AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain"}
{"PMID":12927226,"re_id":3,"annotated sentence":"CONCLUSIONS: <e2>AT1<\\e2> antagonism by <e1>eprosartan<\\e1> lowers heart rate variability and baroreflex gain","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"eprosartan","object":"AT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSIONS: <e2>GENE-Y<\\e2> antagonism by <e1>CHEMICAL<\\e1> lowers heart rate variability and baroreflex gain","sentence":"CONCLUSIONS: AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain"}
{"PMID":1318989,"re_id":0,"annotated sentence":"The antinociceptive activity of the <e2>alpha 2-adrenoceptor<\\e2> agonist <e1>clonidine<\\e1> was also increased in mice treated with alpha N-acetyl beta-endorphin-(1-31)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"clonidine","object":"alpha 2-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The antinociceptive activity of the <e2>GENE-N<\\e2> agonist <e1>CHEMICAL<\\e1> was also increased in mice treated with alpha N-acetyl beta-endorphin-(1-31)","sentence":"The antinociceptive activity of the alpha 2-adrenoceptor agonist clonidine was also increased in mice treated with alpha N-acetyl beta-endorphin-(1-31)"}
{"PMID":1322429,"re_id":0,"annotated sentence":"In seven normal subjects, basal <e2>ACTH<\\e2> plasma levels were significantly suppressed 3 h after <e1>loperamide<\\e1> administration (16 mg, orally) from 5 +\/- 1 to 2 +\/- 0 pmol\/L (P less than 0.0001)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"loperamide","object":"ACTH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In seven normal subjects, basal <e2>GENE-Y<\\e2> plasma levels were significantly suppressed 3 h after <e1>CHEMICAL<\\e1> administration (16 mg, orally) from 5 +\/- 1 to 2 +\/- 0 pmol\/L (P less than 0.0001)","sentence":"In seven normal subjects, basal ACTH plasma levels were significantly suppressed 3 h after loperamide administration (16 mg, orally) from 5 +\/- 1 to 2 +\/- 0 pmol\/L (P less than 0.0001)"}
{"PMID":1322429,"re_id":1,"annotated sentence":"After the combined pituitary stimulation test (100 micrograms <e2>human CRH<\\e2>  100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by <e1>loperamide<\\e1> from 9 +\/- 1 to 4 +\/- 1 pmol\/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +\/- 5 to 23 +\/- 4 pmol\/L.2 h (P less than 0.05)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"loperamide","object":"human CRH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"After the combined pituitary stimulation test (100 micrograms <e2>GENE-Y<\\e2>  100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by <e1>CHEMICAL<\\e1> from 9 +\/- 1 to 4 +\/- 1 pmol\/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +\/- 5 to 23 +\/- 4 pmol\/L.2 h (P less than 0.05)","sentence":"After the combined pituitary stimulation test (100 micrograms human CRH  100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +\/- 1 to 4 +\/- 1 pmol\/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +\/- 5 to 23 +\/- 4 pmol\/L.2 h (P less than 0.05)"}
{"PMID":1322429,"re_id":2,"annotated sentence":"After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms <e2>GnRH<\\e2>  100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by <e1>loperamide<\\e1> from 9 +\/- 1 to 4 +\/- 1 pmol\/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +\/- 5 to 23 +\/- 4 pmol\/L.2 h (P less than 0.05)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"loperamide","object":"GnRH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms <e2>GENE-Y<\\e2>  100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by <e1>CHEMICAL<\\e1> from 9 +\/- 1 to 4 +\/- 1 pmol\/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +\/- 5 to 23 +\/- 4 pmol\/L.2 h (P less than 0.05)","sentence":"After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH  100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +\/- 1 to 4 +\/- 1 pmol\/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +\/- 5 to 23 +\/- 4 pmol\/L.2 h (P less than 0.05)"}
{"PMID":1322429,"re_id":3,"annotated sentence":"After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms <e2>GH-releasing hormone<\\e2>  and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by <e1>loperamide<\\e1> from 9 +\/- 1 to 4 +\/- 1 pmol\/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +\/- 5 to 23 +\/- 4 pmol\/L.2 h (P less than 0.05)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"loperamide","object":"GH-releasing hormone","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms <e2>GENE-Y<\\e2>  and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by <e1>CHEMICAL<\\e1> from 9 +\/- 1 to 4 +\/- 1 pmol\/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +\/- 5 to 23 +\/- 4 pmol\/L.2 h (P less than 0.05)","sentence":"After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone  and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +\/- 1 to 4 +\/- 1 pmol\/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +\/- 5 to 23 +\/- 4 pmol\/L.2 h (P less than 0.05)"}
{"PMID":1322429,"re_id":4,"annotated sentence":"After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms <e2>TRH<\\e2> , the ACTH peak (maximum increase at 30 min) was significantly blunted by <e1>loperamide<\\e1> from 9 +\/- 1 to 4 +\/- 1 pmol\/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +\/- 5 to 23 +\/- 4 pmol\/L.2 h (P less than 0.05)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"loperamide","object":"TRH","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms <e2>GENE-N<\\e2> , the ACTH peak (maximum increase at 30 min) was significantly blunted by <e1>CHEMICAL<\\e1> from 9 +\/- 1 to 4 +\/- 1 pmol\/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +\/- 5 to 23 +\/- 4 pmol\/L.2 h (P less than 0.05)","sentence":"After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms TRH , the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +\/- 1 to 4 +\/- 1 pmol\/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +\/- 5 to 23 +\/- 4 pmol\/L.2 h (P less than 0.05)"}
{"PMID":1322429,"re_id":5,"annotated sentence":"After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the <e2>ACTH<\\e2> peak (maximum increase at 30 min) was significantly blunted by <e1>loperamide<\\e1> from 9 +\/- 1 to 4 +\/- 1 pmol\/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +\/- 5 to 23 +\/- 4 pmol\/L.2 h (P less than 0.05)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"loperamide","object":"ACTH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the <e2>GENE-Y<\\e2> peak (maximum increase at 30 min) was significantly blunted by <e1>CHEMICAL<\\e1> from 9 +\/- 1 to 4 +\/- 1 pmol\/L (P less than 0.001) and the area under the curve of GENE-Y from 0-120 min was reduced from 35 +\/- 5 to 23 +\/- 4 pmol\/L.2 h (P less than 0.05)","sentence":"After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +\/- 1 to 4 +\/- 1 pmol\/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +\/- 5 to 23 +\/- 4 pmol\/L.2 h (P less than 0.05)"}
{"PMID":1322429,"re_id":6,"annotated sentence":"After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by <e1>loperamide<\\e1> from 9 +\/- 1 to 4 +\/- 1 pmol\/L (P less than 0.001) and the area under the curve of <e2>ACTH<\\e2> from 0-120 min was reduced from 35 +\/- 5 to 23 +\/- 4 pmol\/L.2 h (P less than 0.05)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"loperamide","object":"ACTH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the GENE-Y peak (maximum increase at 30 min) was significantly blunted by <e1>CHEMICAL<\\e1> from 9 +\/- 1 to 4 +\/- 1 pmol\/L (P less than 0.001) and the area under the curve of <e2>GENE-Y<\\e2> from 0-120 min was reduced from 35 +\/- 5 to 23 +\/- 4 pmol\/L.2 h (P less than 0.05)","sentence":"After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +\/- 1 to 4 +\/- 1 pmol\/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +\/- 5 to 23 +\/- 4 pmol\/L.2 h (P less than 0.05)"}
{"PMID":1322429,"re_id":7,"annotated sentence":"<e1>Loperamide<\\e1>  an opiate agonist of high specificity for mu-receptors, was recently reported to suppress <e2>ACTH<\\e2> and cortisol levels in normal subjects, but not in patients with proven ACTH-dependent Cushing's disease","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Loperamide","object":"ACTH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  an opiate agonist of high specificity for mu-receptors, was recently reported to suppress <e2>GENE-Y<\\e2> and cortisol levels in normal subjects, but not in patients with proven GENE-Y-dependent Cushing's disease","sentence":"Loperamide  an opiate agonist of high specificity for mu-receptors, was recently reported to suppress ACTH and cortisol levels in normal subjects, but not in patients with proven ACTH-dependent Cushing's disease"}
{"PMID":1322429,"re_id":8,"annotated sentence":"In summary, <e1>loperamide<\\e1> is able to reduce basal and <e2>CRH<\\e2> induced ACTH and cortisol levels in normal subjects, but not in patients with Cushing's disease or secondary adrenal failure of hypothalamic origin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"loperamide","object":"CRH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In summary, <e1>CHEMICAL<\\e1> is able to reduce basal and <e2>GENE-Y<\\e2> induced ACTH and cortisol levels in normal subjects, but not in patients with Cushing's disease or secondary adrenal failure of hypothalamic origin","sentence":"In summary, loperamide is able to reduce basal and CRH induced ACTH and cortisol levels in normal subjects, but not in patients with Cushing's disease or secondary adrenal failure of hypothalamic origin"}
{"PMID":1322429,"re_id":9,"annotated sentence":"In summary, <e1>loperamide<\\e1> is able to reduce basal and CRH-induced <e2>ACTH<\\e2> and cortisol levels in normal subjects, but not in patients with Cushing's disease or secondary adrenal failure of hypothalamic origin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"loperamide","object":"ACTH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In summary, <e1>CHEMICAL<\\e1> is able to reduce basal and CRH-induced <e2>GENE-Y<\\e2> and cortisol levels in normal subjects, but not in patients with Cushing's disease or secondary adrenal failure of hypothalamic origin","sentence":"In summary, loperamide is able to reduce basal and CRH-induced ACTH and cortisol levels in normal subjects, but not in patients with Cushing's disease or secondary adrenal failure of hypothalamic origin"}
{"PMID":1329582,"re_id":0,"annotated sentence":"We also examined the effects of <e1>WEB 2086<\\e1>  a <e2>platelet-activating factor (PAF) receptor<\\e2> antagonist, in parallel","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"WEB 2086","object":"platelet-activating factor (PAF) receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We also examined the effects of <e1>CHEMICAL<\\e1>  a <e2>GENE-Y<\\e2> antagonist, in parallel","sentence":"We also examined the effects of WEB 2086  a platelet-activating factor (PAF) receptor antagonist, in parallel"}
{"PMID":1359745,"re_id":0,"annotated sentence":"The compounds identified as 5-LO inhibitors can be divided into antioxidants, substrate-analogous, and a large miscellaneous group of inhibitors, where <e1>hydroxamic acids<\\e1> are potent and more selective inhibitors of <e2>5-LO<\\e2>  The benzothiophene hydroxyurea, zileuton, is the first selective 5-LO inhibitor evaluated for the treatment of patients with IBD","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"hydroxamic acids","object":"5-LO","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The compounds identified as GENE-Y inhibitors can be divided into antioxidants, substrate-analogous, and a large miscellaneous group of inhibitors, where <e1>CHEMICAL<\\e1> are potent and more selective inhibitors of <e2>GENE-Y<\\e2>  The benzothiophene hydroxyurea, zileuton, is the first selective GENE-Y inhibitor evaluated for the treatment of patients with IBD","sentence":"The compounds identified as 5-LO inhibitors can be divided into antioxidants, substrate-analogous, and a large miscellaneous group of inhibitors, where hydroxamic acids are potent and more selective inhibitors of 5-LO  The benzothiophene hydroxyurea, zileuton, is the first selective 5-LO inhibitor evaluated for the treatment of patients with IBD"}
{"PMID":1359745,"re_id":1,"annotated sentence":"The <e1>benzothiophene hydroxyurea<\\e1>  zileuton, is the first selective <e2>5-LO<\\e2> inhibitor evaluated for the treatment of patients with IBD","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"benzothiophene hydroxyurea","object":"5-LO","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e1>CHEMICAL<\\e1>  zileuton, is the first selective <e2>GENE-Y<\\e2> inhibitor evaluated for the treatment of patients with IBD","sentence":"The benzothiophene hydroxyurea  zileuton, is the first selective 5-LO inhibitor evaluated for the treatment of patients with IBD"}
{"PMID":1359745,"re_id":2,"annotated sentence":"The benzothiophene hydroxyurea, <e1>zileuton<\\e1>  is the first selective <e2>5-LO<\\e2> inhibitor evaluated for the treatment of patients with IBD","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"zileuton","object":"5-LO","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The benzothiophene hydroxyurea, <e1>CHEMICAL<\\e1>  is the first selective <e2>GENE-Y<\\e2> inhibitor evaluated for the treatment of patients with IBD","sentence":"The benzothiophene hydroxyurea, zileuton  is the first selective 5-LO inhibitor evaluated for the treatment of patients with IBD"}
{"PMID":1359745,"re_id":3,"annotated sentence":"The unique role of the enzyme <e2>5-lipoxygenase<\\e2> (5-LO) in the production of <e1>leukotrienes<\\e1> (LTs) makes it a likely target for biochemical manipulation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"leukotrienes","object":"5-lipoxygenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The unique role of the enzyme <e2>GENE-Y<\\e2> (5-LO) in the production of <e1>CHEMICAL<\\e1> (LTs) makes it a likely target for biochemical manipulation","sentence":"The unique role of the enzyme 5-lipoxygenase (5-LO) in the production of leukotrienes (LTs) makes it a likely target for biochemical manipulation"}
{"PMID":1359745,"re_id":4,"annotated sentence":"The unique role of the enzyme 5-lipoxygenase (<e2>5-LO<\\e2>  in the production of <e1>leukotrienes<\\e1> (LTs) makes it a likely target for biochemical manipulation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"leukotrienes","object":"5-LO","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The unique role of the enzyme 5-lipoxygenase (<e2>GENE-Y<\\e2>  in the production of <e1>CHEMICAL<\\e1> (LTs) makes it a likely target for biochemical manipulation","sentence":"The unique role of the enzyme 5-lipoxygenase (5-LO  in the production of leukotrienes (LTs) makes it a likely target for biochemical manipulation"}
{"PMID":1359745,"re_id":5,"annotated sentence":"The unique role of the enzyme <e2>5-lipoxygenase<\\e2> (5-LO) in the production of leukotrienes (<e1>LTs<\\e1>  makes it a likely target for biochemical manipulation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"LTs","object":"5-lipoxygenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The unique role of the enzyme <e2>GENE-Y<\\e2> (5-LO) in the production of leukotrienes (<e1>CHEMICAL<\\e1>  makes it a likely target for biochemical manipulation","sentence":"The unique role of the enzyme 5-lipoxygenase (5-LO) in the production of leukotrienes (LTs  makes it a likely target for biochemical manipulation"}
{"PMID":1359745,"re_id":6,"annotated sentence":"The unique role of the enzyme 5-lipoxygenase (<e2>5-LO<\\e2>  in the production of leukotrienes (<e1>LTs<\\e1>  makes it a likely target for biochemical manipulation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"LTs","object":"5-LO","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The unique role of the enzyme 5-lipoxygenase (<e2>GENE-Y<\\e2>  in the production of leukotrienes (<e1>CHEMICAL<\\e1>  makes it a likely target for biochemical manipulation","sentence":"The unique role of the enzyme 5-lipoxygenase (5-LO  in the production of leukotrienes (LTs  makes it a likely target for biochemical manipulation"}
{"PMID":14583450,"re_id":0,"annotated sentence":"In PC3 cells, <e1>hydroxyurea<\\e1> inhibited <e2>hRRM2<\\e2> and resulted in increased sensitivity to UV irradiation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"hydroxyurea","object":"hRRM2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In PC3 cells, <e1>CHEMICAL<\\e1> inhibited <e2>GENE-Y<\\e2> and resulted in increased sensitivity to UV irradiation","sentence":"In PC3 cells, hydroxyurea inhibited hRRM2 and resulted in increased sensitivity to UV irradiation"}
{"PMID":14583450,"re_id":1,"annotated sentence":"Ribonucleotide reductase (<e2>RR<\\e2>  is responsible for the de novo conversion of the ribonucleoside diphosphates to <e1>deoxyribonucleoside diphosphates<\\e1>  which are essential for DNA synthesis and repair","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"deoxyribonucleoside diphosphates","object":"RR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Ribonucleotide reductase (<e2>GENE-N<\\e2>  is responsible for the de novo conversion of the ribonucleoside diphosphates to <e1>CHEMICAL<\\e1>  which are essential for DNA synthesis and repair","sentence":"Ribonucleotide reductase (RR  is responsible for the de novo conversion of the ribonucleoside diphosphates to deoxyribonucleoside diphosphates  which are essential for DNA synthesis and repair"}
{"PMID":14583450,"re_id":2,"annotated sentence":"<e2>Ribonucleotide reductase<\\e2> (RR) is responsible for the de novo conversion of the ribonucleoside diphosphates to <e1>deoxyribonucleoside diphosphates<\\e1>  which are essential for DNA synthesis and repair","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"deoxyribonucleoside diphosphates","object":"Ribonucleotide reductase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> (RR) is responsible for the de novo conversion of the ribonucleoside diphosphates to <e1>CHEMICAL<\\e1>  which are essential for DNA synthesis and repair","sentence":"Ribonucleotide reductase (RR) is responsible for the de novo conversion of the ribonucleoside diphosphates to deoxyribonucleoside diphosphates  which are essential for DNA synthesis and repair"}
{"PMID":14583450,"re_id":3,"annotated sentence":"Ribonucleotide reductase (<e2>RR<\\e2>  is responsible for the de novo conversion of the <e1>ribonucleoside diphosphates<\\e1> to deoxyribonucleoside diphosphates, which are essential for DNA synthesis and repair","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"ribonucleoside diphosphates","object":"RR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Ribonucleotide reductase (<e2>GENE-N<\\e2>  is responsible for the de novo conversion of the <e1>CHEMICAL<\\e1> to deoxyCHEMICAL, which are essential for DNA synthesis and repair","sentence":"Ribonucleotide reductase (RR  is responsible for the de novo conversion of the ribonucleoside diphosphates to deoxyribonucleoside diphosphates, which are essential for DNA synthesis and repair"}
{"PMID":14583450,"re_id":4,"annotated sentence":"<e2>Ribonucleotide reductase<\\e2> (RR) is responsible for the de novo conversion of the <e1>ribonucleoside diphosphates<\\e1> to deoxyribonucleoside diphosphates, which are essential for DNA synthesis and repair","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"ribonucleoside diphosphates","object":"Ribonucleotide reductase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> (RR) is responsible for the de novo conversion of the <e1>CHEMICAL<\\e1> to deoxyCHEMICAL, which are essential for DNA synthesis and repair","sentence":"Ribonucleotide reductase (RR) is responsible for the de novo conversion of the ribonucleoside diphosphates to deoxyribonucleoside diphosphates, which are essential for DNA synthesis and repair"}
{"PMID":14588118,"re_id":0,"annotated sentence":"Furthermore, RT-PCR analyses revealed that <e1>minocycline<\\e1> treatment increased expression of <e2>interleukin-10<\\e2> mRNA but decreased tumor necrosis factor-alpha expression","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"minocycline","object":"interleukin-10","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, RT-PCR analyses revealed that <e1>CHEMICAL<\\e1> treatment increased expression of <e2>GENE-Y<\\e2> mRNA but decreased tumor necrosis factor-alpha expression","sentence":"Furthermore, RT-PCR analyses revealed that minocycline treatment increased expression of interleukin-10 mRNA but decreased tumor necrosis factor-alpha expression"}
{"PMID":14588118,"re_id":1,"annotated sentence":"In addition, <e1>minocycline<\\e1> treatment significantly reduced the specific <e2>caspase-3<\\e2> activity after SCI as compared to that of vehicle control","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"minocycline","object":"caspase-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e1>CHEMICAL<\\e1> treatment significantly reduced the specific <e2>GENE-Y<\\e2> activity after SCI as compared to that of vehicle control","sentence":"In addition, minocycline treatment significantly reduced the specific caspase-3 activity after SCI as compared to that of vehicle control"}
{"PMID":14588118,"re_id":2,"annotated sentence":"Furthermore, RT-PCR analyses revealed that <e1>minocycline<\\e1> treatment increased expression of interleukin-10 mRNA but decreased <e2>tumor necrosis factor-alpha<\\e2> expression","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"minocycline","object":"tumor necrosis factor-alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, RT-PCR analyses revealed that <e1>CHEMICAL<\\e1> treatment increased expression of interleukin-10 mRNA but decreased <e2>GENE-Y<\\e2> expression","sentence":"Furthermore, RT-PCR analyses revealed that minocycline treatment increased expression of interleukin-10 mRNA but decreased tumor necrosis factor-alpha expression"}
{"PMID":14619588,"re_id":0,"annotated sentence":"CONCLUSION: <e1>Nandrolone phenylpropionate<\\e1> up-regulated the density of <e2>AR<\\e2> in liver tissue, whereas it had no significant effects on the density of AR in testis and ovary tissues","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Nandrolone phenylpropionate","object":"AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSION: <e1>CHEMICAL<\\e1> up-regulated the density of <e2>GENE-Y<\\e2> in liver tissue, whereas it had no significant effects on the density of GENE-Y in testis and ovary tissues","sentence":"CONCLUSION: Nandrolone phenylpropionate up-regulated the density of AR in liver tissue, whereas it had no significant effects on the density of AR in testis and ovary tissues"}
{"PMID":14619588,"re_id":1,"annotated sentence":"RESULTS: The density of <e2>AR<\\e2> in liver tissue in <e1>NP<\\e1> group was higher than that in control group (P < 0.05)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"NP","object":"AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: The density of <e2>GENE-Y<\\e2> in liver tissue in <e1>CHEMICAL<\\e1> group was higher than that in control group (P < 0.05)","sentence":"RESULTS: The density of AR in liver tissue in NP group was higher than that in control group (P < 0.05)"}
{"PMID":14757145,"re_id":0,"annotated sentence":"The pretreatment with <e1>salbutamol<\\e1> induced a 59% down-regulation of left ventricular <e2>beta(2)-adrenoceptors<\\e2> compared to control","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"salbutamol","object":"beta(2)-adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The pretreatment with <e1>CHEMICAL<\\e1> induced a 59% down-regulation of left ventricular <e2>GENE-Y<\\e2> compared to control","sentence":"The pretreatment with salbutamol induced a 59% down-regulation of left ventricular beta(2)-adrenoceptors compared to control"}
{"PMID":14757145,"re_id":1,"annotated sentence":"Rats received a concomitant treatment with the selective beta(1)-adrenoceptor antagonist, bisoprolol (50 mg\/kg\/day p.o.) or were chronically pretreated with the selective <e2>beta(2)-adrenoceptor<\\e2> agonist <e1>salbutamol<\\e1> (40 microg\/kg\/h) for 1 week to induce beta(2)-adrenoceptor desensitization","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"salbutamol","object":"beta(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Rats received a concomitant treatment with the selective beta(1)-adrenoceptor antagonist, bisoprolol (50 mg\/kg\/day p.o.) or were chronically pretreated with the selective <e2>GENE-Y<\\e2> agonist <e1>CHEMICAL<\\e1> (40 microg\/kg\/h) for 1 week to induce GENE-Y desensitization","sentence":"Rats received a concomitant treatment with the selective beta(1)-adrenoceptor antagonist, bisoprolol (50 mg\/kg\/day p.o.) or were chronically pretreated with the selective beta(2)-adrenoceptor agonist salbutamol (40 microg\/kg\/h) for 1 week to induce beta(2)-adrenoceptor desensitization"}
{"PMID":14757145,"re_id":2,"annotated sentence":"Rats received a concomitant treatment with the selective <e2>beta(1)-adrenoceptor<\\e2> antagonist, <e1>bisoprolol<\\e1> (50 mg\/kg\/day p.o.) or were chronically pretreated with the selective beta(2)-adrenoceptor agonist salbutamol (40 microg\/kg\/h) for 1 week to induce beta(2)-adrenoceptor desensitization","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"bisoprolol","object":"beta(1)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Rats received a concomitant treatment with the selective <e2>GENE-Y<\\e2> antagonist, <e1>CHEMICAL<\\e1> (50 mg\/kg\/day p.o.) or were chronically pretreated with the selective beta(2)-adrenoceptor agonist salbutamol (40 microg\/kg\/h) for 1 week to induce beta(2)-adrenoceptor desensitization","sentence":"Rats received a concomitant treatment with the selective beta(1)-adrenoceptor antagonist, bisoprolol (50 mg\/kg\/day p.o.) or were chronically pretreated with the selective beta(2)-adrenoceptor agonist salbutamol (40 microg\/kg\/h) for 1 week to induce beta(2)-adrenoceptor desensitization"}
{"PMID":14757700,"re_id":0,"annotated sentence":"Known VR1 antagonists (BCTC, thio-BCTC and capsazepine) were also able to block the response of <e2>TRPM8<\\e2> to <e1>menthol<\\e1> (IC(50): 0.8+\/-1.0, 3.5+\/-1.1 and 18+\/-1.1 microM, respectively)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"menthol","object":"TRPM8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Known VR1 antagonists (BCTC, thio-BCTC and capsazepine) were also able to block the response of <e2>GENE-Y<\\e2> to <e1>CHEMICAL<\\e1> (IC(50): 0.8+\/-1.0, 3.5+\/-1.1 and 18+\/-1.1 microM, respectively)","sentence":"Known VR1 antagonists (BCTC, thio-BCTC and capsazepine) were also able to block the response of TRPM8 to menthol (IC(50): 0.8+\/-1.0, 3.5+\/-1.1 and 18+\/-1.1 microM, respectively)"}
{"PMID":14757700,"re_id":1,"annotated sentence":"The Ca(2+) response of <e2>hVR1<\\e2> transfected HEK293 cells to the endogenous VR1 agonist <e1>N-arachidonoyl-dopamine<\\e1> was potentiated by low pH","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"N-arachidonoyl-dopamine","object":"hVR1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The Ca(2+) response of <e2>GENE-Y<\\e2> transfected HEK293 cells to the endogenous VR1 agonist <e1>CHEMICAL<\\e1> was potentiated by low pH","sentence":"The Ca(2+) response of hVR1 transfected HEK293 cells to the endogenous VR1 agonist N-arachidonoyl-dopamine was potentiated by low pH"}
{"PMID":14757700,"re_id":2,"annotated sentence":"In contrast, <e1>menthol<\\e1>  and icilin-activated <e2>TRPM8<\\e2> currents were suppressed by low pH","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"menthol","object":"TRPM8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, <e1>CHEMICAL<\\e1>  and icilin-activated <e2>GENE-Y<\\e2> currents were suppressed by low pH","sentence":"In contrast, menthol  and icilin-activated TRPM8 currents were suppressed by low pH"}
{"PMID":14757700,"re_id":3,"annotated sentence":"In contrast, menthol- and <e1>icilin<\\e1> activated <e2>TRPM8<\\e2> currents were suppressed by low pH","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"icilin","object":"TRPM8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, menthol- and <e1>CHEMICAL<\\e1> activated <e2>GENE-Y<\\e2> currents were suppressed by low pH","sentence":"In contrast, menthol- and icilin activated TRPM8 currents were suppressed by low pH"}
{"PMID":14757700,"re_id":4,"annotated sentence":"TRPM8 (<e2>CMR1<\\e2>  is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, <e1>eucalyptol<\\e1> and icilin","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"eucalyptol","object":"CMR1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"TRPM8 (<e2>GENE-Y<\\e2>  is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, <e1>CHEMICAL<\\e1> and icilin","sentence":"TRPM8 (CMR1  is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, eucalyptol and icilin"}
{"PMID":14757700,"re_id":5,"annotated sentence":"TRPM8 (CMR1) is a <e2>Ca(2+)-permeable channel<\\e2>  which can be activated by low temperatures, menthol, <e1>eucalyptol<\\e1> and icilin","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"eucalyptol","object":"Ca(2+)-permeable channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"TRPM8 (CMR1) is a <e2>GENE-N<\\e2>  which can be activated by low temperatures, menthol, <e1>CHEMICAL<\\e1> and icilin","sentence":"TRPM8 (CMR1) is a Ca(2+)-permeable channel  which can be activated by low temperatures, menthol, eucalyptol and icilin"}
{"PMID":14757700,"re_id":6,"annotated sentence":"<e2>TRPM8<\\e2> (CMR1) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, <e1>eucalyptol<\\e1> and icilin","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"eucalyptol","object":"TRPM8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (CMR1) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, <e1>CHEMICAL<\\e1> and icilin","sentence":"TRPM8 (CMR1) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, eucalyptol and icilin"}
{"PMID":14757700,"re_id":7,"annotated sentence":"TRPM8 (<e2>CMR1<\\e2>  is a Ca(2+)-permeable channel, which can be activated by low temperatures, <e1>menthol<\\e1>  eucalyptol and icilin","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"menthol","object":"CMR1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"TRPM8 (<e2>GENE-Y<\\e2>  is a Ca(2+)-permeable channel, which can be activated by low temperatures, <e1>CHEMICAL<\\e1>  eucalyptol and icilin","sentence":"TRPM8 (CMR1  is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol  eucalyptol and icilin"}
{"PMID":14757700,"re_id":8,"annotated sentence":"TRPM8 (CMR1) is a <e2>Ca(2+)-permeable channel<\\e2>  which can be activated by low temperatures, <e1>menthol<\\e1>  eucalyptol and icilin","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"menthol","object":"Ca(2+)-permeable channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"TRPM8 (CMR1) is a <e2>GENE-N<\\e2>  which can be activated by low temperatures, <e1>CHEMICAL<\\e1>  eucalyptol and icilin","sentence":"TRPM8 (CMR1) is a Ca(2+)-permeable channel  which can be activated by low temperatures, menthol  eucalyptol and icilin"}
{"PMID":14757700,"re_id":9,"annotated sentence":"<e2>TRPM8<\\e2> (CMR1) is a Ca(2+)-permeable channel, which can be activated by low temperatures, <e1>menthol<\\e1>  eucalyptol and icilin","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"menthol","object":"TRPM8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (CMR1) is a Ca(2+)-permeable channel, which can be activated by low temperatures, <e1>CHEMICAL<\\e1>  eucalyptol and icilin","sentence":"TRPM8 (CMR1) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol  eucalyptol and icilin"}
{"PMID":14757700,"re_id":10,"annotated sentence":"TRPM8 (<e2>CMR1<\\e2>  is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, eucalyptol and <e1>icilin<\\e1>  It belongs to the transient receptor potential (TRP) family, and therefore is related to vanilloid receptor type-1 (VR1, TRPV1)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"icilin","object":"CMR1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"TRPM8 (<e2>GENE-Y<\\e2>  is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, eucalyptol and <e1>CHEMICAL<\\e1>  It belongs to the transient receptor potential (TRP) family, and therefore is related to vanilloid receptor type-1 (VR1, TRPV1)","sentence":"TRPM8 (CMR1  is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, eucalyptol and icilin  It belongs to the transient receptor potential (TRP) family, and therefore is related to vanilloid receptor type-1 (VR1, TRPV1)"}
{"PMID":14757700,"re_id":11,"annotated sentence":"TRPM8 (CMR1) is a <e2>Ca(2+)-permeable channel<\\e2>  which can be activated by low temperatures, menthol, eucalyptol and <e1>icilin<\\e1>  It belongs to the transient receptor potential (TRP) family, and therefore is related to vanilloid receptor type-1 (VR1, TRPV1)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"icilin","object":"Ca(2+)-permeable channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"TRPM8 (CMR1) is a <e2>GENE-N<\\e2>  which can be activated by low temperatures, menthol, eucalyptol and <e1>CHEMICAL<\\e1>  It belongs to the transient receptor potential (TRP) family, and therefore is related to vanilloid receptor type-1 (VR1, TRPV1)","sentence":"TRPM8 (CMR1) is a Ca(2+)-permeable channel  which can be activated by low temperatures, menthol, eucalyptol and icilin  It belongs to the transient receptor potential (TRP) family, and therefore is related to vanilloid receptor type-1 (VR1, TRPV1)"}
{"PMID":14757700,"re_id":12,"annotated sentence":"<e2>TRPM8<\\e2> (CMR1) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, eucalyptol and <e1>icilin<\\e1>  It belongs to the transient receptor potential (TRP) family, and therefore is related to vanilloid receptor type-1 (VR1, TRPV1)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"icilin","object":"TRPM8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (CMR1) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, eucalyptol and <e1>CHEMICAL<\\e1>  It belongs to the transient receptor potential (TRP) family, and therefore is related to vanilloid receptor type-1 (VR1, TRPV1)","sentence":"TRPM8 (CMR1) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, eucalyptol and icilin  It belongs to the transient receptor potential (TRP) family, and therefore is related to vanilloid receptor type-1 (VR1, TRPV1)"}
{"PMID":14757700,"re_id":13,"annotated sentence":"Known VR1 antagonists (<e1>BCTC<\\e1>  thio-BCTC and capsazepine) were also able to block the response of <e2>TRPM8<\\e2> to menthol (IC(50): 0.8+\/-1.0, 3.5+\/-1.1 and 18+\/-1.1 microM, respectively)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BCTC","object":"TRPM8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Known VR1 antagonists (<e1>CHEMICAL<\\e1>  thio-CHEMICAL and capsazepine) were also able to block the response of <e2>GENE-Y<\\e2> to menthol (IC(50): 0.8+\/-1.0, 3.5+\/-1.1 and 18+\/-1.1 microM, respectively)","sentence":"Known VR1 antagonists (BCTC  thio-BCTC and capsazepine) were also able to block the response of TRPM8 to menthol (IC(50): 0.8+\/-1.0, 3.5+\/-1.1 and 18+\/-1.1 microM, respectively)"}
{"PMID":14757700,"re_id":14,"annotated sentence":"Known VR1 antagonists (BCTC, <e1>thio-BCTC<\\e1> and capsazepine) were also able to block the response of <e2>TRPM8<\\e2> to menthol (IC(50): 0.8+\/-1.0, 3.5+\/-1.1 and 18+\/-1.1 microM, respectively)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"thio-BCTC","object":"TRPM8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Known VR1 antagonists (BCTC, <e1>CHEMICAL<\\e1> and capsazepine) were also able to block the response of <e2>GENE-Y<\\e2> to menthol (IC(50): 0.8+\/-1.0, 3.5+\/-1.1 and 18+\/-1.1 microM, respectively)","sentence":"Known VR1 antagonists (BCTC, thio-BCTC and capsazepine) were also able to block the response of TRPM8 to menthol (IC(50): 0.8+\/-1.0, 3.5+\/-1.1 and 18+\/-1.1 microM, respectively)"}
{"PMID":14757700,"re_id":15,"annotated sentence":"Known VR1 antagonists (BCTC, thio-BCTC and <e1>capsazepine<\\e1>  were also able to block the response of <e2>TRPM8<\\e2> to menthol (IC(50): 0.8+\/-1.0, 3.5+\/-1.1 and 18+\/-1.1 microM, respectively)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"capsazepine","object":"TRPM8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Known VR1 antagonists (BCTC, thio-BCTC and <e1>CHEMICAL<\\e1>  were also able to block the response of <e2>GENE-Y<\\e2> to menthol (IC(50): 0.8+\/-1.0, 3.5+\/-1.1 and 18+\/-1.1 microM, respectively)","sentence":"Known VR1 antagonists (BCTC, thio-BCTC and capsazepine  were also able to block the response of TRPM8 to menthol (IC(50): 0.8+\/-1.0, 3.5+\/-1.1 and 18+\/-1.1 microM, respectively)"}
{"PMID":14757700,"re_id":16,"annotated sentence":"The Ca(2+) response of hVR1-transfected HEK293 cells to the endogenous <e2>VR1<\\e2> agonist <e1>N-arachidonoyl-dopamine<\\e1> was potentiated by low pH","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"N-arachidonoyl-dopamine","object":"VR1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The Ca(2+) response of hGENE-Y-transfected HEK293 cells to the endogenous <e2>GENE-Y<\\e2> agonist <e1>CHEMICAL<\\e1> was potentiated by low pH","sentence":"The Ca(2+) response of hVR1-transfected HEK293 cells to the endogenous VR1 agonist N-arachidonoyl-dopamine was potentiated by low pH"}
{"PMID":14757700,"re_id":17,"annotated sentence":"Known <e2>VR1<\\e2> antagonists (<e1>BCTC<\\e1>  thio-BCTC and capsazepine) were also able to block the response of TRPM8 to menthol (IC(50): 0.8+\/-1.0, 3.5+\/-1.1 and 18+\/-1.1 microM, respectively)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"BCTC","object":"VR1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Known <e2>GENE-Y<\\e2> antagonists (<e1>CHEMICAL<\\e1>  thio-CHEMICAL and capsazepine) were also able to block the response of TRPM8 to menthol (IC(50): 0.8+\/-1.0, 3.5+\/-1.1 and 18+\/-1.1 microM, respectively)","sentence":"Known VR1 antagonists (BCTC  thio-BCTC and capsazepine) were also able to block the response of TRPM8 to menthol (IC(50): 0.8+\/-1.0, 3.5+\/-1.1 and 18+\/-1.1 microM, respectively)"}
{"PMID":14757700,"re_id":18,"annotated sentence":"Known <e2>VR1<\\e2> antagonists (BCTC, <e1>thio-BCTC<\\e1> and capsazepine) were also able to block the response of TRPM8 to menthol (IC(50): 0.8+\/-1.0, 3.5+\/-1.1 and 18+\/-1.1 microM, respectively)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"thio-BCTC","object":"VR1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Known <e2>GENE-Y<\\e2> antagonists (BCTC, <e1>CHEMICAL<\\e1> and capsazepine) were also able to block the response of TRPM8 to menthol (IC(50): 0.8+\/-1.0, 3.5+\/-1.1 and 18+\/-1.1 microM, respectively)","sentence":"Known VR1 antagonists (BCTC, thio-BCTC and capsazepine) were also able to block the response of TRPM8 to menthol (IC(50): 0.8+\/-1.0, 3.5+\/-1.1 and 18+\/-1.1 microM, respectively)"}
{"PMID":14757700,"re_id":19,"annotated sentence":"Known <e2>VR1<\\e2> antagonists (BCTC, thio-BCTC and <e1>capsazepine<\\e1>  were also able to block the response of TRPM8 to menthol (IC(50): 0.8+\/-1.0, 3.5+\/-1.1 and 18+\/-1.1 microM, respectively)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"capsazepine","object":"VR1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Known <e2>GENE-Y<\\e2> antagonists (BCTC, thio-BCTC and <e1>CHEMICAL<\\e1>  were also able to block the response of TRPM8 to menthol (IC(50): 0.8+\/-1.0, 3.5+\/-1.1 and 18+\/-1.1 microM, respectively)","sentence":"Known VR1 antagonists (BCTC, thio-BCTC and capsazepine  were also able to block the response of TRPM8 to menthol (IC(50): 0.8+\/-1.0, 3.5+\/-1.1 and 18+\/-1.1 microM, respectively)"}
{"PMID":15049511,"re_id":0,"annotated sentence":"The inhibitory effects of <e1>tranylcypromine<\\e1>  a nonselective irreversible inhibitor of <e2>monoamine oxidase<\\e2> (MAO), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tranylcypromine","object":"monoamine oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The inhibitory effects of <e1>CHEMICAL<\\e1>  a nonselective irreversible inhibitor of <e2>GENE-N<\\e2> (MAO), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro","sentence":"The inhibitory effects of tranylcypromine  a nonselective irreversible inhibitor of monoamine oxidase (MAO), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro"}
{"PMID":15049511,"re_id":1,"annotated sentence":"The inhibitory effects of <e1>tranylcypromine<\\e1>  a nonselective irreversible inhibitor of monoamine oxidase (<e2>MAO<\\e2> , on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tranylcypromine","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The inhibitory effects of <e1>CHEMICAL<\\e1>  a nonselective irreversible inhibitor of monoamine oxidase (<e2>GENE-N<\\e2> , on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro","sentence":"The inhibitory effects of tranylcypromine  a nonselective irreversible inhibitor of monoamine oxidase (MAO , on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro"}
{"PMID":15049511,"re_id":2,"annotated sentence":"The results demonstrated that <e1>tranylcypromine<\\e1> is a competitive inhibitor of <e2>CYP2C19<\\e2> (Ki = 32 microM) and CYP2D6 (Ki = 367 microM) and a noncompetitive inhibitor of CYP2C9 (Ki = 56 microM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tranylcypromine","object":"CYP2C19","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results demonstrated that <e1>CHEMICAL<\\e1> is a competitive inhibitor of <e2>GENE-Y<\\e2> (Ki = 32 microM) and CYP2D6 (Ki = 367 microM) and a noncompetitive inhibitor of CYP2C9 (Ki = 56 microM)","sentence":"The results demonstrated that tranylcypromine is a competitive inhibitor of CYP2C19 (Ki = 32 microM) and CYP2D6 (Ki = 367 microM) and a noncompetitive inhibitor of CYP2C9 (Ki = 56 microM)"}
{"PMID":15049511,"re_id":3,"annotated sentence":"The results demonstrated that <e1>tranylcypromine<\\e1> is a competitive inhibitor of CYP2C19 (Ki = 32 microM) and <e2>CYP2D6<\\e2> (Ki = 367 microM) and a noncompetitive inhibitor of CYP2C9 (Ki = 56 microM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tranylcypromine","object":"CYP2D6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results demonstrated that <e1>CHEMICAL<\\e1> is a competitive inhibitor of CYP2C19 (Ki = 32 microM) and <e2>GENE-Y<\\e2> (Ki = 367 microM) and a noncompetitive inhibitor of CYP2C9 (Ki = 56 microM)","sentence":"The results demonstrated that tranylcypromine is a competitive inhibitor of CYP2C19 (Ki = 32 microM) and CYP2D6 (Ki = 367 microM) and a noncompetitive inhibitor of CYP2C9 (Ki = 56 microM)"}
{"PMID":15049511,"re_id":4,"annotated sentence":"The results demonstrated that <e1>tranylcypromine<\\e1> is a competitive inhibitor of CYP2C19 (Ki = 32 microM) and CYP2D6 (Ki = 367 microM) and a noncompetitive inhibitor of <e2>CYP2C9<\\e2> (Ki = 56 microM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tranylcypromine","object":"CYP2C9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results demonstrated that <e1>CHEMICAL<\\e1> is a competitive inhibitor of CYP2C19 (Ki = 32 microM) and CYP2D6 (Ki = 367 microM) and a noncompetitive inhibitor of <e2>GENE-Y<\\e2> (Ki = 56 microM)","sentence":"The results demonstrated that tranylcypromine is a competitive inhibitor of CYP2C19 (Ki = 32 microM) and CYP2D6 (Ki = 367 microM) and a noncompetitive inhibitor of CYP2C9 (Ki = 56 microM)"}
{"PMID":15049511,"re_id":5,"annotated sentence":"Inhibitory effects of the <e2>monoamine oxidase<\\e2> inhibitor <e1>tranylcypromine<\\e1> on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tranylcypromine","object":"monoamine oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibitory effects of the <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1> on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6","sentence":"Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6"}
{"PMID":15109613,"re_id":0,"annotated sentence":"Studies in rats, mice and monkeys show that GC-1 lowers cholesterol with 600- to 1400-fold more potency and approximately two- to threefold more efficacy than <e1>atorvastatin<\\e1>  a compound that blocks <e2>HMG-CoA reductase<\\e2>  GC-1 also decreases plasma levels of triglyceride and lipoprotein (a), and induces loss of fat","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"atorvastatin","object":"HMG-CoA reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Studies in rats, mice and monkeys show that GC-1 lowers cholesterol with 600- to 1400-fold more potency and approximately two- to threefold more efficacy than <e1>CHEMICAL<\\e1>  a compound that blocks <e2>GENE-Y<\\e2>  GC-1 also decreases plasma levels of triglyceride and lipoprotein (a), and induces loss of fat","sentence":"Studies in rats, mice and monkeys show that GC-1 lowers cholesterol with 600- to 1400-fold more potency and approximately two- to threefold more efficacy than atorvastatin  a compound that blocks HMG-CoA reductase  GC-1 also decreases plasma levels of triglyceride and lipoprotein (a), and induces loss of fat"}
{"PMID":15180525,"re_id":0,"annotated sentence":"Compounds of several other structural families, including the <e1>quinoxaline<\\e1> AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of <e2>Flt3<\\e2> kinase","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"quinoxaline","object":"Flt3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Compounds of several other structural families, including the <e1>CHEMICAL<\\e1> AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of <e2>GENE-Y<\\e2> kinase","sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 kinase"}
{"PMID":15180525,"re_id":1,"annotated sentence":"Compounds of several other structural families, including the <e1>quinoxaline<\\e1> AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 <e2>kinase<\\e2>  They exhibit different selectivity profiles, both with respect to other kinases and among wildtype Flt3 and its activated versions","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"quinoxaline","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Compounds of several other structural families, including the <e1>CHEMICAL<\\e1> AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 <e2>GENE-N<\\e2>  They exhibit different selectivity profiles, both with respect to other GENE-Ns and among wildtype Flt3 and its activated versions","sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 kinase  They exhibit different selectivity profiles, both with respect to other kinases and among wildtype Flt3 and its activated versions"}
{"PMID":15180525,"re_id":2,"annotated sentence":"Compounds of several other structural families, including the quinoxaline <e1>AG1296<\\e1>  the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of <e2>Flt3<\\e2> kinase","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"AG1296","object":"Flt3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Compounds of several other structural families, including the quinoxaline <e1>CHEMICAL<\\e1>  the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of <e2>GENE-Y<\\e2> kinase","sentence":"Compounds of several other structural families, including the quinoxaline AG1296  the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 kinase"}
{"PMID":15180525,"re_id":3,"annotated sentence":"Compounds of several other structural families, including the quinoxaline <e1>AG1296<\\e1>  the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 <e2>kinase<\\e2>  They exhibit different selectivity profiles, both with respect to other kinases and among wildtype Flt3 and its activated versions","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"AG1296","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Compounds of several other structural families, including the quinoxaline <e1>CHEMICAL<\\e1>  the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 <e2>GENE-N<\\e2>  They exhibit different selectivity profiles, both with respect to other GENE-Ns and among wildtype Flt3 and its activated versions","sentence":"Compounds of several other structural families, including the quinoxaline AG1296  the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 kinase  They exhibit different selectivity profiles, both with respect to other kinases and among wildtype Flt3 and its activated versions"}
{"PMID":15180525,"re_id":4,"annotated sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the <e1>bis(1H-2-indolyl)-1-methanone<\\e1> D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of <e2>Flt3<\\e2> kinase","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"bis(1H-2-indolyl)-1-methanone","object":"Flt3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the <e1>CHEMICAL<\\e1> D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of <e2>GENE-Y<\\e2> kinase","sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 kinase"}
{"PMID":15180525,"re_id":5,"annotated sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the <e1>bis(1H-2-indolyl)-1-methanone<\\e1> D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 <e2>kinase<\\e2>  They exhibit different selectivity profiles, both with respect to other kinases and among wildtype Flt3 and its activated versions","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"bis(1H-2-indolyl)-1-methanone","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the <e1>CHEMICAL<\\e1> D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 <e2>GENE-N<\\e2>  They exhibit different selectivity profiles, both with respect to other GENE-Ns and among wildtype Flt3 and its activated versions","sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 kinase  They exhibit different selectivity profiles, both with respect to other kinases and among wildtype Flt3 and its activated versions"}
{"PMID":15180525,"re_id":6,"annotated sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone <e1>D-65476<\\e1>  the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of <e2>Flt3<\\e2> kinase","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"D-65476","object":"Flt3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone <e1>CHEMICAL<\\e1>  the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of <e2>GENE-Y<\\e2> kinase","sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476  the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 kinase"}
{"PMID":15180525,"re_id":7,"annotated sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone <e1>D-65476<\\e1>  the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 <e2>kinase<\\e2>  They exhibit different selectivity profiles, both with respect to other kinases and among wildtype Flt3 and its activated versions","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"D-65476","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone <e1>CHEMICAL<\\e1>  the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 <e2>GENE-N<\\e2>  They exhibit different selectivity profiles, both with respect to other GENE-Ns and among wildtype Flt3 and its activated versions","sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476  the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 kinase  They exhibit different selectivity profiles, both with respect to other kinases and among wildtype Flt3 and its activated versions"}
{"PMID":15180525,"re_id":8,"annotated sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the <e1>indolinones<\\e1> SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of <e2>Flt3<\\e2> kinase","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"indolinones","object":"Flt3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the <e1>CHEMICAL<\\e1> SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of <e2>GENE-Y<\\e2> kinase","sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 kinase"}
{"PMID":15180525,"re_id":9,"annotated sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the <e1>indolinones<\\e1> SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 <e2>kinase<\\e2>  They exhibit different selectivity profiles, both with respect to other kinases and among wildtype Flt3 and its activated versions","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"indolinones","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the <e1>CHEMICAL<\\e1> SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 <e2>GENE-N<\\e2>  They exhibit different selectivity profiles, both with respect to other GENE-Ns and among wildtype Flt3 and its activated versions","sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 kinase  They exhibit different selectivity profiles, both with respect to other kinases and among wildtype Flt3 and its activated versions"}
{"PMID":15180525,"re_id":10,"annotated sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones <e1>SU5416<\\e1> and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of <e2>Flt3<\\e2> kinase","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SU5416","object":"Flt3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones <e1>CHEMICAL<\\e1> and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of <e2>GENE-Y<\\e2> kinase","sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 kinase"}
{"PMID":15180525,"re_id":11,"annotated sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones <e1>SU5416<\\e1> and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 <e2>kinase<\\e2>  They exhibit different selectivity profiles, both with respect to other kinases and among wildtype Flt3 and its activated versions","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SU5416","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones <e1>CHEMICAL<\\e1> and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 <e2>GENE-N<\\e2>  They exhibit different selectivity profiles, both with respect to other GENE-Ns and among wildtype Flt3 and its activated versions","sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 kinase  They exhibit different selectivity profiles, both with respect to other kinases and among wildtype Flt3 and its activated versions"}
{"PMID":15180525,"re_id":12,"annotated sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and <e1>SU11248<\\e1>  the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of <e2>Flt3<\\e2> kinase","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SU11248","object":"Flt3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and <e1>CHEMICAL<\\e1>  the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of <e2>GENE-Y<\\e2> kinase","sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248  the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 kinase"}
{"PMID":15180525,"re_id":13,"annotated sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and <e1>SU11248<\\e1>  the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 <e2>kinase<\\e2>  They exhibit different selectivity profiles, both with respect to other kinases and among wildtype Flt3 and its activated versions","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SU11248","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and <e1>CHEMICAL<\\e1>  the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 <e2>GENE-N<\\e2>  They exhibit different selectivity profiles, both with respect to other GENE-Ns and among wildtype Flt3 and its activated versions","sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248  the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 kinase  They exhibit different selectivity profiles, both with respect to other kinases and among wildtype Flt3 and its activated versions"}
{"PMID":15180525,"re_id":14,"annotated sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the <e1>indolocarbazoles<\\e1> PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of <e2>Flt3<\\e2> kinase","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"indolocarbazoles","object":"Flt3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the <e1>CHEMICAL<\\e1> PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of <e2>GENE-Y<\\e2> kinase","sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 kinase"}
{"PMID":15180525,"re_id":15,"annotated sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the <e1>indolocarbazoles<\\e1> PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 <e2>kinase<\\e2>  They exhibit different selectivity profiles, both with respect to other kinases and among wildtype Flt3 and its activated versions","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"indolocarbazoles","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the <e1>CHEMICAL<\\e1> PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 <e2>GENE-N<\\e2>  They exhibit different selectivity profiles, both with respect to other GENE-Ns and among wildtype Flt3 and its activated versions","sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 kinase  They exhibit different selectivity profiles, both with respect to other kinases and among wildtype Flt3 and its activated versions"}
{"PMID":15180525,"re_id":16,"annotated sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles <e1>PKC412<\\e1> and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of <e2>Flt3<\\e2> kinase","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PKC412","object":"Flt3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles <e1>CHEMICAL<\\e1> and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of <e2>GENE-Y<\\e2> kinase","sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 kinase"}
{"PMID":15180525,"re_id":17,"annotated sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles <e1>PKC412<\\e1> and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 <e2>kinase<\\e2>  They exhibit different selectivity profiles, both with respect to other kinases and among wildtype Flt3 and its activated versions","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PKC412","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles <e1>CHEMICAL<\\e1> and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 <e2>GENE-N<\\e2>  They exhibit different selectivity profiles, both with respect to other GENE-Ns and among wildtype Flt3 and its activated versions","sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 kinase  They exhibit different selectivity profiles, both with respect to other kinases and among wildtype Flt3 and its activated versions"}
{"PMID":15180525,"re_id":18,"annotated sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and <e1>CEP-701<\\e1>  and the piperazonyl quinazoline CT53518, are potent inhibitors of <e2>Flt3<\\e2> kinase","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CEP-701","object":"Flt3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and <e1>CHEMICAL<\\e1>  and the piperazonyl quinazoline CT53518, are potent inhibitors of <e2>GENE-Y<\\e2> kinase","sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701  and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 kinase"}
{"PMID":15180525,"re_id":19,"annotated sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and <e1>CEP-701<\\e1>  and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 <e2>kinase<\\e2>  They exhibit different selectivity profiles, both with respect to other kinases and among wildtype Flt3 and its activated versions","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CEP-701","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and <e1>CHEMICAL<\\e1>  and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 <e2>GENE-N<\\e2>  They exhibit different selectivity profiles, both with respect to other GENE-Ns and among wildtype Flt3 and its activated versions","sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701  and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 kinase  They exhibit different selectivity profiles, both with respect to other kinases and among wildtype Flt3 and its activated versions"}
{"PMID":15180525,"re_id":20,"annotated sentence":"Although highly homologous to other class III RTKs, Flt3 is resistant to the <e1>phenylaminopyrimidine<\\e1> STI571 (Gleevec, Imatinib), a potent inhibitor of other <e2>RTKs<\\e2> in the family, such as the PDGFbeta-receptor or c-Kit","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenylaminopyrimidine","object":"RTKs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Although highly homologous to other class III GENE-N, Flt3 is resistant to the <e1>CHEMICAL<\\e1> STI571 (Gleevec, Imatinib), a potent inhibitor of other <e2>GENE-N<\\e2> in the family, such as the PDGFbeta-receptor or c-Kit","sentence":"Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit"}
{"PMID":15180525,"re_id":21,"annotated sentence":"Although highly homologous to other class III RTKs, Flt3 is resistant to the <e1>phenylaminopyrimidine<\\e1> STI571 (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the <e2>PDGFbeta-receptor<\\e2> or c-Kit","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenylaminopyrimidine","object":"PDGFbeta-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although highly homologous to other class III RTKs, Flt3 is resistant to the <e1>CHEMICAL<\\e1> STI571 (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the <e2>GENE-Y<\\e2> or c-Kit","sentence":"Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit"}
{"PMID":15180525,"re_id":22,"annotated sentence":"Although highly homologous to other class III RTKs, Flt3 is resistant to the <e1>phenylaminopyrimidine<\\e1> STI571 (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or <e2>c-Kit<\\e2>  STI571 binding to Flt3 is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding Flt3 mutant sensitive to STI571","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenylaminopyrimidine","object":"c-Kit","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although highly homologous to other class III RTKs, Flt3 is resistant to the <e1>CHEMICAL<\\e1> STI571 (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or <e2>GENE-Y<\\e2>  STI571 binding to Flt3 is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding Flt3 mutant sensitive to STI571","sentence":"Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit  STI571 binding to Flt3 is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding Flt3 mutant sensitive to STI571"}
{"PMID":15180525,"re_id":23,"annotated sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the <e1>piperazonyl quinazoline<\\e1> CT53518, are potent inhibitors of <e2>Flt3<\\e2> kinase","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"piperazonyl quinazoline","object":"Flt3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the <e1>CHEMICAL<\\e1> CT53518, are potent inhibitors of <e2>GENE-Y<\\e2> kinase","sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 kinase"}
{"PMID":15180525,"re_id":24,"annotated sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the <e1>piperazonyl quinazoline<\\e1> CT53518, are potent inhibitors of Flt3 <e2>kinase<\\e2>  They exhibit different selectivity profiles, both with respect to other kinases and among wildtype Flt3 and its activated versions","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"piperazonyl quinazoline","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the <e1>CHEMICAL<\\e1> CT53518, are potent inhibitors of Flt3 <e2>GENE-N<\\e2>  They exhibit different selectivity profiles, both with respect to other GENE-Ns and among wildtype Flt3 and its activated versions","sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 kinase  They exhibit different selectivity profiles, both with respect to other kinases and among wildtype Flt3 and its activated versions"}
{"PMID":15180525,"re_id":25,"annotated sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline <e1>CT53518<\\e1>  are potent inhibitors of <e2>Flt3<\\e2> kinase","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CT53518","object":"Flt3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline <e1>CHEMICAL<\\e1>  are potent inhibitors of <e2>GENE-Y<\\e2> kinase","sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518  are potent inhibitors of Flt3 kinase"}
{"PMID":15180525,"re_id":26,"annotated sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline <e1>CT53518<\\e1>  are potent inhibitors of Flt3 <e2>kinase<\\e2>  They exhibit different selectivity profiles, both with respect to other kinases and among wildtype Flt3 and its activated versions","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CT53518","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline <e1>CHEMICAL<\\e1>  are potent inhibitors of Flt3 <e2>GENE-N<\\e2>  They exhibit different selectivity profiles, both with respect to other GENE-Ns and among wildtype Flt3 and its activated versions","sentence":"Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518  are potent inhibitors of Flt3 kinase  They exhibit different selectivity profiles, both with respect to other kinases and among wildtype Flt3 and its activated versions"}
{"PMID":15180525,"re_id":27,"annotated sentence":"Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine <e1>STI571<\\e1> (Gleevec, Imatinib), a potent inhibitor of other <e2>RTKs<\\e2> in the family, such as the PDGFbeta-receptor or c-Kit","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"STI571","object":"RTKs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Although highly homologous to other class III GENE-N, Flt3 is resistant to the phenylaminopyrimidine <e1>CHEMICAL<\\e1> (Gleevec, Imatinib), a potent inhibitor of other <e2>GENE-N<\\e2> in the family, such as the PDGFbeta-receptor or c-Kit","sentence":"Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit"}
{"PMID":15180525,"re_id":28,"annotated sentence":"Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine <e1>STI571<\\e1> (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the <e2>PDGFbeta-receptor<\\e2> or c-Kit","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"STI571","object":"PDGFbeta-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine <e1>CHEMICAL<\\e1> (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the <e2>GENE-Y<\\e2> or c-Kit","sentence":"Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit"}
{"PMID":15180525,"re_id":29,"annotated sentence":"Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine <e1>STI571<\\e1> (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or <e2>c-Kit<\\e2>  STI571 binding to Flt3 is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding Flt3 mutant sensitive to STI571","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"STI571","object":"c-Kit","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine <e1>CHEMICAL<\\e1> (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or <e2>GENE-Y<\\e2>  CHEMICAL binding to Flt3 is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding Flt3 mutant sensitive to CHEMICAL","sentence":"Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit  STI571 binding to Flt3 is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding Flt3 mutant sensitive to STI571"}
{"PMID":15180525,"re_id":30,"annotated sentence":"Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (<e1>Gleevec<\\e1>  Imatinib), a potent inhibitor of other <e2>RTKs<\\e2> in the family, such as the PDGFbeta-receptor or c-Kit","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Gleevec","object":"RTKs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Although highly homologous to other class III GENE-N, Flt3 is resistant to the phenylaminopyrimidine STI571 (<e1>CHEMICAL<\\e1>  Imatinib), a potent inhibitor of other <e2>GENE-N<\\e2> in the family, such as the PDGFbeta-receptor or c-Kit","sentence":"Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec  Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit"}
{"PMID":15180525,"re_id":31,"annotated sentence":"Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (<e1>Gleevec<\\e1>  Imatinib), a potent inhibitor of other RTKs in the family, such as the <e2>PDGFbeta-receptor<\\e2> or c-Kit","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Gleevec","object":"PDGFbeta-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (<e1>CHEMICAL<\\e1>  Imatinib), a potent inhibitor of other RTKs in the family, such as the <e2>GENE-Y<\\e2> or c-Kit","sentence":"Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec  Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit"}
{"PMID":15180525,"re_id":32,"annotated sentence":"Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (<e1>Gleevec<\\e1>  Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or <e2>c-Kit<\\e2>  STI571 binding to Flt3 is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding Flt3 mutant sensitive to STI571","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Gleevec","object":"c-Kit","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (<e1>CHEMICAL<\\e1>  Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or <e2>GENE-Y<\\e2>  STI571 binding to Flt3 is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding Flt3 mutant sensitive to STI571","sentence":"Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec  Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit  STI571 binding to Flt3 is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding Flt3 mutant sensitive to STI571"}
{"PMID":15180525,"re_id":33,"annotated sentence":"Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, <e1>Imatinib<\\e1> , a potent inhibitor of other <e2>RTKs<\\e2> in the family, such as the PDGFbeta-receptor or c-Kit","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Imatinib","object":"RTKs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Although highly homologous to other class III GENE-N, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, <e1>CHEMICAL<\\e1> , a potent inhibitor of other <e2>GENE-N<\\e2> in the family, such as the PDGFbeta-receptor or c-Kit","sentence":"Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, Imatinib , a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit"}
{"PMID":15180525,"re_id":34,"annotated sentence":"Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, <e1>Imatinib<\\e1> , a potent inhibitor of other RTKs in the family, such as the <e2>PDGFbeta-receptor<\\e2> or c-Kit","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Imatinib","object":"PDGFbeta-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, <e1>CHEMICAL<\\e1> , a potent inhibitor of other RTKs in the family, such as the <e2>GENE-Y<\\e2> or c-Kit","sentence":"Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, Imatinib , a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit"}
{"PMID":15180525,"re_id":35,"annotated sentence":"Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, <e1>Imatinib<\\e1> , a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or <e2>c-Kit<\\e2>  STI571 binding to Flt3 is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding Flt3 mutant sensitive to STI571","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Imatinib","object":"c-Kit","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, <e1>CHEMICAL<\\e1> , a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or <e2>GENE-Y<\\e2>  STI571 binding to Flt3 is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding Flt3 mutant sensitive to STI571","sentence":"Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, Imatinib , a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit  STI571 binding to Flt3 is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding Flt3 mutant sensitive to STI571"}
{"PMID":15180525,"re_id":36,"annotated sentence":"STI571 binding to Flt3 is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding <e2>Flt3<\\e2> mutant sensitive to <e1>STI571<\\e1>  Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 kinase","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"STI571","object":"Flt3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CHEMICAL binding to GENE-Y is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding <e2>GENE-Y<\\e2> mutant sensitive to <e1>CHEMICAL<\\e1>  Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of GENE-Y kinase","sentence":"STI571 binding to Flt3 is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding Flt3 mutant sensitive to STI571  Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 kinase"}
{"PMID":15192023,"re_id":0,"annotated sentence":"<e1>Hydralazine<\\e1> induced rapid and transient expression of <e2>HIF-1alpha<\\e2> and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Hydralazine","object":"HIF-1alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induced rapid and transient expression of <e2>GENE-Y<\\e2> and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation","sentence":"Hydralazine induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation"}
{"PMID":15192023,"re_id":1,"annotated sentence":"<e1>Hydralazine<\\e1> induced rapid and transient expression of HIF-1alpha and downstream targets of <e2>HIF<\\e2> (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Hydralazine","object":"HIF","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> induced rapid and transient expression of GENE-N-1alpha and downstream targets of <e2>GENE-N<\\e2> (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation","sentence":"Hydralazine induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation"}
{"PMID":15192023,"re_id":2,"annotated sentence":"<e1>Hydralazine<\\e1> induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (<e2>endothelin-1<\\e2>  adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Hydralazine","object":"endothelin-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (<e2>GENE-Y<\\e2>  adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation","sentence":"Hydralazine induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1  adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation"}
{"PMID":15192023,"re_id":3,"annotated sentence":"<e1>Hydralazine<\\e1> induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, <e2>adrenomedullin<\\e2>  haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Hydralazine","object":"adrenomedullin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, <e2>GENE-Y<\\e2>  haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation","sentence":"Hydralazine induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin  haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation"}
{"PMID":15192023,"re_id":4,"annotated sentence":"<e1>Hydralazine<\\e1> induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, <e2>haem oxygenase 1<\\e2>  and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Hydralazine","object":"haem oxygenase 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, <e2>GENE-Y<\\e2>  and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation","sentence":"Hydralazine induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1  and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation"}
{"PMID":15192023,"re_id":5,"annotated sentence":"<e1>Hydralazine<\\e1> induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and <e2>vascular endothelial growth factor<\\e2> [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Hydralazine","object":"vascular endothelial growth factor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and <e2>GENE-Y<\\e2> [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation","sentence":"Hydralazine induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation"}
{"PMID":15192023,"re_id":6,"annotated sentence":"<e1>Hydralazine<\\e1> induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [<e2>VEGF<\\e2> ) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Hydralazine","object":"VEGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [<e2>GENE-Y<\\e2> ) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation","sentence":"Hydralazine induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF ) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation"}
{"PMID":15192023,"re_id":7,"annotated sentence":"<e1>Hydralazine<\\e1> dose-dependently inhibited PHD activity and induced nonhydroxylated <e2>HIF-1alpha<\\e2>  evidence for HIF stabilization specifically by inhibition of PHD enzyme activity","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Hydralazine","object":"HIF-1alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> dose-dependently inhibited PHD activity and induced nonhydroxylated <e2>GENE-Y<\\e2>  evidence for HIF stabilization specifically by inhibition of PHD enzyme activity","sentence":"Hydralazine dose-dependently inhibited PHD activity and induced nonhydroxylated HIF-1alpha  evidence for HIF stabilization specifically by inhibition of PHD enzyme activity"}
{"PMID":15192023,"re_id":8,"annotated sentence":"In vivo, <e1>hydralazine<\\e1> induced HIF-1alpha and VEGF protein in tissue extracts and elevated plasma <e2>VEGF<\\e2> levels","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"hydralazine","object":"VEGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In vivo, <e1>CHEMICAL<\\e1> induced HIF-1alpha and GENE-Y protein in tissue extracts and elevated plasma <e2>GENE-Y<\\e2> levels","sentence":"In vivo, hydralazine induced HIF-1alpha and VEGF protein in tissue extracts and elevated plasma VEGF levels"}
{"PMID":15192023,"re_id":9,"annotated sentence":"In vivo, <e1>hydralazine<\\e1> induced <e2>HIF-1alpha<\\e2> and VEGF protein in tissue extracts and elevated plasma VEGF levels","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"hydralazine","object":"HIF-1alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In vivo, <e1>CHEMICAL<\\e1> induced <e2>GENE-Y<\\e2> and VEGF protein in tissue extracts and elevated plasma VEGF levels","sentence":"In vivo, hydralazine induced HIF-1alpha and VEGF protein in tissue extracts and elevated plasma VEGF levels"}
{"PMID":15192023,"re_id":10,"annotated sentence":"In vivo, <e1>hydralazine<\\e1> induced HIF-1alpha and <e2>VEGF<\\e2> protein in tissue extracts and elevated plasma VEGF levels","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"hydralazine","object":"VEGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In vivo, <e1>CHEMICAL<\\e1> induced HIF-1alpha and <e2>GENE-Y<\\e2> protein in tissue extracts and elevated plasma GENE-Y levels","sentence":"In vivo, hydralazine induced HIF-1alpha and VEGF protein in tissue extracts and elevated plasma VEGF levels"}
{"PMID":15192023,"re_id":11,"annotated sentence":"Novel mechanism of action for <e1>hydralazine<\\e1>  induction of <e2>hypoxia-inducible factor-1alpha<\\e2>  vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"hydralazine","object":"hypoxia-inducible factor-1alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Novel mechanism of action for <e1>CHEMICAL<\\e1>  induction of <e2>GENE-Y<\\e2>  vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases","sentence":"Novel mechanism of action for hydralazine  induction of hypoxia-inducible factor-1alpha  vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases"}
{"PMID":15192023,"re_id":12,"annotated sentence":"Novel mechanism of action for <e1>hydralazine<\\e1>  induction of hypoxia-inducible factor-1alpha, <e2>vascular endothelial growth factor<\\e2>  and angiogenesis by inhibition of prolyl hydroxylases","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"hydralazine","object":"vascular endothelial growth factor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Novel mechanism of action for <e1>CHEMICAL<\\e1>  induction of hypoxia-inducible factor-1alpha, <e2>GENE-Y<\\e2>  and angiogenesis by inhibition of prolyl hydroxylases","sentence":"Novel mechanism of action for hydralazine  induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor  and angiogenesis by inhibition of prolyl hydroxylases"}
{"PMID":15192023,"re_id":13,"annotated sentence":"Thus, <e1>hydralazine<\\e1> activates the <e2>HIF<\\e2> pathway through inhibition of PHD activity and initiates a pro-angiogenic phenotype","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"hydralazine","object":"HIF","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Thus, <e1>CHEMICAL<\\e1> activates the <e2>GENE-N<\\e2> pathway through inhibition of PHD activity and initiates a pro-angiogenic phenotype","sentence":"Thus, hydralazine activates the HIF pathway through inhibition of PHD activity and initiates a pro-angiogenic phenotype"}
{"PMID":15192023,"re_id":14,"annotated sentence":"<e1>Hydralazine<\\e1> dose-dependently inhibited <e2>PHD<\\e2> activity and induced nonhydroxylated HIF-1alpha, evidence for HIF stabilization specifically by inhibition of PHD enzyme activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Hydralazine","object":"PHD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> dose-dependently inhibited <e2>GENE-N<\\e2> activity and induced nonhydroxylated HIF-1alpha, evidence for HIF stabilization specifically by inhibition of GENE-N enzyme activity","sentence":"Hydralazine dose-dependently inhibited PHD activity and induced nonhydroxylated HIF-1alpha, evidence for HIF stabilization specifically by inhibition of PHD enzyme activity"}
{"PMID":15192023,"re_id":15,"annotated sentence":"<e1>Hydralazine<\\e1> dose-dependently inhibited PHD activity and induced nonhydroxylated HIF-1alpha, evidence for HIF stabilization specifically by inhibition of <e2>PHD<\\e2> enzyme activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Hydralazine","object":"PHD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> dose-dependently inhibited GENE-N activity and induced nonhydroxylated HIF-1alpha, evidence for HIF stabilization specifically by inhibition of <e2>GENE-N<\\e2> enzyme activity","sentence":"Hydralazine dose-dependently inhibited PHD activity and induced nonhydroxylated HIF-1alpha, evidence for HIF stabilization specifically by inhibition of PHD enzyme activity"}
{"PMID":15192023,"re_id":16,"annotated sentence":"Novel mechanism of action for <e1>hydralazine<\\e1>  induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of <e2>prolyl hydroxylases<\\e2>  The vasodilator hydralazine, used clinically in cardiovascular therapy, relaxes arterial smooth muscle by inhibiting accumulation of intracellular free Ca2+ via an unidentified primary target","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"hydralazine","object":"prolyl hydroxylases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Novel mechanism of action for <e1>CHEMICAL<\\e1>  induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of <e2>GENE-N<\\e2>  The vasodilator CHEMICAL, used clinically in cardiovascular therapy, relaxes arterial smooth muscle by inhibiting accumulation of intracellular free Ca2+ via an unidentified primary target","sentence":"Novel mechanism of action for hydralazine  induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases  The vasodilator hydralazine, used clinically in cardiovascular therapy, relaxes arterial smooth muscle by inhibiting accumulation of intracellular free Ca2+ via an unidentified primary target"}
{"PMID":15192023,"re_id":17,"annotated sentence":"Thus, <e1>hydralazine<\\e1> activates the HIF pathway through inhibition of <e2>PHD<\\e2> activity and initiates a pro-angiogenic phenotype","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"hydralazine","object":"PHD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Thus, <e1>CHEMICAL<\\e1> activates the HIF pathway through inhibition of <e2>GENE-N<\\e2> activity and initiates a pro-angiogenic phenotype","sentence":"Thus, hydralazine activates the HIF pathway through inhibition of PHD activity and initiates a pro-angiogenic phenotype"}
{"PMID":15198222,"re_id":0,"annotated sentence":"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas <e1>NS398<\\e1>  carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting <e2>COX-2<\\e2> than COX-1","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NS398","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas <e1>CHEMICAL<\\e1>  carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting <e2>GENE-Y<\\e2> than COX-1","sentence":"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398  carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1"}
{"PMID":15198222,"re_id":1,"annotated sentence":"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas <e1>NS398<\\e1>  carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than <e2>COX-1<\\e2>  All canine tissues examined, including those from the gastrointestinal tract, coexpressed COX-1 and -2 mRNA, although protein expression was observed only for COX-1","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NS398","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas <e1>CHEMICAL<\\e1>  carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than <e2>GENE-Y<\\e2>  All canine tissues examined, including those from the gastrointestinal tract, coexpressed GENE-Y and -2 mRNA, although protein expression was observed only for GENE-Y","sentence":"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398  carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1  All canine tissues examined, including those from the gastrointestinal tract, coexpressed COX-1 and -2 mRNA, although protein expression was observed only for COX-1"}
{"PMID":15198222,"re_id":2,"annotated sentence":"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, <e1>carprofen<\\e1>  tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting <e2>COX-2<\\e2> than COX-1","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"carprofen","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, <e1>CHEMICAL<\\e1>  tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting <e2>GENE-Y<\\e2> than COX-1","sentence":"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen  tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1"}
{"PMID":15198222,"re_id":3,"annotated sentence":"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, <e1>carprofen<\\e1>  tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than <e2>COX-1<\\e2>  All canine tissues examined, including those from the gastrointestinal tract, coexpressed COX-1 and -2 mRNA, although protein expression was observed only for COX-1","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"carprofen","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, <e1>CHEMICAL<\\e1>  tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than <e2>GENE-Y<\\e2>  All canine tissues examined, including those from the gastrointestinal tract, coexpressed GENE-Y and -2 mRNA, although protein expression was observed only for GENE-Y","sentence":"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen  tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1  All canine tissues examined, including those from the gastrointestinal tract, coexpressed COX-1 and -2 mRNA, although protein expression was observed only for COX-1"}
{"PMID":15198222,"re_id":4,"annotated sentence":"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, <e1>tolfenamic acid<\\e1>  nimesulide, and etodolac had more than 5 times greater preference for inhibiting <e2>COX-2<\\e2> than COX-1","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tolfenamic acid","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, <e1>CHEMICAL<\\e1>  nimesulide, and etodolac had more than 5 times greater preference for inhibiting <e2>GENE-Y<\\e2> than COX-1","sentence":"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid  nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1"}
{"PMID":15198222,"re_id":5,"annotated sentence":"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, <e1>tolfenamic acid<\\e1>  nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than <e2>COX-1<\\e2>  All canine tissues examined, including those from the gastrointestinal tract, coexpressed COX-1 and -2 mRNA, although protein expression was observed only for COX-1","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tolfenamic acid","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, <e1>CHEMICAL<\\e1>  nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than <e2>GENE-Y<\\e2>  All canine tissues examined, including those from the gastrointestinal tract, coexpressed GENE-Y and -2 mRNA, although protein expression was observed only for GENE-Y","sentence":"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid  nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1  All canine tissues examined, including those from the gastrointestinal tract, coexpressed COX-1 and -2 mRNA, although protein expression was observed only for COX-1"}
{"PMID":15198222,"re_id":6,"annotated sentence":"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, <e1>nimesulide<\\e1>  and etodolac had more than 5 times greater preference for inhibiting <e2>COX-2<\\e2> than COX-1","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"nimesulide","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, <e1>CHEMICAL<\\e1>  and etodolac had more than 5 times greater preference for inhibiting <e2>GENE-Y<\\e2> than COX-1","sentence":"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide  and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1"}
{"PMID":15198222,"re_id":7,"annotated sentence":"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, <e1>nimesulide<\\e1>  and etodolac had more than 5 times greater preference for inhibiting COX-2 than <e2>COX-1<\\e2>  All canine tissues examined, including those from the gastrointestinal tract, coexpressed COX-1 and -2 mRNA, although protein expression was observed only for COX-1","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"nimesulide","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, <e1>CHEMICAL<\\e1>  and etodolac had more than 5 times greater preference for inhibiting COX-2 than <e2>GENE-Y<\\e2>  All canine tissues examined, including those from the gastrointestinal tract, coexpressed GENE-Y and -2 mRNA, although protein expression was observed only for GENE-Y","sentence":"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide  and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1  All canine tissues examined, including those from the gastrointestinal tract, coexpressed COX-1 and -2 mRNA, although protein expression was observed only for COX-1"}
{"PMID":15198222,"re_id":8,"annotated sentence":"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and <e1>etodolac<\\e1> had more than 5 times greater preference for inhibiting <e2>COX-2<\\e2> than COX-1","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"etodolac","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and <e1>CHEMICAL<\\e1> had more than 5 times greater preference for inhibiting <e2>GENE-Y<\\e2> than COX-1","sentence":"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1"}
{"PMID":15198222,"re_id":9,"annotated sentence":"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and <e1>etodolac<\\e1> had more than 5 times greater preference for inhibiting COX-2 than <e2>COX-1<\\e2>  All canine tissues examined, including those from the gastrointestinal tract, coexpressed COX-1 and -2 mRNA, although protein expression was observed only for COX-1","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"etodolac","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and <e1>CHEMICAL<\\e1> had more than 5 times greater preference for inhibiting COX-2 than <e2>GENE-Y<\\e2>  All canine tissues examined, including those from the gastrointestinal tract, coexpressed GENE-Y and -2 mRNA, although protein expression was observed only for GENE-Y","sentence":"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1  All canine tissues examined, including those from the gastrointestinal tract, coexpressed COX-1 and -2 mRNA, although protein expression was observed only for COX-1"}
{"PMID":15198222,"re_id":10,"annotated sentence":"CONCLUSIONS AND CLINICAL RELEVANCE: <e2>Canine COX-2<\\e2> was selectively inhibited by <e1>etodolac<\\e1>  nimesulide, and NS398; tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"etodolac","object":"Canine COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSIONS AND CLINICAL RELEVANCE: <e2>GENE-Y<\\e2> was selectively inhibited by <e1>CHEMICAL<\\e1>  nimesulide, and NS398; tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs","sentence":"CONCLUSIONS AND CLINICAL RELEVANCE: Canine COX-2 was selectively inhibited by etodolac  nimesulide, and NS398; tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs"}
{"PMID":15198222,"re_id":11,"annotated sentence":"CONCLUSIONS AND CLINICAL RELEVANCE: <e2>Canine COX-2<\\e2> was selectively inhibited by etodolac, <e1>nimesulide<\\e1>  and NS398; tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"nimesulide","object":"Canine COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSIONS AND CLINICAL RELEVANCE: <e2>GENE-Y<\\e2> was selectively inhibited by etodolac, <e1>CHEMICAL<\\e1>  and NS398; tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs","sentence":"CONCLUSIONS AND CLINICAL RELEVANCE: Canine COX-2 was selectively inhibited by etodolac, nimesulide  and NS398; tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs"}
{"PMID":15198222,"re_id":12,"annotated sentence":"CONCLUSIONS AND CLINICAL RELEVANCE: <e2>Canine COX-2<\\e2> was selectively inhibited by etodolac, nimesulide, and <e1>NS398<\\e1>  tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NS398","object":"Canine COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSIONS AND CLINICAL RELEVANCE: <e2>GENE-Y<\\e2> was selectively inhibited by etodolac, nimesulide, and <e1>CHEMICAL<\\e1>  tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs","sentence":"CONCLUSIONS AND CLINICAL RELEVANCE: Canine COX-2 was selectively inhibited by etodolac, nimesulide, and NS398  tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs"}
{"PMID":15198222,"re_id":13,"annotated sentence":"CONCLUSIONS AND CLINICAL RELEVANCE: Canine COX-2 was selectively inhibited by etodolac, nimesulide, and NS398; <e1>tolfenamic acid<\\e1> and carprofen also appeared to be preferential <e2>COX-2<\\e2> inhibitors in dogs","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tolfenamic acid","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSIONS AND CLINICAL RELEVANCE: Canine GENE-Y was selectively inhibited by etodolac, nimesulide, and NS398; <e1>CHEMICAL<\\e1> and carprofen also appeared to be preferential <e2>GENE-Y<\\e2> inhibitors in dogs","sentence":"CONCLUSIONS AND CLINICAL RELEVANCE: Canine COX-2 was selectively inhibited by etodolac, nimesulide, and NS398; tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs"}
{"PMID":15198222,"re_id":14,"annotated sentence":"CONCLUSIONS AND CLINICAL RELEVANCE: Canine COX-2 was selectively inhibited by etodolac, nimesulide, and NS398; tolfenamic acid and <e1>carprofen<\\e1> also appeared to be preferential <e2>COX-2<\\e2> inhibitors in dogs","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"carprofen","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSIONS AND CLINICAL RELEVANCE: Canine GENE-Y was selectively inhibited by etodolac, nimesulide, and NS398; tolfenamic acid and <e1>CHEMICAL<\\e1> also appeared to be preferential <e2>GENE-Y<\\e2> inhibitors in dogs","sentence":"CONCLUSIONS AND CLINICAL RELEVANCE: Canine COX-2 was selectively inhibited by etodolac, nimesulide, and NS398; tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs"}
{"PMID":15292070,"re_id":0,"annotated sentence":"<e1>Acarbose<\\e1> served as inhibitor of an interfering <e2>acid alpha-glucosidase<\\e2> present in neutrophils, which allowed the lysosomal enzyme implicated in Pompe disease to be selectively analyzed","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Acarbose","object":"acid alpha-glucosidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> served as inhibitor of an interfering <e2>GENE-Y<\\e2> present in neutrophils, which allowed the lysosomal enzyme implicated in Pompe disease to be selectively analyzed","sentence":"Acarbose served as inhibitor of an interfering acid alpha-glucosidase present in neutrophils, which allowed the lysosomal enzyme implicated in Pompe disease to be selectively analyzed"}
{"PMID":15325927,"re_id":0,"annotated sentence":"Univariate regression analyses showed that only the use of <e1>carvedilol<\\e1> was correlated with the decrease in <e2>plasma BNP<\\e2> concentration (p <0.03)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"carvedilol","object":"plasma BNP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Univariate regression analyses showed that only the use of <e1>CHEMICAL<\\e1> was correlated with the decrease in <e2>GENE-Y<\\e2> concentration (p <0.03)","sentence":"Univariate regression analyses showed that only the use of carvedilol was correlated with the decrease in plasma BNP concentration (p <0.03)"}
{"PMID":15325927,"re_id":1,"annotated sentence":"After 12 months of treatment, <e1>carvedilol<\\e1> significantly improved all end points (plasma concentration of <e2>B-type natriuretic peptide<\\e2> [BNP] from 175 (35 to 209) to 106 (52 to 160) pg\/ml, mean (95% confidence interval) p <0.01; New York Heart Association functional class from 2.37 (2.13 to 2.61) to 1.56 (1.21 to 1.91), p <0.01; exercise capacity estimated with the Specific Activity Scale from 4.75 (4.50 to 5.00) to 5.68 (5.22 to 6.14) METs, p <0.02), whereas conventional therapy did not (plasma BNP concentration from 150 (114 to 186) to 174 (100 to 248) pg\/ml; New York Heart Association functional class from 2.29 (2.08 to 2.50) to 2.11 (1.73 to 2.49); exercise capacity from 4.57 (4.34 to 4.80) to 4.72 (4.41 to 5.03) METs)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"carvedilol","object":"B-type natriuretic peptide","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"After 12 months of treatment, <e1>CHEMICAL<\\e1> significantly improved all end points (plasma concentration of <e2>GENE-Y<\\e2> [BNP] from 175 (35 to 209) to 106 (52 to 160) pg\/ml, mean (95% confidence interval) p <0.01; New York Heart Association functional class from 2.37 (2.13 to 2.61) to 1.56 (1.21 to 1.91), p <0.01; exercise capacity estimated with the Specific Activity Scale from 4.75 (4.50 to 5.00) to 5.68 (5.22 to 6.14) METs, p <0.02), whereas conventional therapy did not (plasma BNP concentration from 150 (114 to 186) to 174 (100 to 248) pg\/ml; New York Heart Association functional class from 2.29 (2.08 to 2.50) to 2.11 (1.73 to 2.49); exercise capacity from 4.57 (4.34 to 4.80) to 4.72 (4.41 to 5.03) METs)","sentence":"After 12 months of treatment, carvedilol significantly improved all end points (plasma concentration of B-type natriuretic peptide [BNP] from 175 (35 to 209) to 106 (52 to 160) pg\/ml, mean (95% confidence interval) p <0.01; New York Heart Association functional class from 2.37 (2.13 to 2.61) to 1.56 (1.21 to 1.91), p <0.01; exercise capacity estimated with the Specific Activity Scale from 4.75 (4.50 to 5.00) to 5.68 (5.22 to 6.14) METs, p <0.02), whereas conventional therapy did not (plasma BNP concentration from 150 (114 to 186) to 174 (100 to 248) pg\/ml; New York Heart Association functional class from 2.29 (2.08 to 2.50) to 2.11 (1.73 to 2.49); exercise capacity from 4.57 (4.34 to 4.80) to 4.72 (4.41 to 5.03) METs)"}
{"PMID":15325927,"re_id":2,"annotated sentence":"After 12 months of treatment, <e1>carvedilol<\\e1> significantly improved all end points (plasma concentration of B-type natriuretic peptide [<e2>BNP<\\e2>  from 175 (35 to 209) to 106 (52 to 160) pg\/ml, mean (95% confidence interval) p <0.01; New York Heart Association functional class from 2.37 (2.13 to 2.61) to 1.56 (1.21 to 1.91), p <0.01; exercise capacity estimated with the Specific Activity Scale from 4.75 (4.50 to 5.00) to 5.68 (5.22 to 6.14) METs, p <0.02), whereas conventional therapy did not (plasma BNP concentration from 150 (114 to 186) to 174 (100 to 248) pg\/ml; New York Heart Association functional class from 2.29 (2.08 to 2.50) to 2.11 (1.73 to 2.49); exercise capacity from 4.57 (4.34 to 4.80) to 4.72 (4.41 to 5.03) METs)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"carvedilol","object":"BNP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"After 12 months of treatment, <e1>CHEMICAL<\\e1> significantly improved all end points (plasma concentration of B-type natriuretic peptide [<e2>GENE-Y<\\e2>  from 175 (35 to 209) to 106 (52 to 160) pg\/ml, mean (95% confidence interval) p <0.01; New York Heart Association functional class from 2.37 (2.13 to 2.61) to 1.56 (1.21 to 1.91), p <0.01; exercise capacity estimated with the Specific Activity Scale from 4.75 (4.50 to 5.00) to 5.68 (5.22 to 6.14) METs, p <0.02), whereas conventional therapy did not (plasma GENE-Y concentration from 150 (114 to 186) to 174 (100 to 248) pg\/ml; New York Heart Association functional class from 2.29 (2.08 to 2.50) to 2.11 (1.73 to 2.49); exercise capacity from 4.57 (4.34 to 4.80) to 4.72 (4.41 to 5.03) METs)","sentence":"After 12 months of treatment, carvedilol significantly improved all end points (plasma concentration of B-type natriuretic peptide [BNP  from 175 (35 to 209) to 106 (52 to 160) pg\/ml, mean (95% confidence interval) p <0.01; New York Heart Association functional class from 2.37 (2.13 to 2.61) to 1.56 (1.21 to 1.91), p <0.01; exercise capacity estimated with the Specific Activity Scale from 4.75 (4.50 to 5.00) to 5.68 (5.22 to 6.14) METs, p <0.02), whereas conventional therapy did not (plasma BNP concentration from 150 (114 to 186) to 174 (100 to 248) pg\/ml; New York Heart Association functional class from 2.29 (2.08 to 2.50) to 2.11 (1.73 to 2.49); exercise capacity from 4.57 (4.34 to 4.80) to 4.72 (4.41 to 5.03) METs)"}
{"PMID":1543672,"re_id":0,"annotated sentence":"<e1>Terbinafine<\\e1> is a potent non-competitive inhibitor of <e2>squalene epoxidase<\\e2> from Candida (Ki = 30 nM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Terbinafine","object":"squalene epoxidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is a potent non-competitive inhibitor of <e2>GENE-Y<\\e2> from Candida (Ki = 30 nM)","sentence":"Terbinafine is a potent non-competitive inhibitor of squalene epoxidase from Candida (Ki = 30 nM)"}
{"PMID":1543672,"re_id":1,"annotated sentence":"<e1>Terbinafine<\\e1>  mode of action and properties of the <e2>squalene epoxidase<\\e2> inhibition","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Terbinafine","object":"squalene epoxidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  mode of action and properties of the <e2>GENE-Y<\\e2> inhibition","sentence":"Terbinafine  mode of action and properties of the squalene epoxidase inhibition"}
{"PMID":1543672,"re_id":2,"annotated sentence":"<e1>Terbinafine<\\e1> (Lamisil) has primarily fungicidal action against many fungi as a result of its specific mechanism of <e2>squalene epoxidase<\\e2> inhibition","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Terbinafine","object":"squalene epoxidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (Lamisil) has primarily fungicidal action against many fungi as a result of its specific mechanism of <e2>GENE-Y<\\e2> inhibition","sentence":"Terbinafine (Lamisil) has primarily fungicidal action against many fungi as a result of its specific mechanism of squalene epoxidase inhibition"}
{"PMID":1543672,"re_id":3,"annotated sentence":"In contrast, inhibition of <e2>rat liver squalene epoxidase<\\e2> only occurs at higher drug concentrations (Ki = 77 microM), and is competitive with <e1>squalene<\\e1>  Thus, terbinafine has no effect on cholesterol biosynthesis in vivo","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"squalene","object":"rat liver squalene epoxidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, inhibition of <e2>rat liver CHEMICAL epoxidase<\\e2> only occurs at higher drug concentrations (Ki = 77 microM), and is competitive with <e1>CHEMICAL<\\e1>  Thus, terbinafine has no effect on cholesterol biosynthesis in vivo","sentence":"In contrast, inhibition of rat liver squalene epoxidase only occurs at higher drug concentrations (Ki = 77 microM), and is competitive with squalene  Thus, terbinafine has no effect on cholesterol biosynthesis in vivo"}
{"PMID":1543672,"re_id":4,"annotated sentence":"Terbinafine (<e1>Lamisil<\\e1>  has primarily fungicidal action against many fungi as a result of its specific mechanism of <e2>squalene epoxidase<\\e2> inhibition","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Lamisil","object":"squalene epoxidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Terbinafine (<e1>CHEMICAL<\\e1>  has primarily fungicidal action against many fungi as a result of its specific mechanism of <e2>GENE-Y<\\e2> inhibition","sentence":"Terbinafine (Lamisil  has primarily fungicidal action against many fungi as a result of its specific mechanism of squalene epoxidase inhibition"}
{"PMID":15474503,"re_id":0,"annotated sentence":"Based on HMG-CoA reductase inhibition, pitavastatin-induced <e2>apoA-I<\\e2> more efficiently than <e1>simvastatin<\\e1> and atorvastatin","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"simvastatin","object":"apoA-I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Based on HMG-CoA reductase inhibition, pitavastatin-induced <e2>GENE-Y<\\e2> more efficiently than <e1>CHEMICAL<\\e1> and atorvastatin","sentence":"Based on HMG-CoA reductase inhibition, pitavastatin-induced apoA-I more efficiently than simvastatin and atorvastatin"}
{"PMID":15474503,"re_id":1,"annotated sentence":"Based on HMG-CoA reductase inhibition, pitavastatin-induced <e2>apoA-I<\\e2> more efficiently than simvastatin and <e1>atorvastatin<\\e1>  Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"atorvastatin","object":"apoA-I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Based on HMG-CoA reductase inhibition, pitavastatin-induced <e2>GENE-Y<\\e2> more efficiently than simvastatin and <e1>CHEMICAL<\\e1>  Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632) increased GENE-Y production in the HepG2 cells","sentence":"Based on HMG-CoA reductase inhibition, pitavastatin-induced apoA-I more efficiently than simvastatin and atorvastatin  Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells"}
{"PMID":15474503,"re_id":2,"annotated sentence":"Further study revealed that <e1>pitavastatin<\\e1> increased <e2>ABCA1<\\e2> mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"pitavastatin","object":"ABCA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Further study revealed that <e1>CHEMICAL<\\e1> increased <e2>GENE-Y<\\e2> mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells","sentence":"Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells"}
{"PMID":15474503,"re_id":3,"annotated sentence":"Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and <e1>Y27632<\\e1>  increased <e2>apoA-I<\\e2> production in the HepG2 cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Y27632","object":"apoA-I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and <e1>CHEMICAL<\\e1>  increased <e2>GENE-Y<\\e2> production in the HepG2 cells","sentence":"Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632  increased apoA-I production in the HepG2 cells"}
{"PMID":15474503,"re_id":4,"annotated sentence":"These results suggest that <e1>pitavastatin<\\e1> efficiently increases <e2>apoA-I<\\e2> in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"pitavastatin","object":"apoA-I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that <e1>CHEMICAL<\\e1> efficiently increases <e2>GENE-Y<\\e2> in the culture medium of HepG2 cells by promoting GENE-Y production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting GENE-Y from catabolism through ABCA1 induction and lipidation of GENE-Y.","sentence":"These results suggest that pitavastatin efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I."}
{"PMID":15474503,"re_id":5,"annotated sentence":"These results suggest that <e1>pitavastatin<\\e1> efficiently increases apoA-I in the culture medium of HepG2 cells by promoting <e2>apoA-I<\\e2> production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"pitavastatin","object":"apoA-I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that <e1>CHEMICAL<\\e1> efficiently increases GENE-Y in the culture medium of HepG2 cells by promoting <e2>GENE-Y<\\e2> production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting GENE-Y from catabolism through ABCA1 induction and lipidation of GENE-Y.","sentence":"These results suggest that pitavastatin efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I."}
{"PMID":15474503,"re_id":6,"annotated sentence":"These results suggest that <e1>pitavastatin<\\e1> efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through <e2>ABCA1<\\e2> induction and lipidation of apoA-I.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"pitavastatin","object":"ABCA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that <e1>CHEMICAL<\\e1> efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through <e2>GENE-Y<\\e2> induction and lipidation of apoA-I.","sentence":"These results suggest that pitavastatin efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I."}
{"PMID":15474503,"re_id":7,"annotated sentence":"These results suggest that <e1>pitavastatin<\\e1> efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of <e2>apoA-I<\\e2> ","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"pitavastatin","object":"apoA-I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that <e1>CHEMICAL<\\e1> efficiently increases GENE-Y in the culture medium of HepG2 cells by promoting GENE-Y production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting GENE-Y from catabolism through ABCA1 induction and lipidation of <e2>GENE-Y<\\e2> ","sentence":"These results suggest that pitavastatin efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I "}
{"PMID":15474503,"re_id":8,"annotated sentence":"Each statin induced apoA-I expression (mRNA and protein) dose-dependently: the rank order of the <e2>apoA-I<\\e2> induction <e1>pitavastatin<\\e1> (3 microM)>simvastatin (10 microM)>atorvastatin (30 microM)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"pitavastatin","object":"apoA-I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Each statin induced GENE-Y expression (mRNA and protein) dose-dependently: the rank order of the <e2>GENE-Y<\\e2> induction <e1>CHEMICAL<\\e1> (3 microM)>simvastatin (10 microM)>atorvastatin (30 microM)","sentence":"Each statin induced apoA-I expression (mRNA and protein) dose-dependently: the rank order of the apoA-I induction pitavastatin (3 microM)>simvastatin (10 microM)>atorvastatin (30 microM)"}
{"PMID":15474503,"re_id":9,"annotated sentence":"Each statin induced apoA-I expression (mRNA and protein) dose-dependently: the rank order of the <e2>apoA-I<\\e2> induction pitavastatin (3 microM)><e1>simvastatin<\\e1> (10 microM)>atorvastatin (30 microM)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"simvastatin","object":"apoA-I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Each statin induced GENE-Y expression (mRNA and protein) dose-dependently: the rank order of the <e2>GENE-Y<\\e2> induction pitavastatin (3 microM)><e1>CHEMICAL<\\e1> (10 microM)>atorvastatin (30 microM)","sentence":"Each statin induced apoA-I expression (mRNA and protein) dose-dependently: the rank order of the apoA-I induction pitavastatin (3 microM)>simvastatin (10 microM)>atorvastatin (30 microM)"}
{"PMID":15474503,"re_id":10,"annotated sentence":"Each statin induced apoA-I expression (mRNA and protein) dose-dependently: the rank order of the <e2>apoA-I<\\e2> induction pitavastatin (3 microM)>simvastatin (10 microM)><e1>atorvastatin<\\e1> (30 microM)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"atorvastatin","object":"apoA-I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Each statin induced GENE-Y expression (mRNA and protein) dose-dependently: the rank order of the <e2>GENE-Y<\\e2> induction pitavastatin (3 microM)>simvastatin (10 microM)><e1>CHEMICAL<\\e1> (30 microM)","sentence":"Each statin induced apoA-I expression (mRNA and protein) dose-dependently: the rank order of the apoA-I induction pitavastatin (3 microM)>simvastatin (10 microM)>atorvastatin (30 microM)"}
{"PMID":15474503,"re_id":11,"annotated sentence":"Based on HMG-CoA reductase inhibition, <e1>pitavastatin<\\e1> induced <e2>apoA-I<\\e2> more efficiently than simvastatin and atorvastatin","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"pitavastatin","object":"apoA-I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Based on HMG-CoA reductase inhibition, <e1>CHEMICAL<\\e1> induced <e2>GENE-Y<\\e2> more efficiently than simvastatin and atorvastatin","sentence":"Based on HMG-CoA reductase inhibition, pitavastatin induced apoA-I more efficiently than simvastatin and atorvastatin"}
{"PMID":15474503,"re_id":12,"annotated sentence":"Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that <e2>Rho<\\e2> and Rho kinase inhibitor (C3T and <e1>Y27632<\\e1>  increased apoA-I production in the HepG2 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Y27632","object":"Rho","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that <e2>GENE-N<\\e2> and GENE-N kinase inhibitor (C3T and <e1>CHEMICAL<\\e1>  increased apoA-I production in the HepG2 cells","sentence":"Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632  increased apoA-I production in the HepG2 cells"}
{"PMID":15474503,"re_id":13,"annotated sentence":"Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that Rho and <e2>Rho kinase<\\e2> inhibitor (C3T and <e1>Y27632<\\e1>  increased apoA-I production in the HepG2 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Y27632","object":"Rho kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that Rho and <e2>GENE-N<\\e2> inhibitor (C3T and <e1>CHEMICAL<\\e1>  increased apoA-I production in the HepG2 cells","sentence":"Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632  increased apoA-I production in the HepG2 cells"}
{"PMID":15474503,"re_id":14,"annotated sentence":"These results suggest that <e1>pitavastatin<\\e1> efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of <e2>HMG-CoA reductase<\\e2> and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pitavastatin","object":"HMG-CoA reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that <e1>CHEMICAL<\\e1> efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of <e2>GENE-Y<\\e2> and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.","sentence":"These results suggest that pitavastatin efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I."}
{"PMID":15474503,"re_id":15,"annotated sentence":"These results suggest that <e1>pitavastatin<\\e1> efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of <e2>Rho<\\e2> activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pitavastatin","object":"Rho","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These results suggest that <e1>CHEMICAL<\\e1> efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of <e2>GENE-N<\\e2> activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.","sentence":"These results suggest that pitavastatin efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I."}
{"PMID":15474503,"re_id":16,"annotated sentence":"The induction of <e2>apoA-I<\\e2> by statins disappeared with addition of <e1>mevalonate<\\e1>  which indicates that the effect is HMG-CoA reductase inhibition-dependent","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"mevalonate","object":"apoA-I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The induction of <e2>GENE-Y<\\e2> by statins disappeared with addition of <e1>CHEMICAL<\\e1>  which indicates that the effect is HMG-CoA reductase inhibition-dependent","sentence":"The induction of apoA-I by statins disappeared with addition of mevalonate  which indicates that the effect is HMG-CoA reductase inhibition-dependent"}
{"PMID":15557593,"re_id":0,"annotated sentence":"MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two <e2>receptor tyrosine kinase<\\e2> inhibitors, <e1>imatinib<\\e1> and SU11248, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and\/or VEGFR inhibition","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"imatinib","object":"receptor tyrosine kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two <e2>GENE-N<\\e2> inhibitors, <e1>CHEMICAL<\\e1> and SU11248, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and\/or VEGFR inhibition","sentence":"MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, imatinib and SU11248, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and\/or VEGFR inhibition"}
{"PMID":15557593,"re_id":1,"annotated sentence":"MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, <e1>imatinib<\\e1> and SU11248, were used to disrupt <e2>PDGFR<\\e2> mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and\/or VEGFR inhibition","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"imatinib","object":"PDGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, <e1>CHEMICAL<\\e1> and SU11248, were used to disrupt <e2>GENE-Y<\\e2> mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and\/or VEGFR inhibition","sentence":"MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, imatinib and SU11248, were used to disrupt PDGFR mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and\/or VEGFR inhibition"}
{"PMID":15557593,"re_id":2,"annotated sentence":"MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, <e1>imatinib<\\e1> and SU11248, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and\/or <e2>VEGFR<\\e2> inhibition","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"imatinib","object":"VEGFR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, <e1>CHEMICAL<\\e1> and SU11248, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and\/or <e2>GENE-N<\\e2> inhibition","sentence":"MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, imatinib and SU11248, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and\/or VEGFR inhibition"}
{"PMID":15557593,"re_id":3,"annotated sentence":"MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two <e2>receptor tyrosine kinase<\\e2> inhibitors, imatinib and <e1>SU11248<\\e1>  were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and\/or VEGFR inhibition","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SU11248","object":"receptor tyrosine kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two <e2>GENE-N<\\e2> inhibitors, imatinib and <e1>CHEMICAL<\\e1>  were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and\/or VEGFR inhibition","sentence":"MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, imatinib and SU11248  were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and\/or VEGFR inhibition"}
{"PMID":15557593,"re_id":4,"annotated sentence":"MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, imatinib and <e1>SU11248<\\e1>  were used to disrupt <e2>PDGFR<\\e2> mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and\/or VEGFR inhibition","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SU11248","object":"PDGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, imatinib and <e1>CHEMICAL<\\e1>  were used to disrupt <e2>GENE-Y<\\e2> mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and\/or VEGFR inhibition","sentence":"MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, imatinib and SU11248  were used to disrupt PDGFR mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and\/or VEGFR inhibition"}
{"PMID":15557593,"re_id":5,"annotated sentence":"MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, imatinib and <e1>SU11248<\\e1>  were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and\/or <e2>VEGFR<\\e2> inhibition","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SU11248","object":"VEGFR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, imatinib and <e1>CHEMICAL<\\e1>  were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and\/or <e2>GENE-N<\\e2> inhibition","sentence":"MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, imatinib and SU11248  were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and\/or VEGFR inhibition"}
{"PMID":15557593,"re_id":6,"annotated sentence":"RESULTS: <e1>Imatinib<\\e1>  despite equivocal efficacy as monotherapy, reduced pericyte coverage of tumor vessels and enhanced efficacy in combination with metronomic chemotherapy or <e2>VEGFR<\\e2> inhibition","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Imatinib","object":"VEGFR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"RESULTS: <e1>CHEMICAL<\\e1>  despite equivocal efficacy as monotherapy, reduced pericyte coverage of tumor vessels and enhanced efficacy in combination with metronomic chemotherapy or <e2>GENE-N<\\e2> inhibition","sentence":"RESULTS: Imatinib  despite equivocal efficacy as monotherapy, reduced pericyte coverage of tumor vessels and enhanced efficacy in combination with metronomic chemotherapy or VEGFR inhibition"}
{"PMID":15563928,"re_id":0,"annotated sentence":"In addition, both drugs significantly reduced PGE2 levels (P<0.05) 6-h following LPS injection, whereas the probable <e2>COX-1<\\e2> prostanoid TXB2 was significantly reduced by <e1>phenylbutazone<\\e1> (P<0.05), but not etodolac","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenylbutazone","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, both drugs significantly reduced PGE2 levels (P<0.05) 6-h following LPS injection, whereas the probable <e2>GENE-Y<\\e2> prostanoid TXB2 was significantly reduced by <e1>CHEMICAL<\\e1> (P<0.05), but not etodolac","sentence":"In addition, both drugs significantly reduced PGE2 levels (P<0.05) 6-h following LPS injection, whereas the probable COX-1 prostanoid TXB2 was significantly reduced by phenylbutazone (P<0.05), but not etodolac"}
{"PMID":15563928,"re_id":1,"annotated sentence":"The objective of the present study was to compare the anti-inflammatory effects of the preferential COX-2 inhibitor etodolac with the non-selective <e2>COX<\\e2> inhibitor <e1>phenylbutazone<\\e1> in horses with lipopolysaccharide (LPS)-induced synovitis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenylbutazone","object":"COX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The objective of the present study was to compare the anti-inflammatory effects of the preferential GENE-N-2 inhibitor etodolac with the non-selective <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1> in horses with lipopolysaccharide (LPS)-induced synovitis","sentence":"The objective of the present study was to compare the anti-inflammatory effects of the preferential COX-2 inhibitor etodolac with the non-selective COX inhibitor phenylbutazone in horses with lipopolysaccharide (LPS)-induced synovitis"}
{"PMID":15629255,"re_id":0,"annotated sentence":"Effect of <e1>bosentan<\\e1> (<e2>ETA<\\e2> ETB receptor antagonist) on metabolic changes during stress and diabetes","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"bosentan","object":"ETA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Effect of <e1>CHEMICAL<\\e1> (<e2>GENE-Y<\\e2> ETB receptor antagonist) on metabolic changes during stress and diabetes","sentence":"Effect of bosentan (ETA ETB receptor antagonist) on metabolic changes during stress and diabetes"}
{"PMID":15629255,"re_id":1,"annotated sentence":"Effect of <e1>bosentan<\\e1> (ETA\/<e2>ETB<\\e2> receptor antagonist) on metabolic changes during stress and diabetes","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"bosentan","object":"ETB","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Effect of <e1>CHEMICAL<\\e1> (ETA\/<e2>GENE-Y<\\e2> receptor antagonist) on metabolic changes during stress and diabetes","sentence":"Effect of bosentan (ETA\/ETB receptor antagonist) on metabolic changes during stress and diabetes"}
{"PMID":15629255,"re_id":2,"annotated sentence":"To test this, we studied the possible effect of the <e2>endothelin receptor<\\e2> antagonist, <e1>bosentan<\\e1> (50 and 100 mg kg(-1)) on serum glucose and insulin levels as well as on liver glycogen contents in normoglycemic stressed animals","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"bosentan","object":"endothelin receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"To test this, we studied the possible effect of the <e2>GENE-N<\\e2> antagonist, <e1>CHEMICAL<\\e1> (50 and 100 mg kg(-1)) on serum glucose and insulin levels as well as on liver glycogen contents in normoglycemic stressed animals","sentence":"To test this, we studied the possible effect of the endothelin receptor antagonist, bosentan (50 and 100 mg kg(-1)) on serum glucose and insulin levels as well as on liver glycogen contents in normoglycemic stressed animals"}
{"PMID":15646028,"re_id":0,"annotated sentence":"Pre-irradiation administration of RP-1 enhanced levels of <e1>GSH<\\e1> induced increase in <e2>complex I<\\e2> (upto 16 h), complex I\/III (4 h) complex II\/III activity (upto 24 h; p < 0.01) and inhibited the radiation-induced decrease in MMP significantly (24 h; p < 0.01)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"GSH","object":"complex I","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Pre-irradiation administration of RP-1 enhanced levels of <e1>CHEMICAL<\\e1> induced increase in <e2>GENE-N<\\e2> (upto 16 h), GENE-N\/III (4 h) GENE-NI\/III activity (upto 24 h; p < 0.01) and inhibited the radiation-induced decrease in MMP significantly (24 h; p < 0.01)","sentence":"Pre-irradiation administration of RP-1 enhanced levels of GSH induced increase in complex I (upto 16 h), complex I\/III (4 h) complex II\/III activity (upto 24 h; p < 0.01) and inhibited the radiation-induced decrease in MMP significantly (24 h; p < 0.01)"}
{"PMID":15646028,"re_id":1,"annotated sentence":"Pre-irradiation administration of RP-1 enhanced levels of <e1>GSH<\\e1> induced increase in complex I (upto 16 h), <e2>complex I\/III<\\e2> (4 h) complex II\/III activity (upto 24 h; p < 0.01) and inhibited the radiation-induced decrease in MMP significantly (24 h; p < 0.01)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"GSH","object":"complex I\/III","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Pre-irradiation administration of RP-1 enhanced levels of <e1>CHEMICAL<\\e1> induced increase in complex I (upto 16 h), <e2>GENE-N<\\e2> (4 h) complex II\/III activity (upto 24 h; p < 0.01) and inhibited the radiation-induced decrease in MMP significantly (24 h; p < 0.01)","sentence":"Pre-irradiation administration of RP-1 enhanced levels of GSH induced increase in complex I (upto 16 h), complex I\/III (4 h) complex II\/III activity (upto 24 h; p < 0.01) and inhibited the radiation-induced decrease in MMP significantly (24 h; p < 0.01)"}
{"PMID":15646028,"re_id":2,"annotated sentence":"Pre-irradiation administration of RP-1 enhanced levels of <e1>GSH<\\e1> induced increase in complex I (upto 16 h), complex I\/III (4 h) <e2>complex II\/III<\\e2> activity (upto 24 h; p < 0.01) and inhibited the radiation-induced decrease in MMP significantly (24 h; p < 0.01)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"GSH","object":"complex II\/III","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Pre-irradiation administration of RP-1 enhanced levels of <e1>CHEMICAL<\\e1> induced increase in complex I (upto 16 h), complex I\/III (4 h) <e2>GENE-N<\\e2> activity (upto 24 h; p < 0.01) and inhibited the radiation-induced decrease in MMP significantly (24 h; p < 0.01)","sentence":"Pre-irradiation administration of RP-1 enhanced levels of GSH induced increase in complex I (upto 16 h), complex I\/III (4 h) complex II\/III activity (upto 24 h; p < 0.01) and inhibited the radiation-induced decrease in MMP significantly (24 h; p < 0.01)"}
{"PMID":15665864,"re_id":0,"annotated sentence":"Moreover, <e1>minocycline<\\e1> efficiently suppressed the release of <e2>cytochrome c<\\e2> from mitochondria of the liver tissues from Jo2-challenged mice","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"minocycline","object":"cytochrome c","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> efficiently suppressed the release of <e2>GENE-Y<\\e2> from mitochondria of the liver tissues from Jo2-challenged mice","sentence":"Moreover, minocycline efficiently suppressed the release of cytochrome c from mitochondria of the liver tissues from Jo2-challenged mice"}
{"PMID":15665864,"re_id":1,"annotated sentence":"Our results suggest that easing of Fas-triggered fulminant hepatitis by <e1>minocycline<\\e1> may involve a mitochondrial apoptotic pathway, probably through preventing <e2>cytochrome c<\\e2> release and thereby blocking downstream caspase activation.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"minocycline","object":"cytochrome c","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our results suggest that easing of Fas-triggered fulminant hepatitis by <e1>CHEMICAL<\\e1> may involve a mitochondrial apoptotic pathway, probably through preventing <e2>GENE-Y<\\e2> release and thereby blocking downstream caspase activation.","sentence":"Our results suggest that easing of Fas-triggered fulminant hepatitis by minocycline may involve a mitochondrial apoptotic pathway, probably through preventing cytochrome c release and thereby blocking downstream caspase activation."}
{"PMID":15665864,"re_id":2,"annotated sentence":"Our results suggest that easing of Fas-triggered fulminant hepatitis by <e1>minocycline<\\e1> may involve a mitochondrial apoptotic pathway, probably through preventing cytochrome c release and thereby blocking downstream <e2>caspase<\\e2> activation.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"minocycline","object":"caspase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Our results suggest that easing of Fas-triggered fulminant hepatitis by <e1>CHEMICAL<\\e1> may involve a mitochondrial apoptotic pathway, probably through preventing cytochrome c release and thereby blocking downstream <e2>GENE-N<\\e2> activation.","sentence":"Our results suggest that easing of Fas-triggered fulminant hepatitis by minocycline may involve a mitochondrial apoptotic pathway, probably through preventing cytochrome c release and thereby blocking downstream caspase activation."}
{"PMID":15671155,"re_id":0,"annotated sentence":"placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic <e2>myeloperoxidase oxidase<\\e2> (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+\/-0.63; <e1>PAG<\\e1>  2.97+\/-0.39; therapeutic treatment: placebo, 5.48+\/-0.52; PAG, 3.03+\/-0.47; P<0.05 PAG c.f","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"PAG","object":"myeloperoxidase oxidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic <e2>GENE-Y<\\e2> (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+\/-0.63; <e1>CHEMICAL<\\e1>  2.97+\/-0.39; therapeutic treatment: placebo, 5.48+\/-0.52; CHEMICAL, 3.03+\/-0.47; P<0.05 CHEMICAL c.f","sentence":"placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+\/-0.63; PAG  2.97+\/-0.39; therapeutic treatment: placebo, 5.48+\/-0.52; PAG, 3.03+\/-0.47; P<0.05 PAG c.f"}
{"PMID":15671155,"re_id":1,"annotated sentence":"placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (<e2>MPO<\\e2>  activity (fold increase over control) (prophylactic treatment: placebo, 5.78+\/-0.63; <e1>PAG<\\e1>  2.97+\/-0.39; therapeutic treatment: placebo, 5.48+\/-0.52; PAG, 3.03+\/-0.47; P<0.05 PAG c.f","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"PAG","object":"MPO","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (<e2>GENE-Y<\\e2>  activity (fold increase over control) (prophylactic treatment: placebo, 5.78+\/-0.63; <e1>CHEMICAL<\\e1>  2.97+\/-0.39; therapeutic treatment: placebo, 5.48+\/-0.52; CHEMICAL, 3.03+\/-0.47; P<0.05 CHEMICAL c.f","sentence":"placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO  activity (fold increase over control) (prophylactic treatment: placebo, 5.78+\/-0.63; PAG  2.97+\/-0.39; therapeutic treatment: placebo, 5.48+\/-0.52; PAG, 3.03+\/-0.47; P<0.05 PAG c.f"}
{"PMID":15671155,"re_id":2,"annotated sentence":"Also, prophylactic, as well as therapeutic, treatment with the <e2>CSE<\\e2> inhibitor, <e1>DL-propargylglycine<\\e1> (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U\/L) (control, 1204+\/-59); prophylactic treatment: placebo, 10635+\/-305; PAG, 7904+\/-495; therapeutic treatment: placebo, 10427+\/-470; PAG, 7811+\/-428; P<0.05 PAG c.f","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DL-propargylglycine","object":"CSE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Also, prophylactic, as well as therapeutic, treatment with the <e2>GENE-Y<\\e2> inhibitor, <e1>CHEMICAL<\\e1> (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U\/L) (control, 1204+\/-59); prophylactic treatment: placebo, 10635+\/-305; PAG, 7904+\/-495; therapeutic treatment: placebo, 10427+\/-470; PAG, 7811+\/-428; P<0.05 PAG c.f","sentence":"Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U\/L) (control, 1204+\/-59); prophylactic treatment: placebo, 10635+\/-305; PAG, 7904+\/-495; therapeutic treatment: placebo, 10427+\/-470; PAG, 7811+\/-428; P<0.05 PAG c.f"}
{"PMID":15671155,"re_id":3,"annotated sentence":"Also, prophylactic, as well as therapeutic, treatment with the <e2>CSE<\\e2> inhibitor, DL-propargylglycine (<e1>PAG<\\e1> , significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U\/L) (control, 1204+\/-59); prophylactic treatment: placebo, 10635+\/-305; PAG, 7904+\/-495; therapeutic treatment: placebo, 10427+\/-470; PAG, 7811+\/-428; P<0.05 PAG c.f","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PAG","object":"CSE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Also, prophylactic, as well as therapeutic, treatment with the <e2>GENE-Y<\\e2> inhibitor, DL-propargylglycine (<e1>CHEMICAL<\\e1> , significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U\/L) (control, 1204+\/-59); prophylactic treatment: placebo, 10635+\/-305; CHEMICAL, 7904+\/-495; therapeutic treatment: placebo, 10427+\/-470; CHEMICAL, 7811+\/-428; P<0.05 CHEMICAL c.f","sentence":"Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG , significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U\/L) (control, 1204+\/-59); prophylactic treatment: placebo, 10635+\/-305; PAG, 7904+\/-495; therapeutic treatment: placebo, 10427+\/-470; PAG, 7811+\/-428; P<0.05 PAG c.f"}
{"PMID":15671155,"re_id":4,"annotated sentence":"Cystathionine-gamma-lyase (<e2>CSE<\\e2>  and cystathionine-beta-synthase (CBS) utilize <e1>L-cysteine<\\e1> as substrate to form H2S","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-cysteine","object":"CSE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cystathionine-gamma-lyase (<e2>GENE-Y<\\e2>  and cystathionine-beta-synthase (CBS) utilize <e1>CHEMICAL<\\e1> as substrate to form H2S","sentence":"Cystathionine-gamma-lyase (CSE  and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S"}
{"PMID":15671155,"re_id":5,"annotated sentence":"Cystathionine-gamma-lyase (CSE) and <e2>cystathionine-beta-synthase<\\e2> (CBS) utilize <e1>L-cysteine<\\e1> as substrate to form H2S","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-cysteine","object":"cystathionine-beta-synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cystathionine-gamma-lyase (CSE) and <e2>GENE-Y<\\e2> (CBS) utilize <e1>CHEMICAL<\\e1> as substrate to form H2S","sentence":"Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S"}
{"PMID":15671155,"re_id":6,"annotated sentence":"Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (<e2>CBS<\\e2>  utilize <e1>L-cysteine<\\e1> as substrate to form H2S","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-cysteine","object":"CBS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (<e2>GENE-Y<\\e2>  utilize <e1>CHEMICAL<\\e1> as substrate to form H2S","sentence":"Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS  utilize L-cysteine as substrate to form H2S"}
{"PMID":15671155,"re_id":7,"annotated sentence":"<e2>Cystathionine-gamma-lyase<\\e2> (CSE) and cystathionine-beta-synthase (CBS) utilize <e1>L-cysteine<\\e1> as substrate to form H2S","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-cysteine","object":"Cystathionine-gamma-lyase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (CSE) and cystathionine-beta-synthase (CBS) utilize <e1>CHEMICAL<\\e1> as substrate to form H2S","sentence":"Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S"}
{"PMID":15671155,"re_id":8,"annotated sentence":"Cystathionine-gamma-lyase (<e2>CSE<\\e2>  and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form <e1>H2S<\\e1>  Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"H2S","object":"CSE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cystathionine-gamma-lyase (<e2>GENE-Y<\\e2>  and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form <e1>CHEMICAL<\\e1>  Of these two enzymes, cystathionine-gamma-lyase (GENE-Y) is believed to be the key enzyme that forms CHEMICAL in the cardiovascular system","sentence":"Cystathionine-gamma-lyase (CSE  and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S  Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system"}
{"PMID":15671155,"re_id":9,"annotated sentence":"Cystathionine-gamma-lyase (CSE) and <e2>cystathionine-beta-synthase<\\e2> (CBS) utilize L-cysteine as substrate to form <e1>H2S<\\e1>  Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"H2S","object":"cystathionine-beta-synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cystathionine-gamma-lyase (CSE) and <e2>GENE-Y<\\e2> (CBS) utilize L-cysteine as substrate to form <e1>CHEMICAL<\\e1>  Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms CHEMICAL in the cardiovascular system","sentence":"Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S  Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system"}
{"PMID":15671155,"re_id":10,"annotated sentence":"Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (<e2>CBS<\\e2>  utilize L-cysteine as substrate to form <e1>H2S<\\e1>  Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"H2S","object":"CBS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (<e2>GENE-Y<\\e2>  utilize L-cysteine as substrate to form <e1>CHEMICAL<\\e1>  Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms CHEMICAL in the cardiovascular system","sentence":"Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS  utilize L-cysteine as substrate to form H2S  Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system"}
{"PMID":15671155,"re_id":11,"annotated sentence":"<e2>Cystathionine-gamma-lyase<\\e2> (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form <e1>H2S<\\e1>  Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"H2S","object":"Cystathionine-gamma-lyase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form <e1>CHEMICAL<\\e1>  Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms CHEMICAL in the cardiovascular system","sentence":"Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S  Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system"}
{"PMID":15671155,"re_id":12,"annotated sentence":"Of these two enzymes, <e2>cystathionine-gamma-lyase<\\e2> (CSE) is believed to be the key enzyme that forms <e1>H2S<\\e1> in the cardiovascular system","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"H2S","object":"cystathionine-gamma-lyase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Of these two enzymes, <e2>GENE-Y<\\e2> (CSE) is believed to be the key enzyme that forms <e1>CHEMICAL<\\e1> in the cardiovascular system","sentence":"Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system"}
{"PMID":15671155,"re_id":13,"annotated sentence":"Of these two enzymes, cystathionine-gamma-lyase (<e2>CSE<\\e2>  is believed to be the key enzyme that forms <e1>H2S<\\e1> in the cardiovascular system","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"H2S","object":"CSE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Of these two enzymes, cystathionine-gamma-lyase (<e2>GENE-Y<\\e2>  is believed to be the key enzyme that forms <e1>CHEMICAL<\\e1> in the cardiovascular system","sentence":"Of these two enzymes, cystathionine-gamma-lyase (CSE  is believed to be the key enzyme that forms H2S in the cardiovascular system"}
{"PMID":15737409,"re_id":0,"annotated sentence":"ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (<e2>LXRs<\\e2> , which are also activated by oxysterols and some derivatives of plant <e1>sterols<\\e1>  NPC1L1 could recently be identified as a major sterol transporter for the intestinal uptake of cholesterol as well as plant sterols","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"sterols","object":"LXRs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (<e2>GENE-N<\\e2> , which are also activated by oxyCHEMICAL and some derivatives of plant <e1>CHEMICAL<\\e1>  NPC1L1 could recently be identified as a major sterol transporter for the intestinal uptake of cholesterol as well as plant CHEMICAL","sentence":"ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (LXRs , which are also activated by oxysterols and some derivatives of plant sterols  NPC1L1 could recently be identified as a major sterol transporter for the intestinal uptake of cholesterol as well as plant sterols"}
{"PMID":15737409,"re_id":1,"annotated sentence":"<e2>NPC1L1<\\e2> could recently be identified as a major sterol transporter for the intestinal uptake of <e1>cholesterol<\\e1> as well as plant sterols","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cholesterol","object":"NPC1L1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> could recently be identified as a major sterol transporter for the intestinal uptake of <e1>CHEMICAL<\\e1> as well as plant sterols","sentence":"NPC1L1 could recently be identified as a major sterol transporter for the intestinal uptake of cholesterol as well as plant sterols"}
{"PMID":15737409,"re_id":2,"annotated sentence":"NPC1L1 could recently be identified as a major <e2>sterol transporter<\\e2> for the intestinal uptake of <e1>cholesterol<\\e1> as well as plant sterols","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cholesterol","object":"sterol transporter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"NPC1L1 could recently be identified as a major <e2>GENE-N<\\e2> for the intestinal uptake of <e1>CHEMICAL<\\e1> as well as plant sterols","sentence":"NPC1L1 could recently be identified as a major sterol transporter for the intestinal uptake of cholesterol as well as plant sterols"}
{"PMID":15737409,"re_id":3,"annotated sentence":"<e2>NPC1L1<\\e2> could recently be identified as a major sterol transporter for the intestinal uptake of cholesterol as well as plant <e1>sterols<\\e1>  Studies in NPC1L1 knockout mice indicate that this transporter is essential for the intestinal uptake of sterols and that NPC1L1 might also be involved in the mechanism of action of ezetimibe","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"sterols","object":"NPC1L1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> could recently be identified as a major sterol transporter for the intestinal uptake of cholesterol as well as plant <e1>CHEMICAL<\\e1>  Studies in GENE-Y knockout mice indicate that this transporter is essential for the intestinal uptake of CHEMICAL and that GENE-Y might also be involved in the mechanism of action of ezetimibe","sentence":"NPC1L1 could recently be identified as a major sterol transporter for the intestinal uptake of cholesterol as well as plant sterols  Studies in NPC1L1 knockout mice indicate that this transporter is essential for the intestinal uptake of sterols and that NPC1L1 might also be involved in the mechanism of action of ezetimibe"}
{"PMID":15737409,"re_id":4,"annotated sentence":"NPC1L1 could recently be identified as a major <e2>sterol transporter<\\e2> for the intestinal uptake of cholesterol as well as plant <e1>sterols<\\e1>  Studies in NPC1L1 knockout mice indicate that this transporter is essential for the intestinal uptake of sterols and that NPC1L1 might also be involved in the mechanism of action of ezetimibe","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"sterols","object":"sterol transporter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"NPC1L1 could recently be identified as a major <e2>GENE-N<\\e2> for the intestinal uptake of cholesterol as well as plant <e1>CHEMICAL<\\e1>  Studies in NPC1L1 knockout mice indicate that this transporter is essential for the intestinal uptake of CHEMICAL and that NPC1L1 might also be involved in the mechanism of action of ezetimibe","sentence":"NPC1L1 could recently be identified as a major sterol transporter for the intestinal uptake of cholesterol as well as plant sterols  Studies in NPC1L1 knockout mice indicate that this transporter is essential for the intestinal uptake of sterols and that NPC1L1 might also be involved in the mechanism of action of ezetimibe"}
{"PMID":15787205,"re_id":0,"annotated sentence":"<e1>Bupropion<\\e1> has an antidepressant effect through blocking the <e2>dopamine transporter<\\e2>  By 99mTc-TRODAT-SPECT, we measured the baseline DAT activity of depressed patients","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Bupropion","object":"dopamine transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> has an antidepressant effect through blocking the <e2>GENE-Y<\\e2>  By 99mTc-TRODAT-SPECT, we measured the baseline DAT activity of depressed patients","sentence":"Bupropion has an antidepressant effect through blocking the dopamine transporter  By 99mTc-TRODAT-SPECT, we measured the baseline DAT activity of depressed patients"}
{"PMID":15811959,"re_id":0,"annotated sentence":"Our results demonstrate that the combination of denileukin diftitox and bexarotene is well tolerated and that even low doses (150 mg\/day) of <e1>bexarotene<\\e1> are capable of in vivo upregulation of <e2>CD25<\\e2> expression on circulating leukemia cells.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"bexarotene","object":"CD25","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our results demonstrate that the combination of denileukin diftitox and CHEMICAL is well tolerated and that even low doses (150 mg\/day) of <e1>CHEMICAL<\\e1> are capable of in vivo upregulation of <e2>GENE-Y<\\e2> expression on circulating leukemia cells.","sentence":"Our results demonstrate that the combination of denileukin diftitox and bexarotene is well tolerated and that even low doses (150 mg\/day) of bexarotene are capable of in vivo upregulation of CD25 expression on circulating leukemia cells."}
{"PMID":15811959,"re_id":1,"annotated sentence":"In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, <e1>bexarotene<\\e1>  at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the <e2>p55<\\e2> and p75 subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"bexarotene","object":"p55","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, <e1>CHEMICAL<\\e1>  at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the <e2>GENE-Y<\\e2> and p75 subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox","sentence":"In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, bexarotene  at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and p75 subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox"}
{"PMID":15811959,"re_id":2,"annotated sentence":"In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, <e1>bexarotene<\\e1>  at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and <e2>p75<\\e2> subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"bexarotene","object":"p75","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, <e1>CHEMICAL<\\e1>  at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and <e2>GENE-Y<\\e2> subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox","sentence":"In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, bexarotene  at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and p75 subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox"}
{"PMID":15811959,"re_id":3,"annotated sentence":"In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, <e1>bexarotene<\\e1>  at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and p75 subunits of the <e2>IL-2R<\\e2> and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"bexarotene","object":"IL-2R","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, <e1>CHEMICAL<\\e1>  at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and p75 subunits of the <e2>GENE-N<\\e2> and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox","sentence":"In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, bexarotene  at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and p75 subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox"}
{"PMID":15837926,"re_id":0,"annotated sentence":"<e2>PSMA<\\e2> acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including <e1>folate<\\e1>  the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"folate","object":"PSMA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including <e1>CHEMICAL<\\e1>  the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate","sentence":"PSMA acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including folate  the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate"}
{"PMID":15837926,"re_id":1,"annotated sentence":"PSMA acts as a <e2>glutamate carboxypeptidase<\\e2> (GCPII) on small molecule substrates, including <e1>folate<\\e1>  the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"folate","object":"glutamate carboxypeptidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"PSMA acts as a <e2>GENE-N<\\e2> (GCPII) on small molecule substrates, including <e1>CHEMICAL<\\e1>  the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate","sentence":"PSMA acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including folate  the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate"}
{"PMID":15837926,"re_id":2,"annotated sentence":"PSMA acts as a glutamate carboxypeptidase (<e2>GCPII<\\e2>  on small molecule substrates, including <e1>folate<\\e1>  the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"folate","object":"GCPII","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PSMA acts as a glutamate carboxypeptidase (<e2>GENE-Y<\\e2>  on small molecule substrates, including <e1>CHEMICAL<\\e1>  the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate","sentence":"PSMA acts as a glutamate carboxypeptidase (GCPII  on small molecule substrates, including folate  the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate"}
{"PMID":15837926,"re_id":3,"annotated sentence":"<e2>PSMA<\\e2> acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including folate, the anticancer drug <e1>methotrexate<\\e1>  and the neuropeptide N-acetyl-l-aspartyl-l-glutamate","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"methotrexate","object":"PSMA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including folate, the anticancer drug <e1>CHEMICAL<\\e1>  and the neuropeptide N-acetyl-l-aspartyl-l-glutamate","sentence":"PSMA acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including folate, the anticancer drug methotrexate  and the neuropeptide N-acetyl-l-aspartyl-l-glutamate"}
{"PMID":15837926,"re_id":4,"annotated sentence":"PSMA acts as a <e2>glutamate carboxypeptidase<\\e2> (GCPII) on small molecule substrates, including folate, the anticancer drug <e1>methotrexate<\\e1>  and the neuropeptide N-acetyl-l-aspartyl-l-glutamate","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"methotrexate","object":"glutamate carboxypeptidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"PSMA acts as a <e2>GENE-N<\\e2> (GCPII) on small molecule substrates, including folate, the anticancer drug <e1>CHEMICAL<\\e1>  and the neuropeptide N-acetyl-l-aspartyl-l-glutamate","sentence":"PSMA acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including folate, the anticancer drug methotrexate  and the neuropeptide N-acetyl-l-aspartyl-l-glutamate"}
{"PMID":15837926,"re_id":5,"annotated sentence":"PSMA acts as a glutamate carboxypeptidase (<e2>GCPII<\\e2>  on small molecule substrates, including folate, the anticancer drug <e1>methotrexate<\\e1>  and the neuropeptide N-acetyl-l-aspartyl-l-glutamate","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"methotrexate","object":"GCPII","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PSMA acts as a glutamate carboxypeptidase (<e2>GENE-Y<\\e2>  on small molecule substrates, including folate, the anticancer drug <e1>CHEMICAL<\\e1>  and the neuropeptide N-acetyl-l-aspartyl-l-glutamate","sentence":"PSMA acts as a glutamate carboxypeptidase (GCPII  on small molecule substrates, including folate, the anticancer drug methotrexate  and the neuropeptide N-acetyl-l-aspartyl-l-glutamate"}
{"PMID":15837926,"re_id":6,"annotated sentence":"<e2>PSMA<\\e2> acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including folate, the anticancer drug methotrexate, and the neuropeptide <e1>N-acetyl-l-aspartyl-l-glutamate<\\e1>  Here we present the 3.5-A crystal structure of the PSMA ectodomain, which reveals a homodimer with structural similarity to transferrin receptor, a receptor for iron-loaded transferrin that lacks protease activity","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"N-acetyl-l-aspartyl-l-glutamate","object":"PSMA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including folate, the anticancer drug methotrexate, and the neuropeptide <e1>CHEMICAL<\\e1>  Here we present the 3.5-A crystal structure of the GENE-Y ectodomain, which reveals a homodimer with structural similarity to transferrin receptor, a receptor for iron-loaded transferrin that lacks protease activity","sentence":"PSMA acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including folate, the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate  Here we present the 3.5-A crystal structure of the PSMA ectodomain, which reveals a homodimer with structural similarity to transferrin receptor, a receptor for iron-loaded transferrin that lacks protease activity"}
{"PMID":15837926,"re_id":7,"annotated sentence":"PSMA acts as a <e2>glutamate carboxypeptidase<\\e2> (GCPII) on small molecule substrates, including folate, the anticancer drug methotrexate, and the neuropeptide <e1>N-acetyl-l-aspartyl-l-glutamate<\\e1>  Here we present the 3.5-A crystal structure of the PSMA ectodomain, which reveals a homodimer with structural similarity to transferrin receptor, a receptor for iron-loaded transferrin that lacks protease activity","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"N-acetyl-l-aspartyl-l-glutamate","object":"glutamate carboxypeptidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"PSMA acts as a <e2>GENE-N<\\e2> (GCPII) on small molecule substrates, including folate, the anticancer drug methotrexate, and the neuropeptide <e1>CHEMICAL<\\e1>  Here we present the 3.5-A crystal structure of the PSMA ectodomain, which reveals a homodimer with structural similarity to transferrin receptor, a receptor for iron-loaded transferrin that lacks protease activity","sentence":"PSMA acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including folate, the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate  Here we present the 3.5-A crystal structure of the PSMA ectodomain, which reveals a homodimer with structural similarity to transferrin receptor, a receptor for iron-loaded transferrin that lacks protease activity"}
{"PMID":15837926,"re_id":8,"annotated sentence":"Elucidation of the <e2>PSMA<\\e2> structure combined with docking studies and a proposed catalytic mechanism provides insight into the recognition of inhibitors and the natural substrate <e1>N-acetyl-l-aspartyl-l-glutamate<\\e1>  The PSMA structure will facilitate development of chemotherapeutics, cancer-imaging agents, and agents for treatment of neurological disorders.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"N-acetyl-l-aspartyl-l-glutamate","object":"PSMA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Elucidation of the <e2>GENE-Y<\\e2> structure combined with docking studies and a proposed catalytic mechanism provides insight into the recognition of inhibitors and the natural substrate <e1>CHEMICAL<\\e1>  The GENE-Y structure will facilitate development of chemotherapeutics, cancer-imaging agents, and agents for treatment of neurological disorders.","sentence":"Elucidation of the PSMA structure combined with docking studies and a proposed catalytic mechanism provides insight into the recognition of inhibitors and the natural substrate N-acetyl-l-aspartyl-l-glutamate  The PSMA structure will facilitate development of chemotherapeutics, cancer-imaging agents, and agents for treatment of neurological disorders."}
{"PMID":1600046,"re_id":0,"annotated sentence":"While the substituted <e1>benzamide<\\e1> prokinetics (for example, metoclopramide, cisapride) also block <e2>5-HT3<\\e2> receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"benzamide","object":"5-HT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"While the substituted <e1>CHEMICAL<\\e1> prokinetics (for example, metoclopramide, cisapride) also block <e2>GENE-Y<\\e2> receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor","sentence":"While the substituted benzamide prokinetics (for example, metoclopramide, cisapride) also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor"}
{"PMID":1600046,"re_id":1,"annotated sentence":"While the substituted benzamide prokinetics (for example, <e1>metoclopramide<\\e1>  cisapride) also block <e2>5-HT3<\\e2> receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"metoclopramide","object":"5-HT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"While the substituted benzamide prokinetics (for example, <e1>CHEMICAL<\\e1>  cisapride) also block <e2>GENE-Y<\\e2> receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor","sentence":"While the substituted benzamide prokinetics (for example, metoclopramide  cisapride) also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor"}
{"PMID":1600046,"re_id":2,"annotated sentence":"While the substituted benzamide prokinetics (for example, metoclopramide, <e1>cisapride<\\e1>  also block <e2>5-HT3<\\e2> receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cisapride","object":"5-HT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"While the substituted benzamide prokinetics (for example, metoclopramide, <e1>CHEMICAL<\\e1>  also block <e2>GENE-Y<\\e2> receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor","sentence":"While the substituted benzamide prokinetics (for example, metoclopramide, cisapride  also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor"}
{"PMID":1600046,"re_id":3,"annotated sentence":"While the substituted <e1>benzamide<\\e1> prokinetics (for example, metoclopramide, cisapride) also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative <e2>5-HT4<\\e2> receptor","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"benzamide","object":"5-HT4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"While the substituted <e1>CHEMICAL<\\e1> prokinetics (for example, metoclopramide, cisapride) also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative <e2>GENE-Y<\\e2> receptor","sentence":"While the substituted benzamide prokinetics (for example, metoclopramide, cisapride) also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor"}
{"PMID":1600046,"re_id":4,"annotated sentence":"While the substituted benzamide prokinetics (for example, <e1>metoclopramide<\\e1>  cisapride) also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative <e2>5-HT4<\\e2> receptor","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"metoclopramide","object":"5-HT4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"While the substituted benzamide prokinetics (for example, <e1>CHEMICAL<\\e1>  cisapride) also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative <e2>GENE-Y<\\e2> receptor","sentence":"While the substituted benzamide prokinetics (for example, metoclopramide  cisapride) also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor"}
{"PMID":1600046,"re_id":5,"annotated sentence":"While the substituted benzamide prokinetics (for example, metoclopramide, <e1>cisapride<\\e1>  also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative <e2>5-HT4<\\e2> receptor","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"cisapride","object":"5-HT4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"While the substituted benzamide prokinetics (for example, metoclopramide, <e1>CHEMICAL<\\e1>  also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative <e2>GENE-Y<\\e2> receptor","sentence":"While the substituted benzamide prokinetics (for example, metoclopramide, cisapride  also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor"}
{"PMID":1600046,"re_id":6,"annotated sentence":"Some 5-HT3 antagonists have <e2>5-HT4<\\e2> agonist activity (for example, <e1>renzapride<\\e1>  zacopride) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"renzapride","object":"5-HT4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Some 5-HT3 antagonists have <e2>GENE-Y<\\e2> agonist activity (for example, <e1>CHEMICAL<\\e1>  zacopride) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a GENE-Y antagonist","sentence":"Some 5-HT3 antagonists have 5-HT4 agonist activity (for example, renzapride  zacopride) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist"}
{"PMID":1600046,"re_id":7,"annotated sentence":"Some 5-HT3 antagonists have <e2>5-HT4<\\e2> agonist activity (for example, renzapride, <e1>zacopride<\\e1>  and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"zacopride","object":"5-HT4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Some 5-HT3 antagonists have <e2>GENE-Y<\\e2> agonist activity (for example, renzapride, <e1>CHEMICAL<\\e1>  and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a GENE-Y antagonist","sentence":"Some 5-HT3 antagonists have 5-HT4 agonist activity (for example, renzapride, zacopride  and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist"}
{"PMID":1600046,"re_id":8,"annotated sentence":"A number of selective <e2>5-HT3<\\e2> antagonists have been developed including ondansetron, granisetron, tropisetron renzapride and <e1>zacopride<\\e1>  While the substituted benzamide prokinetics (for example, metoclopramide, cisapride) also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"zacopride","object":"5-HT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A number of selective <e2>GENE-Y<\\e2> antagonists have been developed including ondansetron, granisetron, tropisetron renzapride and <e1>CHEMICAL<\\e1>  While the substituted benzamide prokinetics (for example, metoclopramide, cisapride) also block GENE-Y receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor","sentence":"A number of selective 5-HT3 antagonists have been developed including ondansetron, granisetron, tropisetron renzapride and zacopride  While the substituted benzamide prokinetics (for example, metoclopramide, cisapride) also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor"}
{"PMID":1600046,"re_id":9,"annotated sentence":"Some <e2>5-HT3<\\e2> antagonists have 5-HT4 agonist activity (for example, <e1>renzapride<\\e1>  zacopride) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"renzapride","object":"5-HT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Some <e2>GENE-Y<\\e2> antagonists have 5-HT4 agonist activity (for example, <e1>CHEMICAL<\\e1>  zacopride) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist","sentence":"Some 5-HT3 antagonists have 5-HT4 agonist activity (for example, renzapride  zacopride) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist"}
{"PMID":1600046,"re_id":10,"annotated sentence":"Some <e2>5-HT3<\\e2> antagonists have 5-HT4 agonist activity (for example, renzapride, <e1>zacopride<\\e1>  and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"zacopride","object":"5-HT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Some <e2>GENE-Y<\\e2> antagonists have 5-HT4 agonist activity (for example, renzapride, <e1>CHEMICAL<\\e1>  and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist","sentence":"Some 5-HT3 antagonists have 5-HT4 agonist activity (for example, renzapride, zacopride  and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist"}
{"PMID":1600046,"re_id":11,"annotated sentence":"Some 5-HT3 antagonists have 5-HT4 agonist activity (for example, renzapride, zacopride) and others do not (for example, ondansetron, granisetron), while <e1>tropisetron<\\e1> in high concentrations is a <e2>5-HT4<\\e2> antagonist","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"tropisetron","object":"5-HT4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Some 5-HT3 antagonists have GENE-Y agonist activity (for example, renzapride, zacopride) and others do not (for example, ondansetron, granisetron), while <e1>CHEMICAL<\\e1> in high concentrations is a <e2>GENE-Y<\\e2> antagonist","sentence":"Some 5-HT3 antagonists have 5-HT4 agonist activity (for example, renzapride, zacopride) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist"}
{"PMID":1600046,"re_id":12,"annotated sentence":"A number of selective <e2>5-HT3<\\e2> antagonists have been developed including <e1>ondansetron<\\e1>  granisetron, tropisetron renzapride and zacopride","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"ondansetron","object":"5-HT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A number of selective <e2>GENE-Y<\\e2> antagonists have been developed including <e1>CHEMICAL<\\e1>  granisetron, tropisetron renzapride and zacopride","sentence":"A number of selective 5-HT3 antagonists have been developed including ondansetron  granisetron, tropisetron renzapride and zacopride"}
{"PMID":1600046,"re_id":13,"annotated sentence":"A number of selective <e2>5-HT3<\\e2> antagonists have been developed including ondansetron, <e1>granisetron<\\e1>  tropisetron renzapride and zacopride","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"granisetron","object":"5-HT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A number of selective <e2>GENE-Y<\\e2> antagonists have been developed including ondansetron, <e1>CHEMICAL<\\e1>  tropisetron renzapride and zacopride","sentence":"A number of selective 5-HT3 antagonists have been developed including ondansetron, granisetron  tropisetron renzapride and zacopride"}
{"PMID":1600046,"re_id":14,"annotated sentence":"A number of selective <e2>5-HT3<\\e2> antagonists have been developed including ondansetron, granisetron, <e1>tropisetron<\\e1> renzapride and zacopride","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"tropisetron","object":"5-HT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A number of selective <e2>GENE-Y<\\e2> antagonists have been developed including ondansetron, granisetron, <e1>CHEMICAL<\\e1> renzapride and zacopride","sentence":"A number of selective 5-HT3 antagonists have been developed including ondansetron, granisetron, tropisetron renzapride and zacopride"}
{"PMID":1600046,"re_id":15,"annotated sentence":"A number of selective <e2>5-HT3<\\e2> antagonists have been developed including ondansetron, granisetron, tropisetron <e1>renzapride<\\e1> and zacopride","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"renzapride","object":"5-HT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A number of selective <e2>GENE-Y<\\e2> antagonists have been developed including ondansetron, granisetron, tropisetron <e1>CHEMICAL<\\e1> and zacopride","sentence":"A number of selective 5-HT3 antagonists have been developed including ondansetron, granisetron, tropisetron renzapride and zacopride"}
{"PMID":16018973,"re_id":0,"annotated sentence":"We present our studies to demonstrate that HM74A, but not HM74, binds <e1>niacin<\\e1> at high affinities and effectively mediates <e2>Gi<\\e2> signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing HM74A","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"niacin","object":"Gi","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We present our studies to demonstrate that HM74A, but not HM74, binds <e1>CHEMICAL<\\e1> at high affinities and effectively mediates <e2>GENE-N<\\e2> signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing HM74A","sentence":"We present our studies to demonstrate that HM74A, but not HM74, binds niacin at high affinities and effectively mediates Gi signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing HM74A"}
{"PMID":16232421,"re_id":0,"annotated sentence":"When cultured in YPD medium containing 15% glucose under aerobic conditions, the <e2>KGD1<\\e2> (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of <e1>succinate<\\e1> than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"succinate","object":"KGD1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"When cultured in YPD medium containing 15% glucose under aerobic conditions, the <e2>GENE-Y<\\e2> (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of <e1>CHEMICAL<\\e1> than the wild-type strain, while the SDH1 (CHEMICAL dehydrogenase) gene-disrupted mutant produced an increased level of CHEMICAL","sentence":"When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate"}
{"PMID":16232421,"re_id":1,"annotated sentence":"When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (<e2>alpha-ketoglutarate dehydrogenase<\\e2>  gene disrupted mutant produced a lower level of <e1>succinate<\\e1> than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"succinate","object":"alpha-ketoglutarate dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (<e2>GENE-Y<\\e2>  gene disrupted mutant produced a lower level of <e1>CHEMICAL<\\e1> than the wild-type strain, while the SDH1 (CHEMICAL dehydrogenase) gene-disrupted mutant produced an increased level of CHEMICAL","sentence":"When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase  gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate"}
{"PMID":16232421,"re_id":2,"annotated sentence":"When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the <e2>SDH1<\\e2> (succinate dehydrogenase) gene-disrupted mutant produced an increased level of <e1>succinate<\\e1>  On the other hand, the FUM1 (fumarase) gene disrupted mutant produced significantly higher levels of fumarate but did not form malate at all","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"succinate","object":"SDH1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of CHEMICAL than the wild-type strain, while the <e2>GENE-Y<\\e2> (CHEMICAL dehydrogenase) gene-disrupted mutant produced an increased level of <e1>CHEMICAL<\\e1>  On the other hand, the FUM1 (fumarase) gene disrupted mutant produced significantly higher levels of fumarate but did not form malate at all","sentence":"When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate  On the other hand, the FUM1 (fumarase) gene disrupted mutant produced significantly higher levels of fumarate but did not form malate at all"}
{"PMID":16232421,"re_id":3,"annotated sentence":"When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (<e2>succinate dehydrogenase<\\e2>  gene-disrupted mutant produced an increased level of <e1>succinate<\\e1>  On the other hand, the FUM1 (fumarase) gene disrupted mutant produced significantly higher levels of fumarate but did not form malate at all","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"succinate","object":"succinate dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of CHEMICAL than the wild-type strain, while the SDH1 (<e2>CHEMICAL dehydrogenase<\\e2>  gene-disrupted mutant produced an increased level of <e1>CHEMICAL<\\e1>  On the other hand, the FUM1 (fumarase) gene disrupted mutant produced significantly higher levels of fumarate but did not form malate at all","sentence":"When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (succinate dehydrogenase  gene-disrupted mutant produced an increased level of succinate  On the other hand, the FUM1 (fumarase) gene disrupted mutant produced significantly higher levels of fumarate but did not form malate at all"}
{"PMID":16232421,"re_id":4,"annotated sentence":"On the other hand, the <e2>FUM1<\\e2> (fumarase) gene disrupted mutant produced significantly higher levels of <e1>fumarate<\\e1> but did not form malate at all","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"fumarate","object":"FUM1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"On the other hand, the <e2>GENE-Y<\\e2> (fumarase) gene disrupted mutant produced significantly higher levels of <e1>CHEMICAL<\\e1> but did not form malate at all","sentence":"On the other hand, the FUM1 (fumarase) gene disrupted mutant produced significantly higher levels of fumarate but did not form malate at all"}
{"PMID":16232421,"re_id":5,"annotated sentence":"On the other hand, the FUM1 (<e2>fumarase<\\e2>  gene disrupted mutant produced significantly higher levels of <e1>fumarate<\\e1> but did not form malate at all","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"fumarate","object":"fumarase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"On the other hand, the FUM1 (<e2>GENE-Y<\\e2>  gene disrupted mutant produced significantly higher levels of <e1>CHEMICAL<\\e1> but did not form malate at all","sentence":"On the other hand, the FUM1 (fumarase  gene disrupted mutant produced significantly higher levels of fumarate but did not form malate at all"}
{"PMID":16232421,"re_id":6,"annotated sentence":"When the growth condition was shifted from aerobic to anaerobic, the increased level of <e1>succinate<\\e1> in <e2>SDH1<\\e2> disruptants was no longer observed, whereas the decreased level of succinate in the KGD1 diruptant was still observed","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"succinate","object":"SDH1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"When the growth condition was shifted from aerobic to anaerobic, the increased level of <e1>CHEMICAL<\\e1> in <e2>GENE-Y<\\e2> disruptants was no longer observed, whereas the decreased level of CHEMICAL in the KGD1 diruptant was still observed","sentence":"When the growth condition was shifted from aerobic to anaerobic, the increased level of succinate in SDH1 disruptants was no longer observed, whereas the decreased level of succinate in the KGD1 diruptant was still observed"}
{"PMID":16232421,"re_id":7,"annotated sentence":"When the growth condition was shifted from aerobic to anaerobic, the increased level of succinate in SDH1 disruptants was no longer observed, whereas the decreased level of <e1>succinate<\\e1> in the <e2>KGD1<\\e2> diruptant was still observed","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"succinate","object":"KGD1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"When the growth condition was shifted from aerobic to anaerobic, the increased level of CHEMICAL in SDH1 disruptants was no longer observed, whereas the decreased level of <e1>CHEMICAL<\\e1> in the <e2>GENE-Y<\\e2> diruptant was still observed","sentence":"When the growth condition was shifted from aerobic to anaerobic, the increased level of succinate in SDH1 disruptants was no longer observed, whereas the decreased level of succinate in the KGD1 diruptant was still observed"}
{"PMID":16232421,"re_id":8,"annotated sentence":"A double mutant of the two <e2>fumarate reductase<\\e2> isozyme genes (OSM1 and FRDS) showed a <e1>succinate<\\e1> productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"succinate","object":"fumarate reductase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A double mutant of the two <e2>GENE-N<\\e2> isozyme genes (OSM1 and FRDS) showed a <e1>CHEMICAL<\\e1> productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution","sentence":"A double mutant of the two fumarate reductase isozyme genes (OSM1 and FRDS) showed a succinate productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution"}
{"PMID":16232421,"re_id":9,"annotated sentence":"A double mutant of the two fumarate reductase isozyme genes (<e2>OSM1<\\e2> and FRDS) showed a <e1>succinate<\\e1> productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"succinate","object":"OSM1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A double mutant of the two fumarate reductase isozyme genes (<e2>GENE-Y<\\e2> and FRDS) showed a <e1>CHEMICAL<\\e1> productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution","sentence":"A double mutant of the two fumarate reductase isozyme genes (OSM1 and FRDS) showed a succinate productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution"}
{"PMID":16232421,"re_id":10,"annotated sentence":"A double mutant of the two fumarate reductase isozyme genes (OSM1 and <e2>FRDS<\\e2>  showed a <e1>succinate<\\e1> productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"succinate","object":"FRDS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A double mutant of the two fumarate reductase isozyme genes (OSM1 and <e2>GENE-Y<\\e2>  showed a <e1>CHEMICAL<\\e1> productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution","sentence":"A double mutant of the two fumarate reductase isozyme genes (OSM1 and FRDS  showed a succinate productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution"}
{"PMID":16292755,"re_id":0,"annotated sentence":"However, plasma <e2>high-density lipoprotein<\\e2> cholesterol (HDL-C) and HDL-C\/total-C ratio levels and plasma paraoxonase activity were only significantly higher in <e1>vitamin E<\\e1> group after 8 weeks","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"vitamin E","object":"high-density lipoprotein","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, plasma <e2>GENE-N<\\e2> cholesterol (HDL-C) and HDL-C\/total-C ratio levels and plasma paraoxonase activity were only significantly higher in <e1>CHEMICAL<\\e1> group after 8 weeks","sentence":"However, plasma high-density lipoprotein cholesterol (HDL-C) and HDL-C\/total-C ratio levels and plasma paraoxonase activity were only significantly higher in vitamin E group after 8 weeks"}
{"PMID":16292755,"re_id":1,"annotated sentence":"However, plasma high-density lipoprotein-cholesterol (<e2>HDL<\\e2> C) and HDL-C\/total-C ratio levels and plasma paraoxonase activity were only significantly higher in <e1>vitamin E<\\e1> group after 8 weeks","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"vitamin E","object":"HDL","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, plasma high-density lipoprotein-cholesterol (<e2>GENE-N<\\e2> C) and GENE-N-C\/total-C ratio levels and plasma paraoxonase activity were only significantly higher in <e1>CHEMICAL<\\e1> group after 8 weeks","sentence":"However, plasma high-density lipoprotein-cholesterol (HDL C) and HDL-C\/total-C ratio levels and plasma paraoxonase activity were only significantly higher in vitamin E group after 8 weeks"}
{"PMID":16292755,"re_id":2,"annotated sentence":"However, plasma high-density lipoprotein-cholesterol (HDL-C) and <e2>HDL<\\e2> C\/total-C ratio levels and plasma paraoxonase activity were only significantly higher in <e1>vitamin E<\\e1> group after 8 weeks","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"vitamin E","object":"HDL","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, plasma high-density lipoprotein-cholesterol (GENE-N-C) and <e2>GENE-N<\\e2> C\/total-C ratio levels and plasma paraoxonase activity were only significantly higher in <e1>CHEMICAL<\\e1> group after 8 weeks","sentence":"However, plasma high-density lipoprotein-cholesterol (HDL-C) and HDL C\/total-C ratio levels and plasma paraoxonase activity were only significantly higher in vitamin E group after 8 weeks"}
{"PMID":16292755,"re_id":3,"annotated sentence":"However, plasma high-density lipoprotein-cholesterol (HDL-C) and HDL-C\/total-C ratio levels and plasma <e2>paraoxonase<\\e2> activity were only significantly higher in <e1>vitamin E<\\e1> group after 8 weeks","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"vitamin E","object":"paraoxonase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, plasma high-density lipoprotein-cholesterol (HDL-C) and HDL-C\/total-C ratio levels and plasma <e2>GENE-Y<\\e2> activity were only significantly higher in <e1>CHEMICAL<\\e1> group after 8 weeks","sentence":"However, plasma high-density lipoprotein-cholesterol (HDL-C) and HDL-C\/total-C ratio levels and plasma paraoxonase activity were only significantly higher in vitamin E group after 8 weeks"}
{"PMID":16292755,"re_id":4,"annotated sentence":"Hepatic ACAT activity was significantly lower in both vitamin E and probucol groups than in HC-control group, while <e2>HMG-CoA reductase<\\e2> activity was the highest only in the <e1>probucol<\\e1> group","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"probucol","object":"HMG-CoA reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Hepatic ACAT activity was significantly lower in both vitamin E and CHEMICAL groups than in HC-control group, while <e2>GENE-Y<\\e2> activity was the highest only in the <e1>CHEMICAL<\\e1> group","sentence":"Hepatic ACAT activity was significantly lower in both vitamin E and probucol groups than in HC-control group, while HMG-CoA reductase activity was the highest only in the probucol group"}
{"PMID":16292755,"re_id":5,"annotated sentence":"<e1>Vitamin E<\\e1> and probucol significantly suppressed an increase in plasma total-cholesterol (total-C) and <e2>low-density lipoprotein<\\e2> cholesterol compared to HC-control group","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Vitamin E","object":"low-density lipoprotein","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> and probucol significantly suppressed an increase in plasma total-cholesterol (total-C) and <e2>GENE-N<\\e2> cholesterol compared to HC-control group","sentence":"Vitamin E and probucol significantly suppressed an increase in plasma total-cholesterol (total-C) and low-density lipoprotein cholesterol compared to HC-control group"}
{"PMID":16292755,"re_id":6,"annotated sentence":"Vitamin E and <e1>probucol<\\e1> significantly suppressed an increase in plasma total-cholesterol (total-C) and <e2>low-density lipoprotein<\\e2> cholesterol compared to HC-control group","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"probucol","object":"low-density lipoprotein","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Vitamin E and <e1>CHEMICAL<\\e1> significantly suppressed an increase in plasma total-cholesterol (total-C) and <e2>GENE-N<\\e2> cholesterol compared to HC-control group","sentence":"Vitamin E and probucol significantly suppressed an increase in plasma total-cholesterol (total-C) and low-density lipoprotein cholesterol compared to HC-control group"}
{"PMID":16292755,"re_id":7,"annotated sentence":"Hepatic <e2>ACAT<\\e2> activity was significantly lower in both <e1>vitamin E<\\e1> and probucol groups than in HC-control group, while HMG-CoA reductase activity was the highest only in the probucol group","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"vitamin E","object":"ACAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Hepatic <e2>GENE-Y<\\e2> activity was significantly lower in both <e1>CHEMICAL<\\e1> and probucol groups than in HC-control group, while HMG-CoA reductase activity was the highest only in the probucol group","sentence":"Hepatic ACAT activity was significantly lower in both vitamin E and probucol groups than in HC-control group, while HMG-CoA reductase activity was the highest only in the probucol group"}
{"PMID":16292755,"re_id":8,"annotated sentence":"Hepatic <e2>ACAT<\\e2> activity was significantly lower in both vitamin E and <e1>probucol<\\e1> groups than in HC-control group, while HMG-CoA reductase activity was the highest only in the probucol group","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"probucol","object":"ACAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Hepatic <e2>GENE-Y<\\e2> activity was significantly lower in both vitamin E and <e1>CHEMICAL<\\e1> groups than in HC-control group, while HMG-CoA reductase activity was the highest only in the CHEMICAL group","sentence":"Hepatic ACAT activity was significantly lower in both vitamin E and probucol groups than in HC-control group, while HMG-CoA reductase activity was the highest only in the probucol group"}
{"PMID":16292755,"re_id":9,"annotated sentence":"Hepatic mRNA expressions of <e2>apo B-100<\\e2> and apo C-III were significantly lower in <e1>probucol<\\e1> group than in other groups","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"probucol","object":"apo B-100","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Hepatic mRNA expressions of <e2>GENE-Y<\\e2> and apo C-III were significantly lower in <e1>CHEMICAL<\\e1> group than in other groups","sentence":"Hepatic mRNA expressions of apo B-100 and apo C-III were significantly lower in probucol group than in other groups"}
{"PMID":16292755,"re_id":10,"annotated sentence":"Hepatic mRNA expressions of apo B-100 and <e2>apo C-III<\\e2> were significantly lower in <e1>probucol<\\e1> group than in other groups","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"probucol","object":"apo C-III","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Hepatic mRNA expressions of apo B-100 and <e2>GENE-Y<\\e2> were significantly lower in <e1>CHEMICAL<\\e1> group than in other groups","sentence":"Hepatic mRNA expressions of apo B-100 and apo C-III were significantly lower in probucol group than in other groups"}
{"PMID":16292755,"re_id":11,"annotated sentence":"Vitamin E supplementation was found to alter the plasma HDL-C-related factors; meanwhile, <e1>probucol<\\e1> supplementation was very effective in enhancing cholesterol metabolism, except for a negative effect that reduced plasma <e2>HDL<\\e2> C concentration.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"probucol","object":"HDL","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Vitamin E supplementation was found to alter the plasma GENE-N-C-related factors; meanwhile, <e1>CHEMICAL<\\e1> supplementation was very effective in enhancing cholesterol metabolism, except for a negative effect that reduced plasma <e2>GENE-N<\\e2> C concentration.","sentence":"Vitamin E supplementation was found to alter the plasma HDL-C-related factors; meanwhile, probucol supplementation was very effective in enhancing cholesterol metabolism, except for a negative effect that reduced plasma HDL C concentration."}
{"PMID":16298345,"re_id":0,"annotated sentence":"However, as with the human receptor, <e1>maraviroc<\\e1> was shown to be a high affinity, potent functional antagonist of <e2>macaque CCR5<\\e2> thereby indicating that the macaque should be a suitable species in which to evaluate the pharmacology, safety and potential mechanism-related toxicology of novel CCR5 antagonists.","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"maraviroc","object":"macaque CCR5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, as with the human receptor, <e1>CHEMICAL<\\e1> was shown to be a high affinity, potent functional antagonist of <e2>GENE-Y<\\e2> thereby indicating that the macaque should be a suitable species in which to evaluate the pharmacology, safety and potential mechanism-related toxicology of novel CCR5 antagonists.","sentence":"However, as with the human receptor, maraviroc was shown to be a high affinity, potent functional antagonist of macaque CCR5 thereby indicating that the macaque should be a suitable species in which to evaluate the pharmacology, safety and potential mechanism-related toxicology of novel CCR5 antagonists."}
{"PMID":16298345,"re_id":1,"annotated sentence":"However, as with the human receptor, <e1>maraviroc<\\e1> was shown to be a high affinity, potent functional antagonist of macaque CCR5 thereby indicating that the macaque should be a suitable species in which to evaluate the pharmacology, safety and potential mechanism-related toxicology of novel <e2>CCR5<\\e2> antagonists.","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"maraviroc","object":"CCR5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, as with the human receptor, <e1>CHEMICAL<\\e1> was shown to be a high affinity, potent functional antagonist of macaque GENE-Y thereby indicating that the macaque should be a suitable species in which to evaluate the pharmacology, safety and potential mechanism-related toxicology of novel <e2>GENE-Y<\\e2> antagonists.","sentence":"However, as with the human receptor, maraviroc was shown to be a high affinity, potent functional antagonist of macaque CCR5 thereby indicating that the macaque should be a suitable species in which to evaluate the pharmacology, safety and potential mechanism-related toxicology of novel CCR5 antagonists."}
{"PMID":16298345,"re_id":2,"annotated sentence":"The aim of this study was to determine if macaque represents a suitable species for the pre-clinical evaluation of novel <e2>CCR5<\\e2> antagonists, such as <e1>maraviroc<\\e1> (UK-427,857)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"maraviroc","object":"CCR5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The aim of this study was to determine if macaque represents a suitable species for the pre-clinical evaluation of novel <e2>GENE-Y<\\e2> antagonists, such as <e1>CHEMICAL<\\e1> (UK-427,857)","sentence":"The aim of this study was to determine if macaque represents a suitable species for the pre-clinical evaluation of novel CCR5 antagonists, such as maraviroc (UK-427,857)"}
{"PMID":16298345,"re_id":3,"annotated sentence":"The aim of this study was to determine if macaque represents a suitable species for the pre-clinical evaluation of novel <e2>CCR5<\\e2> antagonists, such as maraviroc (<e1>UK-427,857<\\e1> ","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"UK-427,857","object":"CCR5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The aim of this study was to determine if macaque represents a suitable species for the pre-clinical evaluation of novel <e2>GENE-Y<\\e2> antagonists, such as maraviroc (<e1>CHEMICAL<\\e1> ","sentence":"The aim of this study was to determine if macaque represents a suitable species for the pre-clinical evaluation of novel CCR5 antagonists, such as maraviroc (UK-427,857 "}
{"PMID":16298345,"re_id":4,"annotated sentence":"<e1>Maraviroc<\\e1> inhibited binding of [125I]-MIP-1beta to CCR5 from macaque and human with similar potency (IC50 = 17.50 +\/- 1.24 nM and 7.18 +\/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular calcium release mediated through <e2>CCR5<\\e2> from macaque and human with similar potency (IC50 = 17.50 +\/- 3.30 nM and 12.07 +\/- 1.89, respectively)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Maraviroc","object":"CCR5","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> inhibited binding of [125I]-MIP-1beta to GENE-N from macaque and human with similar potency (IC50 = 17.50 +\/- 1.24 nM and 7.18 +\/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular calcium release mediated through <e2>GENE-N<\\e2> from macaque and human with similar potency (IC50 = 17.50 +\/- 3.30 nM and 12.07 +\/- 1.89, respectively)","sentence":"Maraviroc inhibited binding of [125I]-MIP-1beta to CCR5 from macaque and human with similar potency (IC50 = 17.50 +\/- 1.24 nM and 7.18 +\/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular calcium release mediated through CCR5 from macaque and human with similar potency (IC50 = 17.50 +\/- 3.30 nM and 12.07 +\/- 1.89, respectively)"}
{"PMID":16316409,"re_id":0,"annotated sentence":"Hence, re-expression of the p75NTR appears to partially reverse de-differentiation of prostate cancer cells by up-regulating the expression of <e2>CRABPI<\\e2> for localized sequestration of <e1>retinoids<\\e1> that are available to newly up-regulated RAR-beta, RXR-alpha, and RXR-beta.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"retinoids","object":"CRABPI","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Hence, re-expression of the p75NTR appears to partially reverse de-differentiation of prostate cancer cells by up-regulating the expression of <e2>GENE-Y<\\e2> for localized sequestration of <e1>CHEMICAL<\\e1> that are available to newly up-regulated RAR-beta, RXR-alpha, and RXR-beta.","sentence":"Hence, re-expression of the p75NTR appears to partially reverse de-differentiation of prostate cancer cells by up-regulating the expression of CRABPI for localized sequestration of retinoids that are available to newly up-regulated RAR-beta, RXR-alpha, and RXR-beta."}
{"PMID":16322797,"re_id":0,"annotated sentence":"Its special profile of actions, especially the rise in <e2>HDL<\\e2> cholesterol levels induced by <e1>nicotinic acid<\\e1>  is unique among the currently available pharmacological tools to treat lipid disorders","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"nicotinic acid","object":"HDL","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Its special profile of actions, especially the rise in <e2>GENE-N<\\e2> cholesterol levels induced by <e1>CHEMICAL<\\e1>  is unique among the currently available pharmacological tools to treat lipid disorders","sentence":"Its special profile of actions, especially the rise in HDL cholesterol levels induced by nicotinic acid  is unique among the currently available pharmacological tools to treat lipid disorders"}
{"PMID":16344985,"re_id":0,"annotated sentence":"RATIONALE: Several drugs used to treat bipolar disorder (<e1>lithium<\\e1> and carbamazepine), when administered chronically to rats, reduce the turnover of arachidonic acid, but not docosahexaenoic acid, in brain phospholipids by decreasing the activity of an arachidonic acid-selective <e2>phospholipase A(2)<\\e2>  Although chronic valproic acid produces similar effects on brain arachidonic acid and docosahexaenoic acid turnover, it does not alter phospholipase A(2) activity, suggesting that it targets a different enzyme in the turnover pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"lithium","object":"phospholipase A(2)","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"RATIONALE: Several drugs used to treat bipolar disorder (<e1>CHEMICAL<\\e1> and carbamazepine), when administered chronically to rats, reduce the turnover of arachidonic acid, but not docosahexaenoic acid, in brain phospholipids by decreasing the activity of an arachidonic acid-selective <e2>GENE-N<\\e2>  Although chronic valproic acid produces similar effects on brain arachidonic acid and docosahexaenoic acid turnover, it does not alter GENE-N activity, suggesting that it targets a different enzyme in the turnover pathway","sentence":"RATIONALE: Several drugs used to treat bipolar disorder (lithium and carbamazepine), when administered chronically to rats, reduce the turnover of arachidonic acid, but not docosahexaenoic acid, in brain phospholipids by decreasing the activity of an arachidonic acid-selective phospholipase A(2)  Although chronic valproic acid produces similar effects on brain arachidonic acid and docosahexaenoic acid turnover, it does not alter phospholipase A(2) activity, suggesting that it targets a different enzyme in the turnover pathway"}
{"PMID":16344985,"re_id":1,"annotated sentence":"MATERIALS AND METHODS\/RESULTS: By isolating rat brain microsomal long-chain fatty acyl-CoA synthetases (Acsl), we show in vitro that <e1>valproic acid<\\e1> is a non-competitive inhibitor of <e2>Acsl<\\e2>  as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"valproic acid","object":"Acsl","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"MATERIALS AND METHODS\/RESULTS: By isolating rat brain microsomal long-chain fatty acyl-CoA synthetases (GENE-N), we show in vitro that <e1>CHEMICAL<\\e1> is a non-competitive inhibitor of <e2>GENE-N<\\e2>  as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme","sentence":"MATERIALS AND METHODS\/RESULTS: By isolating rat brain microsomal long-chain fatty acyl-CoA synthetases (Acsl), we show in vitro that valproic acid is a non-competitive inhibitor of Acsl  as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme"}
{"PMID":16344985,"re_id":2,"annotated sentence":"RATIONALE: Several drugs used to treat bipolar disorder (lithium and <e1>carbamazepine<\\e1> , when administered chronically to rats, reduce the turnover of arachidonic acid, but not docosahexaenoic acid, in brain phospholipids by decreasing the activity of an arachidonic acid-selective <e2>phospholipase A(2)<\\e2>  Although chronic valproic acid produces similar effects on brain arachidonic acid and docosahexaenoic acid turnover, it does not alter phospholipase A(2) activity, suggesting that it targets a different enzyme in the turnover pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"carbamazepine","object":"phospholipase A(2)","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"RATIONALE: Several drugs used to treat bipolar disorder (lithium and <e1>CHEMICAL<\\e1> , when administered chronically to rats, reduce the turnover of arachidonic acid, but not docosahexaenoic acid, in brain phospholipids by decreasing the activity of an arachidonic acid-selective <e2>GENE-N<\\e2>  Although chronic valproic acid produces similar effects on brain arachidonic acid and docosahexaenoic acid turnover, it does not alter GENE-N activity, suggesting that it targets a different enzyme in the turnover pathway","sentence":"RATIONALE: Several drugs used to treat bipolar disorder (lithium and carbamazepine , when administered chronically to rats, reduce the turnover of arachidonic acid, but not docosahexaenoic acid, in brain phospholipids by decreasing the activity of an arachidonic acid-selective phospholipase A(2)  Although chronic valproic acid produces similar effects on brain arachidonic acid and docosahexaenoic acid turnover, it does not alter phospholipase A(2) activity, suggesting that it targets a different enzyme in the turnover pathway"}
{"PMID":16344985,"re_id":3,"annotated sentence":"<e1>Valproic acid<\\e1> selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by <e2>brain microsomal long-chain fatty acyl-CoA synthetases<\\e2>  relevance to bipolar disorder","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Valproic acid","object":"brain microsomal long-chain fatty acyl-CoA synthetases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by <e2>GENE-N<\\e2>  relevance to bipolar disorder","sentence":"Valproic acid selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by brain microsomal long-chain fatty acyl-CoA synthetases  relevance to bipolar disorder"}
{"PMID":16344985,"re_id":4,"annotated sentence":"CONCLUSIONS: This study shows that <e1>valproic acid<\\e1> acts as a non-competitive inhibitor of <e2>brain microsomal Acsl<\\e2>  and that inhibition is substrate-selective","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"valproic acid","object":"brain microsomal Acsl","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"CONCLUSIONS: This study shows that <e1>CHEMICAL<\\e1> acts as a non-competitive inhibitor of <e2>GENE-N<\\e2>  and that inhibition is substrate-selective","sentence":"CONCLUSIONS: This study shows that valproic acid acts as a non-competitive inhibitor of brain microsomal Acsl  and that inhibition is substrate-selective"}
{"PMID":16344985,"re_id":5,"annotated sentence":"Valproic acid selectively inhibits conversion of <e1>arachidonic acid<\\e1> to arachidonoyl-CoA by <e2>brain microsomal long-chain fatty acyl-CoA synthetases<\\e2>  relevance to bipolar disorder","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"arachidonic acid","object":"brain microsomal long-chain fatty acyl-CoA synthetases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Valproic acid selectively inhibits conversion of <e1>CHEMICAL<\\e1> to arachidonoyl-CoA by <e2>GENE-N<\\e2>  relevance to bipolar disorder","sentence":"Valproic acid selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by brain microsomal long-chain fatty acyl-CoA synthetases  relevance to bipolar disorder"}
{"PMID":16344985,"re_id":6,"annotated sentence":"Valproic acid selectively inhibits conversion of arachidonic acid to <e1>arachidonoyl-CoA<\\e1> by <e2>brain microsomal long-chain fatty acyl-CoA synthetases<\\e2>  relevance to bipolar disorder","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"arachidonoyl-CoA","object":"brain microsomal long-chain fatty acyl-CoA synthetases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Valproic acid selectively inhibits conversion of arachidonic acid to <e1>CHEMICAL<\\e1> by <e2>GENE-N<\\e2>  relevance to bipolar disorder","sentence":"Valproic acid selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by brain microsomal long-chain fatty acyl-CoA synthetases  relevance to bipolar disorder"}
{"PMID":16359899,"re_id":0,"annotated sentence":"On the other hand, holocarboxylase synthetase (<e2>HCS<\\e2>  mRNA levels were markedly low in the deficient animals, and increased upon <e1>biotin<\\e1> injection","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"biotin","object":"HCS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"On the other hand, holocarboxylase synthetase (<e2>GENE-Y<\\e2>  mRNA levels were markedly low in the deficient animals, and increased upon <e1>CHEMICAL<\\e1> injection","sentence":"On the other hand, holocarboxylase synthetase (HCS  mRNA levels were markedly low in the deficient animals, and increased upon biotin injection"}
{"PMID":16359899,"re_id":1,"annotated sentence":"On the other hand, <e2>holocarboxylase synthetase<\\e2> (HCS) mRNA levels were markedly low in the deficient animals, and increased upon <e1>biotin<\\e1> injection","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"biotin","object":"holocarboxylase synthetase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"On the other hand, <e2>GENE-Y<\\e2> (HCS) mRNA levels were markedly low in the deficient animals, and increased upon <e1>CHEMICAL<\\e1> injection","sentence":"On the other hand, holocarboxylase synthetase (HCS) mRNA levels were markedly low in the deficient animals, and increased upon biotin injection"}
{"PMID":16371234,"re_id":0,"annotated sentence":"Furthermore, PS liposome-induced PGE2 production was significantly suppressed by <e1>indomethacin<\\e1>  a preferential <e2>COX-1<\\e2> inhibitor, but not by NS-398, a selective COX-2 inhibitor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"indomethacin","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, PS liposome-induced PGE2 production was significantly suppressed by <e1>CHEMICAL<\\e1>  a preferential <e2>GENE-Y<\\e2> inhibitor, but not by NS-398, a selective COX-2 inhibitor","sentence":"Furthermore, PS liposome-induced PGE2 production was significantly suppressed by indomethacin  a preferential COX-1 inhibitor, but not by NS-398, a selective COX-2 inhibitor"}
{"PMID":16371234,"re_id":1,"annotated sentence":"Furthermore, PS liposome-induced PGE2 production was significantly suppressed by indomethacin, a preferential COX-1 inhibitor, but not by <e1>NS-398<\\e1>  a selective <e2>COX-2<\\e2> inhibitor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NS-398","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, PS liposome-induced PGE2 production was significantly suppressed by indomethacin, a preferential COX-1 inhibitor, but not by <e1>CHEMICAL<\\e1>  a selective <e2>GENE-Y<\\e2> inhibitor","sentence":"Furthermore, PS liposome-induced PGE2 production was significantly suppressed by indomethacin, a preferential COX-1 inhibitor, but not by NS-398  a selective COX-2 inhibitor"}
{"PMID":16371234,"re_id":2,"annotated sentence":"Involvement of <e2>COX-1<\\e2> and up-regulated prostaglandin E synthases in phosphatidylserine liposome-induced <e1>prostaglandin E2<\\e1> production by microglia","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"prostaglandin E2","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Involvement of <e2>GENE-Y<\\e2> and up-regulated prostaglandin E synthases in phosphatidylserine liposome-induced <e1>CHEMICAL<\\e1> production by microglia","sentence":"Involvement of COX-1 and up-regulated prostaglandin E synthases in phosphatidylserine liposome-induced prostaglandin E2 production by microglia"}
{"PMID":16371234,"re_id":3,"annotated sentence":"Involvement of COX-1 and up-regulated <e2>prostaglandin E synthases<\\e2> in phosphatidylserine liposome-induced <e1>prostaglandin E2<\\e1> production by microglia","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"prostaglandin E2","object":"prostaglandin E synthases","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Involvement of COX-1 and up-regulated <e2>GENE-Y<\\e2> in phosphatidylserine liposome-induced <e1>CHEMICAL<\\e1> production by microglia","sentence":"Involvement of COX-1 and up-regulated prostaglandin E synthases in phosphatidylserine liposome-induced prostaglandin E2 production by microglia"}
{"PMID":16371234,"re_id":4,"annotated sentence":"These observations strongly suggest that the up-regulation of terminal <e2>PGESs<\\e2> that are preferentially coupled with COX-1, especially mPGES-2, plays the pivotal role in PS liposome-induced <e1>PGE2<\\e1> production by microglia","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"PGE2","object":"PGESs","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These observations strongly suggest that the up-regulation of terminal <e2>GENE-Y<\\e2> that are preferentially coupled with COX-1, especially mPGES-2, plays the pivotal role in PS liposome-induced <e1>CHEMICAL<\\e1> production by microglia","sentence":"These observations strongly suggest that the up-regulation of terminal PGESs that are preferentially coupled with COX-1, especially mPGES-2, plays the pivotal role in PS liposome-induced PGE2 production by microglia"}
{"PMID":16371234,"re_id":5,"annotated sentence":"These observations strongly suggest that the up-regulation of terminal PGESs that are preferentially coupled with <e2>COX-1<\\e2>  especially mPGES-2, plays the pivotal role in PS liposome-induced <e1>PGE2<\\e1> production by microglia","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"PGE2","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These observations strongly suggest that the up-regulation of terminal PGESs that are preferentially coupled with <e2>GENE-Y<\\e2>  especially mPGES-2, plays the pivotal role in PS liposome-induced <e1>CHEMICAL<\\e1> production by microglia","sentence":"These observations strongly suggest that the up-regulation of terminal PGESs that are preferentially coupled with COX-1  especially mPGES-2, plays the pivotal role in PS liposome-induced PGE2 production by microglia"}
{"PMID":16371234,"re_id":6,"annotated sentence":"These observations strongly suggest that the up-regulation of terminal PGESs that are preferentially coupled with COX-1, especially <e2>mPGES-2<\\e2>  plays the pivotal role in PS liposome-induced <e1>PGE2<\\e1> production by microglia","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"PGE2","object":"mPGES-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These observations strongly suggest that the up-regulation of terminal PGESs that are preferentially coupled with COX-1, especially <e2>GENE-Y<\\e2>  plays the pivotal role in PS liposome-induced <e1>CHEMICAL<\\e1> production by microglia","sentence":"These observations strongly suggest that the up-regulation of terminal PGESs that are preferentially coupled with COX-1, especially mPGES-2  plays the pivotal role in PS liposome-induced PGE2 production by microglia"}
{"PMID":16425993,"re_id":0,"annotated sentence":"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-<e2>kinase<\\e2> inhibitors (MKIs) <e1>sorafenib<\\e1>  sunitinib, and AG013736, which target multiple VEGFRs as well as PDGFR-beta","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sorafenib","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-<e2>GENE-N<\\e2> inhibitors (MKIs) <e1>CHEMICAL<\\e1>  sunitinib, and AG013736, which target multiple VEGFRs as well as PDGFR-beta","sentence":"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib  sunitinib, and AG013736, which target multiple VEGFRs as well as PDGFR-beta"}
{"PMID":16425993,"re_id":1,"annotated sentence":"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) <e1>sorafenib<\\e1>  sunitinib, and AG013736, which target multiple <e2>VEGFRs<\\e2> as well as PDGFR-beta","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sorafenib","object":"VEGFRs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) <e1>CHEMICAL<\\e1>  sunitinib, and AG013736, which target multiple <e2>GENE-N<\\e2> as well as PDGFR-beta","sentence":"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib  sunitinib, and AG013736, which target multiple VEGFRs as well as PDGFR-beta"}
{"PMID":16425993,"re_id":2,"annotated sentence":"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) <e1>sorafenib<\\e1>  sunitinib, and AG013736, which target multiple VEGFRs as well as <e2>PDGFR-beta<\\e2>  Sorafenib has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha\/EGFR signaling and may also enhance its inhibition of VEGFR and PDGFR-beta","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sorafenib","object":"PDGFR-beta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) <e1>CHEMICAL<\\e1>  sunitinib, and AG013736, which target multiple VEGFRs as well as <e2>GENE-Y<\\e2>  Sorafenib has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha\/EGFR signaling and may also enhance its inhibition of VEGFR and GENE-Y","sentence":"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib  sunitinib, and AG013736, which target multiple VEGFRs as well as PDGFR-beta  Sorafenib has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha\/EGFR signaling and may also enhance its inhibition of VEGFR and PDGFR-beta"}
{"PMID":16425993,"re_id":3,"annotated sentence":"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-<e2>kinase<\\e2> inhibitors (MKIs) sorafenib, <e1>sunitinib<\\e1>  and AG013736, which target multiple VEGFRs as well as PDGFR-beta","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sunitinib","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-<e2>GENE-N<\\e2> inhibitors (MKIs) sorafenib, <e1>CHEMICAL<\\e1>  and AG013736, which target multiple VEGFRs as well as PDGFR-beta","sentence":"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, sunitinib  and AG013736, which target multiple VEGFRs as well as PDGFR-beta"}
{"PMID":16425993,"re_id":4,"annotated sentence":"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, <e1>sunitinib<\\e1>  and AG013736, which target multiple <e2>VEGFRs<\\e2> as well as PDGFR-beta","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sunitinib","object":"VEGFRs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, <e1>CHEMICAL<\\e1>  and AG013736, which target multiple <e2>GENE-N<\\e2> as well as PDGFR-beta","sentence":"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, sunitinib  and AG013736, which target multiple VEGFRs as well as PDGFR-beta"}
{"PMID":16425993,"re_id":5,"annotated sentence":"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, <e1>sunitinib<\\e1>  and AG013736, which target multiple VEGFRs as well as <e2>PDGFR-beta<\\e2>  Sorafenib has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha\/EGFR signaling and may also enhance its inhibition of VEGFR and PDGFR-beta","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sunitinib","object":"PDGFR-beta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, <e1>CHEMICAL<\\e1>  and AG013736, which target multiple VEGFRs as well as <e2>GENE-Y<\\e2>  Sorafenib has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha\/EGFR signaling and may also enhance its inhibition of VEGFR and GENE-Y","sentence":"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, sunitinib  and AG013736, which target multiple VEGFRs as well as PDGFR-beta  Sorafenib has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha\/EGFR signaling and may also enhance its inhibition of VEGFR and PDGFR-beta"}
{"PMID":16425993,"re_id":6,"annotated sentence":"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-<e2>kinase<\\e2> inhibitors (MKIs) sorafenib, sunitinib, and <e1>AG013736<\\e1>  which target multiple VEGFRs as well as PDGFR-beta","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"AG013736","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-<e2>GENE-N<\\e2> inhibitors (MKIs) sorafenib, sunitinib, and <e1>CHEMICAL<\\e1>  which target multiple VEGFRs as well as PDGFR-beta","sentence":"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, sunitinib, and AG013736  which target multiple VEGFRs as well as PDGFR-beta"}
{"PMID":16425993,"re_id":7,"annotated sentence":"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, sunitinib, and <e1>AG013736<\\e1>  which target multiple <e2>VEGFRs<\\e2> as well as PDGFR-beta","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"AG013736","object":"VEGFRs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, sunitinib, and <e1>CHEMICAL<\\e1>  which target multiple <e2>GENE-N<\\e2> as well as PDGFR-beta","sentence":"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, sunitinib, and AG013736  which target multiple VEGFRs as well as PDGFR-beta"}
{"PMID":16425993,"re_id":8,"annotated sentence":"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, sunitinib, and <e1>AG013736<\\e1>  which target multiple VEGFRs as well as <e2>PDGFR-beta<\\e2>  Sorafenib has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha\/EGFR signaling and may also enhance its inhibition of VEGFR and PDGFR-beta","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"AG013736","object":"PDGFR-beta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, sunitinib, and <e1>CHEMICAL<\\e1>  which target multiple VEGFRs as well as <e2>GENE-Y<\\e2>  Sorafenib has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha\/EGFR signaling and may also enhance its inhibition of VEGFR and GENE-Y","sentence":"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, sunitinib, and AG013736  which target multiple VEGFRs as well as PDGFR-beta  Sorafenib has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha\/EGFR signaling and may also enhance its inhibition of VEGFR and PDGFR-beta"}
{"PMID":16425993,"re_id":9,"annotated sentence":"<e1>Sorafenib<\\e1> has the added advantage of inhibiting multiple different <e2>Raf<\\e2> isoforms, which enables it to target TGF-alpha\/EGFR signaling and may also enhance its inhibition of VEGFR and PDGFR-beta","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sorafenib","object":"Raf","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> has the added advantage of inhibiting multiple different <e2>GENE-Y<\\e2> isoforms, which enables it to target TGF-alpha\/EGFR signaling and may also enhance its inhibition of VEGFR and PDGFR-beta","sentence":"Sorafenib has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha\/EGFR signaling and may also enhance its inhibition of VEGFR and PDGFR-beta"}
{"PMID":16425993,"re_id":10,"annotated sentence":"<e1>Sorafenib<\\e1> has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target <e2>TGF-alpha<\\e2> EGFR signaling and may also enhance its inhibition of VEGFR and PDGFR-beta","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sorafenib","object":"TGF-alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target <e2>GENE-Y<\\e2> EGFR signaling and may also enhance its inhibition of VEGFR and PDGFR-beta","sentence":"Sorafenib has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha EGFR signaling and may also enhance its inhibition of VEGFR and PDGFR-beta"}
{"PMID":16425993,"re_id":11,"annotated sentence":"<e1>Sorafenib<\\e1> has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha\/<e2>EGFR<\\e2> signaling and may also enhance its inhibition of VEGFR and PDGFR-beta","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sorafenib","object":"EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha\/<e2>GENE-Y<\\e2> signaling and may also enhance its inhibition of VGENE-Y and PDGFR-beta","sentence":"Sorafenib has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha\/EGFR signaling and may also enhance its inhibition of VEGFR and PDGFR-beta"}
{"PMID":16425993,"re_id":12,"annotated sentence":"<e1>Sorafenib<\\e1> has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha\/EGFR signaling and may also enhance its inhibition of <e2>VEGFR<\\e2> and PDGFR-beta","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sorafenib","object":"VEGFR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha\/EGFR signaling and may also enhance its inhibition of <e2>GENE-N<\\e2> and PDGFR-beta","sentence":"Sorafenib has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha\/EGFR signaling and may also enhance its inhibition of VEGFR and PDGFR-beta"}
{"PMID":16425993,"re_id":13,"annotated sentence":"<e1>Sorafenib<\\e1> has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha\/EGFR signaling and may also enhance its inhibition of VEGFR and <e2>PDGFR-beta<\\e2>  This review will examine the recent advances in our understanding of the biology of clear-cell RCC and show how those advances have helped delineate new targets of opportunity for treatment","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sorafenib","object":"PDGFR-beta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha\/EGFR signaling and may also enhance its inhibition of VEGFR and <e2>GENE-Y<\\e2>  This review will examine the recent advances in our understanding of the biology of clear-cell RCC and show how those advances have helped delineate new targets of opportunity for treatment","sentence":"Sorafenib has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha\/EGFR signaling and may also enhance its inhibition of VEGFR and PDGFR-beta  This review will examine the recent advances in our understanding of the biology of clear-cell RCC and show how those advances have helped delineate new targets of opportunity for treatment"}
{"PMID":16596248,"re_id":0,"annotated sentence":"Low <e2>TS<\\e2> expression levels, cytoplasmic expression pattern and C SNP arose as variables associated to longer progression-free survival (PFS) in patients treated with <e1>5FU<\\e1>  Accordingly, patients having at least two favourable or unfavourable variables were classified respectively as 'low risk' and 'high risk', the former showing significantly longer PFS (p=0.0299)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5FU","object":"TS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Low <e2>GENE-Y<\\e2> expression levels, cytoplasmic expression pattern and C SNP arose as variables associated to longer progression-free survival (PFS) in patients treated with <e1>CHEMICAL<\\e1>  Accordingly, patients having at least two favourable or unfavourable variables were classified respectively as 'low risk' and 'high risk', the former showing significantly longer PFS (p=0.0299)","sentence":"Low TS expression levels, cytoplasmic expression pattern and C SNP arose as variables associated to longer progression-free survival (PFS) in patients treated with 5FU  Accordingly, patients having at least two favourable or unfavourable variables were classified respectively as 'low risk' and 'high risk', the former showing significantly longer PFS (p=0.0299)"}
{"PMID":1665782,"re_id":0,"annotated sentence":"Our conclusion is that chronic <e1>DPDPE<\\e1> treatment preferentially reduces <e2>delta-opioid receptor<\\e2> binding activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DPDPE","object":"delta-opioid receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our conclusion is that chronic <e1>CHEMICAL<\\e1> treatment preferentially reduces <e2>GENE-Y<\\e2> binding activity","sentence":"Our conclusion is that chronic DPDPE treatment preferentially reduces delta-opioid receptor binding activity"}
{"PMID":1665782,"re_id":1,"annotated sentence":"Therefore, in the present studies, animals were rendered tolerant to the <e2>delta-opioid receptor<\\e2> selective agonist [D-Pen2,D-Pen5]enkephalin (<e1>DPDPE<\\e1> , and receptor binding activities were measured","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"DPDPE","object":"delta-opioid receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Therefore, in the present studies, animals were rendered tolerant to the <e2>GENE-Y<\\e2> selective agonist [D-Pen2,D-Pen5]enkephalin (<e1>CHEMICAL<\\e1> , and receptor binding activities were measured","sentence":"Therefore, in the present studies, animals were rendered tolerant to the delta-opioid receptor selective agonist [D-Pen2,D-Pen5]enkephalin (DPDPE , and receptor binding activities were measured"}
{"PMID":1665782,"re_id":2,"annotated sentence":"Therefore, in the present studies, animals were rendered tolerant to the <e2>delta-opioid receptor<\\e2> selective agonist <e1>[D-Pen2,D-Pen5]enkephalin<\\e1> (DPDPE), and receptor binding activities were measured","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"[D-Pen2,D-Pen5]enkephalin","object":"delta-opioid receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Therefore, in the present studies, animals were rendered tolerant to the <e2>GENE-Y<\\e2> selective agonist <e1>CHEMICAL<\\e1> (DPDPE), and receptor binding activities were measured","sentence":"Therefore, in the present studies, animals were rendered tolerant to the delta-opioid receptor selective agonist [D-Pen2,D-Pen5]enkephalin (DPDPE), and receptor binding activities were measured"}
{"PMID":1666997,"re_id":0,"annotated sentence":"Complementary experiments using the 5-HT3-dependent Bezold-Jarisch reflex confirmed that <e1>amoxapine<\\e1> really acts in vivo as a <e2>5-HT3<\\e2> antagonist (IC50 = 50 micrograms\/kg i.v.), whereas amitriptyline is essentially inactive on 5-HT3 receptors","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"amoxapine","object":"5-HT3","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Complementary experiments using the GENE-N-dependent Bezold-Jarisch reflex confirmed that <e1>CHEMICAL<\\e1> really acts in vivo as a <e2>GENE-N<\\e2> antagonist (IC50 = 50 micrograms\/kg i.v.), whereas amitriptyline is essentially inactive on GENE-N receptors","sentence":"Complementary experiments using the 5-HT3-dependent Bezold-Jarisch reflex confirmed that amoxapine really acts in vivo as a 5-HT3 antagonist (IC50 = 50 micrograms\/kg i.v.), whereas amitriptyline is essentially inactive on 5-HT3 receptors"}
{"PMID":16675639,"re_id":0,"annotated sentence":"Competitive radioligand binding assays were performed using cells expressing either the <e2>human serotonin (5-HT) transporter<\\e2> (hSERT) or norepinephrine (NE) transporter (hNET) with K(i) values for <e1>DVS<\\e1> of 40.2 +\/- 1.6 and 558.4 +\/- 121.6 nM, respectively","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DVS","object":"human serotonin (5-HT) transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Competitive radioligand binding assays were performed using cells expressing either the <e2>GENE-Y<\\e2> (hSERT) or norepinephrine (NE) transporter (hNET) with K(i) values for <e1>CHEMICAL<\\e1> of 40.2 +\/- 1.6 and 558.4 +\/- 121.6 nM, respectively","sentence":"Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or norepinephrine (NE) transporter (hNET) with K(i) values for DVS of 40.2 +\/- 1.6 and 558.4 +\/- 121.6 nM, respectively"}
{"PMID":16675639,"re_id":1,"annotated sentence":"Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (<e2>hSERT<\\e2>  or norepinephrine (NE) transporter (hNET) with K(i) values for <e1>DVS<\\e1> of 40.2 +\/- 1.6 and 558.4 +\/- 121.6 nM, respectively","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DVS","object":"hSERT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (<e2>GENE-Y<\\e2>  or norepinephrine (NE) transporter (hNET) with K(i) values for <e1>CHEMICAL<\\e1> of 40.2 +\/- 1.6 and 558.4 +\/- 121.6 nM, respectively","sentence":"Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT  or norepinephrine (NE) transporter (hNET) with K(i) values for DVS of 40.2 +\/- 1.6 and 558.4 +\/- 121.6 nM, respectively"}
{"PMID":16675639,"re_id":2,"annotated sentence":"Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or <e2>norepinephrine (NE) transporter<\\e2> (hNET) with K(i) values for <e1>DVS<\\e1> of 40.2 +\/- 1.6 and 558.4 +\/- 121.6 nM, respectively","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DVS","object":"norepinephrine (NE) transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or <e2>GENE-Y<\\e2> (hNET) with K(i) values for <e1>CHEMICAL<\\e1> of 40.2 +\/- 1.6 and 558.4 +\/- 121.6 nM, respectively","sentence":"Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or norepinephrine (NE) transporter (hNET) with K(i) values for DVS of 40.2 +\/- 1.6 and 558.4 +\/- 121.6 nM, respectively"}
{"PMID":16675639,"re_id":3,"annotated sentence":"Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or norepinephrine (NE) transporter (<e2>hNET<\\e2>  with K(i) values for <e1>DVS<\\e1> of 40.2 +\/- 1.6 and 558.4 +\/- 121.6 nM, respectively","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DVS","object":"hNET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or norepinephrine (NE) transporter (<e2>GENE-Y<\\e2>  with K(i) values for <e1>CHEMICAL<\\e1> of 40.2 +\/- 1.6 and 558.4 +\/- 121.6 nM, respectively","sentence":"Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or norepinephrine (NE) transporter (hNET  with K(i) values for DVS of 40.2 +\/- 1.6 and 558.4 +\/- 121.6 nM, respectively"}
{"PMID":16675639,"re_id":4,"annotated sentence":"To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory 5-HT(1A) autoreceptors, a <e2>5-HT(1A)<\\e2> antagonist, <e1>N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclo hexanecarboxamide maleate salt<\\e1> (WAY-100635) (0.3 mg\/kg s.c.), was administered with DVS (30 mg\/kg orally)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclo hexanecarboxamide maleate salt","object":"5-HT(1A)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory GENE-Y autoreceptors, a <e2>GENE-Y<\\e2> antagonist, <e1>CHEMICAL<\\e1> (WAY-100635) (0.3 mg\/kg s.c.), was administered with DVS (30 mg\/kg orally)","sentence":"To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory 5-HT(1A) autoreceptors, a 5-HT(1A) antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclo hexanecarboxamide maleate salt (WAY-100635) (0.3 mg\/kg s.c.), was administered with DVS (30 mg\/kg orally)"}
{"PMID":16675639,"re_id":5,"annotated sentence":"To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory 5-HT(1A) autoreceptors, a <e2>5-HT(1A)<\\e2> antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclo hexanecarboxamide maleate salt (<e1>WAY-100635<\\e1>  (0.3 mg\/kg s.c.), was administered with DVS (30 mg\/kg orally)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"WAY-100635","object":"5-HT(1A)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory GENE-Y autoreceptors, a <e2>GENE-Y<\\e2> antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclo hexanecarboxamide maleate salt (<e1>CHEMICAL<\\e1>  (0.3 mg\/kg s.c.), was administered with DVS (30 mg\/kg orally)","sentence":"To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory 5-HT(1A) autoreceptors, a 5-HT(1A) antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclo hexanecarboxamide maleate salt (WAY-100635  (0.3 mg\/kg s.c.), was administered with DVS (30 mg\/kg orally)"}
{"PMID":16675639,"re_id":6,"annotated sentence":"Inhibition of <e1>[3H]5-HT<\\e1> or [3H]NE uptake by DVS for the <e2>hSERT<\\e2> or hNET produced IC50 values of 47.3 +\/- 19.4 and 531.3 +\/- 113.0 nM, respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"[3H]5-HT","object":"hSERT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of <e1>CHEMICAL<\\e1> or [3H]NE uptake by DVS for the <e2>GENE-Y<\\e2> or hNET produced IC50 values of 47.3 +\/- 19.4 and 531.3 +\/- 113.0 nM, respectively","sentence":"Inhibition of [3H]5-HT or [3H]NE uptake by DVS for the hSERT or hNET produced IC50 values of 47.3 +\/- 19.4 and 531.3 +\/- 113.0 nM, respectively"}
{"PMID":16675639,"re_id":7,"annotated sentence":"Inhibition of [3H]5-HT or <e1>[3H]NE<\\e1> uptake by DVS for the hSERT or <e2>hNET<\\e2> produced IC50 values of 47.3 +\/- 19.4 and 531.3 +\/- 113.0 nM, respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"[3H]NE","object":"hNET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of [3H]5-HT or <e1>CHEMICAL<\\e1> uptake by DVS for the hSERT or <e2>GENE-Y<\\e2> produced IC50 values of 47.3 +\/- 19.4 and 531.3 +\/- 113.0 nM, respectively","sentence":"Inhibition of [3H]5-HT or [3H]NE uptake by DVS for the hSERT or hNET produced IC50 values of 47.3 +\/- 19.4 and 531.3 +\/- 113.0 nM, respectively"}
{"PMID":16763553,"re_id":0,"annotated sentence":"Further, <e1>cholesterol<\\e1> metabolites, predominantly the oxysterols, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of <e2>sterol regulatory element binding protein-1c<\\e2> (SREBP-1c) that bound to the regulatory regions of these genes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cholesterol","object":"sterol regulatory element binding protein-1c","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Further, <e1>CHEMICAL<\\e1> metabolites, predominantly the oxysterols, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of <e2>GENE-Y<\\e2> (SREBP-1c) that bound to the regulatory regions of these genes","sentence":"Further, cholesterol metabolites, predominantly the oxysterols, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of sterol regulatory element binding protein-1c (SREBP-1c) that bound to the regulatory regions of these genes"}
{"PMID":16763553,"re_id":1,"annotated sentence":"Further, <e1>cholesterol<\\e1> metabolites, predominantly the oxysterols, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of sterol regulatory element binding protein-1c (<e2>SREBP-1c<\\e2>  that bound to the regulatory regions of these genes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cholesterol","object":"SREBP-1c","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Further, <e1>CHEMICAL<\\e1> metabolites, predominantly the oxysterols, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of sterol regulatory element binding protein-1c (<e2>GENE-Y<\\e2>  that bound to the regulatory regions of these genes","sentence":"Further, cholesterol metabolites, predominantly the oxysterols, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of sterol regulatory element binding protein-1c (SREBP-1c  that bound to the regulatory regions of these genes"}
{"PMID":16763553,"re_id":2,"annotated sentence":"Further, cholesterol metabolites, predominantly the <e1>oxysterols<\\e1>  the natural ligands for liver X receptor (LXR), induced these genes via upregulation of <e2>sterol regulatory element binding protein-1c<\\e2> (SREBP-1c) that bound to the regulatory regions of these genes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"oxysterols","object":"sterol regulatory element binding protein-1c","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Further, cholesterol metabolites, predominantly the <e1>CHEMICAL<\\e1>  the natural ligands for liver X receptor (LXR), induced these genes via upregulation of <e2>GENE-Y<\\e2> (SREBP-1c) that bound to the regulatory regions of these genes","sentence":"Further, cholesterol metabolites, predominantly the oxysterols  the natural ligands for liver X receptor (LXR), induced these genes via upregulation of sterol regulatory element binding protein-1c (SREBP-1c) that bound to the regulatory regions of these genes"}
{"PMID":16763553,"re_id":3,"annotated sentence":"Further, cholesterol metabolites, predominantly the <e1>oxysterols<\\e1>  the natural ligands for liver X receptor (LXR), induced these genes via upregulation of sterol regulatory element binding protein-1c (<e2>SREBP-1c<\\e2>  that bound to the regulatory regions of these genes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"oxysterols","object":"SREBP-1c","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Further, cholesterol metabolites, predominantly the <e1>CHEMICAL<\\e1>  the natural ligands for liver X receptor (LXR), induced these genes via upregulation of sterol regulatory element binding protein-1c (<e2>GENE-Y<\\e2>  that bound to the regulatory regions of these genes","sentence":"Further, cholesterol metabolites, predominantly the oxysterols  the natural ligands for liver X receptor (LXR), induced these genes via upregulation of sterol regulatory element binding protein-1c (SREBP-1c  that bound to the regulatory regions of these genes"}
{"PMID":16763553,"re_id":4,"annotated sentence":"The tissue RA level is maintained through a cascade of metabolic reactions where <e2>retinal dehydrogenases<\\e2> (RALDHs) catalyze the terminal reaction of <e1>RA<\\e1> biosynthesis from retinal, a rate-limiting step","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"RA","object":"retinal dehydrogenases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The tissue CHEMICAL level is maintained through a cascade of metabolic reactions where <e2>GENE-N<\\e2> (CHEMICALLDHs) catalyze the terminal reaction of <e1>CHEMICAL<\\e1> biosynthesis from retinal, a rate-limiting step","sentence":"The tissue RA level is maintained through a cascade of metabolic reactions where retinal dehydrogenases (RALDHs) catalyze the terminal reaction of RA biosynthesis from retinal, a rate-limiting step"}
{"PMID":16763553,"re_id":5,"annotated sentence":"The tissue RA level is maintained through a cascade of metabolic reactions where retinal dehydrogenases (<e2>RALDHs<\\e2>  catalyze the terminal reaction of <e1>RA<\\e1> biosynthesis from retinal, a rate-limiting step","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"RA","object":"RALDHs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The tissue CHEMICAL level is maintained through a cascade of metabolic reactions where retinal dehydrogenases (<e2>CHEMICALLDHs<\\e2>  catalyze the terminal reaction of <e1>CHEMICAL<\\e1> biosynthesis from retinal, a rate-limiting step","sentence":"The tissue RA level is maintained through a cascade of metabolic reactions where retinal dehydrogenases (RALDHs  catalyze the terminal reaction of RA biosynthesis from retinal, a rate-limiting step"}
{"PMID":16763553,"re_id":6,"annotated sentence":"The tissue RA level is maintained through a cascade of metabolic reactions where <e2>retinal dehydrogenases<\\e2> (RALDHs) catalyze the terminal reaction of RA biosynthesis from <e1>retinal<\\e1>  a rate-limiting step","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"retinal","object":"retinal dehydrogenases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The tissue RA level is maintained through a cascade of metabolic reactions where <e2>CHEMICAL dehydrogenases<\\e2> (RALDHs) catalyze the terminal reaction of RA biosynthesis from <e1>CHEMICAL<\\e1>  a rate-limiting step","sentence":"The tissue RA level is maintained through a cascade of metabolic reactions where retinal dehydrogenases (RALDHs) catalyze the terminal reaction of RA biosynthesis from retinal  a rate-limiting step"}
{"PMID":16763553,"re_id":7,"annotated sentence":"The tissue RA level is maintained through a cascade of metabolic reactions where retinal dehydrogenases (<e2>RALDHs<\\e2>  catalyze the terminal reaction of RA biosynthesis from <e1>retinal<\\e1>  a rate-limiting step","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"retinal","object":"RALDHs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The tissue RA level is maintained through a cascade of metabolic reactions where CHEMICAL dehydrogenases (<e2>GENE-N<\\e2>  catalyze the terminal reaction of RA biosynthesis from <e1>CHEMICAL<\\e1>  a rate-limiting step","sentence":"The tissue RA level is maintained through a cascade of metabolic reactions where retinal dehydrogenases (RALDHs  catalyze the terminal reaction of RA biosynthesis from retinal  a rate-limiting step"}
{"PMID":16769115,"re_id":0,"annotated sentence":"Hypermethlyation of <e2>RELN and GAD67 promoters<\\e2> can be induced by treating mice with <e1>methionine<\\e1>  and these mice display brain and behavioral abnormalities similar to +\/rl","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"methionine","object":"RELN and GAD67 promoters","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Hypermethlyation of <e2>GENE-N<\\e2> can be induced by treating mice with <e1>CHEMICAL<\\e1>  and these mice display brain and behavioral abnormalities similar to +\/rl","sentence":"Hypermethlyation of RELN and GAD67 promoters can be induced by treating mice with methionine  and these mice display brain and behavioral abnormalities similar to +\/rl"}
{"PMID":16775509,"re_id":0,"annotated sentence":"Thus, severe LV dysfunction and accompanying abnormal myocardial bioenergetic phenotype were prevented by the <e2>AT1<\\e2> antagonist <e1>olmesartan medoxomil<\\e1> ","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"olmesartan medoxomil","object":"AT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, severe LV dysfunction and accompanying abnormal myocardial bioenergetic phenotype were prevented by the <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> ","sentence":"Thus, severe LV dysfunction and accompanying abnormal myocardial bioenergetic phenotype were prevented by the AT1 antagonist olmesartan medoxomil "}
{"PMID":16775509,"re_id":1,"annotated sentence":"Functional and bioenergetic consequences of <e2>AT1<\\e2> antagonist <e1>olmesartan medoxomil<\\e1> in hearts with postinfarction LV remodeling","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"olmesartan medoxomil","object":"AT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Functional and bioenergetic consequences of <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> in hearts with postinfarction LV remodeling","sentence":"Functional and bioenergetic consequences of AT1 antagonist olmesartan medoxomil in hearts with postinfarction LV remodeling"}
{"PMID":16782438,"re_id":0,"annotated sentence":"RESULTS: <e1>Imatinib<\\e1> inhibited <e2>RET<\\e2> Y1062 phosphorylation in a dose-dependent manner after 1.5 hours of exposure","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Imatinib","object":"RET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: <e1>CHEMICAL<\\e1> inhibited <e2>GENE-Y<\\e2> Y1062 phosphorylation in a dose-dependent manner after 1.5 hours of exposure","sentence":"RESULTS: Imatinib inhibited RET Y1062 phosphorylation in a dose-dependent manner after 1.5 hours of exposure"}
{"PMID":16782438,"re_id":1,"annotated sentence":"RESULTS: <e1>Imatinib<\\e1> inhibited RET <e2>Y1062<\\e2> phosphorylation in a dose-dependent manner after 1.5 hours of exposure","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Imatinib","object":"Y1062","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"RESULTS: <e1>CHEMICAL<\\e1> inhibited RET <e2>GENE-N<\\e2> phosphorylation in a dose-dependent manner after 1.5 hours of exposure","sentence":"RESULTS: Imatinib inhibited RET Y1062 phosphorylation in a dose-dependent manner after 1.5 hours of exposure"}
{"PMID":16782438,"re_id":2,"annotated sentence":"CONCLUSIONS: <e1>Imatinib<\\e1> inhibits <e2>RET<\\e2> mediated MTC cell growth affecting RET protein levels in vitro in a dose-dependent manner","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Imatinib","object":"RET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSIONS: <e1>CHEMICAL<\\e1> inhibits <e2>GENE-Y<\\e2> mediated MTC cell growth affecting GENE-Y protein levels in vitro in a dose-dependent manner","sentence":"CONCLUSIONS: Imatinib inhibits RET mediated MTC cell growth affecting RET protein levels in vitro in a dose-dependent manner"}
{"PMID":16782438,"re_id":3,"annotated sentence":"CONCLUSIONS: <e1>Imatinib<\\e1> inhibits RET-mediated MTC cell growth affecting <e2>RET<\\e2> protein levels in vitro in a dose-dependent manner","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Imatinib","object":"RET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSIONS: <e1>CHEMICAL<\\e1> inhibits GENE-Y-mediated MTC cell growth affecting <e2>GENE-Y<\\e2> protein levels in vitro in a dose-dependent manner","sentence":"CONCLUSIONS: Imatinib inhibits RET-mediated MTC cell growth affecting RET protein levels in vitro in a dose-dependent manner"}
{"PMID":16782438,"re_id":4,"annotated sentence":"The concentration of <e1>imatinib<\\e1> necessary to inhibit <e2>RET<\\e2> in vitro, however, makes it impossible to conclude that imatinib monotherapy will be a good option for systemic therapy of MTC.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"imatinib","object":"RET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The concentration of <e1>CHEMICAL<\\e1> necessary to inhibit <e2>GENE-Y<\\e2> in vitro, however, makes it impossible to conclude that CHEMICAL monotherapy will be a good option for systemic therapy of MTC.","sentence":"The concentration of imatinib necessary to inhibit RET in vitro, however, makes it impossible to conclude that imatinib monotherapy will be a good option for systemic therapy of MTC."}
{"PMID":16782438,"re_id":5,"annotated sentence":"We evaluated <e1>imatinib<\\e1>  a <e2>tyrosine kinase<\\e2> inhibitor currently used to treat chronic myelogenous leukemia and gastrointestinal stromal tumors, as a potential drug for systemic treatment of MTC, in 2 MTC-derived cell lines expressing multiple endocrine neoplasia-associated mutant RET receptors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"imatinib","object":"tyrosine kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We evaluated <e1>CHEMICAL<\\e1>  a <e2>GENE-N<\\e2> inhibitor currently used to treat chronic myelogenous leukemia and gastrointestinal stromal tumors, as a potential drug for systemic treatment of MTC, in 2 MTC-derived cell lines expressing multiple endocrine neoplasia-associated mutant RET receptors","sentence":"We evaluated imatinib  a tyrosine kinase inhibitor currently used to treat chronic myelogenous leukemia and gastrointestinal stromal tumors, as a potential drug for systemic treatment of MTC, in 2 MTC-derived cell lines expressing multiple endocrine neoplasia-associated mutant RET receptors"}
{"PMID":16784786,"re_id":0,"annotated sentence":"In eukaryotes, the most prominent Mo-enzymes are (1) <e2>sulfite oxidase<\\e2>  which catalyzes the final step in the degradation of <e1>sulfur<\\e1> containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"sulfur","object":"sulfite oxidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In eukaryotes, the most prominent Mo-enzymes are (1) <e2>GENE-Y<\\e2>  which catalyzes the final step in the degradation of <e1>CHEMICAL<\\e1> containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation","sentence":"In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase  which catalyzes the final step in the degradation of sulfur containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation"}
{"PMID":16819260,"re_id":0,"annotated sentence":"<e1>Retinoid<\\e1> is a collective term for compounds which bind to and activate retinoic acid receptors (RARalpha, beta, gamma and RXRalpha, beta, gamma), members of <e2>nuclear hormone receptor<\\e2> superfamily","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Retinoid","object":"nuclear hormone receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is a collective term for compounds which bind to and activate retinoic acid receptors (RARalpha, beta, gamma and RXRalpha, beta, gamma), members of <e2>GENE-N<\\e2> superfamily","sentence":"Retinoid is a collective term for compounds which bind to and activate retinoic acid receptors (RARalpha, beta, gamma and RXRalpha, beta, gamma), members of nuclear hormone receptor superfamily"}
{"PMID":16819260,"re_id":1,"annotated sentence":"<e1>Retinoid<\\e1> is a collective term for compounds which bind to and activate <e2>retinoic acid receptors<\\e2> (RARalpha, beta, gamma and RXRalpha, beta, gamma), members of nuclear hormone receptor superfamily","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Retinoid","object":"retinoic acid receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is a collective term for compounds which bind to and activate <e2>GENE-N<\\e2> (RARalpha, beta, gamma and RXRalpha, beta, gamma), members of nuclear hormone receptor superfamily","sentence":"Retinoid is a collective term for compounds which bind to and activate retinoic acid receptors (RARalpha, beta, gamma and RXRalpha, beta, gamma), members of nuclear hormone receptor superfamily"}
{"PMID":16828882,"re_id":0,"annotated sentence":"<e1>Simvastatin<\\e1> abolished these anti-<e2>CD11a<\\e2> mAb-induced increases in lymphocytic cholinergic activity in a manner independent of its cholesterol-lowering activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Simvastatin","object":"CD11a","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> abolished these anti-<e2>GENE-Y<\\e2> mAb-induced increases in lymphocytic cholinergic activity in a manner independent of its cholesterol-lowering activity","sentence":"Simvastatin abolished these anti-CD11a mAb-induced increases in lymphocytic cholinergic activity in a manner independent of its cholesterol-lowering activity"}
{"PMID":16828882,"re_id":1,"annotated sentence":"The cholesterol-lowering drug <e1>simvastatin<\\e1> inhibits <e2>LFA-1<\\e2> signaling by binding to an allosteric site on CD11a (LFA-1 alpha chain), which leads to immunomodulation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"simvastatin","object":"LFA-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The cholesterol-lowering drug <e1>CHEMICAL<\\e1> inhibits <e2>GENE-Y<\\e2> signaling by binding to an allosteric site on CD11a (GENE-Y alpha chain), which leads to immunomodulation","sentence":"The cholesterol-lowering drug simvastatin inhibits LFA-1 signaling by binding to an allosteric site on CD11a (LFA-1 alpha chain), which leads to immunomodulation"}
{"PMID":16829128,"re_id":0,"annotated sentence":"<e1>Menthol<\\e1>  popularly known for its cooling effect, activates <e2>TRPM8<\\e2> -a cold-activated thermoTRP ion channel","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Menthol","object":"TRPM8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  popularly known for its cooling effect, activates <e2>GENE-Y<\\e2> -a cold-activated thermoTRP ion channel","sentence":"Menthol  popularly known for its cooling effect, activates TRPM8 -a cold-activated thermoTRP ion channel"}
{"PMID":16829128,"re_id":1,"annotated sentence":"<e1>Menthol<\\e1>  popularly known for its cooling effect, activates TRPM8--a cold-activated <e2>thermoTRP ion channel<\\e2>  However, human physiological studies demonstrate a paradoxical role of menthol in modulation of warm sensation, and here, we show that menthol also activates heat-activated TRPV3","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Menthol","object":"thermoTRP ion channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  popularly known for its cooling effect, activates TRPM8--a cold-activated <e2>GENE-N<\\e2>  However, human physiological studies demonstrate a paradoxical role of menthol in modulation of warm sensation, and here, we show that menthol also activates heat-activated TRPV3","sentence":"Menthol  popularly known for its cooling effect, activates TRPM8--a cold-activated thermoTRP ion channel  However, human physiological studies demonstrate a paradoxical role of menthol in modulation of warm sensation, and here, we show that menthol also activates heat-activated TRPV3"}
{"PMID":16829128,"re_id":2,"annotated sentence":"However, human physiological studies demonstrate a paradoxical role of menthol in modulation of warm sensation, and here, we show that <e1>menthol<\\e1> also activates heat-activated <e2>TRPV3<\\e2>  We further show that menthol inhibits TRPA1, potentially explaining the use of menthol as an analgesic","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"menthol","object":"TRPV3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, human physiological studies demonstrate a paradoxical role of CHEMICAL in modulation of warm sensation, and here, we show that <e1>CHEMICAL<\\e1> also activates heat-activated <e2>GENE-Y<\\e2>  We further show that CHEMICAL inhibits TRPA1, potentially explaining the use of CHEMICAL as an analgesic","sentence":"However, human physiological studies demonstrate a paradoxical role of menthol in modulation of warm sensation, and here, we show that menthol also activates heat-activated TRPV3  We further show that menthol inhibits TRPA1, potentially explaining the use of menthol as an analgesic"}
{"PMID":16829128,"re_id":3,"annotated sentence":"Similar to <e1>menthol<\\e1>  both camphor and cinnamaldehyde (initially reported to be specific activators of <e2>TRPV3<\\e2> and TRPA1, respectively) also modulate other thermoTRPs","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"menthol","object":"TRPV3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Similar to <e1>CHEMICAL<\\e1>  both camphor and cinnamaldehyde (initially reported to be specific activators of <e2>GENE-Y<\\e2> and TRPA1, respectively) also modulate other thermoTRPs","sentence":"Similar to menthol  both camphor and cinnamaldehyde (initially reported to be specific activators of TRPV3 and TRPA1, respectively) also modulate other thermoTRPs"}
{"PMID":16829128,"re_id":4,"annotated sentence":"Similar to <e1>menthol<\\e1>  both camphor and cinnamaldehyde (initially reported to be specific activators of TRPV3 and <e2>TRPA1<\\e2>  respectively) also modulate other thermoTRPs","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"menthol","object":"TRPA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Similar to <e1>CHEMICAL<\\e1>  both camphor and cinnamaldehyde (initially reported to be specific activators of TRPV3 and <e2>GENE-Y<\\e2>  respectively) also modulate other thermoTRPs","sentence":"Similar to menthol  both camphor and cinnamaldehyde (initially reported to be specific activators of TRPV3 and TRPA1  respectively) also modulate other thermoTRPs"}
{"PMID":16829128,"re_id":5,"annotated sentence":"Similar to menthol, both <e1>camphor<\\e1> and cinnamaldehyde (initially reported to be specific activators of <e2>TRPV3<\\e2> and TRPA1, respectively) also modulate other thermoTRPs","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"camphor","object":"TRPV3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Similar to menthol, both <e1>CHEMICAL<\\e1> and cinnamaldehyde (initially reported to be specific activators of <e2>GENE-Y<\\e2> and TRPA1, respectively) also modulate other thermoTRPs","sentence":"Similar to menthol, both camphor and cinnamaldehyde (initially reported to be specific activators of TRPV3 and TRPA1, respectively) also modulate other thermoTRPs"}
{"PMID":16829128,"re_id":6,"annotated sentence":"Similar to menthol, both <e1>camphor<\\e1> and cinnamaldehyde (initially reported to be specific activators of TRPV3 and <e2>TRPA1<\\e2>  respectively) also modulate other thermoTRPs","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"camphor","object":"TRPA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Similar to menthol, both <e1>CHEMICAL<\\e1> and cinnamaldehyde (initially reported to be specific activators of TRPV3 and <e2>GENE-Y<\\e2>  respectively) also modulate other thermoTRPs","sentence":"Similar to menthol, both camphor and cinnamaldehyde (initially reported to be specific activators of TRPV3 and TRPA1  respectively) also modulate other thermoTRPs"}
{"PMID":16829128,"re_id":7,"annotated sentence":"Similar to menthol, both camphor and <e1>cinnamaldehyde<\\e1> (initially reported to be specific activators of <e2>TRPV3<\\e2> and TRPA1, respectively) also modulate other thermoTRPs","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cinnamaldehyde","object":"TRPV3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Similar to menthol, both camphor and <e1>CHEMICAL<\\e1> (initially reported to be specific activators of <e2>GENE-Y<\\e2> and TRPA1, respectively) also modulate other thermoTRPs","sentence":"Similar to menthol, both camphor and cinnamaldehyde (initially reported to be specific activators of TRPV3 and TRPA1, respectively) also modulate other thermoTRPs"}
{"PMID":16829128,"re_id":8,"annotated sentence":"Similar to menthol, both camphor and <e1>cinnamaldehyde<\\e1> (initially reported to be specific activators of TRPV3 and <e2>TRPA1<\\e2>  respectively) also modulate other thermoTRPs","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cinnamaldehyde","object":"TRPA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Similar to menthol, both camphor and <e1>CHEMICAL<\\e1> (initially reported to be specific activators of TRPV3 and <e2>GENE-Y<\\e2>  respectively) also modulate other thermoTRPs","sentence":"Similar to menthol, both camphor and cinnamaldehyde (initially reported to be specific activators of TRPV3 and TRPA1  respectively) also modulate other thermoTRPs"}
{"PMID":16829128,"re_id":9,"annotated sentence":"We further show that <e1>menthol<\\e1> inhibits <e2>TRPA1<\\e2>  potentially explaining the use of menthol as an analgesic","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"menthol","object":"TRPA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We further show that <e1>CHEMICAL<\\e1> inhibits <e2>GENE-Y<\\e2>  potentially explaining the use of CHEMICAL as an analgesic","sentence":"We further show that menthol inhibits TRPA1  potentially explaining the use of menthol as an analgesic"}
{"PMID":16855093,"re_id":0,"annotated sentence":"These currents were produced by <e2>glutamate-aspartate transporters<\\e2> (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by <e1>dihydrokainate<\\e1>  an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-\/- cochleas","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dihydrokainate","object":"glutamate-aspartate transporters","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These currents were produced by <e2>GENE-Y<\\e2> (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by <e1>CHEMICAL<\\e1>  an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-\/- cochleas","sentence":"These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate  an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-\/- cochleas"}
{"PMID":16855093,"re_id":1,"annotated sentence":"These currents were produced by glutamate-aspartate transporters (<e2>GLAST<\\e2>  (excitatory amino acid transporter 1) because they were weakly inhibited by <e1>dihydrokainate<\\e1>  an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-\/- cochleas","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dihydrokainate","object":"GLAST","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These currents were produced by glutamate-aspartate transporters (<e2>GENE-Y<\\e2>  (excitatory amino acid transporter 1) because they were weakly inhibited by <e1>CHEMICAL<\\e1>  an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GENE-Y-\/- cochleas","sentence":"These currents were produced by glutamate-aspartate transporters (GLAST  (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate  an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-\/- cochleas"}
{"PMID":16855093,"re_id":2,"annotated sentence":"These currents were produced by glutamate-aspartate transporters (GLAST) (<e2>excitatory amino acid transporter 1<\\e2>  because they were weakly inhibited by <e1>dihydrokainate<\\e1>  an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-\/- cochleas","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dihydrokainate","object":"excitatory amino acid transporter 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These currents were produced by glutamate-aspartate transporters (GLAST) (<e2>GENE-Y<\\e2>  because they were weakly inhibited by <e1>CHEMICAL<\\e1>  an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-\/- cochleas","sentence":"These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1  because they were weakly inhibited by dihydrokainate  an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-\/- cochleas"}
{"PMID":16855093,"re_id":3,"annotated sentence":"These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by <e1>dihydrokainate<\\e1>  an antagonist of <e2>glutamate transporter-1<\\e2> (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-\/- cochleas","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"dihydrokainate","object":"glutamate transporter-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by <e1>CHEMICAL<\\e1>  an antagonist of <e2>GENE-Y<\\e2> (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-\/- cochleas","sentence":"These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate  an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-\/- cochleas"}
{"PMID":16855093,"re_id":4,"annotated sentence":"These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by <e1>dihydrokainate<\\e1>  an antagonist of glutamate transporter-1 (<e2>excitatory amino acid transporter 2<\\e2>  and were absent from IPCs in GLAST-\/- cochleas","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"dihydrokainate","object":"excitatory amino acid transporter 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by <e1>CHEMICAL<\\e1>  an antagonist of glutamate transporter-1 (<e2>GENE-Y<\\e2>  and were absent from IPCs in GLAST-\/- cochleas","sentence":"These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate  an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2  and were absent from IPCs in GLAST-\/- cochleas"}
{"PMID":16855093,"re_id":5,"annotated sentence":"Focal application of the transporter substrate D-aspartate elicited inward currents in IPCs, which were larger in the presence of anions that permeate the transporter-associated <e2>anion channel<\\e2> and blocked by the transporter antagonist <e1>D,L-threo-beta-benzyloxyaspartate<\\e1>  These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-\/- cochleas","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"D,L-threo-beta-benzyloxyaspartate","object":"anion channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Focal application of the transporter substrate D-aspartate elicited inward currents in IPCs, which were larger in the presence of anions that permeate the transporter-associated <e2>GENE-N<\\e2> and blocked by the transporter antagonist <e1>CHEMICAL<\\e1>  These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-\/- cochleas","sentence":"Focal application of the transporter substrate D-aspartate elicited inward currents in IPCs, which were larger in the presence of anions that permeate the transporter-associated anion channel and blocked by the transporter antagonist D,L-threo-beta-benzyloxyaspartate  These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-\/- cochleas"}
{"PMID":16855093,"re_id":6,"annotated sentence":"The glutamate-aspartate transporter <e2>GLAST<\\e2> mediates <e1>glutamate<\\e1> uptake at inner hair cell afferent synapses in the mammalian cochlea","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutamate","object":"GLAST","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The CHEMICAL-aspartate transporter <e2>GENE-N<\\e2> mediates <e1>CHEMICAL<\\e1> uptake at inner hair cell afferent synapses in the mammalian cochlea","sentence":"The glutamate-aspartate transporter GLAST mediates glutamate uptake at inner hair cell afferent synapses in the mammalian cochlea"}
{"PMID":16855093,"re_id":7,"annotated sentence":"The <e2>glutamate-aspartate transporter<\\e2> GLAST mediates <e1>glutamate<\\e1> uptake at inner hair cell afferent synapses in the mammalian cochlea","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutamate","object":"glutamate-aspartate transporter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e2>CHEMICAL-aspartate transporter<\\e2> GLAST mediates <e1>CHEMICAL<\\e1> uptake at inner hair cell afferent synapses in the mammalian cochlea","sentence":"The glutamate-aspartate transporter GLAST mediates glutamate uptake at inner hair cell afferent synapses in the mammalian cochlea"}
{"PMID":16855093,"re_id":8,"annotated sentence":"Furthermore, D-aspartate-induced currents in outside-out patches from IPCs exhibited larger steady-state currents than responses elicited by <e1>L-glutamate<\\e1>  a prominent feature of <e2>GLAST<\\e2>  and examination of cochlea from GLAST-Discosoma red (DsRed) promoter reporter mice revealed that DsRed expression was restricted to IPCs and other supporting cells surrounding IHCs","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-glutamate","object":"GLAST","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, D-aspartate-induced currents in outside-out patches from IPCs exhibited larger steady-state currents than responses elicited by <e1>CHEMICAL<\\e1>  a prominent feature of <e2>GENE-Y<\\e2>  and examination of cochlea from GENE-Y-Discosoma red (DsRed) promoter reporter mice revealed that DsRed expression was restricted to IPCs and other supporting cells surrounding IHCs","sentence":"Furthermore, D-aspartate-induced currents in outside-out patches from IPCs exhibited larger steady-state currents than responses elicited by L-glutamate  a prominent feature of GLAST  and examination of cochlea from GLAST-Discosoma red (DsRed) promoter reporter mice revealed that DsRed expression was restricted to IPCs and other supporting cells surrounding IHCs"}
{"PMID":16874462,"re_id":0,"annotated sentence":"Overexpression of <e2>proline oxidase<\\e2> induces <e1>proline<\\e1> dependent and mitochondria-mediated apoptosis","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"proline","object":"proline oxidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Overexpression of <e2>CHEMICAL oxidase<\\e2> induces <e1>CHEMICAL<\\e1> dependent and mitochondria-mediated apoptosis","sentence":"Overexpression of proline oxidase induces proline dependent and mitochondria-mediated apoptosis"}
{"PMID":16874462,"re_id":1,"annotated sentence":"We conclude that in the presence of <e1>proline<\\e1>  high <e2>POX<\\e2> activity is sufficient to induce mitochondria-mediated apoptosis.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"proline","object":"POX","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We conclude that in the presence of <e1>CHEMICAL<\\e1>  high <e2>GENE-Y<\\e2> activity is sufficient to induce mitochondria-mediated apoptosis.","sentence":"We conclude that in the presence of proline  high POX activity is sufficient to induce mitochondria-mediated apoptosis."}
{"PMID":16874462,"re_id":2,"annotated sentence":"<e2>Proline oxidase<\\e2> (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of <e1>proline<\\e1> to pyrroline- 5-carboxylate (P5C)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"proline","object":"Proline oxidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of <e1>CHEMICAL<\\e1> to pyrroline- 5-carboxylate (P5C)","sentence":"Proline oxidase (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to pyrroline- 5-carboxylate (P5C)"}
{"PMID":16874462,"re_id":3,"annotated sentence":"Proline oxidase (<e2>POX<\\e2> , a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of <e1>proline<\\e1> to pyrroline- 5-carboxylate (P5C)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"proline","object":"POX","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Proline oxidase (<e2>GENE-Y<\\e2> , a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of <e1>CHEMICAL<\\e1> to pyrroline- 5-carboxylate (P5C)","sentence":"Proline oxidase (POX , a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to pyrroline- 5-carboxylate (P5C)"}
{"PMID":16874462,"re_id":4,"annotated sentence":"<e2>Proline oxidase<\\e2> (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to <e1>pyrroline- 5-carboxylate<\\e1> (P5C)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"pyrroline- 5-carboxylate","object":"Proline oxidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to <e1>CHEMICAL<\\e1> (P5C)","sentence":"Proline oxidase (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to pyrroline- 5-carboxylate (P5C)"}
{"PMID":16874462,"re_id":5,"annotated sentence":"Proline oxidase (<e2>POX<\\e2> , a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to <e1>pyrroline- 5-carboxylate<\\e1> (P5C)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"pyrroline- 5-carboxylate","object":"POX","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Proline oxidase (<e2>GENE-Y<\\e2> , a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to <e1>CHEMICAL<\\e1> (P5C)","sentence":"Proline oxidase (POX , a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to pyrroline- 5-carboxylate (P5C)"}
{"PMID":16874462,"re_id":6,"annotated sentence":"<e2>Proline oxidase<\\e2> (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to pyrroline- 5-carboxylate (<e1>P5C<\\e1> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"P5C","object":"Proline oxidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to pyrroline- 5-carboxylate (<e1>CHEMICAL<\\e1> ","sentence":"Proline oxidase (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to pyrroline- 5-carboxylate (P5C "}
{"PMID":16874462,"re_id":7,"annotated sentence":"Proline oxidase (<e2>POX<\\e2> , a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to pyrroline- 5-carboxylate (<e1>P5C<\\e1> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"P5C","object":"POX","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Proline oxidase (<e2>GENE-Y<\\e2> , a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to pyrroline- 5-carboxylate (<e1>CHEMICAL<\\e1> ","sentence":"Proline oxidase (POX , a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to pyrroline- 5-carboxylate (P5C "}
{"PMID":16874462,"re_id":8,"annotated sentence":"To further investigate the molecular basis of POX-induced apoptosis, we utilized the DLD-1.POX cells to show that cells overproducing <e2>POX<\\e2> exhibit an <e1>L-proline<\\e1> dependent apoptotic response","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-proline","object":"POX","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To further investigate the molecular basis of GENE-Y-induced apoptosis, we utilized the DLD-1.GENE-Y cells to show that cells overproducing <e2>GENE-Y<\\e2> exhibit an <e1>CHEMICAL<\\e1> dependent apoptotic response","sentence":"To further investigate the molecular basis of POX-induced apoptosis, we utilized the DLD-1.POX cells to show that cells overproducing POX exhibit an L-proline dependent apoptotic response"}
{"PMID":16874462,"re_id":9,"annotated sentence":"The apoptotic effect is specific for L-proline, detectable at 0.2 mM, maximal at 1 mM, and occurs during 48-72 h following the addition of <e1>L-proline<\\e1> to cells with maximally induced <e2>POX<\\e2>  The apoptotic response is mitochondria-mediated with release of cytochrome c, activation of caspase-9, chromatin condensation\/DNA fragmentation, and cell shrinkage","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-proline","object":"POX","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The apoptotic effect is specific for CHEMICAL, detectable at 0.2 mM, maximal at 1 mM, and occurs during 48-72 h following the addition of <e1>CHEMICAL<\\e1> to cells with maximally induced <e2>GENE-Y<\\e2>  The apoptotic response is mitochondria-mediated with release of cytochrome c, activation of caspase-9, chromatin condensation\/DNA fragmentation, and cell shrinkage","sentence":"The apoptotic effect is specific for L-proline, detectable at 0.2 mM, maximal at 1 mM, and occurs during 48-72 h following the addition of L-proline to cells with maximally induced POX  The apoptotic response is mitochondria-mediated with release of cytochrome c, activation of caspase-9, chromatin condensation\/DNA fragmentation, and cell shrinkage"}
{"PMID":16893531,"re_id":0,"annotated sentence":"The exception was <e1>bupropion<\\e1>  a dual <e2>norepinephrine transporter<\\e2> dopamine transporter blocker, which tended to increase spontaneous locomotor activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"bupropion","object":"norepinephrine transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The exception was <e1>CHEMICAL<\\e1>  a dual <e2>GENE-Y<\\e2> dopamine transporter blocker, which tended to increase spontaneous locomotor activity","sentence":"The exception was bupropion  a dual norepinephrine transporter dopamine transporter blocker, which tended to increase spontaneous locomotor activity"}
{"PMID":16893531,"re_id":1,"annotated sentence":"The exception was <e1>bupropion<\\e1>  a dual norepinephrine transporter\/<e2>dopamine transporter<\\e2> blocker, which tended to increase spontaneous locomotor activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"bupropion","object":"dopamine transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The exception was <e1>CHEMICAL<\\e1>  a dual norepinephrine transporter\/<e2>GENE-Y<\\e2> blocker, which tended to increase spontaneous locomotor activity","sentence":"The exception was bupropion  a dual norepinephrine transporter\/dopamine transporter blocker, which tended to increase spontaneous locomotor activity"}
{"PMID":16893531,"re_id":2,"annotated sentence":"Coadministration of reboxetine and the <e2>dopamine transporter<\\e2> blocker <e1>GBR 12909<\\e1> also increased spontaneous locomotor activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"GBR 12909","object":"dopamine transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Coadministration of reboxetine and the <e2>GENE-Y<\\e2> blocker <e1>CHEMICAL<\\e1> also increased spontaneous locomotor activity","sentence":"Coadministration of reboxetine and the dopamine transporter blocker GBR 12909 also increased spontaneous locomotor activity"}
{"PMID":16917142,"re_id":0,"annotated sentence":"<e1>Fulvestrant<\\e1> is a novel ER antagonist that destroys the <e2>ER<\\e2> and its signaling pathway and is not associated with tamoxifen-like agonist effects","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Fulvestrant","object":"ER","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is a novel GENE-Y antagonist that destroys the <e2>GENE-Y<\\e2> and its signaling pathway and is not associated with tamoxifen-like agonist effects","sentence":"Fulvestrant is a novel ER antagonist that destroys the ER and its signaling pathway and is not associated with tamoxifen-like agonist effects"}
{"PMID":16917142,"re_id":1,"annotated sentence":"<e1>Tamoxifen<\\e1> blocks the action of estrogen by binding to the ER, and possesses both <e2>ER<\\e2> agonist and antagonist properties","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"Tamoxifen","object":"ER","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> blocks the action of estrogen by binding to the GENE-Y, and possesses both <e2>GENE-Y<\\e2> agonist and antagonist properties","sentence":"Tamoxifen blocks the action of estrogen by binding to the ER, and possesses both ER agonist and antagonist properties"}
{"PMID":16917142,"re_id":2,"annotated sentence":"<e1>Tamoxifen<\\e1> blocks the action of estrogen by binding to the ER, and possesses both <e2>ER<\\e2> agonist and antagonist properties","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Tamoxifen","object":"ER","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> blocks the action of estrogen by binding to the GENE-Y, and possesses both <e2>GENE-Y<\\e2> agonist and antagonist properties","sentence":"Tamoxifen blocks the action of estrogen by binding to the ER, and possesses both ER agonist and antagonist properties"}
{"PMID":16917142,"re_id":3,"annotated sentence":"<e1>Fulvestrant<\\e1> is a novel <e2>ER<\\e2> antagonist that destroys the ER and its signaling pathway and is not associated with tamoxifen-like agonist effects","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Fulvestrant","object":"ER","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is a novel <e2>GENE-Y<\\e2> antagonist that destroys the GENE-Y and its signaling pathway and is not associated with tamoxifen-like agonist effects","sentence":"Fulvestrant is a novel ER antagonist that destroys the ER and its signaling pathway and is not associated with tamoxifen-like agonist effects"}
{"PMID":16926278,"re_id":0,"annotated sentence":"Binding of <e1>cGMP<\\e1> to GAF-A increases <e2>cNPK<\\e2> phosphorylation of PDE5 and improves catalytic site affinity for cGMP or inhibitors","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cGMP","object":"cNPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Binding of <e1>CHEMICAL<\\e1> to GAF-A increases <e2>GENE-N<\\e2> phosphorylation of PDE5 and improves catalytic site affinity for CHEMICAL or inhibitors","sentence":"Binding of cGMP to GAF-A increases cNPK phosphorylation of PDE5 and improves catalytic site affinity for cGMP or inhibitors"}
{"PMID":16926278,"re_id":1,"annotated sentence":"Binding of <e1>cGMP<\\e1> to GAF-A increases cNPK phosphorylation of <e2>PDE5<\\e2> and improves catalytic site affinity for cGMP or inhibitors","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cGMP","object":"PDE5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Binding of <e1>CHEMICAL<\\e1> to GAF-A increases cNPK phosphorylation of <e2>GENE-Y<\\e2> and improves catalytic site affinity for CHEMICAL or inhibitors","sentence":"Binding of cGMP to GAF-A increases cNPK phosphorylation of PDE5 and improves catalytic site affinity for cGMP or inhibitors"}
{"PMID":16926278,"re_id":2,"annotated sentence":"<e2>Phosphodiesterase-5<\\e2> (PDE5) contains a catalytic domain (C domain) that hydrolyzes <e1>cGMP<\\e1> and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cGMP","object":"Phosphodiesterase-5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (PDE5) contains a catalytic domain (C domain) that hydrolyzes <e1>CHEMICAL<\\e1> and a regulatory domain (R domain) that contains two mammalian CHEMICAL-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs)","sentence":"Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs)"}
{"PMID":16926278,"re_id":3,"annotated sentence":"Phosphodiesterase-5 (<e2>PDE5<\\e2>  contains a catalytic domain (C domain) that hydrolyzes <e1>cGMP<\\e1> and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cGMP","object":"PDE5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Phosphodiesterase-5 (<e2>GENE-Y<\\e2>  contains a catalytic domain (C domain) that hydrolyzes <e1>CHEMICAL<\\e1> and a regulatory domain (R domain) that contains two mammalian CHEMICAL-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs)","sentence":"Phosphodiesterase-5 (PDE5  contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs)"}
{"PMID":16926278,"re_id":4,"annotated sentence":"K(m) values of the mutants for <e1>cGMP<\\e1> were similar to that of full-length <e2>PDE5<\\e2>  All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cGMP","object":"PDE5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"K(m) values of the mutants for <e1>CHEMICAL<\\e1> were similar to that of full-length <e2>GENE-Y<\\e2>  All GENE-Y constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B","sentence":"K(m) values of the mutants for cGMP were similar to that of full-length PDE5  All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B"}
{"PMID":16938288,"re_id":0,"annotated sentence":"<e1>Telmisartan<\\e1> downregulates angiotensin II type 1 receptor through activation of <e2>peroxisome proliferator-activated receptor gamma<\\e2>  OBJECTIVE: Telmisartan, an angiotensin II type 1 receptor (AT1R) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (PPARgamma)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Telmisartan","object":"peroxisome proliferator-activated receptor gamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> downregulates angiotensin II type 1 receptor through activation of <e2>GENE-Y<\\e2>  OBJECTIVE: CHEMICAL, an angiotensin II type 1 receptor (AT1R) antagonist, was found to have a unique property: it is a partial agonist of GENE-Y (PPARgamma)","sentence":"Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma  OBJECTIVE: Telmisartan, an angiotensin II type 1 receptor (AT1R) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (PPARgamma)"}
{"PMID":16938288,"re_id":1,"annotated sentence":"Since the suppression of <e2>AT1R<\\e2> expression was prevented by pretreatment with <e1>GW9662<\\e1>  a PPARgamma antagonist, PPARgamma should have participated in the process","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"GW9662","object":"AT1R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Since the suppression of <e2>GENE-Y<\\e2> expression was prevented by pretreatment with <e1>CHEMICAL<\\e1>  a PPARgamma antagonist, PPARgamma should have participated in the process","sentence":"Since the suppression of AT1R expression was prevented by pretreatment with GW9662  a PPARgamma antagonist, PPARgamma should have participated in the process"}
{"PMID":16938288,"re_id":2,"annotated sentence":"CONCLUSION: Our data provides a novel insight into an effect of telmisartan: <e1>telmisartan<\\e1> inhibits AT1R gene expression through <e2>PPARgamma<\\e2> activation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"telmisartan","object":"PPARgamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSION: Our data provides a novel insight into an effect of CHEMICAL: <e1>CHEMICAL<\\e1> inhibits AT1R gene expression through <e2>GENE-Y<\\e2> activation","sentence":"CONCLUSION: Our data provides a novel insight into an effect of telmisartan: telmisartan inhibits AT1R gene expression through PPARgamma activation"}
{"PMID":16938288,"re_id":3,"annotated sentence":"Decreased AT1R promoter activity with unchanged mRNA stability suggested that <e1>telmisartan<\\e1> suppressed <e2>AT1R<\\e2> gene expression at the transcriptional level","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"telmisartan","object":"AT1R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Decreased GENE-Y promoter activity with unchanged mRNA stability suggested that <e1>CHEMICAL<\\e1> suppressed <e2>GENE-Y<\\e2> gene expression at the transcriptional level","sentence":"Decreased AT1R promoter activity with unchanged mRNA stability suggested that telmisartan suppressed AT1R gene expression at the transcriptional level"}
{"PMID":16938288,"re_id":4,"annotated sentence":"<e1>Telmisartan<\\e1> downregulates <e2>angiotensin II type 1 receptor<\\e2> through activation of peroxisome proliferator-activated receptor gamma","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Telmisartan","object":"angiotensin II type 1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> downregulates <e2>GENE-Y<\\e2> through activation of peroxisome proliferator-activated receptor gamma","sentence":"Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma"}
{"PMID":16938288,"re_id":5,"annotated sentence":"The deletion and mutation analysis of the <e2>AT1R<\\e2> gene promoter indicated that a GC box located in the proximal promoter region is responsible for the <e1>telmisartan<\\e1> induced downregulation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"telmisartan","object":"AT1R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The deletion and mutation analysis of the <e2>GENE-Y<\\e2> gene promoter indicated that a GC box located in the proximal promoter region is responsible for the <e1>CHEMICAL<\\e1> induced downregulation","sentence":"The deletion and mutation analysis of the AT1R gene promoter indicated that a GC box located in the proximal promoter region is responsible for the telmisartan induced downregulation"}
{"PMID":16938288,"re_id":6,"annotated sentence":"The deletion and mutation analysis of the AT1R gene promoter indicated that a <e2>GC box<\\e2> located in the proximal promoter region is responsible for the <e1>telmisartan<\\e1> induced downregulation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"telmisartan","object":"GC box","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The deletion and mutation analysis of the AT1R gene promoter indicated that a <e2>GENE-N<\\e2> located in the proximal promoter region is responsible for the <e1>CHEMICAL<\\e1> induced downregulation","sentence":"The deletion and mutation analysis of the AT1R gene promoter indicated that a GC box located in the proximal promoter region is responsible for the telmisartan induced downregulation"}
{"PMID":16938288,"re_id":7,"annotated sentence":"CONCLUSION: Our data provides a novel insight into an effect of telmisartan: <e1>telmisartan<\\e1> inhibits <e2>AT1R<\\e2> gene expression through PPARgamma activation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"telmisartan","object":"AT1R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSION: Our data provides a novel insight into an effect of CHEMICAL: <e1>CHEMICAL<\\e1> inhibits <e2>GENE-Y<\\e2> gene expression through PPARgamma activation","sentence":"CONCLUSION: Our data provides a novel insight into an effect of telmisartan: telmisartan inhibits AT1R gene expression through PPARgamma activation"}
{"PMID":16938288,"re_id":8,"annotated sentence":"RESULTS: <e1>Telmisartan<\\e1> decreased the expression of <e2>AT1R<\\e2> at the mRNA and protein levels in a dose- and time-dependent manner","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Telmisartan","object":"AT1R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: <e1>CHEMICAL<\\e1> decreased the expression of <e2>GENE-Y<\\e2> at the mRNA and protein levels in a dose- and time-dependent manner","sentence":"RESULTS: Telmisartan decreased the expression of AT1R at the mRNA and protein levels in a dose- and time-dependent manner"}
{"PMID":16938288,"re_id":9,"annotated sentence":"OBJECTIVE: <e1>Telmisartan<\\e1>  an angiotensin II type 1 receptor (AT1R) antagonist, was found to have a unique property: it is a partial agonist of <e2>peroxisome proliferator-activated receptor gamma<\\e2> (PPARgamma)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"Telmisartan","object":"peroxisome proliferator-activated receptor gamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"OBJECTIVE: <e1>CHEMICAL<\\e1>  an angiotensin II type 1 receptor (AT1R) antagonist, was found to have a unique property: it is a partial agonist of <e2>GENE-Y<\\e2> (PPARgamma)","sentence":"OBJECTIVE: Telmisartan  an angiotensin II type 1 receptor (AT1R) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (PPARgamma)"}
{"PMID":16938288,"re_id":10,"annotated sentence":"OBJECTIVE: <e1>Telmisartan<\\e1>  an angiotensin II type 1 receptor (AT1R) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (<e2>PPARgamma<\\e2> ","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"Telmisartan","object":"PPARgamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"OBJECTIVE: <e1>CHEMICAL<\\e1>  an angiotensin II type 1 receptor (AT1R) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (<e2>GENE-Y<\\e2> ","sentence":"OBJECTIVE: Telmisartan  an angiotensin II type 1 receptor (AT1R) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (PPARgamma "}
{"PMID":16938288,"re_id":11,"annotated sentence":"However, the expression of AT1R was not suppressed by other <e2>AT1R<\\e2> antagonists such as <e1>candesartan<\\e1> or olmesartan","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"candesartan","object":"AT1R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, the expression of GENE-Y was not suppressed by other <e2>GENE-Y<\\e2> antagonists such as <e1>CHEMICAL<\\e1> or olmesartan","sentence":"However, the expression of AT1R was not suppressed by other AT1R antagonists such as candesartan or olmesartan"}
{"PMID":16938288,"re_id":12,"annotated sentence":"However, the expression of AT1R was not suppressed by other <e2>AT1R<\\e2> antagonists such as candesartan or <e1>olmesartan<\\e1>  Since the suppression of AT1R expression was prevented by pretreatment with GW9662, a PPARgamma antagonist, PPARgamma should have participated in the process","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"olmesartan","object":"AT1R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, the expression of GENE-Y was not suppressed by other <e2>GENE-Y<\\e2> antagonists such as candesartan or <e1>CHEMICAL<\\e1>  Since the suppression of GENE-Y expression was prevented by pretreatment with GW9662, a PPARgamma antagonist, PPARgamma should have participated in the process","sentence":"However, the expression of AT1R was not suppressed by other AT1R antagonists such as candesartan or olmesartan  Since the suppression of AT1R expression was prevented by pretreatment with GW9662, a PPARgamma antagonist, PPARgamma should have participated in the process"}
{"PMID":16938288,"re_id":13,"annotated sentence":"OBJECTIVE: <e1>Telmisartan<\\e1>  an <e2>angiotensin II type 1 receptor<\\e2> (AT1R) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (PPARgamma)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Telmisartan","object":"angiotensin II type 1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"OBJECTIVE: <e1>CHEMICAL<\\e1>  an <e2>GENE-Y<\\e2> (AT1R) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (PPARgamma)","sentence":"OBJECTIVE: Telmisartan  an angiotensin II type 1 receptor (AT1R) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (PPARgamma)"}
{"PMID":16938288,"re_id":14,"annotated sentence":"OBJECTIVE: <e1>Telmisartan<\\e1>  an angiotensin II type 1 receptor (<e2>AT1R<\\e2>  antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (PPARgamma)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Telmisartan","object":"AT1R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"OBJECTIVE: <e1>CHEMICAL<\\e1>  an angiotensin II type 1 receptor (<e2>GENE-Y<\\e2>  antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (PPARgamma)","sentence":"OBJECTIVE: Telmisartan  an angiotensin II type 1 receptor (AT1R  antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (PPARgamma)"}
{"PMID":16938288,"re_id":15,"annotated sentence":"Since the suppression of AT1R expression was prevented by pretreatment with <e1>GW9662<\\e1>  a <e2>PPARgamma<\\e2> antagonist, PPARgamma should have participated in the process","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"GW9662","object":"PPARgamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Since the suppression of AT1R expression was prevented by pretreatment with <e1>CHEMICAL<\\e1>  a <e2>GENE-Y<\\e2> antagonist, GENE-Y should have participated in the process","sentence":"Since the suppression of AT1R expression was prevented by pretreatment with GW9662  a PPARgamma antagonist, PPARgamma should have participated in the process"}
{"PMID":16957773,"re_id":0,"annotated sentence":"Upon differentiation, osteoclasts express <e2>vesicular glutamate transporter 1<\\e2> (VGLUT1), which is essential for vesicular storage and subsequent exocytosis of <e1>glutamate<\\e1> in neurons","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutamate","object":"vesicular glutamate transporter 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Upon differentiation, osteoclasts express <e2>vesicular CHEMICAL transporter 1<\\e2> (VGLUT1), which is essential for vesicular storage and subsequent exocytosis of <e1>CHEMICAL<\\e1> in neurons","sentence":"Upon differentiation, osteoclasts express vesicular glutamate transporter 1 (VGLUT1), which is essential for vesicular storage and subsequent exocytosis of glutamate in neurons"}
{"PMID":16957773,"re_id":1,"annotated sentence":"Upon differentiation, osteoclasts express vesicular glutamate transporter 1 (<e2>VGLUT1<\\e2> , which is essential for vesicular storage and subsequent exocytosis of <e1>glutamate<\\e1> in neurons","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutamate","object":"VGLUT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Upon differentiation, osteoclasts express vesicular CHEMICAL transporter 1 (<e2>GENE-Y<\\e2> , which is essential for vesicular storage and subsequent exocytosis of <e1>CHEMICAL<\\e1> in neurons","sentence":"Upon differentiation, osteoclasts express vesicular glutamate transporter 1 (VGLUT1 , which is essential for vesicular storage and subsequent exocytosis of glutamate in neurons"}
{"PMID":16957773,"re_id":2,"annotated sentence":"<e2>VGLUT1<\\e2> is localized in transcytotic vesicles and accumulates <e1>L-glutamate<\\e1>  Osteoclasts secrete L-glutamate and the bone degradation products upon stimulation with KCl or ATP in a Ca2+-dependent manner","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-glutamate","object":"VGLUT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> is localized in transcytotic vesicles and accumulates <e1>CHEMICAL<\\e1>  Osteoclasts secrete CHEMICAL and the bone degradation products upon stimulation with KCl or ATP in a Ca2+-dependent manner","sentence":"VGLUT1 is localized in transcytotic vesicles and accumulates L-glutamate  Osteoclasts secrete L-glutamate and the bone degradation products upon stimulation with KCl or ATP in a Ca2+-dependent manner"}
{"PMID":16971132,"re_id":0,"annotated sentence":"In order to produce potent new leads for anticancer drugs, a new series of quinazoline analogs was designed to resemble <e1>methotrexate<\\e1> (MTX, 1) structure features and fitted with functional groups believed to enhance inhibition of <e2>mammalian DHFR<\\e2> activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"methotrexate","object":"mammalian DHFR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In order to produce potent new leads for anticancer drugs, a new series of quinazoline analogs was designed to resemble <e1>CHEMICAL<\\e1> (MTX, 1) structure features and fitted with functional groups believed to enhance inhibition of <e2>GENE-N<\\e2> activity","sentence":"In order to produce potent new leads for anticancer drugs, a new series of quinazoline analogs was designed to resemble methotrexate (MTX, 1) structure features and fitted with functional groups believed to enhance inhibition of mammalian DHFR activity"}
{"PMID":16971132,"re_id":1,"annotated sentence":"In order to produce potent new leads for anticancer drugs, a new series of quinazoline analogs was designed to resemble methotrexate (<e1>MTX<\\e1>  1) structure features and fitted with functional groups believed to enhance inhibition of <e2>mammalian DHFR<\\e2> activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MTX","object":"mammalian DHFR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In order to produce potent new leads for anticancer drugs, a new series of quinazoline analogs was designed to resemble methotrexate (<e1>CHEMICAL<\\e1>  1) structure features and fitted with functional groups believed to enhance inhibition of <e2>GENE-N<\\e2> activity","sentence":"In order to produce potent new leads for anticancer drugs, a new series of quinazoline analogs was designed to resemble methotrexate (MTX  1) structure features and fitted with functional groups believed to enhance inhibition of mammalian DHFR activity"}
{"PMID":16971132,"re_id":2,"annotated sentence":"In order to produce potent new leads for anticancer drugs, a new series of <e1>quinazoline<\\e1> analogs was designed to resemble methotrexate (MTX, 1) structure features and fitted with functional groups believed to enhance inhibition of <e2>mammalian DHFR<\\e2> activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"quinazoline","object":"mammalian DHFR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In order to produce potent new leads for anticancer drugs, a new series of <e1>CHEMICAL<\\e1> analogs was designed to resemble methotrexate (MTX, 1) structure features and fitted with functional groups believed to enhance inhibition of <e2>GENE-N<\\e2> activity","sentence":"In order to produce potent new leads for anticancer drugs, a new series of quinazoline analogs was designed to resemble methotrexate (MTX, 1) structure features and fitted with functional groups believed to enhance inhibition of mammalian DHFR activity"}
{"PMID":16971132,"re_id":3,"annotated sentence":"Synthesis, <e2>dihydrofolate reductase<\\e2> inhibition, antitumor testing, and molecular modeling study of some new <e1>4(3H)-quinazolinone<\\e1> analogs","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"4(3H)-quinazolinone","object":"dihydrofolate reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Synthesis, <e2>GENE-Y<\\e2> inhibition, antitumor testing, and molecular modeling study of some new <e1>CHEMICAL<\\e1> analogs","sentence":"Synthesis, dihydrofolate reductase inhibition, antitumor testing, and molecular modeling study of some new 4(3H)-quinazolinone analogs"}
{"PMID":16988497,"re_id":0,"annotated sentence":"CONCLUSION: Intake of high <e1>SFAs<\\e1> and MUFAs appears to increase expression of PBMC <e2>D6D<\\e2> and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and D5D genes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"SFAs","object":"D6D","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSION: Intake of high <e1>CHEMICAL<\\e1> and MUFAs appears to increase expression of PBMC <e2>GENE-Y<\\e2> and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC GENE-Y and D5D genes","sentence":"CONCLUSION: Intake of high SFAs and MUFAs appears to increase expression of PBMC D6D and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and D5D genes"}
{"PMID":16988497,"re_id":1,"annotated sentence":"CONCLUSION: Intake of high <e1>SFAs<\\e1> and MUFAs appears to increase expression of PBMC D6D and <e2>D5D<\\e2> genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and D5D genes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"SFAs","object":"D5D","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSION: Intake of high <e1>CHEMICAL<\\e1> and MUFAs appears to increase expression of PBMC D6D and <e2>GENE-Y<\\e2> genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and GENE-Y genes","sentence":"CONCLUSION: Intake of high SFAs and MUFAs appears to increase expression of PBMC D6D and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and D5D genes"}
{"PMID":16988497,"re_id":2,"annotated sentence":"CONCLUSION: Intake of high SFAs and <e1>MUFAs<\\e1> appears to increase expression of PBMC <e2>D6D<\\e2> and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and D5D genes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"MUFAs","object":"D6D","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSION: Intake of high SFAs and <e1>CHEMICAL<\\e1> appears to increase expression of PBMC <e2>GENE-Y<\\e2> and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC GENE-Y and D5D genes","sentence":"CONCLUSION: Intake of high SFAs and MUFAs appears to increase expression of PBMC D6D and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and D5D genes"}
{"PMID":16988497,"re_id":3,"annotated sentence":"CONCLUSION: Intake of high SFAs and <e1>MUFAs<\\e1> appears to increase expression of PBMC D6D and <e2>D5D<\\e2> genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and D5D genes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"MUFAs","object":"D5D","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSION: Intake of high SFAs and <e1>CHEMICAL<\\e1> appears to increase expression of PBMC D6D and <e2>GENE-Y<\\e2> genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and GENE-Y genes","sentence":"CONCLUSION: Intake of high SFAs and MUFAs appears to increase expression of PBMC D6D and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and D5D genes"}
{"PMID":16988497,"re_id":4,"annotated sentence":"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of <e1>linoleic acid<\\e1> (LA) and alpha-linolenic acid (LNA) and the expression of PBMC <e2>D6D<\\e2> and D5D genes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"linoleic acid","object":"D6D","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC GENE-Y and D5D genes, but a significant negative correlation between dietary intake of <e1>CHEMICAL<\\e1> (LA) and alpha-linolenic acid (LNA) and the expression of PBMC <e2>GENE-Y<\\e2> and D5D genes","sentence":"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and D5D genes"}
{"PMID":16988497,"re_id":5,"annotated sentence":"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of <e1>linoleic acid<\\e1> (LA) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and <e2>D5D<\\e2> genes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"linoleic acid","object":"D5D","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and GENE-Y genes, but a significant negative correlation between dietary intake of <e1>CHEMICAL<\\e1> (LA) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and <e2>GENE-Y<\\e2> genes","sentence":"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and D5D genes"}
{"PMID":16988497,"re_id":6,"annotated sentence":"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (<e1>LA<\\e1>  and alpha-linolenic acid (LNA) and the expression of PBMC <e2>D6D<\\e2> and D5D genes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"LA","object":"D6D","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC GENE-Y and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (<e1>CHEMICAL<\\e1>  and alpha-linolenic acid (LNA) and the expression of PBMC <e2>GENE-Y<\\e2> and D5D genes","sentence":"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA  and alpha-linolenic acid (LNA) and the expression of PBMC D6D and D5D genes"}
{"PMID":16988497,"re_id":7,"annotated sentence":"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (<e1>LA<\\e1>  and alpha-linolenic acid (LNA) and the expression of PBMC D6D and <e2>D5D<\\e2> genes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"LA","object":"D5D","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and GENE-Y genes, but a significant negative correlation between dietary intake of linoleic acid (<e1>CHEMICAL<\\e1>  and alpha-linolenic acid (LNA) and the expression of PBMC D6D and <e2>GENE-Y<\\e2> genes","sentence":"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA  and alpha-linolenic acid (LNA) and the expression of PBMC D6D and D5D genes"}
{"PMID":16988497,"re_id":8,"annotated sentence":"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and <e1>alpha-linolenic acid<\\e1> (LNA) and the expression of PBMC <e2>D6D<\\e2> and D5D genes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"alpha-linolenic acid","object":"D6D","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC GENE-Y and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and <e1>CHEMICAL<\\e1> (LNA) and the expression of PBMC <e2>GENE-Y<\\e2> and D5D genes","sentence":"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and D5D genes"}
{"PMID":16988497,"re_id":9,"annotated sentence":"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and <e1>alpha-linolenic acid<\\e1> (LNA) and the expression of PBMC D6D and <e2>D5D<\\e2> genes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"alpha-linolenic acid","object":"D5D","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and GENE-Y genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and <e1>CHEMICAL<\\e1> (LNA) and the expression of PBMC D6D and <e2>GENE-Y<\\e2> genes","sentence":"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and D5D genes"}
{"PMID":16988497,"re_id":10,"annotated sentence":"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (<e1>LNA<\\e1>  and the expression of PBMC <e2>D6D<\\e2> and D5D genes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"LNA","object":"D6D","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC GENE-Y and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (<e1>CHEMICAL<\\e1>  and the expression of PBMC <e2>GENE-Y<\\e2> and D5D genes","sentence":"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (LNA  and the expression of PBMC D6D and D5D genes"}
{"PMID":16988497,"re_id":11,"annotated sentence":"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (<e1>LNA<\\e1>  and the expression of PBMC D6D and <e2>D5D<\\e2> genes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"LNA","object":"D5D","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and GENE-Y genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (<e1>CHEMICAL<\\e1>  and the expression of PBMC D6D and <e2>GENE-Y<\\e2> genes","sentence":"A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (LNA  and the expression of PBMC D6D and D5D genes"}
{"PMID":16988497,"re_id":12,"annotated sentence":"CONCLUSION: Intake of high SFAs and MUFAs appears to increase expression of PBMC D6D and D5D genes, whilst high <e1>EFAs<\\e1> intake appears to decrease expression of PBMC <e2>D6D<\\e2> and D5D genes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"EFAs","object":"D6D","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSION: Intake of high SFAs and MUFAs appears to increase expression of PBMC GENE-Y and D5D genes, whilst high <e1>CHEMICAL<\\e1> intake appears to decrease expression of PBMC <e2>GENE-Y<\\e2> and D5D genes","sentence":"CONCLUSION: Intake of high SFAs and MUFAs appears to increase expression of PBMC D6D and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and D5D genes"}
{"PMID":16988497,"re_id":13,"annotated sentence":"CONCLUSION: Intake of high SFAs and MUFAs appears to increase expression of PBMC D6D and D5D genes, whilst high <e1>EFAs<\\e1> intake appears to decrease expression of PBMC D6D and <e2>D5D<\\e2> genes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"EFAs","object":"D5D","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSION: Intake of high SFAs and MUFAs appears to increase expression of PBMC D6D and GENE-Y genes, whilst high <e1>CHEMICAL<\\e1> intake appears to decrease expression of PBMC D6D and <e2>GENE-Y<\\e2> genes","sentence":"CONCLUSION: Intake of high SFAs and MUFAs appears to increase expression of PBMC D6D and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and D5D genes"}
{"PMID":17023173,"re_id":0,"annotated sentence":"<e1>Decitabine<\\e1> inhibits <e2>DNA methyltransferase<\\e2> and has shown therapeutic effects in patients with hematologic malignancies","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Decitabine","object":"DNA methyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> inhibits <e2>GENE-N<\\e2> and has shown therapeutic effects in patients with hematologic malignancies","sentence":"Decitabine inhibits DNA methyltransferase and has shown therapeutic effects in patients with hematologic malignancies"}
{"PMID":17065601,"re_id":0,"annotated sentence":"Our data suggest that <e1>l-arginine<\\e1> is taken up by Sertoli cells and peritubular cells, principally via system y(+)L (<e2>SLC3A2<\\e2> SLC7A6) and system y(+) (SLC7A1 and SLC7A2), with system B(0+) making a minor contribution","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"l-arginine","object":"SLC3A2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our data suggest that <e1>CHEMICAL<\\e1> is taken up by Sertoli cells and peritubular cells, principally via system y(+)L (<e2>GENE-Y<\\e2> SLC7A6) and system y(+) (SLC7A1 and SLC7A2), with system B(0+) making a minor contribution","sentence":"Our data suggest that l-arginine is taken up by Sertoli cells and peritubular cells, principally via system y(+)L (SLC3A2 SLC7A6) and system y(+) (SLC7A1 and SLC7A2), with system B(0+) making a minor contribution"}
{"PMID":17090056,"re_id":0,"annotated sentence":"KIEs were measured on the arsenolysis of <e1>5'-methylthioadenosine<\\e1> (MTA) catalyzed by <e2>MTAP<\\e2> and were corrected for the forward commitment to catalysis","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"5'-methylthioadenosine","object":"MTAP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"KIEs were measured on the arsenolysis of <e1>CHEMICAL<\\e1> (MTA) catalyzed by <e2>GENE-Y<\\e2> and were corrected for the forward commitment to catalysis","sentence":"KIEs were measured on the arsenolysis of 5'-methylthioadenosine (MTA) catalyzed by MTAP and were corrected for the forward commitment to catalysis"}
{"PMID":17090056,"re_id":1,"annotated sentence":"KIEs were measured on the arsenolysis of 5'-methylthioadenosine (<e1>MTA<\\e1>  catalyzed by <e2>MTAP<\\e2> and were corrected for the forward commitment to catalysis","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"MTA","object":"MTAP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"KIEs were measured on the arsenolysis of 5'-methylthioadenosine (<e1>CHEMICAL<\\e1>  catalyzed by <e2>CHEMICALP<\\e2> and were corrected for the forward commitment to catalysis","sentence":"KIEs were measured on the arsenolysis of 5'-methylthioadenosine (MTA  catalyzed by MTAP and were corrected for the forward commitment to catalysis"}
{"PMID":17098734,"re_id":0,"annotated sentence":"Blocking <e1>retinyl ester<\\e1> formation by a targeted knock down of <e2>Lratb<\\e2> results in significantly increased retinoic acid levels, which lead to severe embryonic patterning defects","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"retinyl ester","object":"Lratb","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Blocking <e1>CHEMICAL<\\e1> formation by a targeted knock down of <e2>GENE-Y<\\e2> results in significantly increased retinoic acid levels, which lead to severe embryonic patterning defects","sentence":"Blocking retinyl ester formation by a targeted knock down of Lratb results in significantly increased retinoic acid levels, which lead to severe embryonic patterning defects"}
{"PMID":17098734,"re_id":1,"annotated sentence":"During embryogenesis, lratb is expressed in mostly non-overlapping domains opposite to <e2>retinal dehydrogenase 2<\\e2> (raldh2), the key enzyme for <e1>retinoic acid<\\e1> synthesis","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"retinoic acid","object":"retinal dehydrogenase 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"During embryogenesis, lratb is expressed in mostly non-overlapping domains opposite to <e2>GENE-Y<\\e2> (raldh2), the key enzyme for <e1>CHEMICAL<\\e1> synthesis","sentence":"During embryogenesis, lratb is expressed in mostly non-overlapping domains opposite to retinal dehydrogenase 2 (raldh2), the key enzyme for retinoic acid synthesis"}
{"PMID":17098734,"re_id":2,"annotated sentence":"During embryogenesis, lratb is expressed in mostly non-overlapping domains opposite to retinal dehydrogenase 2 (<e2>raldh2<\\e2> , the key enzyme for <e1>retinoic acid<\\e1> synthesis","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"retinoic acid","object":"raldh2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"During embryogenesis, lratb is expressed in mostly non-overlapping domains opposite to retinal dehydrogenase 2 (<e2>GENE-Y<\\e2> , the key enzyme for <e1>CHEMICAL<\\e1> synthesis","sentence":"During embryogenesis, lratb is expressed in mostly non-overlapping domains opposite to retinal dehydrogenase 2 (raldh2 , the key enzyme for retinoic acid synthesis"}
{"PMID":17110146,"re_id":0,"annotated sentence":"<e1>ADP<\\e1> initiates platelet aggregation by 'simultaneous activation of two <e2>G protein-coupled receptors<\\e2>  P2Y1 and P2Y12","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ADP","object":"G protein-coupled receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> initiates platelet aggregation by 'simultaneous activation of two <e2>GENE-N<\\e2>  P2Y1 and P2Y12","sentence":"ADP initiates platelet aggregation by 'simultaneous activation of two G protein-coupled receptors  P2Y1 and P2Y12"}
{"PMID":17110146,"re_id":1,"annotated sentence":"<e1>ADP<\\e1> initiates platelet aggregation by 'simultaneous activation of two G protein-coupled receptors, <e2>P2Y1<\\e2> and P2Y12","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ADP","object":"P2Y1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> initiates platelet aggregation by 'simultaneous activation of two G protein-coupled receptors, <e2>GENE-Y<\\e2> and GENE-Y2","sentence":"ADP initiates platelet aggregation by 'simultaneous activation of two G protein-coupled receptors, P2Y1 and P2Y12"}
{"PMID":17110146,"re_id":2,"annotated sentence":"<e1>ADP<\\e1> initiates platelet aggregation by 'simultaneous activation of two G protein-coupled receptors, P2Y1 and <e2>P2Y12<\\e2>  P2Y12 has been shown to be the target of the thienopyridine drugs, ticlopidine and clopidogrel","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ADP","object":"P2Y12","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> initiates platelet aggregation by 'simultaneous activation of two G protein-coupled receptors, P2Y1 and <e2>GENE-Y<\\e2>  GENE-Y has been shown to be the target of the thienopyridine drugs, ticlopidine and clopidogrel","sentence":"ADP initiates platelet aggregation by 'simultaneous activation of two G protein-coupled receptors, P2Y1 and P2Y12  P2Y12 has been shown to be the target of the thienopyridine drugs, ticlopidine and clopidogrel"}
{"PMID":17110146,"re_id":3,"annotated sentence":"Our results imply that <e2>P2Y12<\\e2> has the potential to be inhibited by <e1>ADP<\\e1> ATP analogs, and it suggests that P2Y12 acts as a target of new drugs that inhibit platelet aggregation.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ADP","object":"P2Y12","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our results imply that <e2>GENE-Y<\\e2> has the potential to be inhibited by <e1>CHEMICAL<\\e1> ATP analogs, and it suggests that GENE-Y acts as a target of new drugs that inhibit platelet aggregation.","sentence":"Our results imply that P2Y12 has the potential to be inhibited by ADP ATP analogs, and it suggests that P2Y12 acts as a target of new drugs that inhibit platelet aggregation."}
{"PMID":17110146,"re_id":4,"annotated sentence":"Our results imply that <e2>P2Y12<\\e2> has the potential to be inhibited by ADP\/<e1>ATP<\\e1> analogs, and it suggests that P2Y12 acts as a target of new drugs that inhibit platelet aggregation.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ATP","object":"P2Y12","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our results imply that <e2>GENE-Y<\\e2> has the potential to be inhibited by ADP\/<e1>CHEMICAL<\\e1> analogs, and it suggests that GENE-Y acts as a target of new drugs that inhibit platelet aggregation.","sentence":"Our results imply that P2Y12 has the potential to be inhibited by ADP\/ATP analogs, and it suggests that P2Y12 acts as a target of new drugs that inhibit platelet aggregation."}
{"PMID":17125913,"re_id":0,"annotated sentence":"<e1>Cd<\\e1> rapidly increased <e2>c-jun<\\e2>  c-fos and PDGFA expression","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Cd","object":"c-jun","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> rapidly increased <e2>GENE-N<\\e2>  c-fos and PDGFA expression","sentence":"Cd rapidly increased c-jun  c-fos and PDGFA expression"}
{"PMID":17125913,"re_id":1,"annotated sentence":"<e1>Cd<\\e1> rapidly increased c-jun, <e2>c-fos<\\e2> and PDGFA expression","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Cd","object":"c-fos","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> rapidly increased c-jun, <e2>GENE-N<\\e2> and PDGFA expression","sentence":"Cd rapidly increased c-jun, c-fos and PDGFA expression"}
{"PMID":17125913,"re_id":2,"annotated sentence":"<e1>Cd<\\e1> rapidly increased c-jun, c-fos and <e2>PDGFA<\\e2> expression","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Cd","object":"PDGFA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> rapidly increased c-jun, c-fos and <e2>GENE-Y<\\e2> expression","sentence":"Cd rapidly increased c-jun, c-fos and PDGFA expression"}
{"PMID":17125913,"re_id":3,"annotated sentence":"In conclusion, our results indicate that <e1>Cd<\\e1> increases BC cell proliferation in vitro by stimulating <e2>Akt<\\e2>  ERK1\/2 and PDGFRalpha kinases activity likely by activating c-fos, c-jun and PDGFA by an ERalpha-dependent mechanism.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Cd","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In conclusion, our results indicate that <e1>CHEMICAL<\\e1> increases BC cell proliferation in vitro by stimulating <e2>GENE-N<\\e2>  ERK1\/2 and PDGFRalpha kinases activity likely by activating c-fos, c-jun and PDGFA by an ERalpha-dependent mechanism.","sentence":"In conclusion, our results indicate that Cd increases BC cell proliferation in vitro by stimulating Akt  ERK1\/2 and PDGFRalpha kinases activity likely by activating c-fos, c-jun and PDGFA by an ERalpha-dependent mechanism."}
{"PMID":17125913,"re_id":4,"annotated sentence":"In conclusion, our results indicate that <e1>Cd<\\e1> increases BC cell proliferation in vitro by stimulating Akt, ERK1\/2 and <e2>PDGFRalpha<\\e2> kinases activity likely by activating c-fos, c-jun and PDGFA by an ERalpha-dependent mechanism.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Cd","object":"PDGFRalpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, our results indicate that <e1>CHEMICAL<\\e1> increases BC cell proliferation in vitro by stimulating Akt, ERK1\/2 and <e2>GENE-Y<\\e2> kinases activity likely by activating c-fos, c-jun and PDGFA by an ERalpha-dependent mechanism.","sentence":"In conclusion, our results indicate that Cd increases BC cell proliferation in vitro by stimulating Akt, ERK1\/2 and PDGFRalpha kinases activity likely by activating c-fos, c-jun and PDGFA by an ERalpha-dependent mechanism."}
{"PMID":17125913,"re_id":5,"annotated sentence":"In conclusion, our results indicate that <e1>Cd<\\e1> increases BC cell proliferation in vitro by stimulating Akt, ERK1\/2 and PDGFRalpha <e2>kinases<\\e2> activity likely by activating c-fos, c-jun and PDGFA by an ERalpha-dependent mechanism.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Cd","object":"kinases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In conclusion, our results indicate that <e1>CHEMICAL<\\e1> increases BC cell proliferation in vitro by stimulating Akt, ERK1\/2 and PDGFRalpha <e2>GENE-N<\\e2> activity likely by activating c-fos, c-jun and PDGFA by an ERalpha-dependent mechanism.","sentence":"In conclusion, our results indicate that Cd increases BC cell proliferation in vitro by stimulating Akt, ERK1\/2 and PDGFRalpha kinases activity likely by activating c-fos, c-jun and PDGFA by an ERalpha-dependent mechanism."}
{"PMID":17125913,"re_id":6,"annotated sentence":"In conclusion, our results indicate that <e1>Cd<\\e1> increases BC cell proliferation in vitro by stimulating Akt, ERK1\/2 and PDGFRalpha kinases activity likely by activating <e2>c-fos<\\e2>  c-jun and PDGFA by an ERalpha-dependent mechanism.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Cd","object":"c-fos","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, our results indicate that <e1>CHEMICAL<\\e1> increases BC cell proliferation in vitro by stimulating Akt, ERK1\/2 and PDGFRalpha kinases activity likely by activating <e2>GENE-Y<\\e2>  c-jun and PDGFA by an ERalpha-dependent mechanism.","sentence":"In conclusion, our results indicate that Cd increases BC cell proliferation in vitro by stimulating Akt, ERK1\/2 and PDGFRalpha kinases activity likely by activating c-fos  c-jun and PDGFA by an ERalpha-dependent mechanism."}
{"PMID":17125913,"re_id":7,"annotated sentence":"In conclusion, our results indicate that <e1>Cd<\\e1> increases BC cell proliferation in vitro by stimulating Akt, ERK1\/2 and PDGFRalpha kinases activity likely by activating c-fos, <e2>c-jun<\\e2> and PDGFA by an ERalpha-dependent mechanism.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Cd","object":"c-jun","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, our results indicate that <e1>CHEMICAL<\\e1> increases BC cell proliferation in vitro by stimulating Akt, ERK1\/2 and PDGFRalpha kinases activity likely by activating c-fos, <e2>GENE-Y<\\e2> and PDGFA by an ERalpha-dependent mechanism.","sentence":"In conclusion, our results indicate that Cd increases BC cell proliferation in vitro by stimulating Akt, ERK1\/2 and PDGFRalpha kinases activity likely by activating c-fos, c-jun and PDGFA by an ERalpha-dependent mechanism."}
{"PMID":17125913,"re_id":8,"annotated sentence":"In conclusion, our results indicate that <e1>Cd<\\e1> increases BC cell proliferation in vitro by stimulating Akt, ERK1\/2 and PDGFRalpha kinases activity likely by activating c-fos, c-jun and <e2>PDGFA<\\e2> by an ERalpha-dependent mechanism.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Cd","object":"PDGFA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, our results indicate that <e1>CHEMICAL<\\e1> increases BC cell proliferation in vitro by stimulating Akt, ERK1\/2 and PDGFRalpha kinases activity likely by activating c-fos, c-jun and <e2>GENE-Y<\\e2> by an ERalpha-dependent mechanism.","sentence":"In conclusion, our results indicate that Cd increases BC cell proliferation in vitro by stimulating Akt, ERK1\/2 and PDGFRalpha kinases activity likely by activating c-fos, c-jun and PDGFA by an ERalpha-dependent mechanism."}
{"PMID":17125913,"re_id":9,"annotated sentence":"<e1>Cd<\\e1> also increased ERK1\/2, <e2>Akt<\\e2> and PDGFRalpha phosphorylation while ICI blocked it","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Cd","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> also increased ERK1\/2, <e2>GENE-N<\\e2> and PDGFRalpha phosphorylation while ICI blocked it","sentence":"Cd also increased ERK1\/2, Akt and PDGFRalpha phosphorylation while ICI blocked it"}
{"PMID":17125913,"re_id":10,"annotated sentence":"<e1>Cd<\\e1> also increased ERK1\/2, Akt and <e2>PDGFRalpha<\\e2> phosphorylation while ICI blocked it","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Cd","object":"PDGFRalpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also increased ERK1\/2, Akt and <e2>GENE-Y<\\e2> phosphorylation while ICI blocked it","sentence":"Cd also increased ERK1\/2, Akt and PDGFRalpha phosphorylation while ICI blocked it"}
{"PMID":17125913,"re_id":11,"annotated sentence":"<e1>Cd<\\e1> decreased <e2>ERalpha<\\e2> expression, but not ERbeta","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cd","object":"ERalpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> decreased <e2>GENE-Y<\\e2> expression, but not ERbeta","sentence":"Cd decreased ERalpha expression, but not ERbeta"}
{"PMID":17202804,"re_id":0,"annotated sentence":"Gonadotropin-releasing hormone functionally antagonizes <e1>testosterone<\\e1> activation of the <e2>human androgen receptor<\\e2> in prostate cells through focal adhesion complexes involving Hic-5","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"testosterone","object":"human androgen receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Gonadotropin-releasing hormone functionally antagonizes <e1>CHEMICAL<\\e1> activation of the <e2>GENE-Y<\\e2> in prostate cells through focal adhesion complexes involving Hic-5","sentence":"Gonadotropin-releasing hormone functionally antagonizes testosterone activation of the human androgen receptor in prostate cells through focal adhesion complexes involving Hic-5"}
{"PMID":17202804,"re_id":1,"annotated sentence":"<e1>GnRH<\\e1> induced <e2>Pyk2<\\e2> activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the GnRH-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"GnRH","object":"Pyk2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induced <e2>GENE-Y<\\e2> activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative GENE-Y enhanced the CHEMICAL-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor","sentence":"GnRH induced Pyk2 activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the GnRH-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor"}
{"PMID":17202804,"re_id":2,"annotated sentence":"<e1>GnRH<\\e1> induced <e2>c-Src<\\e2> activation resulted in the phosphorylation of expressed Hic-5 and promoted its association with the human androgen receptor","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"GnRH","object":"c-Src","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induced <e2>GENE-Y<\\e2> activation resulted in the phosphorylation of expressed Hic-5 and promoted its association with the human androgen receptor","sentence":"GnRH induced c-Src activation resulted in the phosphorylation of expressed Hic-5 and promoted its association with the human androgen receptor"}
{"PMID":17202804,"re_id":3,"annotated sentence":"In contrast to <e1>testosterone<\\e1>  GnRH-induced nuclear translocation did not transcriptionally activate the <e2>androgen receptor<\\e2>  We then demonstrated that GnRH can also stimulate androgen receptor mobilization in human prostate PC3, BPH-1 and LNCaP cells, and in cultured rat ventral prostate cells through the same mechanism","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"testosterone","object":"androgen receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast to <e1>CHEMICAL<\\e1>  GnRH-induced nuclear translocation did not transcriptionally activate the <e2>GENE-Y<\\e2>  We then demonstrated that GnRH can also stimulate GENE-Y mobilization in human prostate PC3, BPH-1 and LNCaP cells, and in cultured rat ventral prostate cells through the same mechanism","sentence":"In contrast to testosterone  GnRH-induced nuclear translocation did not transcriptionally activate the androgen receptor  We then demonstrated that GnRH can also stimulate androgen receptor mobilization in human prostate PC3, BPH-1 and LNCaP cells, and in cultured rat ventral prostate cells through the same mechanism"}
{"PMID":17202804,"re_id":4,"annotated sentence":"<e1>GnRH<\\e1> induced Pyk2 activation opposed the association of <e2>Hic-5<\\e2> with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the GnRH-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"GnRH","object":"Hic-5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induced Pyk2 activation opposed the association of <e2>GENE-Y<\\e2> with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the CHEMICAL-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor","sentence":"GnRH induced Pyk2 activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the GnRH-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor"}
{"PMID":17202804,"re_id":5,"annotated sentence":"<e1>GnRH<\\e1> induced Pyk2 activation opposed the association of Hic-5 with <e2>androgen receptor<\\e2> as overexpression of a dominant negative Pyk2 enhanced the GnRH-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"GnRH","object":"androgen receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induced Pyk2 activation opposed the association of Hic-5 with <e2>GENE-Y<\\e2> as overexpression of a dominant negative Pyk2 enhanced the CHEMICAL-induced nuclear translocation of a green fluorescent protein-tagged human GENE-Y","sentence":"GnRH induced Pyk2 activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the GnRH-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor"}
{"PMID":17202804,"re_id":6,"annotated sentence":"<e1>Gonadotropin-releasing hormone<\\e1> functionally antagonizes testosterone activation of the <e2>human androgen receptor<\\e2> in prostate cells through focal adhesion complexes involving Hic-5","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Gonadotropin-releasing hormone","object":"human androgen receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> functionally antagonizes testosterone activation of the <e2>GENE-Y<\\e2> in prostate cells through focal adhesion complexes involving Hic-5","sentence":"Gonadotropin-releasing hormone functionally antagonizes testosterone activation of the human androgen receptor in prostate cells through focal adhesion complexes involving Hic-5"}
{"PMID":17218486,"re_id":0,"annotated sentence":"EC50 values for <e1>S-(+)-METH<\\e1> were 0.89, 0.92, and 4.44 microM for <e2>rTAAR1<\\e2>  mTAAR1, and h-rChTAAR1, respectively","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"S-(+)-METH","object":"rTAAR1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"EC50 values for <e1>CHEMICAL<\\e1> were 0.89, 0.92, and 4.44 microM for <e2>GENE-Y<\\e2>  mTAAR1, and h-rChTAAR1, respectively","sentence":"EC50 values for S-(+)-METH were 0.89, 0.92, and 4.44 microM for rTAAR1  mTAAR1, and h-rChTAAR1, respectively"}
{"PMID":17218486,"re_id":1,"annotated sentence":"EC50 values for <e1>S-(+)-METH<\\e1> were 0.89, 0.92, and 4.44 microM for rTAAR1, <e2>mTAAR1<\\e2>  and h-rChTAAR1, respectively","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"S-(+)-METH","object":"mTAAR1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"EC50 values for <e1>CHEMICAL<\\e1> were 0.89, 0.92, and 4.44 microM for rTAAR1, <e2>GENE-Y<\\e2>  and h-rChTAAR1, respectively","sentence":"EC50 values for S-(+)-METH were 0.89, 0.92, and 4.44 microM for rTAAR1, mTAAR1  and h-rChTAAR1, respectively"}
{"PMID":17218486,"re_id":2,"annotated sentence":"EC50 values for <e1>S-(+)-METH<\\e1> were 0.89, 0.92, and 4.44 microM for rTAAR1, mTAAR1, and <e2>h-rChTAAR1<\\e2>  respectively","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"S-(+)-METH","object":"h-rChTAAR1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"EC50 values for <e1>CHEMICAL<\\e1> were 0.89, 0.92, and 4.44 microM for rTAAR1, mTAAR1, and <e2>GENE-Y<\\e2>  respectively","sentence":"EC50 values for S-(+)-METH were 0.89, 0.92, and 4.44 microM for rTAAR1, mTAAR1, and h-rChTAAR1  respectively"}
{"PMID":17218486,"re_id":3,"annotated sentence":"The discovery that <e1>METH<\\e1> and AMPH activate the <e2>rTAAR1<\\e2> motivated us to study the effect of these drugs on the mouse TAAR1 (mTAAR1) and a human-rat chimera (hrChTAAR1)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"METH","object":"rTAAR1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The discovery that <e1>CHEMICAL<\\e1> and AMPH activate the <e2>GENE-Y<\\e2> motivated us to study the effect of these drugs on the mouse TAAR1 (mTAAR1) and a human-rat chimera (hrChTAAR1)","sentence":"The discovery that METH and AMPH activate the rTAAR1 motivated us to study the effect of these drugs on the mouse TAAR1 (mTAAR1) and a human-rat chimera (hrChTAAR1)"}
{"PMID":17218486,"re_id":4,"annotated sentence":"The discovery that METH and <e1>AMPH<\\e1> activate the <e2>rTAAR1<\\e2> motivated us to study the effect of these drugs on the mouse TAAR1 (mTAAR1) and a human-rat chimera (hrChTAAR1)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"AMPH","object":"rTAAR1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The discovery that METH and <e1>CHEMICAL<\\e1> activate the <e2>GENE-Y<\\e2> motivated us to study the effect of these drugs on the mouse TAAR1 (mTAAR1) and a human-rat chimera (hrChTAAR1)","sentence":"The discovery that METH and AMPH activate the rTAAR1 motivated us to study the effect of these drugs on the mouse TAAR1 (mTAAR1) and a human-rat chimera (hrChTAAR1)"}
{"PMID":17218486,"re_id":5,"annotated sentence":"Furthermore, because S-(+)-isomers of <e1>METH<\\e1> and AMPH are reported to be more potent and efficacious in vivo than R-(-), we determined the enantiomeric selectivity of all three species of <e2>TAAR1<\\e2>  In response to METH, AMPH, or POHA exposure, the accumulation of cAMP by HEK-293 cells stably expressing different species of TAAR1 was concentration- and isomer-dependent","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"METH","object":"TAAR1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, because S-(+)-isomers of <e1>CHEMICAL<\\e1> and AMPH are reported to be more potent and efficacious in vivo than R-(-), we determined the enantiomeric selectivity of all three species of <e2>GENE-Y<\\e2>  In response to CHEMICAL, AMPH, or POHA exposure, the accumulation of cAMP by HEK-293 cells stably expressing different species of GENE-Y was concentration- and isomer-dependent","sentence":"Furthermore, because S-(+)-isomers of METH and AMPH are reported to be more potent and efficacious in vivo than R-(-), we determined the enantiomeric selectivity of all three species of TAAR1  In response to METH, AMPH, or POHA exposure, the accumulation of cAMP by HEK-293 cells stably expressing different species of TAAR1 was concentration- and isomer-dependent"}
{"PMID":17218486,"re_id":6,"annotated sentence":"Furthermore, because S-(+)-isomers of METH and <e1>AMPH<\\e1> are reported to be more potent and efficacious in vivo than R-(-), we determined the enantiomeric selectivity of all three species of <e2>TAAR1<\\e2>  In response to METH, AMPH, or POHA exposure, the accumulation of cAMP by HEK-293 cells stably expressing different species of TAAR1 was concentration- and isomer-dependent","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"AMPH","object":"TAAR1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, because S-(+)-isomers of METH and <e1>CHEMICAL<\\e1> are reported to be more potent and efficacious in vivo than R-(-), we determined the enantiomeric selectivity of all three species of <e2>GENE-Y<\\e2>  In response to METH, CHEMICAL, or POHA exposure, the accumulation of cAMP by HEK-293 cells stably expressing different species of GENE-Y was concentration- and isomer-dependent","sentence":"Furthermore, because S-(+)-isomers of METH and AMPH are reported to be more potent and efficacious in vivo than R-(-), we determined the enantiomeric selectivity of all three species of TAAR1  In response to METH, AMPH, or POHA exposure, the accumulation of cAMP by HEK-293 cells stably expressing different species of TAAR1 was concentration- and isomer-dependent"}
{"PMID":17218486,"re_id":7,"annotated sentence":"<e1>PEA<\\e1> was a potent and full agonist at each species of <e2>TAAR1<\\e2>  whereas TYR was a full agonist for the rodent TAAR1s but was a partial agonist at h-rChTAAR1","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"PEA","object":"TAAR1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> was a potent and full agonist at each species of <e2>GENE-Y<\\e2>  whereas TYR was a full agonist for the rodent GENE-Ys but was a partial agonist at h-rChGENE-Y","sentence":"PEA was a potent and full agonist at each species of TAAR1  whereas TYR was a full agonist for the rodent TAAR1s but was a partial agonist at h-rChTAAR1"}
{"PMID":17218486,"re_id":8,"annotated sentence":"PEA was a potent and full agonist at each species of TAAR1, whereas <e1>TYR<\\e1> was a full agonist for the <e2>rodent TAAR1s<\\e2> but was a partial agonist at h-rChTAAR1","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"TYR","object":"rodent TAAR1s","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PEA was a potent and full agonist at each species of TAAR1, whereas <e1>CHEMICAL<\\e1> was a full agonist for the <e2>GENE-Y<\\e2> but was a partial agonist at h-rChTAAR1","sentence":"PEA was a potent and full agonist at each species of TAAR1, whereas TYR was a full agonist for the rodent TAAR1s but was a partial agonist at h-rChTAAR1"}
{"PMID":17218486,"re_id":9,"annotated sentence":"PEA was a potent and full agonist at each species of TAAR1, whereas <e1>TYR<\\e1> was a full agonist for the rodent TAAR1s but was a partial agonist at <e2>h-rChTAAR1<\\e2>  Interestingly, both isomers of METH were full agonists at mTAAR1 and h-rChTAAR1, whereas both were partial agonists at rTAAR1","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"TYR","object":"h-rChTAAR1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PEA was a potent and full agonist at each species of TAAR1, whereas <e1>CHEMICAL<\\e1> was a full agonist for the rodent TAAR1s but was a partial agonist at <e2>GENE-Y<\\e2>  Interestingly, both isomers of METH were full agonists at mTAAR1 and GENE-Y, whereas both were partial agonists at rTAAR1","sentence":"PEA was a potent and full agonist at each species of TAAR1, whereas TYR was a full agonist for the rodent TAAR1s but was a partial agonist at h-rChTAAR1  Interestingly, both isomers of METH were full agonists at mTAAR1 and h-rChTAAR1, whereas both were partial agonists at rTAAR1"}
{"PMID":17218486,"re_id":10,"annotated sentence":"Interestingly, both isomers of <e1>METH<\\e1> were full agonists at <e2>mTAAR1<\\e2> and h-rChTAAR1, whereas both were partial agonists at rTAAR1","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"METH","object":"mTAAR1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, both isomers of <e1>CHEMICAL<\\e1> were full agonists at <e2>GENE-Y<\\e2> and h-rChTAAR1, whereas both were partial agonists at rTAAR1","sentence":"Interestingly, both isomers of METH were full agonists at mTAAR1 and h-rChTAAR1, whereas both were partial agonists at rTAAR1"}
{"PMID":17218486,"re_id":11,"annotated sentence":"Interestingly, both isomers of <e1>METH<\\e1> were full agonists at mTAAR1 and <e2>h-rChTAAR1<\\e2>  whereas both were partial agonists at rTAAR1","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"METH","object":"h-rChTAAR1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, both isomers of <e1>CHEMICAL<\\e1> were full agonists at mTAAR1 and <e2>GENE-Y<\\e2>  whereas both were partial agonists at rTAAR1","sentence":"Interestingly, both isomers of METH were full agonists at mTAAR1 and h-rChTAAR1  whereas both were partial agonists at rTAAR1"}
{"PMID":17218486,"re_id":12,"annotated sentence":"Interestingly, both isomers of <e1>METH<\\e1> were full agonists at mTAAR1 and h-rChTAAR1, whereas both were partial agonists at <e2>rTAAR1<\\e2>  Taken together, these in vitro results suggest that, in vivo, TAAR1 could be a novel mediator of the effects of these drugs.","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"METH","object":"rTAAR1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, both isomers of <e1>CHEMICAL<\\e1> were full agonists at mTAAR1 and h-rChTAAR1, whereas both were partial agonists at <e2>GENE-Y<\\e2>  Taken together, these in vitro results suggest that, in vivo, TAAR1 could be a novel mediator of the effects of these drugs.","sentence":"Interestingly, both isomers of METH were full agonists at mTAAR1 and h-rChTAAR1, whereas both were partial agonists at rTAAR1  Taken together, these in vitro results suggest that, in vivo, TAAR1 could be a novel mediator of the effects of these drugs."}
{"PMID":17221210,"re_id":0,"annotated sentence":"Finally, we showed that <e1>chlorate<\\e1> activated endocrine cell development by inducing <e2>neurogenin 3<\\e2> (Neurog3) expression in early endocrine progenitor cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"chlorate","object":"neurogenin 3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Finally, we showed that <e1>CHEMICAL<\\e1> activated endocrine cell development by inducing <e2>GENE-Y<\\e2> (Neurog3) expression in early endocrine progenitor cells","sentence":"Finally, we showed that chlorate activated endocrine cell development by inducing neurogenin 3 (Neurog3) expression in early endocrine progenitor cells"}
{"PMID":17221210,"re_id":1,"annotated sentence":"Finally, we showed that <e1>chlorate<\\e1> activated endocrine cell development by inducing neurogenin 3 (<e2>Neurog3<\\e2>  expression in early endocrine progenitor cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"chlorate","object":"Neurog3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Finally, we showed that <e1>CHEMICAL<\\e1> activated endocrine cell development by inducing neurogenin 3 (<e2>GENE-Y<\\e2>  expression in early endocrine progenitor cells","sentence":"Finally, we showed that chlorate activated endocrine cell development by inducing neurogenin 3 (Neurog3  expression in early endocrine progenitor cells"}
{"PMID":17228881,"re_id":0,"annotated sentence":"The metallic taste reported as a side effect after the treatment with systemic <e1>sulfonamides<\\e1> may be due to the inhibition of the <e2>salivary CA VI<\\e2>  Some of the compounds investigated in this study might be used as additives in toothpastes for reducing the acidification produced by the relevant CO2 hydrase activity of enamel CA VI, which leads to the formation of protons and bicarbonate and may have a role in cariogenesis.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sulfonamides","object":"salivary CA VI","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The metallic taste reported as a side effect after the treatment with systemic <e1>CHEMICAL<\\e1> may be due to the inhibition of the <e2>GENE-Y<\\e2>  Some of the compounds investigated in this study might be used as additives in toothpastes for reducing the acidification produced by the relevant CO2 hydrase activity of enamel CA VI, which leads to the formation of protons and bicarbonate and may have a role in cariogenesis.","sentence":"The metallic taste reported as a side effect after the treatment with systemic sulfonamides may be due to the inhibition of the salivary CA VI  Some of the compounds investigated in this study might be used as additives in toothpastes for reducing the acidification produced by the relevant CO2 hydrase activity of enamel CA VI, which leads to the formation of protons and bicarbonate and may have a role in cariogenesis."}
{"PMID":17228881,"re_id":1,"annotated sentence":"Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, <e1>dichlorophenamide<\\e1>  dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective <e2>hCA VI<\\e2> inhibitory activity, with inhibition constants of 0.8-79 nM","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dichlorophenamide","object":"hCA VI","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, <e1>CHEMICAL<\\e1>  dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective <e2>GENE-Y<\\e2> inhibitory activity, with inhibition constants of 0.8-79 nM","sentence":"Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide  dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective hCA VI inhibitory activity, with inhibition constants of 0.8-79 nM"}
{"PMID":17228881,"re_id":2,"annotated sentence":"Some clinically used compounds, such as <e1>acetazolamide<\\e1>  methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective <e2>hCA VI<\\e2> inhibitory activity, with inhibition constants of 0.8-79 nM","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acetazolamide","object":"hCA VI","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Some clinically used compounds, such as <e1>CHEMICAL<\\e1>  methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective <e2>GENE-Y<\\e2> inhibitory activity, with inhibition constants of 0.8-79 nM","sentence":"Some clinically used compounds, such as acetazolamide  methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective hCA VI inhibitory activity, with inhibition constants of 0.8-79 nM"}
{"PMID":17228881,"re_id":3,"annotated sentence":"Some clinically used compounds, such as acetazolamide, <e1>methazolamide<\\e1>  ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective <e2>hCA VI<\\e2> inhibitory activity, with inhibition constants of 0.8-79 nM","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"methazolamide","object":"hCA VI","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Some clinically used compounds, such as acetazolamide, <e1>CHEMICAL<\\e1>  ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective <e2>GENE-Y<\\e2> inhibitory activity, with inhibition constants of 0.8-79 nM","sentence":"Some clinically used compounds, such as acetazolamide, methazolamide  ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective hCA VI inhibitory activity, with inhibition constants of 0.8-79 nM"}
{"PMID":17228881,"re_id":4,"annotated sentence":"Some clinically used compounds, such as acetazolamide, methazolamide, <e1>ethoxzolamide<\\e1>  dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective <e2>hCA VI<\\e2> inhibitory activity, with inhibition constants of 0.8-79 nM","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ethoxzolamide","object":"hCA VI","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Some clinically used compounds, such as acetazolamide, methazolamide, <e1>CHEMICAL<\\e1>  dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective <e2>GENE-Y<\\e2> inhibitory activity, with inhibition constants of 0.8-79 nM","sentence":"Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide  dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective hCA VI inhibitory activity, with inhibition constants of 0.8-79 nM"}
{"PMID":17228881,"re_id":5,"annotated sentence":"DNA cloning, characterization, and inhibition studies of the <e2>human secretory isoform VI<\\e2>  a new target for <e1>sulfonamide<\\e1> and sulfamate inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sulfonamide","object":"human secretory isoform VI","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"DNA cloning, characterization, and inhibition studies of the <e2>GENE-Y<\\e2>  a new target for <e1>CHEMICAL<\\e1> and sulfamate inhibitors","sentence":"DNA cloning, characterization, and inhibition studies of the human secretory isoform VI  a new target for sulfonamide and sulfamate inhibitors"}
{"PMID":17228881,"re_id":6,"annotated sentence":"DNA cloning, characterization, and inhibition studies of the <e2>human secretory isoform VI<\\e2>  a new target for sulfonamide and <e1>sulfamate<\\e1> inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sulfamate","object":"human secretory isoform VI","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"DNA cloning, characterization, and inhibition studies of the <e2>GENE-Y<\\e2>  a new target for sulfonamide and <e1>CHEMICAL<\\e1> inhibitors","sentence":"DNA cloning, characterization, and inhibition studies of the human secretory isoform VI  a new target for sulfonamide and sulfamate inhibitors"}
{"PMID":17228881,"re_id":7,"annotated sentence":"Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, <e1>dorzolamide<\\e1>  brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective <e2>hCA VI<\\e2> inhibitory activity, with inhibition constants of 0.8-79 nM","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dorzolamide","object":"hCA VI","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, <e1>CHEMICAL<\\e1>  brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective <e2>GENE-Y<\\e2> inhibitory activity, with inhibition constants of 0.8-79 nM","sentence":"Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide  brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective hCA VI inhibitory activity, with inhibition constants of 0.8-79 nM"}
{"PMID":17228881,"re_id":8,"annotated sentence":"Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, <e1>brinzolamide<\\e1>  topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective <e2>hCA VI<\\e2> inhibitory activity, with inhibition constants of 0.8-79 nM","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"brinzolamide","object":"hCA VI","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, <e1>CHEMICAL<\\e1>  topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective <e2>GENE-Y<\\e2> inhibitory activity, with inhibition constants of 0.8-79 nM","sentence":"Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide  topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective hCA VI inhibitory activity, with inhibition constants of 0.8-79 nM"}
{"PMID":17228881,"re_id":9,"annotated sentence":"Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, <e1>topiramate<\\e1>  sulpiride, and indisulam, or the orphan drug benzolamide, showed effective <e2>hCA VI<\\e2> inhibitory activity, with inhibition constants of 0.8-79 nM","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"topiramate","object":"hCA VI","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, <e1>CHEMICAL<\\e1>  sulpiride, and indisulam, or the orphan drug benzolamide, showed effective <e2>GENE-Y<\\e2> inhibitory activity, with inhibition constants of 0.8-79 nM","sentence":"Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate  sulpiride, and indisulam, or the orphan drug benzolamide, showed effective hCA VI inhibitory activity, with inhibition constants of 0.8-79 nM"}
{"PMID":17228881,"re_id":10,"annotated sentence":"Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, <e1>sulpiride<\\e1>  and indisulam, or the orphan drug benzolamide, showed effective <e2>hCA VI<\\e2> inhibitory activity, with inhibition constants of 0.8-79 nM","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sulpiride","object":"hCA VI","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, <e1>CHEMICAL<\\e1>  and indisulam, or the orphan drug benzolamide, showed effective <e2>GENE-Y<\\e2> inhibitory activity, with inhibition constants of 0.8-79 nM","sentence":"Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride  and indisulam, or the orphan drug benzolamide, showed effective hCA VI inhibitory activity, with inhibition constants of 0.8-79 nM"}
{"PMID":17228881,"re_id":11,"annotated sentence":"Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and <e1>indisulam<\\e1>  or the orphan drug benzolamide, showed effective <e2>hCA VI<\\e2> inhibitory activity, with inhibition constants of 0.8-79 nM","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"indisulam","object":"hCA VI","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and <e1>CHEMICAL<\\e1>  or the orphan drug benzolamide, showed effective <e2>GENE-Y<\\e2> inhibitory activity, with inhibition constants of 0.8-79 nM","sentence":"Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam  or the orphan drug benzolamide, showed effective hCA VI inhibitory activity, with inhibition constants of 0.8-79 nM"}
{"PMID":17228881,"re_id":12,"annotated sentence":"Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug <e1>benzolamide<\\e1>  showed effective <e2>hCA VI<\\e2> inhibitory activity, with inhibition constants of 0.8-79 nM","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"benzolamide","object":"hCA VI","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug <e1>CHEMICAL<\\e1>  showed effective <e2>GENE-Y<\\e2> inhibitory activity, with inhibition constants of 0.8-79 nM","sentence":"Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide  showed effective hCA VI inhibitory activity, with inhibition constants of 0.8-79 nM"}
{"PMID":17228881,"re_id":13,"annotated sentence":"The best inhibitors were <e1>brinzolamide<\\e1> and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a <e2>CA VI<\\e2> selective inhibitor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"brinzolamide","object":"CA VI","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The best inhibitors were <e1>CHEMICAL<\\e1> and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a <e2>GENE-Y<\\e2> selective inhibitor","sentence":"The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a CA VI selective inhibitor"}
{"PMID":17228881,"re_id":14,"annotated sentence":"The best inhibitors were brinzolamide and <e1>sulpiride<\\e1> (KI values of 0.8-0.9 nM), the latter compound being also a <e2>CA VI<\\e2> selective inhibitor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sulpiride","object":"CA VI","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The best inhibitors were brinzolamide and <e1>CHEMICAL<\\e1> (KI values of 0.8-0.9 nM), the latter compound being also a <e2>GENE-Y<\\e2> selective inhibitor","sentence":"The best inhibitors were brinzolamide and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a CA VI selective inhibitor"}
{"PMID":17228881,"re_id":15,"annotated sentence":"Some of the compounds investigated in this study might be used as additives in toothpastes for reducing the acidification produced by the relevant <e1>CO2<\\e1> hydrase activity of enamel <e2>CA VI<\\e2>  which leads to the formation of protons and bicarbonate and may have a role in cariogenesis.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"CO2","object":"CA VI","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Some of the compounds investigated in this study might be used as additives in toothpastes for reducing the acidification produced by the relevant <e1>CHEMICAL<\\e1> hydrase activity of enamel <e2>GENE-Y<\\e2>  which leads to the formation of protons and bicarbonate and may have a role in cariogenesis.","sentence":"Some of the compounds investigated in this study might be used as additives in toothpastes for reducing the acidification produced by the relevant CO2 hydrase activity of enamel CA VI  which leads to the formation of protons and bicarbonate and may have a role in cariogenesis."}
{"PMID":17228881,"re_id":16,"annotated sentence":"Some of the compounds investigated in this study might be used as additives in toothpastes for reducing the acidification produced by the relevant CO2 hydrase activity of enamel <e2>CA VI<\\e2>  which leads to the formation of protons and <e1>bicarbonate<\\e1> and may have a role in cariogenesis.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"bicarbonate","object":"CA VI","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Some of the compounds investigated in this study might be used as additives in toothpastes for reducing the acidification produced by the relevant CO2 hydrase activity of enamel <e2>GENE-Y<\\e2>  which leads to the formation of protons and <e1>CHEMICAL<\\e1> and may have a role in cariogenesis.","sentence":"Some of the compounds investigated in this study might be used as additives in toothpastes for reducing the acidification produced by the relevant CO2 hydrase activity of enamel CA VI  which leads to the formation of protons and bicarbonate and may have a role in cariogenesis."}
{"PMID":17228881,"re_id":17,"annotated sentence":"The kinetic parameters for the <e1>CO2<\\e1> hydration reaction proved <e2>hCA VI<\\e2> to possess a kcat of 3.4 x 10(5) s-1 and kcat\/KM of 4.9 x 10(7) M-1 s-1 (at pH 7.5 and 20 degrees C)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"CO2","object":"hCA VI","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The kinetic parameters for the <e1>CHEMICAL<\\e1> hydration reaction proved <e2>GENE-Y<\\e2> to possess a kcat of 3.4 x 10(5) s-1 and kcat\/KM of 4.9 x 10(7) M-1 s-1 (at pH 7.5 and 20 degrees C)","sentence":"The kinetic parameters for the CO2 hydration reaction proved hCA VI to possess a kcat of 3.4 x 10(5) s-1 and kcat\/KM of 4.9 x 10(7) M-1 s-1 (at pH 7.5 and 20 degrees C)"}
{"PMID":17229090,"re_id":0,"annotated sentence":"Transmembrane isoforms of <e2>adenylate cyclases<\\e2> (AC) integrate a wide variety of extracellular signals from neurotransmitters to morphogens and can also regulate <e1>cAMP<\\e1> production in response to calcium entry","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cAMP","object":"adenylate cyclases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Transmembrane isoforms of <e2>GENE-N<\\e2> (AC) integrate a wide variety of extracellular signals from neurotransmitters to morphogens and can also regulate <e1>CHEMICAL<\\e1> production in response to calcium entry","sentence":"Transmembrane isoforms of adenylate cyclases (AC) integrate a wide variety of extracellular signals from neurotransmitters to morphogens and can also regulate cAMP production in response to calcium entry"}
{"PMID":17229090,"re_id":1,"annotated sentence":"Transmembrane isoforms of adenylate cyclases (<e2>AC<\\e2>  integrate a wide variety of extracellular signals from neurotransmitters to morphogens and can also regulate <e1>cAMP<\\e1> production in response to calcium entry","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cAMP","object":"AC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Transmembrane isoforms of adenylate cyclases (<e2>GENE-N<\\e2>  integrate a wide variety of extracellular signals from neurotransmitters to morphogens and can also regulate <e1>CHEMICAL<\\e1> production in response to calcium entry","sentence":"Transmembrane isoforms of adenylate cyclases (AC  integrate a wide variety of extracellular signals from neurotransmitters to morphogens and can also regulate cAMP production in response to calcium entry"}
{"PMID":17234158,"re_id":0,"annotated sentence":"Here, we report that the antifibrotic drug <e1>5-methyl-1-phenyl-2-(1H)-pyridone<\\e1> (pirfenidone, PFD) elicits growth-inhibitory effects and reduces <e2>TGF-beta2<\\e2> protein levels in human glioma cell lines","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-methyl-1-phenyl-2-(1H)-pyridone","object":"TGF-beta2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we report that the antifibrotic drug <e1>CHEMICAL<\\e1> (pirfenidone, PFD) elicits growth-inhibitory effects and reduces <e2>GENE-Y<\\e2> protein levels in human glioma cell lines","sentence":"Here, we report that the antifibrotic drug 5-methyl-1-phenyl-2-(1H)-pyridone (pirfenidone, PFD) elicits growth-inhibitory effects and reduces TGF-beta2 protein levels in human glioma cell lines"}
{"PMID":17234158,"re_id":1,"annotated sentence":"Here, we report that the antifibrotic drug 5-methyl-1-phenyl-2-(1H)-pyridone (<e1>pirfenidone<\\e1>  PFD) elicits growth-inhibitory effects and reduces <e2>TGF-beta2<\\e2> protein levels in human glioma cell lines","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pirfenidone","object":"TGF-beta2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we report that the antifibrotic drug 5-methyl-1-phenyl-2-(1H)-pyridone (<e1>CHEMICAL<\\e1>  PFD) elicits growth-inhibitory effects and reduces <e2>GENE-Y<\\e2> protein levels in human glioma cell lines","sentence":"Here, we report that the antifibrotic drug 5-methyl-1-phenyl-2-(1H)-pyridone (pirfenidone  PFD) elicits growth-inhibitory effects and reduces TGF-beta2 protein levels in human glioma cell lines"}
{"PMID":17234158,"re_id":2,"annotated sentence":"Here, we report that the antifibrotic drug 5-methyl-1-phenyl-2-(1H)-pyridone (pirfenidone, <e1>PFD<\\e1>  elicits growth-inhibitory effects and reduces <e2>TGF-beta2<\\e2> protein levels in human glioma cell lines","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PFD","object":"TGF-beta2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we report that the antifibrotic drug 5-methyl-1-phenyl-2-(1H)-pyridone (pirfenidone, <e1>CHEMICAL<\\e1>  elicits growth-inhibitory effects and reduces <e2>GENE-Y<\\e2> protein levels in human glioma cell lines","sentence":"Here, we report that the antifibrotic drug 5-methyl-1-phenyl-2-(1H)-pyridone (pirfenidone, PFD  elicits growth-inhibitory effects and reduces TGF-beta2 protein levels in human glioma cell lines"}
{"PMID":17234158,"re_id":3,"annotated sentence":"This reduction in <e2>TGF-beta2<\\e2> is biologically relevant since <e1>PFD<\\e1> treatment reduces the growth inhibition of TGF-beta-sensitive CCL-64 cells mediated by conditioned media of glioma cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PFD","object":"TGF-beta2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This reduction in <e2>GENE-Y<\\e2> is biologically relevant since <e1>CHEMICAL<\\e1> treatment reduces the growth inhibition of TGF-beta-sensitive CCL-64 cells mediated by conditioned media of glioma cells","sentence":"This reduction in TGF-beta2 is biologically relevant since PFD treatment reduces the growth inhibition of TGF-beta-sensitive CCL-64 cells mediated by conditioned media of glioma cells"}
{"PMID":17234158,"re_id":4,"annotated sentence":"This reduction in TGF-beta2 is biologically relevant since <e1>PFD<\\e1> treatment reduces the growth inhibition of <e2>TGF-beta<\\e2> sensitive CCL-64 cells mediated by conditioned media of glioma cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PFD","object":"TGF-beta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This reduction in GENE-Y2 is biologically relevant since <e1>CHEMICAL<\\e1> treatment reduces the growth inhibition of <e2>GENE-Y<\\e2> sensitive CCL-64 cells mediated by conditioned media of glioma cells","sentence":"This reduction in TGF-beta2 is biologically relevant since PFD treatment reduces the growth inhibition of TGF-beta sensitive CCL-64 cells mediated by conditioned media of glioma cells"}
{"PMID":17234158,"re_id":5,"annotated sentence":"<e1>PFD<\\e1> leads to a reduction of <e2>TGF-beta2<\\e2> mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase furin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PFD","object":"TGF-beta2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> leads to a reduction of <e2>GENE-Y<\\e2> mRNA levels and of the mature GENE-Y protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase furin","sentence":"PFD leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase furin"}
{"PMID":17234158,"re_id":6,"annotated sentence":"<e1>PFD<\\e1> leads to a reduction of TGF-beta2 mRNA levels and of the mature <e2>TGF-beta2<\\e2> protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase furin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PFD","object":"TGF-beta2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> leads to a reduction of GENE-Y mRNA levels and of the mature <e2>GENE-Y<\\e2> protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase furin","sentence":"PFD leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase furin"}
{"PMID":17234158,"re_id":7,"annotated sentence":"<e1>PFD<\\e1> leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the <e2>TGF-beta<\\e2> pro-protein convertase furin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PFD","object":"TGF-beta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> leads to a reduction of GENE-Y2 mRNA levels and of the mature GENE-Y2 protein due to decreased expression and direct inhibition of the <e2>GENE-Y<\\e2> pro-protein convertase furin","sentence":"PFD leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase furin"}
{"PMID":17234158,"re_id":8,"annotated sentence":"<e1>PFD<\\e1> leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta <e2>pro-protein convertase<\\e2> furin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PFD","object":"pro-protein convertase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta <e2>GENE-N<\\e2> furin","sentence":"PFD leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase furin"}
{"PMID":17234158,"re_id":9,"annotated sentence":"<e1>PFD<\\e1> leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase <e2>furin<\\e2>  In addition, PFD reduces the protein levels of the matrix metalloproteinase (MMP)-11, a TGF-beta target gene and furin substrate involved in carcinogenesis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PFD","object":"furin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase <e2>GENE-Y<\\e2>  In addition, CHEMICAL reduces the protein levels of the matrix metalloproteinase (MMP)-11, a TGF-beta target gene and GENE-Y substrate involved in carcinogenesis","sentence":"PFD leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase furin  In addition, PFD reduces the protein levels of the matrix metalloproteinase (MMP)-11, a TGF-beta target gene and furin substrate involved in carcinogenesis"}
{"PMID":17234158,"re_id":10,"annotated sentence":"In addition, <e1>PFD<\\e1> reduces the protein levels of the <e2>matrix metalloproteinase (MMP)-11<\\e2>  a TGF-beta target gene and furin substrate involved in carcinogenesis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PFD","object":"matrix metalloproteinase (MMP)-11","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e1>CHEMICAL<\\e1> reduces the protein levels of the <e2>GENE-Y<\\e2>  a TGF-beta target gene and furin substrate involved in carcinogenesis","sentence":"In addition, PFD reduces the protein levels of the matrix metalloproteinase (MMP)-11  a TGF-beta target gene and furin substrate involved in carcinogenesis"}
{"PMID":17234158,"re_id":11,"annotated sentence":"In addition, <e1>PFD<\\e1> reduces the protein levels of the matrix metalloproteinase (MMP)-11, a <e2>TGF-beta<\\e2> target gene and furin substrate involved in carcinogenesis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PFD","object":"TGF-beta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e1>CHEMICAL<\\e1> reduces the protein levels of the matrix metalloproteinase (MMP)-11, a <e2>GENE-Y<\\e2> target gene and furin substrate involved in carcinogenesis","sentence":"In addition, PFD reduces the protein levels of the matrix metalloproteinase (MMP)-11, a TGF-beta target gene and furin substrate involved in carcinogenesis"}
{"PMID":17234158,"re_id":12,"annotated sentence":"<e1>Pirfenidone<\\e1> inhibits <e2>TGF-beta<\\e2> expression in malignant glioma cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pirfenidone","object":"TGF-beta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits <e2>GENE-Y<\\e2> expression in malignant glioma cells","sentence":"Pirfenidone inhibits TGF-beta expression in malignant glioma cells"}
{"PMID":17256745,"re_id":0,"annotated sentence":"UNLABELLED: <e2>Bile acid-coenzyme A:amino acid N-acyltransferase<\\e2> (BAAT) is the sole enzyme responsible for conjugation of primary and secondary <e1>bile acids<\\e1> to taurine and glycine","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"bile acids","object":"Bile acid-coenzyme A:amino acid N-acyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"UNLABELLED: <e2>GENE-Y<\\e2> (BAAT) is the sole enzyme responsible for conjugation of primary and secondary <e1>CHEMICAL<\\e1> to taurine and glycine","sentence":"UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase (BAAT) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and glycine"}
{"PMID":17256745,"re_id":1,"annotated sentence":"UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase (<e2>BAAT<\\e2>  is the sole enzyme responsible for conjugation of primary and secondary <e1>bile acids<\\e1> to taurine and glycine","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"bile acids","object":"BAAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase (<e2>GENE-Y<\\e2>  is the sole enzyme responsible for conjugation of primary and secondary <e1>CHEMICAL<\\e1> to taurine and glycine","sentence":"UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase (BAAT  is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and glycine"}
{"PMID":17256745,"re_id":2,"annotated sentence":"UNLABELLED: <e2>Bile acid-coenzyme A:amino acid N-acyltransferase<\\e2> (BAAT) is the sole enzyme responsible for conjugation of primary and secondary bile acids to <e1>taurine<\\e1> and glycine","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"taurine","object":"Bile acid-coenzyme A:amino acid N-acyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"UNLABELLED: <e2>GENE-Y<\\e2> (BAAT) is the sole enzyme responsible for conjugation of primary and secondary bile acids to <e1>CHEMICAL<\\e1> and glycine","sentence":"UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase (BAAT) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and glycine"}
{"PMID":17256745,"re_id":3,"annotated sentence":"UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase (<e2>BAAT<\\e2>  is the sole enzyme responsible for conjugation of primary and secondary bile acids to <e1>taurine<\\e1> and glycine","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"taurine","object":"BAAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase (<e2>GENE-Y<\\e2>  is the sole enzyme responsible for conjugation of primary and secondary bile acids to <e1>CHEMICAL<\\e1> and glycine","sentence":"UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase (BAAT  is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and glycine"}
{"PMID":17256745,"re_id":4,"annotated sentence":"UNLABELLED: <e2>Bile acid-coenzyme A:amino acid N-acyltransferase<\\e2> (BAAT) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and <e1>glycine<\\e1>  Previous studies indicate a peroxisomal location of BAAT in peroxisomes with variable amounts up to 95% detected in cytosolic fractions","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glycine","object":"Bile acid-coenzyme A:amino acid N-acyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"UNLABELLED: <e2>GENE-Y<\\e2> (BAAT) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and <e1>CHEMICAL<\\e1>  Previous studies indicate a peroxisomal location of BAAT in peroxisomes with variable amounts up to 95% detected in cytosolic fractions","sentence":"UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase (BAAT) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and glycine  Previous studies indicate a peroxisomal location of BAAT in peroxisomes with variable amounts up to 95% detected in cytosolic fractions"}
{"PMID":17256745,"re_id":5,"annotated sentence":"UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase (<e2>BAAT<\\e2>  is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and <e1>glycine<\\e1>  Previous studies indicate a peroxisomal location of BAAT in peroxisomes with variable amounts up to 95% detected in cytosolic fractions","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glycine","object":"BAAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase (<e2>GENE-Y<\\e2>  is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and <e1>CHEMICAL<\\e1>  Previous studies indicate a peroxisomal location of GENE-Y in peroxisomes with variable amounts up to 95% detected in cytosolic fractions","sentence":"UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase (BAAT  is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and glycine  Previous studies indicate a peroxisomal location of BAAT in peroxisomes with variable amounts up to 95% detected in cytosolic fractions"}
{"PMID":17256745,"re_id":6,"annotated sentence":"The absence or presence of a cytosolic pool of <e2>BAAT<\\e2> has important implications for the intracellular transport of unconjugated\/deconjugated <e1>bile salts<\\e1>  We used immunofluorescence microscopy and digitonin permeabilization assays to determine the subcellular location of endogenous BAAT in primary human and rat hepatocytes","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"bile salts","object":"BAAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The absence or presence of a cytosolic pool of <e2>GENE-Y<\\e2> has important implications for the intracellular transport of unconjugated\/deconjugated <e1>CHEMICAL<\\e1>  We used immunofluorescence microscopy and digitonin permeabilization assays to determine the subcellular location of endogenous GENE-Y in primary human and rat hepatocytes","sentence":"The absence or presence of a cytosolic pool of BAAT has important implications for the intracellular transport of unconjugated\/deconjugated bile salts  We used immunofluorescence microscopy and digitonin permeabilization assays to determine the subcellular location of endogenous BAAT in primary human and rat hepatocytes"}
{"PMID":17290783,"re_id":0,"annotated sentence":"The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the <e2>riboflavin kinase<\\e2>  enzyme that converts <e1>riboflavin<\\e1> to flavinmononucleotide) driven by the strong promoters (the regulated RIB1 or constitutive TEF1 promoter) were isolated","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"riboflavin","object":"riboflavin kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the <e2>CHEMICAL kinase<\\e2>  enzyme that converts <e1>CHEMICAL<\\e1> to flavinmononucleotide) driven by the strong promoters (the regulated RIB1 or constitutive TEF1 promoter) were isolated","sentence":"The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the riboflavin kinase  enzyme that converts riboflavin to flavinmononucleotide) driven by the strong promoters (the regulated RIB1 or constitutive TEF1 promoter) were isolated"}
{"PMID":17290783,"re_id":1,"annotated sentence":"The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the <e2>riboflavin kinase<\\e2>  enzyme that converts riboflavin to <e1>flavinmononucleotide<\\e1>  driven by the strong promoters (the regulated RIB1 or constitutive TEF1 promoter) were isolated","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"flavinmononucleotide","object":"riboflavin kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the <e2>GENE-N<\\e2>  enzyme that converts riboflavin to <e1>CHEMICAL<\\e1>  driven by the strong promoters (the regulated RIB1 or constitutive TEF1 promoter) were isolated","sentence":"The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the riboflavin kinase  enzyme that converts riboflavin to flavinmononucleotide  driven by the strong promoters (the regulated RIB1 or constitutive TEF1 promoter) were isolated"}
{"PMID":1730582,"re_id":0,"annotated sentence":"<e2>Mouse ornithine decarboxylase<\\e2> (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, <e1>alpha-difluoromethylornithine<\\e1> (DFMO)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"alpha-difluoromethylornithine","object":"Mouse ornithine decarboxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, <e1>CHEMICAL<\\e1> (DFMO)","sentence":"Mouse ornithine decarboxylase (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (DFMO)"}
{"PMID":1730582,"re_id":1,"annotated sentence":"Mouse ornithine decarboxylase (<e2>ODC<\\e2>  was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, <e1>alpha-difluoromethylornithine<\\e1> (DFMO)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"alpha-difluoromethylornithine","object":"ODC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Mouse ornithine decarboxylase (<e2>GENE-Y<\\e2>  was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, <e1>CHEMICAL<\\e1> (DFMO)","sentence":"Mouse ornithine decarboxylase (ODC  was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (DFMO)"}
{"PMID":1730582,"re_id":2,"annotated sentence":"<e2>Mouse ornithine decarboxylase<\\e2> (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (<e1>DFMO<\\e1> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DFMO","object":"Mouse ornithine decarboxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (<e1>CHEMICAL<\\e1> ","sentence":"Mouse ornithine decarboxylase (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (DFMO "}
{"PMID":1730582,"re_id":3,"annotated sentence":"Mouse ornithine decarboxylase (<e2>ODC<\\e2>  was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (<e1>DFMO<\\e1> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DFMO","object":"ODC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Mouse ornithine decarboxylase (<e2>GENE-Y<\\e2>  was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (<e1>CHEMICAL<\\e1> ","sentence":"Mouse ornithine decarboxylase (ODC  was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (DFMO "}
{"PMID":1730582,"re_id":4,"annotated sentence":"Mechanism of the irreversible inactivation of <e2>mouse ornithine decarboxylase<\\e2> by <e1>alpha-difluoromethylornithine<\\e1>  Characterization of sequences at the inhibitor and coenzyme binding sites","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"alpha-difluoromethylornithine","object":"mouse ornithine decarboxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Mechanism of the irreversible inactivation of <e2>GENE-Y<\\e2> by <e1>CHEMICAL<\\e1>  Characterization of sequences at the inhibitor and coenzyme binding sites","sentence":"Mechanism of the irreversible inactivation of mouse ornithine decarboxylase by alpha-difluoromethylornithine  Characterization of sequences at the inhibitor and coenzyme binding sites"}
{"PMID":17311416,"re_id":0,"annotated sentence":"Here, we describe a new photolabile <e1>alanine<\\e1> derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by <e2>ASCT2<\\e2>  SNAT1, and SNAT2","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alanine","object":"ASCT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we describe a new photolabile <e1>CHEMICAL<\\e1> derivative based on protection of CHEMICAL with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of CHEMICAL transport by <e2>GENE-Y<\\e2>  SNAT1, and SNAT2","sentence":"Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2  SNAT1, and SNAT2"}
{"PMID":17311416,"re_id":1,"annotated sentence":"Here, we describe a new photolabile <e1>alanine<\\e1> derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, <e2>SNAT1<\\e2>  and SNAT2","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alanine","object":"SNAT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we describe a new photolabile <e1>CHEMICAL<\\e1> derivative based on protection of CHEMICAL with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of CHEMICAL transport by ASCT2, <e2>GENE-Y<\\e2>  and SNAT2","sentence":"Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1  and SNAT2"}
{"PMID":17311416,"re_id":2,"annotated sentence":"Here, we describe a new photolabile <e1>alanine<\\e1> derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1, and <e2>SNAT2<\\e2>  MNI-alanine has favorable photochemical properties and is stable in aqueous solution","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alanine","object":"SNAT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we describe a new photolabile <e1>CHEMICAL<\\e1> derivative based on protection of CHEMICAL with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of CHEMICAL transport by ASCT2, SNAT1, and <e2>GENE-Y<\\e2>  MNI-CHEMICAL has favorable photochemical properties and is stable in aqueous solution","sentence":"Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1, and SNAT2  MNI-alanine has favorable photochemical properties and is stable in aqueous solution"}
{"PMID":17311416,"re_id":3,"annotated sentence":"Here, we describe a new photolabile alanine derivative based on protection of <e1>alanine<\\e1> with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by <e2>ASCT2<\\e2>  SNAT1, and SNAT2","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alanine","object":"ASCT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we describe a new photolabile CHEMICAL derivative based on protection of <e1>CHEMICAL<\\e1> with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of CHEMICAL transport by <e2>GENE-Y<\\e2>  SNAT1, and SNAT2","sentence":"Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2  SNAT1, and SNAT2"}
{"PMID":17311416,"re_id":4,"annotated sentence":"Here, we describe a new photolabile alanine derivative based on protection of <e1>alanine<\\e1> with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, <e2>SNAT1<\\e2>  and SNAT2","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alanine","object":"SNAT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we describe a new photolabile CHEMICAL derivative based on protection of <e1>CHEMICAL<\\e1> with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of CHEMICAL transport by ASCT2, <e2>GENE-Y<\\e2>  and SNAT2","sentence":"Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1  and SNAT2"}
{"PMID":17311416,"re_id":5,"annotated sentence":"Here, we describe a new photolabile alanine derivative based on protection of <e1>alanine<\\e1> with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1, and <e2>SNAT2<\\e2>  MNI-alanine has favorable photochemical properties and is stable in aqueous solution","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alanine","object":"SNAT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we describe a new photolabile CHEMICAL derivative based on protection of <e1>CHEMICAL<\\e1> with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of CHEMICAL transport by ASCT2, SNAT1, and <e2>GENE-Y<\\e2>  MNI-CHEMICAL has favorable photochemical properties and is stable in aqueous solution","sentence":"Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1, and SNAT2  MNI-alanine has favorable photochemical properties and is stable in aqueous solution"}
{"PMID":17311416,"re_id":6,"annotated sentence":"Here, we describe a new photolabile alanine derivative based on protection of alanine with the <e1>4-methoxy-7-nitroindolinyl<\\e1> (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by <e2>ASCT2<\\e2>  SNAT1, and SNAT2","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"4-methoxy-7-nitroindolinyl","object":"ASCT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we describe a new photolabile alanine derivative based on protection of alanine with the <e1>CHEMICAL<\\e1> (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by <e2>GENE-Y<\\e2>  SNAT1, and SNAT2","sentence":"Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2  SNAT1, and SNAT2"}
{"PMID":17311416,"re_id":7,"annotated sentence":"Here, we describe a new photolabile alanine derivative based on protection of alanine with the <e1>4-methoxy-7-nitroindolinyl<\\e1> (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, <e2>SNAT1<\\e2>  and SNAT2","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"4-methoxy-7-nitroindolinyl","object":"SNAT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we describe a new photolabile alanine derivative based on protection of alanine with the <e1>CHEMICAL<\\e1> (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, <e2>GENE-Y<\\e2>  and SNAT2","sentence":"Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1  and SNAT2"}
{"PMID":17311416,"re_id":8,"annotated sentence":"Here, we describe a new photolabile alanine derivative based on protection of alanine with the <e1>4-methoxy-7-nitroindolinyl<\\e1> (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1, and <e2>SNAT2<\\e2>  MNI-alanine has favorable photochemical properties and is stable in aqueous solution","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"4-methoxy-7-nitroindolinyl","object":"SNAT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we describe a new photolabile alanine derivative based on protection of alanine with the <e1>CHEMICAL<\\e1> (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1, and <e2>GENE-Y<\\e2>  MNI-alanine has favorable photochemical properties and is stable in aqueous solution","sentence":"Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1, and SNAT2  MNI-alanine has favorable photochemical properties and is stable in aqueous solution"}
{"PMID":17311416,"re_id":9,"annotated sentence":"Na+-Dependent transmembrane transport of small neutral <e1>amino acids<\\e1>  such as glutamine and alanine, is mediated, among others, by the <e2>neutral amino acid transporters<\\e2> of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"amino acids","object":"neutral amino acid transporters","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Na+-Dependent transmembrane transport of small neutral <e1>CHEMICAL<\\e1>  such as glutamine and alanine, is mediated, among others, by the <e2>GENE-N<\\e2> of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","sentence":"Na+-Dependent transmembrane transport of small neutral amino acids  such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]"}
{"PMID":17311416,"re_id":10,"annotated sentence":"Na+-Dependent transmembrane transport of small neutral <e1>amino acids<\\e1>  such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the <e2>solute carrier 1<\\e2> [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"amino acids","object":"solute carrier 1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Na+-Dependent transmembrane transport of small neutral <e1>CHEMICAL<\\e1>  such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the <e2>GENE-N<\\e2> [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","sentence":"Na+-Dependent transmembrane transport of small neutral amino acids  such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]"}
{"PMID":17311416,"re_id":11,"annotated sentence":"Na+-Dependent transmembrane transport of small neutral <e1>amino acids<\\e1>  such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [<e2>SLC1<\\e2>  alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"amino acids","object":"SLC1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Na+-Dependent transmembrane transport of small neutral <e1>CHEMICAL<\\e1>  such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [<e2>GENE-N<\\e2>  alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","sentence":"Na+-Dependent transmembrane transport of small neutral amino acids  such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1  alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]"}
{"PMID":17311416,"re_id":12,"annotated sentence":"Na+-Dependent transmembrane transport of small neutral <e1>amino acids<\\e1>  such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, <e2>alanine serine cysteine transporter 1<\\e2> (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"amino acids","object":"alanine serine cysteine transporter 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Na+-Dependent transmembrane transport of small neutral <e1>CHEMICAL<\\e1>  such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, <e2>GENE-Y<\\e2> (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","sentence":"Na+-Dependent transmembrane transport of small neutral amino acids  such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]"}
{"PMID":17311416,"re_id":13,"annotated sentence":"Na+-Dependent transmembrane transport of small neutral <e1>amino acids<\\e1>  such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (<e2>ASCT1<\\e2> , and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"amino acids","object":"ASCT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Na+-Dependent transmembrane transport of small neutral <e1>CHEMICAL<\\e1>  such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (<e2>GENE-Y<\\e2> , and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","sentence":"Na+-Dependent transmembrane transport of small neutral amino acids  such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1 , and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]"}
{"PMID":17311416,"re_id":14,"annotated sentence":"Na+-Dependent transmembrane transport of small neutral <e1>amino acids<\\e1>  such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and <e2>ASCT2<\\e2>  and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"amino acids","object":"ASCT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Na+-Dependent transmembrane transport of small neutral <e1>CHEMICAL<\\e1>  such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and <e2>GENE-Y<\\e2>  and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","sentence":"Na+-Dependent transmembrane transport of small neutral amino acids  such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2  and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]"}
{"PMID":17311416,"re_id":15,"annotated sentence":"Na+-Dependent transmembrane transport of small neutral <e1>amino acids<\\e1>  such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and <e2>SLC38<\\e2> families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"amino acids","object":"SLC38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Na+-Dependent transmembrane transport of small neutral <e1>CHEMICAL<\\e1>  such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and <e2>GENE-N<\\e2> families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","sentence":"Na+-Dependent transmembrane transport of small neutral amino acids  such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]"}
{"PMID":17311416,"re_id":16,"annotated sentence":"Na+-Dependent transmembrane transport of small neutral <e1>amino acids<\\e1>  such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [<e2>sodium-coupled neutral amino acid transporter 1<\\e2> (SNAT1), SNAT2, and SNAT4]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"amino acids","object":"sodium-coupled neutral amino acid transporter 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Na+-Dependent transmembrane transport of small neutral <e1>CHEMICAL<\\e1>  such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [<e2>GENE-Y<\\e2> (SNAT1), SNAT2, and SNAT4]","sentence":"Na+-Dependent transmembrane transport of small neutral amino acids  such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]"}
{"PMID":17311416,"re_id":17,"annotated sentence":"Na+-Dependent transmembrane transport of small neutral <e1>amino acids<\\e1>  such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (<e2>SNAT1<\\e2> , SNAT2, and SNAT4]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"amino acids","object":"SNAT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Na+-Dependent transmembrane transport of small neutral <e1>CHEMICAL<\\e1>  such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (<e2>GENE-Y<\\e2> , SNAT2, and SNAT4]","sentence":"Na+-Dependent transmembrane transport of small neutral amino acids  such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1 , SNAT2, and SNAT4]"}
{"PMID":17311416,"re_id":18,"annotated sentence":"Na+-Dependent transmembrane transport of small neutral <e1>amino acids<\\e1>  such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), <e2>SNAT2<\\e2>  and SNAT4]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"amino acids","object":"SNAT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Na+-Dependent transmembrane transport of small neutral <e1>CHEMICAL<\\e1>  such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), <e2>GENE-Y<\\e2>  and SNAT4]","sentence":"Na+-Dependent transmembrane transport of small neutral amino acids  such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2  and SNAT4]"}
{"PMID":17311416,"re_id":19,"annotated sentence":"Na+-Dependent transmembrane transport of small neutral <e1>amino acids<\\e1>  such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and <e2>SNAT4<\\e2> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"amino acids","object":"SNAT4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Na+-Dependent transmembrane transport of small neutral <e1>CHEMICAL<\\e1>  such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and <e2>GENE-Y<\\e2> ","sentence":"Na+-Dependent transmembrane transport of small neutral amino acids  such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4 "}
{"PMID":17311416,"re_id":20,"annotated sentence":"Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (<e1>MNI<\\e1>  caging group, which we use for pre-steady-state kinetic analysis of alanine transport by <e2>ASCT2<\\e2>  SNAT1, and SNAT2","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"MNI","object":"ASCT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (<e1>CHEMICAL<\\e1>  caging group, which we use for pre-steady-state kinetic analysis of alanine transport by <e2>GENE-Y<\\e2>  SNAT1, and SNAT2","sentence":"Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (MNI  caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2  SNAT1, and SNAT2"}
{"PMID":17311416,"re_id":21,"annotated sentence":"Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (<e1>MNI<\\e1>  caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, <e2>SNAT1<\\e2>  and SNAT2","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"MNI","object":"SNAT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (<e1>CHEMICAL<\\e1>  caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, <e2>GENE-Y<\\e2>  and SNAT2","sentence":"Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (MNI  caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1  and SNAT2"}
{"PMID":17311416,"re_id":22,"annotated sentence":"Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (<e1>MNI<\\e1>  caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1, and <e2>SNAT2<\\e2>  MNI-alanine has favorable photochemical properties and is stable in aqueous solution","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"MNI","object":"SNAT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (<e1>CHEMICAL<\\e1>  caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1, and <e2>GENE-Y<\\e2>  CHEMICAL-alanine has favorable photochemical properties and is stable in aqueous solution","sentence":"Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (MNI  caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1, and SNAT2  MNI-alanine has favorable photochemical properties and is stable in aqueous solution"}
{"PMID":17311416,"re_id":23,"annotated sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as <e1>glutamine<\\e1> and alanine, is mediated, among others, by the <e2>neutral amino acid transporters<\\e2> of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutamine","object":"neutral amino acid transporters","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as <e1>CHEMICAL<\\e1> and alanine, is mediated, among others, by the <e2>GENE-N<\\e2> of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]"}
{"PMID":17311416,"re_id":24,"annotated sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as <e1>glutamine<\\e1> and alanine, is mediated, among others, by the neutral amino acid transporters of the <e2>solute carrier 1<\\e2> [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutamine","object":"solute carrier 1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as <e1>CHEMICAL<\\e1> and alanine, is mediated, among others, by the neutral amino acid transporters of the <e2>GENE-N<\\e2> [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]"}
{"PMID":17311416,"re_id":25,"annotated sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as <e1>glutamine<\\e1> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [<e2>SLC1<\\e2>  alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutamine","object":"SLC1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as <e1>CHEMICAL<\\e1> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [<e2>GENE-N<\\e2>  alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1  alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]"}
{"PMID":17311416,"re_id":26,"annotated sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as <e1>glutamine<\\e1> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, <e2>alanine serine cysteine transporter 1<\\e2> (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutamine","object":"alanine serine cysteine transporter 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as <e1>CHEMICAL<\\e1> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, <e2>GENE-Y<\\e2> (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]"}
{"PMID":17311416,"re_id":27,"annotated sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as <e1>glutamine<\\e1> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (<e2>ASCT1<\\e2> , and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutamine","object":"ASCT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as <e1>CHEMICAL<\\e1> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (<e2>GENE-Y<\\e2> , and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1 , and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]"}
{"PMID":17311416,"re_id":28,"annotated sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as <e1>glutamine<\\e1> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and <e2>ASCT2<\\e2>  and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutamine","object":"ASCT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as <e1>CHEMICAL<\\e1> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and <e2>GENE-Y<\\e2>  and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2  and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]"}
{"PMID":17311416,"re_id":29,"annotated sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as <e1>glutamine<\\e1> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and <e2>SLC38<\\e2> families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutamine","object":"SLC38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as <e1>CHEMICAL<\\e1> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and <e2>GENE-N<\\e2> families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]"}
{"PMID":17311416,"re_id":30,"annotated sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as <e1>glutamine<\\e1> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [<e2>sodium-coupled neutral amino acid transporter 1<\\e2> (SNAT1), SNAT2, and SNAT4]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutamine","object":"sodium-coupled neutral amino acid transporter 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as <e1>CHEMICAL<\\e1> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [<e2>GENE-Y<\\e2> (SNAT1), SNAT2, and SNAT4]","sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]"}
{"PMID":17311416,"re_id":31,"annotated sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as <e1>glutamine<\\e1> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (<e2>SNAT1<\\e2> , SNAT2, and SNAT4]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutamine","object":"SNAT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as <e1>CHEMICAL<\\e1> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (<e2>GENE-Y<\\e2> , SNAT2, and SNAT4]","sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1 , SNAT2, and SNAT4]"}
{"PMID":17311416,"re_id":32,"annotated sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as <e1>glutamine<\\e1> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), <e2>SNAT2<\\e2>  and SNAT4]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutamine","object":"SNAT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as <e1>CHEMICAL<\\e1> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), <e2>GENE-Y<\\e2>  and SNAT4]","sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2  and SNAT4]"}
{"PMID":17311416,"re_id":33,"annotated sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as <e1>glutamine<\\e1> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and <e2>SNAT4<\\e2> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutamine","object":"SNAT4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as <e1>CHEMICAL<\\e1> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and <e2>GENE-Y<\\e2> ","sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4 "}
{"PMID":17311416,"re_id":34,"annotated sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>alanine<\\e1>  is mediated, among others, by the <e2>neutral amino acid transporters<\\e2> of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alanine","object":"neutral amino acid transporters","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>CHEMICAL<\\e1>  is mediated, among others, by the <e2>GENE-N<\\e2> of the solute carrier 1 [SLC1, CHEMICAL serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine  is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]"}
{"PMID":17311416,"re_id":35,"annotated sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>alanine<\\e1>  is mediated, among others, by the neutral amino acid transporters of the <e2>solute carrier 1<\\e2> [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alanine","object":"solute carrier 1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>CHEMICAL<\\e1>  is mediated, among others, by the neutral amino acid transporters of the <e2>GENE-N<\\e2> [SLC1, CHEMICAL serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine  is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]"}
{"PMID":17311416,"re_id":36,"annotated sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>alanine<\\e1>  is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [<e2>SLC1<\\e2>  alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alanine","object":"SLC1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>CHEMICAL<\\e1>  is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [<e2>GENE-N<\\e2>  CHEMICAL serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine  is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1  alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]"}
{"PMID":17311416,"re_id":37,"annotated sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>alanine<\\e1>  is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, <e2>alanine serine cysteine transporter 1<\\e2> (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alanine","object":"alanine serine cysteine transporter 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>CHEMICAL<\\e1>  is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, <e2>CHEMICAL serine cysteine transporter 1<\\e2> (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine  is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]"}
{"PMID":17311416,"re_id":38,"annotated sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>alanine<\\e1>  is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (<e2>ASCT1<\\e2> , and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alanine","object":"ASCT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>CHEMICAL<\\e1>  is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, CHEMICAL serine cysteine transporter 1 (<e2>GENE-Y<\\e2> , and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine  is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1 , and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]"}
{"PMID":17311416,"re_id":39,"annotated sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>alanine<\\e1>  is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and <e2>ASCT2<\\e2>  and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alanine","object":"ASCT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>CHEMICAL<\\e1>  is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, CHEMICAL serine cysteine transporter 1 (ASCT1), and <e2>GENE-Y<\\e2>  and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]","sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine  is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2  and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]"}
{"PMID":17311416,"re_id":40,"annotated sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>alanine<\\e1>  is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [<e2>sodium-coupled neutral amino acid transporter 1<\\e2> (SNAT1), SNAT2, and SNAT4]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alanine","object":"sodium-coupled neutral amino acid transporter 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>CHEMICAL<\\e1>  is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, CHEMICAL serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [<e2>GENE-Y<\\e2> (SNAT1), SNAT2, and SNAT4]","sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine  is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4]"}
{"PMID":17311416,"re_id":41,"annotated sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>alanine<\\e1>  is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (<e2>SNAT1<\\e2> , SNAT2, and SNAT4]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alanine","object":"SNAT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>CHEMICAL<\\e1>  is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, CHEMICAL serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (<e2>GENE-Y<\\e2> , SNAT2, and SNAT4]","sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine  is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1 , SNAT2, and SNAT4]"}
{"PMID":17311416,"re_id":42,"annotated sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>alanine<\\e1>  is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), <e2>SNAT2<\\e2>  and SNAT4]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alanine","object":"SNAT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>CHEMICAL<\\e1>  is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, CHEMICAL serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), <e2>GENE-Y<\\e2>  and SNAT4]","sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine  is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2  and SNAT4]"}
{"PMID":17311416,"re_id":43,"annotated sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>alanine<\\e1>  is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and <e2>SNAT4<\\e2> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alanine","object":"SNAT4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and <e1>CHEMICAL<\\e1>  is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, CHEMICAL serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and <e2>GENE-Y<\\e2> ","sentence":"Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine  is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4 "}
{"PMID":17319904,"re_id":0,"annotated sentence":"Stimulated <e2>P-selectin<\\e2> and integrin alpha(IIb)beta(3) expression were also higher in the upper tertile both before and after <e1>aspirin<\\e1>  Platelet COX-2 expression was detected in 12 +\/- 7% (n = 10) of platelets in the upper tertile, and in 7 +\/- 3% (n = 12) of platelets in the lower two tertiles (P = 0.03)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"aspirin","object":"P-selectin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Stimulated <e2>GENE-Y<\\e2> and integrin alpha(IIb)beta(3) expression were also higher in the upper tertile both before and after <e1>CHEMICAL<\\e1>  Platelet COX-2 expression was detected in 12 +\/- 7% (n = 10) of platelets in the upper tertile, and in 7 +\/- 3% (n = 12) of platelets in the lower two tertiles (P = 0.03)","sentence":"Stimulated P-selectin and integrin alpha(IIb)beta(3) expression were also higher in the upper tertile both before and after aspirin  Platelet COX-2 expression was detected in 12 +\/- 7% (n = 10) of platelets in the upper tertile, and in 7 +\/- 3% (n = 12) of platelets in the lower two tertiles (P = 0.03)"}
{"PMID":17319904,"re_id":1,"annotated sentence":"Stimulated P-selectin and <e2>integrin alpha(IIb)beta(3)<\\e2> expression were also higher in the upper tertile both before and after <e1>aspirin<\\e1>  Platelet COX-2 expression was detected in 12 +\/- 7% (n = 10) of platelets in the upper tertile, and in 7 +\/- 3% (n = 12) of platelets in the lower two tertiles (P = 0.03)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"aspirin","object":"integrin alpha(IIb)beta(3)","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Stimulated P-selectin and <e2>GENE-N<\\e2> expression were also higher in the upper tertile both before and after <e1>CHEMICAL<\\e1>  Platelet COX-2 expression was detected in 12 +\/- 7% (n = 10) of platelets in the upper tertile, and in 7 +\/- 3% (n = 12) of platelets in the lower two tertiles (P = 0.03)","sentence":"Stimulated P-selectin and integrin alpha(IIb)beta(3) expression were also higher in the upper tertile both before and after aspirin  Platelet COX-2 expression was detected in 12 +\/- 7% (n = 10) of platelets in the upper tertile, and in 7 +\/- 3% (n = 12) of platelets in the lower two tertiles (P = 0.03)"}
{"PMID":17320868,"re_id":0,"annotated sentence":"Moreover, ERalpha mediated the protection afforded by estrogen since only the ERalpha agonist, HPTE, but not the <e2>ERbeta<\\e2> agonist, <e1>DPN<\\e1>  protected against dopamine cell loss","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"DPN","object":"ERbeta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, ERalpha mediated the protection afforded by estrogen since only the ERalpha agonist, HPTE, but not the <e2>GENE-Y<\\e2> agonist, <e1>CHEMICAL<\\e1>  protected against dopamine cell loss","sentence":"Moreover, ERalpha mediated the protection afforded by estrogen since only the ERalpha agonist, HPTE, but not the ERbeta agonist, DPN  protected against dopamine cell loss"}
{"PMID":17320868,"re_id":1,"annotated sentence":"At least 4 h of estrogen pre-treatment was required to elicit protection, an effect that was blocked by the <e2>ER<\\e2> antagonist, <e1>ICI 182,780<\\e1>  Moreover, ERalpha mediated the protection afforded by estrogen since only the ERalpha agonist, HPTE, but not the ERbeta agonist, DPN, protected against dopamine cell loss","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"ICI 182,780","object":"ER","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"At least 4 h of estrogen pre-treatment was required to elicit protection, an effect that was blocked by the <e2>GENE-Y<\\e2> antagonist, <e1>CHEMICAL<\\e1>  Moreover, GENE-Yalpha mediated the protection afforded by estrogen since only the GENE-Yalpha agonist, HPTE, but not the GENE-Ybeta agonist, DPN, protected against dopamine cell loss","sentence":"At least 4 h of estrogen pre-treatment was required to elicit protection, an effect that was blocked by the ER antagonist, ICI 182,780  Moreover, ERalpha mediated the protection afforded by estrogen since only the ERalpha agonist, HPTE, but not the ERbeta agonist, DPN, protected against dopamine cell loss"}
{"PMID":17324065,"re_id":0,"annotated sentence":"Differential activation of <e2>cAMP response element binding protein<\\e2> in discrete nucleus accumbens subregions during early and late <e1>cocaine<\\e1> sensitization","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cocaine","object":"cAMP response element binding protein","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Differential activation of <e2>GENE-N<\\e2> in discrete nucleus accumbens subregions during early and late <e1>CHEMICAL<\\e1> sensitization","sentence":"Differential activation of cAMP response element binding protein in discrete nucleus accumbens subregions during early and late cocaine sensitization"}
{"PMID":17324065,"re_id":1,"annotated sentence":"The temporal and anatomical determinants of <e1>cocaine<\\e1> induced <e2>CREB<\\e2> activity may indicate functional differences among NAc shell subregions and suggest the involvement of CREB in early and late cocaine effects.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cocaine","object":"CREB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The temporal and anatomical determinants of <e1>CHEMICAL<\\e1> induced <e2>GENE-N<\\e2> activity may indicate functional differences among NAc shell subregions and suggest the involvement of GENE-N in early and late CHEMICAL effects.","sentence":"The temporal and anatomical determinants of cocaine induced CREB activity may indicate functional differences among NAc shell subregions and suggest the involvement of CREB in early and late cocaine effects."}
{"PMID":17324065,"re_id":2,"annotated sentence":"The present study examined the differential <e1>cocaine<\\e1> induced activation of the cyclic adenosine monophosphate (cAMP) response element binding protein (<e2>CREB<\\e2>  throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cocaine","object":"CREB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The present study examined the differential <e1>CHEMICAL<\\e1> induced activation of the cyclic adenosine monophosphate (cAMP) response element binding protein (<e2>GENE-N<\\e2>  throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats","sentence":"The present study examined the differential cocaine induced activation of the cyclic adenosine monophosphate (cAMP) response element binding protein (CREB  throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats"}
{"PMID":17324065,"re_id":3,"annotated sentence":"The present study examined the differential <e1>cocaine<\\e1> induced activation of the <e2>cyclic adenosine monophosphate (cAMP) response element binding protein<\\e2> (CREB) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cocaine","object":"cyclic adenosine monophosphate (cAMP) response element binding protein","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The present study examined the differential <e1>CHEMICAL<\\e1> induced activation of the <e2>GENE-N<\\e2> (CREB) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats","sentence":"The present study examined the differential cocaine induced activation of the cyclic adenosine monophosphate (cAMP) response element binding protein (CREB) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats"}
{"PMID":17324065,"re_id":4,"annotated sentence":"Using immunohistochemistry, the authors analyzed changes in <e2>CREB<\\e2> phosphorylation in the NAc after 5 days of <e1>cocaine<\\e1>  a short or long drug-free period, and a subsequent challenge injection","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cocaine","object":"CREB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Using immunohistochemistry, the authors analyzed changes in <e2>GENE-N<\\e2> phosphorylation in the NAc after 5 days of <e1>CHEMICAL<\\e1>  a short or long drug-free period, and a subsequent challenge injection","sentence":"Using immunohistochemistry, the authors analyzed changes in CREB phosphorylation in the NAc after 5 days of cocaine  a short or long drug-free period, and a subsequent challenge injection"}
{"PMID":17324065,"re_id":5,"annotated sentence":"Repeated <e1>cocaine<\\e1> resulted in <e2>CREB<\\e2> phosphorylation in all analyzed subregions of the NAc excluding the most ventrolateral region of the shell 2 weeks after cessation of repeated cocaine, but rats challenged after 2 drug-free days yielded a more localized activation of CREB in the 3 most dorsomedial zones of the shell","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cocaine","object":"CREB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Repeated <e1>CHEMICAL<\\e1> resulted in <e2>GENE-N<\\e2> phosphorylation in all analyzed subregions of the NAc excluding the most ventrolateral region of the shell 2 weeks after cessation of repeated CHEMICAL, but rats challenged after 2 drug-free days yielded a more localized activation of GENE-N in the 3 most dorsomedial zones of the shell","sentence":"Repeated cocaine resulted in CREB phosphorylation in all analyzed subregions of the NAc excluding the most ventrolateral region of the shell 2 weeks after cessation of repeated cocaine, but rats challenged after 2 drug-free days yielded a more localized activation of CREB in the 3 most dorsomedial zones of the shell"}
{"PMID":17324065,"re_id":6,"annotated sentence":"Repeated cocaine resulted in CREB phosphorylation in all analyzed subregions of the NAc excluding the most ventrolateral region of the shell 2 weeks after cessation of repeated <e1>cocaine<\\e1>  but rats challenged after 2 drug-free days yielded a more localized activation of <e2>CREB<\\e2> in the 3 most dorsomedial zones of the shell","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cocaine","object":"CREB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Repeated CHEMICAL resulted in GENE-N phosphorylation in all analyzed subregions of the NAc excluding the most ventrolateral region of the shell 2 weeks after cessation of repeated <e1>CHEMICAL<\\e1>  but rats challenged after 2 drug-free days yielded a more localized activation of <e2>GENE-N<\\e2> in the 3 most dorsomedial zones of the shell","sentence":"Repeated cocaine resulted in CREB phosphorylation in all analyzed subregions of the NAc excluding the most ventrolateral region of the shell 2 weeks after cessation of repeated cocaine  but rats challenged after 2 drug-free days yielded a more localized activation of CREB in the 3 most dorsomedial zones of the shell"}
{"PMID":17327402,"re_id":0,"annotated sentence":"The carboxylation of <e1>glutamic acid<\\e1> residues to gamma-carboxyglutamic acid (Gla) by the <e2>vitamin K-dependent gamma-glutamyl carboxylase<\\e2> (gamma-carboxylase) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutamic acid","object":"vitamin K-dependent gamma-glutamyl carboxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The carboxylation of <e1>CHEMICAL<\\e1> residues to gamma-carboxyCHEMICAL (Gla) by the <e2>GENE-Y<\\e2> (gamma-carboxylase) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation","sentence":"The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid (Gla) by the vitamin K-dependent gamma-glutamyl carboxylase (gamma-carboxylase) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation"}
{"PMID":17327402,"re_id":1,"annotated sentence":"The carboxylation of <e1>glutamic acid<\\e1> residues to gamma-carboxyglutamic acid (Gla) by the vitamin K-dependent gamma-glutamyl carboxylase (<e2>gamma-carboxylase<\\e2>  is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutamic acid","object":"gamma-carboxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The carboxylation of <e1>CHEMICAL<\\e1> residues to gamma-carboxyCHEMICAL (Gla) by the vitamin K-dependent gamma-glutamyl carboxylase (<e2>GENE-Y<\\e2>  is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation","sentence":"The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid (Gla) by the vitamin K-dependent gamma-glutamyl carboxylase (gamma-carboxylase  is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation"}
{"PMID":17327402,"re_id":2,"annotated sentence":"The carboxylation of glutamic acid residues to <e1>gamma-carboxyglutamic acid<\\e1> (Gla) by the <e2>vitamin K-dependent gamma-glutamyl carboxylase<\\e2> (gamma-carboxylase) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"gamma-carboxyglutamic acid","object":"vitamin K-dependent gamma-glutamyl carboxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The carboxylation of glutamic acid residues to <e1>CHEMICAL<\\e1> (Gla) by the <e2>GENE-Y<\\e2> (gamma-carboxylase) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation","sentence":"The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid (Gla) by the vitamin K-dependent gamma-glutamyl carboxylase (gamma-carboxylase) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation"}
{"PMID":17327402,"re_id":3,"annotated sentence":"The carboxylation of glutamic acid residues to <e1>gamma-carboxyglutamic acid<\\e1> (Gla) by the vitamin K-dependent gamma-glutamyl carboxylase (<e2>gamma-carboxylase<\\e2>  is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"gamma-carboxyglutamic acid","object":"gamma-carboxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The carboxylation of glutamic acid residues to <e1>CHEMICAL<\\e1> (Gla) by the vitamin K-dependent gamma-glutamyl carboxylase (<e2>GENE-Y<\\e2>  is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation","sentence":"The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid (Gla) by the vitamin K-dependent gamma-glutamyl carboxylase (gamma-carboxylase  is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation"}
{"PMID":17327402,"re_id":4,"annotated sentence":"The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid (<e1>Gla<\\e1>  by the <e2>vitamin K-dependent gamma-glutamyl carboxylase<\\e2> (gamma-carboxylase) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Gla","object":"vitamin K-dependent gamma-glutamyl carboxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid (<e1>CHEMICAL<\\e1>  by the <e2>GENE-Y<\\e2> (gamma-carboxylase) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation","sentence":"The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid (Gla  by the vitamin K-dependent gamma-glutamyl carboxylase (gamma-carboxylase) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation"}
{"PMID":17327402,"re_id":5,"annotated sentence":"The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid (<e1>Gla<\\e1>  by the vitamin K-dependent gamma-glutamyl carboxylase (<e2>gamma-carboxylase<\\e2>  is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Gla","object":"gamma-carboxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid (<e1>CHEMICAL<\\e1>  by the vitamin K-dependent gamma-glutamyl carboxylase (<e2>GENE-Y<\\e2>  is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation","sentence":"The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid (Gla  by the vitamin K-dependent gamma-glutamyl carboxylase (gamma-carboxylase  is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation"}
{"PMID":17334413,"re_id":0,"annotated sentence":"<e1>RAMH<\\e1> inhibition of cholangiocyte growth was associated with decreased cAMP levels and <e2>PKA<\\e2> ERK1\/2\/Elk-1 phosphorylation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"RAMH","object":"PKA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> inhibition of cholangiocyte growth was associated with decreased cAMP levels and <e2>GENE-N<\\e2> ERK1\/2\/Elk-1 phosphorylation","sentence":"RAMH inhibition of cholangiocyte growth was associated with decreased cAMP levels and PKA ERK1\/2\/Elk-1 phosphorylation"}
{"PMID":17334413,"re_id":1,"annotated sentence":"<e1>RAMH<\\e1> inhibition of cholangiocyte growth was associated with decreased cAMP levels and PKA\/<e2>ERK1\/2<\\e2> Elk-1 phosphorylation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"RAMH","object":"ERK1\/2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> inhibition of cholangiocyte growth was associated with decreased cAMP levels and PKA\/<e2>GENE-N<\\e2> Elk-1 phosphorylation","sentence":"RAMH inhibition of cholangiocyte growth was associated with decreased cAMP levels and PKA\/ERK1\/2 Elk-1 phosphorylation"}
{"PMID":17334413,"re_id":2,"annotated sentence":"<e1>RAMH<\\e1> inhibition of cholangiocyte growth was associated with decreased cAMP levels and PKA\/ERK1\/2\/<e2>Elk-1<\\e2> phosphorylation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"RAMH","object":"Elk-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibition of cholangiocyte growth was associated with decreased cAMP levels and PKA\/ERK1\/2\/<e2>GENE-Y<\\e2> phosphorylation","sentence":"RAMH inhibition of cholangiocyte growth was associated with decreased cAMP levels and PKA\/ERK1\/2\/Elk-1 phosphorylation"}
{"PMID":17334413,"re_id":3,"annotated sentence":"We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of <e1>(R)-(alpha)-(-)-methylhistamine dihydrobromide<\\e1> (RAMH) (<e2>H3R<\\e2> agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence\/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)\/extracellular signal-regulated kinase 1\/2 (ERK1\/2)\/ets-like gene-1 (Elk-1)? The expression of H3R was evaluated in liver sections by immunohistochemistry and immunofluorescence, and by real-time PCR in cholangiocyte RNA from normal and BDL rats","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"(R)-(alpha)-(-)-methylhistamine dihydrobromide","object":"H3R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We posed the following questions: (1) Do cholangiocytes express GENE-Y? (2) Does in vivo administration of <e1>CHEMICAL<\\e1> (RAMH) (<e2>GENE-Y<\\e2> agonist), thioperamide maleate (GENE-Y antagonist) or histamine, in the absence\/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)\/extracellular signal-regulated kinase 1\/2 (ERK1\/2)\/ets-like gene-1 (Elk-1)? The expression of GENE-Y was evaluated in liver sections by immunohistochemistry and immunofluorescence, and by real-time PCR in cholangiocyte RNA from normal and BDL rats","sentence":"We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence\/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)\/extracellular signal-regulated kinase 1\/2 (ERK1\/2)\/ets-like gene-1 (Elk-1)? The expression of H3R was evaluated in liver sections by immunohistochemistry and immunofluorescence, and by real-time PCR in cholangiocyte RNA from normal and BDL rats"}
{"PMID":17334413,"re_id":4,"annotated sentence":"We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (<e1>RAMH<\\e1>  (<e2>H3R<\\e2> agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence\/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)\/extracellular signal-regulated kinase 1\/2 (ERK1\/2)\/ets-like gene-1 (Elk-1)? The expression of H3R was evaluated in liver sections by immunohistochemistry and immunofluorescence, and by real-time PCR in cholangiocyte RNA from normal and BDL rats","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"RAMH","object":"H3R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We posed the following questions: (1) Do cholangiocytes express GENE-Y? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (<e1>CHEMICAL<\\e1>  (<e2>GENE-Y<\\e2> agonist), thioperamide maleate (GENE-Y antagonist) or histamine, in the absence\/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does CHEMICAL inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)\/extracellular signal-regulated kinase 1\/2 (ERK1\/2)\/ets-like gene-1 (Elk-1)? The expression of GENE-Y was evaluated in liver sections by immunohistochemistry and immunofluorescence, and by real-time PCR in cholangiocyte RNA from normal and BDL rats","sentence":"We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH  (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence\/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)\/extracellular signal-regulated kinase 1\/2 (ERK1\/2)\/ets-like gene-1 (Elk-1)? The expression of H3R was evaluated in liver sections by immunohistochemistry and immunofluorescence, and by real-time PCR in cholangiocyte RNA from normal and BDL rats"}
{"PMID":17334413,"re_id":5,"annotated sentence":"We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), <e1>thioperamide maleate<\\e1> (<e2>H3R<\\e2> antagonist) or histamine, in the absence\/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)\/extracellular signal-regulated kinase 1\/2 (ERK1\/2)\/ets-like gene-1 (Elk-1)? The expression of H3R was evaluated in liver sections by immunohistochemistry and immunofluorescence, and by real-time PCR in cholangiocyte RNA from normal and BDL rats","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"thioperamide maleate","object":"H3R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We posed the following questions: (1) Do cholangiocytes express GENE-Y? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (GENE-Y agonist), <e1>CHEMICAL<\\e1> (<e2>GENE-Y<\\e2> antagonist) or histamine, in the absence\/presence of CHEMICAL, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)\/extracellular signal-regulated kinase 1\/2 (ERK1\/2)\/ets-like gene-1 (Elk-1)? The expression of GENE-Y was evaluated in liver sections by immunohistochemistry and immunofluorescence, and by real-time PCR in cholangiocyte RNA from normal and BDL rats","sentence":"We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence\/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)\/extracellular signal-regulated kinase 1\/2 (ERK1\/2)\/ets-like gene-1 (Elk-1)? The expression of H3R was evaluated in liver sections by immunohistochemistry and immunofluorescence, and by real-time PCR in cholangiocyte RNA from normal and BDL rats"}
{"PMID":17344208,"re_id":0,"annotated sentence":"<e2>Proline dehydrogenase<\\e2> (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of <e1>proline<\\e1> to glutamate","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"proline","object":"Proline dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of <e1>CHEMICAL<\\e1> to glutamate","sentence":"Proline dehydrogenase (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to glutamate"}
{"PMID":17344208,"re_id":1,"annotated sentence":"Proline dehydrogenase (<e2>PRODH<\\e2>  and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of <e1>proline<\\e1> to glutamate","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"proline","object":"PRODH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Proline dehydrogenase (<e2>GENE-Y<\\e2>  and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of <e1>CHEMICAL<\\e1> to glutamate","sentence":"Proline dehydrogenase (PRODH  and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to glutamate"}
{"PMID":17344208,"re_id":2,"annotated sentence":"Proline dehydrogenase (PRODH) and <e2>Delta(1)-pyrroline-5-carboxylate dehydrogenase<\\e2> (P5CDH) catalyze the two-step oxidation of <e1>proline<\\e1> to glutamate","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"proline","object":"Delta(1)-pyrroline-5-carboxylate dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Proline dehydrogenase (PRODH) and <e2>GENE-Y<\\e2> (P5CDH) catalyze the two-step oxidation of <e1>CHEMICAL<\\e1> to glutamate","sentence":"Proline dehydrogenase (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to glutamate"}
{"PMID":17344208,"re_id":3,"annotated sentence":"Proline dehydrogenase (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (<e2>P5CDH<\\e2>  catalyze the two-step oxidation of <e1>proline<\\e1> to glutamate","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"proline","object":"P5CDH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Proline dehydrogenase (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (<e2>GENE-Y<\\e2>  catalyze the two-step oxidation of <e1>CHEMICAL<\\e1> to glutamate","sentence":"Proline dehydrogenase (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH  catalyze the two-step oxidation of proline to glutamate"}
{"PMID":17344208,"re_id":4,"annotated sentence":"<e2>Proline dehydrogenase<\\e2> (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to <e1>glutamate<\\e1>  They are distinct monofunctional enzymes in all eukaryotes and some bacteria but are fused into bifunctional enzymes known as proline utilization A (PutA) in other bacteria","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutamate","object":"Proline dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to <e1>CHEMICAL<\\e1>  They are distinct monofunctional enzymes in all eukaryotes and some bacteria but are fused into bifunctional enzymes known as proline utilization A (PutA) in other bacteria","sentence":"Proline dehydrogenase (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to glutamate  They are distinct monofunctional enzymes in all eukaryotes and some bacteria but are fused into bifunctional enzymes known as proline utilization A (PutA) in other bacteria"}
{"PMID":17344208,"re_id":5,"annotated sentence":"Proline dehydrogenase (<e2>PRODH<\\e2>  and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to <e1>glutamate<\\e1>  They are distinct monofunctional enzymes in all eukaryotes and some bacteria but are fused into bifunctional enzymes known as proline utilization A (PutA) in other bacteria","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutamate","object":"PRODH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Proline dehydrogenase (<e2>GENE-Y<\\e2>  and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to <e1>CHEMICAL<\\e1>  They are distinct monofunctional enzymes in all eukaryotes and some bacteria but are fused into bifunctional enzymes known as proline utilization A (PutA) in other bacteria","sentence":"Proline dehydrogenase (PRODH  and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to glutamate  They are distinct monofunctional enzymes in all eukaryotes and some bacteria but are fused into bifunctional enzymes known as proline utilization A (PutA) in other bacteria"}
{"PMID":17344208,"re_id":6,"annotated sentence":"Proline dehydrogenase (PRODH) and <e2>Delta(1)-pyrroline-5-carboxylate dehydrogenase<\\e2> (P5CDH) catalyze the two-step oxidation of proline to <e1>glutamate<\\e1>  They are distinct monofunctional enzymes in all eukaryotes and some bacteria but are fused into bifunctional enzymes known as proline utilization A (PutA) in other bacteria","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutamate","object":"Delta(1)-pyrroline-5-carboxylate dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Proline dehydrogenase (PRODH) and <e2>GENE-Y<\\e2> (P5CDH) catalyze the two-step oxidation of proline to <e1>CHEMICAL<\\e1>  They are distinct monofunctional enzymes in all eukaryotes and some bacteria but are fused into bifunctional enzymes known as proline utilization A (PutA) in other bacteria","sentence":"Proline dehydrogenase (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to glutamate  They are distinct monofunctional enzymes in all eukaryotes and some bacteria but are fused into bifunctional enzymes known as proline utilization A (PutA) in other bacteria"}
{"PMID":17344208,"re_id":7,"annotated sentence":"Proline dehydrogenase (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (<e2>P5CDH<\\e2>  catalyze the two-step oxidation of proline to <e1>glutamate<\\e1>  They are distinct monofunctional enzymes in all eukaryotes and some bacteria but are fused into bifunctional enzymes known as proline utilization A (PutA) in other bacteria","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutamate","object":"P5CDH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Proline dehydrogenase (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (<e2>GENE-Y<\\e2>  catalyze the two-step oxidation of proline to <e1>CHEMICAL<\\e1>  They are distinct monofunctional enzymes in all eukaryotes and some bacteria but are fused into bifunctional enzymes known as proline utilization A (PutA) in other bacteria","sentence":"Proline dehydrogenase (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH  catalyze the two-step oxidation of proline to glutamate  They are distinct monofunctional enzymes in all eukaryotes and some bacteria but are fused into bifunctional enzymes known as proline utilization A (PutA) in other bacteria"}
{"PMID":17344208,"re_id":8,"annotated sentence":"none","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"O(2)","object":"T. thermophilus PRODH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":17344208,"re_id":9,"annotated sentence":"none","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"superoxide","object":"T. thermophilus PRODH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":17344208,"re_id":10,"annotated sentence":"This is significant because <e1>superoxide<\\e1> production underlies the role of <e2>human PRODH<\\e2> in p53-mediated apoptosis, implying commonalities between eukaryotic and bacterial monofunctional PRODHs.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"superoxide","object":"human PRODH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This is significant because <e1>CHEMICAL<\\e1> production underlies the role of <e2>GENE-Y<\\e2> in p53-mediated apoptosis, implying commonalities between eukaryotic and bacterial monofunctional PRODHs.","sentence":"This is significant because superoxide production underlies the role of human PRODH in p53-mediated apoptosis, implying commonalities between eukaryotic and bacterial monofunctional PRODHs."}
{"PMID":17352685,"re_id":0,"annotated sentence":"Results of early clinical trials with both topically (<e1>cipamfylline<\\e1>  CP80,633) and systemically (CC-10004) active <e2>PDE4<\\e2> inhibitors demonstrated efficacy in atopic dermatitis and in the case of CC-10004, also in psoriasis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cipamfylline","object":"PDE4","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Results of early clinical trials with both topically (<e1>CHEMICAL<\\e1>  CP80,633) and systemically (CC-10004) active <e2>GENE-N<\\e2> inhibitors demonstrated efficacy in atopic dermatitis and in the case of CC-10004, also in psoriasis","sentence":"Results of early clinical trials with both topically (cipamfylline  CP80,633) and systemically (CC-10004) active PDE4 inhibitors demonstrated efficacy in atopic dermatitis and in the case of CC-10004, also in psoriasis"}
{"PMID":17352685,"re_id":1,"annotated sentence":"Results of early clinical trials with both topically (cipamfylline, <e1>CP80,633<\\e1>  and systemically (CC-10004) active <e2>PDE4<\\e2> inhibitors demonstrated efficacy in atopic dermatitis and in the case of CC-10004, also in psoriasis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CP80,633","object":"PDE4","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Results of early clinical trials with both topically (cipamfylline, <e1>CHEMICAL<\\e1>  and systemically (CC-10004) active <e2>GENE-N<\\e2> inhibitors demonstrated efficacy in atopic dermatitis and in the case of CC-10004, also in psoriasis","sentence":"Results of early clinical trials with both topically (cipamfylline, CP80,633  and systemically (CC-10004) active PDE4 inhibitors demonstrated efficacy in atopic dermatitis and in the case of CC-10004, also in psoriasis"}
{"PMID":17352685,"re_id":2,"annotated sentence":"Consequently, <e2>PDE4<\\e2> inhibitors including <e1>cilomilast<\\e1> and AWD 12-281 have been tested in several models of allergic and irritant skin inflammation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cilomilast","object":"PDE4","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Consequently, <e2>GENE-N<\\e2> inhibitors including <e1>CHEMICAL<\\e1> and AWD 12-281 have been tested in several models of allergic and irritant skin inflammation","sentence":"Consequently, PDE4 inhibitors including cilomilast and AWD 12-281 have been tested in several models of allergic and irritant skin inflammation"}
{"PMID":17352685,"re_id":3,"annotated sentence":"Consequently, <e2>PDE4<\\e2> inhibitors including cilomilast and <e1>AWD 12-281<\\e1> have been tested in several models of allergic and irritant skin inflammation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"AWD 12-281","object":"PDE4","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Consequently, <e2>GENE-N<\\e2> inhibitors including cilomilast and <e1>CHEMICAL<\\e1> have been tested in several models of allergic and irritant skin inflammation","sentence":"Consequently, PDE4 inhibitors including cilomilast and AWD 12-281 have been tested in several models of allergic and irritant skin inflammation"}
{"PMID":17352685,"re_id":4,"annotated sentence":"The <e2>phosphodiesterase (PDE) 4<\\e2> is the predominant <e1>cyclic AMP<\\e1> degrading enzyme in a variety of inflammatory cells including eosinophils, neutrophils, macrophages, T cells and monocytes","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cyclic AMP","object":"phosphodiesterase (PDE) 4","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e2>GENE-N<\\e2> is the predominant <e1>CHEMICAL<\\e1> degrading enzyme in a variety of inflammatory cells including eosinophils, neutrophils, macrophages, T cells and monocytes","sentence":"The phosphodiesterase (PDE) 4 is the predominant cyclic AMP degrading enzyme in a variety of inflammatory cells including eosinophils, neutrophils, macrophages, T cells and monocytes"}
{"PMID":17367165,"re_id":0,"annotated sentence":"Although considerable functional diversity exists, most <e2>C2 domains<\\e2> are activated by <e1>Ca2+<\\e1> binding and then dock to a specific cellular membrane","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Ca2+","object":"C2 domains","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Although considerable functional diversity exists, most <e2>GENE-N<\\e2> are activated by <e1>CHEMICAL<\\e1> binding and then dock to a specific cellular membrane","sentence":"Although considerable functional diversity exists, most C2 domains are activated by Ca2+ binding and then dock to a specific cellular membrane"}
{"PMID":17379925,"re_id":0,"annotated sentence":"<e2>Bile acid coenzyme A:amino acid N-acyltransferase<\\e2> (BAT) is responsible for the amidation of <e1>bile acids<\\e1> with the amino acids glycine and taurine","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"bile acids","object":"Bile acid coenzyme A:amino acid N-acyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (BAT) is responsible for the amidation of <e1>CHEMICAL<\\e1> with the amino acids glycine and taurine","sentence":"Bile acid coenzyme A:amino acid N-acyltransferase (BAT) is responsible for the amidation of bile acids with the amino acids glycine and taurine"}
{"PMID":17379925,"re_id":1,"annotated sentence":"Bile acid coenzyme A:amino acid N-acyltransferase (<e2>BAT<\\e2>  is responsible for the amidation of <e1>bile acids<\\e1> with the amino acids glycine and taurine","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"bile acids","object":"BAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Bile acid coenzyme A:amino acid N-acyltransferase (<e2>GENE-Y<\\e2>  is responsible for the amidation of <e1>CHEMICAL<\\e1> with the amino acids glycine and taurine","sentence":"Bile acid coenzyme A:amino acid N-acyltransferase (BAT  is responsible for the amidation of bile acids with the amino acids glycine and taurine"}
{"PMID":17380207,"re_id":0,"annotated sentence":"<e1>Asparagine<\\e1> secretion by MSCs was directly related to their <e2>ASNS<\\e2> expression levels, suggesting a mechanism - increased concentrations of asparagine in the leukemic cell microenvironment - for the protective effects we observed","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Asparagine","object":"ASNS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> secretion by MSCs was directly related to their <e2>GENE-Y<\\e2> expression levels, suggesting a mechanism - increased concentrations of asparagine in the leukemic cell microenvironment - for the protective effects we observed","sentence":"Asparagine secretion by MSCs was directly related to their ASNS expression levels, suggesting a mechanism - increased concentrations of asparagine in the leukemic cell microenvironment - for the protective effects we observed"}
{"PMID":17380207,"re_id":1,"annotated sentence":"Because of their low asparagine synthetase (<e2>ASNS<\\e2>  expression and <e1>asparagine<\\e1> biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to asparagine depletion","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"asparagine","object":"ASNS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Because of their low CHEMICAL synthetase (<e2>GENE-Y<\\e2>  expression and <e1>CHEMICAL<\\e1> biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to CHEMICAL depletion","sentence":"Because of their low asparagine synthetase (ASNS  expression and asparagine biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to asparagine depletion"}
{"PMID":17380207,"re_id":2,"annotated sentence":"Because of their low <e2>asparagine synthetase<\\e2> (ASNS) expression and <e1>asparagine<\\e1> biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to asparagine depletion","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"asparagine","object":"asparagine synthetase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Because of their low <e2>CHEMICAL synthetase<\\e2> (ASNS) expression and <e1>CHEMICAL<\\e1> biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to CHEMICAL depletion","sentence":"Because of their low asparagine synthetase (ASNS) expression and asparagine biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to asparagine depletion"}
{"PMID":17403555,"re_id":0,"annotated sentence":"<e1>MK-801<\\e1> ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive <e2>NMDA receptor<\\e2> antagonist, partially prevented the decrease in cell viability and the energy impairment","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"MK-801","object":"NMDA receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive <e2>GENE-N<\\e2> antagonist, partially prevented the decrease in cell viability and the energy impairment","sentence":"MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive NMDA receptor antagonist, partially prevented the decrease in cell viability and the energy impairment"}
{"PMID":17403555,"re_id":1,"annotated sentence":"MK-801 (<e1>(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate<\\e1> , a noncompetitive <e2>NMDA receptor<\\e2> antagonist, partially prevented the decrease in cell viability and the energy impairment","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate","object":"NMDA receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"MK-801 (<e1>CHEMICAL<\\e1> , a noncompetitive <e2>GENE-N<\\e2> antagonist, partially prevented the decrease in cell viability and the energy impairment","sentence":"MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate , a noncompetitive NMDA receptor antagonist, partially prevented the decrease in cell viability and the energy impairment"}
{"PMID":17409318,"re_id":0,"annotated sentence":"The parallel pattern of accumulation of 24:6n-3 and DHA in response to increasing concentrations of ALA suggests that the competition between 24:5n-3 and ALA for <e2>D6D<\\e2> may contribute to the limited accumulation of <e1>DHA<\\e1> in cell membranes.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"DHA","object":"D6D","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The parallel pattern of accumulation of 24:6n-3 and CHEMICAL in response to increasing concentrations of ALA suggests that the competition between 24:5n-3 and ALA for <e2>GENE-Y<\\e2> may contribute to the limited accumulation of <e1>CHEMICAL<\\e1> in cell membranes.","sentence":"The parallel pattern of accumulation of 24:6n-3 and DHA in response to increasing concentrations of ALA suggests that the competition between 24:5n-3 and ALA for D6D may contribute to the limited accumulation of DHA in cell membranes."}
{"PMID":17409318,"re_id":1,"annotated sentence":"The use of <e2>Delta 6 desaturase<\\e2> (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of <e1>DHA<\\e1> from ALA","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"DHA","object":"Delta 6 desaturase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The use of <e2>GENE-Y<\\e2> (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (CHEMICAL; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of <e1>CHEMICAL<\\e1> from ALA","sentence":"The use of Delta 6 desaturase (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA"}
{"PMID":17409318,"re_id":2,"annotated sentence":"The use of Delta 6 desaturase (<e2>D6D<\\e2>  twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of <e1>DHA<\\e1> from ALA","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"DHA","object":"D6D","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The use of Delta 6 desaturase (<e2>GENE-Y<\\e2>  twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (CHEMICAL; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of <e1>CHEMICAL<\\e1> from ALA","sentence":"The use of Delta 6 desaturase (D6D  twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA"}
{"PMID":17409318,"re_id":3,"annotated sentence":"The use of <e2>Delta 6 desaturase<\\e2> (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from <e1>ALA<\\e1>  We examined this using an in vitro model of fatty acid metabolism to measure the accumulation of the long-chain metabolites of ALA in HepG2 cell phospholipids","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"ALA","object":"Delta 6 desaturase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The use of <e2>GENE-Y<\\e2> (D6D) twice in the conversion of alpha-linolenic acid (CHEMICAL; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from <e1>CHEMICAL<\\e1>  We examined this using an in vitro model of fatty acid metabolism to measure the accumulation of the long-chain metabolites of CHEMICAL in HepG2 cell phospholipids","sentence":"The use of Delta 6 desaturase (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA  We examined this using an in vitro model of fatty acid metabolism to measure the accumulation of the long-chain metabolites of ALA in HepG2 cell phospholipids"}
{"PMID":17409318,"re_id":4,"annotated sentence":"The use of Delta 6 desaturase (<e2>D6D<\\e2>  twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from <e1>ALA<\\e1>  We examined this using an in vitro model of fatty acid metabolism to measure the accumulation of the long-chain metabolites of ALA in HepG2 cell phospholipids","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"ALA","object":"D6D","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The use of Delta 6 desaturase (<e2>GENE-Y<\\e2>  twice in the conversion of alpha-linolenic acid (CHEMICAL; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from <e1>CHEMICAL<\\e1>  We examined this using an in vitro model of fatty acid metabolism to measure the accumulation of the long-chain metabolites of CHEMICAL in HepG2 cell phospholipids","sentence":"The use of Delta 6 desaturase (D6D  twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA  We examined this using an in vitro model of fatty acid metabolism to measure the accumulation of the long-chain metabolites of ALA in HepG2 cell phospholipids"}
{"PMID":17409318,"re_id":5,"annotated sentence":"The use of <e2>Delta 6 desaturase<\\e2> (D6D) twice in the conversion of <e1>alpha-linolenic acid<\\e1> (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alpha-linolenic acid","object":"Delta 6 desaturase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The use of <e2>GENE-Y<\\e2> (D6D) twice in the conversion of <e1>CHEMICAL<\\e1> (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA","sentence":"The use of Delta 6 desaturase (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA"}
{"PMID":17409318,"re_id":6,"annotated sentence":"The use of Delta 6 desaturase (<e2>D6D<\\e2>  twice in the conversion of <e1>alpha-linolenic acid<\\e1> (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alpha-linolenic acid","object":"D6D","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The use of Delta 6 desaturase (<e2>GENE-Y<\\e2>  twice in the conversion of <e1>CHEMICAL<\\e1> (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA","sentence":"The use of Delta 6 desaturase (D6D  twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA"}
{"PMID":17409318,"re_id":7,"annotated sentence":"The accumulation of the post-<e2>D6D<\\e2> products of 22:5n-3, 24:6n-3 and <e1>DHA<\\e1>  in cell phospholipids was saturated at concentrations of >18 microM ALA","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"DHA","object":"D6D","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The accumulation of the post-<e2>GENE-Y<\\e2> products of 22:5n-3, 24:6n-3 and <e1>CHEMICAL<\\e1>  in cell phospholipids was saturated at concentrations of >18 microM ALA","sentence":"The accumulation of the post-D6D products of 22:5n-3, 24:6n-3 and DHA  in cell phospholipids was saturated at concentrations of >18 microM ALA"}
{"PMID":17409318,"re_id":8,"annotated sentence":"The use of <e2>Delta 6 desaturase<\\e2> (D6D) twice in the conversion of alpha-linolenic acid (<e1>ALA<\\e1>  18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"ALA","object":"Delta 6 desaturase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The use of <e2>GENE-Y<\\e2> (D6D) twice in the conversion of alpha-linolenic acid (<e1>CHEMICAL<\\e1>  18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from CHEMICAL","sentence":"The use of Delta 6 desaturase (D6D) twice in the conversion of alpha-linolenic acid (ALA  18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA"}
{"PMID":17409318,"re_id":9,"annotated sentence":"The use of Delta 6 desaturase (<e2>D6D<\\e2>  twice in the conversion of alpha-linolenic acid (<e1>ALA<\\e1>  18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"ALA","object":"D6D","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The use of Delta 6 desaturase (<e2>GENE-Y<\\e2>  twice in the conversion of alpha-linolenic acid (<e1>CHEMICAL<\\e1>  18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from CHEMICAL","sentence":"The use of Delta 6 desaturase (D6D  twice in the conversion of alpha-linolenic acid (ALA  18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA"}
{"PMID":17409318,"re_id":10,"annotated sentence":"The use of <e2>Delta 6 desaturase<\\e2> (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to <e1>docosahexaenoic acid<\\e1> (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"docosahexaenoic acid","object":"Delta 6 desaturase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The use of <e2>GENE-Y<\\e2> (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to <e1>CHEMICAL<\\e1> (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA","sentence":"The use of Delta 6 desaturase (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA"}
{"PMID":17409318,"re_id":11,"annotated sentence":"The use of Delta 6 desaturase (<e2>D6D<\\e2>  twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to <e1>docosahexaenoic acid<\\e1> (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"docosahexaenoic acid","object":"D6D","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The use of Delta 6 desaturase (<e2>GENE-Y<\\e2>  twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to <e1>CHEMICAL<\\e1> (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA","sentence":"The use of Delta 6 desaturase (D6D  twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA"}
{"PMID":17409318,"re_id":12,"annotated sentence":"The use of <e2>Delta 6 desaturase<\\e2> (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (<e1>DHA<\\e1>  22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"DHA","object":"Delta 6 desaturase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The use of <e2>GENE-Y<\\e2> (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (<e1>CHEMICAL<\\e1>  22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of CHEMICAL from ALA","sentence":"The use of Delta 6 desaturase (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (DHA  22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA"}
{"PMID":17409318,"re_id":13,"annotated sentence":"The use of Delta 6 desaturase (<e2>D6D<\\e2>  twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (<e1>DHA<\\e1>  22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"DHA","object":"D6D","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The use of Delta 6 desaturase (<e2>GENE-Y<\\e2>  twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (<e1>CHEMICAL<\\e1>  22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of CHEMICAL from ALA","sentence":"The use of Delta 6 desaturase (D6D  twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (DHA  22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA"}
{"PMID":17409318,"re_id":14,"annotated sentence":"The parallel pattern of accumulation of 24:6n-3 and DHA in response to increasing concentrations of ALA suggests that the competition between 24:5n-3 and <e1>ALA<\\e1> for <e2>D6D<\\e2> may contribute to the limited accumulation of DHA in cell membranes.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"ALA","object":"D6D","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The parallel pattern of accumulation of 24:6n-3 and DHA in response to increasing concentrations of CHEMICAL suggests that the competition between 24:5n-3 and <e1>CHEMICAL<\\e1> for <e2>GENE-Y<\\e2> may contribute to the limited accumulation of DHA in cell membranes.","sentence":"The parallel pattern of accumulation of 24:6n-3 and DHA in response to increasing concentrations of ALA suggests that the competition between 24:5n-3 and ALA for D6D may contribute to the limited accumulation of DHA in cell membranes."}
{"PMID":17468175,"re_id":0,"annotated sentence":"<e2>Dopamine D1 receptor<\\e2> agonist and D2 receptor antagonist effects of the natural product <e1>(-)-stepholidine<\\e1>  molecular modeling and dynamics simulations","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"(-)-stepholidine","object":"Dopamine D1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> agonist and D2 receptor antagonist effects of the natural product <e1>CHEMICAL<\\e1>  molecular modeling and dynamics simulations","sentence":"Dopamine D1 receptor agonist and D2 receptor antagonist effects of the natural product (-)-stepholidine  molecular modeling and dynamics simulations"}
{"PMID":17468175,"re_id":1,"annotated sentence":"<e1>(-)-Stepholidine<\\e1> (SPD), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a <e2>dopamine receptor D1<\\e2> agonist and D2 antagonist","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"(-)-Stepholidine","object":"dopamine receptor D1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (SPD), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a <e2>GENE-Y<\\e2> agonist and D2 antagonist","sentence":"(-)-Stepholidine (SPD), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a dopamine receptor D1 agonist and D2 antagonist"}
{"PMID":17468175,"re_id":2,"annotated sentence":"(-)-Stepholidine (<e1>SPD<\\e1> , an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a <e2>dopamine receptor D1<\\e2> agonist and D2 antagonist","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"SPD","object":"dopamine receptor D1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"(-)-Stepholidine (<e1>CHEMICAL<\\e1> , an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a <e2>GENE-Y<\\e2> agonist and D2 antagonist","sentence":"(-)-Stepholidine (SPD , an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a dopamine receptor D1 agonist and D2 antagonist"}
{"PMID":17468175,"re_id":3,"annotated sentence":"Dopamine D1 receptor agonist and <e2>D2 receptor<\\e2> antagonist effects of the natural product <e1>(-)-stepholidine<\\e1>  molecular modeling and dynamics simulations","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"(-)-stepholidine","object":"D2 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Dopamine D1 receptor agonist and <e2>GENE-Y<\\e2> antagonist effects of the natural product <e1>CHEMICAL<\\e1>  molecular modeling and dynamics simulations","sentence":"Dopamine D1 receptor agonist and D2 receptor antagonist effects of the natural product (-)-stepholidine  molecular modeling and dynamics simulations"}
{"PMID":17468175,"re_id":4,"annotated sentence":"<e1>(-)-Stepholidine<\\e1> (SPD), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a dopamine receptor D1 agonist and <e2>D2<\\e2> antagonist","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"(-)-Stepholidine","object":"D2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (SPD), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a dopamine receptor D1 agonist and <e2>GENE-Y<\\e2> antagonist","sentence":"(-)-Stepholidine (SPD), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a dopamine receptor D1 agonist and D2 antagonist"}
{"PMID":17468175,"re_id":5,"annotated sentence":"(-)-Stepholidine (<e1>SPD<\\e1> , an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a dopamine receptor D1 agonist and <e2>D2<\\e2> antagonist","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"SPD","object":"D2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"(-)-Stepholidine (<e1>CHEMICAL<\\e1> , an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a dopamine receptor D1 agonist and <e2>GENE-Y<\\e2> antagonist","sentence":"(-)-Stepholidine (SPD , an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a dopamine receptor D1 agonist and D2 antagonist"}
{"PMID":17496727,"re_id":0,"annotated sentence":"The Ki for <e1>mycophenolic acid<\\e1> inhibition of the <e2>L263F<\\e2> variant was comparable with the wild-type, and the variant Km for inosine 5'-monophosphate and nicotinamide adenine dinucleotide did not change significantly","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"mycophenolic acid","object":"L263F","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The Ki for <e1>CHEMICAL<\\e1> inhibition of the <e2>GENE-N<\\e2> variant was comparable with the wild-type, and the variant Km for inosine 5'-monophosphate and nicotinamide adenine dinucleotide did not change significantly","sentence":"The Ki for mycophenolic acid inhibition of the L263F variant was comparable with the wild-type, and the variant Km for inosine 5'-monophosphate and nicotinamide adenine dinucleotide did not change significantly"}
{"PMID":17512091,"re_id":0,"annotated sentence":"Ovariectomy downregulates glutaredoxin and renders female mice vulnerable to <e1>L-BOAA<\\e1> toxicity as evidenced by activation of <e2>AP1<\\e2>  loss of GSH and complex I activity indicating the important role of glutaredoxin in neuroprotection","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"L-BOAA","object":"AP1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ovariectomy downregulates glutaredoxin and renders female mice vulnerable to <e1>CHEMICAL<\\e1> toxicity as evidenced by activation of <e2>GENE-Y<\\e2>  loss of GSH and complex I activity indicating the important role of glutaredoxin in neuroprotection","sentence":"Ovariectomy downregulates glutaredoxin and renders female mice vulnerable to L-BOAA toxicity as evidenced by activation of AP1  loss of GSH and complex I activity indicating the important role of glutaredoxin in neuroprotection"}
{"PMID":17512091,"re_id":1,"annotated sentence":"Ovariectomy downregulates glutaredoxin and renders female mice vulnerable to <e1>L-BOAA<\\e1> toxicity as evidenced by activation of AP1, loss of GSH and <e2>complex I<\\e2> activity indicating the important role of glutaredoxin in neuroprotection","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"L-BOAA","object":"complex I","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Ovariectomy downregulates glutaredoxin and renders female mice vulnerable to <e1>CHEMICAL<\\e1> toxicity as evidenced by activation of AP1, loss of GSH and <e2>GENE-N<\\e2> activity indicating the important role of glutaredoxin in neuroprotection","sentence":"Ovariectomy downregulates glutaredoxin and renders female mice vulnerable to L-BOAA toxicity as evidenced by activation of AP1, loss of GSH and complex I activity indicating the important role of glutaredoxin in neuroprotection"}
{"PMID":17512091,"re_id":2,"annotated sentence":"<e1>Estrogen<\\e1> protects against mitochondrial dysfunction caused by excitotoxicity by maintaining cellular redox status through higher constitutive expression of <e2>glutaredoxin<\\e2> in the CNS","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Estrogen","object":"glutaredoxin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> protects against mitochondrial dysfunction caused by excitotoxicity by maintaining cellular redox status through higher constitutive expression of <e2>GENE-N<\\e2> in the CNS","sentence":"Estrogen protects against mitochondrial dysfunction caused by excitotoxicity by maintaining cellular redox status through higher constitutive expression of glutaredoxin in the CNS"}
{"PMID":17512091,"re_id":3,"annotated sentence":"<e1>L-BOAA<\\e1> causes loss of GSH and inhibition of <e2>mitochondrial complex I<\\e2> in lumbosacral cord of male mice through oxidation of thiol groups, while female mice are resistant","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"L-BOAA","object":"mitochondrial complex I","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> causes loss of GSH and inhibition of <e2>GENE-N<\\e2> in lumbosacral cord of male mice through oxidation of thiol groups, while female mice are resistant","sentence":"L-BOAA causes loss of GSH and inhibition of mitochondrial complex I in lumbosacral cord of male mice through oxidation of thiol groups, while female mice are resistant"}
{"PMID":17512091,"re_id":4,"annotated sentence":"Female mice express higher levels of glutaredoxin in certain CNS regions and downregulation of glutaredoxin using antisense oligonucleotides sensitizes them to <e1>L-BOAA<\\e1> toxicity seen as <e2>mitochondrial complex I<\\e2> loss","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"L-BOAA","object":"mitochondrial complex I","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Female mice express higher levels of glutaredoxin in certain CNS regions and downregulation of glutaredoxin using antisense oligonucleotides sensitizes them to <e1>CHEMICAL<\\e1> toxicity seen as <e2>GENE-N<\\e2> loss","sentence":"Female mice express higher levels of glutaredoxin in certain CNS regions and downregulation of glutaredoxin using antisense oligonucleotides sensitizes them to L-BOAA toxicity seen as mitochondrial complex I loss"}
{"PMID":17554001,"re_id":0,"annotated sentence":"We have expressed <e2>VIAAT<\\e2> and the plasmalemmal transporters for glycine and <e1>GABA<\\e1> in a neuroendocrine cell line and measured the quantal release of glycine and GABA using a novel double-sniffer patch-clamp technique","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"GABA","object":"VIAAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We have expressed <e2>GENE-Y<\\e2> and the plasmalemmal transporters for glycine and <e1>CHEMICAL<\\e1> in a neuroendocrine cell line and measured the quantal release of glycine and CHEMICAL using a novel double-sniffer patch-clamp technique","sentence":"We have expressed VIAAT and the plasmalemmal transporters for glycine and GABA in a neuroendocrine cell line and measured the quantal release of glycine and GABA using a novel double-sniffer patch-clamp technique"}
{"PMID":17554001,"re_id":1,"annotated sentence":"We have expressed VIAAT and the <e2>plasmalemmal transporters<\\e2> for glycine and <e1>GABA<\\e1> in a neuroendocrine cell line and measured the quantal release of glycine and GABA using a novel double-sniffer patch-clamp technique","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"GABA","object":"plasmalemmal transporters","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We have expressed VIAAT and the <e2>GENE-N<\\e2> for glycine and <e1>CHEMICAL<\\e1> in a neuroendocrine cell line and measured the quantal release of glycine and CHEMICAL using a novel double-sniffer patch-clamp technique","sentence":"We have expressed VIAAT and the plasmalemmal transporters for glycine and GABA in a neuroendocrine cell line and measured the quantal release of glycine and GABA using a novel double-sniffer patch-clamp technique"}
{"PMID":17554001,"re_id":2,"annotated sentence":"We found that <e1>glycine<\\e1> is released from vesicles when <e2>VIAAT<\\e2> is coexpressed with either the neuronal transporter GlyT2 or the glial transporter GlyT1","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glycine","object":"VIAAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that <e1>CHEMICAL<\\e1> is released from vesicles when <e2>GENE-Y<\\e2> is coexpressed with either the neuronal transporter GlyT2 or the glial transporter GlyT1","sentence":"We found that glycine is released from vesicles when VIAAT is coexpressed with either the neuronal transporter GlyT2 or the glial transporter GlyT1"}
{"PMID":17554001,"re_id":3,"annotated sentence":"However, GlyT2 was more effective than GlyT1, probably because GlyT2 is unable to operate in the reverse mode, which gives it an advantage in maintaining the high cytosolic <e1>glycine<\\e1> concentration required for efficient vesicular loading by <e2>VIAAT<\\e2>  The vesicular inhibitory phenotype was gradually altered from glycinergic to GABAergic through mixed events when GABA is introduced into the secretory cell and competes for uptake by VIAAT","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glycine","object":"VIAAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, GlyT2 was more effective than GlyT1, probably because GlyT2 is unable to operate in the reverse mode, which gives it an advantage in maintaining the high cytosolic <e1>CHEMICAL<\\e1> concentration required for efficient vesicular loading by <e2>GENE-Y<\\e2>  The vesicular inhibitory phenotype was gradually altered from CHEMICALrgic to GABAergic through mixed events when GABA is introduced into the secretory cell and competes for uptake by GENE-Y","sentence":"However, GlyT2 was more effective than GlyT1, probably because GlyT2 is unable to operate in the reverse mode, which gives it an advantage in maintaining the high cytosolic glycine concentration required for efficient vesicular loading by VIAAT  The vesicular inhibitory phenotype was gradually altered from glycinergic to GABAergic through mixed events when GABA is introduced into the secretory cell and competes for uptake by VIAAT"}
{"PMID":17554001,"re_id":4,"annotated sentence":"The vesicular inhibitory phenotype was gradually altered from glycinergic to GABAergic through mixed events when <e1>GABA<\\e1> is introduced into the secretory cell and competes for uptake by <e2>VIAAT<\\e2>  Interestingly, the VIAAT ortholog from Caenorhabditis elegans (UNC-47), a species lacking glycine transmission, also supports glycine exocytosis in the presence of GlyT2, and a point mutation of UNC-47 that abolishes GABA transmission in the worm confers glycine specificity","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"GABA","object":"VIAAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The vesicular inhibitory phenotype was gradually altered from glycinergic to CHEMICALergic through mixed events when <e1>CHEMICAL<\\e1> is introduced into the secretory cell and competes for uptake by <e2>GENE-Y<\\e2>  Interestingly, the GENE-Y ortholog from Caenorhabditis elegans (UNC-47), a species lacking glycine transmission, also supports glycine exocytosis in the presence of GlyT2, and a point mutation of UNC-47 that abolishes CHEMICAL transmission in the worm confers glycine specificity","sentence":"The vesicular inhibitory phenotype was gradually altered from glycinergic to GABAergic through mixed events when GABA is introduced into the secretory cell and competes for uptake by VIAAT  Interestingly, the VIAAT ortholog from Caenorhabditis elegans (UNC-47), a species lacking glycine transmission, also supports glycine exocytosis in the presence of GlyT2, and a point mutation of UNC-47 that abolishes GABA transmission in the worm confers glycine specificity"}
{"PMID":17554001,"re_id":5,"annotated sentence":"Interestingly, the VIAAT ortholog from Caenorhabditis elegans (UNC-47), a species lacking glycine transmission, also supports <e1>glycine<\\e1> exocytosis in the presence of <e2>GlyT2<\\e2>  and a point mutation of UNC-47 that abolishes GABA transmission in the worm confers glycine specificity","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glycine","object":"GlyT2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Interestingly, the VIAAT ortholog from Caenorhabditis elegans (UNC-47), a species lacking CHEMICAL transmission, also supports <e1>CHEMICAL<\\e1> exocytosis in the presence of <e2>GENE-N<\\e2>  and a point mutation of UNC-47 that abolishes GABA transmission in the worm confers CHEMICAL specificity","sentence":"Interestingly, the VIAAT ortholog from Caenorhabditis elegans (UNC-47), a species lacking glycine transmission, also supports glycine exocytosis in the presence of GlyT2  and a point mutation of UNC-47 that abolishes GABA transmission in the worm confers glycine specificity"}
{"PMID":17554001,"re_id":6,"annotated sentence":"Together, these results suggest that an increased cytosolic availability of <e1>glycine<\\e1> in <e2>VIAAT<\\e2> containing terminals was crucial for the emergence of glycinergic transmission in vertebrates.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glycine","object":"VIAAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Together, these results suggest that an increased cytosolic availability of <e1>CHEMICAL<\\e1> in <e2>GENE-Y<\\e2> containing terminals was crucial for the emergence of CHEMICALrgic transmission in vertebrates.","sentence":"Together, these results suggest that an increased cytosolic availability of glycine in VIAAT containing terminals was crucial for the emergence of glycinergic transmission in vertebrates."}
{"PMID":17554001,"re_id":7,"annotated sentence":"The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, <e1>glycine<\\e1> and GABA, share the same <e2>vesicular inhibitory amino acid transporter<\\e2> (VIAAT) and are both present in neurons during postnatal development","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glycine","object":"vesicular inhibitory amino acid transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, <e1>CHEMICAL<\\e1> and GABA, share the same <e2>GENE-Y<\\e2> (VIAAT) and are both present in neurons during postnatal development","sentence":"The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, glycine and GABA, share the same vesicular inhibitory amino acid transporter (VIAAT) and are both present in neurons during postnatal development"}
{"PMID":17554001,"re_id":8,"annotated sentence":"The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, <e1>glycine<\\e1> and GABA, share the same vesicular inhibitory amino acid transporter (<e2>VIAAT<\\e2>  and are both present in neurons during postnatal development","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glycine","object":"VIAAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, <e1>CHEMICAL<\\e1> and GABA, share the same vesicular inhibitory amino acid transporter (<e2>GENE-Y<\\e2>  and are both present in neurons during postnatal development","sentence":"The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, glycine and GABA, share the same vesicular inhibitory amino acid transporter (VIAAT  and are both present in neurons during postnatal development"}
{"PMID":17554001,"re_id":9,"annotated sentence":"The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, glycine and <e1>GABA<\\e1>  share the same <e2>vesicular inhibitory amino acid transporter<\\e2> (VIAAT) and are both present in neurons during postnatal development","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"GABA","object":"vesicular inhibitory amino acid transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, glycine and <e1>CHEMICAL<\\e1>  share the same <e2>GENE-Y<\\e2> (VIAAT) and are both present in neurons during postnatal development","sentence":"The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, glycine and GABA  share the same vesicular inhibitory amino acid transporter (VIAAT) and are both present in neurons during postnatal development"}
{"PMID":17554001,"re_id":10,"annotated sentence":"The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, glycine and <e1>GABA<\\e1>  share the same vesicular inhibitory amino acid transporter (<e2>VIAAT<\\e2>  and are both present in neurons during postnatal development","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"GABA","object":"VIAAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, glycine and <e1>CHEMICAL<\\e1>  share the same vesicular inhibitory amino acid transporter (<e2>GENE-Y<\\e2>  and are both present in neurons during postnatal development","sentence":"The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, glycine and GABA  share the same vesicular inhibitory amino acid transporter (VIAAT  and are both present in neurons during postnatal development"}
{"PMID":17554001,"re_id":11,"annotated sentence":"We have expressed <e2>VIAAT<\\e2> and the plasmalemmal transporters for <e1>glycine<\\e1> and GABA in a neuroendocrine cell line and measured the quantal release of glycine and GABA using a novel double-sniffer patch-clamp technique","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glycine","object":"VIAAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We have expressed <e2>GENE-Y<\\e2> and the plasmalemmal transporters for <e1>CHEMICAL<\\e1> and GABA in a neuroendocrine cell line and measured the quantal release of CHEMICAL and GABA using a novel double-sniffer patch-clamp technique","sentence":"We have expressed VIAAT and the plasmalemmal transporters for glycine and GABA in a neuroendocrine cell line and measured the quantal release of glycine and GABA using a novel double-sniffer patch-clamp technique"}
{"PMID":17554001,"re_id":12,"annotated sentence":"We have expressed VIAAT and the <e2>plasmalemmal transporters<\\e2> for <e1>glycine<\\e1> and GABA in a neuroendocrine cell line and measured the quantal release of glycine and GABA using a novel double-sniffer patch-clamp technique","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glycine","object":"plasmalemmal transporters","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We have expressed VIAAT and the <e2>GENE-N<\\e2> for <e1>CHEMICAL<\\e1> and GABA in a neuroendocrine cell line and measured the quantal release of CHEMICAL and GABA using a novel double-sniffer patch-clamp technique","sentence":"We have expressed VIAAT and the plasmalemmal transporters for glycine and GABA in a neuroendocrine cell line and measured the quantal release of glycine and GABA using a novel double-sniffer patch-clamp technique"}
{"PMID":17581967,"re_id":0,"annotated sentence":"<e1>Na+<\\e1> Cl- dipole couples agonist binding to <e2>kainate receptor<\\e2> activation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Na+","object":"kainate receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> Cl- dipole couples agonist binding to <e2>GENE-N<\\e2> activation","sentence":"Na+ Cl- dipole couples agonist binding to kainate receptor activation"}
{"PMID":17581967,"re_id":1,"annotated sentence":"Na+\/<e1>Cl-<\\e1> dipole couples agonist binding to <e2>kainate receptor<\\e2> activation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Cl-","object":"kainate receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Na+\/<e1>CHEMICAL<\\e1> dipole couples agonist binding to <e2>GENE-N<\\e2> activation","sentence":"Na+\/Cl- dipole couples agonist binding to kainate receptor activation"}
{"PMID":17581967,"re_id":2,"annotated sentence":"<e2>Kainate-selective ionotropic glutamate receptors<\\e2> (GluRs) require external Na+ and Cl- as well as the neurotransmitter <e1>L-glutamate<\\e1> for activation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"L-glutamate","object":"Kainate-selective ionotropic glutamate receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> (GluRs) require external Na+ and Cl- as well as the neurotransmitter <e1>CHEMICAL<\\e1> for activation","sentence":"Kainate-selective ionotropic glutamate receptors (GluRs) require external Na+ and Cl- as well as the neurotransmitter L-glutamate for activation"}
{"PMID":17581967,"re_id":3,"annotated sentence":"Kainate-selective ionotropic glutamate receptors (<e2>GluRs<\\e2>  require external Na+ and Cl- as well as the neurotransmitter <e1>L-glutamate<\\e1> for activation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"L-glutamate","object":"GluRs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Kainate-selective ionotropic glutamate receptors (<e2>GENE-N<\\e2>  require external Na+ and Cl- as well as the neurotransmitter <e1>CHEMICAL<\\e1> for activation","sentence":"Kainate-selective ionotropic glutamate receptors (GluRs  require external Na+ and Cl- as well as the neurotransmitter L-glutamate for activation"}
{"PMID":17581967,"re_id":4,"annotated sentence":"<e2>Kainate-selective ionotropic glutamate receptors<\\e2> (GluRs) require external <e1>Na+<\\e1> and Cl- as well as the neurotransmitter L-glutamate for activation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Na+","object":"Kainate-selective ionotropic glutamate receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> (GluRs) require external <e1>CHEMICAL<\\e1> and Cl- as well as the neurotransmitter L-glutamate for activation","sentence":"Kainate-selective ionotropic glutamate receptors (GluRs) require external Na+ and Cl- as well as the neurotransmitter L-glutamate for activation"}
{"PMID":17581967,"re_id":5,"annotated sentence":"Kainate-selective ionotropic glutamate receptors (<e2>GluRs<\\e2>  require external <e1>Na+<\\e1> and Cl- as well as the neurotransmitter L-glutamate for activation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Na+","object":"GluRs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Kainate-selective ionotropic glutamate receptors (<e2>GENE-N<\\e2>  require external <e1>CHEMICAL<\\e1> and Cl- as well as the neurotransmitter L-glutamate for activation","sentence":"Kainate-selective ionotropic glutamate receptors (GluRs  require external Na+ and Cl- as well as the neurotransmitter L-glutamate for activation"}
{"PMID":17581967,"re_id":6,"annotated sentence":"<e2>Kainate-selective ionotropic glutamate receptors<\\e2> (GluRs) require external Na+ and <e1>Cl-<\\e1> as well as the neurotransmitter L-glutamate for activation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Cl-","object":"Kainate-selective ionotropic glutamate receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> (GluRs) require external Na+ and <e1>CHEMICAL<\\e1> as well as the neurotransmitter L-glutamate for activation","sentence":"Kainate-selective ionotropic glutamate receptors (GluRs) require external Na+ and Cl- as well as the neurotransmitter L-glutamate for activation"}
{"PMID":17581967,"re_id":7,"annotated sentence":"Kainate-selective ionotropic glutamate receptors (<e2>GluRs<\\e2>  require external Na+ and <e1>Cl-<\\e1> as well as the neurotransmitter L-glutamate for activation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Cl-","object":"GluRs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Kainate-selective ionotropic glutamate receptors (<e2>GENE-N<\\e2>  require external Na+ and <e1>CHEMICAL<\\e1> as well as the neurotransmitter L-glutamate for activation","sentence":"Kainate-selective ionotropic glutamate receptors (GluRs  require external Na+ and Cl- as well as the neurotransmitter L-glutamate for activation"}
{"PMID":17581967,"re_id":8,"annotated sentence":"Additionally, <e1>Na+<\\e1> and Cl- ions coactivate <e2>GluR6<\\e2> receptors by establishing a dipole, accounting for their common effect on KARs","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Na+","object":"GluR6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additionally, <e1>CHEMICAL<\\e1> and Cl- ions coactivate <e2>GENE-Y<\\e2> receptors by establishing a dipole, accounting for their common effect on KARs","sentence":"Additionally, Na+ and Cl- ions coactivate GluR6 receptors by establishing a dipole, accounting for their common effect on KARs"}
{"PMID":17581967,"re_id":9,"annotated sentence":"Additionally, Na+ and <e1>Cl-<\\e1> ions coactivate <e2>GluR6<\\e2> receptors by establishing a dipole, accounting for their common effect on KARs","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Cl-","object":"GluR6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additionally, Na+ and <e1>CHEMICAL<\\e1> ions coactivate <e2>GENE-Y<\\e2> receptors by establishing a dipole, accounting for their common effect on KARs","sentence":"Additionally, Na+ and Cl- ions coactivate GluR6 receptors by establishing a dipole, accounting for their common effect on KARs"}
{"PMID":17594192,"re_id":0,"annotated sentence":"<e1>Phenserine<\\e1> apparently reduces translational efficiency of <e2>APP<\\e2> mRNA into protein, a process that may involve an interaction with iron and\/or an iron-responsive element","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Phenserine","object":"APP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> apparently reduces translational efficiency of <e2>GENE-Y<\\e2> mRNA into protein, a process that may involve an interaction with iron and\/or an iron-responsive element","sentence":"Phenserine apparently reduces translational efficiency of APP mRNA into protein, a process that may involve an interaction with iron and\/or an iron-responsive element"}
{"PMID":17594192,"re_id":1,"annotated sentence":"As a consequence, <e1>phenserine<\\e1> reduces <e2>beta-amyloid<\\e2> peptide (Abeta) formation in vitro and in vivo","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenserine","object":"beta-amyloid","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"As a consequence, <e1>CHEMICAL<\\e1> reduces <e2>GENE-Y<\\e2> peptide (Abeta) formation in vitro and in vivo","sentence":"As a consequence, phenserine reduces beta-amyloid peptide (Abeta) formation in vitro and in vivo"}
{"PMID":17594192,"re_id":2,"annotated sentence":"As a consequence, <e1>phenserine<\\e1> reduces beta-amyloid peptide (<e2>Abeta<\\e2>  formation in vitro and in vivo","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenserine","object":"Abeta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"As a consequence, <e1>CHEMICAL<\\e1> reduces beta-amyloid peptide (<e2>GENE-Y<\\e2>  formation in vitro and in vivo","sentence":"As a consequence, phenserine reduces beta-amyloid peptide (Abeta  formation in vitro and in vivo"}
{"PMID":17594192,"re_id":3,"annotated sentence":"<e1>Phenserine<\\e1>  a derivative of physostigmine, was first described as an inhibitor of acetylcholinesterase (<e2>AChE<\\e2>  and was shown to improve cognition in various experimental paradigms in rodents and dogs","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Phenserine","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a derivative of physostigmine, was first described as an inhibitor of acetylcholinesterase (<e2>GENE-N<\\e2>  and was shown to improve cognition in various experimental paradigms in rodents and dogs","sentence":"Phenserine  a derivative of physostigmine, was first described as an inhibitor of acetylcholinesterase (AChE  and was shown to improve cognition in various experimental paradigms in rodents and dogs"}
{"PMID":17594192,"re_id":4,"annotated sentence":"<e1>Phenserine<\\e1>  a derivative of physostigmine, was first described as an inhibitor of <e2>acetylcholinesterase<\\e2> (AChE) and was shown to improve cognition in various experimental paradigms in rodents and dogs","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Phenserine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a derivative of physostigmine, was first described as an inhibitor of <e2>GENE-N<\\e2> (AChE) and was shown to improve cognition in various experimental paradigms in rodents and dogs","sentence":"Phenserine  a derivative of physostigmine, was first described as an inhibitor of acetylcholinesterase (AChE) and was shown to improve cognition in various experimental paradigms in rodents and dogs"}
{"PMID":17594192,"re_id":5,"annotated sentence":"Phenserine is also unique because of differing actions of its enantiomers: <e1>(-)-phenserine<\\e1> is the active enantiomer for inhibition of <e2>AChE<\\e2>  whereas (+)-phenserine ('posiphen') has weak activity as an AChE inhibitor and can be dosed much higher","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"(-)-phenserine","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Phenserine is also unique because of differing actions of its enantiomers: <e1>CHEMICAL<\\e1> is the active enantiomer for inhibition of <e2>GENE-Y<\\e2>  whereas (+)-phenserine ('posiphen') has weak activity as an GENE-Y inhibitor and can be dosed much higher","sentence":"Phenserine is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of AChE  whereas (+)-phenserine ('posiphen') has weak activity as an AChE inhibitor and can be dosed much higher"}
{"PMID":17594192,"re_id":6,"annotated sentence":"Phenserine is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of AChE, whereas <e1>(+)-phenserine<\\e1> ('posiphen') has weak activity as an <e2>AChE<\\e2> inhibitor and can be dosed much higher","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"(+)-phenserine","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Phenserine is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of GENE-Y, whereas <e1>CHEMICAL<\\e1> ('posiphen') has weak activity as an <e2>GENE-Y<\\e2> inhibitor and can be dosed much higher","sentence":"Phenserine is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of AChE, whereas (+)-phenserine ('posiphen') has weak activity as an AChE inhibitor and can be dosed much higher"}
{"PMID":17594192,"re_id":7,"annotated sentence":"Phenserine is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of AChE, whereas (+)-phenserine ('<e1>posiphen<\\e1> ) has weak activity as an <e2>AChE<\\e2> inhibitor and can be dosed much higher","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"posiphen","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Phenserine is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of GENE-Y, whereas (+)-phenserine ('<e1>CHEMICAL<\\e1> ) has weak activity as an <e2>GENE-Y<\\e2> inhibitor and can be dosed much higher","sentence":"Phenserine is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of AChE, whereas (+)-phenserine ('posiphen ) has weak activity as an AChE inhibitor and can be dosed much higher"}
{"PMID":17594192,"re_id":8,"annotated sentence":"Phenserine, a derivative of <e1>physostigmine<\\e1>  was first described as an inhibitor of acetylcholinesterase (<e2>AChE<\\e2>  and was shown to improve cognition in various experimental paradigms in rodents and dogs","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"physostigmine","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Phenserine, a derivative of <e1>CHEMICAL<\\e1>  was first described as an inhibitor of acetylcholinesterase (<e2>GENE-N<\\e2>  and was shown to improve cognition in various experimental paradigms in rodents and dogs","sentence":"Phenserine, a derivative of physostigmine  was first described as an inhibitor of acetylcholinesterase (AChE  and was shown to improve cognition in various experimental paradigms in rodents and dogs"}
{"PMID":17594192,"re_id":9,"annotated sentence":"Phenserine, a derivative of <e1>physostigmine<\\e1>  was first described as an inhibitor of <e2>acetylcholinesterase<\\e2> (AChE) and was shown to improve cognition in various experimental paradigms in rodents and dogs","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"physostigmine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Phenserine, a derivative of <e1>CHEMICAL<\\e1>  was first described as an inhibitor of <e2>GENE-N<\\e2> (AChE) and was shown to improve cognition in various experimental paradigms in rodents and dogs","sentence":"Phenserine, a derivative of physostigmine  was first described as an inhibitor of acetylcholinesterase (AChE) and was shown to improve cognition in various experimental paradigms in rodents and dogs"}
{"PMID":17594192,"re_id":10,"annotated sentence":"<e1>Phenserine<\\e1> deserves attention for an additional quality of action: in addition to inhibiting <e2>AChE<\\e2>  it modulates the amount of beta-amyloid precursor protein (APP) in neuronal cell culture by reducing APP translation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Phenserine","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> deserves attention for an additional quality of action: in addition to inhibiting <e2>GENE-Y<\\e2>  it modulates the amount of beta-amyloid precursor protein (APP) in neuronal cell culture by reducing APP translation","sentence":"Phenserine deserves attention for an additional quality of action: in addition to inhibiting AChE  it modulates the amount of beta-amyloid precursor protein (APP) in neuronal cell culture by reducing APP translation"}
{"PMID":17594192,"re_id":11,"annotated sentence":"<e1>Phenserine<\\e1> deserves attention for an additional quality of action: in addition to inhibiting AChE, it modulates the amount of beta-amyloid precursor protein (APP) in neuronal cell culture by reducing <e2>APP<\\e2> translation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Phenserine","object":"APP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> deserves attention for an additional quality of action: in addition to inhibiting AChE, it modulates the amount of beta-amyloid precursor protein (GENE-Y) in neuronal cell culture by reducing <e2>GENE-Y<\\e2> translation","sentence":"Phenserine deserves attention for an additional quality of action: in addition to inhibiting AChE, it modulates the amount of beta-amyloid precursor protein (APP) in neuronal cell culture by reducing APP translation"}
{"PMID":17603555,"re_id":0,"annotated sentence":"Additional pharmacological effects evoked by <e1>AICAR<\\e1> and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of <e2>AMPK<\\e2> in cell systems where Na+K+ATPase is an important component.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"AICAR","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additional pharmacological effects evoked by <e1>CHEMICAL<\\e1> and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of <e2>GENE-Y<\\e2> in cell systems where Na+K+ATPase is an important component.","sentence":"Additional pharmacological effects evoked by AICAR and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where Na+K+ATPase is an important component."}
{"PMID":17603555,"re_id":1,"annotated sentence":"Additional pharmacological effects evoked by AICAR and <e1>phenformin<\\e1> on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of <e2>AMPK<\\e2> in cell systems where Na+K+ATPase is an important component.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"phenformin","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additional pharmacological effects evoked by AICAR and <e1>CHEMICAL<\\e1> on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of <e2>GENE-Y<\\e2> in cell systems where Na+K+ATPase is an important component.","sentence":"Additional pharmacological effects evoked by AICAR and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where Na+K+ATPase is an important component."}
{"PMID":17603555,"re_id":2,"annotated sentence":"Additional pharmacological effects evoked by AICAR and phenformin on I(<e1>ouabain<\\e1> , with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of <e2>AMPK<\\e2> in cell systems where Na+K+ATPase is an important component.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ouabain","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additional pharmacological effects evoked by AICAR and phenformin on I(<e1>CHEMICAL<\\e1> , with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of <e2>GENE-Y<\\e2> in cell systems where Na+K+ATPase is an important component.","sentence":"Additional pharmacological effects evoked by AICAR and phenformin on I(ouabain , with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where Na+K+ATPase is an important component."}
{"PMID":17603555,"re_id":3,"annotated sentence":"BACKGROUND AND PURPOSE: <e2>AMP-activated protein kinase<\\e2> (AMPK) is activated by metformin, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (<e1>AICAR<\\e1> ","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"AICAR","object":"AMP-activated protein kinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND AND PURPOSE: <e2>GENE-Y<\\e2> (AMPK) is activated by metformin, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (<e1>CHEMICAL<\\e1> ","sentence":"BACKGROUND AND PURPOSE: AMP-activated protein kinase (AMPK) is activated by metformin, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR "}
{"PMID":17603555,"re_id":4,"annotated sentence":"BACKGROUND AND PURPOSE: AMP-activated protein kinase (<e2>AMPK<\\e2>  is activated by metformin, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (<e1>AICAR<\\e1> ","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"AICAR","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND AND PURPOSE: AMP-activated protein kinase (<e2>GENE-Y<\\e2>  is activated by metformin, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (<e1>CHEMICAL<\\e1> ","sentence":"BACKGROUND AND PURPOSE: AMP-activated protein kinase (AMPK  is activated by metformin, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR "}
{"PMID":17603555,"re_id":5,"annotated sentence":"BACKGROUND AND PURPOSE: <e2>AMP-activated protein kinase<\\e2> (AMPK) is activated by <e1>metformin<\\e1>  phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"metformin","object":"AMP-activated protein kinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND AND PURPOSE: <e2>GENE-Y<\\e2> (AMPK) is activated by <e1>CHEMICAL<\\e1>  phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR)","sentence":"BACKGROUND AND PURPOSE: AMP-activated protein kinase (AMPK) is activated by metformin  phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR)"}
{"PMID":17603555,"re_id":6,"annotated sentence":"BACKGROUND AND PURPOSE: AMP-activated protein kinase (<e2>AMPK<\\e2>  is activated by <e1>metformin<\\e1>  phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"metformin","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND AND PURPOSE: AMP-activated protein kinase (<e2>GENE-Y<\\e2>  is activated by <e1>CHEMICAL<\\e1>  phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR)","sentence":"BACKGROUND AND PURPOSE: AMP-activated protein kinase (AMPK  is activated by metformin  phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR)"}
{"PMID":17603555,"re_id":7,"annotated sentence":"BACKGROUND AND PURPOSE: <e2>AMP-activated protein kinase<\\e2> (AMPK) is activated by metformin, <e1>phenformin<\\e1>  and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"phenformin","object":"AMP-activated protein kinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND AND PURPOSE: <e2>GENE-Y<\\e2> (AMPK) is activated by metformin, <e1>CHEMICAL<\\e1>  and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR)","sentence":"BACKGROUND AND PURPOSE: AMP-activated protein kinase (AMPK) is activated by metformin, phenformin  and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR)"}
{"PMID":17603555,"re_id":8,"annotated sentence":"BACKGROUND AND PURPOSE: AMP-activated protein kinase (<e2>AMPK<\\e2>  is activated by metformin, <e1>phenformin<\\e1>  and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"phenformin","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND AND PURPOSE: AMP-activated protein kinase (<e2>GENE-Y<\\e2>  is activated by metformin, <e1>CHEMICAL<\\e1>  and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR)","sentence":"BACKGROUND AND PURPOSE: AMP-activated protein kinase (AMPK  is activated by metformin, phenformin  and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR)"}
{"PMID":17603555,"re_id":9,"annotated sentence":"KEY RESULTS: <e1>Phenformin<\\e1>  AICAR and metformin increased <e2>AMPK (alpha1)<\\e2> activity and decreased I(amiloride)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Phenformin","object":"AMPK (alpha1)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"KEY RESULTS: <e1>CHEMICAL<\\e1>  AICAR and metformin increased <e2>GENE-Y<\\e2> activity and decreased I(amiloride)","sentence":"KEY RESULTS: Phenformin  AICAR and metformin increased AMPK (alpha1) activity and decreased I(amiloride)"}
{"PMID":17603555,"re_id":10,"annotated sentence":"KEY RESULTS: Phenformin, <e1>AICAR<\\e1> and metformin increased <e2>AMPK (alpha1)<\\e2> activity and decreased I(amiloride)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"AICAR","object":"AMPK (alpha1)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"KEY RESULTS: Phenformin, <e1>CHEMICAL<\\e1> and metformin increased <e2>GENE-Y<\\e2> activity and decreased I(amiloride)","sentence":"KEY RESULTS: Phenformin, AICAR and metformin increased AMPK (alpha1) activity and decreased I(amiloride)"}
{"PMID":17603555,"re_id":11,"annotated sentence":"KEY RESULTS: Phenformin, AICAR and <e1>metformin<\\e1> increased <e2>AMPK (alpha1)<\\e2> activity and decreased I(amiloride)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"metformin","object":"AMPK (alpha1)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"KEY RESULTS: Phenformin, AICAR and <e1>CHEMICAL<\\e1> increased <e2>GENE-Y<\\e2> activity and decreased I(amiloride)","sentence":"KEY RESULTS: Phenformin, AICAR and metformin increased AMPK (alpha1) activity and decreased I(amiloride)"}
{"PMID":17603555,"re_id":12,"annotated sentence":"The <e2>AMPK<\\e2> inhibitor Compound C prevented the action of metformin and AICAR but not <e1>phenformin<\\e1>  Phenformin and AICAR decreased I(ouabain) across H441 monolayers and decreased monolayer resistance","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"phenformin","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> inhibitor Compound C prevented the action of metformin and AICAR but not <e1>CHEMICAL<\\e1>  Phenformin and AICAR decreased I(ouabain) across H441 monolayers and decreased monolayer resistance","sentence":"The AMPK inhibitor Compound C prevented the action of metformin and AICAR but not phenformin  Phenformin and AICAR decreased I(ouabain) across H441 monolayers and decreased monolayer resistance"}
{"PMID":17603555,"re_id":13,"annotated sentence":"BACKGROUND AND PURPOSE: <e2>AMP-activated protein kinase<\\e2> (AMPK) is activated by metformin, phenformin, and the AMP mimetic, <e1>5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside<\\e1> (AICAR)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside","object":"AMP-activated protein kinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND AND PURPOSE: <e2>GENE-Y<\\e2> (AMPK) is activated by metformin, phenformin, and the AMP mimetic, <e1>CHEMICAL<\\e1> (AICAR)","sentence":"BACKGROUND AND PURPOSE: AMP-activated protein kinase (AMPK) is activated by metformin, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR)"}
{"PMID":17603555,"re_id":14,"annotated sentence":"BACKGROUND AND PURPOSE: AMP-activated protein kinase (<e2>AMPK<\\e2>  is activated by metformin, phenformin, and the AMP mimetic, <e1>5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside<\\e1> (AICAR)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND AND PURPOSE: AMP-activated protein kinase (<e2>GENE-Y<\\e2>  is activated by metformin, phenformin, and the AMP mimetic, <e1>CHEMICAL<\\e1> (AICAR)","sentence":"BACKGROUND AND PURPOSE: AMP-activated protein kinase (AMPK  is activated by metformin, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR)"}
{"PMID":17604186,"re_id":0,"annotated sentence":"Compared with normal control group, <e1>PTZ<\\e1> kindled mice had significantly higher levels of malondialdehyde, nitrite, <e2>myeloperoxidase<\\e2> but had lower levels of reduced glutathione in the whole brain homogenate","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"PTZ","object":"myeloperoxidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Compared with normal control group, <e1>CHEMICAL<\\e1> kindled mice had significantly higher levels of malondialdehyde, nitrite, <e2>GENE-Y<\\e2> but had lower levels of reduced glutathione in the whole brain homogenate","sentence":"Compared with normal control group, PTZ kindled mice had significantly higher levels of malondialdehyde, nitrite, myeloperoxidase but had lower levels of reduced glutathione in the whole brain homogenate"}
{"PMID":17604186,"re_id":1,"annotated sentence":"Previous studies have explored the protective effect of naproxen (non-selective COX-inhibitor) or <e1>rofecoxib<\\e1> (selective <e2>COX-2<\\e2> inhibitor) against chemical kindling in mice","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"rofecoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Previous studies have explored the protective effect of naproxen (non-selective COX-inhibitor) or <e1>CHEMICAL<\\e1> (selective <e2>GENE-Y<\\e2> inhibitor) against chemical kindling in mice","sentence":"Previous studies have explored the protective effect of naproxen (non-selective COX-inhibitor) or rofecoxib (selective COX-2 inhibitor) against chemical kindling in mice"}
{"PMID":17604186,"re_id":2,"annotated sentence":"With this background, the present study was designed to explore the possible effect of <e1>nimesulide<\\e1> (a preferential <e2>COX-2<\\e2> inhibitor) against pentylenetetrazol (PTZ)-induced kindling epilepsy in mice","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"nimesulide","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"With this background, the present study was designed to explore the possible effect of <e1>CHEMICAL<\\e1> (a preferential <e2>GENE-Y<\\e2> inhibitor) against pentylenetetrazol (PTZ)-induced kindling epilepsy in mice","sentence":"With this background, the present study was designed to explore the possible effect of nimesulide (a preferential COX-2 inhibitor) against pentylenetetrazol (PTZ)-induced kindling epilepsy in mice"}
{"PMID":17604186,"re_id":3,"annotated sentence":"Neuroprotective effect of <e1>nimesulide<\\e1>  a preferential <e2>COX-2<\\e2> inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"nimesulide","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Neuroprotective effect of <e1>CHEMICAL<\\e1>  a preferential <e2>GENE-Y<\\e2> inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice","sentence":"Neuroprotective effect of nimesulide  a preferential COX-2 inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice"}
{"PMID":17604186,"re_id":4,"annotated sentence":"These results suggested that <e1>nimesulide<\\e1>  a preferential <e2>COX-2<\\e2> inhibitor offered neuroprotection against PTZ-induced kindling in mice.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"nimesulide","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggested that <e1>CHEMICAL<\\e1>  a preferential <e2>GENE-Y<\\e2> inhibitor offered neuroprotection against PTZ-induced kindling in mice.","sentence":"These results suggested that nimesulide  a preferential COX-2 inhibitor offered neuroprotection against PTZ-induced kindling in mice."}
{"PMID":17604186,"re_id":5,"annotated sentence":"Previous studies have explored the protective effect of <e1>naproxen<\\e1> (non-selective <e2>COX<\\e2> inhibitor) or rofecoxib (selective COX-2 inhibitor) against chemical kindling in mice","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"naproxen","object":"COX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Previous studies have explored the protective effect of <e1>CHEMICAL<\\e1> (non-selective <e2>GENE-N<\\e2> inhibitor) or rofecoxib (selective GENE-N-2 inhibitor) against chemical kindling in mice","sentence":"Previous studies have explored the protective effect of naproxen (non-selective COX inhibitor) or rofecoxib (selective COX-2 inhibitor) against chemical kindling in mice"}
{"PMID":17604186,"re_id":6,"annotated sentence":"Brain cyclooxygenases (<e2>COX<\\e2> , the rate-limiting enzyme in <e1>prostaglandin<\\e1> synthesis, is rapidly and transiently induced by convulsions in hippocampal and cortical neurons","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"prostaglandin","object":"COX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Brain cyclooxygenases (<e2>GENE-N<\\e2> , the rate-limiting enzyme in <e1>CHEMICAL<\\e1> synthesis, is rapidly and transiently induced by convulsions in hippocampal and cortical neurons","sentence":"Brain cyclooxygenases (COX , the rate-limiting enzyme in prostaglandin synthesis, is rapidly and transiently induced by convulsions in hippocampal and cortical neurons"}
{"PMID":17604186,"re_id":7,"annotated sentence":"Brain <e2>cyclooxygenases<\\e2> (COX), the rate-limiting enzyme in <e1>prostaglandin<\\e1> synthesis, is rapidly and transiently induced by convulsions in hippocampal and cortical neurons","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"prostaglandin","object":"cyclooxygenases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Brain <e2>GENE-N<\\e2> (COX), the rate-limiting enzyme in <e1>CHEMICAL<\\e1> synthesis, is rapidly and transiently induced by convulsions in hippocampal and cortical neurons","sentence":"Brain cyclooxygenases (COX), the rate-limiting enzyme in prostaglandin synthesis, is rapidly and transiently induced by convulsions in hippocampal and cortical neurons"}
{"PMID":17627474,"re_id":0,"annotated sentence":"While vitamin C is essential for PHD activity in vitro, N-acetyl-L-cysteine had no effect, and <e1>gallic acid<\\e1> or n-propyl gallate efficiently inhibited the activity of all three <e2>PHDs<\\e2>  demonstrating different functions of these antioxidants.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"gallic acid","object":"PHDs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"While vitamin C is essential for PHD activity in vitro, N-acetyl-L-cysteine had no effect, and <e1>CHEMICAL<\\e1> or n-propyl gallate efficiently inhibited the activity of all three <e2>GENE-N<\\e2>  demonstrating different functions of these antioxidants.","sentence":"While vitamin C is essential for PHD activity in vitro, N-acetyl-L-cysteine had no effect, and gallic acid or n-propyl gallate efficiently inhibited the activity of all three PHDs  demonstrating different functions of these antioxidants."}
{"PMID":17627474,"re_id":1,"annotated sentence":"While vitamin C is essential for PHD activity in vitro, N-acetyl-L-cysteine had no effect, and gallic acid or <e1>n-propyl gallate<\\e1> efficiently inhibited the activity of all three <e2>PHDs<\\e2>  demonstrating different functions of these antioxidants.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"n-propyl gallate","object":"PHDs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"While vitamin C is essential for PHD activity in vitro, N-acetyl-L-cysteine had no effect, and gallic acid or <e1>CHEMICAL<\\e1> efficiently inhibited the activity of all three <e2>GENE-N<\\e2>  demonstrating different functions of these antioxidants.","sentence":"While vitamin C is essential for PHD activity in vitro, N-acetyl-L-cysteine had no effect, and gallic acid or n-propyl gallate efficiently inhibited the activity of all three PHDs  demonstrating different functions of these antioxidants."}
{"PMID":17632548,"re_id":0,"annotated sentence":"<e2>LTC4 synthase<\\e2> (LTC4S), the pivotal enzyme for the biosynthesis of <e1>LTC4<\\e1> (ref","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"LTC4","object":"LTC4 synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>CHEMICAL synthase<\\e2> (CHEMICALS), the pivotal enzyme for the biosynthesis of <e1>CHEMICAL<\\e1> (ref","sentence":"LTC4 synthase (LTC4S), the pivotal enzyme for the biosynthesis of LTC4 (ref"}
{"PMID":17632548,"re_id":1,"annotated sentence":"LTC4 synthase (<e2>LTC4S<\\e2> , the pivotal enzyme for the biosynthesis of <e1>LTC4<\\e1> (ref","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"LTC4","object":"LTC4S","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CHEMICAL synthase (<e2>CHEMICALS<\\e2> , the pivotal enzyme for the biosynthesis of <e1>CHEMICAL<\\e1> (ref","sentence":"LTC4 synthase (LTC4S , the pivotal enzyme for the biosynthesis of LTC4 (ref"}
{"PMID":17632548,"re_id":2,"annotated sentence":"10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in <e1>eicosanoid<\\e1> and glutathione metabolism that includes 5-lipoxygenase-activating protein, <e2>microsomal glutathione S-transferases<\\e2> (MGSTs), and microsomal prostaglandin E synthase 1 (ref","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"eicosanoid","object":"microsomal glutathione S-transferases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in <e1>CHEMICAL<\\e1> and glutathione metabolism that includes 5-lipoxygenase-activating protein, <e2>GENE-N<\\e2> (MGSTs), and microsomal prostaglandin E synthase 1 (ref","sentence":"10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (MGSTs), and microsomal prostaglandin E synthase 1 (ref"}
{"PMID":17632548,"re_id":3,"annotated sentence":"10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in <e1>eicosanoid<\\e1> and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (<e2>MGSTs<\\e2> , and microsomal prostaglandin E synthase 1 (ref","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"eicosanoid","object":"MGSTs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in <e1>CHEMICAL<\\e1> and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (<e2>GENE-N<\\e2> , and microsomal prostaglandin E synthase 1 (ref","sentence":"10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (MGSTs , and microsomal prostaglandin E synthase 1 (ref"}
{"PMID":17632548,"re_id":4,"annotated sentence":"10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in <e1>eicosanoid<\\e1> and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (MGSTs), and <e2>microsomal prostaglandin E synthase 1<\\e2> (ref","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"eicosanoid","object":"microsomal prostaglandin E synthase 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in <e1>CHEMICAL<\\e1> and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (MGSTs), and <e2>GENE-Y<\\e2> (ref","sentence":"10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (MGSTs), and microsomal prostaglandin E synthase 1 (ref"}
{"PMID":17632548,"re_id":5,"annotated sentence":"10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and <e1>glutathione<\\e1> metabolism that includes 5-lipoxygenase-activating protein, <e2>microsomal glutathione S-transferases<\\e2> (MGSTs), and microsomal prostaglandin E synthase 1 (ref","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutathione","object":"microsomal glutathione S-transferases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and <e1>CHEMICAL<\\e1> metabolism that includes 5-lipoxygenase-activating protein, <e2>microsomal CHEMICAL S-transferases<\\e2> (MGSTs), and microsomal prostaglandin E synthase 1 (ref","sentence":"10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (MGSTs), and microsomal prostaglandin E synthase 1 (ref"}
{"PMID":17632548,"re_id":6,"annotated sentence":"10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and <e1>glutathione<\\e1> metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (<e2>MGSTs<\\e2> , and microsomal prostaglandin E synthase 1 (ref","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutathione","object":"MGSTs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and <e1>CHEMICAL<\\e1> metabolism that includes 5-lipoxygenase-activating protein, microsomal CHEMICAL S-transferases (<e2>GENE-N<\\e2> , and microsomal prostaglandin E synthase 1 (ref","sentence":"10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (MGSTs , and microsomal prostaglandin E synthase 1 (ref"}
{"PMID":17632548,"re_id":7,"annotated sentence":"10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and <e1>glutathione<\\e1> metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (MGSTs), and <e2>microsomal prostaglandin E synthase 1<\\e2> (ref","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutathione","object":"microsomal prostaglandin E synthase 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and <e1>CHEMICAL<\\e1> metabolism that includes 5-lipoxygenase-activating protein, microsomal CHEMICAL S-transferases (MGSTs), and <e2>GENE-Y<\\e2> (ref","sentence":"10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (MGSTs), and microsomal prostaglandin E synthase 1 (ref"}
{"PMID":17768678,"re_id":0,"annotated sentence":"<e1>Phenelzine<\\e1> (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits GABA-transaminase (<e2>GABA-T<\\e2> , markedly increasing brain GABA levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Phenelzine","object":"GABA-T","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits GABA-transaminase (<e2>GENE-Y<\\e2> , markedly increasing brain GABA levels","sentence":"Phenelzine (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits GABA-transaminase (GABA-T , markedly increasing brain GABA levels"}
{"PMID":17768678,"re_id":1,"annotated sentence":"<e1>Phenelzine<\\e1> (PLZ), a nonselective irreversible inhibitor of <e2>monoamine oxidase<\\e2> (MAO), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Phenelzine","object":"monoamine oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (PLZ), a nonselective irreversible inhibitor of <e2>GENE-N<\\e2> (MAO), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels","sentence":"Phenelzine (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels"}
{"PMID":17768678,"re_id":2,"annotated sentence":"<e1>Phenelzine<\\e1> (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (<e2>MAO<\\e2> , also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Phenelzine","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (<e2>GENE-N<\\e2> , also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels","sentence":"Phenelzine (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO , also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels"}
{"PMID":17768678,"re_id":3,"annotated sentence":"<e1>Phenelzine<\\e1> (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits <e2>GABA-transaminase<\\e2> (GABA-T), markedly increasing brain GABA levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Phenelzine","object":"GABA-transaminase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits <e2>GENE-Y<\\e2> (GABA-T), markedly increasing brain GABA levels","sentence":"Phenelzine (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels"}
{"PMID":17768678,"re_id":4,"annotated sentence":"To determine whether a metabolite formed by the action of MAO on PLZ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the <e2>MAO<\\e2> inhibitor <e1>tranylcypromine<\\e1> (TCP) before vehicle or PLZ (15 mg\/kg), and brains collected 3 h later","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tranylcypromine","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"To determine whether a metabolite formed by the action of GENE-N on PLZ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1> (TCP) before vehicle or PLZ (15 mg\/kg), and brains collected 3 h later","sentence":"To determine whether a metabolite formed by the action of MAO on PLZ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the MAO inhibitor tranylcypromine (TCP) before vehicle or PLZ (15 mg\/kg), and brains collected 3 h later"}
{"PMID":17768678,"re_id":5,"annotated sentence":"To determine whether a metabolite formed by the action of MAO on PLZ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the <e2>MAO<\\e2> inhibitor tranylcypromine (<e1>TCP<\\e1>  before vehicle or PLZ (15 mg\/kg), and brains collected 3 h later","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TCP","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"To determine whether a metabolite formed by the action of GENE-N on PLZ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the <e2>GENE-N<\\e2> inhibitor tranylcypromine (<e1>CHEMICAL<\\e1>  before vehicle or PLZ (15 mg\/kg), and brains collected 3 h later","sentence":"To determine whether a metabolite formed by the action of MAO on PLZ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the MAO inhibitor tranylcypromine (TCP  before vehicle or PLZ (15 mg\/kg), and brains collected 3 h later"}
{"PMID":17768678,"re_id":6,"annotated sentence":"<e1>Phenelzine<\\e1> causes an increase in brain ornithine that is prevented by prior <e2>monoamine oxidase<\\e2> inhibition","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Phenelzine","object":"monoamine oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> causes an increase in brain ornithine that is prevented by prior <e2>GENE-N<\\e2> inhibition","sentence":"Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition"}
{"PMID":17768678,"re_id":7,"annotated sentence":"Phenelzine (<e1>PLZ<\\e1> , a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits GABA-transaminase (<e2>GABA-T<\\e2> , markedly increasing brain GABA levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PLZ","object":"GABA-T","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Phenelzine (<e1>CHEMICAL<\\e1> , a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits GABA-transaminase (<e2>GENE-Y<\\e2> , markedly increasing brain GABA levels","sentence":"Phenelzine (PLZ , a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits GABA-transaminase (GABA-T , markedly increasing brain GABA levels"}
{"PMID":17768678,"re_id":8,"annotated sentence":"Phenelzine (<e1>PLZ<\\e1> , a nonselective irreversible inhibitor of <e2>monoamine oxidase<\\e2> (MAO), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PLZ","object":"monoamine oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Phenelzine (<e1>CHEMICAL<\\e1> , a nonselective irreversible inhibitor of <e2>GENE-N<\\e2> (MAO), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels","sentence":"Phenelzine (PLZ , a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels"}
{"PMID":17768678,"re_id":9,"annotated sentence":"Phenelzine (<e1>PLZ<\\e1> , a nonselective irreversible inhibitor of monoamine oxidase (<e2>MAO<\\e2> , also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PLZ","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Phenelzine (<e1>CHEMICAL<\\e1> , a nonselective irreversible inhibitor of monoamine oxidase (<e2>GENE-N<\\e2> , also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels","sentence":"Phenelzine (PLZ , a nonselective irreversible inhibitor of monoamine oxidase (MAO , also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels"}
{"PMID":17768678,"re_id":10,"annotated sentence":"Phenelzine (<e1>PLZ<\\e1> , a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits <e2>GABA-transaminase<\\e2> (GABA-T), markedly increasing brain GABA levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PLZ","object":"GABA-transaminase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Phenelzine (<e1>CHEMICAL<\\e1> , a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits <e2>GENE-Y<\\e2> (GABA-T), markedly increasing brain GABA levels","sentence":"Phenelzine (PLZ , a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels"}
{"PMID":17768678,"re_id":11,"annotated sentence":"Pretreatment with TCP completely abolished the PLZ-induced increase in brain ORN, suggesting, as with GABA, that a metabolite of <e1>PLZ<\\e1> formed by the action of <e2>MAO<\\e2> is responsible for the elevation of brain ORN observed","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"PLZ","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Pretreatment with TCP completely abolished the CHEMICAL-induced increase in brain ORN, suggesting, as with GABA, that a metabolite of <e1>CHEMICAL<\\e1> formed by the action of <e2>GENE-N<\\e2> is responsible for the elevation of brain ORN observed","sentence":"Pretreatment with TCP completely abolished the PLZ-induced increase in brain ORN, suggesting, as with GABA, that a metabolite of PLZ formed by the action of MAO is responsible for the elevation of brain ORN observed"}
{"PMID":17768678,"re_id":12,"annotated sentence":"<e1>PLZ<\\e1> is also a substrate for <e2>MAO<\\e2>  and studies suggest that a metabolite formed by the action of this enzyme on PLZ may be responsible for the increase in GABA observed","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"PLZ","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is also a substrate for <e2>GENE-N<\\e2>  and studies suggest that a metabolite formed by the action of this enzyme on CHEMICAL may be responsible for the increase in GABA observed","sentence":"PLZ is also a substrate for MAO  and studies suggest that a metabolite formed by the action of this enzyme on PLZ may be responsible for the increase in GABA observed"}
{"PMID":17869551,"re_id":0,"annotated sentence":"As further support, <e1>alpha-methyl-DL-aspartate<\\e1>  an inhibitor of <e2>argininosuccinate synthase<\\e2> (AS), a component of the citrulline-NO cycle, inhibited NO production in a dose-dependent manner","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"alpha-methyl-DL-aspartate","object":"argininosuccinate synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"As further support, <e1>CHEMICAL<\\e1>  an inhibitor of <e2>GENE-Y<\\e2> (AS), a component of the citrulline-NO cycle, inhibited NO production in a dose-dependent manner","sentence":"As further support, alpha-methyl-DL-aspartate  an inhibitor of argininosuccinate synthase (AS), a component of the citrulline-NO cycle, inhibited NO production in a dose-dependent manner"}
{"PMID":17869551,"re_id":1,"annotated sentence":"As further support, <e1>alpha-methyl-DL-aspartate<\\e1>  an inhibitor of argininosuccinate synthase (<e2>AS<\\e2> , a component of the citrulline-NO cycle, inhibited NO production in a dose-dependent manner","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"alpha-methyl-DL-aspartate","object":"AS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"As further support, <e1>CHEMICAL<\\e1>  an inhibitor of argininosuccinate synthase (<e2>GENE-Y<\\e2> , a component of the citrulline-NO cycle, inhibited NO production in a dose-dependent manner","sentence":"As further support, alpha-methyl-DL-aspartate  an inhibitor of argininosuccinate synthase (AS , a component of the citrulline-NO cycle, inhibited NO production in a dose-dependent manner"}
{"PMID":17869551,"re_id":2,"annotated sentence":"Nitric oxide (<e1>NO<\\e1>  is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by <e2>endothelial nitric oxide synthase<\\e2> (eNOS)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"NO","object":"endothelial nitric oxide synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Nitric oxide (<e1>CHEMICAL<\\e1>  is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by <e2>GENE-Y<\\e2> (eCHEMICALS)","sentence":"Nitric oxide (NO  is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase (eNOS)"}
{"PMID":17869551,"re_id":3,"annotated sentence":"Nitric oxide (<e1>NO<\\e1>  is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase (<e2>eNOS<\\e2> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"NO","object":"eNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Nitric oxide (<e1>CHEMICAL<\\e1>  is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase (<e2>eCHEMICALS<\\e2> ","sentence":"Nitric oxide (NO  is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase (eNOS "}
{"PMID":17869551,"re_id":4,"annotated sentence":"<e1>Nitric oxide<\\e1> (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by <e2>endothelial nitric oxide synthase<\\e2> (eNOS)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Nitric oxide","object":"endothelial nitric oxide synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by <e2>GENE-Y<\\e2> (eNOS)","sentence":"Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase (eNOS)"}
{"PMID":17869551,"re_id":5,"annotated sentence":"<e1>Nitric oxide<\\e1> (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase (<e2>eNOS<\\e2> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Nitric oxide","object":"eNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase (<e2>GENE-Y<\\e2> ","sentence":"Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase (eNOS "}
{"PMID":17869551,"re_id":6,"annotated sentence":"Nitric oxide (NO) is an important vasorelaxant produced along with <e1>L-citrulline<\\e1> from L-arginine in a reaction catalyzed by <e2>endothelial nitric oxide synthase<\\e2> (eNOS)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-citrulline","object":"endothelial nitric oxide synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Nitric oxide (NO) is an important vasorelaxant produced along with <e1>CHEMICAL<\\e1> from L-arginine in a reaction catalyzed by <e2>GENE-Y<\\e2> (eNOS)","sentence":"Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase (eNOS)"}
{"PMID":17869551,"re_id":7,"annotated sentence":"Nitric oxide (NO) is an important vasorelaxant produced along with <e1>L-citrulline<\\e1> from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase (<e2>eNOS<\\e2> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-citrulline","object":"eNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Nitric oxide (NO) is an important vasorelaxant produced along with <e1>CHEMICAL<\\e1> from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase (<e2>GENE-Y<\\e2> ","sentence":"Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase (eNOS "}
{"PMID":17869551,"re_id":8,"annotated sentence":"Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from <e1>L-arginine<\\e1> in a reaction catalyzed by <e2>endothelial nitric oxide synthase<\\e2> (eNOS)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-arginine","object":"endothelial nitric oxide synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from <e1>CHEMICAL<\\e1> in a reaction catalyzed by <e2>GENE-Y<\\e2> (eNOS)","sentence":"Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase (eNOS)"}
{"PMID":17869551,"re_id":9,"annotated sentence":"Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from <e1>L-arginine<\\e1> in a reaction catalyzed by endothelial nitric oxide synthase (<e2>eNOS<\\e2> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-arginine","object":"eNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from <e1>CHEMICAL<\\e1> in a reaction catalyzed by endothelial nitric oxide synthase (<e2>GENE-Y<\\e2> ","sentence":"Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase (eNOS "}
{"PMID":17916059,"re_id":0,"annotated sentence":"Caution is necessary only when it is coadministered with drugs metabolised by <e2>CYP2D6<\\e2>  such as <e1>metoprolol<\\e1>  or administered to the elderly or patients with severe hepatic or renal impairment","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"metoprolol","object":"CYP2D6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Caution is necessary only when it is coadministered with drugs metabolised by <e2>GENE-Y<\\e2>  such as <e1>CHEMICAL<\\e1>  or administered to the elderly or patients with severe hepatic or renal impairment","sentence":"Caution is necessary only when it is coadministered with drugs metabolised by CYP2D6  such as metoprolol  or administered to the elderly or patients with severe hepatic or renal impairment"}
{"PMID":17980251,"re_id":0,"annotated sentence":"<e1>AZD6140<\\e1> is a reversible oral <e2>P2Y(12)<\\e2> receptor antagonist that has been studied in ACS patients in comparison with clopidogrel (DISPERSE-2 study)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"AZD6140","object":"P2Y(12)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is a reversible oral <e2>GENE-Y<\\e2> receptor antagonist that has been studied in ACS patients in comparison with clopidogrel (DISPERSE-2 study)","sentence":"AZD6140 is a reversible oral P2Y(12) receptor antagonist that has been studied in ACS patients in comparison with clopidogrel (DISPERSE-2 study)"}
{"PMID":17980251,"re_id":1,"annotated sentence":"AZD6140 is a reversible oral <e2>P2Y(12)<\\e2> receptor antagonist that has been studied in ACS patients in comparison with <e1>clopidogrel<\\e1> (DISPERSE-2 study)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"clopidogrel","object":"P2Y(12)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"AZD6140 is a reversible oral <e2>GENE-Y<\\e2> receptor antagonist that has been studied in ACS patients in comparison with <e1>CHEMICAL<\\e1> (DISPERSE-2 study)","sentence":"AZD6140 is a reversible oral P2Y(12) receptor antagonist that has been studied in ACS patients in comparison with clopidogrel (DISPERSE-2 study)"}
{"PMID":17980251,"re_id":2,"annotated sentence":"Inhibition of platelet aggregation by AZD6140, a reversible oral <e2>P2Y12<\\e2> receptor antagonist, compared with <e1>clopidogrel<\\e1> in patients with acute coronary syndromes","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"clopidogrel","object":"P2Y12","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of platelet aggregation by AZD6140, a reversible oral <e2>GENE-Y<\\e2> receptor antagonist, compared with <e1>CHEMICAL<\\e1> in patients with acute coronary syndromes","sentence":"Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes"}
{"PMID":17980251,"re_id":3,"annotated sentence":"Inhibition of platelet aggregation by <e1>AZD6140<\\e1>  a reversible oral <e2>P2Y12<\\e2> receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"AZD6140","object":"P2Y12","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of platelet aggregation by <e1>CHEMICAL<\\e1>  a reversible oral <e2>GENE-Y<\\e2> receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes","sentence":"Inhibition of platelet aggregation by AZD6140  a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes"}
{"PMID":18045203,"re_id":0,"annotated sentence":"<e1>Oxybutynin<\\e1> (1) is a non-selective <e2>muscarinic receptor<\\e2> antagonist that is used clinically for the treatment of urinary incontinence","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Oxybutynin","object":"muscarinic receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (1) is a non-selective <e2>GENE-N<\\e2> antagonist that is used clinically for the treatment of urinary incontinence","sentence":"Oxybutynin (1) is a non-selective muscarinic receptor antagonist that is used clinically for the treatment of urinary incontinence"}
{"PMID":18450949,"re_id":0,"annotated sentence":"Administration of <e1>cevimeline hydrochloride<\\e1>  an M3 muscarinic receptor agonist (10 mg\/kg for 7 days po), but not pilocarpine (0.3 mg\/kg for 7 days po), recovered the <e2>AQP5<\\e2> protein level reduced by CTD and increased the AQP1 protein level above the control one","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cevimeline hydrochloride","object":"AQP5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Administration of <e1>CHEMICAL<\\e1>  an M3 muscarinic receptor agonist (10 mg\/kg for 7 days po), but not pilocarpine (0.3 mg\/kg for 7 days po), recovered the <e2>GENE-Y<\\e2> protein level reduced by CTD and increased the AQP1 protein level above the control one","sentence":"Administration of cevimeline hydrochloride  an M3 muscarinic receptor agonist (10 mg\/kg for 7 days po), but not pilocarpine (0.3 mg\/kg for 7 days po), recovered the AQP5 protein level reduced by CTD and increased the AQP1 protein level above the control one"}
{"PMID":18450949,"re_id":1,"annotated sentence":"Administration of <e1>cevimeline hydrochloride<\\e1>  an M3 muscarinic receptor agonist (10 mg\/kg for 7 days po), but not pilocarpine (0.3 mg\/kg for 7 days po), recovered the AQP5 protein level reduced by CTD and increased the <e2>AQP1<\\e2> protein level above the control one","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cevimeline hydrochloride","object":"AQP1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Administration of <e1>CHEMICAL<\\e1>  an M3 muscarinic receptor agonist (10 mg\/kg for 7 days po), but not pilocarpine (0.3 mg\/kg for 7 days po), recovered the AQP5 protein level reduced by CTD and increased the <e2>GENE-Y<\\e2> protein level above the control one","sentence":"Administration of cevimeline hydrochloride  an M3 muscarinic receptor agonist (10 mg\/kg for 7 days po), but not pilocarpine (0.3 mg\/kg for 7 days po), recovered the AQP5 protein level reduced by CTD and increased the AQP1 protein level above the control one"}
{"PMID":18450949,"re_id":2,"annotated sentence":"Administration of <e1>chloroquine<\\e1> (50 mg\/kg for 7 days po), a denaturant of lysosomes, increased the <e2>AQP5<\\e2> protein level reduced by CTD","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"chloroquine","object":"AQP5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Administration of <e1>CHEMICAL<\\e1> (50 mg\/kg for 7 days po), a denaturant of lysosomes, increased the <e2>GENE-Y<\\e2> protein level reduced by CTD","sentence":"Administration of chloroquine (50 mg\/kg for 7 days po), a denaturant of lysosomes, increased the AQP5 protein level reduced by CTD"}
{"PMID":18450949,"re_id":3,"annotated sentence":"Degradation of submandibular gland <e2>AQP5<\\e2> by parasympathetic denervation of chorda tympani and its recovery by <e1>cevimeline<\\e1>  an M3 muscarinic receptor agonist","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cevimeline","object":"AQP5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Degradation of submandibular gland <e2>GENE-Y<\\e2> by parasympathetic denervation of chorda tympani and its recovery by <e1>CHEMICAL<\\e1>  an M3 muscarinic receptor agonist","sentence":"Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by cevimeline  an M3 muscarinic receptor agonist"}
{"PMID":18450949,"re_id":4,"annotated sentence":"Administration of <e1>cevimeline hydrochloride<\\e1>  an <e2>M3 muscarinic receptor<\\e2> agonist (10 mg\/kg for 7 days po), but not pilocarpine (0.3 mg\/kg for 7 days po), recovered the AQP5 protein level reduced by CTD and increased the AQP1 protein level above the control one","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"cevimeline hydrochloride","object":"M3 muscarinic receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Administration of <e1>CHEMICAL<\\e1>  an <e2>GENE-Y<\\e2> agonist (10 mg\/kg for 7 days po), but not pilocarpine (0.3 mg\/kg for 7 days po), recovered the AQP5 protein level reduced by CTD and increased the AQP1 protein level above the control one","sentence":"Administration of cevimeline hydrochloride  an M3 muscarinic receptor agonist (10 mg\/kg for 7 days po), but not pilocarpine (0.3 mg\/kg for 7 days po), recovered the AQP5 protein level reduced by CTD and increased the AQP1 protein level above the control one"}
{"PMID":18450949,"re_id":5,"annotated sentence":"Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by <e1>cevimeline<\\e1>  an <e2>M3 muscarinic receptor<\\e2> agonist","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"cevimeline","object":"M3 muscarinic receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by <e1>CHEMICAL<\\e1>  an <e2>GENE-Y<\\e2> agonist","sentence":"Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by cevimeline  an M3 muscarinic receptor agonist"}
{"PMID":18480678,"re_id":0,"annotated sentence":"<e1>threo-methylphenidate<\\e1> inhibits the <e2>dopamine transporter<\\e2> and the norepinephrine transporter, resulting in elevations of these monoamines after impulse release","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"threo-methylphenidate","object":"dopamine transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits the <e2>GENE-Y<\\e2> and the norepinephrine transporter, resulting in elevations of these monoamines after impulse release","sentence":"threo-methylphenidate inhibits the dopamine transporter and the norepinephrine transporter, resulting in elevations of these monoamines after impulse release"}
{"PMID":18480678,"re_id":1,"annotated sentence":"<e1>threo-methylphenidate<\\e1> inhibits the dopamine transporter and the <e2>norepinephrine transporter<\\e2>  resulting in elevations of these monoamines after impulse release","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"threo-methylphenidate","object":"norepinephrine transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits the dopamine transporter and the <e2>GENE-Y<\\e2>  resulting in elevations of these monoamines after impulse release","sentence":"threo-methylphenidate inhibits the dopamine transporter and the norepinephrine transporter  resulting in elevations of these monoamines after impulse release"}
{"PMID":18480678,"re_id":2,"annotated sentence":"threo-methylphenidate inhibits the <e2>dopamine transporter<\\e2> and the norepinephrine transporter, resulting in elevations of these <e1>monoamines<\\e1> after impulse release","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"monoamines","object":"dopamine transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"threo-methylphenidate inhibits the <e2>GENE-Y<\\e2> and the norepinephrine transporter, resulting in elevations of these <e1>CHEMICAL<\\e1> after impulse release","sentence":"threo-methylphenidate inhibits the dopamine transporter and the norepinephrine transporter, resulting in elevations of these monoamines after impulse release"}
{"PMID":18480678,"re_id":3,"annotated sentence":"threo-methylphenidate inhibits the dopamine transporter and the <e2>norepinephrine transporter<\\e2>  resulting in elevations of these <e1>monoamines<\\e1> after impulse release","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"monoamines","object":"norepinephrine transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"threo-methylphenidate inhibits the dopamine transporter and the <e2>GENE-Y<\\e2>  resulting in elevations of these <e1>CHEMICAL<\\e1> after impulse release","sentence":"threo-methylphenidate inhibits the dopamine transporter and the norepinephrine transporter  resulting in elevations of these monoamines after impulse release"}
{"PMID":18593927,"re_id":0,"annotated sentence":"The direct inhibition of <e2>stathmin<\\e2> by <e1>CCNU<\\e1> is likely a contributing factor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CCNU","object":"stathmin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The direct inhibition of <e2>GENE-Y<\\e2> by <e1>CHEMICAL<\\e1> is likely a contributing factor","sentence":"The direct inhibition of stathmin by CCNU is likely a contributing factor"}
{"PMID":18604229,"re_id":0,"annotated sentence":"CONCLUSIONS AND IMPLICATIONS: <e1>Amiodarone<\\e1> analogues with better <e2>hERG<\\e2> channel inhibition and cytotoxicity profiles than the parent compound have been identified, demonstrating that cytotoxicity and hERG channel interaction are mechanistically distinct and separable properties of the compounds.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Amiodarone","object":"hERG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSIONS AND IMPLICATIONS: <e1>CHEMICAL<\\e1> analogues with better <e2>GENE-Y<\\e2> channel inhibition and cytotoxicity profiles than the parent compound have been identified, demonstrating that cytotoxicity and GENE-Y channel interaction are mechanistically distinct and separable properties of the compounds.","sentence":"CONCLUSIONS AND IMPLICATIONS: Amiodarone analogues with better hERG channel inhibition and cytotoxicity profiles than the parent compound have been identified, demonstrating that cytotoxicity and hERG channel interaction are mechanistically distinct and separable properties of the compounds."}
{"PMID":18604229,"re_id":1,"annotated sentence":"The principal aim of the study was to find <e1>amiodarone<\\e1> analogues that retained <e2>human ether-a-go-go-related protein (hERG) channel<\\e2> inhibition but with reduced cytotoxicity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"amiodarone","object":"human ether-a-go-go-related protein (hERG) channel","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The principal aim of the study was to find <e1>CHEMICAL<\\e1> analogues that retained <e2>GENE-Y<\\e2> inhibition but with reduced cytotoxicity","sentence":"The principal aim of the study was to find amiodarone analogues that retained human ether-a-go-go-related protein (hERG) channel inhibition but with reduced cytotoxicity"}
{"PMID":18655903,"re_id":0,"annotated sentence":"In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as <e1>carbetocin<\\e1> (<e2>OT<\\e2> agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"carbetocin","object":"OT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition to GENE-Y and to a lesser extent AVP (pitressin), a number of GENE-Y and AVP analogues; such as <e1>CHEMICAL<\\e1> (<e2>GENE-Y<\\e2> agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile GENE-Y antagonist) are also in clinical use","sentence":"In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use"}
{"PMID":18655903,"re_id":1,"annotated sentence":"In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (<e1>desmopressin<\\e1>  <e2>V(2)<\\e2> agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"desmopressin","object":"V(2)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (<e1>CHEMICAL<\\e1>  <e2>GENE-Y<\\e2> agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use","sentence":"In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin  V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use"}
{"PMID":18655903,"re_id":2,"annotated sentence":"In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), <e1>terlipressin<\\e1> (<e2>V(1a)<\\e2> agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"terlipressin","object":"V(1a)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), <e1>CHEMICAL<\\e1> (<e2>GENE-Y<\\e2> agonist), felypressin (GENE-Y agonist) and atosiban (Tractocile OT antagonist) are also in clinical use","sentence":"In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use"}
{"PMID":18655903,"re_id":3,"annotated sentence":"In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), <e1>felypressin<\\e1> (<e2>V(1a)<\\e2> agonist) and atosiban (Tractocile OT antagonist) are also in clinical use","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"felypressin","object":"V(1a)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (GENE-Y agonist), <e1>CHEMICAL<\\e1> (<e2>GENE-Y<\\e2> agonist) and atosiban (Tractocile OT antagonist) are also in clinical use","sentence":"In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use"}
{"PMID":18655903,"re_id":4,"annotated sentence":"In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and <e1>atosiban<\\e1> (Tractocile <e2>OT<\\e2> antagonist) are also in clinical use","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"atosiban","object":"OT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition to GENE-Y and to a lesser extent AVP (pitressin), a number of GENE-Y and AVP analogues; such as carbetocin (GENE-Y agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and <e1>CHEMICAL<\\e1> (Tractocile <e2>GENE-Y<\\e2> antagonist) are also in clinical use","sentence":"In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use"}
{"PMID":18655903,"re_id":5,"annotated sentence":"In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (<e1>Tractocile<\\e1> <e2>OT<\\e2> antagonist) are also in clinical use","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Tractocile","object":"OT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition to GENE-Y and to a lesser extent AVP (pitressin), a number of GENE-Y and AVP analogues; such as carbetocin (GENE-Y agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (<e1>CHEMICAL<\\e1> <e2>GENE-Y<\\e2> antagonist) are also in clinical use","sentence":"In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use"}
{"PMID":18655903,"re_id":6,"annotated sentence":"While a number of orally active non-peptide <e2>V(2)<\\e2> antagonists (Vaptans); notably, <e1>Tolvaptan<\\e1>  Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)\/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Tolvaptan","object":"V(2)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"While a number of orally active non-peptide <e2>GENE-Y<\\e2> antagonists (Vaptans); notably, <e1>CHEMICAL<\\e1>  Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed GENE-Y\/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v","sentence":"While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan  Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)\/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v"}
{"PMID":18655903,"re_id":7,"annotated sentence":"While a number of orally active non-peptide <e2>V(2)<\\e2> antagonists (Vaptans); notably, Tolvaptan, <e1>Lixivaptan<\\e1> and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)\/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Lixivaptan","object":"V(2)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"While a number of orally active non-peptide <e2>GENE-Y<\\e2> antagonists (Vaptans); notably, Tolvaptan, <e1>CHEMICAL<\\e1> and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed GENE-Y\/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v","sentence":"While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)\/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v"}
{"PMID":18655903,"re_id":8,"annotated sentence":"While a number of orally active non-peptide <e2>V(2)<\\e2> antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and <e1>Satavaptan<\\e1>  are currently in Phase III clinical trials; to date, only the mixed V(2)\/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Satavaptan","object":"V(2)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"While a number of orally active non-peptide <e2>GENE-Y<\\e2> antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and <e1>CHEMICAL<\\e1>  are currently in Phase III clinical trials; to date, only the mixed GENE-Y\/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v","sentence":"While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan  are currently in Phase III clinical trials; to date, only the mixed V(2)\/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v"}
{"PMID":18655903,"re_id":9,"annotated sentence":"While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed <e2>V(2)<\\e2> V(1a), antagonist <e1>Conivaptan<\\e1> (Vaprisol), has been approved by the US FDA for clinical use (by i.v","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Conivaptan","object":"V(2)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"While a number of orally active non-peptide GENE-Y antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed <e2>GENE-Y<\\e2> V(1a), antagonist <e1>CHEMICAL<\\e1> (Vaprisol), has been approved by the US FDA for clinical use (by i.v","sentence":"While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2) V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v"}
{"PMID":18655903,"re_id":10,"annotated sentence":"While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)\/<e2>V(1a)<\\e2>  antagonist <e1>Conivaptan<\\e1> (Vaprisol), has been approved by the US FDA for clinical use (by i.v","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Conivaptan","object":"V(1a)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)\/<e2>GENE-Y<\\e2>  antagonist <e1>CHEMICAL<\\e1> (Vaprisol), has been approved by the US FDA for clinical use (by i.v","sentence":"While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)\/V(1a)  antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v"}
{"PMID":18655903,"re_id":11,"annotated sentence":"While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed <e2>V(2)<\\e2> V(1a), antagonist Conivaptan (<e1>Vaprisol<\\e1> , has been approved by the US FDA for clinical use (by i.v","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Vaprisol","object":"V(2)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"While a number of orally active non-peptide GENE-Y antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed <e2>GENE-Y<\\e2> V(1a), antagonist Conivaptan (<e1>CHEMICAL<\\e1> , has been approved by the US FDA for clinical use (by i.v","sentence":"While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2) V(1a), antagonist Conivaptan (Vaprisol , has been approved by the US FDA for clinical use (by i.v"}
{"PMID":18655903,"re_id":12,"annotated sentence":"While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)\/<e2>V(1a)<\\e2>  antagonist Conivaptan (<e1>Vaprisol<\\e1> , has been approved by the US FDA for clinical use (by i.v","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Vaprisol","object":"V(1a)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)\/<e2>GENE-Y<\\e2>  antagonist Conivaptan (<e1>CHEMICAL<\\e1> , has been approved by the US FDA for clinical use (by i.v","sentence":"While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)\/V(1a)  antagonist Conivaptan (Vaprisol , has been approved by the US FDA for clinical use (by i.v"}
{"PMID":1868500,"re_id":0,"annotated sentence":"Absorbable drugs (<e1>fibric acids<\\e1>  nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce <e2>plasma very-low-density lipoproteins<\\e2> (VLDL) and\/or low-density lipoproteins (LDL) by a variety of mechanisms","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"fibric acids","object":"plasma very-low-density lipoproteins","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Absorbable drugs (<e1>CHEMICAL<\\e1>  nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce <e2>GENE-N<\\e2> (VLDL) and\/or low-density lipoproteins (LDL) by a variety of mechanisms","sentence":"Absorbable drugs (fibric acids  nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and\/or low-density lipoproteins (LDL) by a variety of mechanisms"}
{"PMID":1868500,"re_id":1,"annotated sentence":"Absorbable drugs (<e1>fibric acids<\\e1>  nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (<e2>VLDL<\\e2>  and\/or low-density lipoproteins (LDL) by a variety of mechanisms","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"fibric acids","object":"VLDL","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Absorbable drugs (<e1>CHEMICAL<\\e1>  nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (<e2>GENE-N<\\e2>  and\/or low-density lipoproteins (LDL) by a variety of mechanisms","sentence":"Absorbable drugs (fibric acids  nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL  and\/or low-density lipoproteins (LDL) by a variety of mechanisms"}
{"PMID":1868500,"re_id":2,"annotated sentence":"Absorbable drugs (<e1>fibric acids<\\e1>  nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and\/or <e2>low-density lipoproteins<\\e2> (LDL) by a variety of mechanisms","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"fibric acids","object":"low-density lipoproteins","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Absorbable drugs (<e1>CHEMICAL<\\e1>  nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce plasma very-GENE-N (VLDL) and\/or <e2>GENE-N<\\e2> (LDL) by a variety of mechanisms","sentence":"Absorbable drugs (fibric acids  nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and\/or low-density lipoproteins (LDL) by a variety of mechanisms"}
{"PMID":1868500,"re_id":3,"annotated sentence":"Absorbable drugs (<e1>fibric acids<\\e1>  nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and\/or low-density lipoproteins (<e2>LDL<\\e2>  by a variety of mechanisms","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"fibric acids","object":"LDL","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Absorbable drugs (<e1>CHEMICAL<\\e1>  nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VGENE-N) and\/or low-density lipoproteins (<e2>GENE-N<\\e2>  by a variety of mechanisms","sentence":"Absorbable drugs (fibric acids  nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and\/or low-density lipoproteins (LDL  by a variety of mechanisms"}
{"PMID":1868500,"re_id":4,"annotated sentence":"Absorbable drugs (fibric acids, <e1>nicotinic acid<\\e1>  probucol, HMG-CoA reductase inhibitors) reduce <e2>plasma very-low-density lipoproteins<\\e2> (VLDL) and\/or low-density lipoproteins (LDL) by a variety of mechanisms","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"nicotinic acid","object":"plasma very-low-density lipoproteins","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Absorbable drugs (fibric acids, <e1>CHEMICAL<\\e1>  probucol, HMG-CoA reductase inhibitors) reduce <e2>GENE-N<\\e2> (VLDL) and\/or low-density lipoproteins (LDL) by a variety of mechanisms","sentence":"Absorbable drugs (fibric acids, nicotinic acid  probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and\/or low-density lipoproteins (LDL) by a variety of mechanisms"}
{"PMID":1868500,"re_id":5,"annotated sentence":"Absorbable drugs (fibric acids, <e1>nicotinic acid<\\e1>  probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (<e2>VLDL<\\e2>  and\/or low-density lipoproteins (LDL) by a variety of mechanisms","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"nicotinic acid","object":"VLDL","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Absorbable drugs (fibric acids, <e1>CHEMICAL<\\e1>  probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (<e2>GENE-N<\\e2>  and\/or low-density lipoproteins (LDL) by a variety of mechanisms","sentence":"Absorbable drugs (fibric acids, nicotinic acid  probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL  and\/or low-density lipoproteins (LDL) by a variety of mechanisms"}
{"PMID":1868500,"re_id":6,"annotated sentence":"Absorbable drugs (fibric acids, <e1>nicotinic acid<\\e1>  probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and\/or <e2>low-density lipoproteins<\\e2> (LDL) by a variety of mechanisms","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"nicotinic acid","object":"low-density lipoproteins","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Absorbable drugs (fibric acids, <e1>CHEMICAL<\\e1>  probucol, HMG-CoA reductase inhibitors) reduce plasma very-GENE-N (VLDL) and\/or <e2>GENE-N<\\e2> (LDL) by a variety of mechanisms","sentence":"Absorbable drugs (fibric acids, nicotinic acid  probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and\/or low-density lipoproteins (LDL) by a variety of mechanisms"}
{"PMID":1868500,"re_id":7,"annotated sentence":"Absorbable drugs (fibric acids, <e1>nicotinic acid<\\e1>  probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and\/or low-density lipoproteins (<e2>LDL<\\e2>  by a variety of mechanisms","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"nicotinic acid","object":"LDL","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Absorbable drugs (fibric acids, <e1>CHEMICAL<\\e1>  probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VGENE-N) and\/or low-density lipoproteins (<e2>GENE-N<\\e2>  by a variety of mechanisms","sentence":"Absorbable drugs (fibric acids, nicotinic acid  probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and\/or low-density lipoproteins (LDL  by a variety of mechanisms"}
{"PMID":1868500,"re_id":8,"annotated sentence":"Absorbable drugs (fibric acids, nicotinic acid, <e1>probucol<\\e1>  HMG-CoA reductase inhibitors) reduce <e2>plasma very-low-density lipoproteins<\\e2> (VLDL) and\/or low-density lipoproteins (LDL) by a variety of mechanisms","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"probucol","object":"plasma very-low-density lipoproteins","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Absorbable drugs (fibric acids, nicotinic acid, <e1>CHEMICAL<\\e1>  HMG-CoA reductase inhibitors) reduce <e2>GENE-N<\\e2> (VLDL) and\/or low-density lipoproteins (LDL) by a variety of mechanisms","sentence":"Absorbable drugs (fibric acids, nicotinic acid, probucol  HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and\/or low-density lipoproteins (LDL) by a variety of mechanisms"}
{"PMID":1868500,"re_id":9,"annotated sentence":"Absorbable drugs (fibric acids, nicotinic acid, <e1>probucol<\\e1>  HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (<e2>VLDL<\\e2>  and\/or low-density lipoproteins (LDL) by a variety of mechanisms","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"probucol","object":"VLDL","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Absorbable drugs (fibric acids, nicotinic acid, <e1>CHEMICAL<\\e1>  HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (<e2>GENE-N<\\e2>  and\/or low-density lipoproteins (LDL) by a variety of mechanisms","sentence":"Absorbable drugs (fibric acids, nicotinic acid, probucol  HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL  and\/or low-density lipoproteins (LDL) by a variety of mechanisms"}
{"PMID":1868500,"re_id":10,"annotated sentence":"Absorbable drugs (fibric acids, nicotinic acid, <e1>probucol<\\e1>  HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and\/or <e2>low-density lipoproteins<\\e2> (LDL) by a variety of mechanisms","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"probucol","object":"low-density lipoproteins","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Absorbable drugs (fibric acids, nicotinic acid, <e1>CHEMICAL<\\e1>  HMG-CoA reductase inhibitors) reduce plasma very-GENE-N (VLDL) and\/or <e2>GENE-N<\\e2> (LDL) by a variety of mechanisms","sentence":"Absorbable drugs (fibric acids, nicotinic acid, probucol  HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and\/or low-density lipoproteins (LDL) by a variety of mechanisms"}
{"PMID":1868500,"re_id":11,"annotated sentence":"Absorbable drugs (fibric acids, nicotinic acid, <e1>probucol<\\e1>  HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and\/or low-density lipoproteins (<e2>LDL<\\e2>  by a variety of mechanisms","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"probucol","object":"LDL","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Absorbable drugs (fibric acids, nicotinic acid, <e1>CHEMICAL<\\e1>  HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VGENE-N) and\/or low-density lipoproteins (<e2>GENE-N<\\e2>  by a variety of mechanisms","sentence":"Absorbable drugs (fibric acids, nicotinic acid, probucol  HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and\/or low-density lipoproteins (LDL  by a variety of mechanisms"}
{"PMID":1868500,"re_id":12,"annotated sentence":"<e1>Fibric acids<\\e1>  in particular, act by stimulating the catabolism of <e2>VLDL<\\e2> and also, as a consequence, improving LDL delipidation, thus favoring receptor uptake","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Fibric acids","object":"VLDL","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  in particular, act by stimulating the catabolism of <e2>GENE-N<\\e2> and also, as a consequence, improving LDL delipidation, thus favoring receptor uptake","sentence":"Fibric acids  in particular, act by stimulating the catabolism of VLDL and also, as a consequence, improving LDL delipidation, thus favoring receptor uptake"}
{"PMID":1868500,"re_id":13,"annotated sentence":"accelerating reverse transport of <e1>cholesteryl esters<\\e1> from <e2>high-density lipoproteins<\\e2> to lower-density lipoproteins","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cholesteryl esters","object":"high-density lipoproteins","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"accelerating reverse transport of <e1>CHEMICAL<\\e1> from <e2>GENE-N<\\e2> to lower-density lipoproteins","sentence":"accelerating reverse transport of cholesteryl esters from high-density lipoproteins to lower-density lipoproteins"}
{"PMID":1868500,"re_id":14,"annotated sentence":"accelerating reverse transport of <e1>cholesteryl esters<\\e1> from high-density lipoproteins to <e2>lower-density lipoproteins<\\e2>  Finally, HMG-CoA reductase inhibitors, interfering with the biosynthesis of cholesterol, can induce an increased expression of liver high-affinity lipoprotein receptors","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cholesteryl esters","object":"lower-density lipoproteins","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"accelerating reverse transport of <e1>CHEMICAL<\\e1> from high-density lipoproteins to <e2>GENE-N<\\e2>  Finally, HMG-CoA reductase inhibitors, interfering with the biosynthesis of cholesterol, can induce an increased expression of liver high-affinity lipoprotein receptors","sentence":"accelerating reverse transport of cholesteryl esters from high-density lipoproteins to lower-density lipoproteins  Finally, HMG-CoA reductase inhibitors, interfering with the biosynthesis of cholesterol, can induce an increased expression of liver high-affinity lipoprotein receptors"}
{"PMID":18803986,"re_id":0,"annotated sentence":"CONCLUSIONS: <e1>Lapatinib<\\e1> is a dual inhibitor of the <e2>EGFR<\\e2> and HER2 tyrosine kinases","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Lapatinib","object":"EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSIONS: <e1>CHEMICAL<\\e1> is a dual inhibitor of the <e2>GENE-Y<\\e2> and HER2 tyrosine kinases","sentence":"CONCLUSIONS: Lapatinib is a dual inhibitor of the EGFR and HER2 tyrosine kinases"}
{"PMID":18803986,"re_id":1,"annotated sentence":"CONCLUSIONS: <e1>Lapatinib<\\e1> is a dual inhibitor of the EGFR and <e2>HER2<\\e2> tyrosine kinases","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Lapatinib","object":"HER2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSIONS: <e1>CHEMICAL<\\e1> is a dual inhibitor of the EGFR and <e2>GENE-Y<\\e2> tyrosine kinases","sentence":"CONCLUSIONS: Lapatinib is a dual inhibitor of the EGFR and HER2 tyrosine kinases"}
{"PMID":18803986,"re_id":2,"annotated sentence":"CONCLUSIONS: <e1>Lapatinib<\\e1> is a dual inhibitor of the EGFR and HER2 <e2>tyrosine kinases<\\e2>  It is approved by the FDA for use in combination with capecitabine for the treatment of HER2-positive MBC that has progressed with standard treatment","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Lapatinib","object":"tyrosine kinases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"CONCLUSIONS: <e1>CHEMICAL<\\e1> is a dual inhibitor of the EGFR and HER2 <e2>GENE-N<\\e2>  It is approved by the FDA for use in combination with capecitabine for the treatment of HER2-positive MBC that has progressed with standard treatment","sentence":"CONCLUSIONS: Lapatinib is a dual inhibitor of the EGFR and HER2 tyrosine kinases  It is approved by the FDA for use in combination with capecitabine for the treatment of HER2-positive MBC that has progressed with standard treatment"}
{"PMID":18803986,"re_id":3,"annotated sentence":"<e1>Lapatinib<\\e1>  a dual inhibitor of <e2>human epidermal growth factor receptor<\\e2> tyrosine kinases","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Lapatinib","object":"human epidermal growth factor receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a dual inhibitor of <e2>GENE-Y<\\e2> tyrosine kinases","sentence":"Lapatinib  a dual inhibitor of human epidermal growth factor receptor tyrosine kinases"}
{"PMID":18803986,"re_id":4,"annotated sentence":"<e1>Lapatinib<\\e1>  a dual inhibitor of human epidermal growth factor receptor <e2>tyrosine kinases<\\e2>  BACKGROUND: Lapatinib, the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Lapatinib","object":"tyrosine kinases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a dual inhibitor of human epidermal growth factor receptor <e2>GENE-N<\\e2>  BACKGROUND: CHEMICAL, the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) GENE-N, was approved by the US Food and Drug Administration (FDA) in 2007","sentence":"Lapatinib  a dual inhibitor of human epidermal growth factor receptor tyrosine kinases  BACKGROUND: Lapatinib, the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007"}
{"PMID":18803986,"re_id":5,"annotated sentence":"BACKGROUND: <e1>Lapatinib<\\e1>  the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (<e2>HER2<\\e2>  tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Lapatinib","object":"HER2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND: <e1>CHEMICAL<\\e1>  the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (<e2>GENE-Y<\\e2>  tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007","sentence":"BACKGROUND: Lapatinib  the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2  tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007"}
{"PMID":18803986,"re_id":6,"annotated sentence":"BACKGROUND: <e1>Lapatinib<\\e1>  the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) <e2>tyrosine kinases<\\e2>  was approved by the US Food and Drug Administration (FDA) in 2007","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Lapatinib","object":"tyrosine kinases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"BACKGROUND: <e1>CHEMICAL<\\e1>  the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) <e2>GENE-N<\\e2>  was approved by the US Food and Drug Administration (FDA) in 2007","sentence":"BACKGROUND: Lapatinib  the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases  was approved by the US Food and Drug Administration (FDA) in 2007"}
{"PMID":18803986,"re_id":7,"annotated sentence":"BACKGROUND: <e1>Lapatinib<\\e1>  the first dual inhibitor of <e2>epidermal growth factor receptor<\\e2> (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Lapatinib","object":"epidermal growth factor receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND: <e1>CHEMICAL<\\e1>  the first dual inhibitor of <e2>GENE-Y<\\e2> (EGFR) and human GENE-Y 2 (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007","sentence":"BACKGROUND: Lapatinib  the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007"}
{"PMID":18803986,"re_id":8,"annotated sentence":"BACKGROUND: <e1>Lapatinib<\\e1>  the first dual inhibitor of epidermal growth factor receptor (<e2>EGFR<\\e2>  and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Lapatinib","object":"EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND: <e1>CHEMICAL<\\e1>  the first dual inhibitor of epidermal growth factor receptor (<e2>GENE-Y<\\e2>  and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007","sentence":"BACKGROUND: Lapatinib  the first dual inhibitor of epidermal growth factor receptor (EGFR  and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007"}
{"PMID":18803986,"re_id":9,"annotated sentence":"BACKGROUND: <e1>Lapatinib<\\e1>  the first dual inhibitor of epidermal growth factor receptor (EGFR) and <e2>human epidermal growth factor receptor 2<\\e2> (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Lapatinib","object":"human epidermal growth factor receptor 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND: <e1>CHEMICAL<\\e1>  the first dual inhibitor of epidermal growth factor receptor (EGFR) and <e2>GENE-Y<\\e2> (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007","sentence":"BACKGROUND: Lapatinib  the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007"}
{"PMID":18803986,"re_id":10,"annotated sentence":"<e1>Lapatinib<\\e1> is metabolized primarily by the <e2>cytochrome P450 3A4<\\e2> isozyme, with 1 metabolite remaining active against EGFR but not HER2","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Lapatinib","object":"cytochrome P450 3A4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is metabolized primarily by the <e2>GENE-Y<\\e2> isozyme, with 1 metabolite remaining active against EGFR but not HER2","sentence":"Lapatinib is metabolized primarily by the cytochrome P450 3A4 isozyme, with 1 metabolite remaining active against EGFR but not HER2"}
{"PMID":1881457,"re_id":0,"annotated sentence":"Phenelzine is a more potent <e2>monoamine oxidase<\\e2> inhibitor than is <e1>N2-acetylphenelzine<\\e1>  The most marked difference in the profile was that N2-acetylphenelzine had no effect on whole brain levels of the amino acid neurotransmitters alanine and gamma-aminobutyric acid, whereas phenelzine caused dramatic increases","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N2-acetylphenelzine","object":"monoamine oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Phenelzine is a more potent <e2>GENE-N<\\e2> inhibitor than is <e1>CHEMICAL<\\e1>  The most marked difference in the profile was that CHEMICAL had no effect on whole brain levels of the amino acid neurotransmitters alanine and gamma-aminobutyric acid, whereas phenelzine caused dramatic increases","sentence":"Phenelzine is a more potent monoamine oxidase inhibitor than is N2-acetylphenelzine  The most marked difference in the profile was that N2-acetylphenelzine had no effect on whole brain levels of the amino acid neurotransmitters alanine and gamma-aminobutyric acid, whereas phenelzine caused dramatic increases"}
{"PMID":1881457,"re_id":1,"annotated sentence":"Acetylation of <e1>phenelzine<\\e1> at the N2 position presumably interferes with the inhibition of the <e2>transaminase<\\e2> enzymes for gamma-aminobutyric acid and alanine.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenelzine","object":"transaminase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Acetylation of <e1>CHEMICAL<\\e1> at the N2 position presumably interferes with the inhibition of the <e2>GENE-N<\\e2> enzymes for gamma-aminobutyric acid and alanine.","sentence":"Acetylation of phenelzine at the N2 position presumably interferes with the inhibition of the transaminase enzymes for gamma-aminobutyric acid and alanine."}
{"PMID":1881457,"re_id":2,"annotated sentence":"Acetylation of phenelzine at the <e1>N2<\\e1> position presumably interferes with the inhibition of the <e2>transaminase<\\e2> enzymes for gamma-aminobutyric acid and alanine.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N2","object":"transaminase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Acetylation of phenelzine at the <e1>CHEMICAL<\\e1> position presumably interferes with the inhibition of the <e2>GENE-N<\\e2> enzymes for gamma-aminobutyric acid and alanine.","sentence":"Acetylation of phenelzine at the N2 position presumably interferes with the inhibition of the transaminase enzymes for gamma-aminobutyric acid and alanine."}
{"PMID":1881457,"re_id":3,"annotated sentence":"Acetylation of phenelzine at the N2 position presumably interferes with the inhibition of the <e2>transaminase<\\e2> enzymes for <e1>gamma-aminobutyric acid<\\e1> and alanine.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"gamma-aminobutyric acid","object":"transaminase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Acetylation of phenelzine at the N2 position presumably interferes with the inhibition of the <e2>GENE-N<\\e2> enzymes for <e1>CHEMICAL<\\e1> and alanine.","sentence":"Acetylation of phenelzine at the N2 position presumably interferes with the inhibition of the transaminase enzymes for gamma-aminobutyric acid and alanine."}
{"PMID":1881457,"re_id":4,"annotated sentence":"Acetylation of phenelzine at the N2 position presumably interferes with the inhibition of the <e2>transaminase<\\e2> enzymes for gamma-aminobutyric acid and <e1>alanine<\\e1> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"alanine","object":"transaminase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Acetylation of phenelzine at the N2 position presumably interferes with the inhibition of the <e2>GENE-N<\\e2> enzymes for gamma-aminobutyric acid and <e1>CHEMICAL<\\e1> ","sentence":"Acetylation of phenelzine at the N2 position presumably interferes with the inhibition of the transaminase enzymes for gamma-aminobutyric acid and alanine "}
{"PMID":1881457,"re_id":5,"annotated sentence":"<e1>Phenelzine<\\e1> is a more potent <e2>monoamine oxidase<\\e2> inhibitor than is N2-acetylphenelzine","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Phenelzine","object":"monoamine oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is a more potent <e2>GENE-N<\\e2> inhibitor than is N2-acetylphenelzine","sentence":"Phenelzine is a more potent monoamine oxidase inhibitor than is N2-acetylphenelzine"}
{"PMID":18973551,"re_id":0,"annotated sentence":"<e1>Quinpirole<\\e1> and 7-OH-DPAT also increased the phosphorylation of <e2>extracellular signal-regulated kinase<\\e2> (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Quinpirole","object":"extracellular signal-regulated kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> and 7-OH-DPAT also increased the phosphorylation of <e2>GENE-N<\\e2> (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A","sentence":"Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A"}
{"PMID":18973551,"re_id":1,"annotated sentence":"<e1>Quinpirole<\\e1> and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (<e2>ERK<\\e2>  within minutes, an effect blocked by pretreatment with SB-277011-A","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Quinpirole","object":"ERK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (<e2>GENE-N<\\e2>  within minutes, an effect blocked by pretreatment with SB-277011-A","sentence":"Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (ERK  within minutes, an effect blocked by pretreatment with SB-277011-A"}
{"PMID":18973551,"re_id":2,"annotated sentence":"Quinpirole and <e1>7-OH-DPAT<\\e1> also increased the phosphorylation of <e2>extracellular signal-regulated kinase<\\e2> (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"7-OH-DPAT","object":"extracellular signal-regulated kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Quinpirole and <e1>CHEMICAL<\\e1> also increased the phosphorylation of <e2>GENE-N<\\e2> (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A","sentence":"Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A"}
{"PMID":18973551,"re_id":3,"annotated sentence":"Quinpirole and <e1>7-OH-DPAT<\\e1> also increased the phosphorylation of extracellular signal-regulated kinase (<e2>ERK<\\e2>  within minutes, an effect blocked by pretreatment with SB-277011-A","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"7-OH-DPAT","object":"ERK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Quinpirole and <e1>CHEMICAL<\\e1> also increased the phosphorylation of extracellular signal-regulated kinase (<e2>GENE-N<\\e2>  within minutes, an effect blocked by pretreatment with SB-277011-A","sentence":"Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (ERK  within minutes, an effect blocked by pretreatment with SB-277011-A"}
{"PMID":18973551,"re_id":4,"annotated sentence":"Quinpirole and 7-OH-DPAT also increased the phosphorylation of <e2>extracellular signal-regulated kinase<\\e2> (ERK) within minutes, an effect blocked by pretreatment with <e1>SB-277011-A<\\e1>  Inhibition of the D2\/D3 receptor signalling pathway to ERK was obtained with PD98059, GF109203 or LY294002, resulting in blockade of neurotrophic effects","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SB-277011-A","object":"extracellular signal-regulated kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Quinpirole and 7-OH-DPAT also increased the phosphorylation of <e2>GENE-N<\\e2> (ERK) within minutes, an effect blocked by pretreatment with <e1>CHEMICAL<\\e1>  Inhibition of the D2\/D3 receptor signalling pathway to ERK was obtained with PD98059, GF109203 or LY294002, resulting in blockade of neurotrophic effects","sentence":"Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A  Inhibition of the D2\/D3 receptor signalling pathway to ERK was obtained with PD98059, GF109203 or LY294002, resulting in blockade of neurotrophic effects"}
{"PMID":18973551,"re_id":5,"annotated sentence":"Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (<e2>ERK<\\e2>  within minutes, an effect blocked by pretreatment with <e1>SB-277011-A<\\e1>  Inhibition of the D2\/D3 receptor signalling pathway to ERK was obtained with PD98059, GF109203 or LY294002, resulting in blockade of neurotrophic effects","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SB-277011-A","object":"ERK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (<e2>GENE-N<\\e2>  within minutes, an effect blocked by pretreatment with <e1>CHEMICAL<\\e1>  Inhibition of the D2\/D3 receptor signalling pathway to GENE-N was obtained with PD98059, GF109203 or LY294002, resulting in blockade of neurotrophic effects","sentence":"Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (ERK  within minutes, an effect blocked by pretreatment with SB-277011-A  Inhibition of the D2\/D3 receptor signalling pathway to ERK was obtained with PD98059, GF109203 or LY294002, resulting in blockade of neurotrophic effects"}
{"PMID":18973551,"re_id":6,"annotated sentence":"All neurotrophic effects were blocked by the unselective D2\/D3 receptor antagonist sulpiride (5 microm) and by the selective <e2>D3 receptor<\\e2> antagonist <e1>SB-277011-A<\\e1> at a low dose (50 nm)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"SB-277011-A","object":"D3 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"All neurotrophic effects were blocked by the unselective D2\/GENE-Y antagonist sulpiride (5 microm) and by the selective <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> at a low dose (50 nm)","sentence":"All neurotrophic effects were blocked by the unselective D2\/D3 receptor antagonist sulpiride (5 microm) and by the selective D3 receptor antagonist SB-277011-A at a low dose (50 nm)"}
{"PMID":18974361,"re_id":0,"annotated sentence":"This study identified four clinically approved antihypertensive drugs (<e1>efonidipine<\\e1>  felodipine, isradipine, and nitrendipine) as potent <e2>T-channel<\\e2> blockers (IC(50) < 3 microM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"efonidipine","object":"T-channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This study identified four clinically approved antihypertensive drugs (<e1>CHEMICAL<\\e1>  felodipine, isradipine, and nitrendipine) as potent <e2>GENE-N<\\e2> blockers (IC(50) < 3 microM)","sentence":"This study identified four clinically approved antihypertensive drugs (efonidipine  felodipine, isradipine, and nitrendipine) as potent T-channel blockers (IC(50) < 3 microM)"}
{"PMID":18974361,"re_id":1,"annotated sentence":"This study identified four clinically approved antihypertensive drugs (efonidipine, <e1>felodipine<\\e1>  isradipine, and nitrendipine) as potent <e2>T-channel<\\e2> blockers (IC(50) < 3 microM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"felodipine","object":"T-channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This study identified four clinically approved antihypertensive drugs (efonidipine, <e1>CHEMICAL<\\e1>  isradipine, and nitrendipine) as potent <e2>GENE-N<\\e2> blockers (IC(50) < 3 microM)","sentence":"This study identified four clinically approved antihypertensive drugs (efonidipine, felodipine  isradipine, and nitrendipine) as potent T-channel blockers (IC(50) < 3 microM)"}
{"PMID":18974361,"re_id":2,"annotated sentence":"This study identified four clinically approved antihypertensive drugs (efonidipine, felodipine, <e1>isradipine<\\e1>  and nitrendipine) as potent <e2>T-channel<\\e2> blockers (IC(50) < 3 microM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"isradipine","object":"T-channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This study identified four clinically approved antihypertensive drugs (efonidipine, felodipine, <e1>CHEMICAL<\\e1>  and nitrendipine) as potent <e2>GENE-N<\\e2> blockers (IC(50) < 3 microM)","sentence":"This study identified four clinically approved antihypertensive drugs (efonidipine, felodipine, isradipine  and nitrendipine) as potent T-channel blockers (IC(50) < 3 microM)"}
{"PMID":18974361,"re_id":3,"annotated sentence":"This study identified four clinically approved antihypertensive drugs (efonidipine, felodipine, isradipine, and <e1>nitrendipine<\\e1>  as potent <e2>T-channel<\\e2> blockers (IC(50) < 3 microM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"nitrendipine","object":"T-channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This study identified four clinically approved antihypertensive drugs (efonidipine, felodipine, isradipine, and <e1>CHEMICAL<\\e1>  as potent <e2>GENE-N<\\e2> blockers (IC(50) < 3 microM)","sentence":"This study identified four clinically approved antihypertensive drugs (efonidipine, felodipine, isradipine, and nitrendipine  as potent T-channel blockers (IC(50) < 3 microM)"}
{"PMID":19023039,"re_id":0,"annotated sentence":"Triphosphate nucleotides (ATP, GTP, and <e1>UTP<\\e1>  rapidly and reversibly inhibited <e2>Panx1<\\e2> currents via mechanism(s) independent of purine receptors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"UTP","object":"Panx1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Triphosphate nucleotides (ATP, GTP, and <e1>CHEMICAL<\\e1>  rapidly and reversibly inhibited <e2>GENE-Y<\\e2> currents via mechanism(s) independent of purine receptors","sentence":"Triphosphate nucleotides (ATP, GTP, and UTP  rapidly and reversibly inhibited Panx1 currents via mechanism(s) independent of purine receptors"}
{"PMID":19023039,"re_id":1,"annotated sentence":"We found compounds that inhibited <e2>Panx1<\\e2> currents with a rank order of potency: <e1>carbenoxolone<\\e1> > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"carbenoxolone","object":"Panx1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found compounds that inhibited <e2>GENE-Y<\\e2> currents with a rank order of potency: <e1>CHEMICAL<\\e1> > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid","sentence":"We found compounds that inhibited Panx1 currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid"}
{"PMID":19023039,"re_id":2,"annotated sentence":"We found compounds that inhibited <e2>Panx1<\\e2> currents with a rank order of potency: carbenoxolone > <e1>disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate<\\e1> (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate","object":"Panx1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found compounds that inhibited <e2>GENE-Y<\\e2> currents with a rank order of potency: carbenoxolone > <e1>CHEMICAL<\\e1> (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid","sentence":"We found compounds that inhibited Panx1 currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid"}
{"PMID":19023039,"re_id":3,"annotated sentence":"We found compounds that inhibited <e2>Panx1<\\e2> currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (<e1>DIDS<\\e1>  approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DIDS","object":"Panx1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found compounds that inhibited <e2>GENE-Y<\\e2> currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (<e1>CHEMICAL<\\e1>  approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid","sentence":"We found compounds that inhibited Panx1 currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS  approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid"}
{"PMID":19023039,"re_id":4,"annotated sentence":"We found compounds that inhibited <e2>Panx1<\\e2> currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately <e1>disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate<\\e1> approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate","object":"Panx1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found compounds that inhibited <e2>GENE-Y<\\e2> currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately <e1>CHEMICAL<\\e1> approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid","sentence":"We found compounds that inhibited Panx1 currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid"}
{"PMID":19023039,"re_id":5,"annotated sentence":"We found compounds that inhibited <e2>Panx1<\\e2> currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately <e1>5-nitro-2-(3-phenylpropylamino)benzoic acid<\\e1> > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-nitro-2-(3-phenylpropylamino)benzoic acid","object":"Panx1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found compounds that inhibited <e2>GENE-Y<\\e2> currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately <e1>CHEMICAL<\\e1> > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid","sentence":"We found compounds that inhibited Panx1 currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid"}
{"PMID":19023039,"re_id":6,"annotated sentence":"We found compounds that inhibited <e2>Panx1<\\e2> currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > <e1>indanyloxyacetic acid 94<\\e1> >> probenecid >> flufenamic acid = niflumic acid","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"indanyloxyacetic acid 94","object":"Panx1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found compounds that inhibited <e2>GENE-Y<\\e2> currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > <e1>CHEMICAL<\\e1> >> probenecid >> flufenamic acid = niflumic acid","sentence":"We found compounds that inhibited Panx1 currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid"}
{"PMID":19023039,"re_id":7,"annotated sentence":"We found compounds that inhibited <e2>Panx1<\\e2> currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> <e1>probenecid<\\e1> >> flufenamic acid = niflumic acid","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"probenecid","object":"Panx1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found compounds that inhibited <e2>GENE-Y<\\e2> currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> <e1>CHEMICAL<\\e1> >> flufenamic acid = niflumic acid","sentence":"We found compounds that inhibited Panx1 currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid"}
{"PMID":19023039,"re_id":8,"annotated sentence":"We found compounds that inhibited <e2>Panx1<\\e2> currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> <e1>flufenamic acid<\\e1> = niflumic acid","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"flufenamic acid","object":"Panx1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found compounds that inhibited <e2>GENE-Y<\\e2> currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> <e1>CHEMICAL<\\e1> = niflumic acid","sentence":"We found compounds that inhibited Panx1 currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid"}
{"PMID":19023039,"re_id":9,"annotated sentence":"We found compounds that inhibited <e2>Panx1<\\e2> currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = <e1>niflumic acid<\\e1>  Triphosphate nucleotides (ATP, GTP, and UTP) rapidly and reversibly inhibited Panx1 currents via mechanism(s) independent of purine receptors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"niflumic acid","object":"Panx1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found compounds that inhibited <e2>GENE-Y<\\e2> currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = <e1>CHEMICAL<\\e1>  Triphosphate nucleotides (ATP, GTP, and UTP) rapidly and reversibly inhibited GENE-Y currents via mechanism(s) independent of purine receptors","sentence":"We found compounds that inhibited Panx1 currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid  Triphosphate nucleotides (ATP, GTP, and UTP) rapidly and reversibly inhibited Panx1 currents via mechanism(s) independent of purine receptors"}
{"PMID":19023039,"re_id":10,"annotated sentence":"<e1>Triphosphate nucleotides<\\e1> (ATP, GTP, and UTP) rapidly and reversibly inhibited <e2>Panx1<\\e2> currents via mechanism(s) independent of purine receptors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Triphosphate nucleotides","object":"Panx1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (ATP, GTP, and UTP) rapidly and reversibly inhibited <e2>GENE-Y<\\e2> currents via mechanism(s) independent of purine receptors","sentence":"Triphosphate nucleotides (ATP, GTP, and UTP) rapidly and reversibly inhibited Panx1 currents via mechanism(s) independent of purine receptors"}
{"PMID":19023039,"re_id":11,"annotated sentence":"Triphosphate nucleotides (<e1>ATP<\\e1>  GTP, and UTP) rapidly and reversibly inhibited <e2>Panx1<\\e2> currents via mechanism(s) independent of purine receptors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ATP","object":"Panx1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Triphosphate nucleotides (<e1>CHEMICAL<\\e1>  GTP, and UTP) rapidly and reversibly inhibited <e2>GENE-Y<\\e2> currents via mechanism(s) independent of purine receptors","sentence":"Triphosphate nucleotides (ATP  GTP, and UTP) rapidly and reversibly inhibited Panx1 currents via mechanism(s) independent of purine receptors"}
{"PMID":19023039,"re_id":12,"annotated sentence":"Triphosphate nucleotides (ATP, <e1>GTP<\\e1>  and UTP) rapidly and reversibly inhibited <e2>Panx1<\\e2> currents via mechanism(s) independent of purine receptors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"GTP","object":"Panx1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Triphosphate nucleotides (ATP, <e1>CHEMICAL<\\e1>  and UTP) rapidly and reversibly inhibited <e2>GENE-Y<\\e2> currents via mechanism(s) independent of purine receptors","sentence":"Triphosphate nucleotides (ATP, GTP  and UTP) rapidly and reversibly inhibited Panx1 currents via mechanism(s) independent of purine receptors"}
{"PMID":19023039,"re_id":13,"annotated sentence":"When Panx1 was coexpressed with purinergic P2X(7) receptor (P2X(7)R), <e1>DIDS<\\e1> was found to act as a <e2>P2X(7)R<\\e2> antagonist to inhibit ATP-evoked currents, but none of the other compounds inhibited P2X(7)R currents","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"DIDS","object":"P2X(7)R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"When Panx1 was coexpressed with purinergic P2X(7) receptor (GENE-Y), <e1>CHEMICAL<\\e1> was found to act as a <e2>GENE-Y<\\e2> antagonist to inhibit ATP-evoked currents, but none of the other compounds inhibited GENE-Y currents","sentence":"When Panx1 was coexpressed with purinergic P2X(7) receptor (P2X(7)R), DIDS was found to act as a P2X(7)R antagonist to inhibit ATP-evoked currents, but none of the other compounds inhibited P2X(7)R currents"}
{"PMID":19057128,"re_id":0,"annotated sentence":"<e2>MMP-2<\\e2> and MMP-9 expressions and activities in right ventricles increased significantly in <e1>monocrotaline<\\e1> injected rats and captopril inhibited them","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"monocrotaline","object":"MMP-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> and MMP-9 expressions and activities in right ventricles increased significantly in <e1>CHEMICAL<\\e1> injected rats and captopril inhibited them","sentence":"MMP-2 and MMP-9 expressions and activities in right ventricles increased significantly in monocrotaline injected rats and captopril inhibited them"}
{"PMID":19057128,"re_id":1,"annotated sentence":"MMP-2 and <e2>MMP-9<\\e2> expressions and activities in right ventricles increased significantly in <e1>monocrotaline<\\e1> injected rats and captopril inhibited them","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"monocrotaline","object":"MMP-9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"MMP-2 and <e2>GENE-Y<\\e2> expressions and activities in right ventricles increased significantly in <e1>CHEMICAL<\\e1> injected rats and captopril inhibited them","sentence":"MMP-2 and MMP-9 expressions and activities in right ventricles increased significantly in monocrotaline injected rats and captopril inhibited them"}
{"PMID":19057128,"re_id":2,"annotated sentence":"These findings indicate that captopril attenuates the development of <e1>monocrotaline<\\e1> induced right ventricular hypertrophy in association with inhibition of <e2>MMP-2<\\e2> and MMP-9 in rats.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"monocrotaline","object":"MMP-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These findings indicate that captopril attenuates the development of <e1>CHEMICAL<\\e1> induced right ventricular hypertrophy in association with inhibition of <e2>GENE-Y<\\e2> and MMP-9 in rats.","sentence":"These findings indicate that captopril attenuates the development of monocrotaline induced right ventricular hypertrophy in association with inhibition of MMP-2 and MMP-9 in rats."}
{"PMID":19057128,"re_id":3,"annotated sentence":"These findings indicate that captopril attenuates the development of <e1>monocrotaline<\\e1> induced right ventricular hypertrophy in association with inhibition of MMP-2 and <e2>MMP-9<\\e2> in rats.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"monocrotaline","object":"MMP-9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These findings indicate that captopril attenuates the development of <e1>CHEMICAL<\\e1> induced right ventricular hypertrophy in association with inhibition of MMP-2 and <e2>GENE-Y<\\e2> in rats.","sentence":"These findings indicate that captopril attenuates the development of monocrotaline induced right ventricular hypertrophy in association with inhibition of MMP-2 and MMP-9 in rats."}
{"PMID":19057128,"re_id":4,"annotated sentence":"<e2>MMP-2<\\e2> and MMP-9 expressions and activities in right ventricles increased significantly in monocrotaline-injected rats and <e1>captopril<\\e1> inhibited them","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"captopril","object":"MMP-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> and MMP-9 expressions and activities in right ventricles increased significantly in monocrotaline-injected rats and <e1>CHEMICAL<\\e1> inhibited them","sentence":"MMP-2 and MMP-9 expressions and activities in right ventricles increased significantly in monocrotaline-injected rats and captopril inhibited them"}
{"PMID":19057128,"re_id":5,"annotated sentence":"MMP-2 and <e2>MMP-9<\\e2> expressions and activities in right ventricles increased significantly in monocrotaline-injected rats and <e1>captopril<\\e1> inhibited them","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"captopril","object":"MMP-9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"MMP-2 and <e2>GENE-Y<\\e2> expressions and activities in right ventricles increased significantly in monocrotaline-injected rats and <e1>CHEMICAL<\\e1> inhibited them","sentence":"MMP-2 and MMP-9 expressions and activities in right ventricles increased significantly in monocrotaline-injected rats and captopril inhibited them"}
{"PMID":19057128,"re_id":6,"annotated sentence":"These findings indicate that <e1>captopril<\\e1> attenuates the development of monocrotaline-induced right ventricular hypertrophy in association with inhibition of <e2>MMP-2<\\e2> and MMP-9 in rats.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"captopril","object":"MMP-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These findings indicate that <e1>CHEMICAL<\\e1> attenuates the development of monocrotaline-induced right ventricular hypertrophy in association with inhibition of <e2>GENE-Y<\\e2> and MMP-9 in rats.","sentence":"These findings indicate that captopril attenuates the development of monocrotaline-induced right ventricular hypertrophy in association with inhibition of MMP-2 and MMP-9 in rats."}
{"PMID":19057128,"re_id":7,"annotated sentence":"These findings indicate that <e1>captopril<\\e1> attenuates the development of monocrotaline-induced right ventricular hypertrophy in association with inhibition of MMP-2 and <e2>MMP-9<\\e2> in rats.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"captopril","object":"MMP-9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These findings indicate that <e1>CHEMICAL<\\e1> attenuates the development of monocrotaline-induced right ventricular hypertrophy in association with inhibition of MMP-2 and <e2>GENE-Y<\\e2> in rats.","sentence":"These findings indicate that captopril attenuates the development of monocrotaline-induced right ventricular hypertrophy in association with inhibition of MMP-2 and MMP-9 in rats."}
{"PMID":19057128,"re_id":8,"annotated sentence":"We investigated the effect of <e1>captopril<\\e1>  an <e2>ACE<\\e2> inhibitor, on MMP-2 and MMP-9 in monocrotaline-induced right ventricular hypertrophy","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"captopril","object":"ACE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We investigated the effect of <e1>CHEMICAL<\\e1>  an <e2>GENE-Y<\\e2> inhibitor, on MMP-2 and MMP-9 in monocrotaline-induced right ventricular hypertrophy","sentence":"We investigated the effect of captopril  an ACE inhibitor, on MMP-2 and MMP-9 in monocrotaline-induced right ventricular hypertrophy"}
{"PMID":19119014,"re_id":0,"annotated sentence":"Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with <e1>chlorthalidone<\\e1>  trichloromethiazide, and furosemide being efficient inhibitors against <e2>CA II<\\e2> (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"chlorthalidone","object":"CA II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Some of these structurally related compounds have a very different behavior against the widespread isozyme GENE-Y, with <e1>CHEMICAL<\\e1>  trichloromethiazide, and furosemide being efficient inhibitors against <e2>GENE-Y<\\e2> (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM)","sentence":"Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with chlorthalidone  trichloromethiazide, and furosemide being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM)"}
{"PMID":19119014,"re_id":1,"annotated sentence":"Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with chlorthalidone, <e1>trichloromethiazide<\\e1>  and furosemide being efficient inhibitors against <e2>CA II<\\e2> (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"trichloromethiazide","object":"CA II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Some of these structurally related compounds have a very different behavior against the widespread isozyme GENE-Y, with chlorthalidone, <e1>CHEMICAL<\\e1>  and furosemide being efficient inhibitors against <e2>GENE-Y<\\e2> (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM)","sentence":"Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with chlorthalidone, trichloromethiazide  and furosemide being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM)"}
{"PMID":19119014,"re_id":2,"annotated sentence":"Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with chlorthalidone, trichloromethiazide, and <e1>furosemide<\\e1> being efficient inhibitors against <e2>CA II<\\e2> (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"furosemide","object":"CA II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Some of these structurally related compounds have a very different behavior against the widespread isozyme GENE-Y, with chlorthalidone, trichloromethiazide, and <e1>CHEMICAL<\\e1> being efficient inhibitors against <e2>GENE-Y<\\e2> (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM)","sentence":"Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with chlorthalidone, trichloromethiazide, and furosemide being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM)"}
{"PMID":19119014,"re_id":3,"annotated sentence":"Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with chlorthalidone, trichloromethiazide, and furosemide being efficient inhibitors against <e2>CA II<\\e2> (K(I)s of 65-138 nM), whereas <e1>indapamide<\\e1> is a much weaker one (K(I) of 2520 nM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"indapamide","object":"CA II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Some of these structurally related compounds have a very different behavior against the widespread isozyme GENE-Y, with chlorthalidone, trichloromethiazide, and furosemide being efficient inhibitors against <e2>GENE-Y<\\e2> (K(I)s of 65-138 nM), whereas <e1>CHEMICAL<\\e1> is a much weaker one (K(I) of 2520 nM)","sentence":"Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with chlorthalidone, trichloromethiazide, and furosemide being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM)"}
{"PMID":19119014,"re_id":4,"annotated sentence":"<e1>Thiazide<\\e1> and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (<e2>CA<\\e2>  EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Thiazide","object":"CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMIGENE-NL<\\e1> and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (<e2>GENE-N<\\e2>  EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide","sentence":"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA  EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide"}
{"PMID":19119014,"re_id":5,"annotated sentence":"<e1>Thiazide<\\e1> and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, <e2>EC 4.2.1.1<\\e2>  with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Thiazide","object":"EC 4.2.1.1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, <e2>GENE-Y<\\e2>  with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide","sentence":"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, EC 4.2.1.1  with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide"}
{"PMID":19119014,"re_id":6,"annotated sentence":"<e1>Thiazide<\\e1> and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of <e2>carbonic anhydrase<\\e2> (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Thiazide","object":"carbonic anhydrase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of <e2>GENE-N<\\e2> (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide","sentence":"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide"}
{"PMID":19119014,"re_id":7,"annotated sentence":"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (<e2>CA<\\e2>  EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as <e1>acetazolamide<\\e1>  methazolamide, and ethoxzolamide","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acetazolamide","object":"CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (<e2>GENE-N<\\e2>  EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as <e1>CHEMIGENE-NL<\\e1>  methazolamide, and ethoxzolamide","sentence":"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA  EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide  methazolamide, and ethoxzolamide"}
{"PMID":19119014,"re_id":8,"annotated sentence":"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, <e2>EC 4.2.1.1<\\e2>  with a very different profile as compared to classical inhibitors, such as <e1>acetazolamide<\\e1>  methazolamide, and ethoxzolamide","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acetazolamide","object":"EC 4.2.1.1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, <e2>GENE-Y<\\e2>  with a very different profile as compared to classical inhibitors, such as <e1>CHEMICAL<\\e1>  methazolamide, and ethoxzolamide","sentence":"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, EC 4.2.1.1  with a very different profile as compared to classical inhibitors, such as acetazolamide  methazolamide, and ethoxzolamide"}
{"PMID":19119014,"re_id":9,"annotated sentence":"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of <e2>carbonic anhydrase<\\e2> (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as <e1>acetazolamide<\\e1>  methazolamide, and ethoxzolamide","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acetazolamide","object":"carbonic anhydrase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of <e2>GENE-N<\\e2> (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as <e1>CHEMICAL<\\e1>  methazolamide, and ethoxzolamide","sentence":"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide  methazolamide, and ethoxzolamide"}
{"PMID":19119014,"re_id":10,"annotated sentence":"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (<e2>CA<\\e2>  EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, <e1>methazolamide<\\e1>  and ethoxzolamide","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"methazolamide","object":"CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (<e2>GENE-N<\\e2>  EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, <e1>CHEMIGENE-NL<\\e1>  and ethoxzolamide","sentence":"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA  EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide  and ethoxzolamide"}
{"PMID":19119014,"re_id":11,"annotated sentence":"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, <e2>EC 4.2.1.1<\\e2>  with a very different profile as compared to classical inhibitors, such as acetazolamide, <e1>methazolamide<\\e1>  and ethoxzolamide","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"methazolamide","object":"EC 4.2.1.1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, <e2>GENE-Y<\\e2>  with a very different profile as compared to classical inhibitors, such as acetazolamide, <e1>CHEMICAL<\\e1>  and ethoxzolamide","sentence":"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, EC 4.2.1.1  with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide  and ethoxzolamide"}
{"PMID":19119014,"re_id":12,"annotated sentence":"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of <e2>carbonic anhydrase<\\e2> (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, <e1>methazolamide<\\e1>  and ethoxzolamide","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"methazolamide","object":"carbonic anhydrase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of <e2>GENE-N<\\e2> (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, <e1>CHEMICAL<\\e1>  and ethoxzolamide","sentence":"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide  and ethoxzolamide"}
{"PMID":19119014,"re_id":13,"annotated sentence":"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (<e2>CA<\\e2>  EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and <e1>ethoxzolamide<\\e1>  Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with chlorthalidone, trichloromethiazide, and furosemide being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ethoxzolamide","object":"CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (<e2>GENE-N<\\e2>  EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and <e1>CHEMIGENE-NL<\\e1>  Some of these structurally related compounds have a very different behavior against the widespread isozyme GENE-N II, with chlorthalidone, trichloromethiazide, and furosemide being efficient inhibitors against GENE-N II (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM)","sentence":"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA  EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide  Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with chlorthalidone, trichloromethiazide, and furosemide being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM)"}
{"PMID":19119014,"re_id":14,"annotated sentence":"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, <e2>EC 4.2.1.1<\\e2>  with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and <e1>ethoxzolamide<\\e1>  Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with chlorthalidone, trichloromethiazide, and furosemide being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ethoxzolamide","object":"EC 4.2.1.1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, <e2>GENE-Y<\\e2>  with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and <e1>CHEMICAL<\\e1>  Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with chlorthalidone, trichloromethiazide, and furosemide being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM)","sentence":"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, EC 4.2.1.1  with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide  Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with chlorthalidone, trichloromethiazide, and furosemide being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM)"}
{"PMID":19119014,"re_id":15,"annotated sentence":"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of <e2>carbonic anhydrase<\\e2> (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and <e1>ethoxzolamide<\\e1>  Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with chlorthalidone, trichloromethiazide, and furosemide being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ethoxzolamide","object":"carbonic anhydrase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of <e2>GENE-N<\\e2> (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and <e1>CHEMICAL<\\e1>  Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with chlorthalidone, trichloromethiazide, and furosemide being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM)","sentence":"Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide  Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with chlorthalidone, trichloromethiazide, and furosemide being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM)"}
{"PMID":19281809,"re_id":0,"annotated sentence":"We discovered <e1>sergliflozin etabonate<\\e1>  a novel selective <e2>SGLT2<\\e2> inhibitor, and found that selective inhibition of SGLT2 increased urinary glucose excretion and consequently decreased plasma glucose levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sergliflozin etabonate","object":"SGLT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We discovered <e1>CHEMICAL<\\e1>  a novel selective <e2>GENE-Y<\\e2> inhibitor, and found that selective inhibition of GENE-Y increased urinary glucose excretion and consequently decreased plasma glucose levels","sentence":"We discovered sergliflozin etabonate  a novel selective SGLT2 inhibitor, and found that selective inhibition of SGLT2 increased urinary glucose excretion and consequently decreased plasma glucose levels"}
{"PMID":19281809,"re_id":1,"annotated sentence":"We discovered <e1>sergliflozin etabonate<\\e1>  a novel selective SGLT2 inhibitor, and found that selective inhibition of <e2>SGLT2<\\e2> increased urinary glucose excretion and consequently decreased plasma glucose levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sergliflozin etabonate","object":"SGLT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We discovered <e1>CHEMICAL<\\e1>  a novel selective GENE-Y inhibitor, and found that selective inhibition of <e2>GENE-Y<\\e2> increased urinary glucose excretion and consequently decreased plasma glucose levels","sentence":"We discovered sergliflozin etabonate  a novel selective SGLT2 inhibitor, and found that selective inhibition of SGLT2 increased urinary glucose excretion and consequently decreased plasma glucose levels"}
{"PMID":19281809,"re_id":2,"annotated sentence":"In this report, we examined the antihyperglycemic effects of sergliflozin etabonate in normal and diabetic rats in comparison with those of a sulfonylurea (gliclazide) and an <e2>alpha-glucosidase<\\e2> inhibitor (<e1>voglibose<\\e1> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"voglibose","object":"alpha-glucosidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this report, we examined the antihyperglycemic effects of sergliflozin etabonate in normal and diabetic rats in comparison with those of a sulfonylurea (gliclazide) and an <e2>GENE-Y<\\e2> inhibitor (<e1>CHEMICAL<\\e1> ","sentence":"In this report, we examined the antihyperglycemic effects of sergliflozin etabonate in normal and diabetic rats in comparison with those of a sulfonylurea (gliclazide) and an alpha-glucosidase inhibitor (voglibose "}
{"PMID":19281809,"re_id":3,"annotated sentence":"<e1>Sergliflozin etabonate<\\e1>  a selective <e2>SGLT2<\\e2> inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sergliflozin etabonate","object":"SGLT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a selective <e2>GENE-Y<\\e2> inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats","sentence":"Sergliflozin etabonate  a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats"}
{"PMID":19281809,"re_id":4,"annotated sentence":"Chronic treatment with <e1>sergliflozin etabonate<\\e1> reduced the levels of <e2>glycated hemoglobin<\\e2> and fasting plasma glucose, and improved the glycemic response after glucose loading in Zucker fatty rats","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sergliflozin etabonate","object":"glycated hemoglobin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Chronic treatment with <e1>CHEMICAL<\\e1> reduced the levels of <e2>GENE-N<\\e2> and fasting plasma glucose, and improved the glycemic response after glucose loading in Zucker fatty rats","sentence":"Chronic treatment with sergliflozin etabonate reduced the levels of glycated hemoglobin and fasting plasma glucose, and improved the glycemic response after glucose loading in Zucker fatty rats"}
{"PMID":19281809,"re_id":5,"annotated sentence":"The low-affinity <e2>sodium glucose cotransporter<\\e2> (SGLT2) is responsible for most of the <e1>glucose<\\e1> reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glucose","object":"sodium glucose cotransporter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The low-affinity <e2>sodium CHEMICAL cotransporter<\\e2> (SGLT2) is responsible for most of the <e1>CHEMICAL<\\e1> reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes","sentence":"The low-affinity sodium glucose cotransporter (SGLT2) is responsible for most of the glucose reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes"}
{"PMID":19281809,"re_id":6,"annotated sentence":"The low-affinity sodium glucose cotransporter (<e2>SGLT2<\\e2>  is responsible for most of the <e1>glucose<\\e1> reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glucose","object":"SGLT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The low-affinity sodium CHEMICAL cotransporter (<e2>GENE-Y<\\e2>  is responsible for most of the <e1>CHEMICAL<\\e1> reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes","sentence":"The low-affinity sodium glucose cotransporter (SGLT2  is responsible for most of the glucose reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes"}
{"PMID":19293728,"re_id":0,"annotated sentence":"Although the D1-like receptor, by itself, had no effect on VSMC proliferation, stimulation with <e1>fenoldopam<\\e1>  a D1-like receptor agonist, inhibited the stimulatory effect of <e2>insulin<\\e2>  The inhibitory effect of fenoldopam on insulin-mediated VSMC proliferation was receptor specific, because its effect could be blocked by SCH23390, a D1-like receptor antagonist","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"fenoldopam","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although the D1-like receptor, by itself, had no effect on VSMC proliferation, stimulation with <e1>CHEMICAL<\\e1>  a D1-like receptor agonist, inhibited the stimulatory effect of <e2>GENE-Y<\\e2>  The inhibitory effect of CHEMICAL on GENE-Y-mediated VSMC proliferation was receptor specific, because its effect could be blocked by SCH23390, a D1-like receptor antagonist","sentence":"Although the D1-like receptor, by itself, had no effect on VSMC proliferation, stimulation with fenoldopam  a D1-like receptor agonist, inhibited the stimulatory effect of insulin  The inhibitory effect of fenoldopam on insulin-mediated VSMC proliferation was receptor specific, because its effect could be blocked by SCH23390, a D1-like receptor antagonist"}
{"PMID":19293728,"re_id":1,"annotated sentence":"The inhibitory effect of <e1>fenoldopam<\\e1> on <e2>insulin<\\e2> mediated VSMC proliferation was receptor specific, because its effect could be blocked by SCH23390, a D1-like receptor antagonist","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"fenoldopam","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The inhibitory effect of <e1>CHEMICAL<\\e1> on <e2>GENE-Y<\\e2> mediated VSMC proliferation was receptor specific, because its effect could be blocked by SCH23390, a D1-like receptor antagonist","sentence":"The inhibitory effect of fenoldopam on insulin mediated VSMC proliferation was receptor specific, because its effect could be blocked by SCH23390, a D1-like receptor antagonist"}
{"PMID":19293728,"re_id":2,"annotated sentence":"<e1>Fenoldopam<\\e1> also inhibited <e2>insulin receptor<\\e2> mRNA and protein expression, which was time dependent and concentration dependent","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Fenoldopam","object":"insulin receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also inhibited <e2>GENE-Y<\\e2> mRNA and protein expression, which was time dependent and concentration dependent","sentence":"Fenoldopam also inhibited insulin receptor mRNA and protein expression, which was time dependent and concentration dependent"}
{"PMID":19293728,"re_id":3,"annotated sentence":"A PKC or MAP kinase inhibitor blocked the inhibitory effect of <e1>fenoldopam<\\e1> on <e2>insulin receptor<\\e2> expression, indicating that PKC and MAP kinase were involved in the signaling pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"fenoldopam","object":"insulin receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A PKC or MAP kinase inhibitor blocked the inhibitory effect of <e1>CHEMICAL<\\e1> on <e2>GENE-Y<\\e2> expression, indicating that PKC and MAP kinase were involved in the signaling pathway","sentence":"A PKC or MAP kinase inhibitor blocked the inhibitory effect of fenoldopam on insulin receptor expression, indicating that PKC and MAP kinase were involved in the signaling pathway"}
{"PMID":19293728,"re_id":4,"annotated sentence":"Although the D1-like receptor, by itself, had no effect on VSMC proliferation, stimulation with <e1>fenoldopam<\\e1>  a <e2>D1-like receptor<\\e2> agonist, inhibited the stimulatory effect of insulin","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"fenoldopam","object":"D1-like receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Although the GENE-N, by itself, had no effect on VSMC proliferation, stimulation with <e1>CHEMICAL<\\e1>  a <e2>GENE-N<\\e2> agonist, inhibited the stimulatory effect of insulin","sentence":"Although the D1-like receptor, by itself, had no effect on VSMC proliferation, stimulation with fenoldopam  a D1-like receptor agonist, inhibited the stimulatory effect of insulin"}
{"PMID":19293728,"re_id":5,"annotated sentence":"The inhibitory effect of fenoldopam on insulin-mediated VSMC proliferation was receptor specific, because its effect could be blocked by <e1>SCH23390<\\e1>  a <e2>D1-like receptor<\\e2> antagonist","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"SCH23390","object":"D1-like receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The inhibitory effect of fenoldopam on insulin-mediated VSMC proliferation was receptor specific, because its effect could be blocked by <e1>CHEMICAL<\\e1>  a <e2>GENE-N<\\e2> antagonist","sentence":"The inhibitory effect of fenoldopam on insulin-mediated VSMC proliferation was receptor specific, because its effect could be blocked by SCH23390  a D1-like receptor antagonist"}
{"PMID":19472276,"re_id":0,"annotated sentence":"The progress of the enzymatic reaction of the hydrolysis of <e1>acetylthiocholine<\\e1> at pH 8 in the presence of <e2>AChE<\\e2> and the inhibitor studied is determined by measuring at 230 nm the peak area of the reaction product thiocholine (TCh)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acetylthiocholine","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The progress of the enzymatic reaction of the hydrolysis of <e1>CHEMICAL<\\e1> at pH 8 in the presence of <e2>GENE-Y<\\e2> and the inhibitor studied is determined by measuring at 230 nm the peak area of the reaction product thiocholine (TCh)","sentence":"The progress of the enzymatic reaction of the hydrolysis of acetylthiocholine at pH 8 in the presence of AChE and the inhibitor studied is determined by measuring at 230 nm the peak area of the reaction product thiocholine (TCh)"}
{"PMID":19651196,"re_id":0,"annotated sentence":"atropine, <e2>AChE<\\e2> reactivator such as one of the recommended pyridinium oximes (pralidoxime, <e1>trimedoxime<\\e1>  obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"trimedoxime","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"atropine, <e2>GENE-Y<\\e2> reactivator such as one of the recommended pyridinium oximes (pralidoxime, <e1>CHEMICAL<\\e1>  obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans","sentence":"atropine, AChE reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime  obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans"}
{"PMID":19651196,"re_id":1,"annotated sentence":"atropine, <e2>AChE<\\e2> reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, <e1>obidoxime<\\e1> and HI-6) and diazepam are used for the treatment of OP poisoning in humans","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"obidoxime","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"atropine, <e2>GENE-Y<\\e2> reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, <e1>CHEMICAL<\\e1> and HI-6) and diazepam are used for the treatment of OP poisoning in humans","sentence":"atropine, AChE reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans"}
{"PMID":19651196,"re_id":2,"annotated sentence":"atropine, <e2>AChE<\\e2> reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and <e1>HI-6<\\e1>  and diazepam are used for the treatment of OP poisoning in humans","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"HI-6","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"atropine, <e2>GENE-Y<\\e2> reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and <e1>CHEMICAL<\\e1>  and diazepam are used for the treatment of OP poisoning in humans","sentence":"atropine, AChE reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6  and diazepam are used for the treatment of OP poisoning in humans"}
{"PMID":19651196,"re_id":3,"annotated sentence":"atropine, <e2>AChE<\\e2> reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6) and <e1>diazepam<\\e1> are used for the treatment of OP poisoning in humans","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"diazepam","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"atropine, <e2>GENE-Y<\\e2> reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6) and <e1>CHEMICAL<\\e1> are used for the treatment of OP poisoning in humans","sentence":"atropine, AChE reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans"}
{"PMID":19651196,"re_id":4,"annotated sentence":"<e1>atropine<\\e1>  <e2>AChE<\\e2> reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"atropine","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  <e2>GENE-Y<\\e2> reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans","sentence":"atropine  AChE reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans"}
{"PMID":19651196,"re_id":5,"annotated sentence":"atropine, <e2>AChE<\\e2> reactivator such as one of the recommended <e1>pyridinium oximes<\\e1> (pralidoxime, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"pyridinium oximes","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"atropine, <e2>GENE-Y<\\e2> reactivator such as one of the recommended <e1>CHEMICAL<\\e1> (pralidoxime, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans","sentence":"atropine, AChE reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans"}
{"PMID":19651196,"re_id":6,"annotated sentence":"atropine, <e2>AChE<\\e2> reactivator such as one of the recommended pyridinium oximes (<e1>pralidoxime<\\e1>  trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"pralidoxime","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"atropine, <e2>GENE-Y<\\e2> reactivator such as one of the recommended pyridinium oximes (<e1>CHEMICAL<\\e1>  trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans","sentence":"atropine, AChE reactivator such as one of the recommended pyridinium oximes (pralidoxime  trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans"}
{"PMID":19651196,"re_id":7,"annotated sentence":"atropine, <e2>AChE<\\e2> reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of <e1>OP<\\e1> poisoning in humans","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"OP","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"atropine, <e2>GENE-Y<\\e2> reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of <e1>CHEMICAL<\\e1> poisoning in humans","sentence":"atropine, AChE reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans"}
{"PMID":19651196,"re_id":8,"annotated sentence":"The mechanism of <e1>OP<\\e1> poisoning involves inhibition of <e2>acetylcholinesterase<\\e2> (AChE) leading to inactivation of the enzyme which has an important role in neurotransmission","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"OP","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mechanism of <e1>CHEMICAL<\\e1> poisoning involves inhibition of <e2>GENE-Y<\\e2> (AChE) leading to inactivation of the enzyme which has an important role in neurotransmission","sentence":"The mechanism of OP poisoning involves inhibition of acetylcholinesterase (AChE) leading to inactivation of the enzyme which has an important role in neurotransmission"}
{"PMID":19651196,"re_id":9,"annotated sentence":"The mechanism of <e1>OP<\\e1> poisoning involves inhibition of acetylcholinesterase (<e2>AChE<\\e2>  leading to inactivation of the enzyme which has an important role in neurotransmission","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"OP","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mechanism of <e1>CHEMICAL<\\e1> poisoning involves inhibition of acetylcholinesterase (<e2>GENE-Y<\\e2>  leading to inactivation of the enzyme which has an important role in neurotransmission","sentence":"The mechanism of OP poisoning involves inhibition of acetylcholinesterase (AChE  leading to inactivation of the enzyme which has an important role in neurotransmission"}
{"PMID":19651196,"re_id":10,"annotated sentence":"They act by reactivation of <e2>AChE<\\e2> inhibited by <e1>OP<\\e1>  However, they differ in their activity in poisoning with pesticides and warfare nerve agents and there is still no universal broad-spectrum oxime capable of protecting against all known OP","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"OP","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"They act by reactivation of <e2>GENE-Y<\\e2> inhibited by <e1>CHEMICAL<\\e1>  However, they differ in their activity in poisoning with pesticides and warfare nerve agents and there is still no universal broad-spectrum oxime capable of protecting against all known CHEMICAL","sentence":"They act by reactivation of AChE inhibited by OP  However, they differ in their activity in poisoning with pesticides and warfare nerve agents and there is still no universal broad-spectrum oxime capable of protecting against all known OP"}
{"PMID":19852528,"re_id":0,"annotated sentence":"Oral <e1>palonosetron<\\e1> is likely to be a useful addition to oral formulations of other <e2>5-HT3 recepto<\\e2>  antagonists in preventing CINV in patients receiving MEC","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"palonosetron","object":"5-HT3 recepto","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Oral <e1>CHEMICAL<\\e1> is likely to be a useful addition to oral formulations of other <e2>GENE-N<\\e2>  antagonists in preventing CINV in patients receiving MEC","sentence":"Oral palonosetron is likely to be a useful addition to oral formulations of other 5-HT3 recepto  antagonists in preventing CINV in patients receiving MEC"}
{"PMID":19852528,"re_id":1,"annotated sentence":"<e1>Palonosetron<\\e1> is a second-generation serotonin 5-HT3 receptor antagonist, with a distinct pharmacological profile that differs from first-generation <e2>5-HT3 receptor<\\e2> antagonists","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Palonosetron","object":"5-HT3 receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is a second-generation serotonin GENE-N antagonist, with a distinct pharmacological profile that differs from first-generation <e2>GENE-N<\\e2> antagonists","sentence":"Palonosetron is a second-generation serotonin 5-HT3 receptor antagonist, with a distinct pharmacological profile that differs from first-generation 5-HT3 receptor antagonists"}
{"PMID":19852528,"re_id":2,"annotated sentence":"<e1>Palonosetron<\\e1> is a second-generation <e2>serotonin 5-HT3 receptor<\\e2> antagonist, with a distinct pharmacological profile that differs from first-generation 5-HT3 receptor antagonists","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Palonosetron","object":"serotonin 5-HT3 receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is a second-generation <e2>GENE-N<\\e2> antagonist, with a distinct pharmacological profile that differs from first-generation 5-HT3 receptor antagonists","sentence":"Palonosetron is a second-generation serotonin 5-HT3 receptor antagonist, with a distinct pharmacological profile that differs from first-generation 5-HT3 receptor antagonists"}
{"PMID":20053189,"re_id":0,"annotated sentence":"Luteinizing hormone-releasing hormone (LHRH) agonists, such as <e1>buserelin<\\e1>  goserelin, leuprorelin and triptorelin, stimulate the pituitary's <e2>gonadotrophin-releasing hormone (GnRH) receptor<\\e2>  ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"buserelin","object":"gonadotrophin-releasing hormone (GnRH) receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Luteinizing hormone-releasing hormone (LHRH) agonists, such as <e1>CHEMICAL<\\e1>  goserelin, leuprorelin and triptorelin, stimulate the pituitary's <e2>GENE-Y<\\e2>  ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels","sentence":"Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin  goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor  ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels"}
{"PMID":20053189,"re_id":1,"annotated sentence":"Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, <e1>goserelin<\\e1>  leuprorelin and triptorelin, stimulate the pituitary's <e2>gonadotrophin-releasing hormone (GnRH) receptor<\\e2>  ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"goserelin","object":"gonadotrophin-releasing hormone (GnRH) receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, <e1>CHEMICAL<\\e1>  leuprorelin and triptorelin, stimulate the pituitary's <e2>GENE-Y<\\e2>  ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels","sentence":"Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin  leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor  ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels"}
{"PMID":20053189,"re_id":2,"annotated sentence":"Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, <e1>leuprorelin<\\e1> and triptorelin, stimulate the pituitary's <e2>gonadotrophin-releasing hormone (GnRH) receptor<\\e2>  ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"leuprorelin","object":"gonadotrophin-releasing hormone (GnRH) receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, <e1>CHEMICAL<\\e1> and triptorelin, stimulate the pituitary's <e2>GENE-Y<\\e2>  ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels","sentence":"Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor  ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels"}
{"PMID":20053189,"re_id":3,"annotated sentence":"Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and <e1>triptorelin<\\e1>  stimulate the pituitary's <e2>gonadotrophin-releasing hormone (GnRH) receptor<\\e2>  ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"triptorelin","object":"gonadotrophin-releasing hormone (GnRH) receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and <e1>CHEMICAL<\\e1>  stimulate the pituitary's <e2>GENE-Y<\\e2>  ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels","sentence":"Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin  stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor  ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels"}
{"PMID":20053189,"re_id":4,"annotated sentence":"Luteinizing hormone-releasing hormone (LHRH) agonists, such as <e1>buserelin<\\e1>  goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of <e2>LH<\\e2> and testosterone levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"buserelin","object":"LH","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Luteinizing hormone-releasing hormone (GENE-NRH) agonists, such as <e1>CHEMICAL<\\e1>  goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of <e2>GENE-N<\\e2> and testosterone levels","sentence":"Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin  goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels"}
{"PMID":20053189,"re_id":5,"annotated sentence":"Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, <e1>goserelin<\\e1>  leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of <e2>LH<\\e2> and testosterone levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"goserelin","object":"LH","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Luteinizing hormone-releasing hormone (GENE-NRH) agonists, such as buserelin, <e1>CHEMICAL<\\e1>  leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of <e2>GENE-N<\\e2> and testosterone levels","sentence":"Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin  leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels"}
{"PMID":20053189,"re_id":6,"annotated sentence":"Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, <e1>leuprorelin<\\e1> and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of <e2>LH<\\e2> and testosterone levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"leuprorelin","object":"LH","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Luteinizing hormone-releasing hormone (GENE-NRH) agonists, such as buserelin, goserelin, <e1>CHEMICAL<\\e1> and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of <e2>GENE-N<\\e2> and testosterone levels","sentence":"Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels"}
{"PMID":20053189,"re_id":7,"annotated sentence":"Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and <e1>triptorelin<\\e1>  stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of <e2>LH<\\e2> and testosterone levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"triptorelin","object":"LH","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Luteinizing hormone-releasing hormone (GENE-NRH) agonists, such as buserelin, goserelin, leuprorelin and <e1>CHEMICAL<\\e1>  stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of <e2>GENE-N<\\e2> and testosterone levels","sentence":"Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin  stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels"}
{"PMID":20053189,"re_id":8,"annotated sentence":"<e2>Luteinizing hormone-releasing hormone<\\e2> (LHRH) agonists, such as <e1>buserelin<\\e1>  goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"buserelin","object":"Luteinizing hormone-releasing hormone","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (LHRH) agonists, such as <e1>CHEMICAL<\\e1>  goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels","sentence":"Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin  goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels"}
{"PMID":20053189,"re_id":9,"annotated sentence":"Luteinizing hormone-releasing hormone (<e2>LHRH<\\e2>  agonists, such as <e1>buserelin<\\e1>  goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"buserelin","object":"LHRH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Luteinizing hormone-releasing hormone (<e2>GENE-Y<\\e2>  agonists, such as <e1>CHEMICAL<\\e1>  goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels","sentence":"Luteinizing hormone-releasing hormone (LHRH  agonists, such as buserelin  goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels"}
{"PMID":20053189,"re_id":10,"annotated sentence":"<e2>Luteinizing hormone-releasing hormone<\\e2> (LHRH) agonists, such as buserelin, <e1>goserelin<\\e1>  leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"goserelin","object":"Luteinizing hormone-releasing hormone","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (LHRH) agonists, such as buserelin, <e1>CHEMICAL<\\e1>  leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels","sentence":"Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin  leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels"}
{"PMID":20053189,"re_id":11,"annotated sentence":"Luteinizing hormone-releasing hormone (<e2>LHRH<\\e2>  agonists, such as buserelin, <e1>goserelin<\\e1>  leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"goserelin","object":"LHRH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Luteinizing hormone-releasing hormone (<e2>GENE-Y<\\e2>  agonists, such as buserelin, <e1>CHEMICAL<\\e1>  leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels","sentence":"Luteinizing hormone-releasing hormone (LHRH  agonists, such as buserelin, goserelin  leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels"}
{"PMID":20053189,"re_id":12,"annotated sentence":"<e2>Luteinizing hormone-releasing hormone<\\e2> (LHRH) agonists, such as buserelin, goserelin, <e1>leuprorelin<\\e1> and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"leuprorelin","object":"Luteinizing hormone-releasing hormone","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (LHRH) agonists, such as buserelin, goserelin, <e1>CHEMICAL<\\e1> and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels","sentence":"Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels"}
{"PMID":20053189,"re_id":13,"annotated sentence":"Luteinizing hormone-releasing hormone (<e2>LHRH<\\e2>  agonists, such as buserelin, goserelin, <e1>leuprorelin<\\e1> and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"leuprorelin","object":"LHRH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Luteinizing hormone-releasing hormone (<e2>GENE-Y<\\e2>  agonists, such as buserelin, goserelin, <e1>CHEMICAL<\\e1> and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels","sentence":"Luteinizing hormone-releasing hormone (LHRH  agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels"}
{"PMID":20053189,"re_id":14,"annotated sentence":"<e2>Luteinizing hormone-releasing hormone<\\e2> (LHRH) agonists, such as buserelin, goserelin, leuprorelin and <e1>triptorelin<\\e1>  stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"triptorelin","object":"Luteinizing hormone-releasing hormone","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (LHRH) agonists, such as buserelin, goserelin, leuprorelin and <e1>CHEMICAL<\\e1>  stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels","sentence":"Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin  stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels"}
{"PMID":20053189,"re_id":15,"annotated sentence":"Luteinizing hormone-releasing hormone (<e2>LHRH<\\e2>  agonists, such as buserelin, goserelin, leuprorelin and <e1>triptorelin<\\e1>  stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"triptorelin","object":"LHRH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Luteinizing hormone-releasing hormone (<e2>GENE-Y<\\e2>  agonists, such as buserelin, goserelin, leuprorelin and <e1>CHEMICAL<\\e1>  stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels","sentence":"Luteinizing hormone-releasing hormone (LHRH  agonists, such as buserelin, goserelin, leuprorelin and triptorelin  stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels"}
{"PMID":20053189,"re_id":16,"annotated sentence":"Two pure <e2>GnRH<\\e2> antagonists have been developed, <e1>abarelix<\\e1> and degarelix, that are devoid of any agonist effect on the GnRH receptor and consequently do not result in testosterone flare","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"abarelix","object":"GnRH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Two pure <e2>GENE-Y<\\e2> antagonists have been developed, <e1>CHEMICAL<\\e1> and degarelix, that are devoid of any agonist effect on the GENE-Y receptor and consequently do not result in testosterone flare","sentence":"Two pure GnRH antagonists have been developed, abarelix and degarelix, that are devoid of any agonist effect on the GnRH receptor and consequently do not result in testosterone flare"}
{"PMID":20053189,"re_id":17,"annotated sentence":"Two pure <e2>GnRH<\\e2> antagonists have been developed, abarelix and <e1>degarelix<\\e1>  that are devoid of any agonist effect on the GnRH receptor and consequently do not result in testosterone flare","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"degarelix","object":"GnRH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Two pure <e2>GENE-Y<\\e2> antagonists have been developed, abarelix and <e1>CHEMICAL<\\e1>  that are devoid of any agonist effect on the GENE-Y receptor and consequently do not result in testosterone flare","sentence":"Two pure GnRH antagonists have been developed, abarelix and degarelix  that are devoid of any agonist effect on the GnRH receptor and consequently do not result in testosterone flare"}
{"PMID":20053189,"re_id":18,"annotated sentence":"<e1>Abarelix<\\e1> was the first <e2>GnRH<\\e2> antagonist to be developed and was approved by the USA Food and Drug Administration in 2004 for the initiation of hormonal castration in advanced or metastasizing hormone-dependent prostate carcinoma, when rapid androgen suppression is necessary","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Abarelix","object":"GnRH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> was the first <e2>GENE-Y<\\e2> antagonist to be developed and was approved by the USA Food and Drug Administration in 2004 for the initiation of hormonal castration in advanced or metastasizing hormone-dependent prostate carcinoma, when rapid androgen suppression is necessary","sentence":"Abarelix was the first GnRH antagonist to be developed and was approved by the USA Food and Drug Administration in 2004 for the initiation of hormonal castration in advanced or metastasizing hormone-dependent prostate carcinoma, when rapid androgen suppression is necessary"}
{"PMID":20151846,"re_id":0,"annotated sentence":"<e1>Fulvestrant<\\e1>  a pure <e2>estrogen receptor<\\e2> downregulator, is a new addition to the antiestrogen therapeutic armamentarium since its FDA approval in 2002","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Fulvestrant","object":"estrogen receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a pure <e2>GENE-Y<\\e2> downregulator, is a new addition to the antiestrogen therapeutic armamentarium since its FDA approval in 2002","sentence":"Fulvestrant  a pure estrogen receptor downregulator, is a new addition to the antiestrogen therapeutic armamentarium since its FDA approval in 2002"}
{"PMID":2125244,"re_id":0,"annotated sentence":"The concentration of <e1>estramustine phosphate<\\e1> required to inhibit the assembly or to induce the disassembly of <e2>chick brain MAP2<\\e2> tubulin microtubules is markedly dependent upon the microtubule protein concentration","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"estramustine phosphate","object":"chick brain MAP2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The concentration of <e1>CHEMICAL<\\e1> required to inhibit the assembly or to induce the disassembly of <e2>GENE-Y<\\e2> tubulin microtubules is markedly dependent upon the microtubule protein concentration","sentence":"The concentration of estramustine phosphate required to inhibit the assembly or to induce the disassembly of chick brain MAP2 tubulin microtubules is markedly dependent upon the microtubule protein concentration"}
{"PMID":2125244,"re_id":1,"annotated sentence":"The concentration of <e1>estramustine phosphate<\\e1> required to inhibit the assembly or to induce the disassembly of chick brain MAP2:<e2>tubulin<\\e2> microtubules is markedly dependent upon the microtubule protein concentration","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"estramustine phosphate","object":"tubulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The concentration of <e1>CHEMICAL<\\e1> required to inhibit the assembly or to induce the disassembly of chick brain MAP2:<e2>GENE-N<\\e2> microtubules is markedly dependent upon the microtubule protein concentration","sentence":"The concentration of estramustine phosphate required to inhibit the assembly or to induce the disassembly of chick brain MAP2:tubulin microtubules is markedly dependent upon the microtubule protein concentration"}
{"PMID":2125244,"re_id":2,"annotated sentence":"The concentration of <e1>estramustine phosphate<\\e1> required to inhibit the assembly or to induce the disassembly of <e2>chick brain MAP2<\\e2> tubulin microtubules is markedly dependent upon the microtubule protein concentration","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"estramustine phosphate","object":"chick brain MAP2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The concentration of <e1>CHEMICAL<\\e1> required to inhibit the assembly or to induce the disassembly of <e2>GENE-Y<\\e2> tubulin microtubules is markedly dependent upon the microtubule protein concentration","sentence":"The concentration of estramustine phosphate required to inhibit the assembly or to induce the disassembly of chick brain MAP2 tubulin microtubules is markedly dependent upon the microtubule protein concentration"}
{"PMID":2125244,"re_id":3,"annotated sentence":"The concentration of <e1>estramustine phosphate<\\e1> required to inhibit the assembly or to induce the disassembly of chick brain MAP2:<e2>tubulin<\\e2> microtubules is markedly dependent upon the microtubule protein concentration","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"estramustine phosphate","object":"tubulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The concentration of <e1>CHEMICAL<\\e1> required to inhibit the assembly or to induce the disassembly of chick brain MAP2:<e2>GENE-N<\\e2> microtubules is markedly dependent upon the microtubule protein concentration","sentence":"The concentration of estramustine phosphate required to inhibit the assembly or to induce the disassembly of chick brain MAP2:tubulin microtubules is markedly dependent upon the microtubule protein concentration"}
{"PMID":2125244,"re_id":4,"annotated sentence":"It is proposed that two molecules of <e1>estramustine phosphate<\\e1> interact with each of the three tubulin-binding sites of MAP2 and inhibit the <e2>MAP2<\\e2> tubulin interaction by neutralising two highly conserved basic residues.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"estramustine phosphate","object":"MAP2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"It is proposed that two molecules of <e1>CHEMICAL<\\e1> interact with each of the three tubulin-binding sites of GENE-Y and inhibit the <e2>GENE-Y<\\e2> tubulin interaction by neutralising two highly conserved basic residues.","sentence":"It is proposed that two molecules of estramustine phosphate interact with each of the three tubulin-binding sites of MAP2 and inhibit the MAP2 tubulin interaction by neutralising two highly conserved basic residues."}
{"PMID":2125244,"re_id":5,"annotated sentence":"It is proposed that two molecules of <e1>estramustine phosphate<\\e1> interact with each of the three tubulin-binding sites of MAP2 and inhibit the MAP2:<e2>tubulin<\\e2> interaction by neutralising two highly conserved basic residues.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"estramustine phosphate","object":"tubulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"It is proposed that two molecules of <e1>CHEMICAL<\\e1> interact with each of the three GENE-N-binding sites of MAP2 and inhibit the MAP2:<e2>GENE-N<\\e2> interaction by neutralising two highly conserved basic residues.","sentence":"It is proposed that two molecules of estramustine phosphate interact with each of the three tubulin-binding sites of MAP2 and inhibit the MAP2:tubulin interaction by neutralising two highly conserved basic residues."}
{"PMID":21606412,"re_id":0,"annotated sentence":"PURPOSE: XL184 (<e1>cabozantinib<\\e1>  is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (<e2>VEGFR2<\\e2> , and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cabozantinib","object":"VEGFR2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PURPOSE: XL184 (<e1>CHEMICAL<\\e1>  is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (<e2>GENE-Y<\\e2> , and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models","sentence":"PURPOSE: XL184 (cabozantinib  is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2 , and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models"}
{"PMID":21606412,"re_id":1,"annotated sentence":"PURPOSE: XL184 (<e1>cabozantinib<\\e1>  is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and <e2>RET<\\e2>  with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cabozantinib","object":"RET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PURPOSE: XL184 (<e1>CHEMICAL<\\e1>  is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and <e2>GENE-Y<\\e2>  with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models","sentence":"PURPOSE: XL184 (cabozantinib  is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and RET  with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models"}
{"PMID":21606412,"re_id":2,"annotated sentence":"PURPOSE: XL184 (<e1>cabozantinib<\\e1>  is a potent inhibitor of <e2>MET<\\e2>  vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cabozantinib","object":"MET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PURPOSE: XL184 (<e1>CHEMICAL<\\e1>  is a potent inhibitor of <e2>GENE-Y<\\e2>  vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models","sentence":"PURPOSE: XL184 (cabozantinib  is a potent inhibitor of MET  vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models"}
{"PMID":21606412,"re_id":3,"annotated sentence":"PURPOSE: XL184 (<e1>cabozantinib<\\e1>  is a potent inhibitor of MET, <e2>vascular endothelial growth factor receptor 2<\\e2> (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cabozantinib","object":"vascular endothelial growth factor receptor 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PURPOSE: XL184 (<e1>CHEMICAL<\\e1>  is a potent inhibitor of MET, <e2>GENE-Y<\\e2> (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models","sentence":"PURPOSE: XL184 (cabozantinib  is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models"}
{"PMID":21606412,"re_id":4,"annotated sentence":"PURPOSE: <e1>XL184<\\e1> (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (<e2>VEGFR2<\\e2> , and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"XL184","object":"VEGFR2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PURPOSE: <e1>CHEMICAL<\\e1> (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (<e2>GENE-Y<\\e2> , and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models","sentence":"PURPOSE: XL184 (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2 , and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models"}
{"PMID":21606412,"re_id":5,"annotated sentence":"PURPOSE: <e1>XL184<\\e1> (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and <e2>RET<\\e2>  with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"XL184","object":"RET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PURPOSE: <e1>CHEMICAL<\\e1> (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and <e2>GENE-Y<\\e2>  with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models","sentence":"PURPOSE: XL184 (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and RET  with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models"}
{"PMID":21606412,"re_id":6,"annotated sentence":"PURPOSE: <e1>XL184<\\e1> (cabozantinib) is a potent inhibitor of <e2>MET<\\e2>  vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"XL184","object":"MET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PURPOSE: <e1>CHEMICAL<\\e1> (cabozantinib) is a potent inhibitor of <e2>GENE-Y<\\e2>  vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models","sentence":"PURPOSE: XL184 (cabozantinib) is a potent inhibitor of MET  vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models"}
{"PMID":21606412,"re_id":7,"annotated sentence":"PURPOSE: <e1>XL184<\\e1> (cabozantinib) is a potent inhibitor of MET, <e2>vascular endothelial growth factor receptor 2<\\e2> (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"XL184","object":"vascular endothelial growth factor receptor 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PURPOSE: <e1>CHEMICAL<\\e1> (cabozantinib) is a potent inhibitor of MET, <e2>GENE-Y<\\e2> (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models","sentence":"PURPOSE: XL184 (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models"}
{"PMID":21606412,"re_id":8,"annotated sentence":"Activity of <e1>XL184<\\e1> (Cabozantinib), an oral <e2>tyrosine kinase<\\e2> inhibitor, in patients with medullary thyroid cancer","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"XL184","object":"tyrosine kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Activity of <e1>CHEMICAL<\\e1> (Cabozantinib), an oral <e2>GENE-N<\\e2> inhibitor, in patients with medullary thyroid cancer","sentence":"Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer"}
{"PMID":21606412,"re_id":9,"annotated sentence":"Activity of XL184 (<e1>Cabozantinib<\\e1> , an oral <e2>tyrosine kinase<\\e2> inhibitor, in patients with medullary thyroid cancer","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cabozantinib","object":"tyrosine kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Activity of XL184 (<e1>CHEMICAL<\\e1> , an oral <e2>GENE-N<\\e2> inhibitor, in patients with medullary thyroid cancer","sentence":"Activity of XL184 (Cabozantinib , an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer"}
{"PMID":22370636,"re_id":0,"annotated sentence":"Further, we used this model to test the efficacy of <e1>GDC-0941<\\e1>  a <e2>PI3K<\\e2> inhibitor, in clinical development, and showed that the tumors respond to PI3K inhibition.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"GDC-0941","object":"PI3K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Further, we used this model to test the efficacy of <e1>CHEMICAL<\\e1>  a <e2>GENE-N<\\e2> inhibitor, in clinical development, and showed that the tumors respond to GENE-N inhibition.","sentence":"Further, we used this model to test the efficacy of GDC-0941  a PI3K inhibitor, in clinical development, and showed that the tumors respond to PI3K inhibition."}
{"PMID":22370636,"re_id":1,"annotated sentence":"Further, we used this model to test the efficacy of <e1>GDC-0941<\\e1>  a PI3K inhibitor, in clinical development, and showed that the tumors respond to <e2>PI3K<\\e2> inhibition.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"GDC-0941","object":"PI3K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Further, we used this model to test the efficacy of <e1>CHEMICAL<\\e1>  a GENE-N inhibitor, in clinical development, and showed that the tumors respond to <e2>GENE-N<\\e2> inhibition.","sentence":"Further, we used this model to test the efficacy of GDC-0941  a PI3K inhibitor, in clinical development, and showed that the tumors respond to PI3K inhibition."}
{"PMID":2268554,"re_id":0,"annotated sentence":"<e1>4-MA<\\e1>  a well known <e2>5 alpha-reductase<\\e2> inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"4-MA","object":"5 alpha-reductase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a well known <e2>GENE-N<\\e2> inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM","sentence":"4-MA  a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM"}
{"PMID":2268554,"re_id":1,"annotated sentence":"<e1>4-MA<\\e1>  a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of <e2>3 beta-HSD<\\e2> with a Ki value of 56 nM","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"4-MA","object":"3 beta-HSD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of <e2>GENE-N<\\e2> with a Ki value of 56 nM","sentence":"4-MA  a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM"}
{"PMID":2268554,"re_id":2,"annotated sentence":"<e1>Cyproterone acetate<\\e1>  a progestin used in the treatment of hirsutism, acne and prostate cancer as well as norgestrel and norethindrone that are widely used as oral contraceptives also inhibit <e2>3 beta-HSD<\\e2> activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cyproterone acetate","object":"3 beta-HSD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a progestin used in the treatment of hirsutism, acne and prostate cancer as well as norgestrel and norethindrone that are widely used as oral contraceptives also inhibit <e2>GENE-N<\\e2> activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.","sentence":"Cyproterone acetate  a progestin used in the treatment of hirsutism, acne and prostate cancer as well as norgestrel and norethindrone that are widely used as oral contraceptives also inhibit 3 beta-HSD activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively."}
{"PMID":2268554,"re_id":3,"annotated sentence":"Cyproterone acetate, a <e1>progestin<\\e1> used in the treatment of hirsutism, acne and prostate cancer as well as norgestrel and norethindrone that are widely used as oral contraceptives also inhibit <e2>3 beta-HSD<\\e2> activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"progestin","object":"3 beta-HSD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Cyproterone acetate, a <e1>CHEMICAL<\\e1> used in the treatment of hirsutism, acne and prostate cancer as well as norgestrel and norethindrone that are widely used as oral contraceptives also inhibit <e2>GENE-N<\\e2> activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.","sentence":"Cyproterone acetate, a progestin used in the treatment of hirsutism, acne and prostate cancer as well as norgestrel and norethindrone that are widely used as oral contraceptives also inhibit 3 beta-HSD activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively."}
{"PMID":2268554,"re_id":4,"annotated sentence":"Cyproterone acetate, a progestin used in the treatment of hirsutism, acne and prostate cancer as well as <e1>norgestrel<\\e1> and norethindrone that are widely used as oral contraceptives also inhibit <e2>3 beta-HSD<\\e2> activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"norgestrel","object":"3 beta-HSD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Cyproterone acetate, a progestin used in the treatment of hirsutism, acne and prostate cancer as well as <e1>CHEMICAL<\\e1> and norethindrone that are widely used as oral contraceptives also inhibit <e2>GENE-N<\\e2> activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.","sentence":"Cyproterone acetate, a progestin used in the treatment of hirsutism, acne and prostate cancer as well as norgestrel and norethindrone that are widely used as oral contraceptives also inhibit 3 beta-HSD activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively."}
{"PMID":2268554,"re_id":5,"annotated sentence":"Cyproterone acetate, a progestin used in the treatment of hirsutism, acne and prostate cancer as well as norgestrel and <e1>norethindrone<\\e1> that are widely used as oral contraceptives also inhibit <e2>3 beta-HSD<\\e2> activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"norethindrone","object":"3 beta-HSD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Cyproterone acetate, a progestin used in the treatment of hirsutism, acne and prostate cancer as well as norgestrel and <e1>CHEMICAL<\\e1> that are widely used as oral contraceptives also inhibit <e2>GENE-N<\\e2> activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.","sentence":"Cyproterone acetate, a progestin used in the treatment of hirsutism, acne and prostate cancer as well as norgestrel and norethindrone that are widely used as oral contraceptives also inhibit 3 beta-HSD activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively."}
{"PMID":2268554,"re_id":6,"annotated sentence":"Inhibitory effect of synthetic <e1>progestins<\\e1>  4-MA and cyanoketone on <e2>human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene-isomerase<\\e2> activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"progestins","object":"human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene-isomerase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibitory effect of synthetic <e1>CHEMICAL<\\e1>  4-MA and cyanoketone on <e2>GENE-N<\\e2> activity","sentence":"Inhibitory effect of synthetic progestins  4-MA and cyanoketone on human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene-isomerase activity"}
{"PMID":2268554,"re_id":7,"annotated sentence":"Inhibitory effect of synthetic progestins, <e1>4-MA<\\e1> and cyanoketone on <e2>human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene-isomerase<\\e2> activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"4-MA","object":"human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene-isomerase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibitory effect of synthetic progestins, <e1>CHEMICAL<\\e1> and cyanoketone on <e2>GENE-N<\\e2> activity","sentence":"Inhibitory effect of synthetic progestins, 4-MA and cyanoketone on human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene-isomerase activity"}
{"PMID":2268554,"re_id":8,"annotated sentence":"Inhibitory effect of synthetic progestins, 4-MA and <e1>cyanoketone<\\e1> on <e2>human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene-isomerase<\\e2> activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cyanoketone","object":"human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene-isomerase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibitory effect of synthetic progestins, 4-MA and <e1>CHEMICAL<\\e1> on <e2>GENE-N<\\e2> activity","sentence":"Inhibitory effect of synthetic progestins, 4-MA and cyanoketone on human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene-isomerase activity"}
{"PMID":2268554,"re_id":9,"annotated sentence":"<e1>Trilostane<\\e1>  epostane and cyanoketone are potent inhibitors of <e2>3 beta-HSD<\\e2> with Ki values of approximately 50 nM","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Trilostane","object":"3 beta-HSD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  epostane and cyanoketone are potent inhibitors of <e2>GENE-N<\\e2> with Ki values of approximately 50 nM","sentence":"Trilostane  epostane and cyanoketone are potent inhibitors of 3 beta-HSD with Ki values of approximately 50 nM"}
{"PMID":2268554,"re_id":10,"annotated sentence":"Trilostane, <e1>epostane<\\e1> and cyanoketone are potent inhibitors of <e2>3 beta-HSD<\\e2> with Ki values of approximately 50 nM","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"epostane","object":"3 beta-HSD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Trilostane, <e1>CHEMICAL<\\e1> and cyanoketone are potent inhibitors of <e2>GENE-N<\\e2> with Ki values of approximately 50 nM","sentence":"Trilostane, epostane and cyanoketone are potent inhibitors of 3 beta-HSD with Ki values of approximately 50 nM"}
{"PMID":2268554,"re_id":11,"annotated sentence":"Trilostane, epostane and <e1>cyanoketone<\\e1> are potent inhibitors of <e2>3 beta-HSD<\\e2> with Ki values of approximately 50 nM","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cyanoketone","object":"3 beta-HSD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Trilostane, epostane and <e1>CHEMICAL<\\e1> are potent inhibitors of <e2>GENE-N<\\e2> with Ki values of approximately 50 nM","sentence":"Trilostane, epostane and cyanoketone are potent inhibitors of 3 beta-HSD with Ki values of approximately 50 nM"}
{"PMID":2268554,"re_id":12,"annotated sentence":"<e2>Human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene isomerase<\\e2> (3 beta-HSD) purified from human placenta transforms C-21 (<e1>pregnenolone<\\e1> and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"pregnenolone","object":"Human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene isomerase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> (3 beta-HSD) purified from human placenta transforms C-21 (<e1>CHEMICAL<\\e1> and 17 alpha-hydroxy CHEMICAL) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids","sentence":"Human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene isomerase (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids"}
{"PMID":2268554,"re_id":13,"annotated sentence":"Human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene isomerase (<e2>3 beta-HSD<\\e2>  purified from human placenta transforms C-21 (<e1>pregnenolone<\\e1> and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"pregnenolone","object":"3 beta-HSD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene isomerase (<e2>GENE-N<\\e2>  purified from human placenta transforms C-21 (<e1>CHEMICAL<\\e1> and 17 alpha-hydroxy CHEMICAL) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids","sentence":"Human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene isomerase (3 beta-HSD  purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids"}
{"PMID":2268554,"re_id":14,"annotated sentence":"<e2>Human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene isomerase<\\e2> (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and <e1>17 alpha-hydroxy pregnenolone<\\e1>  as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"17 alpha-hydroxy pregnenolone","object":"Human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene isomerase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and <e1>CHEMICAL<\\e1>  as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids","sentence":"Human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene isomerase (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone  as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids"}
{"PMID":2268554,"re_id":15,"annotated sentence":"Human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene isomerase (<e2>3 beta-HSD<\\e2>  purified from human placenta transforms C-21 (pregnenolone and <e1>17 alpha-hydroxy pregnenolone<\\e1>  as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"17 alpha-hydroxy pregnenolone","object":"3 beta-HSD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene isomerase (<e2>GENE-N<\\e2>  purified from human placenta transforms C-21 (pregnenolone and <e1>CHEMICAL<\\e1>  as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids","sentence":"Human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene isomerase (3 beta-HSD  purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone  as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids"}
{"PMID":2268554,"re_id":16,"annotated sentence":"<e2>Human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene isomerase<\\e2> (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (<e1>dehydroepiandrosterone<\\e1> and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"dehydroepiandrosterone","object":"Human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene isomerase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (<e1>CHEMICAL<\\e1> and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids","sentence":"Human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene isomerase (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids"}
{"PMID":2268554,"re_id":17,"annotated sentence":"Human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene isomerase (<e2>3 beta-HSD<\\e2>  purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (<e1>dehydroepiandrosterone<\\e1> and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"dehydroepiandrosterone","object":"3 beta-HSD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene isomerase (<e2>GENE-N<\\e2>  purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (<e1>CHEMICAL<\\e1> and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids","sentence":"Human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene isomerase (3 beta-HSD  purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids"}
{"PMID":2268554,"re_id":18,"annotated sentence":"<e2>Human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene isomerase<\\e2> (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and <e1>androst-5-ene-3 beta, 17 beta-diol<\\e1>  steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"androst-5-ene-3 beta, 17 beta-diol","object":"Human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene isomerase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and <e1>CHEMICAL<\\e1>  steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids","sentence":"Human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene isomerase (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol  steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids"}
{"PMID":2268554,"re_id":19,"annotated sentence":"Human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene isomerase (<e2>3 beta-HSD<\\e2>  purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and <e1>androst-5-ene-3 beta, 17 beta-diol<\\e1>  steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"androst-5-ene-3 beta, 17 beta-diol","object":"3 beta-HSD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene isomerase (<e2>GENE-N<\\e2>  purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and <e1>CHEMICAL<\\e1>  steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids","sentence":"Human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene isomerase (3 beta-HSD  purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol  steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids"}
{"PMID":2268554,"re_id":20,"annotated sentence":"<e2>Human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene isomerase<\\e2> (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding <e1>3-keto-4-ene-steroids<\\e1> and is thus involved in the biosynthesis of all classes of hormonal steroids","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"3-keto-4-ene-steroids","object":"Human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene isomerase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding <e1>CHEMICAL<\\e1> and is thus involved in the biosynthesis of all classes of hormonal steroids","sentence":"Human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene isomerase (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids"}
{"PMID":2268554,"re_id":21,"annotated sentence":"Human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene isomerase (<e2>3 beta-HSD<\\e2>  purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding <e1>3-keto-4-ene-steroids<\\e1> and is thus involved in the biosynthesis of all classes of hormonal steroids","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"3-keto-4-ene-steroids","object":"3 beta-HSD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene isomerase (<e2>GENE-N<\\e2>  purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding <e1>CHEMICAL<\\e1> and is thus involved in the biosynthesis of all classes of hormonal steroids","sentence":"Human placental 3 beta-hydroxysteroid dehydrogenase\/5----4-ene isomerase (3 beta-HSD  purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids"}
{"PMID":22709946,"re_id":0,"annotated sentence":"However, chronic treatment of cLH rats with <e1>MPEP<\\e1> did not reverse learned helplessness, indicating that the enhanced <e2>mGlu5 receptor<\\e2> function is not the only player in the behavioral phenotype of this genetic model of depression","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"MPEP","object":"mGlu5 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, chronic treatment of cLH rats with <e1>CHEMICAL<\\e1> did not reverse learned helplessness, indicating that the enhanced <e2>GENE-Y<\\e2> function is not the only player in the behavioral phenotype of this genetic model of depression","sentence":"However, chronic treatment of cLH rats with MPEP did not reverse learned helplessness, indicating that the enhanced mGlu5 receptor function is not the only player in the behavioral phenotype of this genetic model of depression"}
{"PMID":22722028,"re_id":0,"annotated sentence":"Rescue of both impaired extinction acquisition and deficient extinction consolidation\/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while <e1>MS-275<\\e1> or PEPA (<e2>AMPA receptor<\\e2> potentiator) failed to affect extinction acquisition in S1 mice","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"MS-275","object":"AMPA receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Rescue of both impaired extinction acquisition and deficient extinction consolidation\/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while <e1>CHEMICAL<\\e1> or PEPA (<e2>GENE-N<\\e2> potentiator) failed to affect extinction acquisition in S1 mice","sentence":"Rescue of both impaired extinction acquisition and deficient extinction consolidation\/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice"}
{"PMID":22722028,"re_id":1,"annotated sentence":"Rescue of both impaired extinction acquisition and deficient extinction consolidation\/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or <e1>PEPA<\\e1> (<e2>AMPA receptor<\\e2> potentiator) failed to affect extinction acquisition in S1 mice","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"PEPA","object":"AMPA receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Rescue of both impaired extinction acquisition and deficient extinction consolidation\/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or <e1>CHEMICAL<\\e1> (<e2>GENE-N<\\e2> potentiator) failed to affect extinction acquisition in S1 mice","sentence":"Rescue of both impaired extinction acquisition and deficient extinction consolidation\/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice"}
{"PMID":22722028,"re_id":2,"annotated sentence":"Rescue of both impaired extinction acquisition and deficient extinction consolidation\/retrieval was achieved with prior extinction training administration of <e1>valproic acid<\\e1> (a GABAergic enhancer and <e2>HDAC<\\e2> inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"valproic acid","object":"HDAC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Rescue of both impaired extinction acquisition and deficient extinction consolidation\/retrieval was achieved with prior extinction training administration of <e1>CHEMICAL<\\e1> (a GABAergic enhancer and <e2>GENE-N<\\e2> inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice","sentence":"Rescue of both impaired extinction acquisition and deficient extinction consolidation\/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice"}
{"PMID":22722028,"re_id":3,"annotated sentence":"Rescue of this impaired extinction consolidation\/retrieval was achieved with d-cycloserine (N-methly-d-aspartate partial agonist) or <e1>MS-275<\\e1> (<e2>histone deacetylase<\\e2> (HDAC) inhibitor), applied after extinction training","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MS-275","object":"histone deacetylase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Rescue of this impaired extinction consolidation\/retrieval was achieved with d-cycloserine (N-methly-d-aspartate partial agonist) or <e1>CHEMICAL<\\e1> (<e2>GENE-N<\\e2> (HDAC) inhibitor), applied after extinction training","sentence":"Rescue of this impaired extinction consolidation\/retrieval was achieved with d-cycloserine (N-methly-d-aspartate partial agonist) or MS-275 (histone deacetylase (HDAC) inhibitor), applied after extinction training"}
{"PMID":22722028,"re_id":4,"annotated sentence":"Rescue of this impaired extinction consolidation\/retrieval was achieved with d-cycloserine (N-methly-d-aspartate partial agonist) or <e1>MS-275<\\e1> (histone deacetylase (<e2>HDAC<\\e2>  inhibitor), applied after extinction training","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MS-275","object":"HDAC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Rescue of this impaired extinction consolidation\/retrieval was achieved with d-cycloserine (N-methly-d-aspartate partial agonist) or <e1>CHEMICAL<\\e1> (histone deacetylase (<e2>GENE-N<\\e2>  inhibitor), applied after extinction training","sentence":"Rescue of this impaired extinction consolidation\/retrieval was achieved with d-cycloserine (N-methly-d-aspartate partial agonist) or MS-275 (histone deacetylase (HDAC  inhibitor), applied after extinction training"}
{"PMID":22722028,"re_id":5,"annotated sentence":"Rescue of both impaired extinction acquisition and deficient extinction consolidation\/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or <e1>AMN082<\\e1> [<e2>metabotropic glutamate receptor 7<\\e2> (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"AMN082","object":"metabotropic glutamate receptor 7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Rescue of both impaired extinction acquisition and deficient extinction consolidation\/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or <e1>CHEMICAL<\\e1> [<e2>GENE-Y<\\e2> (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice","sentence":"Rescue of both impaired extinction acquisition and deficient extinction consolidation\/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice"}
{"PMID":22722028,"re_id":6,"annotated sentence":"Rescue of both impaired extinction acquisition and deficient extinction consolidation\/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or <e1>AMN082<\\e1> [metabotropic glutamate receptor 7 (<e2>mGlu7<\\e2>  agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"AMN082","object":"mGlu7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Rescue of both impaired extinction acquisition and deficient extinction consolidation\/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or <e1>CHEMICAL<\\e1> [metabotropic glutamate receptor 7 (<e2>GENE-Y<\\e2>  agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice","sentence":"Rescue of both impaired extinction acquisition and deficient extinction consolidation\/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7  agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice"}
{"PMID":22749926,"re_id":0,"annotated sentence":"These findings suggest that oral consumption of <e1>nicotine<\\e1> enhances the efficacy of <e2>nicotinic acetylcholine receptors<\\e2>  Our findings further suggest that enhanced efficacy of the cholinergic system facilitates memory consolidation in perceptual learning (and possibly other types of non-declarative learning)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"nicotine","object":"nicotinic acetylcholine receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These findings suggest that oral consumption of <e1>CHEMICAL<\\e1> enhances the efficacy of <e2>GENE-N<\\e2>  Our findings further suggest that enhanced efficacy of the cholinergic system facilitates memory consolidation in perceptual learning (and possibly other types of non-declarative learning)","sentence":"These findings suggest that oral consumption of nicotine enhances the efficacy of nicotinic acetylcholine receptors  Our findings further suggest that enhanced efficacy of the cholinergic system facilitates memory consolidation in perceptual learning (and possibly other types of non-declarative learning)"}
{"PMID":22749926,"re_id":1,"annotated sentence":"Electroencephalographic recordings during substance consumption showed reduced alpha activity and <e2>P300<\\e2> latencies in the <e1>nicotine<\\e1> group compared to the control group","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"nicotine","object":"P300","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Electroencephalographic recordings during substance consumption showed reduced alpha activity and <e2>GENE-Y<\\e2> latencies in the <e1>CHEMICAL<\\e1> group compared to the control group","sentence":"Electroencephalographic recordings during substance consumption showed reduced alpha activity and P300 latencies in the nicotine group compared to the control group"}
{"PMID":22956632,"re_id":0,"annotated sentence":"<e1>GDC-0152<\\e1> induces <e2>NF-\u03baB<\\e2> transcriptional activity leading to expression of several chemokines and cytokines, of which tumor necrosis factor alpha (TNF-\u03b1) is the most important for single-agent tumor activity","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"GDC-0152","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> induces <e2>GENE-N<\\e2> transcriptional activity leading to expression of several chemokines and cytokines, of which tumor necrosis factor alpha (TNF-\u03b1) is the most important for single-agent tumor activity","sentence":"GDC-0152 induces NF-\u03baB transcriptional activity leading to expression of several chemokines and cytokines, of which tumor necrosis factor alpha (TNF-\u03b1) is the most important for single-agent tumor activity"}
{"PMID":22956632,"re_id":1,"annotated sentence":"<e1>GDC-0152<\\e1> is a small-molecule drug that triggers tumor cell apoptosis by selectively antagonizing <e2>IAPs<\\e2>  GDC-0152 induces NF-\u03baB transcriptional activity leading to expression of several chemokines and cytokines, of which tumor necrosis factor alpha (TNF-\u03b1) is the most important for single-agent tumor activity","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"GDC-0152","object":"IAPs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is a small-molecule drug that triggers tumor cell apoptosis by selectively antagonizing <e2>GENE-N<\\e2>  CHEMICAL induces NF-\u03baB transcriptional activity leading to expression of several chemokines and cytokines, of which tumor necrosis factor alpha (TNF-\u03b1) is the most important for single-agent tumor activity","sentence":"GDC-0152 is a small-molecule drug that triggers tumor cell apoptosis by selectively antagonizing IAPs  GDC-0152 induces NF-\u03baB transcriptional activity leading to expression of several chemokines and cytokines, of which tumor necrosis factor alpha (TNF-\u03b1) is the most important for single-agent tumor activity"}
{"PMID":22956632,"re_id":2,"annotated sentence":"Toxicity profile of small-molecule <e2>IAP<\\e2> antagonist <e1>GDC-0152<\\e1> is linked to TNF-\u03b1 pharmacology","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"GDC-0152","object":"IAP","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Toxicity profile of small-molecule <e2>GENE-N<\\e2> antagonist <e1>CHEMICAL<\\e1> is linked to TNF-\u03b1 pharmacology","sentence":"Toxicity profile of small-molecule IAP antagonist GDC-0152 is linked to TNF-\u03b1 pharmacology"}
{"PMID":22982218,"re_id":0,"annotated sentence":"In TPC1, BCPAP, FRO, WRO cell lines <e1>PJ34<\\e1> induced a strong increase in <e2>NIS<\\e2> mRNA levels","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"PJ34","object":"NIS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In TPC1, BCPAP, FRO, WRO cell lines <e1>CHEMICAL<\\e1> induced a strong increase in <e2>GENE-Y<\\e2> mRNA levels","sentence":"In TPC1, BCPAP, FRO, WRO cell lines PJ34 induced a strong increase in NIS mRNA levels"}
{"PMID":22982218,"re_id":1,"annotated sentence":"Accordingly, in transfection experiments performed in TPC1 cells, treatment with <e1>PJ34<\\e1> increased <e2>NIS promoter<\\e2> activity without affecting PARP-1 binding to the promoter sequence","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"PJ34","object":"NIS promoter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Accordingly, in transfection experiments performed in TPC1 cells, treatment with <e1>CHEMICAL<\\e1> increased <e2>GENE-N<\\e2> activity without affecting PARP-1 binding to the promoter sequence","sentence":"Accordingly, in transfection experiments performed in TPC1 cells, treatment with PJ34 increased NIS promoter activity without affecting PARP-1 binding to the promoter sequence"}
{"PMID":22982218,"re_id":2,"annotated sentence":"We also investigated the epigenetic status of NIS promoter after <e1>PJ34<\\e1> treatment in TPC1 cell line: in addition to an increase of <e2>histone modification activation marks<\\e2> (H3K9K14ac, H3K4me3), surprisingly we observed also an increase of H3K27me3, a classical repressive mark","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"PJ34","object":"histone modification activation marks","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We also investigated the epigenetic status of NIS promoter after <e1>CHEMICAL<\\e1> treatment in TPC1 cell line: in addition to an increase of <e2>GENE-N<\\e2> (H3K9K14ac, H3K4me3), surprisingly we observed also an increase of H3K27me3, a classical repressive mark","sentence":"We also investigated the epigenetic status of NIS promoter after PJ34 treatment in TPC1 cell line: in addition to an increase of histone modification activation marks (H3K9K14ac, H3K4me3), surprisingly we observed also an increase of H3K27me3, a classical repressive mark"}
{"PMID":22982218,"re_id":3,"annotated sentence":"We also investigated the epigenetic status of NIS promoter after <e1>PJ34<\\e1> treatment in TPC1 cell line: in addition to an increase of histone modification activation marks (<e2>H3K9K14ac<\\e2>  H3K4me3), surprisingly we observed also an increase of H3K27me3, a classical repressive mark","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"PJ34","object":"H3K9K14ac","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We also investigated the epigenetic status of NIS promoter after <e1>CHEMICAL<\\e1> treatment in TPC1 cell line: in addition to an increase of histone modification activation marks (<e2>GENE-N<\\e2>  H3K4me3), surprisingly we observed also an increase of H3K27me3, a classical repressive mark","sentence":"We also investigated the epigenetic status of NIS promoter after PJ34 treatment in TPC1 cell line: in addition to an increase of histone modification activation marks (H3K9K14ac  H3K4me3), surprisingly we observed also an increase of H3K27me3, a classical repressive mark"}
{"PMID":22982218,"re_id":4,"annotated sentence":"We also investigated the epigenetic status of NIS promoter after <e1>PJ34<\\e1> treatment in TPC1 cell line: in addition to an increase of histone modification activation marks (H3K9K14ac, <e2>H3K4me3<\\e2> , surprisingly we observed also an increase of H3K27me3, a classical repressive mark","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"PJ34","object":"H3K4me3","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We also investigated the epigenetic status of NIS promoter after <e1>CHEMICAL<\\e1> treatment in TPC1 cell line: in addition to an increase of histone modification activation marks (H3K9K14ac, <e2>GENE-N<\\e2> , surprisingly we observed also an increase of H3K27me3, a classical repressive mark","sentence":"We also investigated the epigenetic status of NIS promoter after PJ34 treatment in TPC1 cell line: in addition to an increase of histone modification activation marks (H3K9K14ac, H3K4me3 , surprisingly we observed also an increase of H3K27me3, a classical repressive mark"}
{"PMID":22982218,"re_id":5,"annotated sentence":"Since PARP-1 is supposed to be part of a multimeric repressor of sodium iodide symporter (NIS) expression, in this study the effect of the <e2>PARP<\\e2> inhibitor <e1>PJ34<\\e1> on several properties of thyroid cancer cell lines was investigated","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PJ34","object":"PARP","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Since GENE-N-1 is supposed to be part of a multimeric repressor of sodium iodide symporter (NIS) expression, in this study the effect of the <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1> on several properties of thyroid cancer cell lines was investigated","sentence":"Since PARP-1 is supposed to be part of a multimeric repressor of sodium iodide symporter (NIS) expression, in this study the effect of the PARP inhibitor PJ34 on several properties of thyroid cancer cell lines was investigated"}
{"PMID":22982218,"re_id":6,"annotated sentence":"The <e2>PARP<\\e2> inhibitor <e1>PJ34<\\e1> modifies proliferation, NIS expression and epigenetic marks in thyroid cancer cell lines","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PJ34","object":"PARP","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1> modifies proliferation, NIS expression and epigenetic marks in thyroid cancer cell lines","sentence":"The PARP inhibitor PJ34 modifies proliferation, NIS expression and epigenetic marks in thyroid cancer cell lines"}
{"PMID":22989703,"re_id":0,"annotated sentence":"Both <e1>apo-lycopenoic acids<\\e1> also decreased CSE-induced ROS production, 8-OHdG formation and reduced the increase in <e2>NOX-4<\\e2> and COX-2 expressions caused by CSE","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"apo-lycopenoic acids","object":"NOX-4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Both <e1>CHEMICAL<\\e1> also decreased CSE-induced ROS production, 8-OHdG formation and reduced the increase in <e2>GENE-Y<\\e2> and COX-2 expressions caused by CSE","sentence":"Both apo-lycopenoic acids also decreased CSE-induced ROS production, 8-OHdG formation and reduced the increase in NOX-4 and COX-2 expressions caused by CSE"}
{"PMID":22989703,"re_id":1,"annotated sentence":"Both <e1>apo-lycopenoic acids<\\e1> also decreased CSE-induced ROS production, 8-OHdG formation and reduced the increase in NOX-4 and <e2>COX-2<\\e2> expressions caused by CSE","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"apo-lycopenoic acids","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Both <e1>CHEMICAL<\\e1> also decreased CSE-induced ROS production, 8-OHdG formation and reduced the increase in NOX-4 and <e2>GENE-Y<\\e2> expressions caused by CSE","sentence":"Both apo-lycopenoic acids also decreased CSE-induced ROS production, 8-OHdG formation and reduced the increase in NOX-4 and COX-2 expressions caused by CSE"}
{"PMID":23000451,"re_id":0,"annotated sentence":"Here, in expressing <e1>cocaine<\\e1> hydrolyzing mutants of <e2>BChE<\\e2> in Nicotiana benthamiana using the MagnICON virus-assisted transient expression system, and in reporting their initial biochemical analysis, we provide proof-of-principle that plants can express engineered BChE proteins with desired properties.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cocaine","object":"BChE","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Here, in expressing <e1>CHEMICAL<\\e1> hydrolyzing mutants of <e2>GENE-N<\\e2> in Nicotiana benthamiana using the MagnICON virus-assisted transient expression system, and in reporting their initial biochemical analysis, we provide proof-of-principle that plants can express engineered GENE-N proteins with desired properties.","sentence":"Here, in expressing cocaine hydrolyzing mutants of BChE in Nicotiana benthamiana using the MagnICON virus-assisted transient expression system, and in reporting their initial biochemical analysis, we provide proof-of-principle that plants can express engineered BChE proteins with desired properties."}
{"PMID":23000451,"re_id":1,"annotated sentence":"Recent studies, however, have demonstrated a promising potential treatment option with the help of the serum enzyme <e2>butyrylcholinesterase<\\e2> (BChE), which is capable of breaking down naturally occurring <e1>(-)-cocaine<\\e1> before the drug can influence the reward centers of the brain or affect other areas of the body","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"(-)-cocaine","object":"butyrylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Recent studies, however, have demonstrated a promising potential treatment option with the help of the serum enzyme <e2>GENE-Y<\\e2> (BChE), which is capable of breaking down naturally occurring <e1>CHEMICAL<\\e1> before the drug can influence the reward centers of the brain or affect other areas of the body","sentence":"Recent studies, however, have demonstrated a promising potential treatment option with the help of the serum enzyme butyrylcholinesterase (BChE), which is capable of breaking down naturally occurring (-)-cocaine before the drug can influence the reward centers of the brain or affect other areas of the body"}
{"PMID":23000451,"re_id":2,"annotated sentence":"Recent studies, however, have demonstrated a promising potential treatment option with the help of the serum enzyme butyrylcholinesterase (<e2>BChE<\\e2> , which is capable of breaking down naturally occurring <e1>(-)-cocaine<\\e1> before the drug can influence the reward centers of the brain or affect other areas of the body","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"(-)-cocaine","object":"BChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Recent studies, however, have demonstrated a promising potential treatment option with the help of the serum enzyme butyrylcholinesterase (<e2>GENE-Y<\\e2> , which is capable of breaking down naturally occurring <e1>CHEMICAL<\\e1> before the drug can influence the reward centers of the brain or affect other areas of the body","sentence":"Recent studies, however, have demonstrated a promising potential treatment option with the help of the serum enzyme butyrylcholinesterase (BChE , which is capable of breaking down naturally occurring (-)-cocaine before the drug can influence the reward centers of the brain or affect other areas of the body"}
{"PMID":23000451,"re_id":3,"annotated sentence":"This prompted the design of variants of <e2>BChE<\\e2> which exhibit significantly improved catalytic activity against <e1>(-)-cocaine<\\e1>  Plants are a promising means to produce large amounts of these cocaine hydrolase variants of BChE, cheaply, safely with no concerns regarding human pathogens and functionally equivalent to enzymes derived from other sources","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"(-)-cocaine","object":"BChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This prompted the design of variants of <e2>GENE-Y<\\e2> which exhibit significantly improved catalytic activity against <e1>CHEMICAL<\\e1>  Plants are a promising means to produce large amounts of these cocaine hydrolase variants of GENE-Y, cheaply, safely with no concerns regarding human pathogens and functionally equivalent to enzymes derived from other sources","sentence":"This prompted the design of variants of BChE which exhibit significantly improved catalytic activity against (-)-cocaine  Plants are a promising means to produce large amounts of these cocaine hydrolase variants of BChE, cheaply, safely with no concerns regarding human pathogens and functionally equivalent to enzymes derived from other sources"}
{"PMID":23008503,"re_id":0,"annotated sentence":"Second, feeding increased both the expression of <e2>COX<\\e2> isoforms and PGE(2) level in the duodenum, and the effects were markedly inhibited by pretreatment with <e1>cimetidine<\\e1>  Third, COX-1 was localized in goblet and Brunner's gland cells, Meissner's and Auerbach's plexus, smooth muscle cells, and arterioles; and COX-2 was observed in capillaries, venules, and basal granulated cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cimetidine","object":"COX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Second, feeding increased both the expression of <e2>GENE-N<\\e2> isoforms and PGE(2) level in the duodenum, and the effects were markedly inhibited by pretreatment with <e1>CHEMICAL<\\e1>  Third, GENE-N-1 was localized in goblet and Brunner's gland cells, Meissner's and Auerbach's plexus, smooth muscle cells, and arterioles; and GENE-N-2 was observed in capillaries, venules, and basal granulated cells","sentence":"Second, feeding increased both the expression of COX isoforms and PGE(2) level in the duodenum, and the effects were markedly inhibited by pretreatment with cimetidine  Third, COX-1 was localized in goblet and Brunner's gland cells, Meissner's and Auerbach's plexus, smooth muscle cells, and arterioles; and COX-2 was observed in capillaries, venules, and basal granulated cells"}
{"PMID":23008503,"re_id":1,"annotated sentence":"We examined in cats the 1) ulcerogenic effects of selective <e2>COX-1<\\e2> (<e1>SC-560<\\e1>  ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SC-560","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We examined in cats the 1) ulcerogenic effects of selective <e2>GENE-Y<\\e2> (<e1>CHEMICAL<\\e1>  ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum","sentence":"We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560  ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum"}
{"PMID":23008503,"re_id":2,"annotated sentence":"We examined in cats the 1) ulcerogenic effects of selective <e2>COX-1<\\e2> (SC-560, <e1>ketorolac<\\e1>  and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ketorolac","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We examined in cats the 1) ulcerogenic effects of selective <e2>GENE-Y<\\e2> (SC-560, <e1>CHEMICAL<\\e1>  and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum","sentence":"We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac  and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum"}
{"PMID":23008503,"re_id":3,"annotated sentence":"We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and <e2>COX-2<\\e2> (<e1>celecoxib<\\e1>  meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"celecoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and <e2>GENE-Y<\\e2> (<e1>CHEMICAL<\\e1>  meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum","sentence":"We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and COX-2 (celecoxib  meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum"}
{"PMID":23008503,"re_id":4,"annotated sentence":"We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and <e2>COX-2<\\e2> (celecoxib, <e1>meloxicam<\\e1>  inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"meloxicam","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and <e2>GENE-Y<\\e2> (celecoxib, <e1>CHEMICAL<\\e1>  inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum","sentence":"We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and COX-2 (celecoxib, meloxicam  inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum"}
{"PMID":23019137,"re_id":0,"annotated sentence":"Reversal of inhibition by <e2>D2<\\e2> agonist quinpirole was produced by serotonin (50 \u00b5M) and by <e1>neurotensin<\\e1> (5-10 nM)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"neurotensin","object":"D2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reversal of inhibition by <e2>GENE-Y<\\e2> agonist quinpirole was produced by serotonin (50 \u00b5M) and by <e1>CHEMICAL<\\e1> (5-10 nM)","sentence":"Reversal of inhibition by D2 agonist quinpirole was produced by serotonin (50 \u00b5M) and by neurotensin (5-10 nM)"}
{"PMID":23019137,"re_id":1,"annotated sentence":"Reversal of inhibition by <e2>D2<\\e2> agonist quinpirole was produced by <e1>serotonin<\\e1> (50 \u00b5M) and by neurotensin (5-10 nM)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"serotonin","object":"D2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reversal of inhibition by <e2>GENE-Y<\\e2> agonist quinpirole was produced by <e1>CHEMICAL<\\e1> (50 \u00b5M) and by neurotensin (5-10 nM)","sentence":"Reversal of inhibition by D2 agonist quinpirole was produced by serotonin (50 \u00b5M) and by neurotensin (5-10 nM)"}
{"PMID":23019137,"re_id":2,"annotated sentence":"Reversal of inhibition by <e2>D2<\\e2> agonist <e1>quinpirole<\\e1> was produced by serotonin (50 \u00b5M) and by neurotensin (5-10 nM)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"quinpirole","object":"D2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reversal of inhibition by <e2>GENE-Y<\\e2> agonist <e1>CHEMICAL<\\e1> was produced by serotonin (50 \u00b5M) and by neurotensin (5-10 nM)","sentence":"Reversal of inhibition by D2 agonist quinpirole was produced by serotonin (50 \u00b5M) and by neurotensin (5-10 nM)"}
{"PMID":23019137,"re_id":3,"annotated sentence":"Serotonin-induced or neurotensin-induced reversal was blocked by \u03b2-ARK1 inhibitor, dynasore, or <e2>cPKC<\\e2> antagonist <e1>5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile<\\e1> (G\u00f66976)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile","object":"cPKC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Serotonin-induced or neurotensin-induced reversal was blocked by \u03b2-ARK1 inhibitor, dynasore, or <e2>GENE-N<\\e2> antagonist <e1>CHEMICAL<\\e1> (G\u00f66976)","sentence":"Serotonin-induced or neurotensin-induced reversal was blocked by \u03b2-ARK1 inhibitor, dynasore, or cPKC antagonist 5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile (G\u00f66976)"}
{"PMID":23019137,"re_id":4,"annotated sentence":"Serotonin-induced or neurotensin-induced reversal was blocked by \u03b2-ARK1 inhibitor, dynasore, or <e2>cPKC<\\e2> antagonist 5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile (<e1>G\u00f66976<\\e1> ","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"G\u00f66976","object":"cPKC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Serotonin-induced or neurotensin-induced reversal was blocked by \u03b2-ARK1 inhibitor, dynasore, or <e2>GENE-N<\\e2> antagonist 5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile (<e1>CHEMICAL<\\e1> ","sentence":"Serotonin-induced or neurotensin-induced reversal was blocked by \u03b2-ARK1 inhibitor, dynasore, or cPKC antagonist 5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile (G\u00f66976 "}
{"PMID":23042952,"re_id":0,"annotated sentence":"However, <e1>4'G-RSV<\\e1>  but not 3G-RSV, induced <e2>SIRT1<\\e2> dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"4'G-RSV","object":"SIRT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, <e1>CHEMICAL<\\e1>  but not 3G-RSV, induced <e2>GENE-Y<\\e2> dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, GENE-Y knockdown blunted these effects","sentence":"However, 4'G-RSV  but not 3G-RSV, induced SIRT1 dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects"}
{"PMID":23042952,"re_id":1,"annotated sentence":"However, <e1>4'G-RSV<\\e1>  but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and <e2>SOD2<\\e2> expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"4'G-RSV","object":"SOD2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, <e1>CHEMICAL<\\e1>  but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and <e2>GENE-Y<\\e2> expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects","sentence":"However, 4'G-RSV  but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects"}
{"PMID":23042952,"re_id":2,"annotated sentence":"<e1>RSV<\\e1> targets and activates the <e2>NAD(+)-dependent protein deacetylase SIRT1<\\e2>  in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (SOD2)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"RSV","object":"NAD(+)-dependent protein deacetylase SIRT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> targets and activates the <e2>GENE-Y<\\e2>  in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (SOD2)","sentence":"RSV targets and activates the NAD(+)-dependent protein deacetylase SIRT1  in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (SOD2)"}
{"PMID":23042952,"re_id":3,"annotated sentence":"<e1>RSV<\\e1> targets and activates the NAD(+)-dependent protein deacetylase SIRT1; in turn, <e2>SIRT1<\\e2> induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (SOD2)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"RSV","object":"SIRT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> targets and activates the NAD(+)-dependent protein deacetylase GENE-Y; in turn, <e2>GENE-Y<\\e2> induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (SOD2)","sentence":"RSV targets and activates the NAD(+)-dependent protein deacetylase SIRT1; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (SOD2)"}
{"PMID":23042952,"re_id":4,"annotated sentence":"<e1>RSV<\\e1> targets and activates the NAD(+)-dependent protein deacetylase SIRT1; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing <e2>mitochondrial superoxide dismutase<\\e2> (SOD2)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"RSV","object":"mitochondrial superoxide dismutase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> targets and activates the NAD(+)-dependent protein deacetylase SIRT1; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing <e2>GENE-Y<\\e2> (SOD2)","sentence":"RSV targets and activates the NAD(+)-dependent protein deacetylase SIRT1; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (SOD2)"}
{"PMID":23042952,"re_id":5,"annotated sentence":"<e1>RSV<\\e1> targets and activates the NAD(+)-dependent protein deacetylase SIRT1; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (<e2>SOD2<\\e2> ","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"RSV","object":"SOD2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> targets and activates the NAD(+)-dependent protein deacetylase SIRT1; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (<e2>GENE-Y<\\e2> ","sentence":"RSV targets and activates the NAD(+)-dependent protein deacetylase SIRT1; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (SOD2 "}
{"PMID":23042953,"re_id":0,"annotated sentence":"These results provide a rationale for future design of therapeutic apolipoprotein mimetic peptides and provide new insights into the interaction of hydrophobic residues on apolipoproteins with phospholipids in the lipid microdomain created by the <e2>ABCA1<\\e2> transporter during the <e1>cholesterol<\\e1> efflux process.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cholesterol","object":"ABCA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results provide a rationale for future design of therapeutic apolipoprotein mimetic peptides and provide new insights into the interaction of hydrophobic residues on apolipoproteins with phospholipids in the lipid microdomain created by the <e2>GENE-Y<\\e2> transporter during the <e1>CHEMICAL<\\e1> efflux process.","sentence":"These results provide a rationale for future design of therapeutic apolipoprotein mimetic peptides and provide new insights into the interaction of hydrophobic residues on apolipoproteins with phospholipids in the lipid microdomain created by the ABCA1 transporter during the cholesterol efflux process."}
{"PMID":23042953,"re_id":1,"annotated sentence":"The bihelical <e2>apolipoprotein mimetic peptide 5A<\\e2> effluxes <e1>cholesterol<\\e1> from cells and reduces inflammation and atherosclerosis in animal models","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cholesterol","object":"apolipoprotein mimetic peptide 5A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The bihelical <e2>GENE-Y<\\e2> effluxes <e1>CHEMICAL<\\e1> from cells and reduces inflammation and atherosclerosis in animal models","sentence":"The bihelical apolipoprotein mimetic peptide 5A effluxes cholesterol from cells and reduces inflammation and atherosclerosis in animal models"}
{"PMID":23042953,"re_id":2,"annotated sentence":"Compared with active peptides containing F or W, peptides containing E in either of these two positions were more than 10-fold less effective in effluxing <e1>cholesterol<\\e1> by the <e2>ABCA1<\\e2> transporter","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cholesterol","object":"ABCA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Compared with active peptides containing F or W, peptides containing E in either of these two positions were more than 10-fold less effective in effluxing <e1>CHEMICAL<\\e1> by the <e2>GENE-Y<\\e2> transporter","sentence":"Compared with active peptides containing F or W, peptides containing E in either of these two positions were more than 10-fold less effective in effluxing cholesterol by the ABCA1 transporter"}
{"PMID":23042953,"re_id":3,"annotated sentence":"Hydrophobic amino acids in the hinge region of the 5A apolipoprotein mimetic peptide are essential for promoting <e1>cholesterol<\\e1> efflux by the <e2>ABCA1<\\e2> transporter","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cholesterol","object":"ABCA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Hydrophobic amino acids in the hinge region of the 5A apolipoprotein mimetic peptide are essential for promoting <e1>CHEMICAL<\\e1> efflux by the <e2>GENE-Y<\\e2> transporter","sentence":"Hydrophobic amino acids in the hinge region of the 5A apolipoprotein mimetic peptide are essential for promoting cholesterol efflux by the ABCA1 transporter"}
{"PMID":23042954,"re_id":0,"annotated sentence":"To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the <e2>GluK1<\\e2> (GluR5)\/\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist <e1>(3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid<\\e1> (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"(3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid","object":"GluK1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the <e2>GENE-Y<\\e2> (GluR5)\/\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist <e1>CHEMICAL<\\e1> (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman","sentence":"To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (GluR5)\/\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman"}
{"PMID":23042954,"re_id":1,"annotated sentence":"To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (<e2>GluR5<\\e2> \/\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist <e1>(3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid<\\e1> (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"(3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid","object":"GluR5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (<e2>GENE-Y<\\e2> \/\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist <e1>CHEMICAL<\\e1> (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman","sentence":"To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (GluR5 \/\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman"}
{"PMID":23042954,"re_id":2,"annotated sentence":"To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (GluR5)\/<e2>\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor<\\e2> antagonist <e1>(3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid<\\e1> (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"(3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid","object":"\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (GluR5)\/<e2>GENE-N<\\e2> antagonist <e1>CHEMICAL<\\e1> (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman","sentence":"To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (GluR5)\/\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman"}
{"PMID":23042954,"re_id":3,"annotated sentence":"To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the <e2>GluK1<\\e2> (GluR5)\/\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (<e1>LY293558<\\e1>  in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"LY293558","object":"GluK1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the <e2>GENE-Y<\\e2> (GluR5)\/\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (<e1>CHEMICAL<\\e1>  in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman","sentence":"To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (GluR5)\/\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (LY293558  in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman"}
{"PMID":23042954,"re_id":4,"annotated sentence":"To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (<e2>GluR5<\\e2> \/\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (<e1>LY293558<\\e1>  in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"LY293558","object":"GluR5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (<e2>GENE-Y<\\e2> \/\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (<e1>CHEMICAL<\\e1>  in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman","sentence":"To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (GluR5 \/\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (LY293558  in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman"}
{"PMID":23042954,"re_id":5,"annotated sentence":"To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (GluR5)\/<e2>\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor<\\e2> antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (<e1>LY293558<\\e1>  in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"LY293558","object":"\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (GluR5)\/<e2>GENE-N<\\e2> antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (<e1>CHEMICAL<\\e1>  in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman","sentence":"To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (GluR5)\/\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (LY293558  in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman"}
{"PMID":23042954,"re_id":6,"annotated sentence":"Efficacy of the <e2>GluK1<\\e2> AMPA receptor antagonist <e1>LY293558<\\e1> against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"LY293558","object":"GluK1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Efficacy of the <e2>GENE-Y<\\e2> AMPA receptor antagonist <e1>CHEMICAL<\\e1> against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration","sentence":"Efficacy of the GluK1 AMPA receptor antagonist LY293558 against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration"}
{"PMID":23042954,"re_id":7,"annotated sentence":"Efficacy of the GluK1\/<e2>AMPA receptor<\\e2> antagonist <e1>LY293558<\\e1> against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"LY293558","object":"AMPA receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Efficacy of the GluK1\/<e2>GENE-N<\\e2> antagonist <e1>CHEMICAL<\\e1> against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration","sentence":"Efficacy of the GluK1\/AMPA receptor antagonist LY293558 against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration"}
{"PMID":23047022,"re_id":0,"annotated sentence":"Cellular release of <e2>AChE<\\e2> by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists <e1>carbachol<\\e1> or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"carbachol","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cellular release of <e2>GENE-Y<\\e2> by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists <e1>CHEMICAL<\\e1> or muscarine, with the effect of CHEMICAL blocked by the mAChR antagonist atropine","sentence":"Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine"}
{"PMID":23047022,"re_id":1,"annotated sentence":"Cellular release of <e2>AChE<\\e2> by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or <e1>muscarine<\\e1>  with the effect of carbachol blocked by the mAChR antagonist atropine","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"muscarine","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cellular release of <e2>GENE-Y<\\e2> by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or <e1>CHEMICAL<\\e1>  with the effect of carbachol blocked by the mAChR antagonist atropine","sentence":"Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine  with the effect of carbachol blocked by the mAChR antagonist atropine"}
{"PMID":23047022,"re_id":2,"annotated sentence":"Cellular release of <e2>AChE<\\e2> by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of <e1>carbachol<\\e1> blocked by the mAChR antagonist atropine","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"carbachol","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cellular release of <e2>GENE-Y<\\e2> by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists CHEMICAL or muscarine, with the effect of <e1>CHEMICAL<\\e1> blocked by the mAChR antagonist atropine","sentence":"Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine"}
{"PMID":23047022,"re_id":3,"annotated sentence":"Cellular release of <e2>AChE<\\e2> by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist <e1>atropine<\\e1>  AChE has been implicated in the pathogenesis of Alzheimer's disease and it has been shown that it accelerates formation and increases toxicity of amyloid fibrils, which have been closely linked to the pathology of AD","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"atropine","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cellular release of <e2>GENE-Y<\\e2> by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist <e1>CHEMICAL<\\e1>  GENE-Y has been implicated in the pathogenesis of Alzheimer's disease and it has been shown that it accelerates formation and increases toxicity of amyloid fibrils, which have been closely linked to the pathology of AD","sentence":"Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine  AChE has been implicated in the pathogenesis of Alzheimer's disease and it has been shown that it accelerates formation and increases toxicity of amyloid fibrils, which have been closely linked to the pathology of AD"}
{"PMID":23047022,"re_id":4,"annotated sentence":"Cellular release of AChE by SH-SY5Y is significantly enhanced by the <e2>muscarinic acetylcholine receptor<\\e2> (mAChR) agonists <e1>carbachol<\\e1> or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"carbachol","object":"muscarinic acetylcholine receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Cellular release of AChE by SH-SY5Y is significantly enhanced by the <e2>GENE-N<\\e2> (mAChR) agonists <e1>CHEMICAL<\\e1> or muscarine, with the effect of CHEMICAL blocked by the mAChR antagonist atropine","sentence":"Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine"}
{"PMID":23047022,"re_id":5,"annotated sentence":"Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (<e2>mAChR<\\e2>  agonists <e1>carbachol<\\e1> or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"carbachol","object":"mAChR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (<e2>GENE-N<\\e2>  agonists <e1>CHEMICAL<\\e1> or muscarine, with the effect of CHEMICAL blocked by the GENE-N antagonist atropine","sentence":"Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR  agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine"}
{"PMID":23047022,"re_id":6,"annotated sentence":"Cellular release of AChE by SH-SY5Y is significantly enhanced by the <e2>muscarinic acetylcholine receptor<\\e2> (mAChR) agonists carbachol or <e1>muscarine<\\e1>  with the effect of carbachol blocked by the mAChR antagonist atropine","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"muscarine","object":"muscarinic acetylcholine receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Cellular release of AChE by SH-SY5Y is significantly enhanced by the <e2>GENE-N<\\e2> (mAChR) agonists carbachol or <e1>CHEMICAL<\\e1>  with the effect of carbachol blocked by the mAChR antagonist atropine","sentence":"Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine  with the effect of carbachol blocked by the mAChR antagonist atropine"}
{"PMID":23047022,"re_id":7,"annotated sentence":"Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (<e2>mAChR<\\e2>  agonists carbachol or <e1>muscarine<\\e1>  with the effect of carbachol blocked by the mAChR antagonist atropine","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"muscarine","object":"mAChR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (<e2>GENE-N<\\e2>  agonists carbachol or <e1>CHEMICAL<\\e1>  with the effect of carbachol blocked by the GENE-N antagonist atropine","sentence":"Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR  agonists carbachol or muscarine  with the effect of carbachol blocked by the mAChR antagonist atropine"}
{"PMID":23047022,"re_id":8,"annotated sentence":"Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the <e2>mAChR<\\e2> antagonist <e1>atropine<\\e1>  AChE has been implicated in the pathogenesis of Alzheimer's disease and it has been shown that it accelerates formation and increases toxicity of amyloid fibrils, which have been closely linked to the pathology of AD","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"atropine","object":"mAChR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (GENE-N) agonists carbachol or muscarine, with the effect of carbachol blocked by the <e2>GENE-N<\\e2> antagonist <e1>CHEMICAL<\\e1>  AChE has been implicated in the pathogenesis of Alzheimer's disease and it has been shown that it accelerates formation and increases toxicity of amyloid fibrils, which have been closely linked to the pathology of AD","sentence":"Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine  AChE has been implicated in the pathogenesis of Alzheimer's disease and it has been shown that it accelerates formation and increases toxicity of amyloid fibrils, which have been closely linked to the pathology of AD"}
{"PMID":23047022,"re_id":9,"annotated sentence":"Although acetylcholinesterase (<e2>AChE<\\e2>  is primarily a hydrolytic enzyme, metabolising the neurotransmitter <e1>acetylcholine<\\e1> in cholinergic synapses, it also has some non-catalytic functions in the brain which are far less well characterised","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acetylcholine","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although CHEMICALsterase (<e2>GENE-Y<\\e2>  is primarily a hydrolytic enzyme, metabolising the neurotransmitter <e1>CHEMICAL<\\e1> in cholinergic synapses, it also has some non-catalytic functions in the brain which are far less well characterised","sentence":"Although acetylcholinesterase (AChE  is primarily a hydrolytic enzyme, metabolising the neurotransmitter acetylcholine in cholinergic synapses, it also has some non-catalytic functions in the brain which are far less well characterised"}
{"PMID":23047022,"re_id":10,"annotated sentence":"Although <e2>acetylcholinesterase<\\e2> (AChE) is primarily a hydrolytic enzyme, metabolising the neurotransmitter <e1>acetylcholine<\\e1> in cholinergic synapses, it also has some non-catalytic functions in the brain which are far less well characterised","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acetylcholine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although <e2>CHEMICALsterase<\\e2> (AChE) is primarily a hydrolytic enzyme, metabolising the neurotransmitter <e1>CHEMICAL<\\e1> in cholinergic synapses, it also has some non-catalytic functions in the brain which are far less well characterised","sentence":"Although acetylcholinesterase (AChE) is primarily a hydrolytic enzyme, metabolising the neurotransmitter acetylcholine in cholinergic synapses, it also has some non-catalytic functions in the brain which are far less well characterised"}
{"PMID":23047912,"re_id":0,"annotated sentence":"Nevertheless, low <e1>L-BMAA<\\e1> concentrations (\u2265 0.1mM, 48 h) increased protein ubiquitination, <e2>20S proteasomal<\\e2> and caspase 12 activity, expression of the endoplasmic reticulum (ER) stress marker CHOP, and enhanced phosphorylation of elf2\u03b1 in SH-SY5Y cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"L-BMAA","object":"20S proteasomal","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Nevertheless, low <e1>CHEMICAL<\\e1> concentrations (\u2265 0.1mM, 48 h) increased protein ubiquitination, <e2>GENE-N<\\e2> and caspase 12 activity, expression of the endoplasmic reticulum (ER) stress marker CHOP, and enhanced phosphorylation of elf2\u03b1 in SH-SY5Y cells","sentence":"Nevertheless, low L-BMAA concentrations (\u2265 0.1mM, 48 h) increased protein ubiquitination, 20S proteasomal and caspase 12 activity, expression of the endoplasmic reticulum (ER) stress marker CHOP, and enhanced phosphorylation of elf2\u03b1 in SH-SY5Y cells"}
{"PMID":23047912,"re_id":1,"annotated sentence":"Nevertheless, low <e1>L-BMAA<\\e1> concentrations (\u2265 0.1mM, 48 h) increased protein ubiquitination, 20S proteasomal and <e2>caspase 12<\\e2> activity, expression of the endoplasmic reticulum (ER) stress marker CHOP, and enhanced phosphorylation of elf2\u03b1 in SH-SY5Y cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"L-BMAA","object":"caspase 12","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Nevertheless, low <e1>CHEMICAL<\\e1> concentrations (\u2265 0.1mM, 48 h) increased protein ubiquitination, 20S proteasomal and <e2>GENE-Y<\\e2> activity, expression of the endoplasmic reticulum (ER) stress marker CHOP, and enhanced phosphorylation of elf2\u03b1 in SH-SY5Y cells","sentence":"Nevertheless, low L-BMAA concentrations (\u2265 0.1mM, 48 h) increased protein ubiquitination, 20S proteasomal and caspase 12 activity, expression of the endoplasmic reticulum (ER) stress marker CHOP, and enhanced phosphorylation of elf2\u03b1 in SH-SY5Y cells"}
{"PMID":23047912,"re_id":2,"annotated sentence":"Nevertheless, low <e1>L-BMAA<\\e1> concentrations (\u2265 0.1mM, 48 h) increased protein ubiquitination, 20S proteasomal and caspase 12 activity, expression of the endoplasmic reticulum (ER) stress marker <e2>CHOP<\\e2>  and enhanced phosphorylation of elf2\u03b1 in SH-SY5Y cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"L-BMAA","object":"CHOP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Nevertheless, low <e1>CHEMICAL<\\e1> concentrations (\u2265 0.1mM, 48 h) increased protein ubiquitination, 20S proteasomal and caspase 12 activity, expression of the endoplasmic reticulum (ER) stress marker <e2>GENE-Y<\\e2>  and enhanced phosphorylation of elf2\u03b1 in SH-SY5Y cells","sentence":"Nevertheless, low L-BMAA concentrations (\u2265 0.1mM, 48 h) increased protein ubiquitination, 20S proteasomal and caspase 12 activity, expression of the endoplasmic reticulum (ER) stress marker CHOP  and enhanced phosphorylation of elf2\u03b1 in SH-SY5Y cells"}
{"PMID":23047912,"re_id":3,"annotated sentence":"Nevertheless, low <e1>L-BMAA<\\e1> concentrations (\u2265 0.1mM, 48 h) increased protein ubiquitination, 20S proteasomal and caspase 12 activity, expression of the endoplasmic reticulum (ER) stress marker CHOP, and enhanced phosphorylation of <e2>elf2\u03b1<\\e2> in SH-SY5Y cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"L-BMAA","object":"elf2\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Nevertheless, low <e1>CHEMICAL<\\e1> concentrations (\u2265 0.1mM, 48 h) increased protein ubiquitination, 20S proteasomal and caspase 12 activity, expression of the endoplasmic reticulum (ER) stress marker CHOP, and enhanced phosphorylation of <e2>GENE-Y<\\e2> in SH-SY5Y cells","sentence":"Nevertheless, low L-BMAA concentrations (\u2265 0.1mM, 48 h) increased protein ubiquitination, 20S proteasomal and caspase 12 activity, expression of the endoplasmic reticulum (ER) stress marker CHOP, and enhanced phosphorylation of elf2\u03b1 in SH-SY5Y cells"}
{"PMID":23047912,"re_id":4,"annotated sentence":"<e1>L-BMAA<\\e1> induced ER stress and enhanced <e2>caspase 12<\\e2> cleavage in human neuroblastoma SH-SY5Y cells at low nonexcitotoxic concentrations","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"L-BMAA","object":"caspase 12","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induced ER stress and enhanced <e2>GENE-Y<\\e2> cleavage in human neuroblastoma SH-SY5Y cells at low nonexcitotoxic concentrations","sentence":"L-BMAA induced ER stress and enhanced caspase 12 cleavage in human neuroblastoma SH-SY5Y cells at low nonexcitotoxic concentrations"}
{"PMID":23050902,"re_id":0,"annotated sentence":"We found that intracellular GTP depletion by ribavirin as well as other IMPDH (inosine-5'-monophosphate dehydrogenase) inhibitors, such as <e1>mycophenolic acid<\\e1> and 6-mercaptopurine, up-regulated <e2>F7<\\e2> expression","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"mycophenolic acid","object":"F7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that intracellular GTP depletion by ribavirin as well as other IMPDH (inosine-5'-monophosphate dehydrogenase) inhibitors, such as <e1>CHEMICAL<\\e1> and 6-mercaptopurine, up-regulated <e2>GENE-Y<\\e2> expression","sentence":"We found that intracellular GTP depletion by ribavirin as well as other IMPDH (inosine-5'-monophosphate dehydrogenase) inhibitors, such as mycophenolic acid and 6-mercaptopurine, up-regulated F7 expression"}
{"PMID":23050902,"re_id":1,"annotated sentence":"We found that intracellular GTP depletion by ribavirin as well as other IMPDH (inosine-5'-monophosphate dehydrogenase) inhibitors, such as mycophenolic acid and <e1>6-mercaptopurine<\\e1>  up-regulated <e2>F7<\\e2> expression","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"6-mercaptopurine","object":"F7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that intracellular GTP depletion by ribavirin as well as other IMPDH (inosine-5'-monophosphate dehydrogenase) inhibitors, such as mycophenolic acid and <e1>CHEMICAL<\\e1>  up-regulated <e2>GENE-Y<\\e2> expression","sentence":"We found that intracellular GTP depletion by ribavirin as well as other IMPDH (inosine-5'-monophosphate dehydrogenase) inhibitors, such as mycophenolic acid and 6-mercaptopurine  up-regulated F7 expression"}
{"PMID":23050902,"re_id":2,"annotated sentence":"<e1>Ribavirin<\\e1> unregulated <e2>ELL<\\e2> (eleven-nineteen lysine-rich leukaemia) 3 mRNA expression before F7 up-regulation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Ribavirin","object":"ELL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> unregulated <e2>GENE-Y<\\e2> (eleven-nineteen lysine-rich leukaemia) 3 mRNA expression before F7 up-regulation","sentence":"Ribavirin unregulated ELL (eleven-nineteen lysine-rich leukaemia) 3 mRNA expression before F7 up-regulation"}
{"PMID":23050902,"re_id":3,"annotated sentence":"<e1>Ribavirin<\\e1> unregulated ELL (<e2>eleven-nineteen lysine-rich leukaemia) 3<\\e2> mRNA expression before F7 up-regulation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Ribavirin","object":"eleven-nineteen lysine-rich leukaemia) 3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> unregulated ELL (<e2>GENE-Y<\\e2> mRNA expression before F7 up-regulation","sentence":"Ribavirin unregulated ELL (eleven-nineteen lysine-rich leukaemia) 3 mRNA expression before F7 up-regulation"}
{"PMID":23050902,"re_id":4,"annotated sentence":"<e1>Ribavirin<\\e1> unregulated ELL (eleven-nineteen lysine-rich leukaemia) 3 mRNA expression before <e2>F7<\\e2> up-regulation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Ribavirin","object":"F7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> unregulated ELL (eleven-nineteen lysine-rich leukaemia) 3 mRNA expression before <e2>GENE-Y<\\e2> up-regulation","sentence":"Ribavirin unregulated ELL (eleven-nineteen lysine-rich leukaemia) 3 mRNA expression before F7 up-regulation"}
{"PMID":23050902,"re_id":5,"annotated sentence":"We observed that <e1>ribavirin<\\e1> enhanced <e2>ELL3<\\e2> recruitment to F7, whereas knockdown of ELL3 diminished ribavirin-induced FVII mRNA up-regulation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ribavirin","object":"ELL3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We observed that <e1>CHEMICAL<\\e1> enhanced <e2>GENE-Y<\\e2> recruitment to F7, whereas knockdown of GENE-Y diminished CHEMICAL-induced FVII mRNA up-regulation","sentence":"We observed that ribavirin enhanced ELL3 recruitment to F7, whereas knockdown of ELL3 diminished ribavirin-induced FVII mRNA up-regulation"}
{"PMID":23050902,"re_id":6,"annotated sentence":"We observed that <e1>ribavirin<\\e1> enhanced ELL3 recruitment to <e2>F7<\\e2>  whereas knockdown of ELL3 diminished ribavirin-induced FVII mRNA up-regulation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ribavirin","object":"F7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We observed that <e1>CHEMICAL<\\e1> enhanced ELL3 recruitment to <e2>GENE-Y<\\e2>  whereas knockdown of ELL3 diminished CHEMICAL-induced FVII mRNA up-regulation","sentence":"We observed that ribavirin enhanced ELL3 recruitment to F7  whereas knockdown of ELL3 diminished ribavirin-induced FVII mRNA up-regulation"}
{"PMID":23050902,"re_id":7,"annotated sentence":"<e1>Ribavirin<\\e1> induced intracellular GTP depletion activates transcription elongation in <e2>coagulation factor VII<\\e2> gene expression","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Ribavirin","object":"coagulation factor VII","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induced intracellular GTP depletion activates transcription elongation in <e2>GENE-Y<\\e2> gene expression","sentence":"Ribavirin induced intracellular GTP depletion activates transcription elongation in coagulation factor VII gene expression"}
{"PMID":23050902,"re_id":8,"annotated sentence":"We observed that ribavirin enhanced ELL3 recruitment to F7, whereas knockdown of ELL3 diminished <e1>ribavirin<\\e1> induced <e2>FVII<\\e2> mRNA up-regulation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ribavirin","object":"FVII","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We observed that CHEMICAL enhanced ELL3 recruitment to F7, whereas knockdown of ELL3 diminished <e1>CHEMICAL<\\e1> induced <e2>GENE-Y<\\e2> mRNA up-regulation","sentence":"We observed that ribavirin enhanced ELL3 recruitment to F7, whereas knockdown of ELL3 diminished ribavirin induced FVII mRNA up-regulation"}
{"PMID":23050902,"re_id":9,"annotated sentence":"<e1>Ribavirin<\\e1> also enhanced recruitment of <e2>CDK9<\\e2> (cyclin-dependent kinase 9) and AFF4 to F7","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Ribavirin","object":"CDK9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also enhanced recruitment of <e2>GENE-Y<\\e2> (cyclin-dependent kinase 9) and AFF4 to F7","sentence":"Ribavirin also enhanced recruitment of CDK9 (cyclin-dependent kinase 9) and AFF4 to F7"}
{"PMID":23050902,"re_id":10,"annotated sentence":"<e1>Ribavirin<\\e1> also enhanced recruitment of CDK9 (<e2>cyclin-dependent kinase 9<\\e2>  and AFF4 to F7","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Ribavirin","object":"cyclin-dependent kinase 9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also enhanced recruitment of CDK9 (<e2>GENE-Y<\\e2>  and AFF4 to F7","sentence":"Ribavirin also enhanced recruitment of CDK9 (cyclin-dependent kinase 9  and AFF4 to F7"}
{"PMID":23050902,"re_id":11,"annotated sentence":"<e1>Ribavirin<\\e1> also enhanced recruitment of CDK9 (cyclin-dependent kinase 9) and <e2>AFF4<\\e2> to F7","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Ribavirin","object":"AFF4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also enhanced recruitment of CDK9 (cyclin-dependent kinase 9) and <e2>GENE-Y<\\e2> to F7","sentence":"Ribavirin also enhanced recruitment of CDK9 (cyclin-dependent kinase 9) and AFF4 to F7"}
{"PMID":23050902,"re_id":12,"annotated sentence":"<e1>Ribavirin<\\e1> also enhanced recruitment of CDK9 (cyclin-dependent kinase 9) and AFF4 to <e2>F7<\\e2>  These data suggest that ribavirin-induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, AFF4 and ELL3, to F7, and modulates FVII mRNA transcription elongation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Ribavirin","object":"F7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also enhanced recruitment of CDK9 (cyclin-dependent kinase 9) and AFF4 to <e2>GENE-Y<\\e2>  These data suggest that ribavirin-induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, AFF4 and ELL3, to GENE-Y, and modulates FVII mRNA transcription elongation","sentence":"Ribavirin also enhanced recruitment of CDK9 (cyclin-dependent kinase 9) and AFF4 to F7  These data suggest that ribavirin-induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, AFF4 and ELL3, to F7, and modulates FVII mRNA transcription elongation"}
{"PMID":23050902,"re_id":13,"annotated sentence":"These data suggest that <e1>ribavirin<\\e1> induced intracellular GTP depletion recruits a super elongation complex containing <e2>P-TEFb<\\e2>  AFF4 and ELL3, to F7, and modulates FVII mRNA transcription elongation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ribavirin","object":"P-TEFb","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These data suggest that <e1>CHEMICAL<\\e1> induced intracellular GTP depletion recruits a super elongation complex containing <e2>GENE-N<\\e2>  AFF4 and ELL3, to F7, and modulates FVII mRNA transcription elongation","sentence":"These data suggest that ribavirin induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb  AFF4 and ELL3, to F7, and modulates FVII mRNA transcription elongation"}
{"PMID":23050902,"re_id":14,"annotated sentence":"These data suggest that <e1>ribavirin<\\e1> induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, <e2>AFF4<\\e2> and ELL3, to F7, and modulates FVII mRNA transcription elongation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ribavirin","object":"AFF4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These data suggest that <e1>CHEMICAL<\\e1> induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, <e2>GENE-Y<\\e2> and ELL3, to F7, and modulates FVII mRNA transcription elongation","sentence":"These data suggest that ribavirin induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, AFF4 and ELL3, to F7, and modulates FVII mRNA transcription elongation"}
{"PMID":23050902,"re_id":15,"annotated sentence":"These data suggest that <e1>ribavirin<\\e1> induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, AFF4 and <e2>ELL3<\\e2>  to F7, and modulates FVII mRNA transcription elongation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ribavirin","object":"ELL3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These data suggest that <e1>CHEMICAL<\\e1> induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, AFF4 and <e2>GENE-Y<\\e2>  to F7, and modulates FVII mRNA transcription elongation","sentence":"These data suggest that ribavirin induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, AFF4 and ELL3  to F7, and modulates FVII mRNA transcription elongation"}
{"PMID":23050902,"re_id":16,"annotated sentence":"These data suggest that <e1>ribavirin<\\e1> induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, AFF4 and ELL3, to <e2>F7<\\e2>  and modulates FVII mRNA transcription elongation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ribavirin","object":"F7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These data suggest that <e1>CHEMICAL<\\e1> induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, AFF4 and ELL3, to <e2>GENE-Y<\\e2>  and modulates FVII mRNA transcription elongation","sentence":"These data suggest that ribavirin induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, AFF4 and ELL3, to F7  and modulates FVII mRNA transcription elongation"}
{"PMID":23050902,"re_id":17,"annotated sentence":"Collectively, we have elucidated a basal mechanism for <e1>ribavirin<\\e1> induced <e2>FVII<\\e2> mRNA up-regulation by acceleration of transcription elongation, which may be crucial in understanding its pleiotropic functions in\u00a0vivo.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ribavirin","object":"FVII","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Collectively, we have elucidated a basal mechanism for <e1>CHEMICAL<\\e1> induced <e2>GENE-Y<\\e2> mRNA up-regulation by acceleration of transcription elongation, which may be crucial in understanding its pleiotropic functions in\u00a0vivo.","sentence":"Collectively, we have elucidated a basal mechanism for ribavirin induced FVII mRNA up-regulation by acceleration of transcription elongation, which may be crucial in understanding its pleiotropic functions in\u00a0vivo."}
{"PMID":23050902,"re_id":18,"annotated sentence":"It was reported previously that <e2>FVII<\\e2> gene (F7) expression was up-regulated by <e1>ribavirin<\\e1> treatment in hepatitis C virus-infected haemophilia patients; however, its precise mechanism is still unknown","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ribavirin","object":"FVII","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"It was reported previously that <e2>GENE-Y<\\e2> gene (F7) expression was up-regulated by <e1>CHEMICAL<\\e1> treatment in hepatitis C virus-infected haemophilia patients; however, its precise mechanism is still unknown","sentence":"It was reported previously that FVII gene (F7) expression was up-regulated by ribavirin treatment in hepatitis C virus-infected haemophilia patients; however, its precise mechanism is still unknown"}
{"PMID":23050902,"re_id":19,"annotated sentence":"It was reported previously that FVII gene (<e2>F7<\\e2>  expression was up-regulated by <e1>ribavirin<\\e1> treatment in hepatitis C virus-infected haemophilia patients; however, its precise mechanism is still unknown","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ribavirin","object":"F7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"It was reported previously that FVII gene (<e2>GENE-Y<\\e2>  expression was up-regulated by <e1>CHEMICAL<\\e1> treatment in hepatitis C virus-infected haemophilia patients; however, its precise mechanism is still unknown","sentence":"It was reported previously that FVII gene (F7  expression was up-regulated by ribavirin treatment in hepatitis C virus-infected haemophilia patients; however, its precise mechanism is still unknown"}
{"PMID":23050902,"re_id":20,"annotated sentence":"In the present study, we investigated the molecular mechanism of <e1>ribavirin<\\e1> induced up-regulation of <e2>F7<\\e2> expression in HepG2 (human hepatoma cell line)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ribavirin","object":"F7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the present study, we investigated the molecular mechanism of <e1>CHEMICAL<\\e1> induced up-regulation of <e2>GENE-Y<\\e2> expression in HepG2 (human hepatoma cell line)","sentence":"In the present study, we investigated the molecular mechanism of ribavirin induced up-regulation of F7 expression in HepG2 (human hepatoma cell line)"}
{"PMID":23066089,"re_id":0,"annotated sentence":"Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2\/GluK5, and conversely, direct activation of <e2>PKC<\\e2> by <e1>phorbol 12-myristate,13-acetate<\\e1> potentiated GluK2\/GluK5","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"phorbol 12-myristate,13-acetate","object":"PKC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Protein kinase C (GENE-N) inhibition reduced the potentiation by mGlu1 of GluK2\/GluK5, and conversely, direct activation of <e2>GENE-N<\\e2> by <e1>CHEMICAL<\\e1> potentiated GluK2\/GluK5","sentence":"Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2\/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2\/GluK5"}
{"PMID":23066089,"re_id":1,"annotated sentence":"Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2\/GluK5, and conversely, direct activation of PKC by <e1>phorbol 12-myristate,13-acetate<\\e1> potentiated <e2>GluK2<\\e2> GluK5","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"phorbol 12-myristate,13-acetate","object":"GluK2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GENE-Y\/GluK5, and conversely, direct activation of PKC by <e1>CHEMICAL<\\e1> potentiated <e2>GENE-Y<\\e2> GluK5","sentence":"Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2\/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2 GluK5"}
{"PMID":23066089,"re_id":2,"annotated sentence":"Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2\/GluK5, and conversely, direct activation of PKC by <e1>phorbol 12-myristate,13-acetate<\\e1> potentiated GluK2\/<e2>GluK5<\\e2>  Using site-directed mutagenesis, we identified three serines (Ser833, Ser836, and Ser840) within the membrane proximal region of the GluK5 C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of KARs","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"phorbol 12-myristate,13-acetate","object":"GluK5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2\/GENE-Y, and conversely, direct activation of PKC by <e1>CHEMICAL<\\e1> potentiated GluK2\/<e2>GENE-Y<\\e2>  Using site-directed mutagenesis, we identified three serines (Ser833, Ser836, and Ser840) within the membrane proximal region of the GENE-Y C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of KARs","sentence":"Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2\/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2\/GluK5  Using site-directed mutagenesis, we identified three serines (Ser833, Ser836, and Ser840) within the membrane proximal region of the GluK5 C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of KARs"}
{"PMID":23066089,"re_id":3,"annotated sentence":"The potentiation of heteromeric <e2>KARs<\\e2> by mGlu1 activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator <e1>1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid<\\e1> (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid","object":"KARs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The potentiation of heteromeric <e2>GENE-N<\\e2> by mGlu1 activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator <e1>CHEMICAL<\\e1> (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A","sentence":"The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A"}
{"PMID":23066089,"re_id":4,"annotated sentence":"The potentiation of heteromeric KARs by <e2>mGlu1<\\e2> activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator <e1>1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid<\\e1> (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid","object":"mGlu1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The potentiation of heteromeric KARs by <e2>GENE-Y<\\e2> activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator <e1>CHEMICAL<\\e1> (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A","sentence":"The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A"}
{"PMID":23066089,"re_id":5,"annotated sentence":"The potentiation of heteromeric <e2>KARs<\\e2> by mGlu1 activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (<e1>BAPTA<\\e1> , prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BAPTA","object":"KARs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The potentiation of heteromeric <e2>GENE-N<\\e2> by mGlu1 activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (<e1>CHEMICAL<\\e1> , prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A","sentence":"The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA , prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A"}
{"PMID":23066089,"re_id":6,"annotated sentence":"The potentiation of heteromeric KARs by <e2>mGlu1<\\e2> activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (<e1>BAPTA<\\e1> , prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BAPTA","object":"mGlu1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The potentiation of heteromeric KARs by <e2>GENE-Y<\\e2> activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (<e1>CHEMICAL<\\e1> , prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A","sentence":"The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA , prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A"}
{"PMID":23066089,"re_id":7,"annotated sentence":"The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the <e2>phosphatase<\\e2> inhibitor <e1>okadaic acid<\\e1>  but unaffected by the tyrosine kinase inhibitor lavendustin A","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"okadaic acid","object":"phosphatase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1>  but unaffected by the tyrosine kinase inhibitor lavendustin A","sentence":"The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid  but unaffected by the tyrosine kinase inhibitor lavendustin A"}
{"PMID":23066089,"re_id":8,"annotated sentence":"The potentiation of heteromeric <e2>KARs<\\e2> by mGlu1 activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor <e1>okadaic acid<\\e1>  but unaffected by the tyrosine kinase inhibitor lavendustin A","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"okadaic acid","object":"KARs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The potentiation of heteromeric <e2>GENE-N<\\e2> by mGlu1 activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor <e1>CHEMICAL<\\e1>  but unaffected by the tyrosine kinase inhibitor lavendustin A","sentence":"The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid  but unaffected by the tyrosine kinase inhibitor lavendustin A"}
{"PMID":23066089,"re_id":9,"annotated sentence":"The potentiation of heteromeric KARs by <e2>mGlu1<\\e2> activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor <e1>okadaic acid<\\e1>  but unaffected by the tyrosine kinase inhibitor lavendustin A","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"okadaic acid","object":"mGlu1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The potentiation of heteromeric KARs by <e2>GENE-Y<\\e2> activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor <e1>CHEMICAL<\\e1>  but unaffected by the tyrosine kinase inhibitor lavendustin A","sentence":"The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid  but unaffected by the tyrosine kinase inhibitor lavendustin A"}
{"PMID":23066089,"re_id":10,"annotated sentence":"The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the <e2>tyrosine kinase<\\e2> inhibitor <e1>lavendustin A<\\e1>  Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2\/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2\/GluK5","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"lavendustin A","object":"tyrosine kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1>  Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2\/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2\/GluK5","sentence":"The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A  Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2\/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2\/GluK5"}
{"PMID":23066089,"re_id":11,"annotated sentence":"The potentiation of heteromeric <e2>KARs<\\e2> by mGlu1 activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor <e1>lavendustin A<\\e1>  Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2\/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2\/GluK5","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"lavendustin A","object":"KARs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The potentiation of heteromeric <e2>GENE-N<\\e2> by mGlu1 activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor <e1>CHEMICAL<\\e1>  Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2\/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2\/GluK5","sentence":"The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A  Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2\/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2\/GluK5"}
{"PMID":23066089,"re_id":12,"annotated sentence":"The potentiation of heteromeric KARs by <e2>mGlu1<\\e2> activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor <e1>lavendustin A<\\e1>  Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2\/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2\/GluK5","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"lavendustin A","object":"mGlu1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The potentiation of heteromeric KARs by <e2>GENE-Y<\\e2> activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor <e1>CHEMICAL<\\e1>  Protein kinase C (PKC) inhibition reduced the potentiation by GENE-Y of GluK2\/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2\/GluK5","sentence":"The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A  Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2\/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2\/GluK5"}
{"PMID":23073075,"re_id":0,"annotated sentence":"<e1>Fingolimod<\\e1> (FTY720), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different <e2>sphingosine-1-phosphate receptor<\\e2> (S1PR) subtypes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Fingolimod","object":"sphingosine-1-phosphate receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (FTY720), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different <e2>GENE-N<\\e2> (S1PR) subtypes","sentence":"Fingolimod (FTY720), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different sphingosine-1-phosphate receptor (S1PR) subtypes"}
{"PMID":23073075,"re_id":1,"annotated sentence":"<e1>Fingolimod<\\e1> (FTY720), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different sphingosine-1-phosphate receptor (<e2>S1PR<\\e2>  subtypes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Fingolimod","object":"S1PR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (FTY720), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different sphingosine-1-phosphate receptor (<e2>GENE-N<\\e2>  subtypes","sentence":"Fingolimod (FTY720), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different sphingosine-1-phosphate receptor (S1PR  subtypes"}
{"PMID":23073075,"re_id":2,"annotated sentence":"Fingolimod (<e1>FTY720<\\e1> , a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different <e2>sphingosine-1-phosphate receptor<\\e2> (S1PR) subtypes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"FTY720","object":"sphingosine-1-phosphate receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Fingolimod (<e1>CHEMICAL<\\e1> , a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different <e2>GENE-N<\\e2> (S1PR) subtypes","sentence":"Fingolimod (FTY720 , a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different sphingosine-1-phosphate receptor (S1PR) subtypes"}
{"PMID":23073075,"re_id":3,"annotated sentence":"Fingolimod (<e1>FTY720<\\e1> , a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different sphingosine-1-phosphate receptor (<e2>S1PR<\\e2>  subtypes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"FTY720","object":"S1PR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Fingolimod (<e1>CHEMICAL<\\e1> , a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different sphingosine-1-phosphate receptor (<e2>GENE-N<\\e2>  subtypes","sentence":"Fingolimod (FTY720 , a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different sphingosine-1-phosphate receptor (S1PR  subtypes"}
{"PMID":23073075,"re_id":4,"annotated sentence":"Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective <e2>type-1 S1PR<\\e2> (S1P1R) antagonist, <e1>W146<\\e1>  and by inhibitors of the mitogen associated protein kinase (MAPK) and the phosphatidylinositol-3-kinase (PtdIns-3-K) pathways","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"W146","object":"type-1 S1PR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective <e2>GENE-Y<\\e2> (S1P1R) antagonist, <e1>CHEMICAL<\\e1>  and by inhibitors of the mitogen associated protein kinase (MAPK) and the phosphatidylinositol-3-kinase (PtdIns-3-K) pathways","sentence":"Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (S1P1R) antagonist, W146  and by inhibitors of the mitogen associated protein kinase (MAPK) and the phosphatidylinositol-3-kinase (PtdIns-3-K) pathways"}
{"PMID":23073075,"re_id":5,"annotated sentence":"Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (<e2>S1P1R<\\e2>  antagonist, <e1>W146<\\e1>  and by inhibitors of the mitogen associated protein kinase (MAPK) and the phosphatidylinositol-3-kinase (PtdIns-3-K) pathways","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"W146","object":"S1P1R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (<e2>GENE-Y<\\e2>  antagonist, <e1>CHEMICAL<\\e1>  and by inhibitors of the mitogen associated protein kinase (MAPK) and the phosphatidylinositol-3-kinase (PtdIns-3-K) pathways","sentence":"Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (S1P1R  antagonist, W146  and by inhibitors of the mitogen associated protein kinase (MAPK) and the phosphatidylinositol-3-kinase (PtdIns-3-K) pathways"}
{"PMID":23075005,"re_id":0,"annotated sentence":"1.\u2002The disposition of <e1>anagliptin<\\e1>  an orally active, highly selective <e2>dipeptidyl peptidase-4<\\e2> inhibitor, was investigated after a single oral dose of 100 mg\/1.92 MBq [(14)C]anagliptin to six healthy men","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"anagliptin","object":"dipeptidyl peptidase-4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"1.\u2002The disposition of <e1>CHEMICAL<\\e1>  an orally active, highly selective <e2>GENE-Y<\\e2> inhibitor, was investigated after a single oral dose of 100 mg\/1.92 MBq [(14)C]CHEMICAL to six healthy men","sentence":"1.\u2002The disposition of anagliptin  an orally active, highly selective dipeptidyl peptidase-4 inhibitor, was investigated after a single oral dose of 100 mg\/1.92 MBq [(14)C]anagliptin to six healthy men"}
{"PMID":23075005,"re_id":1,"annotated sentence":"Pharmacokinetics and metabolism of <e1>[(14)C]anagliptin<\\e1>  a novel <e2>dipeptidyl peptidase-4<\\e2> inhibitor, in humans","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"[(14)C]anagliptin","object":"dipeptidyl peptidase-4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pharmacokinetics and metabolism of <e1>CHEMICAL<\\e1>  a novel <e2>GENE-Y<\\e2> inhibitor, in humans","sentence":"Pharmacokinetics and metabolism of [(14)C]anagliptin  a novel dipeptidyl peptidase-4 inhibitor, in humans"}
{"PMID":23075005,"re_id":2,"annotated sentence":"Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that <e1>anagliptin<\\e1> may be a substrate of <e2>OAT1<\\e2>  OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"anagliptin","object":"OAT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Renal clearance of unbound CHEMICAL and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that <e1>CHEMICAL<\\e1> may be a substrate of <e2>GENE-Y<\\e2>  OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.","sentence":"Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that anagliptin may be a substrate of OAT1  OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4."}
{"PMID":23075005,"re_id":3,"annotated sentence":"Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that <e1>anagliptin<\\e1> may be a substrate of OAT1, <e2>OAT3<\\e2>  MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"anagliptin","object":"OAT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Renal clearance of unbound CHEMICAL and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that <e1>CHEMICAL<\\e1> may be a substrate of OAT1, <e2>GENE-Y<\\e2>  MDR1 and MRP2, and M1 a substrate of GENE-Y, BCRP, MRP2 and MRP4.","sentence":"Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that anagliptin may be a substrate of OAT1, OAT3  MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4."}
{"PMID":23075005,"re_id":4,"annotated sentence":"Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that <e1>anagliptin<\\e1> may be a substrate of OAT1, OAT3, <e2>MDR1<\\e2> and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"anagliptin","object":"MDR1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Renal clearance of unbound CHEMICAL and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that <e1>CHEMICAL<\\e1> may be a substrate of OAT1, OAT3, <e2>GENE-Y<\\e2> and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.","sentence":"Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that anagliptin may be a substrate of OAT1, OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4."}
{"PMID":23075005,"re_id":5,"annotated sentence":"Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that <e1>anagliptin<\\e1> may be a substrate of OAT1, OAT3, MDR1 and <e2>MRP2<\\e2>  and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"anagliptin","object":"MRP2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Renal clearance of unbound CHEMICAL and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that <e1>CHEMICAL<\\e1> may be a substrate of OAT1, OAT3, MDR1 and <e2>GENE-Y<\\e2>  and M1 a substrate of OAT3, BCRP, GENE-Y and MRP4.","sentence":"Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that anagliptin may be a substrate of OAT1, OAT3, MDR1 and MRP2  and M1 a substrate of OAT3, BCRP, MRP2 and MRP4."}
{"PMID":23091188,"re_id":0,"annotated sentence":"Antiretroviral <e2>protease<\\e2> inhibitors <e1>lopinavir<\\e1> (LPV) and ritonavir (RTV) are reported BSEP inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"lopinavir","object":"protease","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Antiretroviral <e2>GENE-N<\\e2> inhibitors <e1>CHEMICAL<\\e1> (LPV) and ritonavir (RTV) are reported BSEP inhibitors","sentence":"Antiretroviral protease inhibitors lopinavir (LPV) and ritonavir (RTV) are reported BSEP inhibitors"}
{"PMID":23091188,"re_id":1,"annotated sentence":"Antiretroviral protease inhibitors <e1>lopinavir<\\e1> (LPV) and ritonavir (RTV) are reported <e2>BSEP<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"lopinavir","object":"BSEP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Antiretroviral protease inhibitors <e1>CHEMICAL<\\e1> (LPV) and ritonavir (RTV) are reported <e2>GENE-Y<\\e2> inhibitors","sentence":"Antiretroviral protease inhibitors lopinavir (LPV) and ritonavir (RTV) are reported BSEP inhibitors"}
{"PMID":23091188,"re_id":2,"annotated sentence":"Antiretroviral <e2>protease<\\e2> inhibitors lopinavir (<e1>LPV<\\e1>  and ritonavir (RTV) are reported BSEP inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"LPV","object":"protease","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Antiretroviral <e2>GENE-N<\\e2> inhibitors lopinavir (<e1>CHEMICAL<\\e1>  and ritonavir (RTV) are reported BSEP inhibitors","sentence":"Antiretroviral protease inhibitors lopinavir (LPV  and ritonavir (RTV) are reported BSEP inhibitors"}
{"PMID":23091188,"re_id":3,"annotated sentence":"Antiretroviral protease inhibitors lopinavir (<e1>LPV<\\e1>  and ritonavir (RTV) are reported <e2>BSEP<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"LPV","object":"BSEP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Antiretroviral protease inhibitors lopinavir (<e1>CHEMICAL<\\e1>  and ritonavir (RTV) are reported <e2>GENE-Y<\\e2> inhibitors","sentence":"Antiretroviral protease inhibitors lopinavir (LPV  and ritonavir (RTV) are reported BSEP inhibitors"}
{"PMID":23091188,"re_id":4,"annotated sentence":"Antiretroviral <e2>protease<\\e2> inhibitors lopinavir (LPV) and <e1>ritonavir<\\e1> (RTV) are reported BSEP inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ritonavir","object":"protease","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Antiretroviral <e2>GENE-N<\\e2> inhibitors lopinavir (LPV) and <e1>CHEMICAL<\\e1> (RTV) are reported BSEP inhibitors","sentence":"Antiretroviral protease inhibitors lopinavir (LPV) and ritonavir (RTV) are reported BSEP inhibitors"}
{"PMID":23091188,"re_id":5,"annotated sentence":"Antiretroviral protease inhibitors lopinavir (LPV) and <e1>ritonavir<\\e1> (RTV) are reported <e2>BSEP<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ritonavir","object":"BSEP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Antiretroviral protease inhibitors lopinavir (LPV) and <e1>CHEMICAL<\\e1> (RTV) are reported <e2>GENE-Y<\\e2> inhibitors","sentence":"Antiretroviral protease inhibitors lopinavir (LPV) and ritonavir (RTV) are reported BSEP inhibitors"}
{"PMID":23091188,"re_id":6,"annotated sentence":"Antiretroviral <e2>protease<\\e2> inhibitors lopinavir (LPV) and ritonavir (<e1>RTV<\\e1>  are reported BSEP inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"RTV","object":"protease","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Antiretroviral <e2>GENE-N<\\e2> inhibitors lopinavir (LPV) and ritonavir (<e1>CHEMICAL<\\e1>  are reported BSEP inhibitors","sentence":"Antiretroviral protease inhibitors lopinavir (LPV) and ritonavir (RTV  are reported BSEP inhibitors"}
{"PMID":23091188,"re_id":7,"annotated sentence":"Antiretroviral protease inhibitors lopinavir (LPV) and ritonavir (<e1>RTV<\\e1>  are reported <e2>BSEP<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"RTV","object":"BSEP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Antiretroviral protease inhibitors lopinavir (LPV) and ritonavir (<e1>CHEMICAL<\\e1>  are reported <e2>GENE-Y<\\e2> inhibitors","sentence":"Antiretroviral protease inhibitors lopinavir (LPV) and ritonavir (RTV  are reported BSEP inhibitors"}
{"PMID":23099431,"re_id":0,"annotated sentence":"<e1>GHRP-6<\\e1> is a <e2>growth hormone<\\e2> secretagogue that also enhances tissue viability in different organs","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"GHRP-6","object":"growth hormone","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is a <e2>GENE-Y<\\e2> secretagogue that also enhances tissue viability in different organs","sentence":"GHRP-6 is a growth hormone secretagogue that also enhances tissue viability in different organs"}
{"PMID":23102509,"re_id":0,"annotated sentence":"The altered activities of key enzymes such as <e2>glucose-6-phosphatase<\\e2> and fructose-1,6-bisphosphatase of <e1>carbohydrate<\\e1> metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"carbohydrate","object":"glucose-6-phosphatase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The altered activities of key enzymes such as <e2>GENE-Y<\\e2> and fructose-1,6-bisphosphatase of <e1>CHEMICAL<\\e1> metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP)","sentence":"The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP)"}
{"PMID":23102509,"re_id":1,"annotated sentence":"The altered activities of key enzymes such as glucose-6-phosphatase and <e2>fructose-1,6-bisphosphatase<\\e2> of <e1>carbohydrate<\\e1> metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"carbohydrate","object":"fructose-1,6-bisphosphatase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The altered activities of key enzymes such as glucose-6-phosphatase and <e2>GENE-Y<\\e2> of <e1>CHEMICAL<\\e1> metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP)","sentence":"The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP)"}
{"PMID":23103563,"re_id":0,"annotated sentence":"<e1>Ibandronate<\\e1> increases the expression of the pro-apoptotic gene <e2>FAS<\\e2> by epigenetic mechanisms in tumor cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Ibandronate","object":"FAS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> increases the expression of the pro-apoptotic gene <e2>GENE-Y<\\e2> by epigenetic mechanisms in tumor cells","sentence":"Ibandronate increases the expression of the pro-apoptotic gene FAS by epigenetic mechanisms in tumor cells"}
{"PMID":23103563,"re_id":1,"annotated sentence":"Data suggest that <e1>bisphosphonates<\\e1> via modulation of the activity of small-GTPases induce apoptosis in neoplastic cells by DNA-CpG-demethylation and stimulation of <e2>FAS<\\e2> expression","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"bisphosphonates","object":"FAS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Data suggest that <e1>CHEMICAL<\\e1> via modulation of the activity of small-GTPases induce apoptosis in neoplastic cells by DNA-CpG-demethylation and stimulation of <e2>GENE-Y<\\e2> expression","sentence":"Data suggest that bisphosphonates via modulation of the activity of small-GTPases induce apoptosis in neoplastic cells by DNA-CpG-demethylation and stimulation of FAS expression"}
{"PMID":23103563,"re_id":2,"annotated sentence":"Further we found stimulation of FAS-expression as a result of epigenetic DNA demethylation that was due to down-regulation of <e2>DNMT1<\\e2>  which was rescued by re-isoprenylation by both <e1>geranylgeranyl-pyrophosphate<\\e1> and farnesylpyrophosphate","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"geranylgeranyl-pyrophosphate","object":"DNMT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Further we found stimulation of FAS-expression as a result of epigenetic DNA demethylation that was due to down-regulation of <e2>GENE-Y<\\e2>  which was rescued by re-isoprenylation by both <e1>CHEMICAL<\\e1> and farnesylpyrophosphate","sentence":"Further we found stimulation of FAS-expression as a result of epigenetic DNA demethylation that was due to down-regulation of DNMT1  which was rescued by re-isoprenylation by both geranylgeranyl-pyrophosphate and farnesylpyrophosphate"}
{"PMID":23103563,"re_id":3,"annotated sentence":"Further we found stimulation of FAS-expression as a result of epigenetic DNA demethylation that was due to down-regulation of <e2>DNMT1<\\e2>  which was rescued by re-isoprenylation by both geranylgeranyl-pyrophosphate and <e1>farnesylpyrophosphate<\\e1>  In contrast, ibandronate did not affect FAS and DNMT1 expression in MC3T3-E1 non-neoplastic cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"farnesylpyrophosphate","object":"DNMT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Further we found stimulation of FAS-expression as a result of epigenetic DNA demethylation that was due to down-regulation of <e2>GENE-Y<\\e2>  which was rescued by re-isoprenylation by both geranylgeranyl-pyrophosphate and <e1>CHEMICAL<\\e1>  In contrast, ibandronate did not affect FAS and GENE-Y expression in MC3T3-E1 non-neoplastic cells","sentence":"Further we found stimulation of FAS-expression as a result of epigenetic DNA demethylation that was due to down-regulation of DNMT1  which was rescued by re-isoprenylation by both geranylgeranyl-pyrophosphate and farnesylpyrophosphate  In contrast, ibandronate did not affect FAS and DNMT1 expression in MC3T3-E1 non-neoplastic cells"}
{"PMID":23117151,"re_id":0,"annotated sentence":"The AhR target gene <e2>CYP1A1<\\e2> mRNA expression was induced by <e1>TCDD<\\e1>  but was not affected by the AR CAG length","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"CYP1A1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The AhR target gene <e2>GENE-Y<\\e2> mRNA expression was induced by <e1>CHEMICAL<\\e1>  but was not affected by the AR CAG length","sentence":"The AhR target gene CYP1A1 mRNA expression was induced by TCDD  but was not affected by the AR CAG length"}
{"PMID":23117151,"re_id":1,"annotated sentence":"TCDD had no effect on AR activity in PC-3 cells, whereas the shortest <e2>AR<\\e2> variant was induced by <e1>TCDD<\\e1> in PNT1A cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CHEMICAL had no effect on GENE-Y activity in PC-3 cells, whereas the shortest <e2>GENE-Y<\\e2> variant was induced by <e1>CHEMICAL<\\e1> in PNT1A cells","sentence":"TCDD had no effect on AR activity in PC-3 cells, whereas the shortest AR variant was induced by TCDD in PNT1A cells"}
{"PMID":23123257,"re_id":0,"annotated sentence":"Systemic injection to mice of siRNA lipoplexes, rather than of cationic liposome, triggered a production of several cytokines in mice and replacement of plasmid by <e1>polyglutamate<\\e1> reduced the elevation of all assayed <e2>cytokines<\\e2>  In order to enhance siRNA lipoplexes efficiency, the addition of polyglutamate as anionic polymer should be preferred to plasmid DNA as far as in vitro as well as in vivo toxicity is concerned.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"polyglutamate","object":"cytokines","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Systemic injection to mice of siRNA lipoplexes, rather than of cationic liposome, triggered a production of several GENE-N in mice and replacement of plasmid by <e1>CHEMICAL<\\e1> reduced the elevation of all assayed <e2>GENE-N<\\e2>  In order to enhance siRNA lipoplexes efficiency, the addition of CHEMICAL as anionic polymer should be preferred to plasmid DNA as far as in vitro as well as in vivo toxicity is concerned.","sentence":"Systemic injection to mice of siRNA lipoplexes, rather than of cationic liposome, triggered a production of several cytokines in mice and replacement of plasmid by polyglutamate reduced the elevation of all assayed cytokines  In order to enhance siRNA lipoplexes efficiency, the addition of polyglutamate as anionic polymer should be preferred to plasmid DNA as far as in vitro as well as in vivo toxicity is concerned."}
{"PMID":23123298,"re_id":0,"annotated sentence":"We found that <e1>helenalin<\\e1> markedly induced endoplasmic reticulum (ER) stress-related genes, such as <e2>regulated in development and DNA damage responses (REDD) 1<\\e2>  activating transcription factor-4 (ATF4) and\/or the CCAAT enhancer-binding protein-homologous protein (CHOP)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"helenalin","object":"regulated in development and DNA damage responses (REDD) 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that <e1>CHEMICAL<\\e1> markedly induced endoplasmic reticulum (ER) stress-related genes, such as <e2>GENE-Y<\\e2>  activating transcription factor-4 (ATF4) and\/or the CCAAT enhancer-binding protein-homologous protein (CHOP)","sentence":"We found that helenalin markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1  activating transcription factor-4 (ATF4) and\/or the CCAAT enhancer-binding protein-homologous protein (CHOP)"}
{"PMID":23123298,"re_id":1,"annotated sentence":"We found that <e1>helenalin<\\e1> markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, <e2>activating transcription factor-4<\\e2> (ATF4) and\/or the CCAAT enhancer-binding protein-homologous protein (CHOP)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"helenalin","object":"activating transcription factor-4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that <e1>CHEMICAL<\\e1> markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, <e2>GENE-Y<\\e2> (ATF4) and\/or the CCAAT enhancer-binding protein-homologous protein (CHOP)","sentence":"We found that helenalin markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, activating transcription factor-4 (ATF4) and\/or the CCAAT enhancer-binding protein-homologous protein (CHOP)"}
{"PMID":23123298,"re_id":2,"annotated sentence":"We found that <e1>helenalin<\\e1> markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, activating transcription factor-4 (<e2>ATF4<\\e2>  and\/or the CCAAT enhancer-binding protein-homologous protein (CHOP)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"helenalin","object":"ATF4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that <e1>CHEMICAL<\\e1> markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, activating transcription factor-4 (<e2>GENE-Y<\\e2>  and\/or the CCAAT enhancer-binding protein-homologous protein (CHOP)","sentence":"We found that helenalin markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, activating transcription factor-4 (ATF4  and\/or the CCAAT enhancer-binding protein-homologous protein (CHOP)"}
{"PMID":23123298,"re_id":3,"annotated sentence":"We found that <e1>helenalin<\\e1> markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, activating transcription factor-4 (ATF4) and\/or the <e2>CCAAT enhancer-binding protein-homologous protein<\\e2> (CHOP)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"helenalin","object":"CCAAT enhancer-binding protein-homologous protein","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that <e1>CHEMICAL<\\e1> markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, activating transcription factor-4 (ATF4) and\/or the <e2>GENE-Y<\\e2> (CHOP)","sentence":"We found that helenalin markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, activating transcription factor-4 (ATF4) and\/or the CCAAT enhancer-binding protein-homologous protein (CHOP)"}
{"PMID":23123298,"re_id":4,"annotated sentence":"We found that <e1>helenalin<\\e1> markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, activating transcription factor-4 (ATF4) and\/or the CCAAT enhancer-binding protein-homologous protein (<e2>CHOP<\\e2> ","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"helenalin","object":"CHOP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that <e1>CHEMICAL<\\e1> markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, activating transcription factor-4 (ATF4) and\/or the CCAAT enhancer-binding protein-homologous protein (<e2>GENE-Y<\\e2> ","sentence":"We found that helenalin markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, activating transcription factor-4 (ATF4) and\/or the CCAAT enhancer-binding protein-homologous protein (CHOP "}
{"PMID":23123662,"re_id":0,"annotated sentence":"In conclusion, <e2>rCtr1<\\e2> can transport copper and <e1>platinum<\\e1> drugs, and sensitizes cells to their cytotoxicities","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"platinum","object":"rCtr1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, <e2>GENE-Y<\\e2> can transport copper and <e1>CHEMICAL<\\e1> drugs, and sensitizes cells to their cytotoxicities","sentence":"In conclusion, rCtr1 can transport copper and platinum drugs, and sensitizes cells to their cytotoxicities"}
{"PMID":23123662,"re_id":1,"annotated sentence":"DRG neurons display substantial capacity for accumulating <e1>copper<\\e1> via a transport process mediated by <e2>rCtr1<\\e2>  but appear able to resist copper toxicity and use alternative mechanisms to take up oxaliplatin.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"copper","object":"rCtr1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"DRG neurons display substantial capacity for accumulating <e1>CHEMICAL<\\e1> via a transport process mediated by <e2>GENE-Y<\\e2>  but appear able to resist CHEMICAL toxicity and use alternative mechanisms to take up oxaliplatin.","sentence":"DRG neurons display substantial capacity for accumulating copper via a transport process mediated by rCtr1  but appear able to resist copper toxicity and use alternative mechanisms to take up oxaliplatin."}
{"PMID":23123662,"re_id":2,"annotated sentence":"DRG neurons display substantial capacity for accumulating copper via a transport process mediated by <e2>rCtr1<\\e2>  but appear able to resist copper toxicity and use alternative mechanisms to take up <e1>oxaliplatin<\\e1> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"oxaliplatin","object":"rCtr1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"DRG neurons display substantial capacity for accumulating copper via a transport process mediated by <e2>GENE-Y<\\e2>  but appear able to resist copper toxicity and use alternative mechanisms to take up <e1>CHEMICAL<\\e1> ","sentence":"DRG neurons display substantial capacity for accumulating copper via a transport process mediated by rCtr1  but appear able to resist copper toxicity and use alternative mechanisms to take up oxaliplatin "}
{"PMID":23123662,"re_id":3,"annotated sentence":"Heterologous expression of <e2>rCtr1<\\e2> in HEK293 cells (HEK\/rCtr1 cells) increased the uptake and cytotoxicity of <e1>copper<\\e1>  oxaliplatin, cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"copper","object":"rCtr1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Heterologous expression of <e2>GENE-Y<\\e2> in HEK293 cells (HEK\/GENE-Y cells) increased the uptake and cytotoxicity of <e1>CHEMICAL<\\e1>  oxaliplatin, cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells","sentence":"Heterologous expression of rCtr1 in HEK293 cells (HEK\/rCtr1 cells) increased the uptake and cytotoxicity of copper  oxaliplatin, cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells"}
{"PMID":23123662,"re_id":4,"annotated sentence":"Heterologous expression of rCtr1 in HEK293 cells (HEK\/<e2>rCtr1<\\e2> cells) increased the uptake and cytotoxicity of <e1>copper<\\e1>  oxaliplatin, cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"copper","object":"rCtr1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Heterologous expression of GENE-Y in HEK293 cells (HEK\/<e2>GENE-Y<\\e2> cells) increased the uptake and cytotoxicity of <e1>CHEMICAL<\\e1>  oxaliplatin, cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells","sentence":"Heterologous expression of rCtr1 in HEK293 cells (HEK\/rCtr1 cells) increased the uptake and cytotoxicity of copper  oxaliplatin, cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells"}
{"PMID":23123662,"re_id":5,"annotated sentence":"Heterologous expression of <e2>rCtr1<\\e2> in HEK293 cells (HEK\/rCtr1 cells) increased the uptake and cytotoxicity of copper, <e1>oxaliplatin<\\e1>  cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"oxaliplatin","object":"rCtr1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Heterologous expression of <e2>GENE-Y<\\e2> in HEK293 cells (HEK\/GENE-Y cells) increased the uptake and cytotoxicity of copper, <e1>CHEMICAL<\\e1>  cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells","sentence":"Heterologous expression of rCtr1 in HEK293 cells (HEK\/rCtr1 cells) increased the uptake and cytotoxicity of copper, oxaliplatin  cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells"}
{"PMID":23123662,"re_id":6,"annotated sentence":"Heterologous expression of rCtr1 in HEK293 cells (HEK\/<e2>rCtr1<\\e2> cells) increased the uptake and cytotoxicity of copper, <e1>oxaliplatin<\\e1>  cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"oxaliplatin","object":"rCtr1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Heterologous expression of GENE-Y in HEK293 cells (HEK\/<e2>GENE-Y<\\e2> cells) increased the uptake and cytotoxicity of copper, <e1>CHEMICAL<\\e1>  cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells","sentence":"Heterologous expression of rCtr1 in HEK293 cells (HEK\/rCtr1 cells) increased the uptake and cytotoxicity of copper, oxaliplatin  cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells"}
{"PMID":23123662,"re_id":7,"annotated sentence":"Heterologous expression of <e2>rCtr1<\\e2> in HEK293 cells (HEK\/rCtr1 cells) increased the uptake and cytotoxicity of copper, oxaliplatin, <e1>cisplatin<\\e1> and carboplatin, in comparison to isogenic vector-transfected control cells","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cisplatin","object":"rCtr1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Heterologous expression of <e2>GENE-Y<\\e2> in HEK293 cells (HEK\/GENE-Y cells) increased the uptake and cytotoxicity of copper, oxaliplatin, <e1>CHEMICAL<\\e1> and carboplatin, in comparison to isogenic vector-transfected control cells","sentence":"Heterologous expression of rCtr1 in HEK293 cells (HEK\/rCtr1 cells) increased the uptake and cytotoxicity of copper, oxaliplatin, cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells"}
{"PMID":23123662,"re_id":8,"annotated sentence":"Heterologous expression of rCtr1 in HEK293 cells (HEK\/<e2>rCtr1<\\e2> cells) increased the uptake and cytotoxicity of copper, oxaliplatin, <e1>cisplatin<\\e1> and carboplatin, in comparison to isogenic vector-transfected control cells","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cisplatin","object":"rCtr1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Heterologous expression of GENE-Y in HEK293 cells (HEK\/<e2>GENE-Y<\\e2> cells) increased the uptake and cytotoxicity of copper, oxaliplatin, <e1>CHEMICAL<\\e1> and carboplatin, in comparison to isogenic vector-transfected control cells","sentence":"Heterologous expression of rCtr1 in HEK293 cells (HEK\/rCtr1 cells) increased the uptake and cytotoxicity of copper, oxaliplatin, cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells"}
{"PMID":23123662,"re_id":9,"annotated sentence":"Heterologous expression of <e2>rCtr1<\\e2> in HEK293 cells (HEK\/rCtr1 cells) increased the uptake and cytotoxicity of copper, oxaliplatin, cisplatin and <e1>carboplatin<\\e1>  in comparison to isogenic vector-transfected control cells","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"carboplatin","object":"rCtr1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Heterologous expression of <e2>GENE-Y<\\e2> in HEK293 cells (HEK\/GENE-Y cells) increased the uptake and cytotoxicity of copper, oxaliplatin, cisplatin and <e1>CHEMICAL<\\e1>  in comparison to isogenic vector-transfected control cells","sentence":"Heterologous expression of rCtr1 in HEK293 cells (HEK\/rCtr1 cells) increased the uptake and cytotoxicity of copper, oxaliplatin, cisplatin and carboplatin  in comparison to isogenic vector-transfected control cells"}
{"PMID":23123662,"re_id":10,"annotated sentence":"Heterologous expression of rCtr1 in HEK293 cells (HEK\/<e2>rCtr1<\\e2> cells) increased the uptake and cytotoxicity of copper, oxaliplatin, cisplatin and <e1>carboplatin<\\e1>  in comparison to isogenic vector-transfected control cells","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"carboplatin","object":"rCtr1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Heterologous expression of GENE-Y in HEK293 cells (HEK\/<e2>GENE-Y<\\e2> cells) increased the uptake and cytotoxicity of copper, oxaliplatin, cisplatin and <e1>CHEMICAL<\\e1>  in comparison to isogenic vector-transfected control cells","sentence":"Heterologous expression of rCtr1 in HEK293 cells (HEK\/rCtr1 cells) increased the uptake and cytotoxicity of copper, oxaliplatin, cisplatin and carboplatin  in comparison to isogenic vector-transfected control cells"}
{"PMID":23123662,"re_id":11,"annotated sentence":"Cultured rat DRG neurons endogenously expressed <e2>rCtr1<\\e2> protein on their neuronal cell body plasma membranes and cytoplasm, and displayed substantial capacity for taking up <e1>copper<\\e1>  but were resistant to copper toxicity","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"copper","object":"rCtr1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cultured rat DRG neurons endogenously expressed <e2>GENE-Y<\\e2> protein on their neuronal cell body plasma membranes and cytoplasm, and displayed substantial capacity for taking up <e1>CHEMICAL<\\e1>  but were resistant to CHEMICAL toxicity","sentence":"Cultured rat DRG neurons endogenously expressed rCtr1 protein on their neuronal cell body plasma membranes and cytoplasm, and displayed substantial capacity for taking up copper  but were resistant to copper toxicity"}
{"PMID":23123662,"re_id":12,"annotated sentence":"The uptake of <e1>copper<\\e1> by both cultured rat DRG neurons and HEK\/<e2>rCtr1<\\e2> cells was saturable and inhibited by cold temperature, silver and zinc, consistent with it being mediated by rCtr1","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"copper","object":"rCtr1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The uptake of <e1>CHEMICAL<\\e1> by both cultured rat DRG neurons and HEK\/<e2>GENE-Y<\\e2> cells was saturable and inhibited by cold temperature, silver and zinc, consistent with it being mediated by GENE-Y","sentence":"The uptake of copper by both cultured rat DRG neurons and HEK\/rCtr1 cells was saturable and inhibited by cold temperature, silver and zinc, consistent with it being mediated by rCtr1"}
{"PMID":23123662,"re_id":13,"annotated sentence":"Contributions of <e2>rat Ctr1<\\e2> to the uptake and toxicity of <e1>copper<\\e1> and platinum anticancer drugs in dorsal root ganglion neurons","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"copper","object":"rat Ctr1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Contributions of <e2>GENE-Y<\\e2> to the uptake and toxicity of <e1>CHEMICAL<\\e1> and platinum anticancer drugs in dorsal root ganglion neurons","sentence":"Contributions of rat Ctr1 to the uptake and toxicity of copper and platinum anticancer drugs in dorsal root ganglion neurons"}
{"PMID":23123662,"re_id":14,"annotated sentence":"Contributions of <e2>rat Ctr1<\\e2> to the uptake and toxicity of copper and <e1>platinum<\\e1> anticancer drugs in dorsal root ganglion neurons","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"platinum","object":"rat Ctr1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Contributions of <e2>GENE-Y<\\e2> to the uptake and toxicity of copper and <e1>CHEMICAL<\\e1> anticancer drugs in dorsal root ganglion neurons","sentence":"Contributions of rat Ctr1 to the uptake and toxicity of copper and platinum anticancer drugs in dorsal root ganglion neurons"}
{"PMID":23123662,"re_id":15,"annotated sentence":"In conclusion, <e2>rCtr1<\\e2> can transport <e1>copper<\\e1> and platinum drugs, and sensitizes cells to their cytotoxicities","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"copper","object":"rCtr1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, <e2>GENE-Y<\\e2> can transport <e1>CHEMICAL<\\e1> and platinum drugs, and sensitizes cells to their cytotoxicities","sentence":"In conclusion, rCtr1 can transport copper and platinum drugs, and sensitizes cells to their cytotoxicities"}
{"PMID":23128353,"re_id":0,"annotated sentence":"In addition, <e1>glucosamine<\\e1> attenuated p21 protein stability via the proteasomal proteolytic pathway, as well as inducing <e2>p21<\\e2> nuclear accumulation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"glucosamine","object":"p21","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e1>CHEMICAL<\\e1> attenuated GENE-Y protein stability via the proteasomal proteolytic pathway, as well as inducing <e2>GENE-Y<\\e2> nuclear accumulation","sentence":"In addition, glucosamine attenuated p21 protein stability via the proteasomal proteolytic pathway, as well as inducing p21 nuclear accumulation"}
{"PMID":23128353,"re_id":1,"annotated sentence":"Altogether, our results suggest that a high dose of <e1>glucosamine<\\e1> may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)\/G(1) phase, and that this occurs, at least in part, by a reduction in Rb phosphorylation together with modulation of p21, p53 and HO-1 expression, and nuclear <e2>p21<\\e2> accumulation.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"glucosamine","object":"p21","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Altogether, our results suggest that a high dose of <e1>CHEMICAL<\\e1> may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)\/G(1) phase, and that this occurs, at least in part, by a reduction in Rb phosphorylation together with modulation of GENE-Y, p53 and HO-1 expression, and nuclear <e2>GENE-Y<\\e2> accumulation.","sentence":"Altogether, our results suggest that a high dose of glucosamine may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)\/G(1) phase, and that this occurs, at least in part, by a reduction in Rb phosphorylation together with modulation of p21, p53 and HO-1 expression, and nuclear p21 accumulation."}
{"PMID":23128353,"re_id":2,"annotated sentence":"<e1>Glucosamine<\\e1> at 50\u00a0mM was demonstrated to elevate both the mRNA and protein expression of <e2>p53<\\e2> and heme oxygenase-1 (HO-1), but also caused a reduction in p21 protein expression","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Glucosamine","object":"p53","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> at 50\u00a0mM was demonstrated to elevate both the mRNA and protein expression of <e2>GENE-N<\\e2> and heme oxygenase-1 (HO-1), but also caused a reduction in p21 protein expression","sentence":"Glucosamine at 50\u00a0mM was demonstrated to elevate both the mRNA and protein expression of p53 and heme oxygenase-1 (HO-1), but also caused a reduction in p21 protein expression"}
{"PMID":23128353,"re_id":3,"annotated sentence":"<e1>Glucosamine<\\e1> at 50\u00a0mM was demonstrated to elevate both the mRNA and protein expression of p53 and <e2>heme oxygenase-1<\\e2> (HO-1), but also caused a reduction in p21 protein expression","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Glucosamine","object":"heme oxygenase-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> at 50\u00a0mM was demonstrated to elevate both the mRNA and protein expression of p53 and <e2>GENE-Y<\\e2> (HO-1), but also caused a reduction in p21 protein expression","sentence":"Glucosamine at 50\u00a0mM was demonstrated to elevate both the mRNA and protein expression of p53 and heme oxygenase-1 (HO-1), but also caused a reduction in p21 protein expression"}
{"PMID":23128353,"re_id":4,"annotated sentence":"In addition, <e1>glucosamine<\\e1> attenuated <e2>p21<\\e2> protein stability via the proteasomal proteolytic pathway, as well as inducing p21 nuclear accumulation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"glucosamine","object":"p21","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e1>CHEMICAL<\\e1> attenuated <e2>GENE-Y<\\e2> protein stability via the proteasomal proteolytic pathway, as well as inducing GENE-Y nuclear accumulation","sentence":"In addition, glucosamine attenuated p21 protein stability via the proteasomal proteolytic pathway, as well as inducing p21 nuclear accumulation"}
{"PMID":23128353,"re_id":5,"annotated sentence":"Altogether, our results suggest that a high dose of <e1>glucosamine<\\e1> may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)\/G(1) phase, and that this occurs, at least in part, by a reduction in <e2>Rb<\\e2> phosphorylation together with modulation of p21, p53 and HO-1 expression, and nuclear p21 accumulation.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"glucosamine","object":"Rb","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Altogether, our results suggest that a high dose of <e1>CHEMICAL<\\e1> may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)\/G(1) phase, and that this occurs, at least in part, by a reduction in <e2>GENE-Y<\\e2> phosphorylation together with modulation of p21, p53 and HO-1 expression, and nuclear p21 accumulation.","sentence":"Altogether, our results suggest that a high dose of glucosamine may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)\/G(1) phase, and that this occurs, at least in part, by a reduction in Rb phosphorylation together with modulation of p21, p53 and HO-1 expression, and nuclear p21 accumulation."}
{"PMID":23128353,"re_id":6,"annotated sentence":"Examination of phosphorylation in <e2>retinoblastoma (Rb) protein<\\e2>  we found an inhibitory effect by <e1>glucosamine<\\e1> at 20 and 50\u00a0mM","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"glucosamine","object":"retinoblastoma (Rb) protein","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Examination of phosphorylation in <e2>GENE-Y<\\e2>  we found an inhibitory effect by <e1>CHEMICAL<\\e1> at 20 and 50\u00a0mM","sentence":"Examination of phosphorylation in retinoblastoma (Rb) protein  we found an inhibitory effect by glucosamine at 20 and 50\u00a0mM"}
{"PMID":23128353,"re_id":7,"annotated sentence":"<e1>Glucosamine<\\e1> at 50\u00a0mM was demonstrated to elevate both the mRNA and protein expression of p53 and heme oxygenase-1 (HO-1), but also caused a reduction in <e2>p21<\\e2> protein expression","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Glucosamine","object":"p21","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> at 50\u00a0mM was demonstrated to elevate both the mRNA and protein expression of p53 and heme oxygenase-1 (HO-1), but also caused a reduction in <e2>GENE-Y<\\e2> protein expression","sentence":"Glucosamine at 50\u00a0mM was demonstrated to elevate both the mRNA and protein expression of p53 and heme oxygenase-1 (HO-1), but also caused a reduction in p21 protein expression"}
{"PMID":23131177,"re_id":0,"annotated sentence":"Characterization of substituted <e1>phenylpropylamides<\\e1> as highly selective agonists at the <e2>melatonin MT2 receptor<\\e2>  Melatonin is a widely distributed hormone that regulates several major physiological processes, including the circadian rhythm and seasonal adaptation","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"phenylpropylamides","object":"melatonin MT2 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Characterization of substituted <e1>CHEMICAL<\\e1> as highly selective agonists at the <e2>GENE-Y<\\e2>  Melatonin is a widely distributed hormone that regulates several major physiological processes, including the circadian rhythm and seasonal adaptation","sentence":"Characterization of substituted phenylpropylamides as highly selective agonists at the melatonin MT2 receptor  Melatonin is a widely distributed hormone that regulates several major physiological processes, including the circadian rhythm and seasonal adaptation"}
{"PMID":23142699,"re_id":0,"annotated sentence":"We show that the expression of <e2>PIM-1<\\e2> is induced in response to <e1>estradiol<\\e1> in MCF-7 cells and that the induction is mediated by ER\u03b1-regulated enhancers located distally upstream from the gene","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"estradiol","object":"PIM-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We show that the expression of <e2>GENE-Y<\\e2> is induced in response to <e1>CHEMICAL<\\e1> in MCF-7 cells and that the induction is mediated by ER\u03b1-regulated enhancers located distally upstream from the gene","sentence":"We show that the expression of PIM-1 is induced in response to estradiol in MCF-7 cells and that the induction is mediated by ER\u03b1-regulated enhancers located distally upstream from the gene"}
{"PMID":23142699,"re_id":1,"annotated sentence":"We show that the expression of PIM-1 is induced in response to <e1>estradiol<\\e1> in MCF-7 cells and that the induction is mediated by <e2>ER\u03b1<\\e2> regulated enhancers located distally upstream from the gene","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"estradiol","object":"ER\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We show that the expression of PIM-1 is induced in response to <e1>CHEMICAL<\\e1> in MCF-7 cells and that the induction is mediated by <e2>GENE-Y<\\e2> regulated enhancers located distally upstream from the gene","sentence":"We show that the expression of PIM-1 is induced in response to estradiol in MCF-7 cells and that the induction is mediated by ER\u03b1 regulated enhancers located distally upstream from the gene"}
{"PMID":23143891,"re_id":0,"annotated sentence":"In this work, the metabolism of four frequently prescribed inhaled GCs, <e1>triamcinolone acetonide<\\e1>  flunisolide, budesonide, and fluticasone propionate, by the <e2>CYP3A<\\e2> family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"triamcinolone acetonide","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In this work, the metabolism of four frequently prescribed inhaled GCs, <e1>CHEMICAL<\\e1>  flunisolide, budesonide, and fluticasone propionate, by the <e2>GENE-N<\\e2> family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites","sentence":"In this work, the metabolism of four frequently prescribed inhaled GCs, triamcinolone acetonide  flunisolide, budesonide, and fluticasone propionate, by the CYP3A family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites"}
{"PMID":23143891,"re_id":1,"annotated sentence":"In this work, the metabolism of four frequently prescribed inhaled GCs, triamcinolone acetonide, <e1>flunisolide<\\e1>  budesonide, and fluticasone propionate, by the <e2>CYP3A<\\e2> family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"flunisolide","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In this work, the metabolism of four frequently prescribed inhaled GCs, triamcinolone acetonide, <e1>CHEMICAL<\\e1>  budesonide, and fluticasone propionate, by the <e2>GENE-N<\\e2> family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites","sentence":"In this work, the metabolism of four frequently prescribed inhaled GCs, triamcinolone acetonide, flunisolide  budesonide, and fluticasone propionate, by the CYP3A family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites"}
{"PMID":23143891,"re_id":2,"annotated sentence":"In this work, the metabolism of four frequently prescribed inhaled GCs, triamcinolone acetonide, flunisolide, <e1>budesonide<\\e1>  and fluticasone propionate, by the <e2>CYP3A<\\e2> family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"budesonide","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In this work, the metabolism of four frequently prescribed inhaled GCs, triamcinolone acetonide, flunisolide, <e1>CHEMICAL<\\e1>  and fluticasone propionate, by the <e2>GENE-N<\\e2> family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites","sentence":"In this work, the metabolism of four frequently prescribed inhaled GCs, triamcinolone acetonide, flunisolide, budesonide  and fluticasone propionate, by the CYP3A family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites"}
{"PMID":23143891,"re_id":3,"annotated sentence":"In this work, the metabolism of four frequently prescribed inhaled GCs, triamcinolone acetonide, flunisolide, budesonide, and <e1>fluticasone propionate<\\e1>  by the <e2>CYP3A<\\e2> family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"fluticasone propionate","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In this work, the metabolism of four frequently prescribed inhaled GCs, triamcinolone acetonide, flunisolide, budesonide, and <e1>CHEMICAL<\\e1>  by the <e2>GENE-N<\\e2> family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites","sentence":"In this work, the metabolism of four frequently prescribed inhaled GCs, triamcinolone acetonide, flunisolide, budesonide, and fluticasone propionate  by the CYP3A family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites"}
{"PMID":23143891,"re_id":4,"annotated sentence":"<e2>CYP3A5<\\e2>  which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize <e1>triamcinolone acetonide<\\e1>  budesonide, and fluticasone propionate","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"triamcinolone acetonide","object":"CYP3A5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2>  which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize <e1>CHEMICAL<\\e1>  budesonide, and fluticasone propionate","sentence":"CYP3A5  which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize triamcinolone acetonide  budesonide, and fluticasone propionate"}
{"PMID":23143891,"re_id":5,"annotated sentence":"<e2>CYP3A5<\\e2>  which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize triamcinolone acetonide, <e1>budesonide<\\e1>  and fluticasone propionate","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"budesonide","object":"CYP3A5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2>  which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize triamcinolone acetonide, <e1>CHEMICAL<\\e1>  and fluticasone propionate","sentence":"CYP3A5  which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize triamcinolone acetonide, budesonide  and fluticasone propionate"}
{"PMID":23143891,"re_id":6,"annotated sentence":"<e2>CYP3A5<\\e2>  which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize triamcinolone acetonide, budesonide, and <e1>fluticasone propionate<\\e1>  In contrast, flunisolide was only metabolized via CYP3A4, with no significant turnover by CYP3A5 or CYP3A7","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"fluticasone propionate","object":"CYP3A5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2>  which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize triamcinolone acetonide, budesonide, and <e1>CHEMICAL<\\e1>  In contrast, flunisolide was only metabolized via CYP3A4, with no significant turnover by GENE-Y or CYP3A7","sentence":"CYP3A5  which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize triamcinolone acetonide, budesonide, and fluticasone propionate  In contrast, flunisolide was only metabolized via CYP3A4, with no significant turnover by CYP3A5 or CYP3A7"}
{"PMID":23143891,"re_id":7,"annotated sentence":"In contrast, <e1>flunisolide<\\e1> was only metabolized via <e2>CYP3A4<\\e2>  with no significant turnover by CYP3A5 or CYP3A7","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"flunisolide","object":"CYP3A4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, <e1>CHEMICAL<\\e1> was only metabolized via <e2>GENE-Y<\\e2>  with no significant turnover by CYP3A5 or CYP3A7","sentence":"In contrast, flunisolide was only metabolized via CYP3A4  with no significant turnover by CYP3A5 or CYP3A7"}
{"PMID":23159329,"re_id":0,"annotated sentence":"Distinct roles of <e1>methamphetamine<\\e1> in modulating spatial memory consolidation, retrieval, reconsolidation and the accompanying changes of <e2>ERK<\\e2> and CREB activation in hippocampus and prefrontal cortex","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"methamphetamine","object":"ERK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Distinct roles of <e1>CHEMICAL<\\e1> in modulating spatial memory consolidation, retrieval, reconsolidation and the accompanying changes of <e2>GENE-N<\\e2> and CREB activation in hippocampus and prefrontal cortex","sentence":"Distinct roles of methamphetamine in modulating spatial memory consolidation, retrieval, reconsolidation and the accompanying changes of ERK and CREB activation in hippocampus and prefrontal cortex"}
{"PMID":23159329,"re_id":1,"annotated sentence":"Distinct roles of <e1>methamphetamine<\\e1> in modulating spatial memory consolidation, retrieval, reconsolidation and the accompanying changes of ERK and <e2>CREB<\\e2> activation in hippocampus and prefrontal cortex","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"methamphetamine","object":"CREB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Distinct roles of <e1>CHEMICAL<\\e1> in modulating spatial memory consolidation, retrieval, reconsolidation and the accompanying changes of ERK and <e2>GENE-N<\\e2> activation in hippocampus and prefrontal cortex","sentence":"Distinct roles of methamphetamine in modulating spatial memory consolidation, retrieval, reconsolidation and the accompanying changes of ERK and CREB activation in hippocampus and prefrontal cortex"}
{"PMID":23159329,"re_id":2,"annotated sentence":"In contrast, activation of both <e2>ERK<\\e2> and CREB in the PFC was found following memory retrieval but not other processes in <e1>METH<\\e1> treated mouse groups","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"METH","object":"ERK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In contrast, activation of both <e2>GENE-N<\\e2> and CREB in the PFC was found following memory retrieval but not other processes in <e1>CHEMICAL<\\e1> treated mouse groups","sentence":"In contrast, activation of both ERK and CREB in the PFC was found following memory retrieval but not other processes in METH treated mouse groups"}
{"PMID":23159329,"re_id":3,"annotated sentence":"In contrast, activation of both ERK and <e2>CREB<\\e2> in the PFC was found following memory retrieval but not other processes in <e1>METH<\\e1> treated mouse groups","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"METH","object":"CREB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In contrast, activation of both ERK and <e2>GENE-N<\\e2> in the PFC was found following memory retrieval but not other processes in <e1>CHEMICAL<\\e1> treated mouse groups","sentence":"In contrast, activation of both ERK and CREB in the PFC was found following memory retrieval but not other processes in METH treated mouse groups"}
{"PMID":23159329,"re_id":4,"annotated sentence":"Moreover, activation of the <e2>ERK<\\e2> and CREB signaling pathway in the hippocampus might be involved in <e1>METH<\\e1> induced spatial memory changes.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"METH","object":"ERK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moreover, activation of the <e2>GENE-N<\\e2> and CREB signaling pathway in the hippocampus might be involved in <e1>CHEMICAL<\\e1> induced spatial memory changes.","sentence":"Moreover, activation of the ERK and CREB signaling pathway in the hippocampus might be involved in METH induced spatial memory changes."}
{"PMID":23159329,"re_id":5,"annotated sentence":"Moreover, activation of the ERK and <e2>CREB<\\e2> signaling pathway in the hippocampus might be involved in <e1>METH<\\e1> induced spatial memory changes.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"METH","object":"CREB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moreover, activation of the ERK and <e2>GENE-N<\\e2> signaling pathway in the hippocampus might be involved in <e1>CHEMICAL<\\e1> induced spatial memory changes.","sentence":"Moreover, activation of the ERK and CREB signaling pathway in the hippocampus might be involved in METH induced spatial memory changes."}
{"PMID":23161868,"re_id":0,"annotated sentence":"A reporter construct driven by 4 kb of the <e2>chicken ras-dva<\\e2> 5'-flanking region, containing six putative pituitary-specific transcription factor-1 (Pit-1) binding sites and two potential glucocorticoid receptor (GR) binding sites, was highly activated in embryonic pituitary cells and up-regulated by <e1>corticosterone<\\e1>  Mutagenesis of the most proximal Pit-1 site decreased promoter activity in chicken e11 pituitary cells, indicating regulation of ras-dva by Pit-1","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"corticosterone","object":"chicken ras-dva","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A reporter construct driven by 4 kb of the <e2>GENE-Y<\\e2> 5'-flanking region, containing six putative pituitary-specific transcription factor-1 (Pit-1) binding sites and two potential glucocorticoid receptor (GR) binding sites, was highly activated in embryonic pituitary cells and up-regulated by <e1>CHEMICAL<\\e1>  Mutagenesis of the most proximal Pit-1 site decreased promoter activity in chicken e11 pituitary cells, indicating regulation of ras-dva by Pit-1","sentence":"A reporter construct driven by 4 kb of the chicken ras-dva 5'-flanking region, containing six putative pituitary-specific transcription factor-1 (Pit-1) binding sites and two potential glucocorticoid receptor (GR) binding sites, was highly activated in embryonic pituitary cells and up-regulated by corticosterone  Mutagenesis of the most proximal Pit-1 site decreased promoter activity in chicken e11 pituitary cells, indicating regulation of ras-dva by Pit-1"}
{"PMID":23161868,"re_id":1,"annotated sentence":"A reporter construct driven by 4 kb of the chicken ras-dva 5'-flanking region, containing six putative <e2>pituitary-specific transcription factor-1 (Pit-1) binding sites<\\e2> and two potential glucocorticoid receptor (GR) binding sites, was highly activated in embryonic pituitary cells and up-regulated by <e1>corticosterone<\\e1>  Mutagenesis of the most proximal Pit-1 site decreased promoter activity in chicken e11 pituitary cells, indicating regulation of ras-dva by Pit-1","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"corticosterone","object":"pituitary-specific transcription factor-1 (Pit-1) binding sites","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A reporter construct driven by 4 kb of the chicken ras-dva 5'-flanking region, containing six putative <e2>GENE-N<\\e2> and two potential glucocorticoid receptor (GR) binding sites, was highly activated in embryonic pituitary cells and up-regulated by <e1>CHEMICAL<\\e1>  Mutagenesis of the most proximal Pit-1 site decreased promoter activity in chicken e11 pituitary cells, indicating regulation of ras-dva by Pit-1","sentence":"A reporter construct driven by 4 kb of the chicken ras-dva 5'-flanking region, containing six putative pituitary-specific transcription factor-1 (Pit-1) binding sites and two potential glucocorticoid receptor (GR) binding sites, was highly activated in embryonic pituitary cells and up-regulated by corticosterone  Mutagenesis of the most proximal Pit-1 site decreased promoter activity in chicken e11 pituitary cells, indicating regulation of ras-dva by Pit-1"}
{"PMID":23161868,"re_id":2,"annotated sentence":"A reporter construct driven by 4 kb of the chicken ras-dva 5'-flanking region, containing six putative pituitary-specific transcription factor-1 (Pit-1) binding sites and two potential <e2>glucocorticoid receptor (GR) binding sites<\\e2>  was highly activated in embryonic pituitary cells and up-regulated by <e1>corticosterone<\\e1>  Mutagenesis of the most proximal Pit-1 site decreased promoter activity in chicken e11 pituitary cells, indicating regulation of ras-dva by Pit-1","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"corticosterone","object":"glucocorticoid receptor (GR) binding sites","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A reporter construct driven by 4 kb of the chicken ras-dva 5'-flanking region, containing six putative pituitary-specific transcription factor-1 (Pit-1) binding sites and two potential <e2>GENE-N<\\e2>  was highly activated in embryonic pituitary cells and up-regulated by <e1>CHEMICAL<\\e1>  Mutagenesis of the most proximal Pit-1 site decreased promoter activity in chicken e11 pituitary cells, indicating regulation of ras-dva by Pit-1","sentence":"A reporter construct driven by 4 kb of the chicken ras-dva 5'-flanking region, containing six putative pituitary-specific transcription factor-1 (Pit-1) binding sites and two potential glucocorticoid receptor (GR) binding sites  was highly activated in embryonic pituitary cells and up-regulated by corticosterone  Mutagenesis of the most proximal Pit-1 site decreased promoter activity in chicken e11 pituitary cells, indicating regulation of ras-dva by Pit-1"}
{"PMID":23161868,"re_id":3,"annotated sentence":"However, mutating putative <e2>GR binding sites<\\e2> did not substantially reduce induction of ras-dva promoter activity by <e1>corticosterone<\\e1>  suggesting additional DNA elements within the 5'-flanking region are responsible for glucocorticoid regulation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"corticosterone","object":"GR binding sites","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, mutating putative <e2>GENE-N<\\e2> did not substantially reduce induction of ras-dva promoter activity by <e1>CHEMICAL<\\e1>  suggesting additional DNA elements within the 5'-flanking region are responsible for glucocorticoid regulation","sentence":"However, mutating putative GR binding sites did not substantially reduce induction of ras-dva promoter activity by corticosterone  suggesting additional DNA elements within the 5'-flanking region are responsible for glucocorticoid regulation"}
{"PMID":23161868,"re_id":4,"annotated sentence":"However, mutating putative GR binding sites did not substantially reduce induction of <e2>ras-dva promoter<\\e2> activity by <e1>corticosterone<\\e1>  suggesting additional DNA elements within the 5'-flanking region are responsible for glucocorticoid regulation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"corticosterone","object":"ras-dva promoter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, mutating putative GR binding sites did not substantially reduce induction of <e2>GENE-N<\\e2> activity by <e1>CHEMICAL<\\e1>  suggesting additional DNA elements within the 5'-flanking region are responsible for glucocorticoid regulation","sentence":"However, mutating putative GR binding sites did not substantially reduce induction of ras-dva promoter activity by corticosterone  suggesting additional DNA elements within the 5'-flanking region are responsible for glucocorticoid regulation"}
{"PMID":23164615,"re_id":0,"annotated sentence":"To investigate the role of mGluR8 in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of mGluR8, AZ12216052 (AZ) and the <e2>mGluR8<\\e2> specific orthosteric agonist <e1>(S)-3,4-dicarboxyphenylglycine<\\e1> (DCPG)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"(S)-3,4-dicarboxyphenylglycine","object":"mGluR8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To investigate the role of GENE-Y in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of GENE-Y, AZ12216052 (AZ) and the <e2>GENE-Y<\\e2> specific orthosteric agonist <e1>CHEMICAL<\\e1> (DCPG)","sentence":"To investigate the role of mGluR8 in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of mGluR8, AZ12216052 (AZ) and the mGluR8 specific orthosteric agonist (S)-3,4-dicarboxyphenylglycine (DCPG)"}
{"PMID":23164615,"re_id":1,"annotated sentence":"To investigate the role of mGluR8 in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of mGluR8, AZ12216052 (AZ) and the <e2>mGluR8<\\e2> specific orthosteric agonist (S)-3,4-dicarboxyphenylglycine (<e1>DCPG<\\e1> ","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"DCPG","object":"mGluR8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To investigate the role of GENE-Y in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of GENE-Y, AZ12216052 (AZ) and the <e2>GENE-Y<\\e2> specific orthosteric agonist (S)-3,4-dicarboxyphenylglycine (<e1>CHEMICAL<\\e1> ","sentence":"To investigate the role of mGluR8 in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of mGluR8, AZ12216052 (AZ) and the mGluR8 specific orthosteric agonist (S)-3,4-dicarboxyphenylglycine (DCPG "}
{"PMID":23178182,"re_id":0,"annotated sentence":"Here, we compared the effects of a dimeric <e2>PSD-95<\\e2> inhibitor, <e1>UCCB01-125<\\e1>  and the NMDAR antagonist, MK-801, on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"UCCB01-125","object":"PSD-95","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we compared the effects of a dimeric <e2>GENE-Y<\\e2> inhibitor, <e1>CHEMICAL<\\e1>  and the NMDAR antagonist, MK-801, on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain","sentence":"Here, we compared the effects of a dimeric PSD-95 inhibitor, UCCB01-125  and the NMDAR antagonist, MK-801, on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain"}
{"PMID":23178182,"re_id":1,"annotated sentence":"Here, we compared the effects of a dimeric PSD-95 inhibitor, UCCB01-125, and the <e2>NMDAR<\\e2> antagonist, <e1>MK-801<\\e1>  on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"MK-801","object":"NMDAR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Here, we compared the effects of a dimeric PSD-95 inhibitor, UCCB01-125, and the <e2>GENE-N<\\e2> antagonist, <e1>CHEMICAL<\\e1>  on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain","sentence":"Here, we compared the effects of a dimeric PSD-95 inhibitor, UCCB01-125, and the NMDAR antagonist, MK-801  on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain"}
{"PMID":23178182,"re_id":2,"annotated sentence":"UCCB01-125, a dimeric inhibitor of PSD-95, reduces inflammatory pain without disrupting cognitive or motor performance: comparison with the <e2>NMDA receptor<\\e2> antagonist <e1>MK-801<\\e1>  Excessive N-Methyl-d-aspartate receptor (NMDAR)-dependent production of nitric oxide (NO) is involved in the development and maintenance of chronic pain states, and is mediated by postsynaptic density protein-95 (PSD-95)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"MK-801","object":"NMDA receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"UCCB01-125, a dimeric inhibitor of PSD-95, reduces inflammatory pain without disrupting cognitive or motor performance: comparison with the <e2>GENE-N<\\e2> antagonist <e1>CHEMICAL<\\e1>  Excessive N-Methyl-d-aspartate receptor (NMDAR)-dependent production of nitric oxide (NO) is involved in the development and maintenance of chronic pain states, and is mediated by postsynaptic density protein-95 (PSD-95)","sentence":"UCCB01-125, a dimeric inhibitor of PSD-95, reduces inflammatory pain without disrupting cognitive or motor performance: comparison with the NMDA receptor antagonist MK-801  Excessive N-Methyl-d-aspartate receptor (NMDAR)-dependent production of nitric oxide (NO) is involved in the development and maintenance of chronic pain states, and is mediated by postsynaptic density protein-95 (PSD-95)"}
{"PMID":23182766,"re_id":0,"annotated sentence":"The treatment also prevented the high <e1>cholesterol<\\e1> diet-induced increase in serum <e2>creatine kinase<\\e2>  total and isoforms, markers of neurological, cardiac and muscular damage","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cholesterol","object":"creatine kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The treatment also prevented the high <e1>CHEMICAL<\\e1> diet-induced increase in serum <e2>GENE-N<\\e2>  total and isoforms, markers of neurological, cardiac and muscular damage","sentence":"The treatment also prevented the high cholesterol diet-induced increase in serum creatine kinase  total and isoforms, markers of neurological, cardiac and muscular damage"}
{"PMID":23192339,"re_id":0,"annotated sentence":"GIP potentiates <e1>glucose<\\e1> stimulated <e2>insulin<\\e2> secretion and induces energy accumulation into adipose tissue, resulting in obesity","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"glucose","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"GIP potentiates <e1>CHEMICAL<\\e1> stimulated <e2>GENE-Y<\\e2> secretion and induces energy accumulation into adipose tissue, resulting in obesity","sentence":"GIP potentiates glucose stimulated insulin secretion and induces energy accumulation into adipose tissue, resulting in obesity"}
{"PMID":23194076,"re_id":0,"annotated sentence":"We concluded that in overweight and obese women with PCOS <e1>Orlistat<\\e1> administration, combined with diet and physical exercise, for 24 weeks, resulted in significant weight loss, improvement of hyperandrogenism and insulin sensitivity, and increased serum <e2>AMH<\\e2> levels.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Orlistat","object":"AMH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We concluded that in overweight and obese women with PCOS <e1>CHEMICAL<\\e1> administration, combined with diet and physical exercise, for 24 weeks, resulted in significant weight loss, improvement of hyperandrogenism and insulin sensitivity, and increased serum <e2>GENE-Y<\\e2> levels.","sentence":"We concluded that in overweight and obese women with PCOS Orlistat administration, combined with diet and physical exercise, for 24 weeks, resulted in significant weight loss, improvement of hyperandrogenism and insulin sensitivity, and increased serum AMH levels."}
{"PMID":23194076,"re_id":1,"annotated sentence":"Diet, physical exercise and <e1>Orlistat<\\e1> administration increase serum <e2>Anti-M\u00fcllerian Hormone<\\e2> (AMH) levels in women with polycystic ovary syndrome (PCOS)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Orlistat","object":"Anti-M\u00fcllerian Hormone","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Diet, physical exercise and <e1>CHEMICAL<\\e1> administration increase serum <e2>GENE-Y<\\e2> (AMH) levels in women with polycystic ovary syndrome (PCOS)","sentence":"Diet, physical exercise and Orlistat administration increase serum Anti-M\u00fcllerian Hormone (AMH) levels in women with polycystic ovary syndrome (PCOS)"}
{"PMID":23194076,"re_id":2,"annotated sentence":"Diet, physical exercise and <e1>Orlistat<\\e1> administration increase serum Anti-M\u00fcllerian Hormone (<e2>AMH<\\e2>  levels in women with polycystic ovary syndrome (PCOS)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Orlistat","object":"AMH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Diet, physical exercise and <e1>CHEMICAL<\\e1> administration increase serum Anti-M\u00fcllerian Hormone (<e2>GENE-Y<\\e2>  levels in women with polycystic ovary syndrome (PCOS)","sentence":"Diet, physical exercise and Orlistat administration increase serum Anti-M\u00fcllerian Hormone (AMH  levels in women with polycystic ovary syndrome (PCOS)"}
{"PMID":23201003,"re_id":0,"annotated sentence":"Moreover, <e1>1,25(OH)(2)D(3)<\\e1> decreased expression of <e2>Oat1<\\e2> and Oat3 in rat kidney","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"1,25(OH)(2)D(3)","object":"Oat1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> decreased expression of <e2>GENE-Y<\\e2> and Oat3 in rat kidney","sentence":"Moreover, 1,25(OH)(2)D(3) decreased expression of Oat1 and Oat3 in rat kidney"}
{"PMID":23201003,"re_id":1,"annotated sentence":"Moreover, <e1>1,25(OH)(2)D(3)<\\e1> decreased expression of Oat1 and <e2>Oat3<\\e2> in rat kidney","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"1,25(OH)(2)D(3)","object":"Oat3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> decreased expression of Oat1 and <e2>GENE-Y<\\e2> in rat kidney","sentence":"Moreover, 1,25(OH)(2)D(3) decreased expression of Oat1 and Oat3 in rat kidney"}
{"PMID":23201003,"re_id":2,"annotated sentence":"The mechanism of interaction between JBP485 and 1,25(OH)(2)D(3) could be explained at least in part by inhibitory effect of <e1>1,25(OH)(2)D(3)<\\e1> on expression of <e2>Oats<\\e2> in rat kidney.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"1,25(OH)(2)D(3)","object":"Oats","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The mechanism of interaction between JBP485 and CHEMICAL could be explained at least in part by inhibitory effect of <e1>CHEMICAL<\\e1> on expression of <e2>GENE-N<\\e2> in rat kidney.","sentence":"The mechanism of interaction between JBP485 and 1,25(OH)(2)D(3) could be explained at least in part by inhibitory effect of 1,25(OH)(2)D(3) on expression of Oats in rat kidney."}
{"PMID":23220614,"re_id":0,"annotated sentence":"These results demonstrated for the first time that <e1>ISO<\\e1> induces apoptosis in HepG2 cells through inactivating ERK1\/2 kinase and activating <e2>JNK<\\e2> and p38 kinases, and ROS stimulated by ISO is able to activate the MAPK singaling pathway as the upstream signaling molecules","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ISO","object":"JNK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These results demonstrated for the first time that <e1>CHEMICAL<\\e1> induces apoptosis in HepG2 cells through inactivating ERK1\/2 kinase and activating <e2>GENE-N<\\e2> and p38 kinases, and ROS stimulated by CHEMICAL is able to activate the MAPK singaling pathway as the upstream signaling molecules","sentence":"These results demonstrated for the first time that ISO induces apoptosis in HepG2 cells through inactivating ERK1\/2 kinase and activating JNK and p38 kinases, and ROS stimulated by ISO is able to activate the MAPK singaling pathway as the upstream signaling molecules"}
{"PMID":23220614,"re_id":1,"annotated sentence":"These results demonstrated for the first time that <e1>ISO<\\e1> induces apoptosis in HepG2 cells through inactivating ERK1\/2 kinase and activating JNK and <e2>p38<\\e2> kinases, and ROS stimulated by ISO is able to activate the MAPK singaling pathway as the upstream signaling molecules","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ISO","object":"p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These results demonstrated for the first time that <e1>CHEMICAL<\\e1> induces apoptosis in HepG2 cells through inactivating ERK1\/2 kinase and activating JNK and <e2>GENE-N<\\e2> kinases, and ROS stimulated by CHEMICAL is able to activate the MAPK singaling pathway as the upstream signaling molecules","sentence":"These results demonstrated for the first time that ISO induces apoptosis in HepG2 cells through inactivating ERK1\/2 kinase and activating JNK and p38 kinases, and ROS stimulated by ISO is able to activate the MAPK singaling pathway as the upstream signaling molecules"}
{"PMID":23220614,"re_id":2,"annotated sentence":"These results demonstrated for the first time that <e1>ISO<\\e1> induces apoptosis in HepG2 cells through inactivating ERK1\/2 kinase and activating JNK and p38 <e2>kinases<\\e2>  and ROS stimulated by ISO is able to activate the MAPK singaling pathway as the upstream signaling molecules","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ISO","object":"kinases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These results demonstrated for the first time that <e1>CHEMICAL<\\e1> induces apoptosis in HepG2 cells through inactivating ERK1\/2 kinase and activating JNK and p38 <e2>GENE-N<\\e2>  and ROS stimulated by CHEMICAL is able to activate the MAPK singaling pathway as the upstream signaling molecules","sentence":"These results demonstrated for the first time that ISO induces apoptosis in HepG2 cells through inactivating ERK1\/2 kinase and activating JNK and p38 kinases  and ROS stimulated by ISO is able to activate the MAPK singaling pathway as the upstream signaling molecules"}
{"PMID":23220614,"re_id":3,"annotated sentence":"These results demonstrated for the first time that ISO induces apoptosis in HepG2 cells through inactivating ERK1\/2 kinase and activating JNK and p38 kinases, and ROS stimulated by <e1>ISO<\\e1> is able to activate the <e2>MAPK<\\e2> singaling pathway as the upstream signaling molecules","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ISO","object":"MAPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These results demonstrated for the first time that CHEMICAL induces apoptosis in HepG2 cells through inactivating ERK1\/2 kinase and activating JNK and p38 kinases, and ROS stimulated by <e1>CHEMICAL<\\e1> is able to activate the <e2>GENE-N<\\e2> singaling pathway as the upstream signaling molecules","sentence":"These results demonstrated for the first time that ISO induces apoptosis in HepG2 cells through inactivating ERK1\/2 kinase and activating JNK and p38 kinases, and ROS stimulated by ISO is able to activate the MAPK singaling pathway as the upstream signaling molecules"}
{"PMID":23220614,"re_id":4,"annotated sentence":"<e1>ISO<\\e1> significantly inhibited the levels of ERK1\/2 kinase and increased the expression of <e2>JNK<\\e2> and p38 kinases","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ISO","object":"JNK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> significantly inhibited the levels of ERK1\/2 kinase and increased the expression of <e2>GENE-N<\\e2> and p38 kinases","sentence":"ISO significantly inhibited the levels of ERK1\/2 kinase and increased the expression of JNK and p38 kinases"}
{"PMID":23220614,"re_id":5,"annotated sentence":"<e1>ISO<\\e1> significantly inhibited the levels of ERK1\/2 kinase and increased the expression of JNK and <e2>p38<\\e2> kinases","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ISO","object":"p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> significantly inhibited the levels of ERK1\/2 kinase and increased the expression of JNK and <e2>GENE-N<\\e2> kinases","sentence":"ISO significantly inhibited the levels of ERK1\/2 kinase and increased the expression of JNK and p38 kinases"}
{"PMID":23220614,"re_id":6,"annotated sentence":"<e1>ISO<\\e1> significantly inhibited the levels of ERK1\/2 kinase and increased the expression of JNK and p38 <e2>kinases<\\e2>  Furthermore, U0126 (an ERK1\/2 inhibitor) significantly enhanced the ISO-induced the Bax\/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ISO","object":"kinases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> significantly inhibited the levels of ERK1\/2 kinase and increased the expression of JNK and p38 <e2>GENE-N<\\e2>  Furthermore, U0126 (an ERK1\/2 inhibitor) significantly enhanced the CHEMICAL-induced the Bax\/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3","sentence":"ISO significantly inhibited the levels of ERK1\/2 kinase and increased the expression of JNK and p38 kinases  Furthermore, U0126 (an ERK1\/2 inhibitor) significantly enhanced the ISO-induced the Bax\/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3"}
{"PMID":23220614,"re_id":7,"annotated sentence":"Furthermore, <e1>U0126<\\e1> (an ERK1\/2 inhibitor) significantly enhanced the ISO-induced the <e2>Bax<\\e2> Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"U0126","object":"Bax","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> (an ERK1\/2 inhibitor) significantly enhanced the ISO-induced the <e2>GENE-Y<\\e2> Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3","sentence":"Furthermore, U0126 (an ERK1\/2 inhibitor) significantly enhanced the ISO-induced the Bax Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3"}
{"PMID":23220614,"re_id":8,"annotated sentence":"Furthermore, <e1>U0126<\\e1> (an ERK1\/2 inhibitor) significantly enhanced the ISO-induced the Bax\/<e2>Bcl-2<\\e2> ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"U0126","object":"Bcl-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> (an ERK1\/2 inhibitor) significantly enhanced the ISO-induced the Bax\/<e2>GENE-Y<\\e2> ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3","sentence":"Furthermore, U0126 (an ERK1\/2 inhibitor) significantly enhanced the ISO-induced the Bax\/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3"}
{"PMID":23220614,"re_id":9,"annotated sentence":"Furthermore, U0126 (an ERK1\/2 inhibitor) significantly enhanced the <e1>ISO<\\e1> induced the <e2>Bax<\\e2> Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ISO","object":"Bax","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, U0126 (an ERK1\/2 inhibitor) significantly enhanced the <e1>CHEMICAL<\\e1> induced the <e2>GENE-Y<\\e2> Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3","sentence":"Furthermore, U0126 (an ERK1\/2 inhibitor) significantly enhanced the ISO induced the Bax Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3"}
{"PMID":23220614,"re_id":10,"annotated sentence":"Furthermore, U0126 (an ERK1\/2 inhibitor) significantly enhanced the <e1>ISO<\\e1> induced the Bax\/<e2>Bcl-2<\\e2> ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ISO","object":"Bcl-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, U0126 (an ERK1\/2 inhibitor) significantly enhanced the <e1>CHEMICAL<\\e1> induced the Bax\/<e2>GENE-Y<\\e2> ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3","sentence":"Furthermore, U0126 (an ERK1\/2 inhibitor) significantly enhanced the ISO induced the Bax\/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3"}
{"PMID":23220614,"re_id":11,"annotated sentence":"While SP600125 (a <e2>JNK<\\e2> inhibitor) and SB203580 (a p38 inhibitor) markedly prevented the expression of these proteins induced by <e1>ISO<\\e1>  Furthermore, the ROS inhibitor (NAC) notably promoted the inhibited effect of ISO on the ERK1\/2 kinase","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ISO","object":"JNK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"While SP600125 (a <e2>GENE-N<\\e2> inhibitor) and SB203580 (a p38 inhibitor) markedly prevented the expression of these proteins induced by <e1>CHEMICAL<\\e1>  Furthermore, the ROS inhibitor (NAC) notably promoted the inhibited effect of CHEMICAL on the ERK1\/2 kinase","sentence":"While SP600125 (a JNK inhibitor) and SB203580 (a p38 inhibitor) markedly prevented the expression of these proteins induced by ISO  Furthermore, the ROS inhibitor (NAC) notably promoted the inhibited effect of ISO on the ERK1\/2 kinase"}
{"PMID":23220614,"re_id":12,"annotated sentence":"While SP600125 (a JNK inhibitor) and SB203580 (a <e2>p38<\\e2> inhibitor) markedly prevented the expression of these proteins induced by <e1>ISO<\\e1>  Furthermore, the ROS inhibitor (NAC) notably promoted the inhibited effect of ISO on the ERK1\/2 kinase","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ISO","object":"p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"While SP600125 (a JNK inhibitor) and SB203580 (a <e2>GENE-N<\\e2> inhibitor) markedly prevented the expression of these proteins induced by <e1>CHEMICAL<\\e1>  Furthermore, the ROS inhibitor (NAC) notably promoted the inhibited effect of CHEMICAL on the ERK1\/2 kinase","sentence":"While SP600125 (a JNK inhibitor) and SB203580 (a p38 inhibitor) markedly prevented the expression of these proteins induced by ISO  Furthermore, the ROS inhibitor (NAC) notably promoted the inhibited effect of ISO on the ERK1\/2 kinase"}
{"PMID":23220614,"re_id":13,"annotated sentence":"<e1>ISO<\\e1> is able to induce apoptosis through mitochondrial dysfunction and inhibition of <e2>PI3K<\\e2> Akt signaling pathway in HepG2 cells, however, the effects of ISO on MAPK signaling pathways remain unknown","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ISO","object":"PI3K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is able to induce apoptosis through mitochondrial dysfunction and inhibition of <e2>GENE-N<\\e2> Akt signaling pathway in HepG2 cells, however, the effects of CHEMICAL on MAPK signaling pathways remain unknown","sentence":"ISO is able to induce apoptosis through mitochondrial dysfunction and inhibition of PI3K Akt signaling pathway in HepG2 cells, however, the effects of ISO on MAPK signaling pathways remain unknown"}
{"PMID":23220614,"re_id":14,"annotated sentence":"<e1>ISO<\\e1> is able to induce apoptosis through mitochondrial dysfunction and inhibition of PI3K\/<e2>Akt<\\e2> signaling pathway in HepG2 cells, however, the effects of ISO on MAPK signaling pathways remain unknown","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ISO","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is able to induce apoptosis through mitochondrial dysfunction and inhibition of PI3K\/<e2>GENE-N<\\e2> signaling pathway in HepG2 cells, however, the effects of CHEMICAL on MAPK signaling pathways remain unknown","sentence":"ISO is able to induce apoptosis through mitochondrial dysfunction and inhibition of PI3K\/Akt signaling pathway in HepG2 cells, however, the effects of ISO on MAPK signaling pathways remain unknown"}
{"PMID":23220614,"re_id":15,"annotated sentence":"While <e1>SP600125<\\e1> (a <e2>JNK<\\e2> inhibitor) and SB203580 (a p38 inhibitor) markedly prevented the expression of these proteins induced by ISO","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SP600125","object":"JNK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"While <e1>CHEMICAL<\\e1> (a <e2>GENE-N<\\e2> inhibitor) and SB203580 (a p38 inhibitor) markedly prevented the expression of these proteins induced by ISO","sentence":"While SP600125 (a JNK inhibitor) and SB203580 (a p38 inhibitor) markedly prevented the expression of these proteins induced by ISO"}
{"PMID":23220614,"re_id":16,"annotated sentence":"While SP600125 (a JNK inhibitor) and <e1>SB203580<\\e1> (a <e2>p38<\\e2> inhibitor) markedly prevented the expression of these proteins induced by ISO","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SB203580","object":"p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"While SP600125 (a JNK inhibitor) and <e1>CHEMICAL<\\e1> (a <e2>GENE-N<\\e2> inhibitor) markedly prevented the expression of these proteins induced by ISO","sentence":"While SP600125 (a JNK inhibitor) and SB203580 (a p38 inhibitor) markedly prevented the expression of these proteins induced by ISO"}
{"PMID":23220614,"re_id":17,"annotated sentence":"<e1>NAC<\\e1> also suppressed the p-<e2>JNK<\\e2> and p-p38, but failed to reverse the effects of ISO","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NAC","object":"JNK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> also suppressed the p-<e2>GENE-N<\\e2> and p-p38, but failed to reverse the effects of ISO","sentence":"NAC also suppressed the p-JNK and p-p38, but failed to reverse the effects of ISO"}
{"PMID":23220614,"re_id":18,"annotated sentence":"<e1>NAC<\\e1> also suppressed the p-JNK and <e2>p-p38<\\e2>  but failed to reverse the effects of ISO","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NAC","object":"p-p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> also suppressed the p-JNK and <e2>GENE-N<\\e2>  but failed to reverse the effects of ISO","sentence":"NAC also suppressed the p-JNK and p-p38  but failed to reverse the effects of ISO"}
{"PMID":23220618,"re_id":0,"annotated sentence":"Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and <e1>IMG<\\e1> or hyperoside inhibited production of <e2>thrombin<\\e2> and FXa in HUVECs","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"IMG","object":"thrombin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with CHEMICAL and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of GENE-Y and FXa, and <e1>CHEMICAL<\\e1> or hyperoside inhibited production of <e2>GENE-Y<\\e2> and FXa in HUVECs","sentence":"Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs"}
{"PMID":23220618,"re_id":1,"annotated sentence":"Treatment with <e1>IMG<\\e1> and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of <e2>thrombin<\\e2> and FXa, and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"IMG","object":"thrombin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of <e2>GENE-Y<\\e2> and FXa, and CHEMICAL or hyperoside inhibited production of GENE-Y and FXa in HUVECs","sentence":"Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs"}
{"PMID":23220618,"re_id":2,"annotated sentence":"Treatment with <e1>IMG<\\e1> and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and <e2>FXa<\\e2>  and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"IMG","object":"FXa","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and <e2>GENE-Y<\\e2>  and CHEMICAL or hyperoside inhibited production of thrombin and GENE-Y in HUVECs","sentence":"Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa  and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs"}
{"PMID":23220618,"re_id":3,"annotated sentence":"Treatment with IMG and <e1>hyperoside<\\e1> resulted in significantly prolonged aPTT and PT and inhibition of the activities of <e2>thrombin<\\e2> and FXa, and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"hyperoside","object":"thrombin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with IMG and <e1>CHEMICAL<\\e1> resulted in significantly prolonged aPTT and PT and inhibition of the activities of <e2>GENE-Y<\\e2> and FXa, and IMG or CHEMICAL inhibited production of GENE-Y and FXa in HUVECs","sentence":"Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs"}
{"PMID":23220618,"re_id":4,"annotated sentence":"Treatment with IMG and <e1>hyperoside<\\e1> resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and <e2>FXa<\\e2>  and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"hyperoside","object":"FXa","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with IMG and <e1>CHEMICAL<\\e1> resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and <e2>GENE-Y<\\e2>  and IMG or CHEMICAL inhibited production of thrombin and GENE-Y in HUVECs","sentence":"Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa  and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs"}
{"PMID":23220618,"re_id":5,"annotated sentence":"Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and <e1>IMG<\\e1> or hyperoside inhibited production of thrombin and <e2>FXa<\\e2> in HUVECs","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"IMG","object":"FXa","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with CHEMICAL and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and GENE-Y, and <e1>CHEMICAL<\\e1> or hyperoside inhibited production of thrombin and <e2>GENE-Y<\\e2> in HUVECs","sentence":"Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs"}
{"PMID":23220618,"re_id":6,"annotated sentence":"Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and IMG or <e1>hyperoside<\\e1> inhibited production of <e2>thrombin<\\e2> and FXa in HUVECs","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"hyperoside","object":"thrombin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with IMG and CHEMICAL resulted in significantly prolonged aPTT and PT and inhibition of the activities of GENE-Y and FXa, and IMG or <e1>CHEMICAL<\\e1> inhibited production of <e2>GENE-Y<\\e2> and FXa in HUVECs","sentence":"Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs"}
{"PMID":23220618,"re_id":7,"annotated sentence":"Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and IMG or <e1>hyperoside<\\e1> inhibited production of thrombin and <e2>FXa<\\e2> in HUVECs","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"hyperoside","object":"FXa","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with IMG and CHEMICAL resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and GENE-Y, and IMG or <e1>CHEMICAL<\\e1> inhibited production of thrombin and <e2>GENE-Y<\\e2> in HUVECs","sentence":"Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs"}
{"PMID":23220618,"re_id":8,"annotated sentence":"In addition, treatment with <e1>IMG<\\e1> and hyperoside resulted in inhibition of <e2>TNF-\u03b1<\\e2> induced production of PAI-1, and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"IMG","object":"TNF-\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, treatment with <e1>CHEMICAL<\\e1> and hyperoside resulted in inhibition of <e2>GENE-Y<\\e2> induced production of PAI-1, and treatment with CHEMICAL resulted in significant reduction of the PAI-1 to t-PA ratio","sentence":"In addition, treatment with IMG and hyperoside resulted in inhibition of TNF-\u03b1 induced production of PAI-1, and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio"}
{"PMID":23220618,"re_id":9,"annotated sentence":"In addition, treatment with <e1>IMG<\\e1> and hyperoside resulted in inhibition of TNF-\u03b1-induced production of <e2>PAI-1<\\e2>  and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"IMG","object":"PAI-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, treatment with <e1>CHEMICAL<\\e1> and hyperoside resulted in inhibition of TNF-\u03b1-induced production of <e2>GENE-Y<\\e2>  and treatment with CHEMICAL resulted in significant reduction of the GENE-Y to t-PA ratio","sentence":"In addition, treatment with IMG and hyperoside resulted in inhibition of TNF-\u03b1-induced production of PAI-1  and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio"}
{"PMID":23220618,"re_id":10,"annotated sentence":"In addition, treatment with IMG and <e1>hyperoside<\\e1> resulted in inhibition of <e2>TNF-\u03b1<\\e2> induced production of PAI-1, and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"hyperoside","object":"TNF-\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, treatment with IMG and <e1>CHEMICAL<\\e1> resulted in inhibition of <e2>GENE-Y<\\e2> induced production of PAI-1, and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio","sentence":"In addition, treatment with IMG and hyperoside resulted in inhibition of TNF-\u03b1 induced production of PAI-1, and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio"}
{"PMID":23220618,"re_id":11,"annotated sentence":"In addition, treatment with IMG and <e1>hyperoside<\\e1> resulted in inhibition of TNF-\u03b1-induced production of <e2>PAI-1<\\e2>  and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"hyperoside","object":"PAI-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, treatment with IMG and <e1>CHEMICAL<\\e1> resulted in inhibition of TNF-\u03b1-induced production of <e2>GENE-Y<\\e2>  and treatment with IMG resulted in significant reduction of the GENE-Y to t-PA ratio","sentence":"In addition, treatment with IMG and hyperoside resulted in inhibition of TNF-\u03b1-induced production of PAI-1  and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio"}
{"PMID":23220618,"re_id":12,"annotated sentence":"In addition, treatment with IMG and hyperoside resulted in inhibition of TNF-\u03b1-induced production of PAI-1, and treatment with <e1>IMG<\\e1> resulted in significant reduction of the <e2>PAI-1<\\e2> to t-PA ratio","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"IMG","object":"PAI-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, treatment with CHEMICAL and hyperoside resulted in inhibition of TNF-\u03b1-induced production of GENE-Y, and treatment with <e1>CHEMICAL<\\e1> resulted in significant reduction of the <e2>GENE-Y<\\e2> to t-PA ratio","sentence":"In addition, treatment with IMG and hyperoside resulted in inhibition of TNF-\u03b1-induced production of PAI-1, and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio"}
{"PMID":23220618,"re_id":13,"annotated sentence":"In addition, treatment with IMG and hyperoside resulted in inhibition of TNF-\u03b1-induced production of PAI-1, and treatment with <e1>IMG<\\e1> resulted in significant reduction of the PAI-1 to <e2>t-PA<\\e2> ratio","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"IMG","object":"t-PA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, treatment with CHEMICAL and hyperoside resulted in inhibition of TNF-\u03b1-induced production of PAI-1, and treatment with <e1>CHEMICAL<\\e1> resulted in significant reduction of the PAI-1 to <e2>GENE-Y<\\e2> ratio","sentence":"In addition, treatment with IMG and hyperoside resulted in inhibition of TNF-\u03b1-induced production of PAI-1, and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio"}
{"PMID":23220644,"re_id":0,"annotated sentence":"In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (<e1>JMC08-4<\\e1>  for human nonpancreatic secretory phospholipase A(2) (hnps-PLA(2)) and <e2>human leukotriene A(4) hydrolase<\\e2> (LTA(4)H-h) was found","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"JMC08-4","object":"human leukotriene A(4) hydrolase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (<e1>CHEMICAL<\\e1>  for human nonpancreatic secretory phospholipase A(2) (hnps-PLA(2)) and <e2>GENE-Y<\\e2> (LTA(4)H-h) was found","sentence":"In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (JMC08-4  for human nonpancreatic secretory phospholipase A(2) (hnps-PLA(2)) and human leukotriene A(4) hydrolase (LTA(4)H-h) was found"}
{"PMID":23220644,"re_id":1,"annotated sentence":"In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (<e1>JMC08-4<\\e1>  for human nonpancreatic secretory phospholipase A(2) (hnps-PLA(2)) and human leukotriene A(4) hydrolase (<e2>LTA(4)H-h<\\e2>  was found","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"JMC08-4","object":"LTA(4)H-h","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (<e1>CHEMICAL<\\e1>  for human nonpancreatic secretory phospholipase A(2) (hnps-PLA(2)) and human leukotriene A(4) hydrolase (<e2>GENE-Y<\\e2>  was found","sentence":"In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (JMC08-4  for human nonpancreatic secretory phospholipase A(2) (hnps-PLA(2)) and human leukotriene A(4) hydrolase (LTA(4)H-h  was found"}
{"PMID":23220644,"re_id":2,"annotated sentence":"In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (<e1>JMC08-4<\\e1>  for <e2>human nonpancreatic secretory phospholipase A(2)<\\e2> (hnps-PLA(2)) and human leukotriene A(4) hydrolase (LTA(4)H-h) was found","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"JMC08-4","object":"human nonpancreatic secretory phospholipase A(2)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (<e1>CHEMICAL<\\e1>  for <e2>GENE-Y<\\e2> (hnps-PLA(2)) and human leukotriene A(4) hydrolase (LTA(4)H-h) was found","sentence":"In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (JMC08-4  for human nonpancreatic secretory phospholipase A(2) (hnps-PLA(2)) and human leukotriene A(4) hydrolase (LTA(4)H-h) was found"}
{"PMID":23220644,"re_id":3,"annotated sentence":"In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (<e1>JMC08-4<\\e1>  for human nonpancreatic secretory phospholipase A(2) (<e2>hnps-PLA(2)<\\e2>  and human leukotriene A(4) hydrolase (LTA(4)H-h) was found","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"JMC08-4","object":"hnps-PLA(2)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (<e1>CHEMICAL<\\e1>  for human nonpancreatic secretory phospholipase A(2) (<e2>GENE-Y<\\e2>  and human leukotriene A(4) hydrolase (LTA(4)H-h) was found","sentence":"In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (JMC08-4  for human nonpancreatic secretory phospholipase A(2) (hnps-PLA(2)  and human leukotriene A(4) hydrolase (LTA(4)H-h) was found"}
{"PMID":23220644,"re_id":4,"annotated sentence":"Optimization of <e1>5-hydroxytryptamines<\\e1> as dual function inhibitors targeting <e2>phospholipase A2<\\e2> and leukotriene A4 hydrolase","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-hydroxytryptamines","object":"phospholipase A2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Optimization of <e1>CHEMICAL<\\e1> as dual function inhibitors targeting <e2>GENE-N<\\e2> and leukotriene A4 hydrolase","sentence":"Optimization of 5-hydroxytryptamines as dual function inhibitors targeting phospholipase A2 and leukotriene A4 hydrolase"}
{"PMID":23220644,"re_id":5,"annotated sentence":"Optimization of <e1>5-hydroxytryptamines<\\e1> as dual function inhibitors targeting phospholipase A2 and <e2>leukotriene A4 hydrolase<\\e2>  Dual function inhibitors targeting phospholipase A(2) (PLA(2)) and leukotriene A(4) hydrolase (LTA(4)H) may balance the arachidonic acid (AA) metabolic network and be used as new anti-inflammatory drugs","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-hydroxytryptamines","object":"leukotriene A4 hydrolase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Optimization of <e1>CHEMICAL<\\e1> as dual function inhibitors targeting phospholipase A2 and <e2>GENE-Y<\\e2>  Dual function inhibitors targeting phospholipase A(2) (PLA(2)) and leukotriene A(4) hydrolase (LTA(4)H) may balance the arachidonic acid (AA) metabolic network and be used as new anti-inflammatory drugs","sentence":"Optimization of 5-hydroxytryptamines as dual function inhibitors targeting phospholipase A2 and leukotriene A4 hydrolase  Dual function inhibitors targeting phospholipase A(2) (PLA(2)) and leukotriene A(4) hydrolase (LTA(4)H) may balance the arachidonic acid (AA) metabolic network and be used as new anti-inflammatory drugs"}
{"PMID":23220644,"re_id":6,"annotated sentence":"Dual function inhibitors targeting phospholipase A(2) (<e2>PLA(2)<\\e2>  and leukotriene A(4) hydrolase (LTA(4)H) may balance the <e1>arachidonic acid<\\e1> (AA) metabolic network and be used as new anti-inflammatory drugs","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"arachidonic acid","object":"PLA(2)","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Dual function inhibitors targeting phospholipase A(2) (<e2>GENE-N<\\e2>  and leukotriene A(4) hydrolase (LTA(4)H) may balance the <e1>CHEMICAL<\\e1> (AA) metabolic network and be used as new anti-inflammatory drugs","sentence":"Dual function inhibitors targeting phospholipase A(2) (PLA(2)  and leukotriene A(4) hydrolase (LTA(4)H) may balance the arachidonic acid (AA) metabolic network and be used as new anti-inflammatory drugs"}
{"PMID":23220644,"re_id":7,"annotated sentence":"Dual function inhibitors targeting phospholipase A(2) (PLA(2)) and <e2>leukotriene A(4) hydrolase<\\e2> (LTA(4)H) may balance the <e1>arachidonic acid<\\e1> (AA) metabolic network and be used as new anti-inflammatory drugs","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"arachidonic acid","object":"leukotriene A(4) hydrolase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Dual function inhibitors targeting phospholipase A(2) (PLA(2)) and <e2>GENE-Y<\\e2> (LTA(4)H) may balance the <e1>CHEMICAL<\\e1> (AA) metabolic network and be used as new anti-inflammatory drugs","sentence":"Dual function inhibitors targeting phospholipase A(2) (PLA(2)) and leukotriene A(4) hydrolase (LTA(4)H) may balance the arachidonic acid (AA) metabolic network and be used as new anti-inflammatory drugs"}
{"PMID":23220644,"re_id":8,"annotated sentence":"Dual function inhibitors targeting phospholipase A(2) (PLA(2)) and leukotriene A(4) hydrolase (<e2>LTA(4)H<\\e2>  may balance the <e1>arachidonic acid<\\e1> (AA) metabolic network and be used as new anti-inflammatory drugs","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"arachidonic acid","object":"LTA(4)H","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Dual function inhibitors targeting phospholipase A(2) (PLA(2)) and leukotriene A(4) hydrolase (<e2>GENE-Y<\\e2>  may balance the <e1>CHEMICAL<\\e1> (AA) metabolic network and be used as new anti-inflammatory drugs","sentence":"Dual function inhibitors targeting phospholipase A(2) (PLA(2)) and leukotriene A(4) hydrolase (LTA(4)H  may balance the arachidonic acid (AA) metabolic network and be used as new anti-inflammatory drugs"}
{"PMID":23220644,"re_id":9,"annotated sentence":"Dual function inhibitors targeting <e2>phospholipase A(2)<\\e2> (PLA(2)) and leukotriene A(4) hydrolase (LTA(4)H) may balance the <e1>arachidonic acid<\\e1> (AA) metabolic network and be used as new anti-inflammatory drugs","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"arachidonic acid","object":"phospholipase A(2)","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Dual function inhibitors targeting <e2>GENE-N<\\e2> (PLA(2)) and leukotriene A(4) hydrolase (LTA(4)H) may balance the <e1>CHEMICAL<\\e1> (AA) metabolic network and be used as new anti-inflammatory drugs","sentence":"Dual function inhibitors targeting phospholipase A(2) (PLA(2)) and leukotriene A(4) hydrolase (LTA(4)H) may balance the arachidonic acid (AA) metabolic network and be used as new anti-inflammatory drugs"}
{"PMID":23220749,"re_id":0,"annotated sentence":"In addition, we provide evidence that <e1>apomorphine<\\e1> also acts on endogenous TRPA1 in cultured dorsal root ganglion neurons from rats and in the enterochromaffin model cell line QGP-1, from which serotonin is released upon activation of <e2>TRPA1<\\e2>  Our study shows that human TRPA1 is a target for apomorphine, suggesting that an activation of TRPA1 might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with apomorphine.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"apomorphine","object":"TRPA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, we provide evidence that <e1>CHEMICAL<\\e1> also acts on endogenous GENE-Y in cultured dorsal root ganglion neurons from rats and in the enterochromaffin model cell line QGP-1, from which serotonin is released upon activation of <e2>GENE-Y<\\e2>  Our study shows that human GENE-Y is a target for CHEMICAL, suggesting that an activation of GENE-Y might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with CHEMICAL.","sentence":"In addition, we provide evidence that apomorphine also acts on endogenous TRPA1 in cultured dorsal root ganglion neurons from rats and in the enterochromaffin model cell line QGP-1, from which serotonin is released upon activation of TRPA1  Our study shows that human TRPA1 is a target for apomorphine, suggesting that an activation of TRPA1 might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with apomorphine."}
{"PMID":23220749,"re_id":1,"annotated sentence":"Our study shows that human TRPA1 is a target for <e1>apomorphine<\\e1>  suggesting that an activation of <e2>TRPA1<\\e2> might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with apomorphine.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"apomorphine","object":"TRPA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our study shows that human GENE-Y is a target for <e1>CHEMICAL<\\e1>  suggesting that an activation of <e2>GENE-Y<\\e2> might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with CHEMICAL.","sentence":"Our study shows that human TRPA1 is a target for apomorphine  suggesting that an activation of TRPA1 might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with apomorphine."}
{"PMID":23220749,"re_id":2,"annotated sentence":"Our study shows that human TRPA1 is a target for apomorphine, suggesting that an activation of <e2>TRPA1<\\e2> might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with <e1>apomorphine<\\e1> ","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"apomorphine","object":"TRPA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our study shows that human GENE-Y is a target for CHEMICAL, suggesting that an activation of <e2>GENE-Y<\\e2> might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with <e1>CHEMICAL<\\e1> ","sentence":"Our study shows that human TRPA1 is a target for apomorphine, suggesting that an activation of TRPA1 might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with apomorphine "}
{"PMID":23220749,"re_id":3,"annotated sentence":"Whereas the addition of <e1>apomorphine<\\e1> in the low micromolar range produced an irreversible activation of the channel, application of higher concentrations caused a reversible voltage-dependent inhibition of heterologously expressed <e2>TRPA1<\\e2> channels, resulting from a reduction of single-channel open times","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"apomorphine","object":"TRPA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Whereas the addition of <e1>CHEMICAL<\\e1> in the low micromolar range produced an irreversible activation of the channel, application of higher concentrations caused a reversible voltage-dependent inhibition of heterologously expressed <e2>GENE-Y<\\e2> channels, resulting from a reduction of single-channel open times","sentence":"Whereas the addition of apomorphine in the low micromolar range produced an irreversible activation of the channel, application of higher concentrations caused a reversible voltage-dependent inhibition of heterologously expressed TRPA1 channels, resulting from a reduction of single-channel open times"}
{"PMID":23221600,"re_id":0,"annotated sentence":"Dietary <e1>carbohydrates<\\e1> increase <e2>SCD-1<\\e2> gene expression in liver by sterol response element binding protein (SREBP)-1c-dependent and SREBP-1c -independent pathways","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"carbohydrates","object":"SCD-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Dietary <e1>CHEMICAL<\\e1> increase <e2>GENE-Y<\\e2> gene expression in liver by sterol response element binding protein (SREBP)-1c-dependent and SREBP-1c -independent pathways","sentence":"Dietary carbohydrates increase SCD-1 gene expression in liver by sterol response element binding protein (SREBP)-1c-dependent and SREBP-1c -independent pathways"}
{"PMID":23221600,"re_id":1,"annotated sentence":"Previous report demonstrated that <e1>thyroid hormone<\\e1> (TH) negatively regulates <e2>mouse SCD-1 gene promoter<\\e2> before SREBP-1c was revealed","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"thyroid hormone","object":"mouse SCD-1 gene promoter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Previous report demonstrated that <e1>CHEMICAL<\\e1> (TH) negatively regulates <e2>GENE-N<\\e2> before SREBP-1c was revealed","sentence":"Previous report demonstrated that thyroid hormone (TH) negatively regulates mouse SCD-1 gene promoter before SREBP-1c was revealed"}
{"PMID":23221600,"re_id":2,"annotated sentence":"<e2>Human stearoyl-CoA desaturase 1<\\e2> (SCD-1) gene expression is negatively regulated by <e1>thyroid hormone<\\e1> without direct binding of thyroid hormone receptor to the gene promoter","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"thyroid hormone","object":"Human stearoyl-CoA desaturase 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (SCD-1) gene expression is negatively regulated by <e1>CHEMICAL<\\e1> without direct binding of CHEMICAL receptor to the gene promoter","sentence":"Human stearoyl-CoA desaturase 1 (SCD-1) gene expression is negatively regulated by thyroid hormone without direct binding of thyroid hormone receptor to the gene promoter"}
{"PMID":23221600,"re_id":3,"annotated sentence":"Human stearoyl-CoA desaturase 1 (<e2>SCD-1<\\e2>  gene expression is negatively regulated by <e1>thyroid hormone<\\e1> without direct binding of thyroid hormone receptor to the gene promoter","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"thyroid hormone","object":"SCD-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Human stearoyl-CoA desaturase 1 (<e2>GENE-Y<\\e2>  gene expression is negatively regulated by <e1>CHEMICAL<\\e1> without direct binding of CHEMICAL receptor to the gene promoter","sentence":"Human stearoyl-CoA desaturase 1 (SCD-1  gene expression is negatively regulated by thyroid hormone without direct binding of thyroid hormone receptor to the gene promoter"}
{"PMID":23223177,"re_id":0,"annotated sentence":"Finally, chronic administration of <e1>metformin<\\e1> in diabetic mice restored cardiac autophagy by activating <e2>JNK1<\\e2> Bcl-2 pathways and dissociating Beclin1 and Bcl-2","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"metformin","object":"JNK1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Finally, chronic administration of <e1>CHEMICAL<\\e1> in diabetic mice restored cardiac autophagy by activating <e2>GENE-Y<\\e2> Bcl-2 pathways and dissociating Beclin1 and Bcl-2","sentence":"Finally, chronic administration of metformin in diabetic mice restored cardiac autophagy by activating JNK1 Bcl-2 pathways and dissociating Beclin1 and Bcl-2"}
{"PMID":23223177,"re_id":1,"annotated sentence":"Finally, chronic administration of <e1>metformin<\\e1> in diabetic mice restored cardiac autophagy by activating JNK1-<e2>Bcl-2<\\e2> pathways and dissociating Beclin1 and Bcl-2","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"metformin","object":"Bcl-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Finally, chronic administration of <e1>CHEMICAL<\\e1> in diabetic mice restored cardiac autophagy by activating JNK1-<e2>GENE-Y<\\e2> pathways and dissociating Beclin1 and GENE-Y","sentence":"Finally, chronic administration of metformin in diabetic mice restored cardiac autophagy by activating JNK1-Bcl-2 pathways and dissociating Beclin1 and Bcl-2"}
{"PMID":23223177,"re_id":2,"annotated sentence":"Exposure of H9c2 cells to high <e1>glucose<\\e1> reduced <e2>AMPK<\\e2> activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"glucose","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Exposure of H9c2 cells to high <e1>CHEMICAL<\\e1> reduced <e2>GENE-Y<\\e2> activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2","sentence":"Exposure of H9c2 cells to high glucose reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2"}
{"PMID":23223177,"re_id":3,"annotated sentence":"Exposure of H9c2 cells to high <e1>glucose<\\e1> reduced AMPK activity, inhibited <e2>Jun NH2-terminal kinase 1<\\e2> (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"glucose","object":"Jun NH2-terminal kinase 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Exposure of H9c2 cells to high <e1>CHEMICAL<\\e1> reduced AMPK activity, inhibited <e2>GENE-Y<\\e2> (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2","sentence":"Exposure of H9c2 cells to high glucose reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2"}
{"PMID":23223177,"re_id":4,"annotated sentence":"Exposure of H9c2 cells to high <e1>glucose<\\e1> reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (<e2>JNK1<\\e2> -B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"glucose","object":"JNK1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Exposure of H9c2 cells to high <e1>CHEMICAL<\\e1> reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (<e2>GENE-Y<\\e2> -B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2","sentence":"Exposure of H9c2 cells to high glucose reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (JNK1 -B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2"}
{"PMID":23223177,"re_id":5,"annotated sentence":"Exposure of H9c2 cells to high <e1>glucose<\\e1> reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-<e2>B-cell lymphoma 2<\\e2> (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"glucose","object":"B-cell lymphoma 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Exposure of H9c2 cells to high <e1>CHEMICAL<\\e1> reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-<e2>GENE-Y<\\e2> (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2","sentence":"Exposure of H9c2 cells to high glucose reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2"}
{"PMID":23223177,"re_id":6,"annotated sentence":"Exposure of H9c2 cells to high <e1>glucose<\\e1> reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (<e2>Bcl-2<\\e2>  signaling, and promoted Beclin1 binding to Bcl-2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"glucose","object":"Bcl-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Exposure of H9c2 cells to high <e1>CHEMICAL<\\e1> reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (<e2>GENE-Y<\\e2>  signaling, and promoted Beclin1 binding to GENE-Y","sentence":"Exposure of H9c2 cells to high glucose reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (Bcl-2  signaling, and promoted Beclin1 binding to Bcl-2"}
{"PMID":23228696,"re_id":0,"annotated sentence":"In this current study, <e1>paclitaxel<\\e1> was found to increase phosphorylation of <e2>mitogen-activated protein kinase<\\e2> (MAPK) kinase 3\/6 (MKK3\/6)-p38 MAPK as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"paclitaxel","object":"mitogen-activated protein kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In this current study, <e1>CHEMICAL<\\e1> was found to increase phosphorylation of <e2>GENE-N<\\e2> (MAPK) kinase 3\/6 (MKK3\/6)-p38 MAPK as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells","sentence":"In this current study, paclitaxel was found to increase phosphorylation of mitogen-activated protein kinase (MAPK) kinase 3\/6 (MKK3\/6)-p38 MAPK as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells"}
{"PMID":23228696,"re_id":1,"annotated sentence":"In this current study, <e1>paclitaxel<\\e1> was found to increase phosphorylation of mitogen-activated protein kinase (MAPK) kinase 3\/6 (MKK3\/6)-<e2>p38<\\e2> MAPK as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"paclitaxel","object":"p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In this current study, <e1>CHEMICAL<\\e1> was found to increase phosphorylation of mitogen-activated protein kinase (MAPK) kinase 3\/6 (MKK3\/6)-<e2>GENE-N<\\e2> MAPK as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells","sentence":"In this current study, paclitaxel was found to increase phosphorylation of mitogen-activated protein kinase (MAPK) kinase 3\/6 (MKK3\/6)-p38 MAPK as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells"}
{"PMID":23228696,"re_id":2,"annotated sentence":"In this current study, <e1>paclitaxel<\\e1> was found to increase phosphorylation of mitogen-activated protein kinase (MAPK) kinase 3\/6 (MKK3\/6)-p38 <e2>MAPK<\\e2> as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"paclitaxel","object":"MAPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In this current study, <e1>CHEMICAL<\\e1> was found to increase phosphorylation of mitogen-activated protein kinase (GENE-N) kinase 3\/6 (MKK3\/6)-p38 <e2>GENE-N<\\e2> as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells","sentence":"In this current study, paclitaxel was found to increase phosphorylation of mitogen-activated protein kinase (MAPK) kinase 3\/6 (MKK3\/6)-p38 MAPK as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells"}
{"PMID":23228696,"re_id":3,"annotated sentence":"In this current study, <e1>paclitaxel<\\e1> was found to increase phosphorylation of mitogen-activated protein kinase (MAPK) kinase 3\/6 (MKK3\/6)-p38 MAPK as well as protein and mRNA levels of <e2>ERCC1<\\e2> in H1650 and H1703 cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"paclitaxel","object":"ERCC1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this current study, <e1>CHEMICAL<\\e1> was found to increase phosphorylation of mitogen-activated protein kinase (MAPK) kinase 3\/6 (MKK3\/6)-p38 MAPK as well as protein and mRNA levels of <e2>GENE-Y<\\e2> in H1650 and H1703 cells","sentence":"In this current study, paclitaxel was found to increase phosphorylation of mitogen-activated protein kinase (MAPK) kinase 3\/6 (MKK3\/6)-p38 MAPK as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells"}
{"PMID":23228696,"re_id":4,"annotated sentence":"Moreover, <e1>paclitaxel<\\e1> induced <e2>ERCC1<\\e2> protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 MAPK inhibitor SB202190 or p38 knockdown with specific small interfering RNA (siRNA)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"paclitaxel","object":"ERCC1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> induced <e2>GENE-Y<\\e2> protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 MAPK inhibitor SB202190 or p38 knockdown with specific small interfering RNA (siRNA)","sentence":"Moreover, paclitaxel induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 MAPK inhibitor SB202190 or p38 knockdown with specific small interfering RNA (siRNA)"}
{"PMID":23228696,"re_id":5,"annotated sentence":"Furthermore, metformin was able to not only decrease the <e1>paclitaxel<\\e1> induced <e2>p38<\\e2> MAPK-mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"paclitaxel","object":"p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, metformin was able to not only decrease the <e1>CHEMICAL<\\e1> induced <e2>GENE-N<\\e2> MAPK-mediated ERCC1 expression, but also augment the cytotoxic effect induced by CHEMICAL","sentence":"Furthermore, metformin was able to not only decrease the paclitaxel induced p38 MAPK-mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel"}
{"PMID":23228696,"re_id":6,"annotated sentence":"Furthermore, metformin was able to not only decrease the <e1>paclitaxel<\\e1> induced p38 <e2>MAPK<\\e2> mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"paclitaxel","object":"MAPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, metformin was able to not only decrease the <e1>CHEMICAL<\\e1> induced p38 <e2>GENE-N<\\e2> mediated ERCC1 expression, but also augment the cytotoxic effect induced by CHEMICAL","sentence":"Furthermore, metformin was able to not only decrease the paclitaxel induced p38 MAPK mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel"}
{"PMID":23228696,"re_id":7,"annotated sentence":"Furthermore, metformin was able to not only decrease the <e1>paclitaxel<\\e1> induced p38 MAPK-mediated <e2>ERCC1<\\e2> expression, but also augment the cytotoxic effect induced by paclitaxel","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"paclitaxel","object":"ERCC1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, metformin was able to not only decrease the <e1>CHEMICAL<\\e1> induced p38 MAPK-mediated <e2>GENE-Y<\\e2> expression, but also augment the cytotoxic effect induced by CHEMICAL","sentence":"Furthermore, metformin was able to not only decrease the paclitaxel induced p38 MAPK-mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel"}
{"PMID":23228696,"re_id":8,"annotated sentence":"Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of <e2>p38<\\e2> activity by either a p38 MAPK inhibitor <e1>SB202190<\\e1> or p38 knockdown with specific small interfering RNA (siRNA)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SB202190","object":"p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of <e2>GENE-N<\\e2> activity by either a GENE-N MAPK inhibitor <e1>CHEMICAL<\\e1> or GENE-N knockdown with specific small interfering RNA (siRNA)","sentence":"Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 MAPK inhibitor SB202190 or p38 knockdown with specific small interfering RNA (siRNA)"}
{"PMID":23228696,"re_id":9,"annotated sentence":"Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a <e2>p38<\\e2> MAPK inhibitor <e1>SB202190<\\e1> or p38 knockdown with specific small interfering RNA (siRNA)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SB202190","object":"p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of GENE-N activity by either a <e2>GENE-N<\\e2> MAPK inhibitor <e1>CHEMICAL<\\e1> or GENE-N knockdown with specific small interfering RNA (siRNA)","sentence":"Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 MAPK inhibitor SB202190 or p38 knockdown with specific small interfering RNA (siRNA)"}
{"PMID":23228696,"re_id":10,"annotated sentence":"Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 <e2>MAPK<\\e2> inhibitor <e1>SB202190<\\e1> or p38 knockdown with specific small interfering RNA (siRNA)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SB202190","object":"MAPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1> or p38 knockdown with specific small interfering RNA (siRNA)","sentence":"Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 MAPK inhibitor SB202190 or p38 knockdown with specific small interfering RNA (siRNA)"}
{"PMID":23228696,"re_id":11,"annotated sentence":"<e1>Metformin<\\e1> mediated downregulation of <e2>p38<\\e2> mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Metformin","object":"p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> mediated downregulation of <e2>GENE-N<\\e2> mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel","sentence":"Metformin mediated downregulation of p38 mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel"}
{"PMID":23228696,"re_id":12,"annotated sentence":"<e1>Metformin<\\e1> mediated downregulation of p38 <e2>mitogen-activated protein kinase<\\e2> dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Metformin","object":"mitogen-activated protein kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> mediated downregulation of p38 <e2>GENE-N<\\e2> dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel","sentence":"Metformin mediated downregulation of p38 mitogen-activated protein kinase dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel"}
{"PMID":23228696,"re_id":13,"annotated sentence":"Furthermore, <e1>metformin<\\e1> was able to not only decrease the paclitaxel-induced <e2>p38<\\e2> MAPK-mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"metformin","object":"p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> was able to not only decrease the paclitaxel-induced <e2>GENE-N<\\e2> MAPK-mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel","sentence":"Furthermore, metformin was able to not only decrease the paclitaxel-induced p38 MAPK-mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel"}
{"PMID":23228696,"re_id":14,"annotated sentence":"Furthermore, <e1>metformin<\\e1> was able to not only decrease the paclitaxel-induced p38 <e2>MAPK<\\e2> mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"metformin","object":"MAPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> was able to not only decrease the paclitaxel-induced p38 <e2>GENE-N<\\e2> mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel","sentence":"Furthermore, metformin was able to not only decrease the paclitaxel-induced p38 MAPK mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel"}
{"PMID":23228696,"re_id":15,"annotated sentence":"Furthermore, <e1>metformin<\\e1> was able to not only decrease the paclitaxel-induced p38 MAPK-mediated <e2>ERCC1<\\e2> expression, but also augment the cytotoxic effect induced by paclitaxel","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"metformin","object":"ERCC1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> was able to not only decrease the paclitaxel-induced p38 MAPK-mediated <e2>GENE-Y<\\e2> expression, but also augment the cytotoxic effect induced by paclitaxel","sentence":"Furthermore, metformin was able to not only decrease the paclitaxel-induced p38 MAPK-mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel"}
{"PMID":23228696,"re_id":16,"annotated sentence":"Finally, expression of constitutive activate MKK6 or HA-p38 MAPK vectors in lung cancer cells was able to abrogate <e2>ERCC1<\\e2> downregulation by <e1>metformin<\\e1> and paclitaxel as well as cell viability and DNA repair capacity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"metformin","object":"ERCC1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Finally, expression of constitutive activate MKK6 or HA-p38 MAPK vectors in lung cancer cells was able to abrogate <e2>GENE-Y<\\e2> downregulation by <e1>CHEMICAL<\\e1> and paclitaxel as well as cell viability and DNA repair capacity","sentence":"Finally, expression of constitutive activate MKK6 or HA-p38 MAPK vectors in lung cancer cells was able to abrogate ERCC1 downregulation by metformin and paclitaxel as well as cell viability and DNA repair capacity"}
{"PMID":23228696,"re_id":17,"annotated sentence":"Finally, expression of constitutive activate MKK6 or HA-p38 MAPK vectors in lung cancer cells was able to abrogate <e2>ERCC1<\\e2> downregulation by metformin and <e1>paclitaxel<\\e1> as well as cell viability and DNA repair capacity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"paclitaxel","object":"ERCC1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Finally, expression of constitutive activate MKK6 or HA-p38 MAPK vectors in lung cancer cells was able to abrogate <e2>GENE-Y<\\e2> downregulation by metformin and <e1>CHEMICAL<\\e1> as well as cell viability and DNA repair capacity","sentence":"Finally, expression of constitutive activate MKK6 or HA-p38 MAPK vectors in lung cancer cells was able to abrogate ERCC1 downregulation by metformin and paclitaxel as well as cell viability and DNA repair capacity"}
{"PMID":23228696,"re_id":18,"annotated sentence":"Overall, our results suggest that inhibition of the <e2>p38<\\e2> MAPK signaling by <e1>metformin<\\e1> coupled with paclitaxel therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"metformin","object":"p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Overall, our results suggest that inhibition of the <e2>GENE-N<\\e2> MAPK signaling by <e1>CHEMICAL<\\e1> coupled with paclitaxel therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation.","sentence":"Overall, our results suggest that inhibition of the p38 MAPK signaling by metformin coupled with paclitaxel therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation."}
{"PMID":23228696,"re_id":19,"annotated sentence":"Overall, our results suggest that inhibition of the p38 <e2>MAPK<\\e2> signaling by <e1>metformin<\\e1> coupled with paclitaxel therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"metformin","object":"MAPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Overall, our results suggest that inhibition of the p38 <e2>GENE-N<\\e2> signaling by <e1>CHEMICAL<\\e1> coupled with paclitaxel therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation.","sentence":"Overall, our results suggest that inhibition of the p38 MAPK signaling by metformin coupled with paclitaxel therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation."}
{"PMID":23228697,"re_id":0,"annotated sentence":"Contrary to the hypothesis, orlistat at 1 nM inhibited <e2>CES2<\\e2> activity by 75% but no inhibition on CES1, placing CES2 one of the most sensitive targets of <e1>orlistat<\\e1>  The inhibition varied among some CES2 polymorphic variants","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"orlistat","object":"CES2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Contrary to the hypothesis, CHEMICAL at 1 nM inhibited <e2>GENE-Y<\\e2> activity by 75% but no inhibition on CES1, placing GENE-Y one of the most sensitive targets of <e1>CHEMICAL<\\e1>  The inhibition varied among some GENE-Y polymorphic variants","sentence":"Contrary to the hypothesis, orlistat at 1 nM inhibited CES2 activity by 75% but no inhibition on CES1, placing CES2 one of the most sensitive targets of orlistat  The inhibition varied among some CES2 polymorphic variants"}
{"PMID":23228697,"re_id":1,"annotated sentence":"Contrary to the hypothesis, orlistat at 1 nM inhibited CES2 activity by 75% but no inhibition on CES1, placing <e2>CES2<\\e2> one of the most sensitive targets of <e1>orlistat<\\e1>  The inhibition varied among some CES2 polymorphic variants","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"orlistat","object":"CES2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Contrary to the hypothesis, CHEMICAL at 1 nM inhibited GENE-Y activity by 75% but no inhibition on CES1, placing <e2>GENE-Y<\\e2> one of the most sensitive targets of <e1>CHEMICAL<\\e1>  The inhibition varied among some GENE-Y polymorphic variants","sentence":"Contrary to the hypothesis, orlistat at 1 nM inhibited CES2 activity by 75% but no inhibition on CES1, placing CES2 one of the most sensitive targets of orlistat  The inhibition varied among some CES2 polymorphic variants"}
{"PMID":23228697,"re_id":2,"annotated sentence":"<e1>Orlistat<\\e1> has been the most used anti-obesity drug and the mechanism of its action is to reduce lipid absorption by inhibiting gastrointestinal <e2>lipases<\\e2>  These enzymes, like carboxylesterases (CESs), structurally belong to the \u03b1\/\u03b2 hydrolase fold superfamily","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Orlistat","object":"lipases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> has been the most used anti-obesity drug and the mechanism of its action is to reduce lipid absorption by inhibiting gastrointestinal <e2>GENE-N<\\e2>  These enzymes, like carboxylesterases (CESs), structurally belong to the \u03b1\/\u03b2 hydrolase fold superfamily","sentence":"Orlistat has been the most used anti-obesity drug and the mechanism of its action is to reduce lipid absorption by inhibiting gastrointestinal lipases  These enzymes, like carboxylesterases (CESs), structurally belong to the \u03b1\/\u03b2 hydrolase fold superfamily"}
{"PMID":23228697,"re_id":3,"annotated sentence":"Inhibition of this <e2>carboxylesterase<\\e2> probably presents a major source for altered therapeutic activity of these medicines if co-administered with <e1>orlistat<\\e1>  In addition, orlistat has been linked to various types of organ toxicities, and this study provides an alternative target potentially involved in these toxicological responses.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"orlistat","object":"carboxylesterase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibition of this <e2>GENE-N<\\e2> probably presents a major source for altered therapeutic activity of these medicines if co-administered with <e1>CHEMICAL<\\e1>  In addition, CHEMICAL has been linked to various types of organ toxicities, and this study provides an alternative target potentially involved in these toxicological responses.","sentence":"Inhibition of this carboxylesterase probably presents a major source for altered therapeutic activity of these medicines if co-administered with orlistat  In addition, orlistat has been linked to various types of organ toxicities, and this study provides an alternative target potentially involved in these toxicological responses."}
{"PMID":23228697,"re_id":4,"annotated sentence":"This study was designed to test the hypothesis that <e1>orlistat<\\e1> inhibits <e2>CESs<\\e2> with higher potency toward CES1 than CES2, a carboxylesterase with little lipase activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"orlistat","object":"CESs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This study was designed to test the hypothesis that <e1>CHEMICAL<\\e1> inhibits <e2>GENE-N<\\e2> with higher potency toward CES1 than CES2, a carboxylesterase with little lipase activity","sentence":"This study was designed to test the hypothesis that orlistat inhibits CESs with higher potency toward CES1 than CES2, a carboxylesterase with little lipase activity"}
{"PMID":23228697,"re_id":5,"annotated sentence":"This study was designed to test the hypothesis that <e1>orlistat<\\e1> inhibits CESs with higher potency toward <e2>CES1<\\e2> than CES2, a carboxylesterase with little lipase activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"orlistat","object":"CES1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This study was designed to test the hypothesis that <e1>CHEMICAL<\\e1> inhibits CESs with higher potency toward <e2>GENE-Y<\\e2> than CES2, a carboxylesterase with little lipase activity","sentence":"This study was designed to test the hypothesis that orlistat inhibits CESs with higher potency toward CES1 than CES2, a carboxylesterase with little lipase activity"}
{"PMID":23228697,"re_id":6,"annotated sentence":"This study was designed to test the hypothesis that <e1>orlistat<\\e1> inhibits CESs with higher potency toward CES1 than <e2>CES2<\\e2>  a carboxylesterase with little lipase activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"orlistat","object":"CES2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This study was designed to test the hypothesis that <e1>CHEMICAL<\\e1> inhibits CESs with higher potency toward CES1 than <e2>GENE-Y<\\e2>  a carboxylesterase with little lipase activity","sentence":"This study was designed to test the hypothesis that orlistat inhibits CESs with higher potency toward CES1 than CES2  a carboxylesterase with little lipase activity"}
{"PMID":23228697,"re_id":7,"annotated sentence":"This study was designed to test the hypothesis that <e1>orlistat<\\e1> inhibits CESs with higher potency toward CES1 than CES2, a <e2>carboxylesterase<\\e2> with little lipase activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"orlistat","object":"carboxylesterase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This study was designed to test the hypothesis that <e1>CHEMICAL<\\e1> inhibits CESs with higher potency toward CES1 than CES2, a <e2>GENE-N<\\e2> with little lipase activity","sentence":"This study was designed to test the hypothesis that orlistat inhibits CESs with higher potency toward CES1 than CES2, a carboxylesterase with little lipase activity"}
{"PMID":23228697,"re_id":8,"annotated sentence":"This study was designed to test the hypothesis that <e1>orlistat<\\e1> inhibits CESs with higher potency toward CES1 than CES2, a carboxylesterase with little <e2>lipase<\\e2> activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"orlistat","object":"lipase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This study was designed to test the hypothesis that <e1>CHEMICAL<\\e1> inhibits CESs with higher potency toward CES1 than CES2, a carboxylesterase with little <e2>GENE-N<\\e2> activity","sentence":"This study was designed to test the hypothesis that orlistat inhibits CESs with higher potency toward CES1 than CES2, a carboxylesterase with little lipase activity"}
{"PMID":23229509,"re_id":0,"annotated sentence":"On stimulation by G(s), the activities of <e2>ACs<\\e2> can be further selectively modulated by other pathways to ensure precise control of intracellular <e1>cAMP<\\e1> responses to specific stimuli","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cAMP","object":"ACs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"On stimulation by G(s), the activities of <e2>GENE-N<\\e2> can be further selectively modulated by other pathways to ensure precise control of intracellular <e1>CHEMICAL<\\e1> responses to specific stimuli","sentence":"On stimulation by G(s), the activities of ACs can be further selectively modulated by other pathways to ensure precise control of intracellular cAMP responses to specific stimuli"}
{"PMID":23229509,"re_id":1,"annotated sentence":"Regulation of multiple <e2>adenylyl cyclases<\\e2> (AC) provides unique inputs to mediate the synthesis of <e1>cAMP<\\e1>  a ubiquitous second messenger that controls many aspects of cellular function","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cAMP","object":"adenylyl cyclases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Regulation of multiple <e2>GENE-N<\\e2> (AC) provides unique inputs to mediate the synthesis of <e1>CHEMICAL<\\e1>  a ubiquitous second messenger that controls many aspects of cellular function","sentence":"Regulation of multiple adenylyl cyclases (AC) provides unique inputs to mediate the synthesis of cAMP  a ubiquitous second messenger that controls many aspects of cellular function"}
{"PMID":23229509,"re_id":2,"annotated sentence":"Regulation of multiple adenylyl cyclases (<e2>AC<\\e2>  provides unique inputs to mediate the synthesis of <e1>cAMP<\\e1>  a ubiquitous second messenger that controls many aspects of cellular function","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cAMP","object":"AC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Regulation of multiple adenylyl cyclases (<e2>GENE-N<\\e2>  provides unique inputs to mediate the synthesis of <e1>CHEMICAL<\\e1>  a ubiquitous second messenger that controls many aspects of cellular function","sentence":"Regulation of multiple adenylyl cyclases (AC  provides unique inputs to mediate the synthesis of cAMP  a ubiquitous second messenger that controls many aspects of cellular function"}
{"PMID":23229510,"re_id":0,"annotated sentence":"We identified one compound, <e1>E235<\\e1> (N-(1-benzyl-piperidin-4-yl)-2-(4-fluoro-phenyl)-benzo[d]imidazo[2,1-b]thiazole-7-carboxamide), that activated the ISR and dose-dependently increased levels of <e2>ATF4<\\e2> in transformed cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"E235","object":"ATF4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We identified one compound, <e1>CHEMICAL<\\e1> (N-(1-benzyl-piperidin-4-yl)-2-(4-fluoro-phenyl)-benzo[d]imidazo[2,1-b]thiazole-7-carboxamide), that activated the ISR and dose-dependently increased levels of <e2>GENE-Y<\\e2> in transformed cells","sentence":"We identified one compound, E235 (N-(1-benzyl-piperidin-4-yl)-2-(4-fluoro-phenyl)-benzo[d]imidazo[2,1-b]thiazole-7-carboxamide), that activated the ISR and dose-dependently increased levels of ATF4 in transformed cells"}
{"PMID":23229510,"re_id":1,"annotated sentence":"We identified one compound, E235 <e1>(N-(1-benzyl-piperidin-4-yl)-2-(4-fluoro-phenyl)-benzo[d]imidazo[2,1-b]thiazole-7-carboxamide)<\\e1>  that activated the ISR and dose-dependently increased levels of <e2>ATF4<\\e2> in transformed cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"(N-(1-benzyl-piperidin-4-yl)-2-(4-fluoro-phenyl)-benzo[d]imidazo[2,1-b]thiazole-7-carboxamide)","object":"ATF4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We identified one compound, E235 <e1>CHEMICAL<\\e1>  that activated the ISR and dose-dependently increased levels of <e2>GENE-Y<\\e2> in transformed cells","sentence":"We identified one compound, E235 (N-(1-benzyl-piperidin-4-yl)-2-(4-fluoro-phenyl)-benzo[d]imidazo[2,1-b]thiazole-7-carboxamide)  that activated the ISR and dose-dependently increased levels of ATF4 in transformed cells"}
{"PMID":23229510,"re_id":2,"annotated sentence":"<e1>E235<\\e1> also activated DNA damage response signaling, resulting in increased levels of Ser15-<e2>phosphorylated p53<\\e2>  \u03b3-H2AX, and phosphorylated checkpoint kinase 2 (Chk2), although E235 does not appear to cause physical DNA damage","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"E235","object":"phosphorylated p53","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also activated DNA damage response signaling, resulting in increased levels of Ser15-<e2>GENE-Y<\\e2>  \u03b3-H2AX, and phosphorylated checkpoint kinase 2 (Chk2), although CHEMICAL does not appear to cause physical DNA damage","sentence":"E235 also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53  \u03b3-H2AX, and phosphorylated checkpoint kinase 2 (Chk2), although E235 does not appear to cause physical DNA damage"}
{"PMID":23229510,"re_id":3,"annotated sentence":"<e1>E235<\\e1> also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, <e2>\u03b3-H2AX<\\e2>  and phosphorylated checkpoint kinase 2 (Chk2), although E235 does not appear to cause physical DNA damage","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"E235","object":"\u03b3-H2AX","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, <e2>GENE-Y<\\e2>  and phosphorylated checkpoint kinase 2 (Chk2), although CHEMICAL does not appear to cause physical DNA damage","sentence":"E235 also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, \u03b3-H2AX  and phosphorylated checkpoint kinase 2 (Chk2), although E235 does not appear to cause physical DNA damage"}
{"PMID":23229510,"re_id":4,"annotated sentence":"<e1>E235<\\e1> also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, \u03b3-H2AX, and <e2>phosphorylated checkpoint kinase 2<\\e2> (Chk2), although E235 does not appear to cause physical DNA damage","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"E235","object":"phosphorylated checkpoint kinase 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, \u03b3-H2AX, and <e2>GENE-Y<\\e2> (Chk2), although CHEMICAL does not appear to cause physical DNA damage","sentence":"E235 also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, \u03b3-H2AX, and phosphorylated checkpoint kinase 2 (Chk2), although E235 does not appear to cause physical DNA damage"}
{"PMID":23229510,"re_id":5,"annotated sentence":"<e1>E235<\\e1> also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, \u03b3-H2AX, and phosphorylated checkpoint kinase 2 (<e2>Chk2<\\e2> , although E235 does not appear to cause physical DNA damage","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"E235","object":"Chk2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, \u03b3-H2AX, and phosphorylated checkpoint kinase 2 (<e2>GENE-Y<\\e2> , although CHEMICAL does not appear to cause physical DNA damage","sentence":"E235 also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, \u03b3-H2AX, and phosphorylated checkpoint kinase 2 (Chk2 , although E235 does not appear to cause physical DNA damage"}
{"PMID":23240892,"re_id":0,"annotated sentence":"Cell culture studies demonstrated that <e1>PKAA<\\e1> is capable of delivering anti-TNF (tumor necrosis factor)-\u03b1 siRNA to lipopolysaccharide (LPS)-stimulated macrophages and significantly inhibits the expression of <e2>TNF-\u03b1<\\e2>  A mouse model of acetaminophen (APAP)-induced acute liver failure was used to evaluate in vivo siRNA delivery efficacy of PKAA","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PKAA","object":"TNF-\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cell culture studies demonstrated that <e1>CHEMICAL<\\e1> is capable of delivering anti-TNF (tumor necrosis factor)-\u03b1 siRNA to lipopolysaccharide (LPS)-stimulated macrophages and significantly inhibits the expression of <e2>GENE-Y<\\e2>  A mouse model of acetaminophen (APAP)-induced acute liver failure was used to evaluate in vivo siRNA delivery efficacy of CHEMICAL","sentence":"Cell culture studies demonstrated that PKAA is capable of delivering anti-TNF (tumor necrosis factor)-\u03b1 siRNA to lipopolysaccharide (LPS)-stimulated macrophages and significantly inhibits the expression of TNF-\u03b1  A mouse model of acetaminophen (APAP)-induced acute liver failure was used to evaluate in vivo siRNA delivery efficacy of PKAA"}
{"PMID":23240892,"re_id":1,"annotated sentence":"<e1>PKAA<\\e1> anti-TNF-\u03b1 siRNA nanocomplexes significantly reduced the <e2>ALT<\\e2> (alanine transaminase) and the hepatic cellular damages in APAP-intoxicated mice","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PKAA","object":"ALT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> anti-TNF-\u03b1 siRNA nanocomplexes significantly reduced the <e2>GENE-N<\\e2> (alanine transaminase) and the hepatic cellular damages in APAP-intoxicated mice","sentence":"PKAA anti-TNF-\u03b1 siRNA nanocomplexes significantly reduced the ALT (alanine transaminase) and the hepatic cellular damages in APAP-intoxicated mice"}
{"PMID":23240892,"re_id":2,"annotated sentence":"<e1>PKAA<\\e1> anti-TNF-\u03b1 siRNA nanocomplexes significantly reduced the ALT (<e2>alanine transaminase<\\e2>  and the hepatic cellular damages in APAP-intoxicated mice","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PKAA","object":"alanine transaminase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> anti-TNF-\u03b1 siRNA nanocomplexes significantly reduced the ALT (<e2>GENE-N<\\e2>  and the hepatic cellular damages in APAP-intoxicated mice","sentence":"PKAA anti-TNF-\u03b1 siRNA nanocomplexes significantly reduced the ALT (alanine transaminase  and the hepatic cellular damages in APAP-intoxicated mice"}
{"PMID":23246481,"re_id":0,"annotated sentence":"Moreover, wogonin repressed <e1>anisomycin<\\e1> induced phosphorylation of <e2>p38<\\e2>  cav-1 and vascular permeability","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"anisomycin","object":"p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moreover, wogonin repressed <e1>CHEMICAL<\\e1> induced phosphorylation of <e2>GENE-N<\\e2>  cav-1 and vascular permeability","sentence":"Moreover, wogonin repressed anisomycin induced phosphorylation of p38  cav-1 and vascular permeability"}
{"PMID":23246481,"re_id":1,"annotated sentence":"Moreover, wogonin repressed <e1>anisomycin<\\e1> induced phosphorylation of p38, <e2>cav-1<\\e2> and vascular permeability","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"anisomycin","object":"cav-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, wogonin repressed <e1>CHEMICAL<\\e1> induced phosphorylation of p38, <e2>GENE-Y<\\e2> and vascular permeability","sentence":"Moreover, wogonin repressed anisomycin induced phosphorylation of p38, cav-1 and vascular permeability"}
{"PMID":23246481,"re_id":2,"annotated sentence":"These results suggested that wogonin could inhibit <e1>H2O2<\\e1> induced vascular permeability by downregulating the phosphorylation of <e2>cav-1<\\e2>  and that it might have a therapeutic potential for the diseases associated with the development of both oxidant and vascular permeability.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"H2O2","object":"cav-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggested that wogonin could inhibit <e1>CHEMICAL<\\e1> induced vascular permeability by downregulating the phosphorylation of <e2>GENE-Y<\\e2>  and that it might have a therapeutic potential for the diseases associated with the development of both oxidant and vascular permeability.","sentence":"These results suggested that wogonin could inhibit H2O2 induced vascular permeability by downregulating the phosphorylation of cav-1  and that it might have a therapeutic potential for the diseases associated with the development of both oxidant and vascular permeability."}
{"PMID":23246481,"re_id":3,"annotated sentence":"Wogonin inhibits <e1>H2O2<\\e1> induced vascular permeability through suppressing the phosphorylation of <e2>caveolin-1<\\e2>  Wogonin, a naturally occurring monoflavonoid extracted from the root of Scutellaria baicalensis Georgi, has been reported for its anti-oxidant activity","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"H2O2","object":"caveolin-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Wogonin inhibits <e1>CHEMICAL<\\e1> induced vascular permeability through suppressing the phosphorylation of <e2>GENE-Y<\\e2>  Wogonin, a naturally occurring monoflavonoid extracted from the root of Scutellaria baicalensis Georgi, has been reported for its anti-oxidant activity","sentence":"Wogonin inhibits H2O2 induced vascular permeability through suppressing the phosphorylation of caveolin-1  Wogonin, a naturally occurring monoflavonoid extracted from the root of Scutellaria baicalensis Georgi, has been reported for its anti-oxidant activity"}
{"PMID":23246481,"re_id":4,"annotated sentence":"We found that wogonin can suppress the <e1>H2O2<\\e1> stimulated <e2>actin<\\e2> remodeling and albumin uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"H2O2","object":"actin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We found that wogonin can suppress the <e1>CHEMICAL<\\e1> stimulated <e2>GENE-N<\\e2> remodeling and albumin uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231","sentence":"We found that wogonin can suppress the H2O2 stimulated actin remodeling and albumin uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231"}
{"PMID":23246481,"re_id":5,"annotated sentence":"We found that wogonin can suppress the <e1>H2O2<\\e1> stimulated actin remodeling and <e2>albumin<\\e2> uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"H2O2","object":"albumin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that wogonin can suppress the <e1>CHEMICAL<\\e1> stimulated actin remodeling and <e2>GENE-Y<\\e2> uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231","sentence":"We found that wogonin can suppress the H2O2 stimulated actin remodeling and albumin uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231"}
{"PMID":23246481,"re_id":6,"annotated sentence":"The mechanism revealed that wogonin inhibited <e1>H2O2<\\e1> induced phosphorylation of <e2>caveolin-1<\\e2> (cav-1) associating with the suppression of stabilization of VE-cadherin and \u03b2-catenin","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"H2O2","object":"caveolin-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mechanism revealed that wogonin inhibited <e1>CHEMICAL<\\e1> induced phosphorylation of <e2>GENE-Y<\\e2> (cav-1) associating with the suppression of stabilization of VE-cadherin and \u03b2-catenin","sentence":"The mechanism revealed that wogonin inhibited H2O2 induced phosphorylation of caveolin-1 (cav-1) associating with the suppression of stabilization of VE-cadherin and \u03b2-catenin"}
{"PMID":23246481,"re_id":7,"annotated sentence":"The mechanism revealed that wogonin inhibited <e1>H2O2<\\e1> induced phosphorylation of caveolin-1 (<e2>cav-1<\\e2>  associating with the suppression of stabilization of VE-cadherin and \u03b2-catenin","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"H2O2","object":"cav-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mechanism revealed that wogonin inhibited <e1>CHEMICAL<\\e1> induced phosphorylation of caveolin-1 (<e2>GENE-Y<\\e2>  associating with the suppression of stabilization of VE-cadherin and \u03b2-catenin","sentence":"The mechanism revealed that wogonin inhibited H2O2 induced phosphorylation of caveolin-1 (cav-1  associating with the suppression of stabilization of VE-cadherin and \u03b2-catenin"}
{"PMID":23246481,"re_id":8,"annotated sentence":"Moreover, <e1>wogonin<\\e1> repressed anisomycin-induced phosphorylation of <e2>p38<\\e2>  cav-1 and vascular permeability","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"wogonin","object":"p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> repressed anisomycin-induced phosphorylation of <e2>GENE-N<\\e2>  cav-1 and vascular permeability","sentence":"Moreover, wogonin repressed anisomycin-induced phosphorylation of p38  cav-1 and vascular permeability"}
{"PMID":23246481,"re_id":9,"annotated sentence":"Moreover, <e1>wogonin<\\e1> repressed anisomycin-induced phosphorylation of p38, <e2>cav-1<\\e2> and vascular permeability","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"wogonin","object":"cav-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> repressed anisomycin-induced phosphorylation of p38, <e2>GENE-Y<\\e2> and vascular permeability","sentence":"Moreover, wogonin repressed anisomycin-induced phosphorylation of p38, cav-1 and vascular permeability"}
{"PMID":23246481,"re_id":10,"annotated sentence":"These results suggested that <e1>wogonin<\\e1> could inhibit H2O2-induced vascular permeability by downregulating the phosphorylation of <e2>cav-1<\\e2>  and that it might have a therapeutic potential for the diseases associated with the development of both oxidant and vascular permeability.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"wogonin","object":"cav-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggested that <e1>CHEMICAL<\\e1> could inhibit H2O2-induced vascular permeability by downregulating the phosphorylation of <e2>GENE-Y<\\e2>  and that it might have a therapeutic potential for the diseases associated with the development of both oxidant and vascular permeability.","sentence":"These results suggested that wogonin could inhibit H2O2-induced vascular permeability by downregulating the phosphorylation of cav-1  and that it might have a therapeutic potential for the diseases associated with the development of both oxidant and vascular permeability."}
{"PMID":23246481,"re_id":11,"annotated sentence":"<e1>Wogonin<\\e1> inhibits H2O2-induced vascular permeability through suppressing the phosphorylation of <e2>caveolin-1<\\e2>  Wogonin, a naturally occurring monoflavonoid extracted from the root of Scutellaria baicalensis Georgi, has been reported for its anti-oxidant activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Wogonin","object":"caveolin-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits H2O2-induced vascular permeability through suppressing the phosphorylation of <e2>GENE-Y<\\e2>  CHEMICAL, a naturally occurring monoflavonoid extracted from the root of Scutellaria baicalensis Georgi, has been reported for its anti-oxidant activity","sentence":"Wogonin inhibits H2O2-induced vascular permeability through suppressing the phosphorylation of caveolin-1  Wogonin, a naturally occurring monoflavonoid extracted from the root of Scutellaria baicalensis Georgi, has been reported for its anti-oxidant activity"}
{"PMID":23246481,"re_id":12,"annotated sentence":"We found that <e1>wogonin<\\e1> can suppress the H2O2-stimulated <e2>actin<\\e2> remodeling and albumin uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"wogonin","object":"actin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We found that <e1>CHEMICAL<\\e1> can suppress the H2O2-stimulated <e2>GENE-N<\\e2> remodeling and albumin uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231","sentence":"We found that wogonin can suppress the H2O2-stimulated actin remodeling and albumin uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231"}
{"PMID":23246481,"re_id":13,"annotated sentence":"We found that <e1>wogonin<\\e1> can suppress the H2O2-stimulated actin remodeling and <e2>albumin<\\e2> uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"wogonin","object":"albumin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that <e1>CHEMICAL<\\e1> can suppress the H2O2-stimulated actin remodeling and <e2>GENE-Y<\\e2> uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231","sentence":"We found that wogonin can suppress the H2O2-stimulated actin remodeling and albumin uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231"}
{"PMID":23246481,"re_id":14,"annotated sentence":"The mechanism revealed that <e1>wogonin<\\e1> inhibited H2O2-induced phosphorylation of <e2>caveolin-1<\\e2> (cav-1) associating with the suppression of stabilization of VE-cadherin and \u03b2-catenin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"wogonin","object":"caveolin-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mechanism revealed that <e1>CHEMICAL<\\e1> inhibited H2O2-induced phosphorylation of <e2>GENE-Y<\\e2> (cav-1) associating with the suppression of stabilization of VE-cadherin and \u03b2-catenin","sentence":"The mechanism revealed that wogonin inhibited H2O2-induced phosphorylation of caveolin-1 (cav-1) associating with the suppression of stabilization of VE-cadherin and \u03b2-catenin"}
{"PMID":23246481,"re_id":15,"annotated sentence":"The mechanism revealed that <e1>wogonin<\\e1> inhibited H2O2-induced phosphorylation of caveolin-1 (<e2>cav-1<\\e2>  associating with the suppression of stabilization of VE-cadherin and \u03b2-catenin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"wogonin","object":"cav-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mechanism revealed that <e1>CHEMICAL<\\e1> inhibited H2O2-induced phosphorylation of caveolin-1 (<e2>GENE-Y<\\e2>  associating with the suppression of stabilization of VE-cadherin and \u03b2-catenin","sentence":"The mechanism revealed that wogonin inhibited H2O2-induced phosphorylation of caveolin-1 (cav-1  associating with the suppression of stabilization of VE-cadherin and \u03b2-catenin"}
{"PMID":23246481,"re_id":16,"annotated sentence":"The mechanism revealed that <e1>wogonin<\\e1> inhibited H2O2-induced phosphorylation of caveolin-1 (cav-1) associating with the suppression of stabilization of <e2>VE-cadherin<\\e2> and \u03b2-catenin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"wogonin","object":"VE-cadherin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mechanism revealed that <e1>CHEMICAL<\\e1> inhibited H2O2-induced phosphorylation of caveolin-1 (cav-1) associating with the suppression of stabilization of <e2>GENE-Y<\\e2> and \u03b2-catenin","sentence":"The mechanism revealed that wogonin inhibited H2O2-induced phosphorylation of caveolin-1 (cav-1) associating with the suppression of stabilization of VE-cadherin and \u03b2-catenin"}
{"PMID":23246481,"re_id":17,"annotated sentence":"The mechanism revealed that <e1>wogonin<\\e1> inhibited H2O2-induced phosphorylation of caveolin-1 (cav-1) associating with the suppression of stabilization of VE-cadherin and <e2>\u03b2-catenin<\\e2>  Moreover, wogonin repressed anisomycin-induced phosphorylation of p38, cav-1 and vascular permeability","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"wogonin","object":"\u03b2-catenin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mechanism revealed that <e1>CHEMICAL<\\e1> inhibited H2O2-induced phosphorylation of caveolin-1 (cav-1) associating with the suppression of stabilization of VE-cadherin and <e2>GENE-Y<\\e2>  Moreover, CHEMICAL repressed anisomycin-induced phosphorylation of p38, cav-1 and vascular permeability","sentence":"The mechanism revealed that wogonin inhibited H2O2-induced phosphorylation of caveolin-1 (cav-1) associating with the suppression of stabilization of VE-cadherin and \u03b2-catenin  Moreover, wogonin repressed anisomycin-induced phosphorylation of p38, cav-1 and vascular permeability"}
{"PMID":23253441,"re_id":0,"annotated sentence":"In an attempt to further improve overall profiles of the oxadiazine series of GSMs, in particular the hERG activity, conformational modifications of the core structure resulted in the identification of fused <e1>oxadiazepines<\\e1> such as 7i which had an improved <e2>hERG<\\e2> inhibition profile and was a highly efficacious GSM in vitro and in vivo in rats","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"oxadiazepines","object":"hERG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In an attempt to further improve overall profiles of the oxadiazine series of GSMs, in particular the GENE-Y activity, conformational modifications of the core structure resulted in the identification of fused <e1>CHEMICAL<\\e1> such as 7i which had an improved <e2>GENE-Y<\\e2> inhibition profile and was a highly efficacious GSM in vitro and in vivo in rats","sentence":"In an attempt to further improve overall profiles of the oxadiazine series of GSMs, in particular the hERG activity, conformational modifications of the core structure resulted in the identification of fused oxadiazepines such as 7i which had an improved hERG inhibition profile and was a highly efficacious GSM in vitro and in vivo in rats"}
{"PMID":23254198,"re_id":0,"annotated sentence":"Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of <e2>MAPK<\\e2>  Akt, and p70S6K and up-regulation of antiapoptotic factors survivin, Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by <e1>BZA<\\e1>  Gene expression studies demonstrated that CE and E(2) were equally potent on expression of cMyc, pS2, and WNT1 inducible signaling pathway protein 2, whereas the stimulatory effects of CE on progesterone receptor and amphiregulin expression were weaker than E(2)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BZA","object":"MAPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of <e2>GENE-N<\\e2>  Akt, and p70S6K and up-regulation of antiapoptotic factors survivin, Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by <e1>CHEMICAL<\\e1>  Gene expression studies demonstrated that CE and E(2) were equally potent on expression of cMyc, pS2, and WNT1 inducible signaling pathway protein 2, whereas the stimulatory effects of CE on progesterone receptor and amphiregulin expression were weaker than E(2)","sentence":"Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK  Akt, and p70S6K and up-regulation of antiapoptotic factors survivin, Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by BZA  Gene expression studies demonstrated that CE and E(2) were equally potent on expression of cMyc, pS2, and WNT1 inducible signaling pathway protein 2, whereas the stimulatory effects of CE on progesterone receptor and amphiregulin expression were weaker than E(2)"}
{"PMID":23254198,"re_id":1,"annotated sentence":"Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, <e2>Akt<\\e2>  and p70S6K and up-regulation of antiapoptotic factors survivin, Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by <e1>BZA<\\e1>  Gene expression studies demonstrated that CE and E(2) were equally potent on expression of cMyc, pS2, and WNT1 inducible signaling pathway protein 2, whereas the stimulatory effects of CE on progesterone receptor and amphiregulin expression were weaker than E(2)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BZA","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, <e2>GENE-N<\\e2>  and p70S6K and up-regulation of antiapoptotic factors survivin, Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by <e1>CHEMICAL<\\e1>  Gene expression studies demonstrated that CE and E(2) were equally potent on expression of cMyc, pS2, and WNT1 inducible signaling pathway protein 2, whereas the stimulatory effects of CE on progesterone receptor and amphiregulin expression were weaker than E(2)","sentence":"Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt  and p70S6K and up-regulation of antiapoptotic factors survivin, Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by BZA  Gene expression studies demonstrated that CE and E(2) were equally potent on expression of cMyc, pS2, and WNT1 inducible signaling pathway protein 2, whereas the stimulatory effects of CE on progesterone receptor and amphiregulin expression were weaker than E(2)"}
{"PMID":23254198,"re_id":2,"annotated sentence":"Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and <e2>p70S6K<\\e2> and up-regulation of antiapoptotic factors survivin, Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by <e1>BZA<\\e1>  Gene expression studies demonstrated that CE and E(2) were equally potent on expression of cMyc, pS2, and WNT1 inducible signaling pathway protein 2, whereas the stimulatory effects of CE on progesterone receptor and amphiregulin expression were weaker than E(2)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BZA","object":"p70S6K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and <e2>GENE-N<\\e2> and up-regulation of antiapoptotic factors survivin, Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by <e1>CHEMICAL<\\e1>  Gene expression studies demonstrated that CE and E(2) were equally potent on expression of cMyc, pS2, and WNT1 inducible signaling pathway protein 2, whereas the stimulatory effects of CE on progesterone receptor and amphiregulin expression were weaker than E(2)","sentence":"Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and p70S6K and up-regulation of antiapoptotic factors survivin, Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by BZA  Gene expression studies demonstrated that CE and E(2) were equally potent on expression of cMyc, pS2, and WNT1 inducible signaling pathway protein 2, whereas the stimulatory effects of CE on progesterone receptor and amphiregulin expression were weaker than E(2)"}
{"PMID":23254198,"re_id":3,"annotated sentence":"Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and p70S6K and up-regulation of antiapoptotic factors <e2>survivin<\\e2>  Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by <e1>BZA<\\e1>  Gene expression studies demonstrated that CE and E(2) were equally potent on expression of cMyc, pS2, and WNT1 inducible signaling pathway protein 2, whereas the stimulatory effects of CE on progesterone receptor and amphiregulin expression were weaker than E(2)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BZA","object":"survivin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and p70S6K and up-regulation of antiapoptotic factors <e2>GENE-Y<\\e2>  Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by <e1>CHEMICAL<\\e1>  Gene expression studies demonstrated that CE and E(2) were equally potent on expression of cMyc, pS2, and WNT1 inducible signaling pathway protein 2, whereas the stimulatory effects of CE on progesterone receptor and amphiregulin expression were weaker than E(2)","sentence":"Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and p70S6K and up-regulation of antiapoptotic factors survivin  Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by BZA  Gene expression studies demonstrated that CE and E(2) were equally potent on expression of cMyc, pS2, and WNT1 inducible signaling pathway protein 2, whereas the stimulatory effects of CE on progesterone receptor and amphiregulin expression were weaker than E(2)"}
{"PMID":23254198,"re_id":4,"annotated sentence":"Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and p70S6K and up-regulation of antiapoptotic factors survivin, <e2>Bcl-2<\\e2>  and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by <e1>BZA<\\e1>  Gene expression studies demonstrated that CE and E(2) were equally potent on expression of cMyc, pS2, and WNT1 inducible signaling pathway protein 2, whereas the stimulatory effects of CE on progesterone receptor and amphiregulin expression were weaker than E(2)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BZA","object":"Bcl-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and p70S6K and up-regulation of antiapoptotic factors survivin, <e2>GENE-Y<\\e2>  and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by <e1>CHEMICAL<\\e1>  Gene expression studies demonstrated that CE and E(2) were equally potent on expression of cMyc, pS2, and WNT1 inducible signaling pathway protein 2, whereas the stimulatory effects of CE on progesterone receptor and amphiregulin expression were weaker than E(2)","sentence":"Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and p70S6K and up-regulation of antiapoptotic factors survivin, Bcl-2  and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by BZA  Gene expression studies demonstrated that CE and E(2) were equally potent on expression of cMyc, pS2, and WNT1 inducible signaling pathway protein 2, whereas the stimulatory effects of CE on progesterone receptor and amphiregulin expression were weaker than E(2)"}
{"PMID":23254198,"re_id":5,"annotated sentence":"Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and p70S6K and up-regulation of antiapoptotic factors survivin, Bcl-2, and <e2>X-linked inhibitor of apoptosis protein<\\e2>  These effects could be completely blocked by <e1>BZA<\\e1>  Gene expression studies demonstrated that CE and E(2) were equally potent on expression of cMyc, pS2, and WNT1 inducible signaling pathway protein 2, whereas the stimulatory effects of CE on progesterone receptor and amphiregulin expression were weaker than E(2)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BZA","object":"X-linked inhibitor of apoptosis protein","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and p70S6K and up-regulation of antiapoptotic factors survivin, Bcl-2, and <e2>GENE-Y<\\e2>  These effects could be completely blocked by <e1>CHEMICAL<\\e1>  Gene expression studies demonstrated that CE and E(2) were equally potent on expression of cMyc, pS2, and WNT1 inducible signaling pathway protein 2, whereas the stimulatory effects of CE on progesterone receptor and amphiregulin expression were weaker than E(2)","sentence":"Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and p70S6K and up-regulation of antiapoptotic factors survivin, Bcl-2, and X-linked inhibitor of apoptosis protein  These effects could be completely blocked by BZA  Gene expression studies demonstrated that CE and E(2) were equally potent on expression of cMyc, pS2, and WNT1 inducible signaling pathway protein 2, whereas the stimulatory effects of CE on progesterone receptor and amphiregulin expression were weaker than E(2)"}
{"PMID":23261524,"re_id":0,"annotated sentence":"The reduction of BiFC signal mediated by <e1>nutlin-3<\\e1> was correlated with an increase in <e2>Puma<\\e2> transactivation, PARP cleavage, and cell death","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"nutlin-3","object":"Puma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The reduction of BiFC signal mediated by <e1>CHEMICAL<\\e1> was correlated with an increase in <e2>GENE-Y<\\e2> transactivation, PARP cleavage, and cell death","sentence":"The reduction of BiFC signal mediated by nutlin-3 was correlated with an increase in Puma transactivation, PARP cleavage, and cell death"}
{"PMID":23261524,"re_id":1,"annotated sentence":"The reduction of BiFC signal mediated by <e1>nutlin-3<\\e1> was correlated with an increase in Puma transactivation, <e2>PARP<\\e2> cleavage, and cell death","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"nutlin-3","object":"PARP","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The reduction of BiFC signal mediated by <e1>CHEMICAL<\\e1> was correlated with an increase in Puma transactivation, <e2>GENE-N<\\e2> cleavage, and cell death","sentence":"The reduction of BiFC signal mediated by nutlin-3 was correlated with an increase in Puma transactivation, PARP cleavage, and cell death"}
{"PMID":23261524,"re_id":2,"annotated sentence":"We used <e1>nutlin-3<\\e1>  a well-known disruptor of <e2>p53<\\e2> Mdm2 interaction, to validate the specificity of the assay","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"nutlin-3","object":"p53","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We used <e1>CHEMICAL<\\e1>  a well-known disruptor of <e2>GENE-Y<\\e2> Mdm2 interaction, to validate the specificity of the assay","sentence":"We used nutlin-3  a well-known disruptor of p53 Mdm2 interaction, to validate the specificity of the assay"}
{"PMID":23261524,"re_id":3,"annotated sentence":"We used <e1>nutlin-3<\\e1>  a well-known disruptor of p53-<e2>Mdm2<\\e2> interaction, to validate the specificity of the assay","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"nutlin-3","object":"Mdm2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We used <e1>CHEMICAL<\\e1>  a well-known disruptor of p53-<e2>GENE-Y<\\e2> interaction, to validate the specificity of the assay","sentence":"We used nutlin-3  a well-known disruptor of p53-Mdm2 interaction, to validate the specificity of the assay"}
{"PMID":23261589,"re_id":0,"annotated sentence":"<e1>Sal<\\e1> toxicity coincided with reduced <e2>pAkt<\\e2> level and its downstream effectors: pCREB, pGSK-3\u03b2, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K\/Akt signaling","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sal","object":"pAkt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> toxicity coincided with reduced <e2>GENE-N<\\e2> level and its downstream effectors: pCREB, pGSK-3\u03b2, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K\/Akt signaling","sentence":"Sal toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3\u03b2, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K\/Akt signaling"}
{"PMID":23261589,"re_id":1,"annotated sentence":"<e1>Sal<\\e1> toxicity coincided with reduced pAkt level and its downstream effectors: <e2>pCREB<\\e2>  pGSK-3\u03b2, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K\/Akt signaling","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sal","object":"pCREB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> toxicity coincided with reduced pAkt level and its downstream effectors: <e2>GENE-N<\\e2>  pGSK-3\u03b2, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K\/Akt signaling","sentence":"Sal toxicity coincided with reduced pAkt level and its downstream effectors: pCREB  pGSK-3\u03b2, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K\/Akt signaling"}
{"PMID":23261589,"re_id":2,"annotated sentence":"<e1>Sal<\\e1> toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, <e2>pGSK-3\u03b2<\\e2>  Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K\/Akt signaling","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sal","object":"pGSK-3\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, <e2>GENE-Y<\\e2>  Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K\/Akt signaling","sentence":"Sal toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3\u03b2  Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K\/Akt signaling"}
{"PMID":23261589,"re_id":3,"annotated sentence":"<e1>Sal<\\e1> toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3\u03b2, <e2>Bcl-2<\\e2> and neurotrophins GDNF, BDNF suggesting repressed PI3K\/Akt signaling","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sal","object":"Bcl-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3\u03b2, <e2>GENE-Y<\\e2> and neurotrophins GDNF, BDNF suggesting repressed PI3K\/Akt signaling","sentence":"Sal toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3\u03b2, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K\/Akt signaling"}
{"PMID":23261589,"re_id":4,"annotated sentence":"<e1>Sal<\\e1> toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3\u03b2, Bcl-2 and <e2>neurotrophins<\\e2> GDNF, BDNF suggesting repressed PI3K\/Akt signaling","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sal","object":"neurotrophins","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3\u03b2, Bcl-2 and <e2>GENE-N<\\e2> GDNF, BDNF suggesting repressed PI3K\/Akt signaling","sentence":"Sal toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3\u03b2, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K\/Akt signaling"}
{"PMID":23261589,"re_id":5,"annotated sentence":"<e1>Sal<\\e1> toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3\u03b2, Bcl-2 and neurotrophins <e2>GDNF<\\e2>  BDNF suggesting repressed PI3K\/Akt signaling","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sal","object":"GDNF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3\u03b2, Bcl-2 and neurotrophins <e2>GENE-Y<\\e2>  BDNF suggesting repressed PI3K\/Akt signaling","sentence":"Sal toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3\u03b2, Bcl-2 and neurotrophins GDNF  BDNF suggesting repressed PI3K\/Akt signaling"}
{"PMID":23261589,"re_id":6,"annotated sentence":"<e1>Sal<\\e1> toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3\u03b2, Bcl-2 and neurotrophins GDNF, <e2>BDNF<\\e2> suggesting repressed PI3K\/Akt signaling","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sal","object":"BDNF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3\u03b2, Bcl-2 and neurotrophins GDNF, <e2>GENE-Y<\\e2> suggesting repressed PI3K\/Akt signaling","sentence":"Sal toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3\u03b2, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K\/Akt signaling"}
{"PMID":23261589,"re_id":7,"annotated sentence":"<e1>Sal<\\e1> toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3\u03b2, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed <e2>PI3K<\\e2> Akt signaling","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sal","object":"PI3K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3\u03b2, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed <e2>GENE-N<\\e2> Akt signaling","sentence":"Sal toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3\u03b2, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K Akt signaling"}
{"PMID":23261589,"re_id":8,"annotated sentence":"<e1>Sal<\\e1> toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3\u03b2, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K\/<e2>Akt<\\e2> signaling","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sal","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> toxicity coincided with reduced pGENE-N level and its downstream effectors: pCREB, pGSK-3\u03b2, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K\/<e2>GENE-N<\\e2> signaling","sentence":"Sal toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3\u03b2, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K\/Akt signaling"}
{"PMID":23261589,"re_id":9,"annotated sentence":"This was confirmed on adding <e1>LY294002<\\e1> the <e2>PI3K<\\e2> inhibitor which abolished the protection","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"LY294002","object":"PI3K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This was confirmed on adding <e1>CHEMICAL<\\e1> the <e2>GENE-N<\\e2> inhibitor which abolished the protection","sentence":"This was confirmed on adding LY294002 the PI3K inhibitor which abolished the protection"}
{"PMID":23261676,"re_id":0,"annotated sentence":"<e1>Isoproterenol<\\e1> induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities\/levels of heart mitochondrial <e2>glutathione peroxidase<\\e2>  glutathione reductase, reduced glutathione, isocitrate, succinate, malate, \u03b1-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Isoproterenol","object":"glutathione peroxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities\/levels of heart mitochondrial <e2>GENE-N<\\e2>  glutathione reductase, reduced glutathione, isocitrate, succinate, malate, \u03b1-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate","sentence":"Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities\/levels of heart mitochondrial glutathione peroxidase  glutathione reductase, reduced glutathione, isocitrate, succinate, malate, \u03b1-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate"}
{"PMID":23261676,"re_id":1,"annotated sentence":"<e1>Isoproterenol<\\e1> induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities\/levels of heart mitochondrial glutathione peroxidase, <e2>glutathione reductase<\\e2>  reduced glutathione, isocitrate, succinate, malate, \u03b1-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Isoproterenol","object":"glutathione reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities\/levels of heart mitochondrial glutathione peroxidase, <e2>GENE-Y<\\e2>  reduced glutathione, isocitrate, succinate, malate, \u03b1-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate","sentence":"Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities\/levels of heart mitochondrial glutathione peroxidase, glutathione reductase  reduced glutathione, isocitrate, succinate, malate, \u03b1-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate"}
{"PMID":23261676,"re_id":2,"annotated sentence":"<e1>Isoproterenol<\\e1> induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities\/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, \u03b1-ketoglutarate and <e2>NADH-dehydrogenases<\\e2>  cytochrome-C-oxidase and adenosine triphosphate","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Isoproterenol","object":"NADH-dehydrogenases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities\/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, \u03b1-ketoglutarate and <e2>GENE-N<\\e2>  cytochrome-C-oxidase and adenosine triphosphate","sentence":"Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities\/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, \u03b1-ketoglutarate and NADH-dehydrogenases  cytochrome-C-oxidase and adenosine triphosphate"}
{"PMID":23261676,"re_id":3,"annotated sentence":"<e1>Isoproterenol<\\e1> induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities\/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, \u03b1-ketoglutarate and NADH-dehydrogenases, <e2>cytochrome-C-oxidase<\\e2> and adenosine triphosphate","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Isoproterenol","object":"cytochrome-C-oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities\/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, \u03b1-ketoglutarate and NADH-dehydrogenases, <e2>GENE-N<\\e2> and adenosine triphosphate","sentence":"Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities\/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, \u03b1-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate"}
{"PMID":23261757,"re_id":0,"annotated sentence":"Increased urinary excretion of <e2>albumin<\\e2>  hemopexin, transferrin and VDBP correlates with chronic sensitization to <e1>gentamicin<\\e1> nephrotoxicity in rats","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"gentamicin","object":"albumin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Increased urinary excretion of <e2>GENE-N<\\e2>  hemopexin, transferrin and VDBP correlates with chronic sensitization to <e1>CHEMICAL<\\e1> nephrotoxicity in rats","sentence":"Increased urinary excretion of albumin  hemopexin, transferrin and VDBP correlates with chronic sensitization to gentamicin nephrotoxicity in rats"}
{"PMID":23261757,"re_id":1,"annotated sentence":"Increased urinary excretion of albumin, <e2>hemopexin<\\e2>  transferrin and VDBP correlates with chronic sensitization to <e1>gentamicin<\\e1> nephrotoxicity in rats","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"gentamicin","object":"hemopexin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Increased urinary excretion of albumin, <e2>GENE-Y<\\e2>  transferrin and VDBP correlates with chronic sensitization to <e1>CHEMICAL<\\e1> nephrotoxicity in rats","sentence":"Increased urinary excretion of albumin, hemopexin  transferrin and VDBP correlates with chronic sensitization to gentamicin nephrotoxicity in rats"}
{"PMID":23261757,"re_id":2,"annotated sentence":"Increased urinary excretion of albumin, hemopexin, <e2>transferrin<\\e2> and VDBP correlates with chronic sensitization to <e1>gentamicin<\\e1> nephrotoxicity in rats","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"gentamicin","object":"transferrin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Increased urinary excretion of albumin, hemopexin, <e2>GENE-Y<\\e2> and VDBP correlates with chronic sensitization to <e1>CHEMICAL<\\e1> nephrotoxicity in rats","sentence":"Increased urinary excretion of albumin, hemopexin, transferrin and VDBP correlates with chronic sensitization to gentamicin nephrotoxicity in rats"}
{"PMID":23261757,"re_id":3,"annotated sentence":"Increased urinary excretion of albumin, hemopexin, transferrin and <e2>VDBP<\\e2> correlates with chronic sensitization to <e1>gentamicin<\\e1> nephrotoxicity in rats","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"gentamicin","object":"VDBP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Increased urinary excretion of albumin, hemopexin, transferrin and <e2>GENE-Y<\\e2> correlates with chronic sensitization to <e1>CHEMICAL<\\e1> nephrotoxicity in rats","sentence":"Increased urinary excretion of albumin, hemopexin, transferrin and VDBP correlates with chronic sensitization to gentamicin nephrotoxicity in rats"}
{"PMID":23265905,"re_id":0,"annotated sentence":"Design and synthesis of novel <e1>2-methyl-4,5-substitutedbenzo[f]-3,3a,4,5-tetrahydro-pyrazolo[1,5-d][1,4]oxazepin-8(7H)-one<\\e1> derivatives as <e2>telomerase<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"2-methyl-4,5-substitutedbenzo[f]-3,3a,4,5-tetrahydro-pyrazolo[1,5-d][1,4]oxazepin-8(7H)-one","object":"telomerase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Design and synthesis of novel <e1>CHEMICAL<\\e1> derivatives as <e2>GENE-N<\\e2> inhibitors","sentence":"Design and synthesis of novel 2-methyl-4,5-substitutedbenzo[f]-3,3a,4,5-tetrahydro-pyrazolo[1,5-d][1,4]oxazepin-8(7H)-one derivatives as telomerase inhibitors"}
{"PMID":23266270,"re_id":0,"annotated sentence":"<e1>DPEP<\\e1> inhibited LPS-induced phosphorylation of <e2>ERK<\\e2>  JNK, and p38","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DPEP","object":"ERK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> inhibited LPS-induced phosphorylation of <e2>GENE-N<\\e2>  JNK, and p38","sentence":"DPEP inhibited LPS-induced phosphorylation of ERK  JNK, and p38"}
{"PMID":23266270,"re_id":1,"annotated sentence":"<e1>DPEP<\\e1> inhibited LPS-induced phosphorylation of ERK, <e2>JNK<\\e2>  and p38","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DPEP","object":"JNK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> inhibited LPS-induced phosphorylation of ERK, <e2>GENE-N<\\e2>  and p38","sentence":"DPEP inhibited LPS-induced phosphorylation of ERK, JNK  and p38"}
{"PMID":23266270,"re_id":2,"annotated sentence":"<e1>DPEP<\\e1> inhibited LPS-induced phosphorylation of ERK, JNK, and <e2>p38<\\e2>  Furthermore, DPEP inhibited the LPS-induced phosphorylation of inhibitor \u03baB (I\u03baB)-\u03b1 and NF-\u03baB p50","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DPEP","object":"p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> inhibited LPS-induced phosphorylation of ERK, JNK, and <e2>GENE-N<\\e2>  Furthermore, CHEMICAL inhibited the LPS-induced phosphorylation of inhibitor \u03baB (I\u03baB)-\u03b1 and NF-\u03baB p50","sentence":"DPEP inhibited LPS-induced phosphorylation of ERK, JNK, and p38  Furthermore, DPEP inhibited the LPS-induced phosphorylation of inhibitor \u03baB (I\u03baB)-\u03b1 and NF-\u03baB p50"}
{"PMID":23266270,"re_id":3,"annotated sentence":"Furthermore, <e1>DPEP<\\e1> inhibited the LPS-induced phosphorylation of inhibitor \u03baB (I\u03baB)-\u03b1 and NF-\u03baB <e2>p50<\\e2>  Taken together, the results of this study demonstrate that DPEP inhibits LPS-stimulated inflammation by blocking the NF-\u03baB and MAPK pathways in macrophages.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DPEP","object":"p50","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> inhibited the LPS-induced phosphorylation of inhibitor \u03baB (I\u03baB)-\u03b1 and NF-\u03baB <e2>GENE-Y<\\e2>  Taken together, the results of this study demonstrate that CHEMICAL inhibits LPS-stimulated inflammation by blocking the NF-\u03baB and MAPK pathways in macrophages.","sentence":"Furthermore, DPEP inhibited the LPS-induced phosphorylation of inhibitor \u03baB (I\u03baB)-\u03b1 and NF-\u03baB p50  Taken together, the results of this study demonstrate that DPEP inhibits LPS-stimulated inflammation by blocking the NF-\u03baB and MAPK pathways in macrophages."}
{"PMID":23266270,"re_id":4,"annotated sentence":"Furthermore, <e1>DPEP<\\e1> inhibited the LPS-induced phosphorylation of <e2>inhibitor \u03baB (I\u03baB)-\u03b1<\\e2> and NF-\u03baB p50","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DPEP","object":"inhibitor \u03baB (I\u03baB)-\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> inhibited the LPS-induced phosphorylation of <e2>GENE-Y<\\e2> and NF-\u03baB p50","sentence":"Furthermore, DPEP inhibited the LPS-induced phosphorylation of inhibitor \u03baB (I\u03baB)-\u03b1 and NF-\u03baB p50"}
{"PMID":23266270,"re_id":5,"annotated sentence":"Furthermore, <e1>DPEP<\\e1> inhibited the LPS-induced phosphorylation of inhibitor \u03baB (I\u03baB)-\u03b1 and <e2>NF-\u03baB<\\e2> p50","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DPEP","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> inhibited the LPS-induced phosphorylation of inhibitor \u03baB (I\u03baB)-\u03b1 and <e2>GENE-N<\\e2> p50","sentence":"Furthermore, DPEP inhibited the LPS-induced phosphorylation of inhibitor \u03baB (I\u03baB)-\u03b1 and NF-\u03baB p50"}
{"PMID":23266270,"re_id":6,"annotated sentence":"Taken together, the results of this study demonstrate that <e1>DPEP<\\e1> inhibits LPS-stimulated inflammation by blocking the <e2>NF-\u03baB<\\e2> and MAPK pathways in macrophages.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DPEP","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Taken together, the results of this study demonstrate that <e1>CHEMICAL<\\e1> inhibits LPS-stimulated inflammation by blocking the <e2>GENE-N<\\e2> and MAPK pathways in macrophages.","sentence":"Taken together, the results of this study demonstrate that DPEP inhibits LPS-stimulated inflammation by blocking the NF-\u03baB and MAPK pathways in macrophages."}
{"PMID":23266270,"re_id":7,"annotated sentence":"Taken together, the results of this study demonstrate that <e1>DPEP<\\e1> inhibits LPS-stimulated inflammation by blocking the NF-\u03baB and <e2>MAPK<\\e2> pathways in macrophages.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DPEP","object":"MAPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Taken together, the results of this study demonstrate that <e1>CHEMICAL<\\e1> inhibits LPS-stimulated inflammation by blocking the NF-\u03baB and <e2>GENE-N<\\e2> pathways in macrophages.","sentence":"Taken together, the results of this study demonstrate that DPEP inhibits LPS-stimulated inflammation by blocking the NF-\u03baB and MAPK pathways in macrophages."}
{"PMID":23266270,"re_id":8,"annotated sentence":"<e1>DPEP<\\e1> induced dose-dependent reduction of the protein levels of <e2>inducible nitric oxide synthase<\\e2> (iNOS) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2))","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DPEP","object":"inducible nitric oxide synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induced dose-dependent reduction of the protein levels of <e2>GENE-Y<\\e2> (iNOS) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2))","sentence":"DPEP induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2))"}
{"PMID":23266270,"re_id":9,"annotated sentence":"<e1>DPEP<\\e1> induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (<e2>iNOS<\\e2>  and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2))","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DPEP","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (<e2>GENE-Y<\\e2>  and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2))","sentence":"DPEP induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS  and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2))"}
{"PMID":23266270,"re_id":10,"annotated sentence":"<e1>DPEP<\\e1> induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and <e2>cyclooxygenase-2<\\e2> (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2))","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DPEP","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and <e2>GENE-Y<\\e2> (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2))","sentence":"DPEP induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2))"}
{"PMID":23266270,"re_id":11,"annotated sentence":"<e1>DPEP<\\e1> induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (<e2>COX-2<\\e2>  and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2))","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DPEP","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (<e2>GENE-Y<\\e2>  and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2))","sentence":"DPEP induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2  and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2))"}
{"PMID":23266270,"re_id":12,"annotated sentence":"Additionally, <e1>DPEP<\\e1> suppressed the production of inflammatory <e2>cytokines<\\e2>  including tumor necrosis factor-\u03b1 (TNF-\u03b1), interleukin (IL)-1\u03b2, and IL-6","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DPEP","object":"cytokines","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Additionally, <e1>CHEMICAL<\\e1> suppressed the production of inflammatory <e2>GENE-N<\\e2>  including tumor necrosis factor-\u03b1 (TNF-\u03b1), interleukin (IL)-1\u03b2, and IL-6","sentence":"Additionally, DPEP suppressed the production of inflammatory cytokines  including tumor necrosis factor-\u03b1 (TNF-\u03b1), interleukin (IL)-1\u03b2, and IL-6"}
{"PMID":23266270,"re_id":13,"annotated sentence":"Additionally, <e1>DPEP<\\e1> suppressed the production of inflammatory cytokines, including <e2>tumor necrosis factor-\u03b1<\\e2> (TNF-\u03b1), interleukin (IL)-1\u03b2, and IL-6","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DPEP","object":"tumor necrosis factor-\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additionally, <e1>CHEMICAL<\\e1> suppressed the production of inflammatory cytokines, including <e2>GENE-Y<\\e2> (TNF-\u03b1), interleukin (IL)-1\u03b2, and IL-6","sentence":"Additionally, DPEP suppressed the production of inflammatory cytokines, including tumor necrosis factor-\u03b1 (TNF-\u03b1), interleukin (IL)-1\u03b2, and IL-6"}
{"PMID":23266270,"re_id":14,"annotated sentence":"Additionally, <e1>DPEP<\\e1> suppressed the production of inflammatory cytokines, including tumor necrosis factor-\u03b1 (<e2>TNF-\u03b1<\\e2> , interleukin (IL)-1\u03b2, and IL-6","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DPEP","object":"TNF-\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additionally, <e1>CHEMICAL<\\e1> suppressed the production of inflammatory cytokines, including tumor necrosis factor-\u03b1 (<e2>GENE-Y<\\e2> , interleukin (IL)-1\u03b2, and IL-6","sentence":"Additionally, DPEP suppressed the production of inflammatory cytokines, including tumor necrosis factor-\u03b1 (TNF-\u03b1 , interleukin (IL)-1\u03b2, and IL-6"}
{"PMID":23266270,"re_id":15,"annotated sentence":"Additionally, <e1>DPEP<\\e1> suppressed the production of inflammatory cytokines, including tumor necrosis factor-\u03b1 (TNF-\u03b1), <e2>interleukin (IL)-1\u03b2<\\e2>  and IL-6","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DPEP","object":"interleukin (IL)-1\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additionally, <e1>CHEMICAL<\\e1> suppressed the production of inflammatory cytokines, including tumor necrosis factor-\u03b1 (TNF-\u03b1), <e2>GENE-Y<\\e2>  and IL-6","sentence":"Additionally, DPEP suppressed the production of inflammatory cytokines, including tumor necrosis factor-\u03b1 (TNF-\u03b1), interleukin (IL)-1\u03b2  and IL-6"}
{"PMID":23266270,"re_id":16,"annotated sentence":"Additionally, <e1>DPEP<\\e1> suppressed the production of inflammatory cytokines, including tumor necrosis factor-\u03b1 (TNF-\u03b1), interleukin (IL)-1\u03b2, and <e2>IL-6<\\e2>  We investigated the mechanism by which DPEP inhibits NO and PGE(2) by examining the level of nuclear factor-\u03baB (NF-\u03baB) activation within the mitogen-activated protein kinase (MAPK) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DPEP","object":"IL-6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additionally, <e1>CHEMICAL<\\e1> suppressed the production of inflammatory cytokines, including tumor necrosis factor-\u03b1 (TNF-\u03b1), interleukin (IL)-1\u03b2, and <e2>GENE-Y<\\e2>  We investigated the mechanism by which CHEMICAL inhibits NO and PGE(2) by examining the level of nuclear factor-\u03baB (NF-\u03baB) activation within the mitogen-activated protein kinase (MAPK) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells","sentence":"Additionally, DPEP suppressed the production of inflammatory cytokines, including tumor necrosis factor-\u03b1 (TNF-\u03b1), interleukin (IL)-1\u03b2, and IL-6  We investigated the mechanism by which DPEP inhibits NO and PGE(2) by examining the level of nuclear factor-\u03baB (NF-\u03baB) activation within the mitogen-activated protein kinase (MAPK) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells"}
{"PMID":23267840,"re_id":0,"annotated sentence":"This leads to decreased expression of <e2>glutamate aspartate transporter<\\e2>  which in turn reduces <e1>glutamate<\\e1> transport","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutamate","object":"glutamate aspartate transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This leads to decreased expression of <e2>CHEMICAL aspartate transporter<\\e2>  which in turn reduces <e1>CHEMICAL<\\e1> transport","sentence":"This leads to decreased expression of glutamate aspartate transporter  which in turn reduces glutamate transport"}
{"PMID":23281812,"re_id":0,"annotated sentence":"<e1>Tetrahydropyrroloquinolinone<\\e1> type dual inhibitors of <e2>aromatase<\\e2> aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Tetrahydropyrroloquinolinone","object":"aromatase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> type dual inhibitors of <e2>GENE-Y<\\e2> aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks","sentence":"Tetrahydropyrroloquinolinone type dual inhibitors of aromatase aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks"}
{"PMID":23281812,"re_id":1,"annotated sentence":"<e1>Tetrahydropyrroloquinolinone<\\e1> type dual inhibitors of aromatase\/<e2>aldosterone synthase<\\e2> as a novel strategy for breast cancer patients with elevated cardiovascular risks","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Tetrahydropyrroloquinolinone","object":"aldosterone synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> type dual inhibitors of aromatase\/<e2>GENE-Y<\\e2> as a novel strategy for breast cancer patients with elevated cardiovascular risks","sentence":"Tetrahydropyrroloquinolinone type dual inhibitors of aromatase\/aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks"}
{"PMID":23282066,"re_id":0,"annotated sentence":"Furthermore, <e1>MDZ<\\e1> caused mechanism-based inactivation of <e2>cytochrome P450 3A<\\e2> dependent TRZ 1'-hydroxylation in mouse, rat and human intestinal microsomes with similar potencies","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MDZ","object":"cytochrome P450 3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> caused mechanism-based inactivation of <e2>GENE-N<\\e2> dependent TRZ 1'-hydroxylation in mouse, rat and human intestinal microsomes with similar potencies","sentence":"Furthermore, MDZ caused mechanism-based inactivation of cytochrome P450 3A dependent TRZ 1'-hydroxylation in mouse, rat and human intestinal microsomes with similar potencies"}
{"PMID":23282066,"re_id":1,"annotated sentence":"Furthermore, MDZ caused mechanism-based inactivation of <e2>cytochrome P450 3A<\\e2> dependent <e1>TRZ<\\e1> 1'-hydroxylation in mouse, rat and human intestinal microsomes with similar potencies","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"TRZ","object":"cytochrome P450 3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, MDZ caused mechanism-based inactivation of <e2>GENE-N<\\e2> dependent <e1>CHEMICAL<\\e1> 1'-hydroxylation in mouse, rat and human intestinal microsomes with similar potencies","sentence":"Furthermore, MDZ caused mechanism-based inactivation of cytochrome P450 3A dependent TRZ 1'-hydroxylation in mouse, rat and human intestinal microsomes with similar potencies"}
{"PMID":23295740,"re_id":0,"annotated sentence":"<e1>Tamoxifen<\\e1> represses miR-200 microRNAs and promotes epithelial-to-mesenchymal transition by up-regulating <e2>c-Myc<\\e2> in endometrial carcinoma cell lines","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Tamoxifen","object":"c-Myc","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> represses miR-200 microRNAs and promotes epithelial-to-mesenchymal transition by up-regulating <e2>GENE-Y<\\e2> in endometrial carcinoma cell lines","sentence":"Tamoxifen represses miR-200 microRNAs and promotes epithelial-to-mesenchymal transition by up-regulating c-Myc in endometrial carcinoma cell lines"}
{"PMID":23295740,"re_id":1,"annotated sentence":"Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as <e2>Snail<\\e2> and N-cadherin increased, whereas E-cadherin decreased in the <e1>TAM<\\e1> treated cells, contributing to TAM-induced EMT in these endometrial cancer cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TAM","object":"Snail","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as <e2>GENE-Y<\\e2> and N-cadherin increased, whereas E-cadherin decreased in the <e1>CHEMICAL<\\e1> treated cells, contributing to CHEMICAL-induced EMT in these endometrial cancer cells","sentence":"Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas E-cadherin decreased in the TAM treated cells, contributing to TAM-induced EMT in these endometrial cancer cells"}
{"PMID":23295740,"re_id":2,"annotated sentence":"Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and <e2>N-cadherin<\\e2> increased, whereas E-cadherin decreased in the <e1>TAM<\\e1> treated cells, contributing to TAM-induced EMT in these endometrial cancer cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TAM","object":"N-cadherin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and <e2>GENE-Y<\\e2> increased, whereas E-cadherin decreased in the <e1>CHEMICAL<\\e1> treated cells, contributing to CHEMICAL-induced EMT in these endometrial cancer cells","sentence":"Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas E-cadherin decreased in the TAM treated cells, contributing to TAM-induced EMT in these endometrial cancer cells"}
{"PMID":23295740,"re_id":3,"annotated sentence":"Collectively, our data suggest that <e1>TAM<\\e1> can repress the miR-200 family and induce EMT via the up-regulation of <e2>c-Myc<\\e2> in endometrial cancer cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TAM","object":"c-Myc","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Collectively, our data suggest that <e1>CHEMICAL<\\e1> can repress the miR-200 family and induce EMT via the up-regulation of <e2>GENE-Y<\\e2> in endometrial cancer cells","sentence":"Collectively, our data suggest that TAM can repress the miR-200 family and induce EMT via the up-regulation of c-Myc in endometrial cancer cells"}
{"PMID":23295740,"re_id":4,"annotated sentence":"<e2>miR-200<\\e2>  a miRNA family with tumor suppressive functions in a wide range of cancers, was found reduced in response to <e1>TAM<\\e1> treatment","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TAM","object":"miR-200","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2>  a miRNA family with tumor suppressive functions in a wide range of cancers, was found reduced in response to <e1>CHEMICAL<\\e1> treatment","sentence":"miR-200  a miRNA family with tumor suppressive functions in a wide range of cancers, was found reduced in response to TAM treatment"}
{"PMID":23295740,"re_id":5,"annotated sentence":"<e1>Tamoxifen<\\e1> represses <e2>miR-200<\\e2> microRNAs and promotes epithelial-to-mesenchymal transition by up-regulating c-Myc in endometrial carcinoma cell lines","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Tamoxifen","object":"miR-200","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> represses <e2>GENE-N<\\e2> microRNAs and promotes epithelial-to-mesenchymal transition by up-regulating c-Myc in endometrial carcinoma cell lines","sentence":"Tamoxifen represses miR-200 microRNAs and promotes epithelial-to-mesenchymal transition by up-regulating c-Myc in endometrial carcinoma cell lines"}
{"PMID":23295740,"re_id":6,"annotated sentence":"Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas <e2>E-cadherin<\\e2> decreased in the <e1>TAM<\\e1> treated cells, contributing to TAM-induced EMT in these endometrial cancer cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TAM","object":"E-cadherin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas <e2>GENE-Y<\\e2> decreased in the <e1>CHEMICAL<\\e1> treated cells, contributing to CHEMICAL-induced EMT in these endometrial cancer cells","sentence":"Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas E-cadherin decreased in the TAM treated cells, contributing to TAM-induced EMT in these endometrial cancer cells"}
{"PMID":23295740,"re_id":7,"annotated sentence":"In addition, we showed that c-Myc directly binds to and represses the promoter of miR-200 miRNAs, and its up-regulation in <e1>TAM<\\e1> treated endometrial cancer cells leads to the down-regulation of <e2>miR-200<\\e2> and eventually to EMT","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TAM","object":"miR-200","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition, we showed that c-Myc directly binds to and represses the promoter of GENE-N miRNAs, and its up-regulation in <e1>CHEMICAL<\\e1> treated endometrial cancer cells leads to the down-regulation of <e2>GENE-N<\\e2> and eventually to EMT","sentence":"In addition, we showed that c-Myc directly binds to and represses the promoter of miR-200 miRNAs, and its up-regulation in TAM treated endometrial cancer cells leads to the down-regulation of miR-200 and eventually to EMT"}
{"PMID":23295740,"re_id":8,"annotated sentence":"Collectively, our data suggest that <e1>TAM<\\e1> can repress the <e2>miR-200<\\e2> family and induce EMT via the up-regulation of c-Myc in endometrial cancer cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TAM","object":"miR-200","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Collectively, our data suggest that <e1>CHEMICAL<\\e1> can repress the <e2>GENE-N<\\e2> family and induce EMT via the up-regulation of c-Myc in endometrial cancer cells","sentence":"Collectively, our data suggest that TAM can repress the miR-200 family and induce EMT via the up-regulation of c-Myc in endometrial cancer cells"}
{"PMID":23297412,"re_id":0,"annotated sentence":"Here, we show that oral administration of <e1>resveratrol<\\e1>  which leads to activation of an <e2>NAD(+)-dependent protein deacetylase SIRT1<\\e2>  suppresses cardiac hypertrophy and fibrosis and restores cardiac diastolic function in dystrophin-deficient mdx mice","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"resveratrol","object":"NAD(+)-dependent protein deacetylase SIRT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we show that oral administration of <e1>CHEMICAL<\\e1>  which leads to activation of an <e2>GENE-Y<\\e2>  suppresses cardiac hypertrophy and fibrosis and restores cardiac diastolic function in dystrophin-deficient mdx mice","sentence":"Here, we show that oral administration of resveratrol  which leads to activation of an NAD(+)-dependent protein deacetylase SIRT1  suppresses cardiac hypertrophy and fibrosis and restores cardiac diastolic function in dystrophin-deficient mdx mice"}
{"PMID":23297412,"re_id":1,"annotated sentence":"The pro-hypertrophic co-activator p300 protein but not p300 mRNA was up-regulated in the mdx heart, and <e1>resveratrol<\\e1> administration down-regulated the <e2>p300<\\e2> protein level","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"resveratrol","object":"p300","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The pro-hypertrophic co-activator GENE-Y protein but not GENE-Y mRNA was up-regulated in the mdx heart, and <e1>CHEMICAL<\\e1> administration down-regulated the <e2>GENE-Y<\\e2> protein level","sentence":"The pro-hypertrophic co-activator p300 protein but not p300 mRNA was up-regulated in the mdx heart, and resveratrol administration down-regulated the p300 protein level"}
{"PMID":23297412,"re_id":2,"annotated sentence":"In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the \u03b1(1)-agonist phenylephrine was inhibited by the overexpression of SIRT1 as well as <e1>resveratrol<\\e1>  both of which down-regulated <e2>p300<\\e2> protein levels but not p300 mRNA levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"resveratrol","object":"p300","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the \u03b1(1)-agonist phenylephrine was inhibited by the overexpression of SIRT1 as well as <e1>CHEMICAL<\\e1>  both of which down-regulated <e2>GENE-Y<\\e2> protein levels but not GENE-Y mRNA levels","sentence":"In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the \u03b1(1)-agonist phenylephrine was inhibited by the overexpression of SIRT1 as well as resveratrol  both of which down-regulated p300 protein levels but not p300 mRNA levels"}
{"PMID":23305921,"re_id":0,"annotated sentence":"We previously reported that caffeoyl-amino acidyl-hydroxamic acid (<e1>CA-Xaa-NHOH<\\e1>  acted as both a good antioxidant and <e2>tyrosinase<\\e2> inhibitor, in particular when caffeic acid was conjugated with proline or amino acids having aromatic ring like phenylalanine","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CA-Xaa-NHOH","object":"tyrosinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We previously reported that caffeoyl-amino acidyl-hydroxamic acid (<e1>CHEMICAL<\\e1>  acted as both a good antioxidant and <e2>GENE-Y<\\e2> inhibitor, in particular when caffeic acid was conjugated with proline or amino acids having aromatic ring like phenylalanine","sentence":"We previously reported that caffeoyl-amino acidyl-hydroxamic acid (CA-Xaa-NHOH  acted as both a good antioxidant and tyrosinase inhibitor, in particular when caffeic acid was conjugated with proline or amino acids having aromatic ring like phenylalanine"}
{"PMID":23305921,"re_id":1,"annotated sentence":"In addition, derivatives of <e1>caffeic acid<\\e1> and sinapic acid efficiently inhibited <e2>tyrosinase<\\e2> activity and reduced melanin content in melanocytes Mel-Ab cell.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"caffeic acid","object":"tyrosinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, derivatives of <e1>CHEMICAL<\\e1> and sinapic acid efficiently inhibited <e2>GENE-Y<\\e2> activity and reduced melanin content in melanocytes Mel-Ab cell.","sentence":"In addition, derivatives of caffeic acid and sinapic acid efficiently inhibited tyrosinase activity and reduced melanin content in melanocytes Mel-Ab cell."}
{"PMID":23305921,"re_id":2,"annotated sentence":"In addition, derivatives of caffeic acid and <e1>sinapic acid<\\e1> efficiently inhibited <e2>tyrosinase<\\e2> activity and reduced melanin content in melanocytes Mel-Ab cell.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sinapic acid","object":"tyrosinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, derivatives of caffeic acid and <e1>CHEMICAL<\\e1> efficiently inhibited <e2>GENE-Y<\\e2> activity and reduced melanin content in melanocytes Mel-Ab cell.","sentence":"In addition, derivatives of caffeic acid and sinapic acid efficiently inhibited tyrosinase activity and reduced melanin content in melanocytes Mel-Ab cell."}
{"PMID":23305921,"re_id":3,"annotated sentence":"Synthesis and dual biological effects of <e1>hydroxycinnamoyl phenylalanyl<\\e1> prolyl hydroxamic acid derivatives as <e2>tyrosinase<\\e2> inhibitor and antioxidant","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"hydroxycinnamoyl phenylalanyl","object":"tyrosinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Synthesis and dual biological effects of <e1>CHEMICAL<\\e1> prolyl hydroxamic acid derivatives as <e2>GENE-Y<\\e2> inhibitor and antioxidant","sentence":"Synthesis and dual biological effects of hydroxycinnamoyl phenylalanyl prolyl hydroxamic acid derivatives as tyrosinase inhibitor and antioxidant"}
{"PMID":23305921,"re_id":4,"annotated sentence":"Synthesis and dual biological effects of hydroxycinnamoyl phenylalanyl\/<e1>prolyl hydroxamic acid<\\e1> derivatives as <e2>tyrosinase<\\e2> inhibitor and antioxidant","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"prolyl hydroxamic acid","object":"tyrosinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Synthesis and dual biological effects of hydroxycinnamoyl phenylalanyl\/<e1>CHEMICAL<\\e1> derivatives as <e2>GENE-Y<\\e2> inhibitor and antioxidant","sentence":"Synthesis and dual biological effects of hydroxycinnamoyl phenylalanyl\/prolyl hydroxamic acid derivatives as tyrosinase inhibitor and antioxidant"}
{"PMID":23305921,"re_id":5,"annotated sentence":"We previously reported that <e1>caffeoyl-amino acidyl-hydroxamic acid<\\e1> (CA-Xaa-NHOH) acted as both a good antioxidant and <e2>tyrosinase<\\e2> inhibitor, in particular when caffeic acid was conjugated with proline or amino acids having aromatic ring like phenylalanine","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"caffeoyl-amino acidyl-hydroxamic acid","object":"tyrosinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We previously reported that <e1>CHEMICAL<\\e1> (CA-Xaa-NHOH) acted as both a good antioxidant and <e2>GENE-Y<\\e2> inhibitor, in particular when caffeic acid was conjugated with proline or amino acids having aromatic ring like phenylalanine","sentence":"We previously reported that caffeoyl-amino acidyl-hydroxamic acid (CA-Xaa-NHOH) acted as both a good antioxidant and tyrosinase inhibitor, in particular when caffeic acid was conjugated with proline or amino acids having aromatic ring like phenylalanine"}
{"PMID":23307549,"re_id":0,"annotated sentence":"<e1>Ruxolitinib<\\e1> is a small-molecule inhibitor\u00a0of <e2>JAK1<\\e2> and JAK2 and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Ruxolitinib","object":"JAK1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is a small-molecule inhibitor\u00a0of <e2>GENE-Y<\\e2> and JAK2 and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis","sentence":"Ruxolitinib is a small-molecule inhibitor\u00a0of JAK1 and JAK2 and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis"}
{"PMID":23307549,"re_id":1,"annotated sentence":"<e1>Ruxolitinib<\\e1> is a small-molecule inhibitor\u00a0of JAK1 and <e2>JAK2<\\e2> and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Ruxolitinib","object":"JAK2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is a small-molecule inhibitor\u00a0of JAK1 and <e2>GENE-Y<\\e2> and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis","sentence":"Ruxolitinib is a small-molecule inhibitor\u00a0of JAK1 and JAK2 and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis"}
{"PMID":23318731,"re_id":0,"annotated sentence":"<e1>Pb<\\e1> and BaP treatments significantly increased active <e2>caspase-3<\\e2> levels in a time-dependent manner","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Pb","object":"caspase-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and BaP treatments significantly increased active <e2>GENE-Y<\\e2> levels in a time-dependent manner","sentence":"Pb and BaP treatments significantly increased active caspase-3 levels in a time-dependent manner"}
{"PMID":23318731,"re_id":1,"annotated sentence":"Pb and <e1>BaP<\\e1> treatments significantly increased active <e2>caspase-3<\\e2> levels in a time-dependent manner","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"BaP","object":"caspase-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pb and <e1>CHEMICAL<\\e1> treatments significantly increased active <e2>GENE-Y<\\e2> levels in a time-dependent manner","sentence":"Pb and BaP treatments significantly increased active caspase-3 levels in a time-dependent manner"}
{"PMID":23318833,"re_id":0,"annotated sentence":"<e1>TAA<\\e1> increased the number and area of <e2>glutathione S-transferase placental form<\\e2> (GST-P)(+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TAA","object":"glutathione S-transferase placental form","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> increased the number and area of <e2>GENE-N<\\e2> (GST-P)(+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections","sentence":"TAA increased the number and area of glutathione S-transferase placental form (GST-P)(+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections"}
{"PMID":23318833,"re_id":1,"annotated sentence":"<e1>TAA<\\e1> increased the number and area of glutathione S-transferase placental form (<e2>GST-P<\\e2> (+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TAA","object":"GST-P","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> increased the number and area of glutathione S-transferase placental form (<e2>GENE-N<\\e2> (+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections","sentence":"TAA increased the number and area of glutathione S-transferase placental form (GST-P (+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections"}
{"PMID":23318833,"re_id":2,"annotated sentence":"<e1>TAA<\\e1> also increased the numbers of ED2(+), <e2>cyclooxygenase-2<\\e2> +), and heme oxygenase-1(+) liver cells, as well as the number of CD3(+) lymphocytes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TAA","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also increased the numbers of ED2(+), <e2>GENE-Y<\\e2> +), and heme oxygenase-1(+) liver cells, as well as the number of CD3(+) lymphocytes","sentence":"TAA also increased the numbers of ED2(+), cyclooxygenase-2 +), and heme oxygenase-1(+) liver cells, as well as the number of CD3(+) lymphocytes"}
{"PMID":23318833,"re_id":3,"annotated sentence":"<e1>TAA<\\e1> also increased the numbers of ED2(+), cyclooxygenase-2(+), and <e2>heme oxygenase-1<\\e2> +) liver cells, as well as the number of CD3(+) lymphocytes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TAA","object":"heme oxygenase-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also increased the numbers of ED2(+), cyclooxygenase-2(+), and <e2>GENE-Y<\\e2> +) liver cells, as well as the number of CD3(+) lymphocytes","sentence":"TAA also increased the numbers of ED2(+), cyclooxygenase-2(+), and heme oxygenase-1 +) liver cells, as well as the number of CD3(+) lymphocytes"}
{"PMID":23318833,"re_id":4,"annotated sentence":"<e1>TAA<\\e1> also increased the numbers of ED2(+), cyclooxygenase-2(+), and heme oxygenase-1(+) liver cells, as well as the number of <e2>CD3<\\e2> +) lymphocytes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TAA","object":"CD3","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> also increased the numbers of ED2(+), cyclooxygenase-2(+), and heme oxygenase-1(+) liver cells, as well as the number of <e2>GENE-N<\\e2> +) lymphocytes","sentence":"TAA also increased the numbers of ED2(+), cyclooxygenase-2(+), and heme oxygenase-1(+) liver cells, as well as the number of CD3 +) lymphocytes"}
{"PMID":23319419,"re_id":0,"annotated sentence":"Although <e1>ICA<\\e1> greatly attenuates <e2>ERG<\\e2> inactivation by shifting its voltage dependence to more positive potentials, it enhances the rate and extent of EAG inactivation without altering its voltage dependence","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ICA","object":"ERG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although <e1>CHEMICAL<\\e1> greatly attenuates <e2>GENE-Y<\\e2> inactivation by shifting its voltage dependence to more positive potentials, it enhances the rate and extent of EAG inactivation without altering its voltage dependence","sentence":"Although ICA greatly attenuates ERG inactivation by shifting its voltage dependence to more positive potentials, it enhances the rate and extent of EAG inactivation without altering its voltage dependence"}
{"PMID":23319419,"re_id":1,"annotated sentence":"<e1>ICA-105574<\\e1> interacts with a common binding site to elicit opposite effects on inactivation gating of <e2>EAG<\\e2> and ERG potassium channels","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ICA-105574","object":"EAG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> interacts with a common binding site to elicit opposite effects on inactivation gating of <e2>GENE-Y<\\e2> and ERG potassium channels","sentence":"ICA-105574 interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and ERG potassium channels"}
{"PMID":23319419,"re_id":2,"annotated sentence":"<e1>ICA-105574<\\e1> interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and <e2>ERG<\\e2> potassium channels","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ICA-105574","object":"ERG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and <e2>GENE-Y<\\e2> potassium channels","sentence":"ICA-105574 interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and ERG potassium channels"}
{"PMID":23319419,"re_id":3,"annotated sentence":"<e1>ICA-105574<\\e1> interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and ERG <e2>potassium channels<\\e2>  Rapid and voltage-dependent inactivation greatly attenuates outward currents in ether-a-go-go-related gene (ERG) K(+) channels","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ICA-105574","object":"potassium channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and ERG <e2>GENE-N<\\e2>  Rapid and voltage-dependent inactivation greatly attenuates outward currents in ether-a-go-go-related gene (ERG) K(+) channels","sentence":"ICA-105574 interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and ERG potassium channels  Rapid and voltage-dependent inactivation greatly attenuates outward currents in ether-a-go-go-related gene (ERG) K(+) channels"}
{"PMID":23319419,"re_id":4,"annotated sentence":"Although <e1>ICA<\\e1> greatly attenuates ERG inactivation by shifting its voltage dependence to more positive potentials, it enhances the rate and extent of <e2>EAG<\\e2> inactivation without altering its voltage dependence","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ICA","object":"EAG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although <e1>CHEMICAL<\\e1> greatly attenuates ERG inactivation by shifting its voltage dependence to more positive potentials, it enhances the rate and extent of <e2>GENE-Y<\\e2> inactivation without altering its voltage dependence","sentence":"Although ICA greatly attenuates ERG inactivation by shifting its voltage dependence to more positive potentials, it enhances the rate and extent of EAG inactivation without altering its voltage dependence"}
{"PMID":23319419,"re_id":5,"annotated sentence":"<e1>ICA<\\e1> is a mixed agonist of mutant <e2>EAG<\\e2> and EAG\/ERG chimera channels that inactivate by a combination of slow and fast mechanisms","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"ICA","object":"EAG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is a mixed agonist of mutant <e2>GENE-Y<\\e2> and GENE-Y\/ERG chimera channels that inactivate by a combination of slow and fast mechanisms","sentence":"ICA is a mixed agonist of mutant EAG and EAG\/ERG chimera channels that inactivate by a combination of slow and fast mechanisms"}
{"PMID":23319419,"re_id":6,"annotated sentence":"<e1>ICA<\\e1> is a mixed agonist of mutant EAG and <e2>EAG<\\e2> ERG chimera channels that inactivate by a combination of slow and fast mechanisms","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"ICA","object":"EAG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is a mixed agonist of mutant GENE-Y and <e2>GENE-Y<\\e2> ERG chimera channels that inactivate by a combination of slow and fast mechanisms","sentence":"ICA is a mixed agonist of mutant EAG and EAG ERG chimera channels that inactivate by a combination of slow and fast mechanisms"}
{"PMID":23319419,"re_id":7,"annotated sentence":"<e1>ICA<\\e1> is a mixed agonist of mutant EAG and EAG\/<e2>ERG<\\e2> chimera channels that inactivate by a combination of slow and fast mechanisms","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"ICA","object":"ERG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is a mixed agonist of mutant EAG and EAG\/<e2>GENE-Y<\\e2> chimera channels that inactivate by a combination of slow and fast mechanisms","sentence":"ICA is a mixed agonist of mutant EAG and EAG\/ERG chimera channels that inactivate by a combination of slow and fast mechanisms"}
{"PMID":23321689,"re_id":0,"annotated sentence":"PNU-282987 on the other hand displayed an increase in anxiety-like behavior at a higher dose (10\u00a0mg\/kg) that was significantly reduced by the <e2>serotonin 5-HT1a receptor<\\e2> antagonist <e1>WAY-100135<\\e1>  However the \u03b17 receptor antagonist methyllycaconitine was unable to reverse these anxiety-like effects seen with PNU-282987","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"WAY-100135","object":"serotonin 5-HT1a receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PNU-282987 on the other hand displayed an increase in anxiety-like behavior at a higher dose (10\u00a0mg\/kg) that was significantly reduced by the <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1>  However the \u03b17 receptor antagonist methyllycaconitine was unable to reverse these anxiety-like effects seen with PNU-282987","sentence":"PNU-282987 on the other hand displayed an increase in anxiety-like behavior at a higher dose (10\u00a0mg\/kg) that was significantly reduced by the serotonin 5-HT1a receptor antagonist WAY-100135  However the \u03b17 receptor antagonist methyllycaconitine was unable to reverse these anxiety-like effects seen with PNU-282987"}
{"PMID":23321689,"re_id":1,"annotated sentence":"However the <e2>\u03b17 receptor<\\e2> antagonist <e1>methyllycaconitine<\\e1> was unable to reverse these anxiety-like effects seen with PNU-282987","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"methyllycaconitine","object":"\u03b17 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However the <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> was unable to reverse these anxiety-like effects seen with PNU-282987","sentence":"However the \u03b17 receptor antagonist methyllycaconitine was unable to reverse these anxiety-like effects seen with PNU-282987"}
{"PMID":23322164,"re_id":0,"annotated sentence":"<e2>Carnitine palmitoyltransferase 2<\\e2> and carnitine\/acylcarnitine translocase are involved in the mitochondrial synthesis and export of <e1>acylcarnitines<\\e1> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acylcarnitines","object":"Carnitine palmitoyltransferase 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> and carnitine\/acylcarnitine translocase are involved in the mitochondrial synthesis and export of <e1>CHEMICAL<\\e1> ","sentence":"Carnitine palmitoyltransferase 2 and carnitine\/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines "}
{"PMID":23322164,"re_id":1,"annotated sentence":"Carnitine palmitoyltransferase 2 and <e2>carnitine\/acylcarnitine translocase<\\e2> are involved in the mitochondrial synthesis and export of <e1>acylcarnitines<\\e1> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acylcarnitines","object":"carnitine\/acylcarnitine translocase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Carnitine palmitoyltransferase 2 and <e2>GENE-Y<\\e2> are involved in the mitochondrial synthesis and export of <e1>CHEMICAL<\\e1> ","sentence":"Carnitine palmitoyltransferase 2 and carnitine\/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines "}
{"PMID":23322164,"re_id":2,"annotated sentence":"<e2>Carnitine palmitoyltransferase 2<\\e2> and carnitine\/acylcarnitine translocase are involved in the mitochondrial synthesis and export of <e1>acylcarnitines<\\e1>  Acylcarnitines are commonly used in the diagnosis of mitochondrial fatty acid \u03b2-oxidation disorders (mFAODs)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acylcarnitines","object":"Carnitine palmitoyltransferase 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> and carnitine\/acylcarnitine translocase are involved in the mitochondrial synthesis and export of <e1>CHEMICAL<\\e1>  Acylcarnitines are commonly used in the diagnosis of mitochondrial fatty acid \u03b2-oxidation disorders (mFAODs)","sentence":"Carnitine palmitoyltransferase 2 and carnitine\/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines  Acylcarnitines are commonly used in the diagnosis of mitochondrial fatty acid \u03b2-oxidation disorders (mFAODs)"}
{"PMID":23322164,"re_id":3,"annotated sentence":"Carnitine palmitoyltransferase 2 and <e2>carnitine\/acylcarnitine translocase<\\e2> are involved in the mitochondrial synthesis and export of <e1>acylcarnitines<\\e1>  Acylcarnitines are commonly used in the diagnosis of mitochondrial fatty acid \u03b2-oxidation disorders (mFAODs)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acylcarnitines","object":"carnitine\/acylcarnitine translocase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Carnitine palmitoyltransferase 2 and <e2>GENE-Y<\\e2> are involved in the mitochondrial synthesis and export of <e1>CHEMICAL<\\e1>  Acylcarnitines are commonly used in the diagnosis of mitochondrial fatty acid \u03b2-oxidation disorders (mFAODs)","sentence":"Carnitine palmitoyltransferase 2 and carnitine\/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines  Acylcarnitines are commonly used in the diagnosis of mitochondrial fatty acid \u03b2-oxidation disorders (mFAODs)"}
{"PMID":23322164,"re_id":4,"annotated sentence":"This shows that <e2>CPT2<\\e2> and CACT are crucial for mitochondrial <e1>acylcarnitine<\\e1> formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acylcarnitine","object":"CPT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This shows that <e2>GENE-Y<\\e2> and CACT are crucial for mitochondrial <e1>CHEMICAL<\\e1> formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R","sentence":"This shows that CPT2 and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R"}
{"PMID":23322164,"re_id":5,"annotated sentence":"This shows that CPT2 and <e2>CACT<\\e2> are crucial for mitochondrial <e1>acylcarnitine<\\e1> formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acylcarnitine","object":"CACT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This shows that CPT2 and <e2>GENE-Y<\\e2> are crucial for mitochondrial <e1>CHEMICAL<\\e1> formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R","sentence":"This shows that CPT2 and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R"}
{"PMID":23327794,"re_id":0,"annotated sentence":"As a result of this study, <e1>microgrewiapine A<\\e1> (1) was found to be a selective cytotoxic agent for colon cancer cells over normal colon cells and to exhibit <e2>nicotinic receptor<\\e2> antagonistic activity for both the h\u03b13\u03b24 and h\u03b14\u03b22 receptor subtypes.","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"microgrewiapine A","object":"nicotinic receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"As a result of this study, <e1>CHEMICAL<\\e1> (1) was found to be a selective cytotoxic agent for colon cancer cells over normal colon cells and to exhibit <e2>GENE-N<\\e2> antagonistic activity for both the h\u03b13\u03b24 and h\u03b14\u03b22 receptor subtypes.","sentence":"As a result of this study, microgrewiapine A (1) was found to be a selective cytotoxic agent for colon cancer cells over normal colon cells and to exhibit nicotinic receptor antagonistic activity for both the h\u03b13\u03b24 and h\u03b14\u03b22 receptor subtypes."}
{"PMID":23334403,"re_id":0,"annotated sentence":"PURPOSE: To characterise further the previously observed cytochrome P450 3A4 (CYP3A4) interaction of the dual <e2>orexin receptor<\\e2> antagonist <e1>almorexant<\\e1>  METHODS: Pharmacokinetic interactions were investigated (n\u2009=\u200914 healthy male subjects in two treatment groups) between almorexant at steady-state when administered either concomitantly or 2\u00a0h after administration of single doses of simvastatin (40\u00a0mg) or atorvastatin (40\u00a0mg)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"almorexant","object":"orexin receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"PURPOSE: To characterise further the previously observed cytochrome P450 3A4 (CYP3A4) interaction of the dual <e2>GENE-N<\\e2> antagonist <e1>CHEMICAL<\\e1>  METHODS: Pharmacokinetic interactions were investigated (n\u2009=\u200914 healthy male subjects in two treatment groups) between CHEMICAL at steady-state when administered either concomitantly or 2\u00a0h after administration of single doses of simvastatin (40\u00a0mg) or atorvastatin (40\u00a0mg)","sentence":"PURPOSE: To characterise further the previously observed cytochrome P450 3A4 (CYP3A4) interaction of the dual orexin receptor antagonist almorexant  METHODS: Pharmacokinetic interactions were investigated (n\u2009=\u200914 healthy male subjects in two treatment groups) between almorexant at steady-state when administered either concomitantly or 2\u00a0h after administration of single doses of simvastatin (40\u00a0mg) or atorvastatin (40\u00a0mg)"}
{"PMID":23353901,"re_id":0,"annotated sentence":"In\u00a0vitro molecular pharmacology studies showed that 5-HT2C agonists potent for attenuating the DOI-elicited-HTR also reduced the efficacy of <e1>DOI<\\e1> to activate <e2>mouse 5-HT2C<\\e2> receptor-mediated PLC signaling in HEK cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"DOI","object":"mouse 5-HT2C","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In\u00a0vitro molecular pharmacology studies showed that 5-HT2C agonists potent for attenuating the CHEMICAL-elicited-HTR also reduced the efficacy of <e1>CHEMICAL<\\e1> to activate <e2>GENE-Y<\\e2> receptor-mediated PLC signaling in HEK cells","sentence":"In\u00a0vitro molecular pharmacology studies showed that 5-HT2C agonists potent for attenuating the DOI-elicited-HTR also reduced the efficacy of DOI to activate mouse 5-HT2C receptor-mediated PLC signaling in HEK cells"}
{"PMID":23353901,"re_id":1,"annotated sentence":"Commercially-available <e2>5-HT2C<\\e2> agonists (<e1>CP 809101<\\e1>  Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A\/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B\/2C (SB-206553) receptors attenuated the DOI-elicited-HTR","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"CP 809101","object":"5-HT2C","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Commercially-available <e2>GENE-Y<\\e2> agonists (<e1>CHEMICAL<\\e1>  Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type GENE-Y agonists (with 5-HT2A\/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), GENE-Y (SB-242084), and 5-HT2B\/2C (SB-206553) receptors attenuated the DOI-elicited-HTR","sentence":"Commercially-available 5-HT2C agonists (CP 809101  Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A\/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B\/2C (SB-206553) receptors attenuated the DOI-elicited-HTR"}
{"PMID":23353901,"re_id":2,"annotated sentence":"Commercially-available <e2>5-HT2C<\\e2> agonists (CP 809101, <e1>Ro 60-0175<\\e1>  WAY 161503, mCPP, and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A\/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B\/2C (SB-206553) receptors attenuated the DOI-elicited-HTR","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"Ro 60-0175","object":"5-HT2C","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Commercially-available <e2>GENE-Y<\\e2> agonists (CP 809101, <e1>CHEMICAL<\\e1>  WAY 161503, mCPP, and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type GENE-Y agonists (with 5-HT2A\/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), GENE-Y (SB-242084), and 5-HT2B\/2C (SB-206553) receptors attenuated the DOI-elicited-HTR","sentence":"Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175  WAY 161503, mCPP, and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A\/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B\/2C (SB-206553) receptors attenuated the DOI-elicited-HTR"}
{"PMID":23353901,"re_id":3,"annotated sentence":"Commercially-available <e2>5-HT2C<\\e2> agonists (CP 809101, Ro 60-0175, <e1>WAY 161503<\\e1>  mCPP, and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A\/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B\/2C (SB-206553) receptors attenuated the DOI-elicited-HTR","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"WAY 161503","object":"5-HT2C","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Commercially-available <e2>GENE-Y<\\e2> agonists (CP 809101, Ro 60-0175, <e1>CHEMICAL<\\e1>  mCPP, and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type GENE-Y agonists (with 5-HT2A\/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), GENE-Y (SB-242084), and 5-HT2B\/2C (SB-206553) receptors attenuated the DOI-elicited-HTR","sentence":"Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503  mCPP, and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A\/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B\/2C (SB-206553) receptors attenuated the DOI-elicited-HTR"}
{"PMID":23353901,"re_id":4,"annotated sentence":"Commercially-available <e2>5-HT2C<\\e2> agonists (CP 809101, Ro 60-0175, WAY 161503, <e1>mCPP<\\e1>  and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A\/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B\/2C (SB-206553) receptors attenuated the DOI-elicited-HTR","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"mCPP","object":"5-HT2C","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Commercially-available <e2>GENE-Y<\\e2> agonists (CP 809101, Ro 60-0175, WAY 161503, <e1>CHEMICAL<\\e1>  and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type GENE-Y agonists (with 5-HT2A\/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), GENE-Y (SB-242084), and 5-HT2B\/2C (SB-206553) receptors attenuated the DOI-elicited-HTR","sentence":"Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP  and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A\/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B\/2C (SB-206553) receptors attenuated the DOI-elicited-HTR"}
{"PMID":23353901,"re_id":5,"annotated sentence":"Commercially-available <e2>5-HT2C<\\e2> agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and <e1>1-methylpsilocin<\\e1> , novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A\/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B\/2C (SB-206553) receptors attenuated the DOI-elicited-HTR","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"1-methylpsilocin","object":"5-HT2C","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Commercially-available <e2>GENE-Y<\\e2> agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and <e1>CHEMICAL<\\e1> , novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type GENE-Y agonists (with 5-HT2A\/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), GENE-Y (SB-242084), and 5-HT2B\/2C (SB-206553) receptors attenuated the DOI-elicited-HTR","sentence":"Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin , novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A\/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B\/2C (SB-206553) receptors attenuated the DOI-elicited-HTR"}
{"PMID":23353901,"re_id":6,"annotated sentence":"Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel\u00a0<e1>4-phenyl-2-N,N-dimethyl-aminotetralin<\\e1> (PAT)-type <e2>5-HT2C<\\e2> agonists (with 5-HT2A\/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B\/2C (SB-206553) receptors attenuated the DOI-elicited-HTR","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"4-phenyl-2-N,N-dimethyl-aminotetralin","object":"5-HT2C","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Commercially-available GENE-Y agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel\u00a0<e1>CHEMICAL<\\e1> (PAT)-type <e2>GENE-Y<\\e2> agonists (with 5-HT2A\/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), GENE-Y (SB-242084), and 5-HT2B\/2C (SB-206553) receptors attenuated the DOI-elicited-HTR","sentence":"Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A\/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B\/2C (SB-206553) receptors attenuated the DOI-elicited-HTR"}
{"PMID":23353901,"re_id":7,"annotated sentence":"Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (<e1>PAT<\\e1> -type <e2>5-HT2C<\\e2> agonists (with 5-HT2A\/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B\/2C (SB-206553) receptors attenuated the DOI-elicited-HTR","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"PAT","object":"5-HT2C","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Commercially-available GENE-Y agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (<e1>CHEMICAL<\\e1> -type <e2>GENE-Y<\\e2> agonists (with 5-HT2A\/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), GENE-Y (SB-242084), and 5-HT2B\/2C (SB-206553) receptors attenuated the DOI-elicited-HTR","sentence":"Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT -type 5-HT2C agonists (with 5-HT2A\/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B\/2C (SB-206553) receptors attenuated the DOI-elicited-HTR"}
{"PMID":23353901,"re_id":8,"annotated sentence":"Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A\/2B antagonist activity), and antagonists selective for <e2>5-HT2A<\\e2> (<e1>M100907<\\e1> , 5-HT2C (SB-242084), and 5-HT2B\/2C (SB-206553) receptors attenuated the DOI-elicited-HTR","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"M100907","object":"5-HT2A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with GENE-Y\/2B antagonist activity), and antagonists selective for <e2>GENE-Y<\\e2> (<e1>CHEMICAL<\\e1> , 5-HT2C (SB-242084), and 5-HT2B\/2C (SB-206553) receptors attenuated the DOI-elicited-HTR","sentence":"Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A\/2B antagonist activity), and antagonists selective for 5-HT2A (M100907 , 5-HT2C (SB-242084), and 5-HT2B\/2C (SB-206553) receptors attenuated the DOI-elicited-HTR"}
{"PMID":23353901,"re_id":9,"annotated sentence":"Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A\/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), <e2>5-HT2C<\\e2> (<e1>SB-242084<\\e1> , and 5-HT2B\/2C (SB-206553) receptors attenuated the DOI-elicited-HTR","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"SB-242084","object":"5-HT2C","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Commercially-available GENE-Y agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type GENE-Y agonists (with 5-HT2A\/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), <e2>GENE-Y<\\e2> (<e1>CHEMICAL<\\e1> , and 5-HT2B\/2C (SB-206553) receptors attenuated the DOI-elicited-HTR","sentence":"Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A\/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084 , and 5-HT2B\/2C (SB-206553) receptors attenuated the DOI-elicited-HTR"}
{"PMID":23361846,"re_id":0,"annotated sentence":"This investigation tested the hypothesis that CYP2B6 is a prominent CYP isoform responsible for clinical methadone N-demethylation and clearance, using the in vivo mechanism-based <e2>CYP2B6<\\e2> inhibitor <e1>ticlopidine<\\e1>  given orally for 4 days","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ticlopidine","object":"CYP2B6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This investigation tested the hypothesis that GENE-Y is a prominent CYP isoform responsible for clinical methadone N-demethylation and clearance, using the in vivo mechanism-based <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1>  given orally for 4 days","sentence":"This investigation tested the hypothesis that CYP2B6 is a prominent CYP isoform responsible for clinical methadone N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine  given orally for 4 days"}
{"PMID":23361846,"re_id":1,"annotated sentence":"<e1>Methadone<\\e1> N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and CYP3A4, but clinical disposition is often attributed to <e2>CYP3A4<\\e2>  This investigation tested the hypothesis that CYP2B6 is a prominent CYP isoform responsible for clinical methadone N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Methadone","object":"CYP3A4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and GENE-Y, but clinical disposition is often attributed to <e2>GENE-Y<\\e2>  This investigation tested the hypothesis that CYP2B6 is a prominent CYP isoform responsible for clinical methadone N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days","sentence":"Methadone N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and CYP3A4, but clinical disposition is often attributed to CYP3A4  This investigation tested the hypothesis that CYP2B6 is a prominent CYP isoform responsible for clinical methadone N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days"}
{"PMID":23361846,"re_id":2,"annotated sentence":"<e1>Methadone<\\e1> N-demethylation in vitro is catalyzed by hepatic <e2>cytochrome P4502B6<\\e2> (CYP2B6) and CYP3A4, but clinical disposition is often attributed to CYP3A4","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Methadone","object":"cytochrome P4502B6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> N-demethylation in vitro is catalyzed by hepatic <e2>GENE-Y<\\e2> (CYP2B6) and CYP3A4, but clinical disposition is often attributed to CYP3A4","sentence":"Methadone N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and CYP3A4, but clinical disposition is often attributed to CYP3A4"}
{"PMID":23361846,"re_id":3,"annotated sentence":"<e1>Methadone<\\e1> N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (<e2>CYP2B6<\\e2>  and CYP3A4, but clinical disposition is often attributed to CYP3A4","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Methadone","object":"CYP2B6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (<e2>GENE-Y<\\e2>  and CYP3A4, but clinical disposition is often attributed to CYP3A4","sentence":"Methadone N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6  and CYP3A4, but clinical disposition is often attributed to CYP3A4"}
{"PMID":23361846,"re_id":4,"annotated sentence":"<e1>Methadone<\\e1> N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and <e2>CYP3A4<\\e2>  but clinical disposition is often attributed to CYP3A4","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Methadone","object":"CYP3A4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and <e2>GENE-Y<\\e2>  but clinical disposition is often attributed to GENE-Y","sentence":"Methadone N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and CYP3A4  but clinical disposition is often attributed to CYP3A4"}
{"PMID":23361846,"re_id":5,"annotated sentence":"Methadone <e1>N<\\e1> demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and CYP3A4, but clinical disposition is often attributed to <e2>CYP3A4<\\e2>  This investigation tested the hypothesis that CYP2B6 is a prominent CYP isoform responsible for clinical methadone N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"N","object":"CYP3A4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Methadone <e1>CHEMICAL<\\e1> demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and GENE-Y, but clinical disposition is often attributed to <e2>GENE-Y<\\e2>  This investigation tested the hypothesis that CYP2B6 is a prominent CYP isoform responsible for clinical methadone CHEMICAL-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days","sentence":"Methadone N demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and CYP3A4, but clinical disposition is often attributed to CYP3A4  This investigation tested the hypothesis that CYP2B6 is a prominent CYP isoform responsible for clinical methadone N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days"}
{"PMID":23361846,"re_id":6,"annotated sentence":"Methadone <e1>N<\\e1> demethylation in vitro is catalyzed by hepatic <e2>cytochrome P4502B6<\\e2> (CYP2B6) and CYP3A4, but clinical disposition is often attributed to CYP3A4","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"N","object":"cytochrome P4502B6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Methadone <e1>CHEMICAL<\\e1> demethylation in vitro is catalyzed by hepatic <e2>GENE-Y<\\e2> (CYP2B6) and CYP3A4, but clinical disposition is often attributed to CYP3A4","sentence":"Methadone N demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and CYP3A4, but clinical disposition is often attributed to CYP3A4"}
{"PMID":23361846,"re_id":7,"annotated sentence":"Methadone <e1>N<\\e1> demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (<e2>CYP2B6<\\e2>  and CYP3A4, but clinical disposition is often attributed to CYP3A4","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"N","object":"CYP2B6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Methadone <e1>CHEMICAL<\\e1> demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (<e2>GENE-Y<\\e2>  and CYP3A4, but clinical disposition is often attributed to CYP3A4","sentence":"Methadone N demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6  and CYP3A4, but clinical disposition is often attributed to CYP3A4"}
{"PMID":23361846,"re_id":8,"annotated sentence":"Methadone <e1>N<\\e1> demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and <e2>CYP3A4<\\e2>  but clinical disposition is often attributed to CYP3A4","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"N","object":"CYP3A4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Methadone <e1>CHEMICAL<\\e1> demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and <e2>GENE-Y<\\e2>  but clinical disposition is often attributed to GENE-Y","sentence":"Methadone N demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and CYP3A4  but clinical disposition is often attributed to CYP3A4"}
{"PMID":23361846,"re_id":9,"annotated sentence":"CYP2B6 inhibition reduces methadone N-demethylation and clearance, and alters methadone concentrations, demonstrating an important role for <e2>CYP2B6<\\e2> in clinical <e1>methadone<\\e1> disposition.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"methadone","object":"CYP2B6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"GENE-Y inhibition reduces CHEMICAL N-demethylation and clearance, and alters CHEMICAL concentrations, demonstrating an important role for <e2>GENE-Y<\\e2> in clinical <e1>CHEMICAL<\\e1> disposition.","sentence":"CYP2B6 inhibition reduces methadone N-demethylation and clearance, and alters methadone concentrations, demonstrating an important role for CYP2B6 in clinical methadone disposition."}
{"PMID":23361846,"re_id":10,"annotated sentence":"This investigation tested the hypothesis that <e2>CYP2B6<\\e2> is a prominent CYP isoform responsible for clinical <e1>methadone<\\e1> N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"methadone","object":"CYP2B6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This investigation tested the hypothesis that <e2>GENE-Y<\\e2> is a prominent CYP isoform responsible for clinical <e1>CHEMICAL<\\e1> N-demethylation and clearance, using the in vivo mechanism-based GENE-Y inhibitor ticlopidine, given orally for 4 days","sentence":"This investigation tested the hypothesis that CYP2B6 is a prominent CYP isoform responsible for clinical methadone N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days"}
{"PMID":23361846,"re_id":11,"annotated sentence":"This investigation tested the hypothesis that CYP2B6 is a prominent <e2>CYP<\\e2> isoform responsible for clinical <e1>methadone<\\e1> N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"methadone","object":"CYP","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This investigation tested the hypothesis that GENE-N2B6 is a prominent <e2>GENE-N<\\e2> isoform responsible for clinical <e1>CHEMICAL<\\e1> N-demethylation and clearance, using the in vivo mechanism-based GENE-N2B6 inhibitor ticlopidine, given orally for 4 days","sentence":"This investigation tested the hypothesis that CYP2B6 is a prominent CYP isoform responsible for clinical methadone N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days"}
{"PMID":23361846,"re_id":12,"annotated sentence":"This investigation tested the hypothesis that <e2>CYP2B6<\\e2> is a prominent CYP isoform responsible for clinical methadone <e1>N<\\e1> demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"N","object":"CYP2B6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This investigation tested the hypothesis that <e2>GENE-Y<\\e2> is a prominent CYP isoform responsible for clinical methadone <e1>CHEMICAL<\\e1> demethylation and clearance, using the in vivo mechanism-based GENE-Y inhibitor ticlopidine, given orally for 4 days","sentence":"This investigation tested the hypothesis that CYP2B6 is a prominent CYP isoform responsible for clinical methadone N demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days"}
{"PMID":23361846,"re_id":13,"annotated sentence":"This investigation tested the hypothesis that CYP2B6 is a prominent <e2>CYP<\\e2> isoform responsible for clinical methadone <e1>N<\\e1> demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"N","object":"CYP","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This investigation tested the hypothesis that GENE-N2B6 is a prominent <e2>GENE-N<\\e2> isoform responsible for clinical methadone <e1>CHEMICAL<\\e1> demethylation and clearance, using the in vivo mechanism-based GENE-N2B6 inhibitor ticlopidine, given orally for 4 days","sentence":"This investigation tested the hypothesis that CYP2B6 is a prominent CYP isoform responsible for clinical methadone N demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days"}
{"PMID":23373701,"re_id":0,"annotated sentence":"We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, <e1>quinpirole<\\e1>  triggered an increase in the expression of <e2>GDNF<\\e2> that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"quinpirole","object":"GDNF","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, <e1>CHEMICAL<\\e1>  triggered an increase in the expression of <e2>GENE-N<\\e2> that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene","sentence":"We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, quinpirole  triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene"}
{"PMID":23373701,"re_id":1,"annotated sentence":"We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, <e1>quinpirole<\\e1>  triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of <e2>zinc-finger protein 268<\\e2> (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"quinpirole","object":"zinc-finger protein 268","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, <e1>CHEMICAL<\\e1>  triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of <e2>GENE-N<\\e2> (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene","sentence":"We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, quinpirole  triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene"}
{"PMID":23373701,"re_id":2,"annotated sentence":"We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, <e1>quinpirole<\\e1>  triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (<e2>Zif268<\\e2> , a DNA-binding transcription factor encoded by an immediate-early gene","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"quinpirole","object":"Zif268","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, <e1>CHEMICAL<\\e1>  triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (<e2>GENE-N<\\e2> , a DNA-binding transcription factor encoded by an immediate-early gene","sentence":"We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, quinpirole  triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268 , a DNA-binding transcription factor encoded by an immediate-early gene"}
{"PMID":23373701,"re_id":3,"annotated sentence":"Moreover, the <e2>D2R<\\e2> inhibitor <e1>raclopride<\\e1> blocked the increase of both GDNF and Zif268 expression following potassium-evoked dopamine release in SH-SY5Y cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"raclopride","object":"D2R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, the <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1> blocked the increase of both GDNF and Zif268 expression following potassium-evoked dopamine release in SH-SY5Y cells","sentence":"Moreover, the D2R inhibitor raclopride blocked the increase of both GDNF and Zif268 expression following potassium-evoked dopamine release in SH-SY5Y cells"}
{"PMID":23373701,"re_id":4,"annotated sentence":"Moreover, the D2R inhibitor <e1>raclopride<\\e1> blocked the increase of both <e2>GDNF<\\e2> and Zif268 expression following potassium-evoked dopamine release in SH-SY5Y cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"raclopride","object":"GDNF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, the D2R inhibitor <e1>CHEMICAL<\\e1> blocked the increase of both <e2>GENE-Y<\\e2> and Zif268 expression following potassium-evoked dopamine release in SH-SY5Y cells","sentence":"Moreover, the D2R inhibitor raclopride blocked the increase of both GDNF and Zif268 expression following potassium-evoked dopamine release in SH-SY5Y cells"}
{"PMID":23373701,"re_id":5,"annotated sentence":"Moreover, the D2R inhibitor <e1>raclopride<\\e1> blocked the increase of both GDNF and <e2>Zif268<\\e2> expression following potassium-evoked dopamine release in SH-SY5Y cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"raclopride","object":"Zif268","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, the D2R inhibitor <e1>CHEMICAL<\\e1> blocked the increase of both GDNF and <e2>GENE-Y<\\e2> expression following potassium-evoked dopamine release in SH-SY5Y cells","sentence":"Moreover, the D2R inhibitor raclopride blocked the increase of both GDNF and Zif268 expression following potassium-evoked dopamine release in SH-SY5Y cells"}
{"PMID":23373701,"re_id":6,"annotated sentence":"We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the <e2>dopamine D2 receptor<\\e2> (D2R) agonist, <e1>quinpirole<\\e1>  triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"quinpirole","object":"dopamine D2 receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the <e2>GENE-N<\\e2> (D2R) agonist, <e1>CHEMICAL<\\e1>  triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene","sentence":"We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, quinpirole  triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene"}
{"PMID":23373701,"re_id":7,"annotated sentence":"We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (<e2>D2R<\\e2>  agonist, <e1>quinpirole<\\e1>  triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"quinpirole","object":"D2R","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (<e2>GENE-N<\\e2>  agonist, <e1>CHEMICAL<\\e1>  triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene","sentence":"We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R  agonist, quinpirole  triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene"}
{"PMID":23376249,"re_id":0,"annotated sentence":"In this paper a series of new <e1>1,3,4-thiadiazole<\\e1> derivatives has been designed, synthesized and evaluated as the <e2>acetyl- and butyrylcholinesterase<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"1,3,4-thiadiazole","object":"acetyl- and butyrylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In this paper a series of new <e1>CHEMICAL<\\e1> derivatives has been designed, synthesized and evaluated as the <e2>GENE-N<\\e2> inhibitors","sentence":"In this paper a series of new 1,3,4-thiadiazole derivatives has been designed, synthesized and evaluated as the acetyl- and butyrylcholinesterase inhibitors"}
{"PMID":23376249,"re_id":1,"annotated sentence":"Synthesis and biological evaluation of <e1>1,3,4-thiadiazole<\\e1> analogues as novel <e2>AChE<\\e2> and BuChE inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"1,3,4-thiadiazole","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Synthesis and biological evaluation of <e1>CHEMICAL<\\e1> analogues as novel <e2>GENE-Y<\\e2> and BuChE inhibitors","sentence":"Synthesis and biological evaluation of 1,3,4-thiadiazole analogues as novel AChE and BuChE inhibitors"}
{"PMID":23376249,"re_id":2,"annotated sentence":"Synthesis and biological evaluation of <e1>1,3,4-thiadiazole<\\e1> analogues as novel AChE and <e2>BuChE<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"1,3,4-thiadiazole","object":"BuChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Synthesis and biological evaluation of <e1>CHEMICAL<\\e1> analogues as novel AChE and <e2>GENE-Y<\\e2> inhibitors","sentence":"Synthesis and biological evaluation of 1,3,4-thiadiazole analogues as novel AChE and BuChE inhibitors"}
{"PMID":23376356,"re_id":0,"annotated sentence":"<e1>LY294002<\\e1>  a specific PI3K\/AKT inhibitor, selectively activated the <e2>p38<\\e2> MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"LY294002","object":"p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a specific PI3K\/AKT inhibitor, selectively activated the <e2>GENE-N<\\e2> MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK","sentence":"LY294002  a specific PI3K\/AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK"}
{"PMID":23376356,"re_id":1,"annotated sentence":"<e1>LY294002<\\e1>  a specific PI3K\/AKT inhibitor, selectively activated the p38 <e2>MAPK<\\e2> kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"LY294002","object":"MAPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a specific PI3K\/AKT inhibitor, selectively activated the p38 <e2>GENE-N<\\e2> kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK","sentence":"LY294002  a specific PI3K\/AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK"}
{"PMID":23376356,"re_id":2,"annotated sentence":"<e1>LY294002<\\e1>  a specific PI3K\/AKT inhibitor, selectively activated the p38 MAPK <e2>kinase<\\e2> pathway and enhanced c-Jun phosphorylation, but did not activate JNK","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"LY294002","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a specific PI3K\/AKT inhibitor, selectively activated the p38 MAPK <e2>GENE-N<\\e2> pathway and enhanced c-Jun phosphorylation, but did not activate JNK","sentence":"LY294002  a specific PI3K\/AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK"}
{"PMID":23376356,"re_id":3,"annotated sentence":"<e1>LY294002<\\e1>  a specific PI3K\/AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced <e2>c-Jun<\\e2> phosphorylation, but did not activate JNK","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"LY294002","object":"c-Jun","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a specific PI3K\/AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced <e2>GENE-Y<\\e2> phosphorylation, but did not activate JNK","sentence":"LY294002  a specific PI3K\/AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK"}
{"PMID":23376356,"re_id":4,"annotated sentence":"<e1>LY294002<\\e1>  a specific <e2>PI3K<\\e2> AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"LY294002","object":"PI3K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a specific <e2>GENE-N<\\e2> AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK","sentence":"LY294002  a specific PI3K AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK"}
{"PMID":23376356,"re_id":5,"annotated sentence":"<e1>LY294002<\\e1>  a specific PI3K\/<e2>AKT<\\e2> inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"LY294002","object":"AKT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a specific PI3K\/<e2>GENE-N<\\e2> inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK","sentence":"LY294002  a specific PI3K\/AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK"}
{"PMID":23376356,"re_id":6,"annotated sentence":"The pharmacological inhibitors <e1>SB203580<\\e1> (<e2>p38<\\e2> inhibitor) and SP600125 (a JNK inhibitor) protected primary cultures of rat CGCs from LY294002-induced apoptosis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SB203580","object":"p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The pharmacological inhibitors <e1>CHEMICAL<\\e1> (<e2>GENE-N<\\e2> inhibitor) and SP600125 (a JNK inhibitor) protected primary cultures of rat CGCs from LY294002-induced apoptosis","sentence":"The pharmacological inhibitors SB203580 (p38 inhibitor) and SP600125 (a JNK inhibitor) protected primary cultures of rat CGCs from LY294002-induced apoptosis"}
{"PMID":23376356,"re_id":7,"annotated sentence":"The pharmacological inhibitors SB203580 (p38 inhibitor) and <e1>SP600125<\\e1> (a <e2>JNK<\\e2> inhibitor) protected primary cultures of rat CGCs from LY294002-induced apoptosis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SP600125","object":"JNK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The pharmacological inhibitors SB203580 (p38 inhibitor) and <e1>CHEMICAL<\\e1> (a <e2>GENE-N<\\e2> inhibitor) protected primary cultures of rat CGCs from LY294002-induced apoptosis","sentence":"The pharmacological inhibitors SB203580 (p38 inhibitor) and SP600125 (a JNK inhibitor) protected primary cultures of rat CGCs from LY294002-induced apoptosis"}
{"PMID":23380477,"re_id":0,"annotated sentence":"Today, we used <e1>cobalt chloride<\\e1>  a hypoxia mimetic that inhibits proteasomal <e2>HIF-1<\\e2> degradation and generates reactive oxygen species (ROS)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cobalt chloride","object":"HIF-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Today, we used <e1>CHEMICAL<\\e1>  a hypoxia mimetic that inhibits proteasomal <e2>GENE-Y<\\e2> degradation and generates reactive oxygen species (ROS)","sentence":"Today, we used cobalt chloride  a hypoxia mimetic that inhibits proteasomal HIF-1 degradation and generates reactive oxygen species (ROS)"}
{"PMID":23380477,"re_id":1,"annotated sentence":"An autophagic signaling was evidenced by an increase of Beclin-1, ATG 5-12, and LC3-II expression whereas the <e2>p53<\\e2> mut) presence decreased with <e1>CoCl2<\\e1> time exposure","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CoCl2","object":"p53","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"An autophagic signaling was evidenced by an increase of Beclin-1, ATG 5-12, and LC3-II expression whereas the <e2>GENE-Y<\\e2> mut) presence decreased with <e1>CHEMICAL<\\e1> time exposure","sentence":"An autophagic signaling was evidenced by an increase of Beclin-1, ATG 5-12, and LC3-II expression whereas the p53 mut) presence decreased with CoCl2 time exposure"}
{"PMID":23382381,"re_id":0,"annotated sentence":"Cellular responses to DNA damage induced by <e1>etoposide<\\e1> or doxorubicin include down-regulation of endogenous supervillin coincident with increases in <e2>p53<\\e2>  In DNA-damaged supervillin knockdown cells, p53 knockdown or inhibition partially rescues the loss of cell metabolic activity, a measure of cell proliferation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"etoposide","object":"p53","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cellular responses to DNA damage induced by <e1>CHEMICAL<\\e1> or doxorubicin include down-regulation of endogenous supervillin coincident with increases in <e2>GENE-Y<\\e2>  In DNA-damaged supervillin knockdown cells, GENE-Y knockdown or inhibition partially rescues the loss of cell metabolic activity, a measure of cell proliferation","sentence":"Cellular responses to DNA damage induced by etoposide or doxorubicin include down-regulation of endogenous supervillin coincident with increases in p53  In DNA-damaged supervillin knockdown cells, p53 knockdown or inhibition partially rescues the loss of cell metabolic activity, a measure of cell proliferation"}
{"PMID":23382381,"re_id":1,"annotated sentence":"Cellular responses to DNA damage induced by etoposide or <e1>doxorubicin<\\e1> include down-regulation of endogenous supervillin coincident with increases in <e2>p53<\\e2>  In DNA-damaged supervillin knockdown cells, p53 knockdown or inhibition partially rescues the loss of cell metabolic activity, a measure of cell proliferation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"doxorubicin","object":"p53","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cellular responses to DNA damage induced by etoposide or <e1>CHEMICAL<\\e1> include down-regulation of endogenous supervillin coincident with increases in <e2>GENE-Y<\\e2>  In DNA-damaged supervillin knockdown cells, GENE-Y knockdown or inhibition partially rescues the loss of cell metabolic activity, a measure of cell proliferation","sentence":"Cellular responses to DNA damage induced by etoposide or doxorubicin include down-regulation of endogenous supervillin coincident with increases in p53  In DNA-damaged supervillin knockdown cells, p53 knockdown or inhibition partially rescues the loss of cell metabolic activity, a measure of cell proliferation"}
{"PMID":23382381,"re_id":2,"annotated sentence":"Cellular responses to DNA damage induced by <e1>etoposide<\\e1> or doxorubicin include down-regulation of endogenous <e2>supervillin<\\e2> coincident with increases in p53","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"etoposide","object":"supervillin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cellular responses to DNA damage induced by <e1>CHEMICAL<\\e1> or doxorubicin include down-regulation of endogenous <e2>GENE-Y<\\e2> coincident with increases in p53","sentence":"Cellular responses to DNA damage induced by etoposide or doxorubicin include down-regulation of endogenous supervillin coincident with increases in p53"}
{"PMID":23382381,"re_id":3,"annotated sentence":"Cellular responses to DNA damage induced by etoposide or <e1>doxorubicin<\\e1> include down-regulation of endogenous <e2>supervillin<\\e2> coincident with increases in p53","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"doxorubicin","object":"supervillin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cellular responses to DNA damage induced by etoposide or <e1>CHEMICAL<\\e1> include down-regulation of endogenous <e2>GENE-Y<\\e2> coincident with increases in p53","sentence":"Cellular responses to DNA damage induced by etoposide or doxorubicin include down-regulation of endogenous supervillin coincident with increases in p53"}
{"PMID":23384387,"re_id":0,"annotated sentence":"Novel <e1>acylethanolamide<\\e1> derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (<e2>POMC<\\e2>  and\/or decreased neuropeptide Y (NPY)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"acylethanolamide","object":"POMC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Novel <e1>CHEMICAL<\\e1> derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (<e2>GENE-Y<\\e2>  and\/or decreased neuropeptide Y (NPY)","sentence":"Novel acylethanolamide derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC  and\/or decreased neuropeptide Y (NPY)"}
{"PMID":23384387,"re_id":1,"annotated sentence":"Novel <e1>acylethanolamide<\\e1> derivatives that modulate body weight through enhancement of hypothalamic <e2>pro-opiomelanocortin<\\e2> (POMC) and\/or decreased neuropeptide Y (NPY)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"acylethanolamide","object":"pro-opiomelanocortin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Novel <e1>CHEMICAL<\\e1> derivatives that modulate body weight through enhancement of hypothalamic <e2>GENE-Y<\\e2> (POMC) and\/or decreased neuropeptide Y (NPY)","sentence":"Novel acylethanolamide derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and\/or decreased neuropeptide Y (NPY)"}
{"PMID":23384387,"re_id":2,"annotated sentence":"Novel <e1>acylethanolamide<\\e1> derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and\/or decreased <e2>neuropeptide Y<\\e2> (NPY)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acylethanolamide","object":"neuropeptide Y","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Novel <e1>CHEMICAL<\\e1> derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and\/or decreased <e2>GENE-Y<\\e2> (NPY)","sentence":"Novel acylethanolamide derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and\/or decreased neuropeptide Y (NPY)"}
{"PMID":23384387,"re_id":3,"annotated sentence":"Novel <e1>acylethanolamide<\\e1> derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and\/or decreased neuropeptide Y (<e2>NPY<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acylethanolamide","object":"NPY","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Novel <e1>CHEMICAL<\\e1> derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and\/or decreased neuropeptide Y (<e2>GENE-Y<\\e2> ","sentence":"Novel acylethanolamide derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and\/or decreased neuropeptide Y (NPY "}
{"PMID":23397032,"re_id":0,"annotated sentence":"<e1>Dexamethasone<\\e1> suppressed <e2>IL-11<\\e2> gene transcription enhanced by PTH(1-34) without affecting \u0394FosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with \u0394FosB","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Dexamethasone","object":"IL-11","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> suppressed <e2>GENE-Y<\\e2> gene transcription enhanced by PTH(1-34) without affecting \u0394FosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with \u0394FosB","sentence":"Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting \u0394FosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with \u0394FosB"}
{"PMID":23402856,"re_id":0,"annotated sentence":"Number and area of preneoplastic foci positive for <e2>glutathione S-transferase placental form<\\e2> (GST-P) were consistently higher in these groups than the sum of individual values in the groups treated with <e1>HEP<\\e1> or HCB alone","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"HEP","object":"glutathione S-transferase placental form","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Number and area of preneoplastic foci positive for <e2>GENE-N<\\e2> (GST-P) were consistently higher in these groups than the sum of individual values in the groups treated with <e1>CHEMICAL<\\e1> or HCB alone","sentence":"Number and area of preneoplastic foci positive for glutathione S-transferase placental form (GST-P) were consistently higher in these groups than the sum of individual values in the groups treated with HEP or HCB alone"}
{"PMID":23402856,"re_id":1,"annotated sentence":"Number and area of preneoplastic foci positive for glutathione S-transferase placental form (<e2>GST-P<\\e2>  were consistently higher in these groups than the sum of individual values in the groups treated with <e1>HEP<\\e1> or HCB alone","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"HEP","object":"GST-P","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Number and area of preneoplastic foci positive for glutathione S-transferase placental form (<e2>GENE-N<\\e2>  were consistently higher in these groups than the sum of individual values in the groups treated with <e1>CHEMICAL<\\e1> or HCB alone","sentence":"Number and area of preneoplastic foci positive for glutathione S-transferase placental form (GST-P  were consistently higher in these groups than the sum of individual values in the groups treated with HEP or HCB alone"}
{"PMID":23402856,"re_id":2,"annotated sentence":"Number and area of preneoplastic foci positive for <e2>glutathione S-transferase placental form<\\e2> (GST-P) were consistently higher in these groups than the sum of individual values in the groups treated with HEP or <e1>HCB<\\e1> alone","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"HCB","object":"glutathione S-transferase placental form","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Number and area of preneoplastic foci positive for <e2>GENE-N<\\e2> (GST-P) were consistently higher in these groups than the sum of individual values in the groups treated with HEP or <e1>CHEMICAL<\\e1> alone","sentence":"Number and area of preneoplastic foci positive for glutathione S-transferase placental form (GST-P) were consistently higher in these groups than the sum of individual values in the groups treated with HEP or HCB alone"}
{"PMID":23402856,"re_id":3,"annotated sentence":"Number and area of preneoplastic foci positive for glutathione S-transferase placental form (<e2>GST-P<\\e2>  were consistently higher in these groups than the sum of individual values in the groups treated with HEP or <e1>HCB<\\e1> alone","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"HCB","object":"GST-P","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Number and area of preneoplastic foci positive for glutathione S-transferase placental form (<e2>GENE-N<\\e2>  were consistently higher in these groups than the sum of individual values in the groups treated with HEP or <e1>CHEMICAL<\\e1> alone","sentence":"Number and area of preneoplastic foci positive for glutathione S-transferase placental form (GST-P  were consistently higher in these groups than the sum of individual values in the groups treated with HEP or HCB alone"}
{"PMID":23402856,"re_id":4,"annotated sentence":"On the basis of these findings, we conclude that <e1>HEP<\\e1> and HCB have additive and synergistic effects on the development of <e2>GST-P<\\e2> positive foci and that higher risks are associated with a combination of residual organochlorine pesticides in foods than with individual residual organochlorine pesticides.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"HEP","object":"GST-P","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"On the basis of these findings, we conclude that <e1>CHEMICAL<\\e1> and HCB have additive and synergistic effects on the development of <e2>GENE-N<\\e2> positive foci and that higher risks are associated with a combination of residual organochlorine pesticides in foods than with individual residual organochlorine pesticides.","sentence":"On the basis of these findings, we conclude that HEP and HCB have additive and synergistic effects on the development of GST-P positive foci and that higher risks are associated with a combination of residual organochlorine pesticides in foods than with individual residual organochlorine pesticides."}
{"PMID":23402856,"re_id":5,"annotated sentence":"On the basis of these findings, we conclude that HEP and <e1>HCB<\\e1> have additive and synergistic effects on the development of <e2>GST-P<\\e2> positive foci and that higher risks are associated with a combination of residual organochlorine pesticides in foods than with individual residual organochlorine pesticides.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"HCB","object":"GST-P","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"On the basis of these findings, we conclude that HEP and <e1>CHEMICAL<\\e1> have additive and synergistic effects on the development of <e2>GENE-N<\\e2> positive foci and that higher risks are associated with a combination of residual organochlorine pesticides in foods than with individual residual organochlorine pesticides.","sentence":"On the basis of these findings, we conclude that HEP and HCB have additive and synergistic effects on the development of GST-P positive foci and that higher risks are associated with a combination of residual organochlorine pesticides in foods than with individual residual organochlorine pesticides."}
{"PMID":23403092,"re_id":0,"annotated sentence":"Taken together these results indicate that in vivo or ex vivo exposure of intestinal tissue to <e1>DON<\\e1> lead to similar intestinal lesions and activation of <e2>MAPK<\\e2>  These effects could impair the homeostasis of intestinal tissue in the aspects of barrier function and immune protection","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"DON","object":"MAPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Taken together these results indicate that in vivo or ex vivo exposure of intestinal tissue to <e1>CHEMICAL<\\e1> lead to similar intestinal lesions and activation of <e2>GENE-N<\\e2>  These effects could impair the homeostasis of intestinal tissue in the aspects of barrier function and immune protection","sentence":"Taken together these results indicate that in vivo or ex vivo exposure of intestinal tissue to DON lead to similar intestinal lesions and activation of MAPK  These effects could impair the homeostasis of intestinal tissue in the aspects of barrier function and immune protection"}
{"PMID":23403092,"re_id":1,"annotated sentence":"The food contaminant <e1>deoxynivalenol<\\e1> activates the <e2>mitogen activated protein kinases<\\e2> in the intestine: interest of ex vivo models as an alternative to in vivo experiments","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"deoxynivalenol","object":"mitogen activated protein kinases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The food contaminant <e1>CHEMICAL<\\e1> activates the <e2>GENE-N<\\e2> in the intestine: interest of ex vivo models as an alternative to in vivo experiments","sentence":"The food contaminant deoxynivalenol activates the mitogen activated protein kinases in the intestine: interest of ex vivo models as an alternative to in vivo experiments"}
{"PMID":23403272,"re_id":0,"annotated sentence":"In particular, we showed that <e1>Paeoniflorin<\\e1> significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and <e2>superoxide dismutase<\\e2> (SOD) in EA.hy926 cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Paeoniflorin","object":"superoxide dismutase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In particular, we showed that <e1>CHEMICAL<\\e1> significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and <e2>GENE-N<\\e2> (SOD) in EA.hy926 cells","sentence":"In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells"}
{"PMID":23403272,"re_id":1,"annotated sentence":"In particular, we showed that <e1>Paeoniflorin<\\e1> significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (<e2>SOD<\\e2>  in EA.hy926 cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Paeoniflorin","object":"SOD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In particular, we showed that <e1>CHEMICAL<\\e1> significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (<e2>GENE-N<\\e2>  in EA.hy926 cells","sentence":"In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD  in EA.hy926 cells"}
{"PMID":23403272,"re_id":2,"annotated sentence":"Treatment of these cells with <e1>Paeoniflorin<\\e1> significantly induced <e2>HO-1<\\e2> expression","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Paeoniflorin","object":"HO-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment of these cells with <e1>CHEMICAL<\\e1> significantly induced <e2>GENE-Y<\\e2> expression","sentence":"Treatment of these cells with Paeoniflorin significantly induced HO-1 expression"}
{"PMID":23403272,"re_id":3,"annotated sentence":"<e1>Paeoniflorin<\\e1> protects human EA.hy926 endothelial cells against gamma-radiation induced oxidative injury by activating the <e2>NF-E2-related factor 2<\\e2> heme oxygenase-1 pathway","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Paeoniflorin","object":"NF-E2-related factor 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> protects human EA.hy926 endothelial cells against gamma-radiation induced oxidative injury by activating the <e2>GENE-Y<\\e2> heme oxygenase-1 pathway","sentence":"Paeoniflorin protects human EA.hy926 endothelial cells against gamma-radiation induced oxidative injury by activating the NF-E2-related factor 2 heme oxygenase-1 pathway"}
{"PMID":23403272,"re_id":4,"annotated sentence":"<e1>Paeoniflorin<\\e1> protects human EA.hy926 endothelial cells against gamma-radiation induced oxidative injury by activating the NF-E2-related factor 2\/<e2>heme oxygenase-1<\\e2> pathway","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Paeoniflorin","object":"heme oxygenase-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> protects human EA.hy926 endothelial cells against gamma-radiation induced oxidative injury by activating the NF-E2-related factor 2\/<e2>GENE-Y<\\e2> pathway","sentence":"Paeoniflorin protects human EA.hy926 endothelial cells against gamma-radiation induced oxidative injury by activating the NF-E2-related factor 2\/heme oxygenase-1 pathway"}
{"PMID":23403272,"re_id":5,"annotated sentence":"The <e1>Paeoniflorin<\\e1> induced <e2>HO-1<\\e2> expression was abrogated by Nrf2 siRNA","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Paeoniflorin","object":"HO-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e1>CHEMICAL<\\e1> induced <e2>GENE-Y<\\e2> expression was abrogated by Nrf2 siRNA","sentence":"The Paeoniflorin induced HO-1 expression was abrogated by Nrf2 siRNA"}
{"PMID":23403272,"re_id":6,"annotated sentence":"Furthermore, inhibition of <e2>HO-1<\\e2> with zinc protoporphyrin IX (ZNPP) significantly reversed the protective effect of <e1>Paeoniflorin<\\e1> against radiation-induced damage in EA.hy926 cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Paeoniflorin","object":"HO-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, inhibition of <e2>GENE-Y<\\e2> with zinc protoporphyrin IX (ZNPP) significantly reversed the protective effect of <e1>CHEMICAL<\\e1> against radiation-induced damage in EA.hy926 cells","sentence":"Furthermore, inhibition of HO-1 with zinc protoporphyrin IX (ZNPP) significantly reversed the protective effect of Paeoniflorin against radiation-induced damage in EA.hy926 cells"}
{"PMID":23403272,"re_id":7,"annotated sentence":"Our findings confirmed that <e1>Paeoniflorin<\\e1> protected EA.hy926 cells against radiation-induced injury through the <e2>Nrf2<\\e2> HO-1 pathway.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Paeoniflorin","object":"Nrf2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our findings confirmed that <e1>CHEMICAL<\\e1> protected EA.hy926 cells against radiation-induced injury through the <e2>GENE-Y<\\e2> HO-1 pathway.","sentence":"Our findings confirmed that Paeoniflorin protected EA.hy926 cells against radiation-induced injury through the Nrf2 HO-1 pathway."}
{"PMID":23403272,"re_id":8,"annotated sentence":"Our findings confirmed that <e1>Paeoniflorin<\\e1> protected EA.hy926 cells against radiation-induced injury through the Nrf2\/<e2>HO-1<\\e2> pathway.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Paeoniflorin","object":"HO-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our findings confirmed that <e1>CHEMICAL<\\e1> protected EA.hy926 cells against radiation-induced injury through the Nrf2\/<e2>GENE-Y<\\e2> pathway.","sentence":"Our findings confirmed that Paeoniflorin protected EA.hy926 cells against radiation-induced injury through the Nrf2\/HO-1 pathway."}
{"PMID":23403272,"re_id":9,"annotated sentence":"In particular, we showed that <e1>Paeoniflorin<\\e1> significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and <e2>lactate dehydrogenase<\\e2> (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Paeoniflorin","object":"lactate dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In particular, we showed that <e1>CHEMICAL<\\e1> significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and <e2>GENE-N<\\e2> (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells","sentence":"In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells"}
{"PMID":23403272,"re_id":10,"annotated sentence":"In particular, we showed that <e1>Paeoniflorin<\\e1> significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (<e2>LDH<\\e2>  leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Paeoniflorin","object":"LDH","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In particular, we showed that <e1>CHEMICAL<\\e1> significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (<e2>GENE-N<\\e2>  leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells","sentence":"In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH  leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells"}
{"PMID":23403272,"re_id":11,"annotated sentence":"Furthermore, inhibition of <e2>HO-1<\\e2> with <e1>zinc protoporphyrin IX<\\e1> (ZNPP) significantly reversed the protective effect of Paeoniflorin against radiation-induced damage in EA.hy926 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"zinc protoporphyrin IX","object":"HO-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, inhibition of <e2>GENE-Y<\\e2> with <e1>CHEMICAL<\\e1> (ZNPP) significantly reversed the protective effect of Paeoniflorin against radiation-induced damage in EA.hy926 cells","sentence":"Furthermore, inhibition of HO-1 with zinc protoporphyrin IX (ZNPP) significantly reversed the protective effect of Paeoniflorin against radiation-induced damage in EA.hy926 cells"}
{"PMID":23403272,"re_id":12,"annotated sentence":"Furthermore, inhibition of <e2>HO-1<\\e2> with zinc protoporphyrin IX (<e1>ZNPP<\\e1>  significantly reversed the protective effect of Paeoniflorin against radiation-induced damage in EA.hy926 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ZNPP","object":"HO-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, inhibition of <e2>GENE-Y<\\e2> with zinc protoporphyrin IX (<e1>CHEMICAL<\\e1>  significantly reversed the protective effect of Paeoniflorin against radiation-induced damage in EA.hy926 cells","sentence":"Furthermore, inhibition of HO-1 with zinc protoporphyrin IX (ZNPP  significantly reversed the protective effect of Paeoniflorin against radiation-induced damage in EA.hy926 cells"}
{"PMID":23404093,"re_id":0,"annotated sentence":"<e1>Palonosetron<\\e1>  a second-generation <e2>5-HT3<\\e2> receptor antagonist with a different half-life, a different binding capacity and a different mechanism of action than the first-generation 5-HT3 receptor antagonists appears to be the most effective agent in its class","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Palonosetron","object":"5-HT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a second-generation <e2>GENE-Y<\\e2> receptor antagonist with a different half-life, a different binding capacity and a different mechanism of action than the first-generation GENE-Y receptor antagonists appears to be the most effective agent in its class","sentence":"Palonosetron  a second-generation 5-HT3 receptor antagonist with a different half-life, a different binding capacity and a different mechanism of action than the first-generation 5-HT3 receptor antagonists appears to be the most effective agent in its class"}
{"PMID":23404093,"re_id":1,"annotated sentence":"<e1>Aprepitant<\\e1>  the first and only agent clinically available in the <e2>NK1 receptor<\\e2> antagonist drug class has been used effectively as an additive agent to the 5-HT3 receptor antagonists and dexamethasone to control CINV","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Aprepitant","object":"NK1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  the first and only agent clinically available in the <e2>GENE-Y<\\e2> antagonist drug class has been used effectively as an additive agent to the 5-HT3 receptor antagonists and dexamethasone to control CINV","sentence":"Aprepitant  the first and only agent clinically available in the NK1 receptor antagonist drug class has been used effectively as an additive agent to the 5-HT3 receptor antagonists and dexamethasone to control CINV"}
{"PMID":23404093,"re_id":2,"annotated sentence":"<e1>Rolapitant<\\e1> and netupitant are other <e2>NK1 receptor<\\e2> antagonists that are currently in phase III clinical trials","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Rolapitant","object":"NK1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and netupitant are other <e2>GENE-Y<\\e2> antagonists that are currently in phase III clinical trials","sentence":"Rolapitant and netupitant are other NK1 receptor antagonists that are currently in phase III clinical trials"}
{"PMID":23404093,"re_id":3,"annotated sentence":"Rolapitant and <e1>netupitant<\\e1> are other <e2>NK1 receptor<\\e2> antagonists that are currently in phase III clinical trials","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"netupitant","object":"NK1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Rolapitant and <e1>CHEMICAL<\\e1> are other <e2>GENE-Y<\\e2> antagonists that are currently in phase III clinical trials","sentence":"Rolapitant and netupitant are other NK1 receptor antagonists that are currently in phase III clinical trials"}
{"PMID":23411235,"re_id":0,"annotated sentence":"Moderate inhibitory effect of <e2>LDL<\\e2> C oxidation by <e1>phytosteryl phenolates<\\e1> was observed","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phytosteryl phenolates","object":"LDL","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moderate inhibitory effect of <e2>GENE-N<\\e2> C oxidation by <e1>CHEMICAL<\\e1> was observed","sentence":"Moderate inhibitory effect of LDL C oxidation by phytosteryl phenolates was observed"}
{"PMID":23411279,"re_id":0,"annotated sentence":"Aqueous <e1>ethanol<\\e1> (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting <e2>15-LOX<\\e2> (IC(50), 55 \u03bcg\/ml), with moderate COX-1 (IC(50), 66 \u03bcg\/ml) and COX-2 (IC(50), 119 \u03bcg\/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ethanol","object":"15-LOX","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Aqueous <e1>CHEMICAL<\\e1> (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting <e2>GENE-Y<\\e2> (IC(50), 55 \u03bcg\/ml), with moderate COX-1 (IC(50), 66 \u03bcg\/ml) and COX-2 (IC(50), 119 \u03bcg\/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.","sentence":"Aqueous ethanol (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-LOX (IC(50), 55 \u03bcg\/ml), with moderate COX-1 (IC(50), 66 \u03bcg\/ml) and COX-2 (IC(50), 119 \u03bcg\/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity."}
{"PMID":23411279,"re_id":1,"annotated sentence":"Aqueous <e1>ethanol<\\e1> (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-LOX (IC(50), 55 \u03bcg\/ml), with moderate <e2>COX-1<\\e2> (IC(50), 66 \u03bcg\/ml) and COX-2 (IC(50), 119 \u03bcg\/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ethanol","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Aqueous <e1>CHEMICAL<\\e1> (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-LOX (IC(50), 55 \u03bcg\/ml), with moderate <e2>GENE-Y<\\e2> (IC(50), 66 \u03bcg\/ml) and COX-2 (IC(50), 119 \u03bcg\/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.","sentence":"Aqueous ethanol (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-LOX (IC(50), 55 \u03bcg\/ml), with moderate COX-1 (IC(50), 66 \u03bcg\/ml) and COX-2 (IC(50), 119 \u03bcg\/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity."}
{"PMID":23411279,"re_id":2,"annotated sentence":"Aqueous <e1>ethanol<\\e1> (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-LOX (IC(50), 55 \u03bcg\/ml), with moderate COX-1 (IC(50), 66 \u03bcg\/ml) and <e2>COX-2<\\e2> (IC(50), 119 \u03bcg\/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ethanol","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Aqueous <e1>CHEMICAL<\\e1> (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-LOX (IC(50), 55 \u03bcg\/ml), with moderate COX-1 (IC(50), 66 \u03bcg\/ml) and <e2>GENE-Y<\\e2> (IC(50), 119 \u03bcg\/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.","sentence":"Aqueous ethanol (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-LOX (IC(50), 55 \u03bcg\/ml), with moderate COX-1 (IC(50), 66 \u03bcg\/ml) and COX-2 (IC(50), 119 \u03bcg\/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity."}
{"PMID":23411279,"re_id":3,"annotated sentence":"Aqueous <e1>ethanol<\\e1> (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-LOX (IC(50), 55 \u03bcg\/ml), with moderate COX-1 (IC(50), 66 \u03bcg\/ml) and COX-2 (IC(50), 119 \u03bcg\/ml) inhibitory effects on the <e2>COX<\\e2> pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ethanol","object":"COX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Aqueous <e1>CHEMICAL<\\e1> (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-LOX (IC(50), 55 \u03bcg\/ml), with moderate GENE-N-1 (IC(50), 66 \u03bcg\/ml) and GENE-N-2 (IC(50), 119 \u03bcg\/ml) inhibitory effects on the <e2>GENE-N<\\e2> pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.","sentence":"Aqueous ethanol (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-LOX (IC(50), 55 \u03bcg\/ml), with moderate COX-1 (IC(50), 66 \u03bcg\/ml) and COX-2 (IC(50), 119 \u03bcg\/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity."}
{"PMID":23411279,"re_id":4,"annotated sentence":"Aqueous <e1>ethanol<\\e1> (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-LOX (IC(50), 55 \u03bcg\/ml), with moderate COX-1 (IC(50), 66 \u03bcg\/ml) and COX-2 (IC(50), 119 \u03bcg\/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild <e2>LOX<\\e2> inhibitory activity.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ethanol","object":"LOX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Aqueous <e1>CHEMICAL<\\e1> (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-GENE-N (IC(50), 55 \u03bcg\/ml), with moderate COX-1 (IC(50), 66 \u03bcg\/ml) and COX-2 (IC(50), 119 \u03bcg\/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild <e2>GENE-N<\\e2> inhibitory activity.","sentence":"Aqueous ethanol (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-LOX (IC(50), 55 \u03bcg\/ml), with moderate COX-1 (IC(50), 66 \u03bcg\/ml) and COX-2 (IC(50), 119 \u03bcg\/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity."}
{"PMID":23411280,"re_id":0,"annotated sentence":"We searched for inhibitors of <e2>HDC<\\e2> from the <e1>ethyl acetate<\\e1> extract of the petal of Filipendula ulmaria, also called meadowsweet","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ethyl acetate","object":"HDC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We searched for inhibitors of <e2>GENE-Y<\\e2> from the <e1>CHEMICAL<\\e1> extract of the petal of Filipendula ulmaria, also called meadowsweet","sentence":"We searched for inhibitors of HDC from the ethyl acetate extract of the petal of Filipendula ulmaria, also called meadowsweet"}
{"PMID":23411280,"re_id":1,"annotated sentence":"<e2>Histidine decarboxylase<\\e2> (HDC) catalyses the formation of histamine, a bioactive <e1>amine<\\e1>  Agents that control HDC activity are beneficial for treating histamine-mediated symptoms, such as allergies and stomach ulceration","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"amine","object":"Histidine decarboxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (HDC) catalyses the formation of histCHEMICAL, a bioactive <e1>CHEMICAL<\\e1>  Agents that control HDC activity are beneficial for treating histCHEMICAL-mediated symptoms, such as allergies and stomach ulceration","sentence":"Histidine decarboxylase (HDC) catalyses the formation of histamine, a bioactive amine  Agents that control HDC activity are beneficial for treating histamine-mediated symptoms, such as allergies and stomach ulceration"}
{"PMID":23411280,"re_id":2,"annotated sentence":"Histidine decarboxylase (<e2>HDC<\\e2>  catalyses the formation of histamine, a bioactive <e1>amine<\\e1>  Agents that control HDC activity are beneficial for treating histamine-mediated symptoms, such as allergies and stomach ulceration","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"amine","object":"HDC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Histidine decarboxylase (<e2>GENE-Y<\\e2>  catalyses the formation of histCHEMICAL, a bioactive <e1>CHEMICAL<\\e1>  Agents that control GENE-Y activity are beneficial for treating histCHEMICAL-mediated symptoms, such as allergies and stomach ulceration","sentence":"Histidine decarboxylase (HDC  catalyses the formation of histamine, a bioactive amine  Agents that control HDC activity are beneficial for treating histamine-mediated symptoms, such as allergies and stomach ulceration"}
{"PMID":23411280,"re_id":3,"annotated sentence":"<e2>Histidine decarboxylase<\\e2> (HDC) catalyses the formation of <e1>histamine<\\e1>  a bioactive amine","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"histamine","object":"Histidine decarboxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (HDC) catalyses the formation of <e1>CHEMICAL<\\e1>  a bioactive amine","sentence":"Histidine decarboxylase (HDC) catalyses the formation of histamine  a bioactive amine"}
{"PMID":23411280,"re_id":4,"annotated sentence":"Histidine decarboxylase (<e2>HDC<\\e2>  catalyses the formation of <e1>histamine<\\e1>  a bioactive amine","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"histamine","object":"HDC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Histidine decarboxylase (<e2>GENE-Y<\\e2>  catalyses the formation of <e1>CHEMICAL<\\e1>  a bioactive amine","sentence":"Histidine decarboxylase (HDC  catalyses the formation of histamine  a bioactive amine"}
{"PMID":23414838,"re_id":0,"annotated sentence":"High throughput screening led to the identification of a novel series of <e1>quinolone<\\e1> \u03b17 nicotinic acetylcholine receptor (<e2>nAChR<\\e2>  agonists","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"quinolone","object":"nAChR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"High throughput screening led to the identification of a novel series of <e1>CHEMICAL<\\e1> \u03b17 nicotinic acetylcholine receptor (<e2>GENE-N<\\e2>  agonists","sentence":"High throughput screening led to the identification of a novel series of quinolone \u03b17 nicotinic acetylcholine receptor (nAChR  agonists"}
{"PMID":23414838,"re_id":1,"annotated sentence":"High throughput screening led to the identification of a novel series of <e1>quinolone<\\e1> <e2>\u03b17 nicotinic acetylcholine receptor<\\e2> (nAChR) agonists","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"quinolone","object":"\u03b17 nicotinic acetylcholine receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"High throughput screening led to the identification of a novel series of <e1>CHEMICAL<\\e1> <e2>GENE-Y<\\e2> (nAChR) agonists","sentence":"High throughput screening led to the identification of a novel series of quinolone \u03b17 nicotinic acetylcholine receptor (nAChR) agonists"}
{"PMID":23414838,"re_id":2,"annotated sentence":"Discovery of a novel series of <e1>quinolone<\\e1> <e2>\u03b17 nicotinic acetylcholine receptor<\\e2> agonists","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"quinolone","object":"\u03b17 nicotinic acetylcholine receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Discovery of a novel series of <e1>CHEMICAL<\\e1> <e2>GENE-Y<\\e2> agonists","sentence":"Discovery of a novel series of quinolone \u03b17 nicotinic acetylcholine receptor agonists"}
{"PMID":23416002,"re_id":0,"annotated sentence":"This is distinct from <e2>Rock<\\e2> inhibitors based on non-<e1>amino acid<\\e1> derived quinazolinones, where high selectivity against PKA could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of Rock, nanomolar potency in ppMLC cell based assays, low to fair cytochrome P-450 inhibition, and good human microsomal stability.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"amino acid","object":"Rock","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This is distinct from <e2>GENE-N<\\e2> inhibitors based on non-<e1>CHEMICAL<\\e1> derived quinazolinones, where high selectivity against PKA could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of GENE-N, nanomolar potency in ppMLC cell based assays, low to fair cytochrome P-450 inhibition, and good human microsomal stability.","sentence":"This is distinct from Rock inhibitors based on non-amino acid derived quinazolinones, where high selectivity against PKA could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of Rock, nanomolar potency in ppMLC cell based assays, low to fair cytochrome P-450 inhibition, and good human microsomal stability."}
{"PMID":23416002,"re_id":1,"annotated sentence":"This is distinct from Rock inhibitors based on non-<e1>amino acid<\\e1> derived quinazolinones, where high selectivity against <e2>PKA<\\e2> could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of Rock, nanomolar potency in ppMLC cell based assays, low to fair cytochrome P-450 inhibition, and good human microsomal stability.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"amino acid","object":"PKA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This is distinct from Rock inhibitors based on non-<e1>CHEMICAL<\\e1> derived quinazolinones, where high selectivity against <e2>GENE-N<\\e2> could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of Rock, nanomolar potency in ppMLC cell based assays, low to fair cytochrome P-450 inhibition, and good human microsomal stability.","sentence":"This is distinct from Rock inhibitors based on non-amino acid derived quinazolinones, where high selectivity against PKA could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of Rock, nanomolar potency in ppMLC cell based assays, low to fair cytochrome P-450 inhibition, and good human microsomal stability."}
{"PMID":23416002,"re_id":2,"annotated sentence":"This is distinct from <e2>Rock<\\e2> inhibitors based on non-amino acid derived <e1>quinazolinones<\\e1>  where high selectivity against PKA could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of Rock, nanomolar potency in ppMLC cell based assays, low to fair cytochrome P-450 inhibition, and good human microsomal stability.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"quinazolinones","object":"Rock","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This is distinct from <e2>GENE-N<\\e2> inhibitors based on non-amino acid derived <e1>CHEMICAL<\\e1>  where high selectivity against PKA could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of GENE-N, nanomolar potency in ppMLC cell based assays, low to fair cytochrome P-450 inhibition, and good human microsomal stability.","sentence":"This is distinct from Rock inhibitors based on non-amino acid derived quinazolinones  where high selectivity against PKA could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of Rock, nanomolar potency in ppMLC cell based assays, low to fair cytochrome P-450 inhibition, and good human microsomal stability."}
{"PMID":23416002,"re_id":3,"annotated sentence":"This is distinct from Rock inhibitors based on non-amino acid derived <e1>quinazolinones<\\e1>  where high selectivity against <e2>PKA<\\e2> could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of Rock, nanomolar potency in ppMLC cell based assays, low to fair cytochrome P-450 inhibition, and good human microsomal stability.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"quinazolinones","object":"PKA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This is distinct from Rock inhibitors based on non-amino acid derived <e1>CHEMICAL<\\e1>  where high selectivity against <e2>GENE-N<\\e2> could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of Rock, nanomolar potency in ppMLC cell based assays, low to fair cytochrome P-450 inhibition, and good human microsomal stability.","sentence":"This is distinct from Rock inhibitors based on non-amino acid derived quinazolinones  where high selectivity against PKA could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of Rock, nanomolar potency in ppMLC cell based assays, low to fair cytochrome P-450 inhibition, and good human microsomal stability."}
{"PMID":23416002,"re_id":4,"annotated sentence":"SAR and lead optimization studies for <e2>Rock<\\e2> inhibitors based on <e1>amino acid<\\e1> derived quinazolines are described","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"amino acid","object":"Rock","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"SAR and lead optimization studies for <e2>GENE-N<\\e2> inhibitors based on <e1>CHEMICAL<\\e1> derived quinazolines are described","sentence":"SAR and lead optimization studies for Rock inhibitors based on amino acid derived quinazolines are described"}
{"PMID":23416002,"re_id":5,"annotated sentence":"SAR and lead optimization studies for <e2>Rock<\\e2> inhibitors based on amino acid-derived <e1>quinazolines<\\e1> are described","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"quinazolines","object":"Rock","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"SAR and lead optimization studies for <e2>GENE-N<\\e2> inhibitors based on amino acid-derived <e1>CHEMICAL<\\e1> are described","sentence":"SAR and lead optimization studies for Rock inhibitors based on amino acid-derived quinazolines are described"}
{"PMID":23416002,"re_id":6,"annotated sentence":"<e1>Amino acid<\\e1> derived quinazolines as <e2>Rock<\\e2> PKA inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Amino acid","object":"Rock","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> derived quinazolines as <e2>GENE-N<\\e2> PKA inhibitors","sentence":"Amino acid derived quinazolines as Rock PKA inhibitors"}
{"PMID":23416002,"re_id":7,"annotated sentence":"<e1>Amino acid<\\e1> derived quinazolines as Rock\/<e2>PKA<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Amino acid","object":"PKA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> derived quinazolines as Rock\/<e2>GENE-N<\\e2> inhibitors","sentence":"Amino acid derived quinazolines as Rock\/PKA inhibitors"}
{"PMID":23416002,"re_id":8,"annotated sentence":"Amino acid derived <e1>quinazolines<\\e1> as <e2>Rock<\\e2> PKA inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"quinazolines","object":"Rock","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Amino acid derived <e1>CHEMICAL<\\e1> as <e2>GENE-N<\\e2> PKA inhibitors","sentence":"Amino acid derived quinazolines as Rock PKA inhibitors"}
{"PMID":23416002,"re_id":9,"annotated sentence":"Amino acid derived <e1>quinazolines<\\e1> as Rock\/<e2>PKA<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"quinazolines","object":"PKA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Amino acid derived <e1>CHEMICAL<\\e1> as Rock\/<e2>GENE-N<\\e2> inhibitors","sentence":"Amino acid derived quinazolines as Rock\/PKA inhibitors"}
{"PMID":23416065,"re_id":0,"annotated sentence":"The <e2>cyclooxygenase-2<\\e2> inhibitor, <e1>diflunisal<\\e1>  is used in the clinic for its anti-inflammatory activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"diflunisal","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> inhibitor, <e1>CHEMICAL<\\e1>  is used in the clinic for its anti-inflammatory activity","sentence":"The cyclooxygenase-2 inhibitor, diflunisal  is used in the clinic for its anti-inflammatory activity"}
{"PMID":23424204,"re_id":0,"annotated sentence":"Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, <e1>BPA<\\e1> significantly decreased the IR, <e2>Akt<\\e2> and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BPA","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Although there was no change in the levels of insulin receptor (IR), GENE-N (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, <e1>CHEMICAL<\\e1> significantly decreased the IR, <e2>GENE-N<\\e2> and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle","sentence":"Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, BPA significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle"}
{"PMID":23424204,"re_id":1,"annotated sentence":"Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, <e1>BPA<\\e1> significantly decreased the IR, Akt and <e2>GLUT4<\\e2> protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BPA","object":"GLUT4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and glucose transporter-4 (GENE-Y) messenger RNA, <e1>CHEMICAL<\\e1> significantly decreased the IR, Akt and <e2>GENE-Y<\\e2> protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle","sentence":"Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, BPA significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle"}
{"PMID":23424204,"re_id":2,"annotated sentence":"Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, <e1>BPA<\\e1> significantly decreased the <e2>IR<\\e2>  Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BPA","object":"IR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although there was no change in the levels of insulin receptor (GENE-Y), Akt (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, <e1>CHEMICAL<\\e1> significantly decreased the <e2>GENE-Y<\\e2>  Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle","sentence":"Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, BPA significantly decreased the IR  Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle"}
{"PMID":23424204,"re_id":3,"annotated sentence":"In conclusion, <e1>BPA<\\e1> has adverse effects on phosphorylation of <e2>Akt<\\e2>  GLUT4 translocation and (14)C-glucose oxidation.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BPA","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In conclusion, <e1>CHEMICAL<\\e1> has adverse effects on phosphorylation of <e2>GENE-N<\\e2>  GLUT4 translocation and (14)C-glucose oxidation.","sentence":"In conclusion, BPA has adverse effects on phosphorylation of Akt  GLUT4 translocation and (14)C-glucose oxidation."}
{"PMID":23424204,"re_id":4,"annotated sentence":"In conclusion, <e1>BPA<\\e1> has adverse effects on phosphorylation of Akt, <e2>GLUT4<\\e2> translocation and (14)C-glucose oxidation.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BPA","object":"GLUT4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, <e1>CHEMICAL<\\e1> has adverse effects on phosphorylation of Akt, <e2>GENE-Y<\\e2> translocation and (14)C-glucose oxidation.","sentence":"In conclusion, BPA has adverse effects on phosphorylation of Akt, GLUT4 translocation and (14)C-glucose oxidation."}
{"PMID":23424207,"re_id":0,"annotated sentence":"The obtained results showed that <e1>Cd<\\e1> increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, <e2>lactate dehydrogenase<\\e2>  acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3\u03b2-hydroxysteroid dehydrogenase (HSD), 17\u03b2-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cd","object":"lactate dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The obtained results showed that <e1>CHEMICAL<\\e1> increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, <e2>GENE-N<\\e2>  acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3\u03b2-hydroxysteroid dehydrogenase (HSD), 17\u03b2-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values","sentence":"The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase  acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3\u03b2-hydroxysteroid dehydrogenase (HSD), 17\u03b2-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values"}
{"PMID":23424207,"re_id":1,"annotated sentence":"The obtained results showed that <e1>Cd<\\e1> increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, <e2>acid phosphatase<\\e2>  alkaline phosphatase and testicular steroidogenic enzymes: 3\u03b2-hydroxysteroid dehydrogenase (HSD), 17\u03b2-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cd","object":"acid phosphatase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The obtained results showed that <e1>CHEMICAL<\\e1> increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, <e2>GENE-N<\\e2>  alkaline phosphatase and testicular steroidogenic enzymes: 3\u03b2-hydroxysteroid dehydrogenase (HSD), 17\u03b2-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values","sentence":"The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase  alkaline phosphatase and testicular steroidogenic enzymes: 3\u03b2-hydroxysteroid dehydrogenase (HSD), 17\u03b2-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values"}
{"PMID":23424207,"re_id":2,"annotated sentence":"The obtained results showed that <e1>Cd<\\e1> increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, <e2>alkaline phosphatase<\\e2> and testicular steroidogenic enzymes: 3\u03b2-hydroxysteroid dehydrogenase (HSD), 17\u03b2-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cd","object":"alkaline phosphatase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The obtained results showed that <e1>CHEMICAL<\\e1> increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, <e2>GENE-N<\\e2> and testicular steroidogenic enzymes: 3\u03b2-hydroxysteroid dehydrogenase (HSD), 17\u03b2-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values","sentence":"The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3\u03b2-hydroxysteroid dehydrogenase (HSD), 17\u03b2-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values"}
{"PMID":23424207,"re_id":3,"annotated sentence":"The obtained results showed that <e1>Cd<\\e1> increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and <e2>testicular steroidogenic enzymes<\\e2>  3\u03b2-hydroxysteroid dehydrogenase (HSD), 17\u03b2-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cd","object":"testicular steroidogenic enzymes","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The obtained results showed that <e1>CHEMICAL<\\e1> increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and <e2>GENE-N<\\e2>  3\u03b2-hydroxysteroid dehydrogenase (HSD), 17\u03b2-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values","sentence":"The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes  3\u03b2-hydroxysteroid dehydrogenase (HSD), 17\u03b2-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values"}
{"PMID":23424207,"re_id":4,"annotated sentence":"The obtained results showed that <e1>Cd<\\e1> increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: <e2>3\u03b2-hydroxysteroid dehydrogenase<\\e2> (HSD), 17\u03b2-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cd","object":"3\u03b2-hydroxysteroid dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The obtained results showed that <e1>CHEMICAL<\\e1> increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: <e2>GENE-N<\\e2> (HSD), 17\u03b2-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values","sentence":"The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3\u03b2-hydroxysteroid dehydrogenase (HSD), 17\u03b2-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values"}
{"PMID":23424207,"re_id":5,"annotated sentence":"The obtained results showed that <e1>Cd<\\e1> increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3\u03b2-hydroxysteroid dehydrogenase (<e2>HSD<\\e2> , 17\u03b2-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cd","object":"HSD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The obtained results showed that <e1>CHEMICAL<\\e1> increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3\u03b2-hydroxysteroid dehydrogenase (<e2>GENE-N<\\e2> , 17\u03b2-GENE-N activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values","sentence":"The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3\u03b2-hydroxysteroid dehydrogenase (HSD , 17\u03b2-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values"}
{"PMID":23424207,"re_id":6,"annotated sentence":"The obtained results showed that <e1>Cd<\\e1> increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3\u03b2-hydroxysteroid dehydrogenase (HSD), <e2>17\u03b2-HSD<\\e2> activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cd","object":"17\u03b2-HSD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The obtained results showed that <e1>CHEMICAL<\\e1> increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3\u03b2-hydroxysteroid dehydrogenase (HSD), <e2>GENE-N<\\e2> activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values","sentence":"The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3\u03b2-hydroxysteroid dehydrogenase (HSD), 17\u03b2-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values"}
{"PMID":23424207,"re_id":7,"annotated sentence":"Acute intoxication with <e1>Cd<\\e1> was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (<e2>GST<\\e2> )","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cd","object":"GST","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Acute intoxication with <e1>CHEMICAL<\\e1> was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (<e2>GENE-N<\\e2> )","sentence":"Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST )"}
{"PMID":23424207,"re_id":8,"annotated sentence":"Acute intoxication with <e1>Cd<\\e1> was also followed by significantly decreased activity of the antioxidant defence system (<e2>superoxide dismutase<\\e2> (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST))","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cd","object":"superoxide dismutase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Acute intoxication with <e1>CHEMICAL<\\e1> was also followed by significantly decreased activity of the antioxidant defence system (<e2>GENE-N<\\e2> (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST))","sentence":"Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST))"}
{"PMID":23424207,"re_id":9,"annotated sentence":"Acute intoxication with <e1>Cd<\\e1> was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (<e2>SOD<\\e2> , catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST))","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cd","object":"SOD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Acute intoxication with <e1>CHEMICAL<\\e1> was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (<e2>GENE-N<\\e2> , catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST))","sentence":"Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD , catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST))"}
{"PMID":23424207,"re_id":10,"annotated sentence":"Acute intoxication with <e1>Cd<\\e1> was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), <e2>catalase<\\e2> (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST))","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cd","object":"catalase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Acute intoxication with <e1>CHEMICAL<\\e1> was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), <e2>GENE-Y<\\e2> (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST))","sentence":"Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST))"}
{"PMID":23424207,"re_id":11,"annotated sentence":"Acute intoxication with <e1>Cd<\\e1> was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (<e2>CAT<\\e2> , glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST))","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cd","object":"CAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Acute intoxication with <e1>CHEMICAL<\\e1> was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (<e2>GENE-Y<\\e2> , glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST))","sentence":"Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT , glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST))"}
{"PMID":23424207,"re_id":12,"annotated sentence":"Acute intoxication with <e1>Cd<\\e1> was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), <e2>glutathione peroxidase<\\e2> (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST))","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cd","object":"glutathione peroxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Acute intoxication with <e1>CHEMICAL<\\e1> was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), <e2>GENE-N<\\e2> (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST))","sentence":"Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST))"}
{"PMID":23424207,"re_id":13,"annotated sentence":"Acute intoxication with <e1>Cd<\\e1> was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (<e2>GSH-Px<\\e2> , glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST))","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cd","object":"GSH-Px","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Acute intoxication with <e1>CHEMICAL<\\e1> was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (<e2>GENE-N<\\e2> , glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST))","sentence":"Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px , glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST))"}
{"PMID":23424207,"re_id":14,"annotated sentence":"Acute intoxication with <e1>Cd<\\e1> was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), <e2>glutathione reductase<\\e2> (GR), glutathione (GSH), and glutathione-S-transferase (GST))","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cd","object":"glutathione reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Acute intoxication with <e1>CHEMICAL<\\e1> was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), <e2>GENE-Y<\\e2> (GR), glutathione (GSH), and glutathione-S-transferase (GST))","sentence":"Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST))"}
{"PMID":23424207,"re_id":15,"annotated sentence":"Acute intoxication with <e1>Cd<\\e1> was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (<e2>GR<\\e2> , glutathione (GSH), and glutathione-S-transferase (GST))","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cd","object":"GR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Acute intoxication with <e1>CHEMICAL<\\e1> was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (<e2>GENE-Y<\\e2> , glutathione (GSH), and glutathione-S-transferase (GST))","sentence":"Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR , glutathione (GSH), and glutathione-S-transferase (GST))"}
{"PMID":23424207,"re_id":16,"annotated sentence":"Acute intoxication with <e1>Cd<\\e1> was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and <e2>glutathione-S-transferase<\\e2> (GST))","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cd","object":"glutathione-S-transferase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Acute intoxication with <e1>CHEMICAL<\\e1> was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and <e2>GENE-N<\\e2> (GST))","sentence":"Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST))"}
{"PMID":23425605,"re_id":0,"annotated sentence":"MeHg significantly increased DA precursor accumulation in cells treated with 3-hydroxybenzylhydrazine (10\u00b5M), revealing that <e1>MeHg<\\e1> increases <e2>tyrosine hydroxylase<\\e2> activity","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"MeHg","object":"tyrosine hydroxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CHEMICAL significantly increased DA precursor accumulation in cells treated with 3-hydroxybenzylhydrazine (10\u00b5M), revealing that <e1>CHEMICAL<\\e1> increases <e2>GENE-Y<\\e2> activity","sentence":"MeHg significantly increased DA precursor accumulation in cells treated with 3-hydroxybenzylhydrazine (10\u00b5M), revealing that MeHg increases tyrosine hydroxylase activity"}
{"PMID":23425605,"re_id":1,"annotated sentence":"The <e2>tyrosine hydroxylase<\\e2> inhibitor <e1>\u03b1-methyltyrosine<\\e1> (300\u00b5M, 24h) completely abolished MeHg-induced DA release","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"\u03b1-methyltyrosine","object":"tyrosine hydroxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1> (300\u00b5M, 24h) completely abolished MeHg-induced DA release","sentence":"The tyrosine hydroxylase inhibitor \u03b1-methyltyrosine (300\u00b5M, 24h) completely abolished MeHg-induced DA release"}
{"PMID":23428155,"re_id":0,"annotated sentence":"The solubility-driven structural modification of (pyridin-3-yl) benzoxazinyl-oxazolidinones is described, which resulted in the development of a new series of <e1>benzoxazinyl-oxazolidinone<\\e1> analogues with high antibacterial activity against Gram-positive pathogens, including that against linezolid-resistant strains and low <e2>hERG<\\e2> inhibition","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"benzoxazinyl-oxazolidinone","object":"hERG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The solubility-driven structural modification of (pyridin-3-yl) CHEMICALs is described, which resulted in the development of a new series of <e1>CHEMICAL<\\e1> analogues with high antibacterial activity against Gram-positive pathogens, including that against linezolid-resistant strains and low <e2>GENE-Y<\\e2> inhibition","sentence":"The solubility-driven structural modification of (pyridin-3-yl) benzoxazinyl-oxazolidinones is described, which resulted in the development of a new series of benzoxazinyl-oxazolidinone analogues with high antibacterial activity against Gram-positive pathogens, including that against linezolid-resistant strains and low hERG inhibition"}
{"PMID":23430109,"re_id":0,"annotated sentence":"Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the <e2>FLT3<\\e2> inhibitors <e1>AC220<\\e1> (quizartinib) and sorafenib","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"AC220","object":"FLT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Secondary point mutations in the Fms-like tyrosine kinase 3 (GENE-Y) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the <e2>GENE-Y<\\e2> inhibitors <e1>CHEMICAL<\\e1> (quizartinib) and sorafenib","sentence":"Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the FLT3 inhibitors AC220 (quizartinib) and sorafenib"}
{"PMID":23430109,"re_id":1,"annotated sentence":"Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the <e2>FLT3<\\e2> inhibitors AC220 (<e1>quizartinib<\\e1>  and sorafenib","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"quizartinib","object":"FLT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Secondary point mutations in the Fms-like tyrosine kinase 3 (GENE-Y) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the <e2>GENE-Y<\\e2> inhibitors AC220 (<e1>CHEMICAL<\\e1>  and sorafenib","sentence":"Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the FLT3 inhibitors AC220 (quizartinib  and sorafenib"}
{"PMID":23430109,"re_id":2,"annotated sentence":"Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the <e2>FLT3<\\e2> inhibitors AC220 (quizartinib) and <e1>sorafenib<\\e1>  Ponatinib (AP24534) is a multikinase inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sorafenib","object":"FLT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Secondary point mutations in the Fms-like tyrosine kinase 3 (GENE-Y) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the <e2>GENE-Y<\\e2> inhibitors AC220 (quizartinib) and <e1>CHEMICAL<\\e1>  Ponatinib (AP24534) is a multikinase inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation","sentence":"Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the FLT3 inhibitors AC220 (quizartinib) and sorafenib  Ponatinib (AP24534) is a multikinase inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation"}
{"PMID":23430109,"re_id":3,"annotated sentence":"<e1>Ponatinib<\\e1> (AP24534) is a <e2>multikinase<\\e2> inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Ponatinib","object":"multikinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (AP24534) is a <e2>GENE-N<\\e2> inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation","sentence":"Ponatinib (AP24534) is a multikinase inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation"}
{"PMID":23430109,"re_id":4,"annotated sentence":"Ponatinib (<e1>AP24534<\\e1>  is a <e2>multikinase<\\e2> inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"AP24534","object":"multikinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Ponatinib (<e1>CHEMICAL<\\e1>  is a <e2>GENE-N<\\e2> inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation","sentence":"Ponatinib (AP24534  is a multikinase inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation"}
{"PMID":23432582,"re_id":0,"annotated sentence":"However, the involvement of the caspase-dependent pathway in the process of cell death induced by either BSC 3g or 3n is discarded since cell death could not be prevented by pretreatment with the pan<e2>caspase<\\e2> inhibitor <e1>z-VAD-fmk<\\e1>  Moreover, since reduced levels of p21CIP1 and Chk2 proteins but no change in p53 levels could be detected in MCF-7 cells after BSC 3g or 3n treatment our results suggest that BSC treated cells die from lethal mitosis.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"z-VAD-fmk","object":"caspase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, the involvement of the GENE-N-dependent pathway in the process of cell death induced by either BSC 3g or 3n is discarded since cell death could not be prevented by pretreatment with the pan<e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1>  Moreover, since reduced levels of p21CIP1 and Chk2 proteins but no change in p53 levels could be detected in MCF-7 cells after BSC 3g or 3n treatment our results suggest that BSC treated cells die from lethal mitosis.","sentence":"However, the involvement of the caspase-dependent pathway in the process of cell death induced by either BSC 3g or 3n is discarded since cell death could not be prevented by pretreatment with the pancaspase inhibitor z-VAD-fmk  Moreover, since reduced levels of p21CIP1 and Chk2 proteins but no change in p53 levels could be detected in MCF-7 cells after BSC 3g or 3n treatment our results suggest that BSC treated cells die from lethal mitosis."}
{"PMID":23432582,"re_id":1,"annotated sentence":"Moreover, since reduced levels of <e2>p21CIP1<\\e2> and Chk2 proteins but no change in p53 levels could be detected in MCF-7 cells after <e1>BSC<\\e1> 3g or 3n treatment our results suggest that BSC treated cells die from lethal mitosis.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BSC","object":"p21CIP1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, since reduced levels of <e2>GENE-Y<\\e2> and Chk2 proteins but no change in p53 levels could be detected in MCF-7 cells after <e1>CHEMICAL<\\e1> 3g or 3n treatment our results suggest that CHEMICAL treated cells die from lethal mitosis.","sentence":"Moreover, since reduced levels of p21CIP1 and Chk2 proteins but no change in p53 levels could be detected in MCF-7 cells after BSC 3g or 3n treatment our results suggest that BSC treated cells die from lethal mitosis."}
{"PMID":23432582,"re_id":2,"annotated sentence":"Moreover, since reduced levels of p21CIP1 and <e2>Chk2<\\e2> proteins but no change in p53 levels could be detected in MCF-7 cells after <e1>BSC<\\e1> 3g or 3n treatment our results suggest that BSC treated cells die from lethal mitosis.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BSC","object":"Chk2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, since reduced levels of p21CIP1 and <e2>GENE-Y<\\e2> proteins but no change in p53 levels could be detected in MCF-7 cells after <e1>CHEMICAL<\\e1> 3g or 3n treatment our results suggest that CHEMICAL treated cells die from lethal mitosis.","sentence":"Moreover, since reduced levels of p21CIP1 and Chk2 proteins but no change in p53 levels could be detected in MCF-7 cells after BSC 3g or 3n treatment our results suggest that BSC treated cells die from lethal mitosis."}
{"PMID":23434223,"re_id":0,"annotated sentence":"These compounds were evaluated for their acetylcholinesterase (AChE) inhibitory activity and <e1>5-amino-2,7-bis(4-methoxyphenyl)-2,3-dihydrobenzo[b]thiophene-4,6-dicarbonitrile<\\e1> was found to be the most potent against <e2>AChE<\\e2> with IC50 4.16 \u03bcmol\/L.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-amino-2,7-bis(4-methoxyphenyl)-2,3-dihydrobenzo[b]thiophene-4,6-dicarbonitrile","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These compounds were evaluated for their acetylcholinesterase (GENE-Y) inhibitory activity and <e1>CHEMICAL<\\e1> was found to be the most potent against <e2>GENE-Y<\\e2> with IC50 4.16 \u03bcmol\/L.","sentence":"These compounds were evaluated for their acetylcholinesterase (AChE) inhibitory activity and 5-amino-2,7-bis(4-methoxyphenyl)-2,3-dihydrobenzo[b]thiophene-4,6-dicarbonitrile was found to be the most potent against AChE with IC50 4.16 \u03bcmol\/L."}
{"PMID":23434223,"re_id":1,"annotated sentence":"A one-pot domino synthesis and discovery of highly functionalized <e1>dihydrobenzo[b]thiophenes<\\e1> as <e2>AChE<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dihydrobenzo[b]thiophenes","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A one-pot domino synthesis and discovery of highly functionalized <e1>CHEMICAL<\\e1> as <e2>GENE-Y<\\e2> inhibitors","sentence":"A one-pot domino synthesis and discovery of highly functionalized dihydrobenzo[b]thiophenes as AChE inhibitors"}
{"PMID":23434829,"re_id":0,"annotated sentence":"Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including <e1>paclitaxel<\\e1>  doxorubicin, actinomycin-D, and rapamycin, which are also <e2>P-gp<\\e2> substrates","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"paclitaxel","object":"P-gp","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including <e1>CHEMICAL<\\e1>  doxorubicin, actinomycin-D, and rapamycin, which are also <e2>GENE-N<\\e2> substrates","sentence":"Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel  doxorubicin, actinomycin-D, and rapamycin, which are also P-gp substrates"}
{"PMID":23434829,"re_id":1,"annotated sentence":"Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, <e1>doxorubicin<\\e1>  actinomycin-D, and rapamycin, which are also <e2>P-gp<\\e2> substrates","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"doxorubicin","object":"P-gp","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, <e1>CHEMICAL<\\e1>  actinomycin-D, and rapamycin, which are also <e2>GENE-N<\\e2> substrates","sentence":"Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, doxorubicin  actinomycin-D, and rapamycin, which are also P-gp substrates"}
{"PMID":23434829,"re_id":2,"annotated sentence":"Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, <e1>actinomycin-D<\\e1>  and rapamycin, which are also <e2>P-gp<\\e2> substrates","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"actinomycin-D","object":"P-gp","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, <e1>CHEMICAL<\\e1>  and rapamycin, which are also <e2>GENE-N<\\e2> substrates","sentence":"Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, actinomycin-D  and rapamycin, which are also P-gp substrates"}
{"PMID":23434829,"re_id":3,"annotated sentence":"Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, actinomycin-D, and <e1>rapamycin<\\e1>  which are also <e2>P-gp<\\e2> substrates","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"rapamycin","object":"P-gp","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, actinomycin-D, and <e1>CHEMICAL<\\e1>  which are also <e2>GENE-N<\\e2> substrates","sentence":"Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, actinomycin-D, and rapamycin  which are also P-gp substrates"}
{"PMID":23454148,"re_id":0,"annotated sentence":"Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1\/2 activities and PM-<e1>MMC<\\e1> rats showed higher <e2>quinone reductase<\\e2> and depleted xanthine oxidase activities","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"MMC","object":"quinone reductase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1\/2 activities and PM-<e1>CHEMICAL<\\e1> rats showed higher <e2>GENE-N<\\e2> and depleted xanthine oxidase activities","sentence":"Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1\/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities"}
{"PMID":23454148,"re_id":1,"annotated sentence":"Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1\/2 activities and PM-<e1>MMC<\\e1> rats showed higher quinone reductase and depleted <e2>xanthine oxidase<\\e2> activities","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MMC","object":"xanthine oxidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1\/2 activities and PM-<e1>CHEMICAL<\\e1> rats showed higher quinone reductase and depleted <e2>GENE-Y<\\e2> activities","sentence":"Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1\/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities"}
{"PMID":23454148,"re_id":2,"annotated sentence":"Conclusively, protein malnutrition alters CP, FU and <e1>MMC<\\e1> metabolism in rat stomach by enhancing <e2>CCBL<\\e2> pathway for CP activation, delaying FU elimination and activating two-electron reduction of MMC, potentiating their gastrotoxicity.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"MMC","object":"CCBL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Conclusively, protein malnutrition alters CP, FU and <e1>CHEMICAL<\\e1> metabolism in rat stomach by enhancing <e2>GENE-Y<\\e2> pathway for CP activation, delaying FU elimination and activating two-electron reduction of CHEMICAL, potentiating their gastrotoxicity.","sentence":"Conclusively, protein malnutrition alters CP, FU and MMC metabolism in rat stomach by enhancing CCBL pathway for CP activation, delaying FU elimination and activating two-electron reduction of MMC, potentiating their gastrotoxicity."}
{"PMID":23454527,"re_id":0,"annotated sentence":"N-acetylcysteine (NAC, 33 mM) and the c-jun N-terminal kinase (<e2>JNK<\\e2>  inhibitor (<e1>SP600125<\\e1>  33 \u03bcM) further decreased the viability in the presence of DEP (200 \u03bcg\/ml) and 3.3% FCS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SP600125","object":"JNK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"N-acetylcysteine (NAC, 33 mM) and the c-jun N-terminal kinase (<e2>GENE-N<\\e2>  inhibitor (<e1>CHEMICAL<\\e1>  33 \u03bcM) further decreased the viability in the presence of DEP (200 \u03bcg\/ml) and 3.3% FCS","sentence":"N-acetylcysteine (NAC, 33 mM) and the c-jun N-terminal kinase (JNK  inhibitor (SP600125  33 \u03bcM) further decreased the viability in the presence of DEP (200 \u03bcg\/ml) and 3.3% FCS"}
{"PMID":23454527,"re_id":1,"annotated sentence":"N-acetylcysteine (NAC, 33 mM) and the <e2>c-jun N-terminal kinase<\\e2> (JNK) inhibitor (<e1>SP600125<\\e1>  33 \u03bcM) further decreased the viability in the presence of DEP (200 \u03bcg\/ml) and 3.3% FCS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SP600125","object":"c-jun N-terminal kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"N-acetylcysteine (NAC, 33 mM) and the <e2>GENE-N<\\e2> (JNK) inhibitor (<e1>CHEMICAL<\\e1>  33 \u03bcM) further decreased the viability in the presence of DEP (200 \u03bcg\/ml) and 3.3% FCS","sentence":"N-acetylcysteine (NAC, 33 mM) and the c-jun N-terminal kinase (JNK) inhibitor (SP600125  33 \u03bcM) further decreased the viability in the presence of DEP (200 \u03bcg\/ml) and 3.3% FCS"}
{"PMID":23455312,"re_id":0,"annotated sentence":"<e1>HENA<\\e1> activated the <e2>BK (cbv1 + \u03b21) channels<\\e2> cloned from rat cerebral artery myocytes with a potency (EC50 = 53 \u03bcM) similar to and an efficacy (\u00d72.5 potentiation) significantly greater than that of LCA","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"HENA","object":"BK (cbv1 + \u03b21) channels","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> activated the <e2>GENE-Y<\\e2> cloned from rat cerebral artery myocytes with a potency (EC50 = 53 \u03bcM) similar to and an efficacy (\u00d72.5 potentiation) significantly greater than that of LCA","sentence":"HENA activated the BK (cbv1 + \u03b21) channels cloned from rat cerebral artery myocytes with a potency (EC50 = 53 \u03bcM) similar to and an efficacy (\u00d72.5 potentiation) significantly greater than that of LCA"}
{"PMID":23455312,"re_id":1,"annotated sentence":"HENA activated the <e2>BK (cbv1 + \u03b21) channels<\\e2> cloned from rat cerebral artery myocytes with a potency (EC50 = 53 \u03bcM) similar to and an efficacy (\u00d72.5 potentiation) significantly greater than that of <e1>LCA<\\e1>  This HENA action was replicated on native channels in rat cerebral artery myocytes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"LCA","object":"BK (cbv1 + \u03b21) channels","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"HENA activated the <e2>GENE-Y<\\e2> cloned from rat cerebral artery myocytes with a potency (EC50 = 53 \u03bcM) similar to and an efficacy (\u00d72.5 potentiation) significantly greater than that of <e1>CHEMICAL<\\e1>  This HENA action was replicated on native channels in rat cerebral artery myocytes","sentence":"HENA activated the BK (cbv1 + \u03b21) channels cloned from rat cerebral artery myocytes with a potency (EC50 = 53 \u03bcM) similar to and an efficacy (\u00d72.5 potentiation) significantly greater than that of LCA  This HENA action was replicated on native channels in rat cerebral artery myocytes"}
{"PMID":23455312,"re_id":2,"annotated sentence":"<e1>HENA<\\e1> failed to activate the channels made of cbv1 + \u03b22, \u03b23, \u03b24, or \u03b21T169A, indicating that this drug selectively targets <e2>\u03b21-containing BK channels<\\e2> via the BK \u03b21 steroid-sensing site","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"HENA","object":"\u03b21-containing BK channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> failed to activate the channels made of cbv1 + \u03b22, \u03b23, \u03b24, or \u03b21T169A, indicating that this drug selectively targets <e2>GENE-N<\\e2> via the BK \u03b21 steroid-sensing site","sentence":"HENA failed to activate the channels made of cbv1 + \u03b22, \u03b23, \u03b24, or \u03b21T169A, indicating that this drug selectively targets \u03b21-containing BK channels via the BK \u03b21 steroid-sensing site"}
{"PMID":23455597,"re_id":0,"annotated sentence":"RATIONALE: <e2>Histamine H3 receptor<\\e2> antagonists, such as <e1>ABT-288<\\e1>  have been shown to possess cognitive-enhancing and wakefulness-promoting effects","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"ABT-288","object":"Histamine H3 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RATIONALE: <e2>GENE-Y<\\e2> antagonists, such as <e1>CHEMICAL<\\e1>  have been shown to possess cognitive-enhancing and wakefulness-promoting effects","sentence":"RATIONALE: Histamine H3 receptor antagonists, such as ABT-288  have been shown to possess cognitive-enhancing and wakefulness-promoting effects"}
{"PMID":23455597,"re_id":1,"annotated sentence":"Assessment of the abuse liability of <e1>ABT-288<\\e1>  a novel <e2>histamine H3 receptor<\\e2> antagonist","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"ABT-288","object":"histamine H3 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Assessment of the abuse liability of <e1>CHEMICAL<\\e1>  a novel <e2>GENE-Y<\\e2> antagonist","sentence":"Assessment of the abuse liability of ABT-288  a novel histamine H3 receptor antagonist"}
{"PMID":23455597,"re_id":2,"annotated sentence":"CONCLUSIONS: The sum of these preclinical data, the first of their kind applied to H3 antagonists, indicates that <e1>ABT-288<\\e1> is unlikely to possess a high potential for abuse in the human population and suggests that <e2>H3<\\e2> antagonists, as a class, are similar in this regard.","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"ABT-288","object":"H3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSIONS: The sum of these preclinical data, the first of their kind applied to GENE-Y antagonists, indicates that <e1>CHEMICAL<\\e1> is unlikely to possess a high potential for abuse in the human population and suggests that <e2>GENE-Y<\\e2> antagonists, as a class, are similar in this regard.","sentence":"CONCLUSIONS: The sum of these preclinical data, the first of their kind applied to H3 antagonists, indicates that ABT-288 is unlikely to possess a high potential for abuse in the human population and suggests that H3 antagonists, as a class, are similar in this regard."}
{"PMID":23461378,"re_id":0,"annotated sentence":"This methodology was subsequently used to assess the relative contribution of <e2>OATP1B1<\\e2> uptake in human hepatocytes for olmesartan (42%-62%), valsartan (28%-81%), rosuvastatin (64%-72%), <e1>pitavastatin<\\e1> (84%-98%) and lopinavir (64%-89%)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"pitavastatin","object":"OATP1B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This methodology was subsequently used to assess the relative contribution of <e2>GENE-Y<\\e2> uptake in human hepatocytes for olmesartan (42%-62%), valsartan (28%-81%), rosuvastatin (64%-72%), <e1>CHEMICAL<\\e1> (84%-98%) and lopinavir (64%-89%)","sentence":"This methodology was subsequently used to assess the relative contribution of OATP1B1 uptake in human hepatocytes for olmesartan (42%-62%), valsartan (28%-81%), rosuvastatin (64%-72%), pitavastatin (84%-98%) and lopinavir (64%-89%)"}
{"PMID":23461378,"re_id":1,"annotated sentence":"This methodology was subsequently used to assess the relative contribution of <e2>OATP1B1<\\e2> uptake in human hepatocytes for olmesartan (42%-62%), valsartan (28%-81%), rosuvastatin (64%-72%), pitavastatin (84%-98%) and <e1>lopinavir<\\e1> (64%-89%)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"lopinavir","object":"OATP1B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This methodology was subsequently used to assess the relative contribution of <e2>GENE-Y<\\e2> uptake in human hepatocytes for olmesartan (42%-62%), valsartan (28%-81%), rosuvastatin (64%-72%), pitavastatin (84%-98%) and <e1>CHEMICAL<\\e1> (64%-89%)","sentence":"This methodology was subsequently used to assess the relative contribution of OATP1B1 uptake in human hepatocytes for olmesartan (42%-62%), valsartan (28%-81%), rosuvastatin (64%-72%), pitavastatin (84%-98%) and lopinavir (64%-89%)"}
{"PMID":23461378,"re_id":2,"annotated sentence":"Uptake of <e1>estrone-3-sulfate<\\e1> (5\u2009nM) by <e2>OATP1B1<\\e2> was reduced by 82%-95%","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"estrone-3-sulfate","object":"OATP1B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Uptake of <e1>CHEMICAL<\\e1> (5\u2009nM) by <e2>GENE-Y<\\e2> was reduced by 82%-95%","sentence":"Uptake of estrone-3-sulfate (5\u2009nM) by OATP1B1 was reduced by 82%-95%"}
{"PMID":23461378,"re_id":3,"annotated sentence":"This methodology was subsequently used to assess the relative contribution of <e2>OATP1B1<\\e2> uptake in human hepatocytes for <e1>olmesartan<\\e1> (42%-62%), valsartan (28%-81%), rosuvastatin (64%-72%), pitavastatin (84%-98%) and lopinavir (64%-89%)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"olmesartan","object":"OATP1B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This methodology was subsequently used to assess the relative contribution of <e2>GENE-Y<\\e2> uptake in human hepatocytes for <e1>CHEMICAL<\\e1> (42%-62%), valsartan (28%-81%), rosuvastatin (64%-72%), pitavastatin (84%-98%) and lopinavir (64%-89%)","sentence":"This methodology was subsequently used to assess the relative contribution of OATP1B1 uptake in human hepatocytes for olmesartan (42%-62%), valsartan (28%-81%), rosuvastatin (64%-72%), pitavastatin (84%-98%) and lopinavir (64%-89%)"}
{"PMID":23461378,"re_id":4,"annotated sentence":"This methodology was subsequently used to assess the relative contribution of <e2>OATP1B1<\\e2> uptake in human hepatocytes for olmesartan (42%-62%), <e1>valsartan<\\e1> (28%-81%), rosuvastatin (64%-72%), pitavastatin (84%-98%) and lopinavir (64%-89%)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"valsartan","object":"OATP1B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This methodology was subsequently used to assess the relative contribution of <e2>GENE-Y<\\e2> uptake in human hepatocytes for olmesartan (42%-62%), <e1>CHEMICAL<\\e1> (28%-81%), rosuvastatin (64%-72%), pitavastatin (84%-98%) and lopinavir (64%-89%)","sentence":"This methodology was subsequently used to assess the relative contribution of OATP1B1 uptake in human hepatocytes for olmesartan (42%-62%), valsartan (28%-81%), rosuvastatin (64%-72%), pitavastatin (84%-98%) and lopinavir (64%-89%)"}
{"PMID":23461378,"re_id":5,"annotated sentence":"This methodology was subsequently used to assess the relative contribution of <e2>OATP1B1<\\e2> uptake in human hepatocytes for olmesartan (42%-62%), valsartan (28%-81%), <e1>rosuvastatin<\\e1> (64%-72%), pitavastatin (84%-98%) and lopinavir (64%-89%)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"rosuvastatin","object":"OATP1B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This methodology was subsequently used to assess the relative contribution of <e2>GENE-Y<\\e2> uptake in human hepatocytes for olmesartan (42%-62%), valsartan (28%-81%), <e1>CHEMICAL<\\e1> (64%-72%), pitavastatin (84%-98%) and lopinavir (64%-89%)","sentence":"This methodology was subsequently used to assess the relative contribution of OATP1B1 uptake in human hepatocytes for olmesartan (42%-62%), valsartan (28%-81%), rosuvastatin (64%-72%), pitavastatin (84%-98%) and lopinavir (64%-89%)"}
{"PMID":23466488,"re_id":0,"annotated sentence":"<e1>l-glutamine<\\e1> decreased plasma glucose, increased plasma and pancreatic <e2>insulin<\\e2>  increased plasma and colonic active GLP-1 (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-nicotinamide induced diabetic rats.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"l-glutamine","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> decreased plasma glucose, increased plasma and pancreatic <e2>GENE-N<\\e2>  increased plasma and colonic active GLP-1 (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-nicotinamide induced diabetic rats.","sentence":"l-glutamine decreased plasma glucose, increased plasma and pancreatic insulin  increased plasma and colonic active GLP-1 (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-nicotinamide induced diabetic rats."}
{"PMID":23466488,"re_id":1,"annotated sentence":"<e1>l-glutamine<\\e1> decreased plasma glucose, increased plasma and pancreatic insulin, increased plasma and colonic active <e2>GLP-1<\\e2> (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-nicotinamide induced diabetic rats.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"l-glutamine","object":"GLP-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> decreased plasma glucose, increased plasma and pancreatic insulin, increased plasma and colonic active <e2>GENE-Y<\\e2> (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-nicotinamide induced diabetic rats.","sentence":"l-glutamine decreased plasma glucose, increased plasma and pancreatic insulin, increased plasma and colonic active GLP-1 (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-nicotinamide induced diabetic rats."}
{"PMID":23466488,"re_id":2,"annotated sentence":"The objective of the present investigation was to evaluate <e1>l-glutamine<\\e1> increases <e2>glucagon like peptide-1<\\e2> (GLP-1) (7-36) amide secretion in streptozotocin-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"l-glutamine","object":"glucagon like peptide-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The objective of the present investigation was to evaluate <e1>CHEMICAL<\\e1> increases <e2>GENE-Y<\\e2> (GLP-1) (7-36) amide secretion in streptozotocin-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats","sentence":"The objective of the present investigation was to evaluate l-glutamine increases glucagon like peptide-1 (GLP-1) (7-36) amide secretion in streptozotocin-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats"}
{"PMID":23466488,"re_id":3,"annotated sentence":"The objective of the present investigation was to evaluate <e1>l-glutamine<\\e1> increases glucagon like peptide-1 (<e2>GLP-1<\\e2>  (7-36) amide secretion in streptozotocin-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"l-glutamine","object":"GLP-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The objective of the present investigation was to evaluate <e1>CHEMICAL<\\e1> increases glucagon like peptide-1 (<e2>GENE-Y<\\e2>  (7-36) amide secretion in streptozotocin-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats","sentence":"The objective of the present investigation was to evaluate l-glutamine increases glucagon like peptide-1 (GLP-1  (7-36) amide secretion in streptozotocin-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats"}
{"PMID":23466488,"re_id":4,"annotated sentence":"Oral <e1>l-glutamine<\\e1> increases active <e2>GLP-1<\\e2> (7-36) amide secretion and improves glycemic control in stretpozotocin-nicotinamide induced diabetic rats","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"l-glutamine","object":"GLP-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Oral <e1>CHEMICAL<\\e1> increases active <e2>GENE-Y<\\e2> (7-36) amide secretion and improves glycemic control in stretpozotocin-nicotinamide induced diabetic rats","sentence":"Oral l-glutamine increases active GLP-1 (7-36) amide secretion and improves glycemic control in stretpozotocin-nicotinamide induced diabetic rats"}
{"PMID":23473801,"re_id":0,"annotated sentence":"In the present study, <e1>hinokitiol<\\e1> (1 and 2\u03bcM) inhibited the <e2>collagen<\\e2> induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including thrombin, arachidonic acid, and ADP","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"hinokitiol","object":"collagen","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the present study, <e1>CHEMICAL<\\e1> (1 and 2\u03bcM) inhibited the <e2>GENE-N<\\e2> induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including thrombin, arachidonic acid, and ADP","sentence":"In the present study, hinokitiol (1 and 2\u03bcM) inhibited the collagen induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including thrombin, arachidonic acid, and ADP"}
{"PMID":23473801,"re_id":1,"annotated sentence":"<e1>Hinokitiol<\\e1> inhibited the phosphorylation of <e2>phospholipase C (PLC)\u03b32<\\e2>  protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Hinokitiol","object":"phospholipase C (PLC)\u03b32","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibited the phosphorylation of <e2>GENE-Y<\\e2>  protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation","sentence":"Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)\u03b32  protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation"}
{"PMID":23473801,"re_id":2,"annotated sentence":"<e1>Hinokitiol<\\e1> inhibited the phosphorylation of phospholipase C (PLC)\u03b32, <e2>protein kinase C<\\e2> (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Hinokitiol","object":"protein kinase C","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> inhibited the phosphorylation of phospholipase C (PLC)\u03b32, <e2>GENE-N<\\e2> (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation","sentence":"Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)\u03b32, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation"}
{"PMID":23473801,"re_id":3,"annotated sentence":"<e1>Hinokitiol<\\e1> inhibited the phosphorylation of phospholipase C (PLC)\u03b32, protein kinase C (<e2>PKC<\\e2> , mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Hinokitiol","object":"PKC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> inhibited the phosphorylation of phospholipase C (PLC)\u03b32, protein kinase C (<e2>GENE-N<\\e2> , mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation","sentence":"Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)\u03b32, protein kinase C (PKC , mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation"}
{"PMID":23473801,"re_id":4,"annotated sentence":"<e1>Hinokitiol<\\e1> inhibited the phosphorylation of phospholipase C (PLC)\u03b32, protein kinase C (PKC), <e2>mitogen-activated protein kinases<\\e2> (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Hinokitiol","object":"mitogen-activated protein kinases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> inhibited the phosphorylation of phospholipase C (PLC)\u03b32, protein kinase C (PKC), <e2>GENE-N<\\e2> (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation","sentence":"Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)\u03b32, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation"}
{"PMID":23473801,"re_id":5,"annotated sentence":"<e1>Hinokitiol<\\e1> inhibited the phosphorylation of phospholipase C (PLC)\u03b32, protein kinase C (PKC), mitogen-activated protein kinases (<e2>MAPKs<\\e2> , and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Hinokitiol","object":"MAPKs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> inhibited the phosphorylation of phospholipase C (PLC)\u03b32, protein kinase C (PKC), mitogen-activated protein kinases (<e2>GENE-N<\\e2> , and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation","sentence":"Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)\u03b32, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs , and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation"}
{"PMID":23473801,"re_id":6,"annotated sentence":"<e1>Hinokitiol<\\e1> inhibited the phosphorylation of phospholipase C (PLC)\u03b32, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and <e2>Akt<\\e2> in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Hinokitiol","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> inhibited the phosphorylation of phospholipase C (PLC)\u03b32, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and <e2>GENE-N<\\e2> in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation","sentence":"Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)\u03b32, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation"}
{"PMID":23473801,"re_id":7,"annotated sentence":"<e1>Hinokitiol<\\e1> inhibited the phosphorylation of phospholipase C (PLC)\u03b32, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in <e2>collagen<\\e2> activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Hinokitiol","object":"collagen","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> inhibited the phosphorylation of phospholipase C (PLC)\u03b32, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in <e2>GENE-N<\\e2> activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation","sentence":"Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)\u03b32, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation"}
{"PMID":23473801,"re_id":8,"annotated sentence":"<e1>Hinokitiol<\\e1> also reduced the <e2>PKC<\\e2> activation and platelet aggregation stimulated by PDBu","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Hinokitiol","object":"PKC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> also reduced the <e2>GENE-N<\\e2> activation and platelet aggregation stimulated by PDBu","sentence":"Hinokitiol also reduced the PKC activation and platelet aggregation stimulated by PDBu"}
{"PMID":23473801,"re_id":9,"annotated sentence":"In conclusion, <e1>hinokitiol<\\e1> may inhibit platelet activation by inhibiting the <e2>PLC\u03b32<\\e2> PKC cascade and hydroxyl radical formation, followed by suppressing the activation of MAPKs and Akt","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"hinokitiol","object":"PLC\u03b32","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, <e1>CHEMICAL<\\e1> may inhibit platelet activation by inhibiting the <e2>GENE-Y<\\e2> PKC cascade and hydroxyl radical formation, followed by suppressing the activation of MAPKs and Akt","sentence":"In conclusion, hinokitiol may inhibit platelet activation by inhibiting the PLC\u03b32 PKC cascade and hydroxyl radical formation, followed by suppressing the activation of MAPKs and Akt"}
{"PMID":23473801,"re_id":10,"annotated sentence":"In conclusion, <e1>hinokitiol<\\e1> may inhibit platelet activation by inhibiting the PLC\u03b32-<e2>PKC<\\e2> cascade and hydroxyl radical formation, followed by suppressing the activation of MAPKs and Akt","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"hinokitiol","object":"PKC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In conclusion, <e1>CHEMICAL<\\e1> may inhibit platelet activation by inhibiting the PLC\u03b32-<e2>GENE-N<\\e2> cascade and hydroxyl radical formation, followed by suppressing the activation of MAPKs and Akt","sentence":"In conclusion, hinokitiol may inhibit platelet activation by inhibiting the PLC\u03b32-PKC cascade and hydroxyl radical formation, followed by suppressing the activation of MAPKs and Akt"}
{"PMID":23473801,"re_id":11,"annotated sentence":"In conclusion, <e1>hinokitiol<\\e1> may inhibit platelet activation by inhibiting the PLC\u03b32-PKC cascade and hydroxyl radical formation, followed by suppressing the activation of <e2>MAPKs<\\e2> and Akt","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"hinokitiol","object":"MAPKs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In conclusion, <e1>CHEMICAL<\\e1> may inhibit platelet activation by inhibiting the PLC\u03b32-PKC cascade and hydroxyl radical formation, followed by suppressing the activation of <e2>GENE-N<\\e2> and Akt","sentence":"In conclusion, hinokitiol may inhibit platelet activation by inhibiting the PLC\u03b32-PKC cascade and hydroxyl radical formation, followed by suppressing the activation of MAPKs and Akt"}
{"PMID":23473801,"re_id":12,"annotated sentence":"In conclusion, <e1>hinokitiol<\\e1> may inhibit platelet activation by inhibiting the PLC\u03b32-PKC cascade and hydroxyl radical formation, followed by suppressing the activation of MAPKs and <e2>Akt<\\e2>  Our study suggests that hinokitiol may represent a potential therapeutic agent for the prevention or treatment of thromboembolic disorders.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"hinokitiol","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In conclusion, <e1>CHEMICAL<\\e1> may inhibit platelet activation by inhibiting the PLC\u03b32-PKC cascade and hydroxyl radical formation, followed by suppressing the activation of MAPKs and <e2>GENE-N<\\e2>  Our study suggests that CHEMICAL may represent a potential therapeutic agent for the prevention or treatment of thromboembolic disorders.","sentence":"In conclusion, hinokitiol may inhibit platelet activation by inhibiting the PLC\u03b32-PKC cascade and hydroxyl radical formation, followed by suppressing the activation of MAPKs and Akt  Our study suggests that hinokitiol may represent a potential therapeutic agent for the prevention or treatment of thromboembolic disorders."}
{"PMID":23474386,"re_id":0,"annotated sentence":"Novel <e1>5-(benzyloxy)pyridin-2(1H)-one<\\e1> derivatives as potent <e2>c-Met<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-(benzyloxy)pyridin-2(1H)-one","object":"c-Met","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Novel <e1>CHEMICAL<\\e1> derivatives as potent <e2>GENE-Y<\\e2> inhibitors","sentence":"Novel 5-(benzyloxy)pyridin-2(1H)-one derivatives as potent c-Met inhibitors"}
{"PMID":23477419,"re_id":0,"annotated sentence":"Design, Synthesis, and Pharmacological Characterization of Novel <e1>Endomorphin-1<\\e1> Analogues as Extremely Potent <e2>\u03bc-Opioid<\\e2> Agonists","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"Endomorphin-1","object":"\u03bc-Opioid","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Design, Synthesis, and Pharmacological Characterization of Novel <e1>CHEMICAL<\\e1> Analogues as Extremely Potent <e2>GENE-Y<\\e2> Agonists","sentence":"Design, Synthesis, and Pharmacological Characterization of Novel Endomorphin-1 Analogues as Extremely Potent \u03bc-Opioid Agonists"}
{"PMID":23494106,"re_id":0,"annotated sentence":"Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12\/23p40 and TNF\u03b1 levels) was seen in LPS-stimulated human PBMCs, except with <e1>JWH-210<\\e1> and JWH-122 which caused a decrease of <e2>TNF\u03b1<\\e2> and IL-12\/23p40","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"JWH-210","object":"TNF\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12\/23p40 and GENE-Y levels) was seen in LPS-stimulated human PBMCs, except with <e1>CHEMICAL<\\e1> and JWH-122 which caused a decrease of <e2>GENE-Y<\\e2> and IL-12\/23p40","sentence":"Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12\/23p40 and TNF\u03b1 levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and JWH-122 which caused a decrease of TNF\u03b1 and IL-12\/23p40"}
{"PMID":23494106,"re_id":1,"annotated sentence":"Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12\/23p40 and TNF\u03b1 levels) was seen in LPS-stimulated human PBMCs, except with <e1>JWH-210<\\e1> and JWH-122 which caused a decrease of TNF\u03b1 and <e2>IL-12<\\e2> 23p40","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"JWH-210","object":"IL-12","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, GENE-N\/23p40 and TNF\u03b1 levels) was seen in LPS-stimulated human PBMCs, except with <e1>CHEMICAL<\\e1> and JWH-122 which caused a decrease of TNF\u03b1 and <e2>GENE-N<\\e2> 23p40","sentence":"Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12\/23p40 and TNF\u03b1 levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and JWH-122 which caused a decrease of TNF\u03b1 and IL-12 23p40"}
{"PMID":23494106,"re_id":2,"annotated sentence":"Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12\/23p40 and TNF\u03b1 levels) was seen in LPS-stimulated human PBMCs, except with <e1>JWH-210<\\e1> and JWH-122 which caused a decrease of TNF\u03b1 and IL-12\/<e2>23p40<\\e2>  All toxic effects were observed with concentrations higher than those expected in body fluids of users","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"JWH-210","object":"23p40","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12\/GENE-Y and TNF\u03b1 levels) was seen in LPS-stimulated human PBMCs, except with <e1>CHEMICAL<\\e1> and JWH-122 which caused a decrease of TNF\u03b1 and IL-12\/<e2>GENE-Y<\\e2>  All toxic effects were observed with concentrations higher than those expected in body fluids of users","sentence":"Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12\/23p40 and TNF\u03b1 levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and JWH-122 which caused a decrease of TNF\u03b1 and IL-12\/23p40  All toxic effects were observed with concentrations higher than those expected in body fluids of users"}
{"PMID":23494106,"re_id":3,"annotated sentence":"Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12\/23p40 and TNF\u03b1 levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and <e1>JWH-122<\\e1> which caused a decrease of <e2>TNF\u03b1<\\e2> and IL-12\/23p40","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"JWH-122","object":"TNF\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12\/23p40 and GENE-Y levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and <e1>CHEMICAL<\\e1> which caused a decrease of <e2>GENE-Y<\\e2> and IL-12\/23p40","sentence":"Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12\/23p40 and TNF\u03b1 levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and JWH-122 which caused a decrease of TNF\u03b1 and IL-12\/23p40"}
{"PMID":23494106,"re_id":4,"annotated sentence":"Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12\/23p40 and TNF\u03b1 levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and <e1>JWH-122<\\e1> which caused a decrease of TNF\u03b1 and <e2>IL-12<\\e2> 23p40","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"JWH-122","object":"IL-12","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, GENE-N\/23p40 and TNF\u03b1 levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and <e1>CHEMICAL<\\e1> which caused a decrease of TNF\u03b1 and <e2>GENE-N<\\e2> 23p40","sentence":"Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12\/23p40 and TNF\u03b1 levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and JWH-122 which caused a decrease of TNF\u03b1 and IL-12 23p40"}
{"PMID":23494106,"re_id":5,"annotated sentence":"Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12\/23p40 and TNF\u03b1 levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and <e1>JWH-122<\\e1> which caused a decrease of TNF\u03b1 and IL-12\/<e2>23p40<\\e2>  All toxic effects were observed with concentrations higher than those expected in body fluids of users","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"JWH-122","object":"23p40","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12\/GENE-Y and TNF\u03b1 levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and <e1>CHEMICAL<\\e1> which caused a decrease of TNF\u03b1 and IL-12\/<e2>GENE-Y<\\e2>  All toxic effects were observed with concentrations higher than those expected in body fluids of users","sentence":"Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12\/23p40 and TNF\u03b1 levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and JWH-122 which caused a decrease of TNF\u03b1 and IL-12\/23p40  All toxic effects were observed with concentrations higher than those expected in body fluids of users"}
{"PMID":23494944,"re_id":0,"annotated sentence":"GTLE pretreatment completely reversed the damaging effects of <e1>AlCl3<\\e1> on AA and <e2>superoxide dismutase<\\e2> activity, markedly corrected COX and AChE activities, and moderately improved TGC","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"AlCl3","object":"superoxide dismutase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"GTLE pretreatment completely reversed the damaging effects of <e1>CHEMICAL<\\e1> on AA and <e2>GENE-N<\\e2> activity, markedly corrected COX and AChE activities, and moderately improved TGC","sentence":"GTLE pretreatment completely reversed the damaging effects of AlCl3 on AA and superoxide dismutase activity, markedly corrected COX and AChE activities, and moderately improved TGC"}
{"PMID":23494944,"re_id":1,"annotated sentence":"GTLE pretreatment completely reversed the damaging effects of <e1>AlCl3<\\e1> on AA and superoxide dismutase activity, markedly corrected <e2>COX<\\e2> and AChE activities, and moderately improved TGC","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"AlCl3","object":"COX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"GTLE pretreatment completely reversed the damaging effects of <e1>CHEMICAL<\\e1> on AA and superoxide dismutase activity, markedly corrected <e2>GENE-N<\\e2> and AChE activities, and moderately improved TGC","sentence":"GTLE pretreatment completely reversed the damaging effects of AlCl3 on AA and superoxide dismutase activity, markedly corrected COX and AChE activities, and moderately improved TGC"}
{"PMID":23494944,"re_id":2,"annotated sentence":"GTLE pretreatment completely reversed the damaging effects of <e1>AlCl3<\\e1> on AA and superoxide dismutase activity, markedly corrected COX and <e2>AChE<\\e2> activities, and moderately improved TGC","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"AlCl3","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"GTLE pretreatment completely reversed the damaging effects of <e1>CHEMICAL<\\e1> on AA and superoxide dismutase activity, markedly corrected COX and <e2>GENE-Y<\\e2> activities, and moderately improved TGC","sentence":"GTLE pretreatment completely reversed the damaging effects of AlCl3 on AA and superoxide dismutase activity, markedly corrected COX and AChE activities, and moderately improved TGC"}
{"PMID":23494944,"re_id":3,"annotated sentence":"<e1>AlCl3<\\e1> markedly reduced AA performance and activities of <e2>cytochrome c oxidase<\\e2> (COX) and acetylcholinesterase (AChE) in all regions","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"AlCl3","object":"cytochrome c oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> markedly reduced AA performance and activities of <e2>GENE-N<\\e2> (COX) and acetylcholinesterase (AChE) in all regions","sentence":"AlCl3 markedly reduced AA performance and activities of cytochrome c oxidase (COX) and acetylcholinesterase (AChE) in all regions"}
{"PMID":23494944,"re_id":4,"annotated sentence":"<e1>AlCl3<\\e1> markedly reduced AA performance and activities of cytochrome c oxidase (<e2>COX<\\e2>  and acetylcholinesterase (AChE) in all regions","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"AlCl3","object":"COX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> markedly reduced AA performance and activities of cytochrome c oxidase (<e2>GENE-N<\\e2>  and acetylcholinesterase (AChE) in all regions","sentence":"AlCl3 markedly reduced AA performance and activities of cytochrome c oxidase (COX  and acetylcholinesterase (AChE) in all regions"}
{"PMID":23494944,"re_id":5,"annotated sentence":"<e1>AlCl3<\\e1> markedly reduced AA performance and activities of cytochrome c oxidase (COX) and <e2>acetylcholinesterase<\\e2> (AChE) in all regions","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"AlCl3","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> markedly reduced AA performance and activities of cytochrome c oxidase (COX) and <e2>GENE-Y<\\e2> (AChE) in all regions","sentence":"AlCl3 markedly reduced AA performance and activities of cytochrome c oxidase (COX) and acetylcholinesterase (AChE) in all regions"}
{"PMID":23494944,"re_id":6,"annotated sentence":"<e1>AlCl3<\\e1> markedly reduced AA performance and activities of cytochrome c oxidase (COX) and acetylcholinesterase (<e2>AChE<\\e2>  in all regions","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"AlCl3","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> markedly reduced AA performance and activities of cytochrome c oxidase (COX) and acetylcholinesterase (<e2>GENE-Y<\\e2>  in all regions","sentence":"AlCl3 markedly reduced AA performance and activities of cytochrome c oxidase (COX) and acetylcholinesterase (AChE  in all regions"}
{"PMID":23500387,"re_id":0,"annotated sentence":"Our study demonstrated that <e1>curcumin<\\e1> inhibited OVA-induced increases in eosinophil count; interleukin (IL)-17A level were recovered in bronchoalveolar lavage fluid increased <e2>IL-10<\\e2> level in bronchoalveolar lavage fluid","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"curcumin","object":"IL-10","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our study demonstrated that <e1>CHEMICAL<\\e1> inhibited OVA-induced increases in eosinophil count; interleukin (IL)-17A level were recovered in bronchoalveolar lavage fluid increased <e2>GENE-Y<\\e2> level in bronchoalveolar lavage fluid","sentence":"Our study demonstrated that curcumin inhibited OVA-induced increases in eosinophil count; interleukin (IL)-17A level were recovered in bronchoalveolar lavage fluid increased IL-10 level in bronchoalveolar lavage fluid"}
{"PMID":23500387,"re_id":1,"annotated sentence":"Histological studies demonstrated that <e1>curcumin<\\e1> substantially inhibited <e2>OVA<\\e2> induced eosinophilia in lung tissue","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"curcumin","object":"OVA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Histological studies demonstrated that <e1>CHEMICAL<\\e1> substantially inhibited <e2>GENE-Y<\\e2> induced eosinophilia in lung tissue","sentence":"Histological studies demonstrated that curcumin substantially inhibited OVA induced eosinophilia in lung tissue"}
{"PMID":23500387,"re_id":2,"annotated sentence":"The results in vivo show <e2>ovalbumin<\\e2> induced significantly broke Treg\/Th17 balance; <e1>curcumin<\\e1> treatments markedly attenuated the inflammatory in asthma model by regulating Treg\/Th17 balance","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"curcumin","object":"ovalbumin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results in vivo show <e2>GENE-Y<\\e2> induced significantly broke Treg\/Th17 balance; <e1>CHEMICAL<\\e1> treatments markedly attenuated the inflammatory in asthma model by regulating Treg\/Th17 balance","sentence":"The results in vivo show ovalbumin induced significantly broke Treg\/Th17 balance; curcumin treatments markedly attenuated the inflammatory in asthma model by regulating Treg\/Th17 balance"}
{"PMID":23500387,"re_id":3,"annotated sentence":"Our study demonstrated that <e1>curcumin<\\e1> inhibited <e2>OVA<\\e2> induced increases in eosinophil count; interleukin (IL)-17A level were recovered in bronchoalveolar lavage fluid increased IL-10 level in bronchoalveolar lavage fluid","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"curcumin","object":"OVA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our study demonstrated that <e1>CHEMICAL<\\e1> inhibited <e2>GENE-Y<\\e2> induced increases in eosinophil count; interleukin (IL)-17A level were recovered in bronchoalveolar lavage fluid increased IL-10 level in bronchoalveolar lavage fluid","sentence":"Our study demonstrated that curcumin inhibited OVA induced increases in eosinophil count; interleukin (IL)-17A level were recovered in bronchoalveolar lavage fluid increased IL-10 level in bronchoalveolar lavage fluid"}
{"PMID":23500387,"re_id":4,"annotated sentence":"Our study demonstrated that <e1>curcumin<\\e1> inhibited OVA-induced increases in eosinophil count; <e2>interleukin (IL)-17A<\\e2> level were recovered in bronchoalveolar lavage fluid increased IL-10 level in bronchoalveolar lavage fluid","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"curcumin","object":"interleukin (IL)-17A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our study demonstrated that <e1>CHEMICAL<\\e1> inhibited OVA-induced increases in eosinophil count; <e2>GENE-Y<\\e2> level were recovered in bronchoalveolar lavage fluid increased IL-10 level in bronchoalveolar lavage fluid","sentence":"Our study demonstrated that curcumin inhibited OVA-induced increases in eosinophil count; interleukin (IL)-17A level were recovered in bronchoalveolar lavage fluid increased IL-10 level in bronchoalveolar lavage fluid"}
{"PMID":23511016,"re_id":0,"annotated sentence":"To overcome this limitation, we de novo synthesized a conjugate that covalently combines a <e1>Gd<\\e1> based MRI contrast agent, encaged with a chelating agent (DOTA), with pantoprazole, which is a widely used <e2>proton pump<\\e2> inhibitor that binds to proton pumps in the stomach and colon","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Gd","object":"proton pump","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"To overcome this limitation, we de novo synthesized a conjugate that covalently combines a <e1>CHEMICAL<\\e1> based MRI contrast agent, encaged with a chelating agent (DOTA), with pantoprazole, which is a widely used <e2>GENE-N<\\e2> inhibitor that binds to GENE-Ns in the stomach and colon","sentence":"To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd based MRI contrast agent, encaged with a chelating agent (DOTA), with pantoprazole, which is a widely used proton pump inhibitor that binds to proton pumps in the stomach and colon"}
{"PMID":23511016,"re_id":1,"annotated sentence":"To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent (<e1>DOTA<\\e1> , with pantoprazole, which is a widely used <e2>proton pump<\\e2> inhibitor that binds to proton pumps in the stomach and colon","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DOTA","object":"proton pump","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent (<e1>CHEMICAL<\\e1> , with pantoprazole, which is a widely used <e2>GENE-N<\\e2> inhibitor that binds to GENE-Ns in the stomach and colon","sentence":"To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent (DOTA , with pantoprazole, which is a widely used proton pump inhibitor that binds to proton pumps in the stomach and colon"}
{"PMID":23511016,"re_id":2,"annotated sentence":"To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent (DOTA), with <e1>pantoprazole<\\e1>  which is a widely used <e2>proton pump<\\e2> inhibitor that binds to proton pumps in the stomach and colon","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pantoprazole","object":"proton pump","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent (DOTA), with <e1>CHEMICAL<\\e1>  which is a widely used <e2>GENE-N<\\e2> inhibitor that binds to GENE-Ns in the stomach and colon","sentence":"To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent (DOTA), with pantoprazole  which is a widely used proton pump inhibitor that binds to proton pumps in the stomach and colon"}
{"PMID":23511016,"re_id":3,"annotated sentence":"Synthesis of a <e1>DOTA<\\e1> (Gd(3+))-conjugate of <e2>proton-pump<\\e2> inhibitor pantoprazole for gastric wall imaging studies","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DOTA","object":"proton-pump","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Synthesis of a <e1>CHEMICAL<\\e1> (Gd(3+))-conjugate of <e2>GENE-N<\\e2> inhibitor pantoprazole for gastric wall imaging studies","sentence":"Synthesis of a DOTA (Gd(3+))-conjugate of proton-pump inhibitor pantoprazole for gastric wall imaging studies"}
{"PMID":23511016,"re_id":4,"annotated sentence":"Synthesis of a DOTA (<e1>Gd(3+)<\\e1> -conjugate of <e2>proton-pump<\\e2> inhibitor pantoprazole for gastric wall imaging studies","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Gd(3+)","object":"proton-pump","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Synthesis of a DOTA (<e1>CHEMICAL<\\e1> -conjugate of <e2>GENE-N<\\e2> inhibitor pantoprazole for gastric wall imaging studies","sentence":"Synthesis of a DOTA (Gd(3+) -conjugate of proton-pump inhibitor pantoprazole for gastric wall imaging studies"}
{"PMID":23511016,"re_id":5,"annotated sentence":"Synthesis of a DOTA (Gd(3+))-conjugate of <e2>proton-pump<\\e2> inhibitor <e1>pantoprazole<\\e1> for gastric wall imaging studies","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pantoprazole","object":"proton-pump","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Synthesis of a DOTA (Gd(3+))-conjugate of <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1> for gastric wall imaging studies","sentence":"Synthesis of a DOTA (Gd(3+))-conjugate of proton-pump inhibitor pantoprazole for gastric wall imaging studies"}
{"PMID":23511125,"re_id":0,"annotated sentence":"Second, EPSCs were recorded from rat hippocampal slices before and after their superfusion with the reversible <e2>AChE<\\e2> inhibitor <e1>donepezil<\\e1> (100nM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"donepezil","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Second, EPSCs were recorded from rat hippocampal slices before and after their superfusion with the reversible <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1> (100nM)","sentence":"Second, EPSCs were recorded from rat hippocampal slices before and after their superfusion with the reversible AChE inhibitor donepezil (100nM)"}
{"PMID":23511711,"re_id":0,"annotated sentence":"<e2>CYP3A5<\\e2> carrier status had no influence on midazolam oral clearance or its inhibition by <e1>ketoconazole<\\e1>  This is the first study showing that midazolam pharmacokinetics is linear in a 30,000-fold concentration range, and therefore that nano- and microgram doses of midazolam can reliably predict the pharmacokinetics of midazolam in therapeutic doses and can be used to assess CYP3A activity even in the presence of strong CYP3A inhibitors.Clinical Pharmacology & Therapeutics (2013); advance online publication 20 March 2013","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ketoconazole","object":"CYP3A5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> carrier status had no influence on midazolam oral clearance or its inhibition by <e1>CHEMICAL<\\e1>  This is the first study showing that midazolam pharmacokinetics is linear in a 30,000-fold concentration range, and therefore that nano- and microgram doses of midazolam can reliably predict the pharmacokinetics of midazolam in therapeutic doses and can be used to assess CYP3A activity even in the presence of strong CYP3A inhibitors.Clinical Pharmacology & Therapeutics (2013); advance online publication 20 March 2013","sentence":"CYP3A5 carrier status had no influence on midazolam oral clearance or its inhibition by ketoconazole  This is the first study showing that midazolam pharmacokinetics is linear in a 30,000-fold concentration range, and therefore that nano- and microgram doses of midazolam can reliably predict the pharmacokinetics of midazolam in therapeutic doses and can be used to assess CYP3A activity even in the presence of strong CYP3A inhibitors.Clinical Pharmacology & Therapeutics (2013); advance online publication 20 March 2013"}
{"PMID":23511711,"re_id":1,"annotated sentence":"We then evaluated the interactions with the <e2>CYP3A<\\e2> inhibitor <e1>ketoconazole<\\e1> (400\u2009mg q.d.) after nanogram and regular doses of midazolam","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ketoconazole","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We then evaluated the interactions with the <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1> (400\u2009mg q.d.) after nanogram and regular doses of midazolam","sentence":"We then evaluated the interactions with the CYP3A inhibitor ketoconazole (400\u2009mg q.d.) after nanogram and regular doses of midazolam"}
{"PMID":23511711,"re_id":2,"annotated sentence":"A Nanogram Dose of the <e2>CYP3A<\\e2> Probe Substrate <e1>Midazolam<\\e1> to Evaluate Drug Interactions","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Midazolam","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A Nanogram Dose of the <e2>GENE-N<\\e2> Probe Substrate <e1>CHEMICAL<\\e1> to Evaluate Drug Interactions","sentence":"A Nanogram Dose of the CYP3A Probe Substrate Midazolam to Evaluate Drug Interactions"}
{"PMID":23511711,"re_id":3,"annotated sentence":"<e2>CYP3A5<\\e2> carrier status had no influence on <e1>midazolam<\\e1> oral clearance or its inhibition by ketoconazole","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"midazolam","object":"CYP3A5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> carrier status had no influence on <e1>CHEMICAL<\\e1> oral clearance or its inhibition by ketoconazole","sentence":"CYP3A5 carrier status had no influence on midazolam oral clearance or its inhibition by ketoconazole"}
{"PMID":23512537,"re_id":0,"annotated sentence":"These studies show that <e2>CYP3A4<\\e2> and CYP3A5 metabolize <e1>BDP<\\e1> to inactive metabolites and suggest that differences in the expression or function of these enzymes in the lung and\/or liver could influence BDP disposition in humans.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"BDP","object":"CYP3A4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These studies show that <e2>GENE-Y<\\e2> and CYP3A5 metabolize <e1>CHEMICAL<\\e1> to inactive metabolites and suggest that differences in the expression or function of these enzymes in the lung and\/or liver could influence CHEMICAL disposition in humans.","sentence":"These studies show that CYP3A4 and CYP3A5 metabolize BDP to inactive metabolites and suggest that differences in the expression or function of these enzymes in the lung and\/or liver could influence BDP disposition in humans."}
{"PMID":23512537,"re_id":1,"annotated sentence":"These studies show that CYP3A4 and <e2>CYP3A5<\\e2> metabolize <e1>BDP<\\e1> to inactive metabolites and suggest that differences in the expression or function of these enzymes in the lung and\/or liver could influence BDP disposition in humans.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"BDP","object":"CYP3A5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These studies show that CYP3A4 and <e2>GENE-Y<\\e2> metabolize <e1>CHEMICAL<\\e1> to inactive metabolites and suggest that differences in the expression or function of these enzymes in the lung and\/or liver could influence CHEMICAL disposition in humans.","sentence":"These studies show that CYP3A4 and CYP3A5 metabolize BDP to inactive metabolites and suggest that differences in the expression or function of these enzymes in the lung and\/or liver could influence BDP disposition in humans."}
{"PMID":23512537,"re_id":2,"annotated sentence":"It is possible that variations in <e2>cytochrome P450 3A<\\e2> enzyme-mediated metabolism of <e1>BDP<\\e1> may contribute to this phenomenon","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"BDP","object":"cytochrome P450 3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"It is possible that variations in <e2>GENE-N<\\e2> enzyme-mediated metabolism of <e1>CHEMICAL<\\e1> may contribute to this phenomenon","sentence":"It is possible that variations in cytochrome P450 3A enzyme-mediated metabolism of BDP may contribute to this phenomenon"}
{"PMID":23512537,"re_id":3,"annotated sentence":"This hypothesis was explored by evaluating the contributions of CYP3A4, 3A5, 3A7, and <e2>esterase<\\e2> enzymes in the metabolism of <e1>BDP<\\e1> in vitro and relating metabolism to changes in CYP3A enzyme mRNA expression via the glucocorticoid receptor in lung and liver cells","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"BDP","object":"esterase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This hypothesis was explored by evaluating the contributions of CYP3A4, 3A5, 3A7, and <e2>GENE-N<\\e2> enzymes in the metabolism of <e1>CHEMICAL<\\e1> in vitro and relating metabolism to changes in CYP3A enzyme mRNA expression via the glucocorticoid receptor in lung and liver cells","sentence":"This hypothesis was explored by evaluating the contributions of CYP3A4, 3A5, 3A7, and esterase enzymes in the metabolism of BDP in vitro and relating metabolism to changes in CYP3A enzyme mRNA expression via the glucocorticoid receptor in lung and liver cells"}
{"PMID":23512537,"re_id":4,"annotated sentence":"<e2>CYP3A4<\\e2> and CYP3A5 metabolized <e1>BDP<\\e1> via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; CYP3A7 did not metabolize BDP","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"BDP","object":"CYP3A4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> and CYP3A5 metabolized <e1>CHEMICAL<\\e1> via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; CYP3A7 did not metabolize CHEMICAL","sentence":"CYP3A4 and CYP3A5 metabolized BDP via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; CYP3A7 did not metabolize BDP"}
{"PMID":23512537,"re_id":5,"annotated sentence":"CYP3A4 and <e2>CYP3A5<\\e2> metabolized <e1>BDP<\\e1> via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; CYP3A7 did not metabolize BDP","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"BDP","object":"CYP3A5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CYP3A4 and <e2>GENE-Y<\\e2> metabolized <e1>CHEMICAL<\\e1> via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; CYP3A7 did not metabolize CHEMICAL","sentence":"CYP3A4 and CYP3A5 metabolized BDP via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; CYP3A7 did not metabolize BDP"}
{"PMID":23512537,"re_id":6,"annotated sentence":"Metabolism of <e1>Beclomethasone Dipropionate<\\e1> by <e2>Cytochrome P450 3A<\\e2> Enzymes","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Beclomethasone Dipropionate","object":"Cytochrome P450 3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Metabolism of <e1>CHEMICAL<\\e1> by <e2>GENE-N<\\e2> Enzymes","sentence":"Metabolism of Beclomethasone Dipropionate by Cytochrome P450 3A Enzymes"}
{"PMID":23512754,"re_id":0,"annotated sentence":"In macrophages, levels of <e2>TNF-\u03b1<\\e2>  IFN-\u03b3, NO, IL-6 and IL-10 were increased by <e1>CDM<\\e1> used alone or in combination with HSV-2","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CDM","object":"TNF-\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In macrophages, levels of <e2>GENE-Y<\\e2>  IFN-\u03b3, NO, IL-6 and IL-10 were increased by <e1>CHEMICAL<\\e1> used alone or in combination with HSV-2","sentence":"In macrophages, levels of TNF-\u03b1  IFN-\u03b3, NO, IL-6 and IL-10 were increased by CDM used alone or in combination with HSV-2"}
{"PMID":23512754,"re_id":1,"annotated sentence":"In macrophages, levels of TNF-\u03b1, <e2>IFN-\u03b3<\\e2>  NO, IL-6 and IL-10 were increased by <e1>CDM<\\e1> used alone or in combination with HSV-2","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CDM","object":"IFN-\u03b3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In macrophages, levels of TNF-\u03b1, <e2>GENE-Y<\\e2>  NO, IL-6 and IL-10 were increased by <e1>CHEMICAL<\\e1> used alone or in combination with HSV-2","sentence":"In macrophages, levels of TNF-\u03b1, IFN-\u03b3  NO, IL-6 and IL-10 were increased by CDM used alone or in combination with HSV-2"}
{"PMID":23512754,"re_id":2,"annotated sentence":"In macrophages, levels of TNF-\u03b1, IFN-\u03b3, NO, <e2>IL-6<\\e2> and IL-10 were increased by <e1>CDM<\\e1> used alone or in combination with HSV-2","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CDM","object":"IL-6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In macrophages, levels of TNF-\u03b1, IFN-\u03b3, NO, <e2>GENE-Y<\\e2> and IL-10 were increased by <e1>CHEMICAL<\\e1> used alone or in combination with HSV-2","sentence":"In macrophages, levels of TNF-\u03b1, IFN-\u03b3, NO, IL-6 and IL-10 were increased by CDM used alone or in combination with HSV-2"}
{"PMID":23512754,"re_id":3,"annotated sentence":"In macrophages, levels of TNF-\u03b1, IFN-\u03b3, NO, IL-6 and <e2>IL-10<\\e2> were increased by <e1>CDM<\\e1> used alone or in combination with HSV-2","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CDM","object":"IL-10","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In macrophages, levels of TNF-\u03b1, IFN-\u03b3, NO, IL-6 and <e2>GENE-Y<\\e2> were increased by <e1>CHEMICAL<\\e1> used alone or in combination with HSV-2","sentence":"In macrophages, levels of TNF-\u03b1, IFN-\u03b3, NO, IL-6 and IL-10 were increased by CDM used alone or in combination with HSV-2"}
{"PMID":23512754,"re_id":4,"annotated sentence":"Besides, <e1>CDM<\\e1> not only synergized <e2>TNF-\u03b1<\\e2> production combined with IFN-\u03b3, but also prolonged its expression in time","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CDM","object":"TNF-\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Besides, <e1>CHEMICAL<\\e1> not only synergized <e2>GENE-Y<\\e2> production combined with IFN-\u03b3, but also prolonged its expression in time","sentence":"Besides, CDM not only synergized TNF-\u03b1 production combined with IFN-\u03b3, but also prolonged its expression in time"}
{"PMID":23512754,"re_id":5,"annotated sentence":"Besides, <e1>CDM<\\e1> not only synergized TNF-\u03b1 production combined with <e2>IFN-\u03b3<\\e2>  but also prolonged its expression in time","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CDM","object":"IFN-\u03b3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Besides, <e1>CHEMICAL<\\e1> not only synergized TNF-\u03b1 production combined with <e2>GENE-Y<\\e2>  but also prolonged its expression in time","sentence":"Besides, CDM not only synergized TNF-\u03b1 production combined with IFN-\u03b3  but also prolonged its expression in time"}
{"PMID":23512754,"re_id":6,"annotated sentence":"Results indicate that <e1>CDM<\\e1> inhibits HSV-2 multiplication in epithelial cells and also increases <e2>cytokine<\\e2> production in macrophages, both important actions to the clearance of infecting virus in the mouse vagina","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CDM","object":"cytokine","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Results indicate that <e1>CHEMICAL<\\e1> inhibits HSV-2 multiplication in epithelial cells and also increases <e2>GENE-N<\\e2> production in macrophages, both important actions to the clearance of infecting virus in the mouse vagina","sentence":"Results indicate that CDM inhibits HSV-2 multiplication in epithelial cells and also increases cytokine production in macrophages, both important actions to the clearance of infecting virus in the mouse vagina"}
{"PMID":23517558,"re_id":0,"annotated sentence":"A catheterized rat model was used to define the intestinal and hepatic components of oral bioavailability for an <e2>11\u03b2-HSD1<\\e2> inhibitor, <e1>AMG 221<\\e1>  These data were integrated with standard in vivo metabolism studies to elucidate the components contributing to the oral disposition of a novel drug candidate","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"AMG 221","object":"11\u03b2-HSD1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A catheterized rat model was used to define the intestinal and hepatic components of oral bioavailability for an <e2>GENE-Y<\\e2> inhibitor, <e1>CHEMICAL<\\e1>  These data were integrated with standard in vivo metabolism studies to elucidate the components contributing to the oral disposition of a novel drug candidate","sentence":"A catheterized rat model was used to define the intestinal and hepatic components of oral bioavailability for an 11\u03b2-HSD1 inhibitor, AMG 221  These data were integrated with standard in vivo metabolism studies to elucidate the components contributing to the oral disposition of a novel drug candidate"}
{"PMID":23517558,"re_id":1,"annotated sentence":"Intestinal and hepatic first-pass extraction of the <e2>11\u03b2-HSD1<\\e2> inhibitor <e1>AMG 221<\\e1> in rats with chronic vascular catheters","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"AMG 221","object":"11\u03b2-HSD1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Intestinal and hepatic first-pass extraction of the <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1> in rats with chronic vascular catheters","sentence":"Intestinal and hepatic first-pass extraction of the 11\u03b2-HSD1 inhibitor AMG 221 in rats with chronic vascular catheters"}
{"PMID":23519149,"re_id":0,"annotated sentence":"In DU-PM cells with acquired resistance to <e1>elisidepsin<\\e1>  ErbB3 expression was decreased, while <e2>Bcl2<\\e2> was increased","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"elisidepsin","object":"Bcl2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In DU-PM cells with acquired resistance to <e1>CHEMICAL<\\e1>  ErbB3 expression was decreased, while <e2>GENE-Y<\\e2> was increased","sentence":"In DU-PM cells with acquired resistance to elisidepsin  ErbB3 expression was decreased, while Bcl2 was increased"}
{"PMID":23519149,"re_id":1,"annotated sentence":"In DU-PM cells with acquired resistance to <e1>elisidepsin<\\e1>  <e2>ErbB3<\\e2> expression was decreased, while Bcl2 was increased","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"elisidepsin","object":"ErbB3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In DU-PM cells with acquired resistance to <e1>CHEMICAL<\\e1>  <e2>GENE-Y<\\e2> expression was decreased, while Bcl2 was increased","sentence":"In DU-PM cells with acquired resistance to elisidepsin  ErbB3 expression was decreased, while Bcl2 was increased"}
{"PMID":23523780,"re_id":0,"annotated sentence":"Administration of <e1>bicuculline<\\e1>  a <e2>GABAA<\\e2> inhibitor, isolated a single response to \u03c9-agatoxin, which was characterized by a reduction in network activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"bicuculline","object":"GABAA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Administration of <e1>CHEMICAL<\\e1>  a <e2>GENE-N<\\e2> inhibitor, isolated a single response to \u03c9-agatoxin, which was characterized by a reduction in network activity","sentence":"Administration of bicuculline  a GABAA inhibitor, isolated a single response to \u03c9-agatoxin, which was characterized by a reduction in network activity"}
{"PMID":23523780,"re_id":1,"annotated sentence":"Administration of <e1>bicuculline<\\e1>  a GABAA inhibitor, isolated a single response to <e2>\u03c9-agatoxin<\\e2>  which was characterized by a reduction in network activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"bicuculline","object":"\u03c9-agatoxin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Administration of <e1>CHEMICAL<\\e1>  a GABAA inhibitor, isolated a single response to <e2>GENE-N<\\e2>  which was characterized by a reduction in network activity","sentence":"Administration of bicuculline  a GABAA inhibitor, isolated a single response to \u03c9-agatoxin  which was characterized by a reduction in network activity"}
{"PMID":23526814,"re_id":0,"annotated sentence":"Compounds 8\u2009b and 10\u2009c selectively inhibited HDAC6 at the nanomolar level, whereas the other <e1>hydroxamates<\\e1> effected an increase in <e2>acetyl-\u03b1-tubulin<\\e2> levels in human acute myeloid leukemia U937 cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"hydroxamates","object":"acetyl-\u03b1-tubulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Compounds 8\u2009b and 10\u2009c selectively inhibited HDAC6 at the nanomolar level, whereas the other <e1>CHEMICAL<\\e1> effected an increase in <e2>GENE-N<\\e2> levels in human acute myeloid leukemia U937 cells","sentence":"Compounds 8\u2009b and 10\u2009c selectively inhibited HDAC6 at the nanomolar level, whereas the other hydroxamates effected an increase in acetyl-\u03b1-tubulin levels in human acute myeloid leukemia U937 cells"}
{"PMID":23526814,"re_id":1,"annotated sentence":"Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the <e1>tert-butylcarbamate<\\e1> group at the CAP moiety as <e2>histone deacetylase<\\e2> (HDAC) inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tert-butylcarbamate","object":"histone deacetylase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the <e1>CHEMICAL<\\e1> group at the CAP moiety as <e2>GENE-N<\\e2> (HDAC) inhibitors","sentence":"Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC) inhibitors"}
{"PMID":23526814,"re_id":2,"annotated sentence":"Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the <e1>tert-butylcarbamate<\\e1> group at the CAP moiety as histone deacetylase (<e2>HDAC<\\e2>  inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tert-butylcarbamate","object":"HDAC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the <e1>CHEMICAL<\\e1> group at the CAP moiety as histone deacetylase (<e2>GENE-N<\\e2>  inhibitors","sentence":"Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC  inhibitors"}
{"PMID":23526814,"re_id":3,"annotated sentence":"Herein we report novel <e1>pyrrole<\\e1>  and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as <e2>histone deacetylase<\\e2> (HDAC) inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pyrrole","object":"histone deacetylase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Herein we report novel <e1>CHEMICAL<\\e1>  and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as <e2>GENE-N<\\e2> (HDAC) inhibitors","sentence":"Herein we report novel pyrrole  and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC) inhibitors"}
{"PMID":23526814,"re_id":4,"annotated sentence":"Herein we report novel <e1>pyrrole<\\e1>  and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (<e2>HDAC<\\e2>  inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pyrrole","object":"HDAC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Herein we report novel <e1>CHEMICAL<\\e1>  and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (<e2>GENE-N<\\e2>  inhibitors","sentence":"Herein we report novel pyrrole  and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC  inhibitors"}
{"PMID":23526814,"re_id":5,"annotated sentence":"Herein we report novel pyrrole- and <e1>benzene<\\e1> based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as <e2>histone deacetylase<\\e2> (HDAC) inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"benzene","object":"histone deacetylase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Herein we report novel pyrrole- and <e1>CHEMICAL<\\e1> based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as <e2>GENE-N<\\e2> (HDAC) inhibitors","sentence":"Herein we report novel pyrrole- and benzene based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC) inhibitors"}
{"PMID":23526814,"re_id":6,"annotated sentence":"Herein we report novel pyrrole- and <e1>benzene<\\e1> based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (<e2>HDAC<\\e2>  inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"benzene","object":"HDAC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Herein we report novel pyrrole- and <e1>CHEMICAL<\\e1> based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (<e2>GENE-N<\\e2>  inhibitors","sentence":"Herein we report novel pyrrole- and benzene based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC  inhibitors"}
{"PMID":23526814,"re_id":7,"annotated sentence":"Herein we report novel pyrrole- and benzene-based <e1>hydroxamates<\\e1> (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as <e2>histone deacetylase<\\e2> (HDAC) inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"hydroxamates","object":"histone deacetylase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Herein we report novel pyrrole- and benzene-based <e1>CHEMICAL<\\e1> (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as <e2>GENE-N<\\e2> (HDAC) inhibitors","sentence":"Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC) inhibitors"}
{"PMID":23526814,"re_id":8,"annotated sentence":"Herein we report novel pyrrole- and benzene-based <e1>hydroxamates<\\e1> (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (<e2>HDAC<\\e2>  inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"hydroxamates","object":"HDAC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Herein we report novel pyrrole- and benzene-based <e1>CHEMICAL<\\e1> (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (<e2>GENE-N<\\e2>  inhibitors","sentence":"Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC  inhibitors"}
{"PMID":23526814,"re_id":9,"annotated sentence":"Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and <e1>2'-aminoanilides<\\e1> (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as <e2>histone deacetylase<\\e2> (HDAC) inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"2'-aminoanilides","object":"histone deacetylase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and <e1>CHEMICAL<\\e1> (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as <e2>GENE-N<\\e2> (HDAC) inhibitors","sentence":"Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC) inhibitors"}
{"PMID":23526814,"re_id":10,"annotated sentence":"Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and <e1>2'-aminoanilides<\\e1> (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (<e2>HDAC<\\e2>  inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"2'-aminoanilides","object":"HDAC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and <e1>CHEMICAL<\\e1> (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (<e2>GENE-N<\\e2>  inhibitors","sentence":"Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC  inhibitors"}
{"PMID":23526814,"re_id":11,"annotated sentence":"<e1>tert-Butylcarbamate<\\e1> Containing <e2>Histone Deacetylase<\\e2> Inhibitors: Apoptosis Induction, Cytodifferentiation, and Antiproliferative Activities in Cancer Cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tert-Butylcarbamate","object":"Histone Deacetylase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> Containing <e2>GENE-N<\\e2> Inhibitors: Apoptosis Induction, Cytodifferentiation, and Antiproliferative Activities in Cancer Cells","sentence":"tert-Butylcarbamate Containing Histone Deacetylase Inhibitors: Apoptosis Induction, Cytodifferentiation, and Antiproliferative Activities in Cancer Cells"}
{"PMID":23528299,"re_id":0,"annotated sentence":"As a potent synthetic <e2>APN<\\e2> inhibitor (IC50=850nM, versus <e1>bestatin<\\e1> of 8.1\u03bcM), LB-4b was determined to have more significant block effects to cancer cell invasion and angiogenesis than bestatin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"bestatin","object":"APN","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"As a potent synthetic <e2>GENE-Y<\\e2> inhibitor (IC50=850nM, versus <e1>CHEMICAL<\\e1> of 8.1\u03bcM), LB-4b was determined to have more significant block effects to cancer cell invasion and angiogenesis than CHEMICAL","sentence":"As a potent synthetic APN inhibitor (IC50=850nM, versus bestatin of 8.1\u03bcM), LB-4b was determined to have more significant block effects to cancer cell invasion and angiogenesis than bestatin"}
{"PMID":23528299,"re_id":1,"annotated sentence":"As a potent synthetic <e2>APN<\\e2> inhibitor (IC50=850nM, versus bestatin of 8.1\u03bcM), <e1>LB-4b<\\e1> was determined to have more significant block effects to cancer cell invasion and angiogenesis than bestatin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"LB-4b","object":"APN","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"As a potent synthetic <e2>GENE-Y<\\e2> inhibitor (IC50=850nM, versus bestatin of 8.1\u03bcM), <e1>CHEMICAL<\\e1> was determined to have more significant block effects to cancer cell invasion and angiogenesis than bestatin","sentence":"As a potent synthetic APN inhibitor (IC50=850nM, versus bestatin of 8.1\u03bcM), LB-4b was determined to have more significant block effects to cancer cell invasion and angiogenesis than bestatin"}
{"PMID":23528299,"re_id":2,"annotated sentence":"As a potent synthetic <e2>APN<\\e2> inhibitor (IC50=850nM, versus bestatin of 8.1\u03bcM), LB-4b was determined to have more significant block effects to cancer cell invasion and angiogenesis than <e1>bestatin<\\e1>  Besides, it is able to be easily synthesized with a high total yield, while the reported synthetic methods of bestatin are much more complex.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"bestatin","object":"APN","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"As a potent synthetic <e2>GENE-Y<\\e2> inhibitor (IC50=850nM, versus CHEMICAL of 8.1\u03bcM), LB-4b was determined to have more significant block effects to cancer cell invasion and angiogenesis than <e1>CHEMICAL<\\e1>  Besides, it is able to be easily synthesized with a high total yield, while the reported synthetic methods of CHEMICAL are much more complex.","sentence":"As a potent synthetic APN inhibitor (IC50=850nM, versus bestatin of 8.1\u03bcM), LB-4b was determined to have more significant block effects to cancer cell invasion and angiogenesis than bestatin  Besides, it is able to be easily synthesized with a high total yield, while the reported synthetic methods of bestatin are much more complex."}
{"PMID":23528299,"re_id":3,"annotated sentence":"<e1>LB-4b<\\e1> is the first synthetic <e2>APN<\\e2> inhibitor to be evaluated for both of its anti-invasion and anti-angiogenesis effects","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"LB-4b","object":"APN","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is the first synthetic <e2>GENE-Y<\\e2> inhibitor to be evaluated for both of its anti-invasion and anti-angiogenesis effects","sentence":"LB-4b is the first synthetic APN inhibitor to be evaluated for both of its anti-invasion and anti-angiogenesis effects"}
{"PMID":23528299,"re_id":4,"annotated sentence":"Discovery of a synthetic <e2>Aminopeptidase N<\\e2> inhibitor <e1>LB-4b<\\e1> as a potential anticancer agent","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"LB-4b","object":"Aminopeptidase N","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Discovery of a synthetic <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1> as a potential anticancer agent","sentence":"Discovery of a synthetic Aminopeptidase N inhibitor LB-4b as a potential anticancer agent"}
{"PMID":23530959,"re_id":0,"annotated sentence":"Both types of granules contain <e2>catechol oxidase<\\e2> that catalyzes oxidative cross-linking of <e1>L-DOPA<\\e1>  Co-secretion of catechol oxidase guarantees rapid and spatially homogeneous curing with limited mixing of the preassembled adhesive packets","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-DOPA","object":"catechol oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Both types of granules contain <e2>GENE-N<\\e2> that catalyzes oxidative cross-linking of <e1>CHEMICAL<\\e1>  Co-secretion of GENE-N guarantees rapid and spatially homogeneous curing with limited mixing of the preassembled adhesive packets","sentence":"Both types of granules contain catechol oxidase that catalyzes oxidative cross-linking of L-DOPA  Co-secretion of catechol oxidase guarantees rapid and spatially homogeneous curing with limited mixing of the preassembled adhesive packets"}
{"PMID":23535337,"re_id":0,"annotated sentence":"Under <e1>NaCl<\\e1> and sorbitol stresses, <e2>catalase<\\e2> (CAT) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"NaCl","object":"catalase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Under <e1>CHEMICAL<\\e1> and sorbitol stresses, <e2>GENE-N<\\e2> (CAT) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively","sentence":"Under NaCl and sorbitol stresses, catalase (CAT) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively"}
{"PMID":23535337,"re_id":1,"annotated sentence":"Under <e1>NaCl<\\e1> and sorbitol stresses, catalase (<e2>CAT<\\e2>  activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"NaCl","object":"CAT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Under <e1>CHEMICAL<\\e1> and sorbitol stresses, catalase (<e2>GENE-N<\\e2>  activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively","sentence":"Under NaCl and sorbitol stresses, catalase (CAT  activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively"}
{"PMID":23535337,"re_id":2,"annotated sentence":"Under NaCl and <e1>sorbitol<\\e1> stresses, <e2>catalase<\\e2> (CAT) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"sorbitol","object":"catalase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Under NaCl and <e1>CHEMICAL<\\e1> stresses, <e2>GENE-N<\\e2> (CAT) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively","sentence":"Under NaCl and sorbitol stresses, catalase (CAT) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively"}
{"PMID":23535337,"re_id":3,"annotated sentence":"Under NaCl and <e1>sorbitol<\\e1> stresses, catalase (<e2>CAT<\\e2>  activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"sorbitol","object":"CAT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Under NaCl and <e1>CHEMICAL<\\e1> stresses, catalase (<e2>GENE-N<\\e2>  activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively","sentence":"Under NaCl and sorbitol stresses, catalase (CAT  activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively"}
{"PMID":23536314,"re_id":0,"annotated sentence":"Immunofluorescence staining and western blotting demonstrated that <e1>cilostazol<\\e1> treatment reduced GFAP and <e2>VEGF<\\e2> expression in the retinas of OLETF rats","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cilostazol","object":"VEGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Immunofluorescence staining and western blotting demonstrated that <e1>CHEMICAL<\\e1> treatment reduced GFAP and <e2>GENE-Y<\\e2> expression in the retinas of OLETF rats","sentence":"Immunofluorescence staining and western blotting demonstrated that cilostazol treatment reduced GFAP and VEGF expression in the retinas of OLETF rats"}
{"PMID":23536314,"re_id":1,"annotated sentence":"Immunofluorescence staining and western blotting demonstrated that <e1>cilostazol<\\e1> treatment reduced <e2>GFAP<\\e2> and VEGF expression in the retinas of OLETF rats","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cilostazol","object":"GFAP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Immunofluorescence staining and western blotting demonstrated that <e1>CHEMICAL<\\e1> treatment reduced <e2>GENE-Y<\\e2> and VEGF expression in the retinas of OLETF rats","sentence":"Immunofluorescence staining and western blotting demonstrated that cilostazol treatment reduced GFAP and VEGF expression in the retinas of OLETF rats"}
{"PMID":23537661,"re_id":0,"annotated sentence":"Other dams received 1.8ng\/kg\/day of a mixture of <e2>aryl hydrocarbon receptor<\\e2> (AhR) agonists (non-ortho PCBs, PC-dibenzodioxins and <e1>PC-dibenzofurans<\\e1>  without or with 0.5M (0.5MAhR)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"PC-dibenzofurans","object":"aryl hydrocarbon receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Other dams received 1.8ng\/kg\/day of a mixture of <e2>GENE-Y<\\e2> (AhR) agonists (non-ortho PCBs, PC-dibenzodioxins and <e1>CHEMICAL<\\e1>  without or with 0.5M (0.5MAhR)","sentence":"Other dams received 1.8ng\/kg\/day of a mixture of aryl hydrocarbon receptor (AhR) agonists (non-ortho PCBs, PC-dibenzodioxins and PC-dibenzofurans  without or with 0.5M (0.5MAhR)"}
{"PMID":23537661,"re_id":1,"annotated sentence":"Other dams received 1.8ng\/kg\/day of a mixture of <e2>aryl hydrocarbon receptor<\\e2> (AhR) agonists (<e1>non-ortho PCB<\\e1> , PC-dibenzodioxins and PC-dibenzofurans) without or with 0.5M (0.5MAhR)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"non-ortho PCB","object":"aryl hydrocarbon receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Other dams received 1.8ng\/kg\/day of a mixture of <e2>GENE-Y<\\e2> (AhR) agonists (<e1>CHEMICAL<\\e1> , PC-dibenzodioxins and PC-dibenzofurans) without or with 0.5M (0.5MAhR)","sentence":"Other dams received 1.8ng\/kg\/day of a mixture of aryl hydrocarbon receptor (AhR) agonists (non-ortho PCB , PC-dibenzodioxins and PC-dibenzofurans) without or with 0.5M (0.5MAhR)"}
{"PMID":23537661,"re_id":2,"annotated sentence":"Other dams received 1.8ng\/kg\/day of a mixture of <e2>aryl hydrocarbon receptor<\\e2> (AhR) agonists (non-ortho PCBs, <e1>PC-dibenzodioxins<\\e1> and PC-dibenzofurans) without or with 0.5M (0.5MAhR)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"PC-dibenzodioxins","object":"aryl hydrocarbon receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Other dams received 1.8ng\/kg\/day of a mixture of <e2>GENE-Y<\\e2> (AhR) agonists (non-ortho PCBs, <e1>CHEMICAL<\\e1> and PC-dibenzofurans) without or with 0.5M (0.5MAhR)","sentence":"Other dams received 1.8ng\/kg\/day of a mixture of aryl hydrocarbon receptor (AhR) agonists (non-ortho PCBs, PC-dibenzodioxins and PC-dibenzofurans) without or with 0.5M (0.5MAhR)"}
{"PMID":23541670,"re_id":0,"annotated sentence":"We report the discovery of a novel series of ATP-competitive <e2>Janus kinase 3<\\e2> (JAK3) inhibitors based on the <e1>5H-pyrrolo[2,3-b]pyrazine<\\e1> scaffold","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5H-pyrrolo[2,3-b]pyrazine","object":"Janus kinase 3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We report the discovery of a novel series of ATP-competitive <e2>GENE-Y<\\e2> (JAK3) inhibitors based on the <e1>CHEMICAL<\\e1> scaffold","sentence":"We report the discovery of a novel series of ATP-competitive Janus kinase 3 (JAK3) inhibitors based on the 5H-pyrrolo[2,3-b]pyrazine scaffold"}
{"PMID":23541670,"re_id":1,"annotated sentence":"We report the discovery of a novel series of ATP-competitive Janus kinase 3 (<e2>JAK3<\\e2>  inhibitors based on the <e1>5H-pyrrolo[2,3-b]pyrazine<\\e1> scaffold","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5H-pyrrolo[2,3-b]pyrazine","object":"JAK3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We report the discovery of a novel series of ATP-competitive Janus kinase 3 (<e2>GENE-Y<\\e2>  inhibitors based on the <e1>CHEMICAL<\\e1> scaffold","sentence":"We report the discovery of a novel series of ATP-competitive Janus kinase 3 (JAK3  inhibitors based on the 5H-pyrrolo[2,3-b]pyrazine scaffold"}
{"PMID":23541670,"re_id":2,"annotated sentence":"Discovery of a series of novel <e1>5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers<\\e1>  as potent <e2>JAK3<\\e2> kinase inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers","object":"JAK3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Discovery of a series of novel <e1>CHEMICAL<\\e1>  as potent <e2>GENE-Y<\\e2> kinase inhibitors","sentence":"Discovery of a series of novel 5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers  as potent JAK3 kinase inhibitors"}
{"PMID":23541670,"re_id":3,"annotated sentence":"Discovery of a series of novel <e1>5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers<\\e1>  as potent JAK3 <e2>kinase<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Discovery of a series of novel <e1>CHEMICAL<\\e1>  as potent JAK3 <e2>GENE-N<\\e2> inhibitors","sentence":"Discovery of a series of novel 5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers  as potent JAK3 kinase inhibitors"}
{"PMID":23542114,"re_id":0,"annotated sentence":"<e1>ATO<\\e1> inhibited the phosphorylation and activation of AKT and <e2>STAT3<\\e2> through Notch signaling blockade","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ATO","object":"STAT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibited the phosphorylation and activation of AKT and <e2>GENE-Y<\\e2> through Notch signaling blockade","sentence":"ATO inhibited the phosphorylation and activation of AKT and STAT3 through Notch signaling blockade"}
{"PMID":23542114,"re_id":1,"annotated sentence":"<e1>ATO<\\e1> inhibited the phosphorylation and activation of AKT and STAT3 through <e2>Notch<\\e2> signaling blockade","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ATO","object":"Notch","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> inhibited the phosphorylation and activation of AKT and STAT3 through <e2>GENE-N<\\e2> signaling blockade","sentence":"ATO inhibited the phosphorylation and activation of AKT and STAT3 through Notch signaling blockade"}
{"PMID":23542114,"re_id":2,"annotated sentence":"<e1>ATO<\\e1> inhibited the phosphorylation and activation of <e2>AKT<\\e2> and STAT3 through Notch signaling blockade","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ATO","object":"AKT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> inhibited the phosphorylation and activation of <e2>GENE-N<\\e2> and STAT3 through Notch signaling blockade","sentence":"ATO inhibited the phosphorylation and activation of AKT and STAT3 through Notch signaling blockade"}
{"PMID":23542114,"re_id":3,"annotated sentence":"These data show that the <e1>ATO<\\e1> is a promising new approach to decrease glioblastoma proliferation and recurrence by downregulation of <e2>Notch<\\e2> pathway.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ATO","object":"Notch","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These data show that the <e1>CHEMICAL<\\e1> is a promising new approach to decrease glioblastoma proliferation and recurrence by downregulation of <e2>GENE-N<\\e2> pathway.","sentence":"These data show that the ATO is a promising new approach to decrease glioblastoma proliferation and recurrence by downregulation of Notch pathway."}
{"PMID":23542114,"re_id":4,"annotated sentence":"<e1>Arsenic trioxide<\\e1> depletes cancer stem-like cells and inhibits repopulation of neurosphere derived from glioblastoma by downregulation of <e2>Notch<\\e2> pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Arsenic trioxide","object":"Notch","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> depletes cancer stem-like cells and inhibits repopulation of neurosphere derived from glioblastoma by downregulation of <e2>GENE-N<\\e2> pathway","sentence":"Arsenic trioxide depletes cancer stem-like cells and inhibits repopulation of neurosphere derived from glioblastoma by downregulation of Notch pathway"}
{"PMID":23561166,"re_id":0,"annotated sentence":"Finally, epididymal mRNA abundance of <e2>GLUT4<\\e2> was significantly increased by <e1>fisetin<\\e1> supplementation, compared to levels in the control and HF groups","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"fisetin","object":"GLUT4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Finally, epididymal mRNA abundance of <e2>GENE-Y<\\e2> was significantly increased by <e1>CHEMICAL<\\e1> supplementation, compared to levels in the control and HF groups","sentence":"Finally, epididymal mRNA abundance of GLUT4 was significantly increased by fisetin supplementation, compared to levels in the control and HF groups"}
{"PMID":23561166,"re_id":1,"annotated sentence":"Enhancement of <e2>GLUT4<\\e2> expression by <e1>fisetin<\\e1> was further confirmed in differentiated 3T3-L1 adipocytes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"fisetin","object":"GLUT4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Enhancement of <e2>GENE-Y<\\e2> expression by <e1>CHEMICAL<\\e1> was further confirmed in differentiated 3T3-L1 adipocytes","sentence":"Enhancement of GLUT4 expression by fisetin was further confirmed in differentiated 3T3-L1 adipocytes"}
{"PMID":23561166,"re_id":2,"annotated sentence":"The high fat diet significantly increased hepatic mRNA expressions of <e2>PPAR\u03b3<\\e2>  SREBP1C and SCD-1 genes in comparison to the control diet, which was subsequently reversed by supplementation with <e1>fisetin<\\e1>  In addition, fisetin supplementation significantly reduced hepatic mRNA abundance of FAS, ATPCL and G6Pase compared to the control group","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"fisetin","object":"PPAR\u03b3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The high fat diet significantly increased hepatic mRNA expressions of <e2>GENE-Y<\\e2>  SREBP1C and SCD-1 genes in comparison to the control diet, which was subsequently reversed by supplementation with <e1>CHEMICAL<\\e1>  In addition, CHEMICAL supplementation significantly reduced hepatic mRNA abundance of FAS, ATPCL and G6Pase compared to the control group","sentence":"The high fat diet significantly increased hepatic mRNA expressions of PPAR\u03b3  SREBP1C and SCD-1 genes in comparison to the control diet, which was subsequently reversed by supplementation with fisetin  In addition, fisetin supplementation significantly reduced hepatic mRNA abundance of FAS, ATPCL and G6Pase compared to the control group"}
{"PMID":23561166,"re_id":3,"annotated sentence":"The high fat diet significantly increased hepatic mRNA expressions of PPAR\u03b3, <e2>SREBP1C<\\e2> and SCD-1 genes in comparison to the control diet, which was subsequently reversed by supplementation with <e1>fisetin<\\e1>  In addition, fisetin supplementation significantly reduced hepatic mRNA abundance of FAS, ATPCL and G6Pase compared to the control group","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"fisetin","object":"SREBP1C","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The high fat diet significantly increased hepatic mRNA expressions of PPAR\u03b3, <e2>GENE-Y<\\e2> and SCD-1 genes in comparison to the control diet, which was subsequently reversed by supplementation with <e1>CHEMICAL<\\e1>  In addition, CHEMICAL supplementation significantly reduced hepatic mRNA abundance of FAS, ATPCL and G6Pase compared to the control group","sentence":"The high fat diet significantly increased hepatic mRNA expressions of PPAR\u03b3, SREBP1C and SCD-1 genes in comparison to the control diet, which was subsequently reversed by supplementation with fisetin  In addition, fisetin supplementation significantly reduced hepatic mRNA abundance of FAS, ATPCL and G6Pase compared to the control group"}
{"PMID":23561166,"re_id":4,"annotated sentence":"The high fat diet significantly increased hepatic mRNA expressions of PPAR\u03b3, SREBP1C and <e2>SCD-1<\\e2> genes in comparison to the control diet, which was subsequently reversed by supplementation with <e1>fisetin<\\e1>  In addition, fisetin supplementation significantly reduced hepatic mRNA abundance of FAS, ATPCL and G6Pase compared to the control group","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"fisetin","object":"SCD-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The high fat diet significantly increased hepatic mRNA expressions of PPAR\u03b3, SREBP1C and <e2>GENE-Y<\\e2> genes in comparison to the control diet, which was subsequently reversed by supplementation with <e1>CHEMICAL<\\e1>  In addition, CHEMICAL supplementation significantly reduced hepatic mRNA abundance of FAS, ATPCL and G6Pase compared to the control group","sentence":"The high fat diet significantly increased hepatic mRNA expressions of PPAR\u03b3, SREBP1C and SCD-1 genes in comparison to the control diet, which was subsequently reversed by supplementation with fisetin  In addition, fisetin supplementation significantly reduced hepatic mRNA abundance of FAS, ATPCL and G6Pase compared to the control group"}
{"PMID":23561166,"re_id":5,"annotated sentence":"In addition, <e1>fisetin<\\e1> supplementation significantly reduced hepatic mRNA abundance of <e2>FAS<\\e2>  ATPCL and G6Pase compared to the control group","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"fisetin","object":"FAS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e1>CHEMICAL<\\e1> supplementation significantly reduced hepatic mRNA abundance of <e2>GENE-Y<\\e2>  ATPCL and G6Pase compared to the control group","sentence":"In addition, fisetin supplementation significantly reduced hepatic mRNA abundance of FAS  ATPCL and G6Pase compared to the control group"}
{"PMID":23561166,"re_id":6,"annotated sentence":"In addition, <e1>fisetin<\\e1> supplementation significantly reduced hepatic mRNA abundance of FAS, <e2>ATPCL<\\e2> and G6Pase compared to the control group","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"fisetin","object":"ATPCL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e1>CHEMICAL<\\e1> supplementation significantly reduced hepatic mRNA abundance of FAS, <e2>GENE-Y<\\e2> and G6Pase compared to the control group","sentence":"In addition, fisetin supplementation significantly reduced hepatic mRNA abundance of FAS, ATPCL and G6Pase compared to the control group"}
{"PMID":23561166,"re_id":7,"annotated sentence":"In addition, <e1>fisetin<\\e1> supplementation significantly reduced hepatic mRNA abundance of FAS, ATPCL and <e2>G6Pase<\\e2> compared to the control group","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"fisetin","object":"G6Pase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e1>CHEMICAL<\\e1> supplementation significantly reduced hepatic mRNA abundance of FAS, ATPCL and <e2>GENE-Y<\\e2> compared to the control group","sentence":"In addition, fisetin supplementation significantly reduced hepatic mRNA abundance of FAS, ATPCL and G6Pase compared to the control group"}
{"PMID":23567243,"re_id":0,"annotated sentence":"Western blot assay demonstrated that <e1>DICO<\\e1> decreased Bcl-2 level and induced <e2>Bax<\\e2> translocation to cause cytochrome c release","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"DICO","object":"Bax","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Western blot assay demonstrated that <e1>CHEMICAL<\\e1> decreased Bcl-2 level and induced <e2>GENE-Y<\\e2> translocation to cause cytochrome c release","sentence":"Western blot assay demonstrated that DICO decreased Bcl-2 level and induced Bax translocation to cause cytochrome c release"}
{"PMID":23567243,"re_id":1,"annotated sentence":"Western blot assay demonstrated that <e1>DICO<\\e1> decreased Bcl-2 level and induced Bax translocation to cause <e2>cytochrome c<\\e2> release","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"DICO","object":"cytochrome c","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Western blot assay demonstrated that <e1>CHEMICAL<\\e1> decreased Bcl-2 level and induced Bax translocation to cause <e2>GENE-Y<\\e2> release","sentence":"Western blot assay demonstrated that DICO decreased Bcl-2 level and induced Bax translocation to cause cytochrome c release"}
{"PMID":23567243,"re_id":2,"annotated sentence":"Western blot assay demonstrated that <e1>DICO<\\e1> decreased <e2>Bcl-2<\\e2> level and induced Bax translocation to cause cytochrome c release","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DICO","object":"Bcl-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Western blot assay demonstrated that <e1>CHEMICAL<\\e1> decreased <e2>GENE-Y<\\e2> level and induced Bax translocation to cause cytochrome c release","sentence":"Western blot assay demonstrated that DICO decreased Bcl-2 level and induced Bax translocation to cause cytochrome c release"}
{"PMID":23570998,"re_id":0,"annotated sentence":"<e1>Quercetin<\\e1> and rutin also increased <e2>alkaline phosphatase<\\e2> activity by about 150 and 240% and demonstrated mineralization up to 110 and 200% respectively as compared to control (which was considered as 100%)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Quercetin","object":"alkaline phosphatase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> and rutin also increased <e2>GENE-N<\\e2> activity by about 150 and 240% and demonstrated mineralization up to 110 and 200% respectively as compared to control (which was considered as 100%)","sentence":"Quercetin and rutin also increased alkaline phosphatase activity by about 150 and 240% and demonstrated mineralization up to 110 and 200% respectively as compared to control (which was considered as 100%)"}
{"PMID":23570998,"re_id":1,"annotated sentence":"Quercetin and <e1>rutin<\\e1> also increased <e2>alkaline phosphatase<\\e2> activity by about 150 and 240% and demonstrated mineralization up to 110 and 200% respectively as compared to control (which was considered as 100%)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"rutin","object":"alkaline phosphatase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Quercetin and <e1>CHEMICAL<\\e1> also increased <e2>GENE-N<\\e2> activity by about 150 and 240% and demonstrated mineralization up to 110 and 200% respectively as compared to control (which was considered as 100%)","sentence":"Quercetin and rutin also increased alkaline phosphatase activity by about 150 and 240% and demonstrated mineralization up to 110 and 200% respectively as compared to control (which was considered as 100%)"}
{"PMID":23570998,"re_id":2,"annotated sentence":"Further, both the <e1>flavonoids<\\e1> were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like <e2>osteopontin<\\e2>  osterix, RunX2, osteoprotegerin and osteocalcin","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"flavonoids","object":"osteopontin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Further, both the <e1>CHEMICAL<\\e1> were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like <e2>GENE-Y<\\e2>  osterix, RunX2, osteoprotegerin and osteocalcin","sentence":"Further, both the flavonoids were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin  osterix, RunX2, osteoprotegerin and osteocalcin"}
{"PMID":23570998,"re_id":3,"annotated sentence":"Further, both the <e1>flavonoids<\\e1> were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, <e2>osterix<\\e2>  RunX2, osteoprotegerin and osteocalcin","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"flavonoids","object":"osterix","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Further, both the <e1>CHEMICAL<\\e1> were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, <e2>GENE-Y<\\e2>  RunX2, osteoprotegerin and osteocalcin","sentence":"Further, both the flavonoids were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, osterix  RunX2, osteoprotegerin and osteocalcin"}
{"PMID":23570998,"re_id":4,"annotated sentence":"Further, both the <e1>flavonoids<\\e1> were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, osterix, <e2>RunX2<\\e2>  osteoprotegerin and osteocalcin","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"flavonoids","object":"RunX2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Further, both the <e1>CHEMICAL<\\e1> were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, osterix, <e2>GENE-Y<\\e2>  osteoprotegerin and osteocalcin","sentence":"Further, both the flavonoids were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, osterix, RunX2  osteoprotegerin and osteocalcin"}
{"PMID":23570998,"re_id":5,"annotated sentence":"Further, both the <e1>flavonoids<\\e1> were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, osterix, RunX2, <e2>osteoprotegerin<\\e2> and osteocalcin","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"flavonoids","object":"osteoprotegerin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Further, both the <e1>CHEMICAL<\\e1> were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, osterix, RunX2, <e2>GENE-Y<\\e2> and osteocalcin","sentence":"Further, both the flavonoids were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, osterix, RunX2, osteoprotegerin and osteocalcin"}
{"PMID":23570998,"re_id":6,"annotated sentence":"Further, both the <e1>flavonoids<\\e1> were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, osterix, RunX2, osteoprotegerin and <e2>osteocalcin<\\e2>  The current data suggests that certain classes of flavonoids like rutin and quercetin can be used in the cure and management of osteodegenerative disorders due to their osteoblast specific differentiation activities.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"flavonoids","object":"osteocalcin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Further, both the <e1>CHEMICAL<\\e1> were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, osterix, RunX2, osteoprotegerin and <e2>GENE-Y<\\e2>  The current data suggests that certain classes of CHEMICAL like rutin and quercetin can be used in the cure and management of osteodegenerative disorders due to their osteoblast specific differentiation activities.","sentence":"Further, both the flavonoids were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, osterix, RunX2, osteoprotegerin and osteocalcin  The current data suggests that certain classes of flavonoids like rutin and quercetin can be used in the cure and management of osteodegenerative disorders due to their osteoblast specific differentiation activities."}
{"PMID":23578993,"re_id":0,"annotated sentence":"LPO was increased while as GSH, <e2>CAT<\\e2> and GPx decreased by the administration of CCl4 and TAA (p<0.001); co-administration of <e1>NAC<\\e1> restored these liver markers to normal levels (p<0.001)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"NAC","object":"CAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"LPO was increased while as GSH, <e2>GENE-Y<\\e2> and GPx decreased by the administration of CCl4 and TAA (p<0.001); co-administration of <e1>CHEMICAL<\\e1> restored these liver markers to normal levels (p<0.001)","sentence":"LPO was increased while as GSH, CAT and GPx decreased by the administration of CCl4 and TAA (p<0.001); co-administration of NAC restored these liver markers to normal levels (p<0.001)"}
{"PMID":23578993,"re_id":1,"annotated sentence":"LPO was increased while as GSH, CAT and <e2>GPx<\\e2> decreased by the administration of CCl4 and TAA (p<0.001); co-administration of <e1>NAC<\\e1> restored these liver markers to normal levels (p<0.001)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"NAC","object":"GPx","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"LPO was increased while as GSH, CAT and <e2>GENE-N<\\e2> decreased by the administration of CCl4 and TAA (p<0.001); co-administration of <e1>CHEMICAL<\\e1> restored these liver markers to normal levels (p<0.001)","sentence":"LPO was increased while as GSH, CAT and GPx decreased by the administration of CCl4 and TAA (p<0.001); co-administration of NAC restored these liver markers to normal levels (p<0.001)"}
{"PMID":23578993,"re_id":2,"annotated sentence":"Serum markers of liver damage (<e2>AST<\\e2>  ALT, ALP and Bilirubin) were increased by <e1>CCl4<\\e1> and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CCl4","object":"AST","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Serum markers of liver damage (<e2>GENE-N<\\e2>  ALT, ALP and Bilirubin) were increased by <e1>CHEMICAL<\\e1> and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001)","sentence":"Serum markers of liver damage (AST  ALT, ALP and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001)"}
{"PMID":23578993,"re_id":3,"annotated sentence":"Serum markers of liver damage (AST, <e2>ALT<\\e2>  ALP and Bilirubin) were increased by <e1>CCl4<\\e1> and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CCl4","object":"ALT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Serum markers of liver damage (AST, <e2>GENE-N<\\e2>  ALP and Bilirubin) were increased by <e1>CHEMICAL<\\e1> and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001)","sentence":"Serum markers of liver damage (AST, ALT  ALP and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001)"}
{"PMID":23578993,"re_id":4,"annotated sentence":"Serum markers of liver damage (AST, ALT, <e2>ALP<\\e2> and Bilirubin) were increased by <e1>CCl4<\\e1> and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CCl4","object":"ALP","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Serum markers of liver damage (AST, ALT, <e2>GENE-N<\\e2> and Bilirubin) were increased by <e1>CHEMICAL<\\e1> and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001)","sentence":"Serum markers of liver damage (AST, ALT, ALP and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001)"}
{"PMID":23578993,"re_id":5,"annotated sentence":"Serum markers of liver damage (<e2>AST<\\e2>  ALT, ALP and Bilirubin) were increased by CCl4 and <e1>TAA<\\e1> intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TAA","object":"AST","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Serum markers of liver damage (<e2>GENE-N<\\e2>  ALT, ALP and Bilirubin) were increased by CCl4 and <e1>CHEMICAL<\\e1> intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001)","sentence":"Serum markers of liver damage (AST  ALT, ALP and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001)"}
{"PMID":23578993,"re_id":6,"annotated sentence":"Serum markers of liver damage (AST, <e2>ALT<\\e2>  ALP and Bilirubin) were increased by CCl4 and <e1>TAA<\\e1> intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TAA","object":"ALT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Serum markers of liver damage (AST, <e2>GENE-N<\\e2>  ALP and Bilirubin) were increased by CCl4 and <e1>CHEMICAL<\\e1> intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001)","sentence":"Serum markers of liver damage (AST, ALT  ALP and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001)"}
{"PMID":23578993,"re_id":7,"annotated sentence":"Serum markers of liver damage (AST, ALT, <e2>ALP<\\e2> and Bilirubin) were increased by CCl4 and <e1>TAA<\\e1> intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TAA","object":"ALP","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Serum markers of liver damage (AST, ALT, <e2>GENE-N<\\e2> and Bilirubin) were increased by CCl4 and <e1>CHEMICAL<\\e1> intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001)","sentence":"Serum markers of liver damage (AST, ALT, ALP and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001)"}
{"PMID":23578993,"re_id":8,"annotated sentence":"Serum markers of liver damage (<e2>AST<\\e2>  ALT, ALP and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with <e1>NAC<\\e1> reversed such changes (p<0.001)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NAC","object":"AST","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Serum markers of liver damage (<e2>GENE-N<\\e2>  ALT, ALP and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with <e1>CHEMICAL<\\e1> reversed such changes (p<0.001)","sentence":"Serum markers of liver damage (AST  ALT, ALP and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001)"}
{"PMID":23578993,"re_id":9,"annotated sentence":"Serum markers of liver damage (AST, <e2>ALT<\\e2>  ALP and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with <e1>NAC<\\e1> reversed such changes (p<0.001)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NAC","object":"ALT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Serum markers of liver damage (AST, <e2>GENE-N<\\e2>  ALP and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with <e1>CHEMICAL<\\e1> reversed such changes (p<0.001)","sentence":"Serum markers of liver damage (AST, ALT  ALP and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001)"}
{"PMID":23578993,"re_id":10,"annotated sentence":"Serum markers of liver damage (AST, ALT, <e2>ALP<\\e2> and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with <e1>NAC<\\e1> reversed such changes (p<0.001)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NAC","object":"ALP","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Serum markers of liver damage (AST, ALT, <e2>GENE-N<\\e2> and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with <e1>CHEMICAL<\\e1> reversed such changes (p<0.001)","sentence":"Serum markers of liver damage (AST, ALT, ALP and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001)"}
{"PMID":23578993,"re_id":11,"annotated sentence":"<e2>Cytochrome P450 2E1<\\e2> (CYP 450 2E1), activity was determined as hydroxylation of <e1>aniline<\\e1> in liver microsomes","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"aniline","object":"Cytochrome P450 2E1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (CYP 450 2E1), activity was determined as hydroxylation of <e1>CHEMICAL<\\e1> in liver microsomes","sentence":"Cytochrome P450 2E1 (CYP 450 2E1), activity was determined as hydroxylation of aniline in liver microsomes"}
{"PMID":23578993,"re_id":12,"annotated sentence":"Cytochrome P450 2E1 (<e2>CYP 450 2E1<\\e2> , activity was determined as hydroxylation of <e1>aniline<\\e1> in liver microsomes","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"aniline","object":"CYP 450 2E1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cytochrome P450 2E1 (<e2>GENE-Y<\\e2> , activity was determined as hydroxylation of <e1>CHEMICAL<\\e1> in liver microsomes","sentence":"Cytochrome P450 2E1 (CYP 450 2E1 , activity was determined as hydroxylation of aniline in liver microsomes"}
{"PMID":23583258,"re_id":0,"annotated sentence":"This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory <e2>interleukins<\\e2>  IL-6 and IL-8, caused by a mixture of <e1>oxysterols<\\e1> representative of a high cholesterol diet","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"oxysterols","object":"interleukins","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory <e2>GENE-N<\\e2>  IL-6 and IL-8, caused by a mixture of <e1>CHEMICAL<\\e1> representative of a high cholesterol diet","sentence":"This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins  IL-6 and IL-8, caused by a mixture of oxysterols representative of a high cholesterol diet"}
{"PMID":23583258,"re_id":1,"annotated sentence":"This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins, <e2>IL-6<\\e2> and IL-8, caused by a mixture of <e1>oxysterols<\\e1> representative of a high cholesterol diet","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"oxysterols","object":"IL-6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins, <e2>GENE-Y<\\e2> and IL-8, caused by a mixture of <e1>CHEMICAL<\\e1> representative of a high cholesterol diet","sentence":"This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins, IL-6 and IL-8, caused by a mixture of oxysterols representative of a high cholesterol diet"}
{"PMID":23583258,"re_id":2,"annotated sentence":"This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins, IL-6 and <e2>IL-8<\\e2>  caused by a mixture of <e1>oxysterols<\\e1> representative of a high cholesterol diet","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"oxysterols","object":"IL-8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins, IL-6 and <e2>GENE-Y<\\e2>  caused by a mixture of <e1>CHEMICAL<\\e1> representative of a high cholesterol diet","sentence":"This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins, IL-6 and IL-8  caused by a mixture of oxysterols representative of a high cholesterol diet"}
{"PMID":23583258,"re_id":3,"annotated sentence":"This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory <e2>interleukins<\\e2>  IL-6 and IL-8, caused by a mixture of oxysterols representative of a high <e1>cholesterol<\\e1> diet","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cholesterol","object":"interleukins","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory <e2>GENE-N<\\e2>  IL-6 and IL-8, caused by a mixture of oxysterols representative of a high <e1>CHEMICAL<\\e1> diet","sentence":"This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins  IL-6 and IL-8, caused by a mixture of oxysterols representative of a high cholesterol diet"}
{"PMID":23583258,"re_id":4,"annotated sentence":"This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins, <e2>IL-6<\\e2> and IL-8, caused by a mixture of oxysterols representative of a high <e1>cholesterol<\\e1> diet","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cholesterol","object":"IL-6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins, <e2>GENE-Y<\\e2> and IL-8, caused by a mixture of oxysterols representative of a high <e1>CHEMICAL<\\e1> diet","sentence":"This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins, IL-6 and IL-8, caused by a mixture of oxysterols representative of a high cholesterol diet"}
{"PMID":23583258,"re_id":5,"annotated sentence":"This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins, IL-6 and <e2>IL-8<\\e2>  caused by a mixture of oxysterols representative of a high <e1>cholesterol<\\e1> diet","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cholesterol","object":"IL-8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins, IL-6 and <e2>GENE-Y<\\e2>  caused by a mixture of oxysterols representative of a high <e1>CHEMICAL<\\e1> diet","sentence":"This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins, IL-6 and IL-8  caused by a mixture of oxysterols representative of a high cholesterol diet"}
{"PMID":23583258,"re_id":6,"annotated sentence":"<e1>Oxysterol<\\e1> dependent <e2>NOX1<\\e2> activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and flavonoids","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Oxysterol","object":"NOX1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> dependent <e2>GENE-Y<\\e2> activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and flavonoids","sentence":"Oxysterol dependent NOX1 activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and flavonoids"}
{"PMID":23583258,"re_id":7,"annotated sentence":"<e1>Oxysterol<\\e1> dependent NOX1 activation, as well as <e2>interleukin<\\e2> synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and flavonoids","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Oxysterol","object":"interleukin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> dependent NOX1 activation, as well as <e2>GENE-N<\\e2> synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and flavonoids","sentence":"Oxysterol dependent NOX1 activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and flavonoids"}
{"PMID":23583258,"re_id":8,"annotated sentence":"Conversely, cell pre-treatment with Vermentino white wine extract with smaller phenolic fraction showed only a partial <e2>NOX1<\\e2> down-regulation and was ineffective in interleukin synthesis induced by dietary <e1>oxysterols<\\e1>  It is thus likely that the effects of Sardinian wine extracts against intestinal inflammation induced by dietary oxysterols are mainly due to their high phenolic content: low doses of phenolics would be responsible only for direct scavenging oxysterol-dependent ROS production","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"oxysterols","object":"NOX1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Conversely, cell pre-treatment with Vermentino white wine extract with smaller phenolic fraction showed only a partial <e2>GENE-Y<\\e2> down-regulation and was ineffective in interleukin synthesis induced by dietary <e1>CHEMICAL<\\e1>  It is thus likely that the effects of Sardinian wine extracts against intestinal inflammation induced by dietary CHEMICAL are mainly due to their high phenolic content: low doses of phenolics would be responsible only for direct scavenging oxysterol-dependent ROS production","sentence":"Conversely, cell pre-treatment with Vermentino white wine extract with smaller phenolic fraction showed only a partial NOX1 down-regulation and was ineffective in interleukin synthesis induced by dietary oxysterols  It is thus likely that the effects of Sardinian wine extracts against intestinal inflammation induced by dietary oxysterols are mainly due to their high phenolic content: low doses of phenolics would be responsible only for direct scavenging oxysterol-dependent ROS production"}
{"PMID":23583258,"re_id":9,"annotated sentence":"Conversely, cell pre-treatment with Vermentino white wine extract with smaller phenolic fraction showed only a partial NOX1 down-regulation and was ineffective in <e2>interleukin<\\e2> synthesis induced by dietary <e1>oxysterols<\\e1>  It is thus likely that the effects of Sardinian wine extracts against intestinal inflammation induced by dietary oxysterols are mainly due to their high phenolic content: low doses of phenolics would be responsible only for direct scavenging oxysterol-dependent ROS production","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"oxysterols","object":"interleukin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Conversely, cell pre-treatment with Vermentino white wine extract with smaller phenolic fraction showed only a partial NOX1 down-regulation and was ineffective in <e2>GENE-N<\\e2> synthesis induced by dietary <e1>CHEMICAL<\\e1>  It is thus likely that the effects of Sardinian wine extracts against intestinal inflammation induced by dietary CHEMICAL are mainly due to their high phenolic content: low doses of phenolics would be responsible only for direct scavenging oxysterol-dependent ROS production","sentence":"Conversely, cell pre-treatment with Vermentino white wine extract with smaller phenolic fraction showed only a partial NOX1 down-regulation and was ineffective in interleukin synthesis induced by dietary oxysterols  It is thus likely that the effects of Sardinian wine extracts against intestinal inflammation induced by dietary oxysterols are mainly due to their high phenolic content: low doses of phenolics would be responsible only for direct scavenging oxysterol-dependent ROS production"}
{"PMID":23583258,"re_id":10,"annotated sentence":"Besides this direct activity, an excess of phenolic compounds detectable in red wine, may exert an additional indirect action by blocking <e1>oxysterol<\\e1> related <e2>NOX1<\\e2> induction, thus totally preventing the pro-oxidant and pro-inflammatory events triggered by dietary oxysterols.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"oxysterol","object":"NOX1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Besides this direct activity, an excess of phenolic compounds detectable in red wine, may exert an additional indirect action by blocking <e1>CHEMICAL<\\e1> related <e2>GENE-Y<\\e2> induction, thus totally preventing the pro-oxidant and pro-inflammatory events triggered by dietary CHEMICALs.","sentence":"Besides this direct activity, an excess of phenolic compounds detectable in red wine, may exert an additional indirect action by blocking oxysterol related NOX1 induction, thus totally preventing the pro-oxidant and pro-inflammatory events triggered by dietary oxysterols."}
{"PMID":23583258,"re_id":11,"annotated sentence":"Oxysterol-dependent <e2>NOX1<\\e2> activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular <e1>phenolic acids<\\e1> and flavonoids","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenolic acids","object":"NOX1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Oxysterol-dependent <e2>GENE-Y<\\e2> activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular <e1>CHEMICAL<\\e1> and flavonoids","sentence":"Oxysterol-dependent NOX1 activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and flavonoids"}
{"PMID":23583258,"re_id":12,"annotated sentence":"Oxysterol-dependent NOX1 activation, as well as <e2>interleukin<\\e2> synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular <e1>phenolic acids<\\e1> and flavonoids","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenolic acids","object":"interleukin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Oxysterol-dependent NOX1 activation, as well as <e2>GENE-N<\\e2> synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular <e1>CHEMICAL<\\e1> and flavonoids","sentence":"Oxysterol-dependent NOX1 activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and flavonoids"}
{"PMID":23583258,"re_id":13,"annotated sentence":"Oxysterol-dependent <e2>NOX1<\\e2> activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and <e1>flavonoids<\\e1>  Conversely, cell pre-treatment with Vermentino white wine extract with smaller phenolic fraction showed only a partial NOX1 down-regulation and was ineffective in interleukin synthesis induced by dietary oxysterols","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"flavonoids","object":"NOX1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Oxysterol-dependent <e2>GENE-Y<\\e2> activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and <e1>CHEMICAL<\\e1>  Conversely, cell pre-treatment with Vermentino white wine extract with smaller phenolic fraction showed only a partial GENE-Y down-regulation and was ineffective in interleukin synthesis induced by dietary oxysterols","sentence":"Oxysterol-dependent NOX1 activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and flavonoids  Conversely, cell pre-treatment with Vermentino white wine extract with smaller phenolic fraction showed only a partial NOX1 down-regulation and was ineffective in interleukin synthesis induced by dietary oxysterols"}
{"PMID":23583258,"re_id":14,"annotated sentence":"Oxysterol-dependent NOX1 activation, as well as <e2>interleukin<\\e2> synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and <e1>flavonoids<\\e1>  Conversely, cell pre-treatment with Vermentino white wine extract with smaller phenolic fraction showed only a partial NOX1 down-regulation and was ineffective in interleukin synthesis induced by dietary oxysterols","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"flavonoids","object":"interleukin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Oxysterol-dependent NOX1 activation, as well as <e2>GENE-N<\\e2> synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and <e1>CHEMICAL<\\e1>  Conversely, cell pre-treatment with Vermentino white wine extract with smaller phenolic fraction showed only a partial NOX1 down-regulation and was ineffective in GENE-N synthesis induced by dietary oxysterols","sentence":"Oxysterol-dependent NOX1 activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and flavonoids  Conversely, cell pre-treatment with Vermentino white wine extract with smaller phenolic fraction showed only a partial NOX1 down-regulation and was ineffective in interleukin synthesis induced by dietary oxysterols"}
{"PMID":23583258,"re_id":15,"annotated sentence":"Besides this direct activity, an excess of <e1>phenolic<\\e1> compounds detectable in red wine, may exert an additional indirect action by blocking oxysterol-related <e2>NOX1<\\e2> induction, thus totally preventing the pro-oxidant and pro-inflammatory events triggered by dietary oxysterols.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenolic","object":"NOX1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Besides this direct activity, an excess of <e1>CHEMICAL<\\e1> compounds detectable in red wine, may exert an additional indirect action by blocking oxysterol-related <e2>GENE-Y<\\e2> induction, thus totally preventing the pro-oxidant and pro-inflammatory events triggered by dietary oxysterols.","sentence":"Besides this direct activity, an excess of phenolic compounds detectable in red wine, may exert an additional indirect action by blocking oxysterol-related NOX1 induction, thus totally preventing the pro-oxidant and pro-inflammatory events triggered by dietary oxysterols."}
{"PMID":23589329,"re_id":0,"annotated sentence":"<e1>Arsenic<\\e1> inhibits autophagic flux activating the <e2>Nrf2<\\e2> Keap1 pathway in a p62-dependent manner","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Arsenic","object":"Nrf2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits autophagic flux activating the <e2>GENE-Y<\\e2> Keap1 pathway in a p62-dependent manner","sentence":"Arsenic inhibits autophagic flux activating the Nrf2 Keap1 pathway in a p62-dependent manner"}
{"PMID":23589329,"re_id":1,"annotated sentence":"<e1>Arsenic<\\e1> inhibits autophagic flux activating the Nrf2-<e2>Keap1<\\e2> pathway in a p62-dependent manner","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Arsenic","object":"Keap1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits autophagic flux activating the Nrf2-<e2>GENE-Y<\\e2> pathway in a p62-dependent manner","sentence":"Arsenic inhibits autophagic flux activating the Nrf2-Keap1 pathway in a p62-dependent manner"}
{"PMID":23589329,"re_id":2,"annotated sentence":"Collectively, these findings provide evidence that <e1>arsenic<\\e1> causes prolonged activation of <e2>Nrf2<\\e2> through autophagy dysfunction, possibly providing a similar scenario to constitutive activation of Nrf2 found in certain human cancers","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"arsenic","object":"Nrf2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Collectively, these findings provide evidence that <e1>CHEMICAL<\\e1> causes prolonged activation of <e2>GENE-Y<\\e2> through autophagy dysfunction, possibly providing a similar scenario to constitutive activation of GENE-Y found in certain human cancers","sentence":"Collectively, these findings provide evidence that arsenic causes prolonged activation of Nrf2 through autophagy dysfunction, possibly providing a similar scenario to constitutive activation of Nrf2 found in certain human cancers"}
{"PMID":23589329,"re_id":3,"annotated sentence":"Collectively, these findings provide evidence that <e1>arsenic<\\e1> causes prolonged activation of Nrf2 through autophagy dysfunction, possibly providing a similar scenario to constitutive activation of <e2>Nrf2<\\e2> found in certain human cancers","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"arsenic","object":"Nrf2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Collectively, these findings provide evidence that <e1>CHEMICAL<\\e1> causes prolonged activation of GENE-Y through autophagy dysfunction, possibly providing a similar scenario to constitutive activation of <e2>GENE-Y<\\e2> found in certain human cancers","sentence":"Collectively, these findings provide evidence that arsenic causes prolonged activation of Nrf2 through autophagy dysfunction, possibly providing a similar scenario to constitutive activation of Nrf2 found in certain human cancers"}
{"PMID":23589329,"re_id":4,"annotated sentence":"Thus, <e1>arsenic<\\e1> activates <e2>Nrf2<\\e2> through a non-canonical mechanism (p62-dependent), leading to a chronic, sustained activation of Nrf2","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"arsenic","object":"Nrf2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, <e1>CHEMICAL<\\e1> activates <e2>GENE-Y<\\e2> through a non-canonical mechanism (p62-dependent), leading to a chronic, sustained activation of GENE-Y","sentence":"Thus, arsenic activates Nrf2 through a non-canonical mechanism (p62-dependent), leading to a chronic, sustained activation of Nrf2"}
{"PMID":23589329,"re_id":5,"annotated sentence":"Thus, <e1>arsenic<\\e1> activates Nrf2 through a non-canonical mechanism (p62-dependent), leading to a chronic, sustained activation of <e2>Nrf2<\\e2>  In contrast, activation of Nrf2 by sulforaphane and tert-butylhydroquinone depend upon Keap1-C151 and not p62 (the canonical mechanism)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"arsenic","object":"Nrf2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, <e1>CHEMICAL<\\e1> activates GENE-Y through a non-canonical mechanism (p62-dependent), leading to a chronic, sustained activation of <e2>GENE-Y<\\e2>  In contrast, activation of GENE-Y by sulforaphane and tert-butylhydroquinone depend upon Keap1-C151 and not p62 (the canonical mechanism)","sentence":"Thus, arsenic activates Nrf2 through a non-canonical mechanism (p62-dependent), leading to a chronic, sustained activation of Nrf2  In contrast, activation of Nrf2 by sulforaphane and tert-butylhydroquinone depend upon Keap1-C151 and not p62 (the canonical mechanism)"}
{"PMID":23589329,"re_id":6,"annotated sentence":"In contrast, activation of <e2>Nrf2<\\e2> by <e1>sulforaphane<\\e1> and tert-butylhydroquinone depend upon Keap1-C151 and not p62 (the canonical mechanism)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"sulforaphane","object":"Nrf2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, activation of <e2>GENE-Y<\\e2> by <e1>CHEMICAL<\\e1> and tert-butylhydroquinone depend upon Keap1-C151 and not p62 (the canonical mechanism)","sentence":"In contrast, activation of Nrf2 by sulforaphane and tert-butylhydroquinone depend upon Keap1-C151 and not p62 (the canonical mechanism)"}
{"PMID":23589329,"re_id":7,"annotated sentence":"In contrast, activation of <e2>Nrf2<\\e2> by sulforaphane and <e1>tert-butylhydroquinone<\\e1> depend upon Keap1-C151 and not p62 (the canonical mechanism)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"tert-butylhydroquinone","object":"Nrf2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, activation of <e2>GENE-Y<\\e2> by sulforaphane and <e1>CHEMICAL<\\e1> depend upon Keap1-C151 and not p62 (the canonical mechanism)","sentence":"In contrast, activation of Nrf2 by sulforaphane and tert-butylhydroquinone depend upon Keap1-C151 and not p62 (the canonical mechanism)"}
{"PMID":23589329,"re_id":8,"annotated sentence":"<e1>Arsenic<\\e1> deregulates the autophagic pathway through blockage of autophagic flux, resulting in accumulation of autophagosomes and sequestration of <e2>p62<\\e2>  Keap1, and LC3","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Arsenic","object":"p62","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> deregulates the autophagic pathway through blockage of autophagic flux, resulting in accumulation of autophagosomes and sequestration of <e2>GENE-Y<\\e2>  Keap1, and LC3","sentence":"Arsenic deregulates the autophagic pathway through blockage of autophagic flux, resulting in accumulation of autophagosomes and sequestration of p62  Keap1, and LC3"}
{"PMID":23589329,"re_id":9,"annotated sentence":"<e1>Arsenic<\\e1> deregulates the autophagic pathway through blockage of autophagic flux, resulting in accumulation of autophagosomes and sequestration of p62, <e2>Keap1<\\e2>  and LC3","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Arsenic","object":"Keap1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> deregulates the autophagic pathway through blockage of autophagic flux, resulting in accumulation of autophagosomes and sequestration of p62, <e2>GENE-Y<\\e2>  and LC3","sentence":"Arsenic deregulates the autophagic pathway through blockage of autophagic flux, resulting in accumulation of autophagosomes and sequestration of p62, Keap1  and LC3"}
{"PMID":23589329,"re_id":10,"annotated sentence":"<e1>Arsenic<\\e1> deregulates the autophagic pathway through blockage of autophagic flux, resulting in accumulation of autophagosomes and sequestration of p62, Keap1, and <e2>LC3<\\e2>  Thus, arsenic activates Nrf2 through a non-canonical mechanism (p62-dependent), leading to a chronic, sustained activation of Nrf2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Arsenic","object":"LC3","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> deregulates the autophagic pathway through blockage of autophagic flux, resulting in accumulation of autophagosomes and sequestration of p62, Keap1, and <e2>GENE-N<\\e2>  Thus, arsenic activates Nrf2 through a non-canonical mechanism (p62-dependent), leading to a chronic, sustained activation of Nrf2","sentence":"Arsenic deregulates the autophagic pathway through blockage of autophagic flux, resulting in accumulation of autophagosomes and sequestration of p62, Keap1, and LC3  Thus, arsenic activates Nrf2 through a non-canonical mechanism (p62-dependent), leading to a chronic, sustained activation of Nrf2"}
{"PMID":23591044,"re_id":0,"annotated sentence":"<e2>MT1R<\\e2> was increased in ovaries and uteri of <e1>melatonin<\\e1> treated rats","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"melatonin","object":"MT1R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> was increased in ovaries and uteri of <e1>CHEMICAL<\\e1> treated rats","sentence":"MT1R was increased in ovaries and uteri of melatonin treated rats"}
{"PMID":23591044,"re_id":1,"annotated sentence":"Ovarian AR was not influenced by either treatment, and oviduct <e2>AR<\\e2> was reduced after <e1>ethanol<\\e1> melatonin combination","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ethanol","object":"AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ovarian GENE-Y was not influenced by either treatment, and oviduct <e2>GENE-Y<\\e2> was reduced after <e1>CHEMICAL<\\e1> melatonin combination","sentence":"Ovarian AR was not influenced by either treatment, and oviduct AR was reduced after ethanol melatonin combination"}
{"PMID":23591044,"re_id":2,"annotated sentence":"Ovarian AR was not influenced by either treatment, and oviduct <e2>AR<\\e2> was reduced after ethanol-<e1>melatonin<\\e1> combination","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"melatonin","object":"AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ovarian GENE-Y was not influenced by either treatment, and oviduct <e2>GENE-Y<\\e2> was reduced after ethanol-<e1>CHEMICAL<\\e1> combination","sentence":"Ovarian AR was not influenced by either treatment, and oviduct AR was reduced after ethanol-melatonin combination"}
{"PMID":23591044,"re_id":3,"annotated sentence":"Oviduct <e2>ER-\u03b1<\\e2>  ER-\u03b2 and uterine ER-\u03b2 were down-regulated by either <e1>ethanol<\\e1> or melatonin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ethanol","object":"ER-\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Oviduct <e2>GENE-Y<\\e2>  ER-\u03b2 and uterine ER-\u03b2 were down-regulated by either <e1>CHEMICAL<\\e1> or melatonin","sentence":"Oviduct ER-\u03b1  ER-\u03b2 and uterine ER-\u03b2 were down-regulated by either ethanol or melatonin"}
{"PMID":23591044,"re_id":4,"annotated sentence":"Oviduct ER-\u03b1, <e2>ER-\u03b2<\\e2> and uterine ER-\u03b2 were down-regulated by either <e1>ethanol<\\e1> or melatonin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ethanol","object":"ER-\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Oviduct ER-\u03b1, <e2>GENE-Y<\\e2> and uterine GENE-Y were down-regulated by either <e1>CHEMICAL<\\e1> or melatonin","sentence":"Oviduct ER-\u03b1, ER-\u03b2 and uterine ER-\u03b2 were down-regulated by either ethanol or melatonin"}
{"PMID":23591044,"re_id":5,"annotated sentence":"Oviduct ER-\u03b1, ER-\u03b2 and uterine <e2>ER-\u03b2<\\e2> were down-regulated by either <e1>ethanol<\\e1> or melatonin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ethanol","object":"ER-\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Oviduct ER-\u03b1, GENE-Y and uterine <e2>GENE-Y<\\e2> were down-regulated by either <e1>CHEMICAL<\\e1> or melatonin","sentence":"Oviduct ER-\u03b1, ER-\u03b2 and uterine ER-\u03b2 were down-regulated by either ethanol or melatonin"}
{"PMID":23591044,"re_id":6,"annotated sentence":"Oviduct <e2>ER-\u03b1<\\e2>  ER-\u03b2 and uterine ER-\u03b2 were down-regulated by either ethanol or <e1>melatonin<\\e1>  Conversely, ovarian PRA and PRB were positively regulated by ethanol and ethanol-melatonin combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"melatonin","object":"ER-\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Oviduct <e2>GENE-Y<\\e2>  ER-\u03b2 and uterine ER-\u03b2 were down-regulated by either ethanol or <e1>CHEMICAL<\\e1>  Conversely, ovarian PRA and PRB were positively regulated by ethanol and ethanol-CHEMICAL combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption","sentence":"Oviduct ER-\u03b1  ER-\u03b2 and uterine ER-\u03b2 were down-regulated by either ethanol or melatonin  Conversely, ovarian PRA and PRB were positively regulated by ethanol and ethanol-melatonin combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption"}
{"PMID":23591044,"re_id":7,"annotated sentence":"Oviduct ER-\u03b1, <e2>ER-\u03b2<\\e2> and uterine ER-\u03b2 were down-regulated by either ethanol or <e1>melatonin<\\e1>  Conversely, ovarian PRA and PRB were positively regulated by ethanol and ethanol-melatonin combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"melatonin","object":"ER-\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Oviduct ER-\u03b1, <e2>GENE-Y<\\e2> and uterine GENE-Y were down-regulated by either ethanol or <e1>CHEMICAL<\\e1>  Conversely, ovarian PRA and PRB were positively regulated by ethanol and ethanol-CHEMICAL combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption","sentence":"Oviduct ER-\u03b1, ER-\u03b2 and uterine ER-\u03b2 were down-regulated by either ethanol or melatonin  Conversely, ovarian PRA and PRB were positively regulated by ethanol and ethanol-melatonin combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption"}
{"PMID":23591044,"re_id":8,"annotated sentence":"Oviduct ER-\u03b1, ER-\u03b2 and uterine <e2>ER-\u03b2<\\e2> were down-regulated by either ethanol or <e1>melatonin<\\e1>  Conversely, ovarian PRA and PRB were positively regulated by ethanol and ethanol-melatonin combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"melatonin","object":"ER-\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Oviduct ER-\u03b1, GENE-Y and uterine <e2>GENE-Y<\\e2> were down-regulated by either ethanol or <e1>CHEMICAL<\\e1>  Conversely, ovarian PRA and PRB were positively regulated by ethanol and ethanol-CHEMICAL combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption","sentence":"Oviduct ER-\u03b1, ER-\u03b2 and uterine ER-\u03b2 were down-regulated by either ethanol or melatonin  Conversely, ovarian PRA and PRB were positively regulated by ethanol and ethanol-melatonin combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption"}
{"PMID":23591044,"re_id":9,"annotated sentence":"Conversely, ovarian PRA and PRB were positively regulated by ethanol and ethanol-melatonin combination, whereas <e2>PRA<\\e2> was down-regulated in the uterus and oviduct after <e1>ethanol<\\e1> consumption","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ethanol","object":"PRA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Conversely, ovarian GENE-Y and PRB were positively regulated by CHEMICAL and CHEMICAL-melatonin combination, whereas <e2>GENE-Y<\\e2> was down-regulated in the uterus and oviduct after <e1>CHEMICAL<\\e1> consumption","sentence":"Conversely, ovarian PRA and PRB were positively regulated by ethanol and ethanol-melatonin combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption"}
{"PMID":23597507,"re_id":0,"annotated sentence":"Intraplantar or intrathecal administered Ph\u03b11\u03b2 reduced both nocifensive behavior and mechanical hypersensitivity induced by capsaicin similarly to that observed with <e1>SB366791<\\e1>  a specific <e2>TRPV1<\\e2> antagonist","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"SB366791","object":"TRPV1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Intraplantar or intrathecal administered Ph\u03b11\u03b2 reduced both nocifensive behavior and mechanical hypersensitivity induced by capsaicin similarly to that observed with <e1>CHEMICAL<\\e1>  a specific <e2>GENE-Y<\\e2> antagonist","sentence":"Intraplantar or intrathecal administered Ph\u03b11\u03b2 reduced both nocifensive behavior and mechanical hypersensitivity induced by capsaicin similarly to that observed with SB366791  a specific TRPV1 antagonist"}
{"PMID":23598363,"re_id":0,"annotated sentence":"We found that, before apoptosis, <e1>cisplatin<\\e1> induces <e2>c-Abl<\\e2> and TAp73 expression in the oocyte","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cisplatin","object":"c-Abl","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that, before apoptosis, <e1>CHEMICAL<\\e1> induces <e2>GENE-Y<\\e2> and TAp73 expression in the oocyte","sentence":"We found that, before apoptosis, cisplatin induces c-Abl and TAp73 expression in the oocyte"}
{"PMID":23598363,"re_id":1,"annotated sentence":"We found that, before apoptosis, <e1>cisplatin<\\e1> induces c-Abl and <e2>TAp73<\\e2> expression in the oocyte","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cisplatin","object":"TAp73","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that, before apoptosis, <e1>CHEMICAL<\\e1> induces c-Abl and <e2>GENE-Y<\\e2> expression in the oocyte","sentence":"We found that, before apoptosis, cisplatin induces c-Abl and TAp73 expression in the oocyte"}
{"PMID":23598363,"re_id":2,"annotated sentence":"While imatinib was unable to block <e1>cisplatin<\\e1> induced DNA damage and damage response, such as the upregulation of <e2>p53<\\e2>  imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl\/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cisplatin","object":"p53","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"While imatinib was unable to block <e1>CHEMICAL<\\e1> induced DNA damage and damage response, such as the upregulation of <e2>GENE-Y<\\e2>  imatinib inhibited the CHEMICAL-induced nuclear accumulation of c-Abl\/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death","sentence":"While imatinib was unable to block cisplatin induced DNA damage and damage response, such as the upregulation of p53  imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl\/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death"}
{"PMID":23598363,"re_id":3,"annotated sentence":"While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, <e1>imatinib<\\e1> inhibited the cisplatin-induced nuclear accumulation of c-Abl\/TAp73 and the subsequent downregulation of <e2>TAp63<\\e2> and upregulation of Bax, thereby abrogating oocyte cell death","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"imatinib","object":"TAp63","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"While CHEMICAL was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, <e1>CHEMICAL<\\e1> inhibited the cisplatin-induced nuclear accumulation of c-Abl\/TAp73 and the subsequent downregulation of <e2>GENE-Y<\\e2> and upregulation of Bax, thereby abrogating oocyte cell death","sentence":"While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl\/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death"}
{"PMID":23598363,"re_id":4,"annotated sentence":"While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the <e1>cisplatin<\\e1> induced nuclear accumulation of <e2>c-Abl<\\e2> TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cisplatin","object":"c-Abl","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"While imatinib was unable to block CHEMICAL-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the <e1>CHEMICAL<\\e1> induced nuclear accumulation of <e2>GENE-Y<\\e2> TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death","sentence":"While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin induced nuclear accumulation of c-Abl TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death"}
{"PMID":23598363,"re_id":5,"annotated sentence":"While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the <e1>cisplatin<\\e1> induced nuclear accumulation of c-Abl\/<e2>TAp73<\\e2> and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cisplatin","object":"TAp73","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"While imatinib was unable to block CHEMICAL-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the <e1>CHEMICAL<\\e1> induced nuclear accumulation of c-Abl\/<e2>GENE-Y<\\e2> and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death","sentence":"While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin induced nuclear accumulation of c-Abl\/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death"}
{"PMID":23598363,"re_id":6,"annotated sentence":"While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the <e1>cisplatin<\\e1> induced nuclear accumulation of c-Abl\/TAp73 and the subsequent downregulation of TAp63 and upregulation of <e2>Bax<\\e2>  thereby abrogating oocyte cell death","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cisplatin","object":"Bax","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"While imatinib was unable to block CHEMICAL-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the <e1>CHEMICAL<\\e1> induced nuclear accumulation of c-Abl\/TAp73 and the subsequent downregulation of TAp63 and upregulation of <e2>GENE-Y<\\e2>  thereby abrogating oocyte cell death","sentence":"While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin induced nuclear accumulation of c-Abl\/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax  thereby abrogating oocyte cell death"}
{"PMID":23598363,"re_id":7,"annotated sentence":"Surprisingly, the conditional deletion of Trp63, but not \u0394Np63, in oocytes inhibited apoptosis, as well as the accumulation of <e2>c-Abl<\\e2> and TAp73 caused by <e1>cisplatin<\\e1>  These data suggest that TAp63 is the master regulator of cisplatin-induced oocyte death","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cisplatin","object":"c-Abl","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Surprisingly, the conditional deletion of Trp63, but not \u0394Np63, in oocytes inhibited apoptosis, as well as the accumulation of <e2>GENE-Y<\\e2> and TAp73 caused by <e1>CHEMICAL<\\e1>  These data suggest that TAp63 is the master regulator of CHEMICAL-induced oocyte death","sentence":"Surprisingly, the conditional deletion of Trp63, but not \u0394Np63, in oocytes inhibited apoptosis, as well as the accumulation of c-Abl and TAp73 caused by cisplatin  These data suggest that TAp63 is the master regulator of cisplatin-induced oocyte death"}
{"PMID":23598363,"re_id":8,"annotated sentence":"Surprisingly, the conditional deletion of Trp63, but not \u0394Np63, in oocytes inhibited apoptosis, as well as the accumulation of c-Abl and <e2>TAp73<\\e2> caused by <e1>cisplatin<\\e1>  These data suggest that TAp63 is the master regulator of cisplatin-induced oocyte death","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cisplatin","object":"TAp73","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Surprisingly, the conditional deletion of Trp63, but not \u0394Np63, in oocytes inhibited apoptosis, as well as the accumulation of c-Abl and <e2>GENE-Y<\\e2> caused by <e1>CHEMICAL<\\e1>  These data suggest that TAp63 is the master regulator of CHEMICAL-induced oocyte death","sentence":"Surprisingly, the conditional deletion of Trp63, but not \u0394Np63, in oocytes inhibited apoptosis, as well as the accumulation of c-Abl and TAp73 caused by cisplatin  These data suggest that TAp63 is the master regulator of cisplatin-induced oocyte death"}
{"PMID":23598363,"re_id":9,"annotated sentence":"The expression kinetics of TAp63, c-Abl and TAp73 suggest that <e1>cisplatin<\\e1> activates <e2>TAp63<\\e2> dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced BAX expression","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cisplatin","object":"TAp63","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The expression kinetics of GENE-Y, c-Abl and TAp73 suggest that <e1>CHEMICAL<\\e1> activates <e2>GENE-Y<\\e2> dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced BAX expression","sentence":"The expression kinetics of TAp63, c-Abl and TAp73 suggest that cisplatin activates TAp63 dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced BAX expression"}
{"PMID":23598363,"re_id":10,"annotated sentence":"The expression kinetics of TAp63, c-Abl and TAp73 suggest that <e1>cisplatin<\\e1> activates TAp63-dependent expression of <e2>c-Abl<\\e2> and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced BAX expression","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cisplatin","object":"c-Abl","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The expression kinetics of TAp63, GENE-Y and TAp73 suggest that <e1>CHEMICAL<\\e1> activates TAp63-dependent expression of <e2>GENE-Y<\\e2> and TAp73 and, in turn, the activation of TAp73 by GENE-Y-induced BAX expression","sentence":"The expression kinetics of TAp63, c-Abl and TAp73 suggest that cisplatin activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced BAX expression"}
{"PMID":23598363,"re_id":11,"annotated sentence":"The expression kinetics of TAp63, c-Abl and TAp73 suggest that <e1>cisplatin<\\e1> activates TAp63-dependent expression of c-Abl and <e2>TAp73<\\e2> and, in turn, the activation of TAp73 by c-Abl-induced BAX expression","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cisplatin","object":"TAp73","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The expression kinetics of TAp63, c-Abl and GENE-Y suggest that <e1>CHEMICAL<\\e1> activates TAp63-dependent expression of c-Abl and <e2>GENE-Y<\\e2> and, in turn, the activation of GENE-Y by c-Abl-induced BAX expression","sentence":"The expression kinetics of TAp63, c-Abl and TAp73 suggest that cisplatin activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced BAX expression"}
{"PMID":23598363,"re_id":12,"annotated sentence":"The expression kinetics of TAp63, c-Abl and TAp73 suggest that <e1>cisplatin<\\e1> activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of <e2>TAp73<\\e2> by c-Abl-induced BAX expression","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cisplatin","object":"TAp73","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The expression kinetics of TAp63, c-Abl and GENE-Y suggest that <e1>CHEMICAL<\\e1> activates TAp63-dependent expression of c-Abl and GENE-Y and, in turn, the activation of <e2>GENE-Y<\\e2> by c-Abl-induced BAX expression","sentence":"The expression kinetics of TAp63, c-Abl and TAp73 suggest that cisplatin activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced BAX expression"}
{"PMID":23598363,"re_id":13,"annotated sentence":"The expression kinetics of TAp63, c-Abl and TAp73 suggest that <e1>cisplatin<\\e1> activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by <e2>c-Abl<\\e2> induced BAX expression","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cisplatin","object":"c-Abl","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The expression kinetics of TAp63, GENE-Y and TAp73 suggest that <e1>CHEMICAL<\\e1> activates TAp63-dependent expression of GENE-Y and TAp73 and, in turn, the activation of TAp73 by <e2>GENE-Y<\\e2> induced BAX expression","sentence":"The expression kinetics of TAp63, c-Abl and TAp73 suggest that cisplatin activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl induced BAX expression"}
{"PMID":23598363,"re_id":14,"annotated sentence":"The expression kinetics of TAp63, c-Abl and TAp73 suggest that <e1>cisplatin<\\e1> activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced <e2>BAX<\\e2> expression","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cisplatin","object":"BAX","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The expression kinetics of TAp63, c-Abl and TAp73 suggest that <e1>CHEMICAL<\\e1> activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced <e2>GENE-Y<\\e2> expression","sentence":"The expression kinetics of TAp63, c-Abl and TAp73 suggest that cisplatin activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced BAX expression"}
{"PMID":23598363,"re_id":15,"annotated sentence":"Our findings indicate that <e1>imatinib<\\e1> protects oocytes from cisplatin-induced cell death by inhibiting c-Abl <e2>kinase<\\e2>  which would otherwise activate TAp73-BAX-mediated apoptosis","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"imatinib","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Our findings indicate that <e1>CHEMICAL<\\e1> protects oocytes from cisplatin-induced cell death by inhibiting c-Abl <e2>GENE-N<\\e2>  which would otherwise activate TAp73-BAX-mediated apoptosis","sentence":"Our findings indicate that imatinib protects oocytes from cisplatin-induced cell death by inhibiting c-Abl kinase  which would otherwise activate TAp73-BAX-mediated apoptosis"}
{"PMID":23598363,"re_id":16,"annotated sentence":"Our findings indicate that imatinib protects oocytes from <e1>cisplatin<\\e1> induced cell death by inhibiting <e2>c-Abl<\\e2> kinase, which would otherwise activate TAp73-BAX-mediated apoptosis","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cisplatin","object":"c-Abl","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our findings indicate that imatinib protects oocytes from <e1>CHEMICAL<\\e1> induced cell death by inhibiting <e2>GENE-Y<\\e2> kinase, which would otherwise activate TAp73-BAX-mediated apoptosis","sentence":"Our findings indicate that imatinib protects oocytes from cisplatin induced cell death by inhibiting c-Abl kinase, which would otherwise activate TAp73-BAX-mediated apoptosis"}
{"PMID":23598363,"re_id":17,"annotated sentence":"Our findings indicate that imatinib protects oocytes from <e1>cisplatin<\\e1> induced cell death by inhibiting c-Abl <e2>kinase<\\e2>  which would otherwise activate TAp73-BAX-mediated apoptosis","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cisplatin","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Our findings indicate that imatinib protects oocytes from <e1>CHEMICAL<\\e1> induced cell death by inhibiting c-Abl <e2>GENE-N<\\e2>  which would otherwise activate TAp73-BAX-mediated apoptosis","sentence":"Our findings indicate that imatinib protects oocytes from cisplatin induced cell death by inhibiting c-Abl kinase  which would otherwise activate TAp73-BAX-mediated apoptosis"}
{"PMID":23598363,"re_id":18,"annotated sentence":"Our findings indicate that imatinib protects oocytes from <e1>cisplatin<\\e1> induced cell death by inhibiting c-Abl kinase, which would otherwise activate <e2>TAp73<\\e2> BAX-mediated apoptosis","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cisplatin","object":"TAp73","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our findings indicate that imatinib protects oocytes from <e1>CHEMICAL<\\e1> induced cell death by inhibiting c-Abl kinase, which would otherwise activate <e2>GENE-Y<\\e2> BAX-mediated apoptosis","sentence":"Our findings indicate that imatinib protects oocytes from cisplatin induced cell death by inhibiting c-Abl kinase, which would otherwise activate TAp73 BAX-mediated apoptosis"}
{"PMID":23598363,"re_id":19,"annotated sentence":"Our findings indicate that imatinib protects oocytes from <e1>cisplatin<\\e1> induced cell death by inhibiting c-Abl kinase, which would otherwise activate TAp73-<e2>BAX<\\e2> mediated apoptosis","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cisplatin","object":"BAX","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our findings indicate that imatinib protects oocytes from <e1>CHEMICAL<\\e1> induced cell death by inhibiting c-Abl kinase, which would otherwise activate TAp73-<e2>GENE-Y<\\e2> mediated apoptosis","sentence":"Our findings indicate that imatinib protects oocytes from cisplatin induced cell death by inhibiting c-Abl kinase, which would otherwise activate TAp73-BAX mediated apoptosis"}
{"PMID":23598363,"re_id":20,"annotated sentence":"Recently, the <e2>c-Abl<\\e2> kinase inhibitor <e1>imatinib mesylate<\\e1> (imatinib) has become the focus of research as a fertoprotective drug against cisplatin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"imatinib mesylate","object":"c-Abl","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Recently, the <e2>GENE-Y<\\e2> kinase inhibitor <e1>CHEMICAL<\\e1> (imatinib) has become the focus of research as a fertoprotective drug against cisplatin","sentence":"Recently, the c-Abl kinase inhibitor imatinib mesylate (imatinib) has become the focus of research as a fertoprotective drug against cisplatin"}
{"PMID":23598363,"re_id":21,"annotated sentence":"Recently, the c-Abl <e2>kinase<\\e2> inhibitor <e1>imatinib mesylate<\\e1> (imatinib) has become the focus of research as a fertoprotective drug against cisplatin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"imatinib mesylate","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Recently, the c-Abl <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1> (imatinib) has become the focus of research as a fertoprotective drug against cisplatin","sentence":"Recently, the c-Abl kinase inhibitor imatinib mesylate (imatinib) has become the focus of research as a fertoprotective drug against cisplatin"}
{"PMID":23598363,"re_id":22,"annotated sentence":"Recently, the <e2>c-Abl<\\e2> kinase inhibitor imatinib mesylate (<e1>imatinib<\\e1>  has become the focus of research as a fertoprotective drug against cisplatin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"imatinib","object":"c-Abl","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Recently, the <e2>GENE-Y<\\e2> kinase inhibitor CHEMICAL mesylate (<e1>CHEMICAL<\\e1>  has become the focus of research as a fertoprotective drug against cisplatin","sentence":"Recently, the c-Abl kinase inhibitor imatinib mesylate (imatinib  has become the focus of research as a fertoprotective drug against cisplatin"}
{"PMID":23598363,"re_id":23,"annotated sentence":"Recently, the c-Abl <e2>kinase<\\e2> inhibitor imatinib mesylate (<e1>imatinib<\\e1>  has become the focus of research as a fertoprotective drug against cisplatin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"imatinib","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Recently, the c-Abl <e2>GENE-N<\\e2> inhibitor CHEMICAL mesylate (<e1>CHEMICAL<\\e1>  has become the focus of research as a fertoprotective drug against cisplatin","sentence":"Recently, the c-Abl kinase inhibitor imatinib mesylate (imatinib  has become the focus of research as a fertoprotective drug against cisplatin"}
{"PMID":23598363,"re_id":24,"annotated sentence":"While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, <e1>imatinib<\\e1> inhibited the cisplatin-induced nuclear accumulation of <e2>c-Abl<\\e2> TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"imatinib","object":"c-Abl","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"While CHEMICAL was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, <e1>CHEMICAL<\\e1> inhibited the cisplatin-induced nuclear accumulation of <e2>GENE-Y<\\e2> TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death","sentence":"While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death"}
{"PMID":23598363,"re_id":25,"annotated sentence":"While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, <e1>imatinib<\\e1> inhibited the cisplatin-induced nuclear accumulation of c-Abl\/<e2>TAp73<\\e2> and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"imatinib","object":"TAp73","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"While CHEMICAL was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, <e1>CHEMICAL<\\e1> inhibited the cisplatin-induced nuclear accumulation of c-Abl\/<e2>GENE-Y<\\e2> and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death","sentence":"While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl\/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death"}
{"PMID":23598363,"re_id":26,"annotated sentence":"While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, <e1>imatinib<\\e1> inhibited the cisplatin-induced nuclear accumulation of c-Abl\/TAp73 and the subsequent downregulation of TAp63 and upregulation of <e2>Bax<\\e2>  thereby abrogating oocyte cell death","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"imatinib","object":"Bax","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"While CHEMICAL was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, <e1>CHEMICAL<\\e1> inhibited the cisplatin-induced nuclear accumulation of c-Abl\/TAp73 and the subsequent downregulation of TAp63 and upregulation of <e2>GENE-Y<\\e2>  thereby abrogating oocyte cell death","sentence":"While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl\/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax  thereby abrogating oocyte cell death"}
{"PMID":23598363,"re_id":27,"annotated sentence":"While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the <e1>cisplatin<\\e1> induced nuclear accumulation of c-Abl\/TAp73 and the subsequent downregulation of <e2>TAp63<\\e2> and upregulation of Bax, thereby abrogating oocyte cell death","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cisplatin","object":"TAp63","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"While imatinib was unable to block CHEMICAL-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the <e1>CHEMICAL<\\e1> induced nuclear accumulation of c-Abl\/TAp73 and the subsequent downregulation of <e2>GENE-Y<\\e2> and upregulation of Bax, thereby abrogating oocyte cell death","sentence":"While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin induced nuclear accumulation of c-Abl\/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death"}
{"PMID":23598363,"re_id":28,"annotated sentence":"Our findings indicate that <e1>imatinib<\\e1> protects oocytes from cisplatin-induced cell death by inhibiting <e2>c-Abl<\\e2> kinase, which would otherwise activate TAp73-BAX-mediated apoptosis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"imatinib","object":"c-Abl","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our findings indicate that <e1>CHEMICAL<\\e1> protects oocytes from cisplatin-induced cell death by inhibiting <e2>GENE-Y<\\e2> kinase, which would otherwise activate TAp73-BAX-mediated apoptosis","sentence":"Our findings indicate that imatinib protects oocytes from cisplatin-induced cell death by inhibiting c-Abl kinase, which would otherwise activate TAp73-BAX-mediated apoptosis"}
{"PMID":23598363,"re_id":29,"annotated sentence":"Our findings indicate that <e1>imatinib<\\e1> protects oocytes from cisplatin-induced cell death by inhibiting c-Abl kinase, which would otherwise activate <e2>TAp73<\\e2> BAX-mediated apoptosis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"imatinib","object":"TAp73","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our findings indicate that <e1>CHEMICAL<\\e1> protects oocytes from cisplatin-induced cell death by inhibiting c-Abl kinase, which would otherwise activate <e2>GENE-Y<\\e2> BAX-mediated apoptosis","sentence":"Our findings indicate that imatinib protects oocytes from cisplatin-induced cell death by inhibiting c-Abl kinase, which would otherwise activate TAp73 BAX-mediated apoptosis"}
{"PMID":23598363,"re_id":30,"annotated sentence":"Our findings indicate that <e1>imatinib<\\e1> protects oocytes from cisplatin-induced cell death by inhibiting c-Abl kinase, which would otherwise activate TAp73-<e2>BAX<\\e2> mediated apoptosis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"imatinib","object":"BAX","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our findings indicate that <e1>CHEMICAL<\\e1> protects oocytes from cisplatin-induced cell death by inhibiting c-Abl kinase, which would otherwise activate TAp73-<e2>GENE-Y<\\e2> mediated apoptosis","sentence":"Our findings indicate that imatinib protects oocytes from cisplatin-induced cell death by inhibiting c-Abl kinase, which would otherwise activate TAp73-BAX mediated apoptosis"}
{"PMID":23598363,"re_id":31,"annotated sentence":"Thus, <e1>imatinib<\\e1> and other <e2>c-Abl<\\e2> kinase inhibitors provide an intriguing new way to halt cisplatin-induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.Cell Death and Differentiation advance online publication, 19 April 2013; doi:10.1038\/cdd.2013.31.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"imatinib","object":"c-Abl","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, <e1>CHEMICAL<\\e1> and other <e2>GENE-Y<\\e2> kinase inhibitors provide an intriguing new way to halt cisplatin-induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.Cell Death and Differentiation advance online publication, 19 April 2013; doi:10.1038\/cdd.2013.31.","sentence":"Thus, imatinib and other c-Abl kinase inhibitors provide an intriguing new way to halt cisplatin-induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.Cell Death and Differentiation advance online publication, 19 April 2013; doi:10.1038\/cdd.2013.31."}
{"PMID":23598363,"re_id":32,"annotated sentence":"Thus, <e1>imatinib<\\e1> and other c-Abl <e2>kinase<\\e2> inhibitors provide an intriguing new way to halt cisplatin-induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.Cell Death and Differentiation advance online publication, 19 April 2013; doi:10.1038\/cdd.2013.31.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"imatinib","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Thus, <e1>CHEMICAL<\\e1> and other c-Abl <e2>GENE-N<\\e2> inhibitors provide an intriguing new way to halt cisplatin-induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.Cell Death and Differentiation advance online publication, 19 April 2013; doi:10.1038\/cdd.2013.31.","sentence":"Thus, imatinib and other c-Abl kinase inhibitors provide an intriguing new way to halt cisplatin-induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.Cell Death and Differentiation advance online publication, 19 April 2013; doi:10.1038\/cdd.2013.31."}
{"PMID":23598904,"re_id":0,"annotated sentence":"These results suggest that <e2>ZIP8<\\e2> plays a pivotal role in the transport and toxicity of <e1>Cd(2+)<\\e1> and Mn(2+) in RBL-2H3 cells.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Cd(2+)","object":"ZIP8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that <e2>GENE-Y<\\e2> plays a pivotal role in the transport and toxicity of <e1>CHEMICAL<\\e1> and Mn(2+) in RBL-2H3 cells.","sentence":"These results suggest that ZIP8 plays a pivotal role in the transport and toxicity of Cd(2+) and Mn(2+) in RBL-2H3 cells."}
{"PMID":23598904,"re_id":1,"annotated sentence":"Among the possible transporters involved in the uptake of <e1>Cd(2+)<\\e1> and Mn(2+), the expression of ZIP8 (Zrt-, Irt-related protein 8), encoded by <e2>Slc39a8<\\e2>  showed a marked suppression in both RBL-Cdr and RBL-Mnr cells","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Cd(2+)","object":"Slc39a8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Among the possible transporters involved in the uptake of <e1>CHEMICAL<\\e1> and Mn(2+), the expression of ZIP8 (Zrt-, Irt-related protein 8), encoded by <e2>GENE-Y<\\e2>  showed a marked suppression in both RBL-Cdr and RBL-Mnr cells","sentence":"Among the possible transporters involved in the uptake of Cd(2+) and Mn(2+), the expression of ZIP8 (Zrt-, Irt-related protein 8), encoded by Slc39a8  showed a marked suppression in both RBL-Cdr and RBL-Mnr cells"}
{"PMID":23598904,"re_id":2,"annotated sentence":"Among the possible transporters involved in the uptake of <e1>Cd(2+)<\\e1> and Mn(2+), the expression of <e2>ZIP8<\\e2> (Zrt-, Irt-related protein 8), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Cd(2+)","object":"ZIP8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Among the possible transporters involved in the uptake of <e1>CHEMICAL<\\e1> and Mn(2+), the expression of <e2>GENE-Y<\\e2> (Zrt-, Irt-related protein 8), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells","sentence":"Among the possible transporters involved in the uptake of Cd(2+) and Mn(2+), the expression of ZIP8 (Zrt-, Irt-related protein 8), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells"}
{"PMID":23598904,"re_id":3,"annotated sentence":"Among the possible transporters involved in the uptake of <e1>Cd(2+)<\\e1> and Mn(2+), the expression of ZIP8 (<e2>Zrt-, Irt-related protein 8<\\e2> , encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Cd(2+)","object":"Zrt-, Irt-related protein 8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Among the possible transporters involved in the uptake of <e1>CHEMICAL<\\e1> and Mn(2+), the expression of ZIP8 (<e2>GENE-Y<\\e2> , encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells","sentence":"Among the possible transporters involved in the uptake of Cd(2+) and Mn(2+), the expression of ZIP8 (Zrt-, Irt-related protein 8 , encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells"}
{"PMID":23598904,"re_id":4,"annotated sentence":"Among the possible transporters involved in the uptake of Cd(2+) and <e1>Mn(2+)<\\e1>  the expression of ZIP8 (Zrt-, Irt-related protein 8), encoded by <e2>Slc39a8<\\e2>  showed a marked suppression in both RBL-Cdr and RBL-Mnr cells","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Mn(2+)","object":"Slc39a8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Among the possible transporters involved in the uptake of Cd(2+) and <e1>CHEMICAL<\\e1>  the expression of ZIP8 (Zrt-, Irt-related protein 8), encoded by <e2>GENE-Y<\\e2>  showed a marked suppression in both RBL-Cdr and RBL-Mnr cells","sentence":"Among the possible transporters involved in the uptake of Cd(2+) and Mn(2+)  the expression of ZIP8 (Zrt-, Irt-related protein 8), encoded by Slc39a8  showed a marked suppression in both RBL-Cdr and RBL-Mnr cells"}
{"PMID":23598904,"re_id":5,"annotated sentence":"Among the possible transporters involved in the uptake of Cd(2+) and <e1>Mn(2+)<\\e1>  the expression of <e2>ZIP8<\\e2> (Zrt-, Irt-related protein 8), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Mn(2+)","object":"ZIP8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Among the possible transporters involved in the uptake of Cd(2+) and <e1>CHEMICAL<\\e1>  the expression of <e2>GENE-Y<\\e2> (Zrt-, Irt-related protein 8), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells","sentence":"Among the possible transporters involved in the uptake of Cd(2+) and Mn(2+)  the expression of ZIP8 (Zrt-, Irt-related protein 8), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells"}
{"PMID":23598904,"re_id":6,"annotated sentence":"Among the possible transporters involved in the uptake of Cd(2+) and <e1>Mn(2+)<\\e1>  the expression of ZIP8 (<e2>Zrt-, Irt-related protein 8<\\e2> , encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Mn(2+)","object":"Zrt-, Irt-related protein 8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Among the possible transporters involved in the uptake of Cd(2+) and <e1>CHEMICAL<\\e1>  the expression of ZIP8 (<e2>GENE-Y<\\e2> , encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells","sentence":"Among the possible transporters involved in the uptake of Cd(2+) and Mn(2+)  the expression of ZIP8 (Zrt-, Irt-related protein 8 , encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells"}
{"PMID":23598904,"re_id":7,"annotated sentence":"These results suggest that <e2>ZIP8<\\e2> plays a pivotal role in the transport and toxicity of Cd(2+) and <e1>Mn(2+)<\\e1> in RBL-2H3 cells.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Mn(2+)","object":"ZIP8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that <e2>GENE-Y<\\e2> plays a pivotal role in the transport and toxicity of Cd(2+) and <e1>CHEMICAL<\\e1> in RBL-2H3 cells.","sentence":"These results suggest that ZIP8 plays a pivotal role in the transport and toxicity of Cd(2+) and Mn(2+) in RBL-2H3 cells."}
{"PMID":23601710,"re_id":0,"annotated sentence":"Detailed structure-activity relationships of the C3-phenyl moiety that allow for the optimization of antiviral potency of a series of <e1>1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione<\\e1> inhibitors of <e2>HIV capsid<\\e2> (CA) assembly are described","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione","object":"HIV capsid","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Detailed structure-activity relationships of the C3-phenyl moiety that allow for the optimization of antiviral potency of a series of <e1>CHEMICAL<\\e1> inhibitors of <e2>GENE-N<\\e2> (CA) assembly are described","sentence":"Detailed structure-activity relationships of the C3-phenyl moiety that allow for the optimization of antiviral potency of a series of 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione inhibitors of HIV capsid (CA) assembly are described"}
{"PMID":23601710,"re_id":1,"annotated sentence":"Detailed structure-activity relationships of the C3-phenyl moiety that allow for the optimization of antiviral potency of a series of <e1>1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione<\\e1> inhibitors of HIV capsid (<e2>CA<\\e2>  assembly are described","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione","object":"CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Detailed structure-activity relationships of the C3-phenyl moiety that allow for the optimization of antiviral potency of a series of <e1>CHEMIGENE-NL<\\e1> inhibitors of HIV capsid (<e2>GENE-N<\\e2>  assembly are described","sentence":"Detailed structure-activity relationships of the C3-phenyl moiety that allow for the optimization of antiviral potency of a series of 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione inhibitors of HIV capsid (CA  assembly are described"}
{"PMID":23601710,"re_id":2,"annotated sentence":"Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of <e2>HIV capsid<\\e2> assembly inhibitors 2: Structure-activity relationships (SAR) of the C3-<e1>phenyl<\\e1> moiety","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenyl","object":"HIV capsid","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of <e2>GENE-N<\\e2> assembly inhibitors 2: Structure-activity relationships (SAR) of the C3-<e1>CHEMICAL<\\e1> moiety","sentence":"Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of HIV capsid assembly inhibitors 2: Structure-activity relationships (SAR) of the C3-phenyl moiety"}
{"PMID":23601710,"re_id":3,"annotated sentence":"Optimization of a <e1>1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione<\\e1> series of <e2>HIV capsid<\\e2> assembly inhibitors 2: Structure-activity relationships (SAR) of the C3-phenyl moiety","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione","object":"HIV capsid","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Optimization of a <e1>CHEMICAL<\\e1> series of <e2>GENE-N<\\e2> assembly inhibitors 2: Structure-activity relationships (SAR) of the C3-phenyl moiety","sentence":"Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of HIV capsid assembly inhibitors 2: Structure-activity relationships (SAR) of the C3-phenyl moiety"}
{"PMID":23603059,"re_id":0,"annotated sentence":"<e1>Arsenic<\\e1> upregulates the expression of <e2>angiotensin II Type I receptor<\\e2> in mouse aortic endothelial cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Arsenic","object":"angiotensin II Type I receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> upregulates the expression of <e2>GENE-N<\\e2> in mouse aortic endothelial cells","sentence":"Arsenic upregulates the expression of angiotensin II Type I receptor in mouse aortic endothelial cells"}
{"PMID":23603059,"re_id":1,"annotated sentence":"Taken together, our results indicate that <e1>arsenic<\\e1> indeed upregulates the <e2>AT1R<\\e2> expression, thus highlighting a role of arsenic-induced aberrant AT1R signaling in the pathogenesis of hypertension.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"arsenic","object":"AT1R","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Taken together, our results indicate that <e1>CHEMICAL<\\e1> indeed upregulates the <e2>GENE-N<\\e2> expression, thus highlighting a role of CHEMICAL-induced aberrant GENE-N signaling in the pathogenesis of hypertension.","sentence":"Taken together, our results indicate that arsenic indeed upregulates the AT1R expression, thus highlighting a role of arsenic-induced aberrant AT1R signaling in the pathogenesis of hypertension."}
{"PMID":23603059,"re_id":2,"annotated sentence":"Taken together, our results indicate that arsenic indeed upregulates the AT1R expression, thus highlighting a role of <e1>arsenic<\\e1> induced aberrant <e2>AT1R<\\e2> signaling in the pathogenesis of hypertension.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"arsenic","object":"AT1R","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Taken together, our results indicate that CHEMICAL indeed upregulates the GENE-N expression, thus highlighting a role of <e1>CHEMICAL<\\e1> induced aberrant <e2>GENE-N<\\e2> signaling in the pathogenesis of hypertension.","sentence":"Taken together, our results indicate that arsenic indeed upregulates the AT1R expression, thus highlighting a role of arsenic induced aberrant AT1R signaling in the pathogenesis of hypertension."}
{"PMID":23603059,"re_id":3,"annotated sentence":"Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 <e2>AT1R<\\e2> subtypes, AT1AR and AT1BR following <e1>sodium arsenite<\\e1> (SA) treatment","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"sodium arsenite","object":"AT1R","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 <e2>GENE-N<\\e2> subtypes, AT1AR and AT1BR following <e1>CHEMICAL<\\e1> (SA) treatment","sentence":"Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 AT1R subtypes, AT1AR and AT1BR following sodium arsenite (SA) treatment"}
{"PMID":23603059,"re_id":4,"annotated sentence":"Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 AT1R subtypes, <e2>AT1AR<\\e2> and AT1BR following <e1>sodium arsenite<\\e1> (SA) treatment","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"sodium arsenite","object":"AT1AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 AT1R subtypes, <e2>GENE-Y<\\e2> and AT1BR following <e1>CHEMICAL<\\e1> (SA) treatment","sentence":"Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 AT1R subtypes, AT1AR and AT1BR following sodium arsenite (SA) treatment"}
{"PMID":23603059,"re_id":5,"annotated sentence":"Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 AT1R subtypes, AT1AR and <e2>AT1BR<\\e2> following <e1>sodium arsenite<\\e1> (SA) treatment","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"sodium arsenite","object":"AT1BR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 AT1R subtypes, AT1AR and <e2>GENE-Y<\\e2> following <e1>CHEMICAL<\\e1> (SA) treatment","sentence":"Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 AT1R subtypes, AT1AR and AT1BR following sodium arsenite (SA) treatment"}
{"PMID":23603059,"re_id":6,"annotated sentence":"Finally, SA-induced AT1R expression was found to be prevented both by NAC and specific <e2>JNK<\\e2> inhibitor, <e1>SP6001325<\\e1>  strongly indicating that AT1R upregulation is a result of the ROS-mediated activation of the JNK signaling pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SP6001325","object":"JNK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Finally, SA-induced AT1R expression was found to be prevented both by NAC and specific <e2>GENE-N<\\e2> inhibitor, <e1>CHEMICAL<\\e1>  strongly indicating that AT1R upregulation is a result of the ROS-mediated activation of the GENE-N signaling pathway","sentence":"Finally, SA-induced AT1R expression was found to be prevented both by NAC and specific JNK inhibitor, SP6001325  strongly indicating that AT1R upregulation is a result of the ROS-mediated activation of the JNK signaling pathway"}
{"PMID":23603059,"re_id":7,"annotated sentence":"Finally, SA-induced <e2>AT1R<\\e2> expression was found to be prevented both by NAC and specific JNK inhibitor, <e1>SP6001325<\\e1>  strongly indicating that AT1R upregulation is a result of the ROS-mediated activation of the JNK signaling pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SP6001325","object":"AT1R","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Finally, SA-induced <e2>GENE-N<\\e2> expression was found to be prevented both by NAC and specific JNK inhibitor, <e1>CHEMICAL<\\e1>  strongly indicating that GENE-N upregulation is a result of the ROS-mediated activation of the JNK signaling pathway","sentence":"Finally, SA-induced AT1R expression was found to be prevented both by NAC and specific JNK inhibitor, SP6001325  strongly indicating that AT1R upregulation is a result of the ROS-mediated activation of the JNK signaling pathway"}
{"PMID":23603382,"re_id":0,"annotated sentence":"The expressions of <e2>HSP70<\\e2> and HO-1 were significantly (P<0.05) increased in the <e1>NaAsO2<\\e1> group and reduced in the combined treatment group","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"NaAsO2","object":"HSP70","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The expressions of <e2>GENE-N<\\e2> and HO-1 were significantly (P<0.05) increased in the <e1>CHEMICAL<\\e1> group and reduced in the combined treatment group","sentence":"The expressions of HSP70 and HO-1 were significantly (P<0.05) increased in the NaAsO2 group and reduced in the combined treatment group"}
{"PMID":23603382,"re_id":1,"annotated sentence":"The expressions of HSP70 and <e2>HO-1<\\e2> were significantly (P<0.05) increased in the <e1>NaAsO2<\\e1> group and reduced in the combined treatment group","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"NaAsO2","object":"HO-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The expressions of HSP70 and <e2>GENE-Y<\\e2> were significantly (P<0.05) increased in the <e1>CHEMICAL<\\e1> group and reduced in the combined treatment group","sentence":"The expressions of HSP70 and HO-1 were significantly (P<0.05) increased in the NaAsO2 group and reduced in the combined treatment group"}
{"PMID":23603382,"re_id":2,"annotated sentence":"The mRNA levels of <e2>SOD1<\\e2>  CAT, GPx and Txnrd1 were increased significantly (P<0.05) in the combined <e1>Na2SeO3<\\e1> NaAsO2 treatment group","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Na2SeO3","object":"SOD1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mRNA levels of <e2>GENE-Y<\\e2>  CAT, GPx and Txnrd1 were increased significantly (P<0.05) in the combined <e1>CHEMICAL<\\e1> NaAsO2 treatment group","sentence":"The mRNA levels of SOD1  CAT, GPx and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3 NaAsO2 treatment group"}
{"PMID":23603382,"re_id":3,"annotated sentence":"The mRNA levels of SOD1, <e2>CAT<\\e2>  GPx and Txnrd1 were increased significantly (P<0.05) in the combined <e1>Na2SeO3<\\e1> NaAsO2 treatment group","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Na2SeO3","object":"CAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mRNA levels of SOD1, <e2>GENE-Y<\\e2>  GPx and Txnrd1 were increased significantly (P<0.05) in the combined <e1>CHEMICAL<\\e1> NaAsO2 treatment group","sentence":"The mRNA levels of SOD1, CAT  GPx and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3 NaAsO2 treatment group"}
{"PMID":23603382,"re_id":4,"annotated sentence":"The mRNA levels of SOD1, CAT, <e2>GPx<\\e2> and Txnrd1 were increased significantly (P<0.05) in the combined <e1>Na2SeO3<\\e1> NaAsO2 treatment group","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Na2SeO3","object":"GPx","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The mRNA levels of SOD1, CAT, <e2>GENE-N<\\e2> and Txnrd1 were increased significantly (P<0.05) in the combined <e1>CHEMICAL<\\e1> NaAsO2 treatment group","sentence":"The mRNA levels of SOD1, CAT, GPx and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3 NaAsO2 treatment group"}
{"PMID":23603382,"re_id":5,"annotated sentence":"The mRNA levels of <e2>SOD1<\\e2>  CAT, GPx and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+<e1>NaAsO2<\\e1> treatment group","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NaAsO2","object":"SOD1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mRNA levels of <e2>GENE-Y<\\e2>  CAT, GPx and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+<e1>CHEMICAL<\\e1> treatment group","sentence":"The mRNA levels of SOD1  CAT, GPx and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+NaAsO2 treatment group"}
{"PMID":23603382,"re_id":6,"annotated sentence":"The mRNA levels of SOD1, <e2>CAT<\\e2>  GPx and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+<e1>NaAsO2<\\e1> treatment group","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NaAsO2","object":"CAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mRNA levels of SOD1, <e2>GENE-Y<\\e2>  GPx and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+<e1>CHEMICAL<\\e1> treatment group","sentence":"The mRNA levels of SOD1, CAT  GPx and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+NaAsO2 treatment group"}
{"PMID":23603382,"re_id":7,"annotated sentence":"The mRNA levels of SOD1, CAT, <e2>GPx<\\e2> and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+<e1>NaAsO2<\\e1> treatment group","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NaAsO2","object":"GPx","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The mRNA levels of SOD1, CAT, <e2>GENE-N<\\e2> and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+<e1>CHEMICAL<\\e1> treatment group","sentence":"The mRNA levels of SOD1, CAT, GPx and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+NaAsO2 treatment group"}
{"PMID":23603382,"re_id":8,"annotated sentence":"The mRNA levels of SOD1, CAT, GPx and <e2>Txnrd1<\\e2> were increased significantly (P<0.05) in the combined Na2SeO3+<e1>NaAsO2<\\e1> treatment group","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NaAsO2","object":"Txnrd1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mRNA levels of SOD1, CAT, GPx and <e2>GENE-Y<\\e2> were increased significantly (P<0.05) in the combined Na2SeO3+<e1>CHEMICAL<\\e1> treatment group","sentence":"The mRNA levels of SOD1, CAT, GPx and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+NaAsO2 treatment group"}
{"PMID":23603382,"re_id":9,"annotated sentence":"The mRNA levels of SOD1, CAT, GPx and <e2>Txnrd1<\\e2> were increased significantly (P<0.05) in the combined <e1>Na2SeO3<\\e1> NaAsO2 treatment group","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Na2SeO3","object":"Txnrd1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mRNA levels of SOD1, CAT, GPx and <e2>GENE-Y<\\e2> were increased significantly (P<0.05) in the combined <e1>CHEMICAL<\\e1> NaAsO2 treatment group","sentence":"The mRNA levels of SOD1, CAT, GPx and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3 NaAsO2 treatment group"}
{"PMID":23604720,"re_id":0,"annotated sentence":"In the kinetic analyses using Lineweaver-Burk plots of 1\/velocity and 1\/substrate, <e1>methyl-3,5-di-O-caffeoylquinate<\\e1> showed competitive inhibition of <e2>rhAR<\\e2>  Furthermore, methyl-3,5-di-O-caffeoylquinate inhibited galactitol formation in the rat lens and in erythrocytes incubated with a high concentration of glucose, indicating that this compound may be effective in preventing diabetic complications.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"methyl-3,5-di-O-caffeoylquinate","object":"rhAR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the kinetic analyses using Lineweaver-Burk plots of 1\/velocity and 1\/substrate, <e1>CHEMICAL<\\e1> showed competitive inhibition of <e2>GENE-Y<\\e2>  Furthermore, CHEMICAL inhibited galactitol formation in the rat lens and in erythrocytes incubated with a high concentration of glucose, indicating that this compound may be effective in preventing diabetic complications.","sentence":"In the kinetic analyses using Lineweaver-Burk plots of 1\/velocity and 1\/substrate, methyl-3,5-di-O-caffeoylquinate showed competitive inhibition of rhAR  Furthermore, methyl-3,5-di-O-caffeoylquinate inhibited galactitol formation in the rat lens and in erythrocytes incubated with a high concentration of glucose, indicating that this compound may be effective in preventing diabetic complications."}
{"PMID":23604720,"re_id":1,"annotated sentence":"From the 10 isolated compounds, <e1>methyl-3,5-di-O-caffeoylquinate<\\e1> showed the most potent inhibition, with IC50 values of 0.30 and 0.67\u00a0\u03bcM for <e2>rAR<\\e2> and rhAR, respectively","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"methyl-3,5-di-O-caffeoylquinate","object":"rAR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"From the 10 isolated compounds, <e1>CHEMICAL<\\e1> showed the most potent inhibition, with IC50 values of 0.30 and 0.67\u00a0\u03bcM for <e2>GENE-Y<\\e2> and rhAR, respectively","sentence":"From the 10 isolated compounds, methyl-3,5-di-O-caffeoylquinate showed the most potent inhibition, with IC50 values of 0.30 and 0.67\u00a0\u03bcM for rAR and rhAR, respectively"}
{"PMID":23604720,"re_id":2,"annotated sentence":"From the 10 isolated compounds, <e1>methyl-3,5-di-O-caffeoylquinate<\\e1> showed the most potent inhibition, with IC50 values of 0.30 and 0.67\u00a0\u03bcM for rAR and <e2>rhAR<\\e2>  respectively","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"methyl-3,5-di-O-caffeoylquinate","object":"rhAR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"From the 10 isolated compounds, <e1>CHEMICAL<\\e1> showed the most potent inhibition, with IC50 values of 0.30 and 0.67\u00a0\u03bcM for rAR and <e2>GENE-Y<\\e2>  respectively","sentence":"From the 10 isolated compounds, methyl-3,5-di-O-caffeoylquinate showed the most potent inhibition, with IC50 values of 0.30 and 0.67\u00a0\u03bcM for rAR and rhAR  respectively"}
{"PMID":23611809,"re_id":0,"annotated sentence":"Using recombinant <e2>UGT2B10<\\e2>  we found that it catalyzes the N-glucuronidation of <e1>amitriptyline<\\e1>  imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"amitriptyline","object":"UGT2B10","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using recombinant <e2>GENE-Y<\\e2>  we found that it catalyzes the N-glucuronidation of <e1>CHEMICAL<\\e1>  imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam","sentence":"Using recombinant UGT2B10  we found that it catalyzes the N-glucuronidation of amitriptyline  imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam"}
{"PMID":23611809,"re_id":1,"annotated sentence":"Using recombinant <e2>UGT2B10<\\e2>  we found that it catalyzes the N-glucuronidation of amitriptyline, <e1>imipramine<\\e1>  ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"imipramine","object":"UGT2B10","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using recombinant <e2>GENE-Y<\\e2>  we found that it catalyzes the N-glucuronidation of amitriptyline, <e1>CHEMICAL<\\e1>  ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam","sentence":"Using recombinant UGT2B10  we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine  ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam"}
{"PMID":23611809,"re_id":2,"annotated sentence":"Using recombinant <e2>UGT2B10<\\e2>  we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, <e1>ketotifen<\\e1>  pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"ketotifen","object":"UGT2B10","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using recombinant <e2>GENE-Y<\\e2>  we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, <e1>CHEMICAL<\\e1>  pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam","sentence":"Using recombinant UGT2B10  we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen  pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam"}
{"PMID":23611809,"re_id":3,"annotated sentence":"Using recombinant <e2>UGT2B10<\\e2>  we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, <e1>pizotifen<\\e1>  olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"pizotifen","object":"UGT2B10","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using recombinant <e2>GENE-Y<\\e2>  we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, <e1>CHEMICAL<\\e1>  olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam","sentence":"Using recombinant UGT2B10  we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen  olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam"}
{"PMID":23611809,"re_id":4,"annotated sentence":"Using recombinant <e2>UGT2B10<\\e2>  we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, <e1>olanzapine<\\e1>  diphenhydramine, tamoxifen, ketoconazole and midazolam","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"olanzapine","object":"UGT2B10","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using recombinant <e2>GENE-Y<\\e2>  we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, <e1>CHEMICAL<\\e1>  diphenhydramine, tamoxifen, ketoconazole and midazolam","sentence":"Using recombinant UGT2B10  we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine  diphenhydramine, tamoxifen, ketoconazole and midazolam"}
{"PMID":23611809,"re_id":5,"annotated sentence":"Using recombinant <e2>UGT2B10<\\e2>  we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, <e1>diphenhydramine<\\e1>  tamoxifen, ketoconazole and midazolam","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"diphenhydramine","object":"UGT2B10","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using recombinant <e2>GENE-Y<\\e2>  we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, <e1>CHEMICAL<\\e1>  tamoxifen, ketoconazole and midazolam","sentence":"Using recombinant UGT2B10  we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine  tamoxifen, ketoconazole and midazolam"}
{"PMID":23611809,"re_id":6,"annotated sentence":"Using recombinant <e2>UGT2B10<\\e2>  we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, <e1>tamoxifen<\\e1>  ketoconazole and midazolam","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"tamoxifen","object":"UGT2B10","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using recombinant <e2>GENE-Y<\\e2>  we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, <e1>CHEMICAL<\\e1>  ketoconazole and midazolam","sentence":"Using recombinant UGT2B10  we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen  ketoconazole and midazolam"}
{"PMID":23611809,"re_id":7,"annotated sentence":"Using recombinant <e2>UGT2B10<\\e2>  we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, <e1>ketoconazole<\\e1> and midazolam","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"ketoconazole","object":"UGT2B10","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using recombinant <e2>GENE-Y<\\e2>  we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, <e1>CHEMICAL<\\e1> and midazolam","sentence":"Using recombinant UGT2B10  we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam"}
{"PMID":23611809,"re_id":8,"annotated sentence":"Using recombinant <e2>UGT2B10<\\e2>  we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and <e1>midazolam<\\e1>  These are drugs that were previously reported to be substrates for UGT1A4 or UGT1A3 and that contain in their structure either tertiary aliphatic amines, cyclic amines, or an imidazole group","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"midazolam","object":"UGT2B10","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using recombinant <e2>GENE-Y<\\e2>  we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and <e1>CHEMICAL<\\e1>  These are drugs that were previously reported to be substrates for UGT1A4 or UGT1A3 and that contain in their structure either tertiary aliphatic amines, cyclic amines, or an imidazole group","sentence":"Using recombinant UGT2B10  we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam  These are drugs that were previously reported to be substrates for UGT1A4 or UGT1A3 and that contain in their structure either tertiary aliphatic amines, cyclic amines, or an imidazole group"}
{"PMID":23611809,"re_id":9,"annotated sentence":"This group of drugs contains secondary or primary amines, and these results suggest that <e2>UGT2B10<\\e2> preferably conjugates <e1>tertiary amines<\\e1>  This preference is partial because UGT2B10 did not conjugate the tertiary cyclic amine in trifluoperazine","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"tertiary amines","object":"UGT2B10","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This group of drugs contains secondary or primary amines, and these results suggest that <e2>GENE-Y<\\e2> preferably conjugates <e1>CHEMICAL<\\e1>  This preference is partial because GENE-Y did not conjugate the tertiary cyclic amine in trifluoperazine","sentence":"This group of drugs contains secondary or primary amines, and these results suggest that UGT2B10 preferably conjugates tertiary amines  This preference is partial because UGT2B10 did not conjugate the tertiary cyclic amine in trifluoperazine"}
{"PMID":23611809,"re_id":10,"annotated sentence":"Recent observations revealed that <e2>human UDP-glucuronosyltransferase (UGT) 2B10<\\e2> catalyzes N-glucuronidation of <e1>amine<\\e1> containing compounds","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"amine","object":"human UDP-glucuronosyltransferase (UGT) 2B10","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Recent observations revealed that <e2>GENE-Y<\\e2> catalyzes N-glucuronidation of <e1>CHEMICAL<\\e1> containing compounds","sentence":"Recent observations revealed that human UDP-glucuronosyltransferase (UGT) 2B10 catalyzes N-glucuronidation of amine containing compounds"}
{"PMID":23611809,"re_id":11,"annotated sentence":"Kinetic analyses revealed that the affinity and clearance of <e2>UGT2B10<\\e2> for <e1>amitriptyline<\\e1>  imipramine, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"amitriptyline","object":"UGT2B10","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Kinetic analyses revealed that the affinity and clearance of <e2>GENE-Y<\\e2> for <e1>CHEMICAL<\\e1>  imipramine, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher","sentence":"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline  imipramine, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher"}
{"PMID":23611809,"re_id":12,"annotated sentence":"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for <e1>amitriptyline<\\e1>  imipramine, and diphenhydramine are significantly higher than the corresponding values of <e2>UGT1A4<\\e2> and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"amitriptyline","object":"UGT1A4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for <e1>CHEMICAL<\\e1>  imipramine, and diphenhydramine are significantly higher than the corresponding values of <e2>GENE-Y<\\e2> and UGT1A3, although the Vmax values of GENE-Y toward these drugs are considerably higher","sentence":"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline  imipramine, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher"}
{"PMID":23611809,"re_id":13,"annotated sentence":"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for <e1>amitriptyline<\\e1>  imipramine, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of <e2>UGT1A4<\\e2> toward these drugs are considerably higher","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"amitriptyline","object":"UGT1A4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for <e1>CHEMICAL<\\e1>  imipramine, and diphenhydramine are significantly higher than the corresponding values of GENE-Y and UGT1A3, although the Vmax values of <e2>GENE-Y<\\e2> toward these drugs are considerably higher","sentence":"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline  imipramine, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher"}
{"PMID":23611809,"re_id":14,"annotated sentence":"Kinetic analyses revealed that the affinity and clearance of <e2>UGT2B10<\\e2> for amitriptyline, <e1>imipramine<\\e1>  and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"imipramine","object":"UGT2B10","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Kinetic analyses revealed that the affinity and clearance of <e2>GENE-Y<\\e2> for amitriptyline, <e1>CHEMICAL<\\e1>  and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher","sentence":"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine  and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher"}
{"PMID":23611809,"re_id":15,"annotated sentence":"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, <e1>imipramine<\\e1>  and diphenhydramine are significantly higher than the corresponding values of <e2>UGT1A4<\\e2> and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"imipramine","object":"UGT1A4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, <e1>CHEMICAL<\\e1>  and diphenhydramine are significantly higher than the corresponding values of <e2>GENE-Y<\\e2> and UGT1A3, although the Vmax values of GENE-Y toward these drugs are considerably higher","sentence":"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine  and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher"}
{"PMID":23611809,"re_id":16,"annotated sentence":"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, <e1>imipramine<\\e1>  and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and <e2>UGT1A3<\\e2>  although the Vmax values of UGT1A4 toward these drugs are considerably higher","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"imipramine","object":"UGT1A3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, <e1>CHEMICAL<\\e1>  and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and <e2>GENE-Y<\\e2>  although the Vmax values of UGT1A4 toward these drugs are considerably higher","sentence":"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine  and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3  although the Vmax values of UGT1A4 toward these drugs are considerably higher"}
{"PMID":23611809,"re_id":17,"annotated sentence":"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, <e1>imipramine<\\e1>  and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of <e2>UGT1A4<\\e2> toward these drugs are considerably higher","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"imipramine","object":"UGT1A4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, <e1>CHEMICAL<\\e1>  and diphenhydramine are significantly higher than the corresponding values of GENE-Y and UGT1A3, although the Vmax values of <e2>GENE-Y<\\e2> toward these drugs are considerably higher","sentence":"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine  and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher"}
{"PMID":23611809,"re_id":18,"annotated sentence":"Kinetic analyses revealed that the affinity and clearance of <e2>UGT2B10<\\e2> for amitriptyline, imipramine, and <e1>diphenhydramine<\\e1> are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"diphenhydramine","object":"UGT2B10","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Kinetic analyses revealed that the affinity and clearance of <e2>GENE-Y<\\e2> for amitriptyline, imipramine, and <e1>CHEMICAL<\\e1> are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher","sentence":"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher"}
{"PMID":23611809,"re_id":19,"annotated sentence":"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and <e1>diphenhydramine<\\e1> are significantly higher than the corresponding values of <e2>UGT1A4<\\e2> and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"diphenhydramine","object":"UGT1A4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and <e1>CHEMICAL<\\e1> are significantly higher than the corresponding values of <e2>GENE-Y<\\e2> and UGT1A3, although the Vmax values of GENE-Y toward these drugs are considerably higher","sentence":"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher"}
{"PMID":23611809,"re_id":20,"annotated sentence":"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and <e1>diphenhydramine<\\e1> are significantly higher than the corresponding values of UGT1A4 and <e2>UGT1A3<\\e2>  although the Vmax values of UGT1A4 toward these drugs are considerably higher","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"diphenhydramine","object":"UGT1A3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and <e1>CHEMICAL<\\e1> are significantly higher than the corresponding values of UGT1A4 and <e2>GENE-Y<\\e2>  although the Vmax values of UGT1A4 toward these drugs are considerably higher","sentence":"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3  although the Vmax values of UGT1A4 toward these drugs are considerably higher"}
{"PMID":23611809,"re_id":21,"annotated sentence":"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and <e1>diphenhydramine<\\e1> are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of <e2>UGT1A4<\\e2> toward these drugs are considerably higher","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"diphenhydramine","object":"UGT1A4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and <e1>CHEMICAL<\\e1> are significantly higher than the corresponding values of GENE-Y and UGT1A3, although the Vmax values of <e2>GENE-Y<\\e2> toward these drugs are considerably higher","sentence":"Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher"}
{"PMID":23611809,"re_id":22,"annotated sentence":"In conclusion, this study expands the understanding of the substrate specificity of <e2>UGT2B10<\\e2>  highlighting its preference for <e1>tertiary amines<\\e1> with higher affinities and clearance values than those of UGT1A4 and UGT1A3.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"tertiary amines","object":"UGT2B10","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, this study expands the understanding of the substrate specificity of <e2>GENE-Y<\\e2>  highlighting its preference for <e1>CHEMICAL<\\e1> with higher affinities and clearance values than those of UGT1A4 and UGT1A3.","sentence":"In conclusion, this study expands the understanding of the substrate specificity of UGT2B10  highlighting its preference for tertiary amines with higher affinities and clearance values than those of UGT1A4 and UGT1A3."}
{"PMID":23611809,"re_id":23,"annotated sentence":"In conclusion, this study expands the understanding of the substrate specificity of UGT2B10, highlighting its preference for <e1>tertiary amines<\\e1> with higher affinities and clearance values than those of <e2>UGT1A4<\\e2> and UGT1A3.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"tertiary amines","object":"UGT1A4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, this study expands the understanding of the substrate specificity of UGT2B10, highlighting its preference for <e1>CHEMICAL<\\e1> with higher affinities and clearance values than those of <e2>GENE-Y<\\e2> and UGT1A3.","sentence":"In conclusion, this study expands the understanding of the substrate specificity of UGT2B10, highlighting its preference for tertiary amines with higher affinities and clearance values than those of UGT1A4 and UGT1A3."}
{"PMID":23611809,"re_id":24,"annotated sentence":"In conclusion, this study expands the understanding of the substrate specificity of UGT2B10, highlighting its preference for <e1>tertiary amines<\\e1> with higher affinities and clearance values than those of UGT1A4 and <e2>UGT1A3<\\e2> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"tertiary amines","object":"UGT1A3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, this study expands the understanding of the substrate specificity of UGT2B10, highlighting its preference for <e1>CHEMICAL<\\e1> with higher affinities and clearance values than those of UGT1A4 and <e2>GENE-Y<\\e2> ","sentence":"In conclusion, this study expands the understanding of the substrate specificity of UGT2B10, highlighting its preference for tertiary amines with higher affinities and clearance values than those of UGT1A4 and UGT1A3 "}
{"PMID":23611835,"re_id":0,"annotated sentence":"<e1>SB225002<\\e1> (SB) is an IL-8 receptor B (IL-8RB) antagonist that has previously been shown to inhibit <e2>IL-8<\\e2> based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SB225002","object":"IL-8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (SB) is an GENE-Y receptor B (GENE-YRB) antagonist that has previously been shown to inhibit <e2>GENE-Y<\\e2> based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects","sentence":"SB225002 (SB) is an IL-8 receptor B (IL-8RB) antagonist that has previously been shown to inhibit IL-8 based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects"}
{"PMID":23611835,"re_id":1,"annotated sentence":"<e1>SB225002<\\e1> (SB) is an <e2>IL-8 receptor B<\\e2> (IL-8RB) antagonist that has previously been shown to inhibit IL-8-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"SB225002","object":"IL-8 receptor B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (SB) is an <e2>GENE-Y<\\e2> (IL-8RB) antagonist that has previously been shown to inhibit IL-8-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects","sentence":"SB225002 (SB) is an IL-8 receptor B (IL-8RB) antagonist that has previously been shown to inhibit IL-8-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects"}
{"PMID":23611835,"re_id":2,"annotated sentence":"<e1>SB225002<\\e1> (SB) is an IL-8 receptor B (<e2>IL-8RB<\\e2>  antagonist that has previously been shown to inhibit IL-8-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"SB225002","object":"IL-8RB","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (SB) is an IL-8 receptor B (<e2>GENE-Y<\\e2>  antagonist that has previously been shown to inhibit IL-8-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects","sentence":"SB225002 (SB) is an IL-8 receptor B (IL-8RB  antagonist that has previously been shown to inhibit IL-8-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects"}
{"PMID":23611835,"re_id":3,"annotated sentence":"Of note, <e1>SB265610<\\e1> which is a close structural analogue of SB225002 with a potent <e2>IL-8RB<\\e2> antagonistic activity did not exhibit a similar antimitotic activity","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"SB265610","object":"IL-8RB","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Of note, <e1>CHEMICAL<\\e1> which is a close structural analogue of SB225002 with a potent <e2>GENE-Y<\\e2> antagonistic activity did not exhibit a similar antimitotic activity","sentence":"Of note, SB265610 which is a close structural analogue of SB225002 with a potent IL-8RB antagonistic activity did not exhibit a similar antimitotic activity"}
{"PMID":23611835,"re_id":4,"annotated sentence":"Of note, SB265610 which is a close structural analogue of <e1>SB225002<\\e1> with a potent <e2>IL-8RB<\\e2> antagonistic activity did not exhibit a similar antimitotic activity","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"SB225002","object":"IL-8RB","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Of note, SB265610 which is a close structural analogue of <e1>CHEMICAL<\\e1> with a potent <e2>GENE-Y<\\e2> antagonistic activity did not exhibit a similar antimitotic activity","sentence":"Of note, SB265610 which is a close structural analogue of SB225002 with a potent IL-8RB antagonistic activity did not exhibit a similar antimitotic activity"}
{"PMID":23614643,"re_id":0,"annotated sentence":"In support of this observation, elongation can be reversed by the <e2>tyrosine kinase<\\e2> inhibitor <e1>SU5402<\\e1>  mRNA for the FGFR antagonist sprouty4, or FGF8 morpholino","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SU5402","object":"tyrosine kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In support of this observation, elongation can be reversed by the <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1>  mRNA for the FGFR antagonist sprouty4, or FGF8 morpholino","sentence":"In support of this observation, elongation can be reversed by the tyrosine kinase inhibitor SU5402  mRNA for the FGFR antagonist sprouty4, or FGF8 morpholino"}
{"PMID":23615471,"re_id":0,"annotated sentence":"Treatment with <e1>CAPE<\\e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor <e2>p27Kip<\\e2>  Overexpression of Akt1 or Akt2 in TW2.6 cells rescued growth inhibition caused by CAPE treatment","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CAPE","object":"p27Kip","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor <e2>GENE-Y<\\e2>  Overexpression of Akt1 or Akt2 in TW2.6 cells rescued growth inhibition caused by CHEMICAL treatment","sentence":"Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip  Overexpression of Akt1 or Akt2 in TW2.6 cells rescued growth inhibition caused by CAPE treatment"}
{"PMID":23615471,"re_id":1,"annotated sentence":"<e1>Caffeic Acid Phenethyl Ester<\\e1> Suppresses Proliferation and Survival of TW2.6 Human Oral Cancer Cells via Inhibition of <e2>Akt<\\e2> Signaling","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Caffeic Acid Phenethyl Ester","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> Suppresses Proliferation and Survival of TW2.6 Human Oral Cancer Cells via Inhibition of <e2>GENE-N<\\e2> Signaling","sentence":"Caffeic Acid Phenethyl Ester Suppresses Proliferation and Survival of TW2.6 Human Oral Cancer Cells via Inhibition of Akt Signaling"}
{"PMID":23615471,"re_id":2,"annotated sentence":"Treatment with <e1>CAPE<\\e1> decreased protein abundance of <e2>Akt<\\e2>  Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CAPE","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> decreased protein abundance of <e2>GENE-N<\\e2>  GENE-N1, GENE-N2, GENE-N3, phospho-GENE-N Ser473, phospho-GENE-N Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip","sentence":"Treatment with CAPE decreased protein abundance of Akt  Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip"}
{"PMID":23615471,"re_id":3,"annotated sentence":"Treatment with <e1>CAPE<\\e1> decreased protein abundance of Akt, <e2>Akt1<\\e2>  Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CAPE","object":"Akt1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> decreased protein abundance of Akt, <e2>GENE-Y<\\e2>  Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip","sentence":"Treatment with CAPE decreased protein abundance of Akt, Akt1  Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip"}
{"PMID":23615471,"re_id":4,"annotated sentence":"Treatment with <e1>CAPE<\\e1> decreased protein abundance of Akt, Akt1, <e2>Akt2<\\e2>  Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CAPE","object":"Akt2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> decreased protein abundance of Akt, Akt1, <e2>GENE-Y<\\e2>  Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip","sentence":"Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2  Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip"}
{"PMID":23615471,"re_id":5,"annotated sentence":"Treatment with <e1>CAPE<\\e1> decreased protein abundance of Akt, Akt1, Akt2, <e2>Akt3<\\e2>  phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CAPE","object":"Akt3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> decreased protein abundance of Akt, Akt1, Akt2, <e2>GENE-Y<\\e2>  phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip","sentence":"Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3  phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip"}
{"PMID":23615471,"re_id":6,"annotated sentence":"Treatment with <e1>CAPE<\\e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, <e2>phospho-Akt<\\e2> Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CAPE","object":"phospho-Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, <e2>GENE-N<\\e2> Ser473, GENE-N Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip","sentence":"Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip"}
{"PMID":23615471,"re_id":7,"annotated sentence":"Treatment with <e1>CAPE<\\e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, <e2>phospho-Akt<\\e2> Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CAPE","object":"phospho-Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, GENE-N Ser473, <e2>GENE-N<\\e2> Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip","sentence":"Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip"}
{"PMID":23615471,"re_id":8,"annotated sentence":"Treatment with <e1>CAPE<\\e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, <e2>GSK3\u03b2<\\e2>  FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CAPE","object":"GSK3\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, <e2>GENE-Y<\\e2>  FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip","sentence":"Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2  FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip"}
{"PMID":23615471,"re_id":9,"annotated sentence":"Treatment with <e1>CAPE<\\e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, <e2>FOXO1<\\e2>  FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CAPE","object":"FOXO1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, <e2>GENE-Y<\\e2>  FOXO3a, phospho-GENE-Y Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip","sentence":"Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1  FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip"}
{"PMID":23615471,"re_id":10,"annotated sentence":"Treatment with <e1>CAPE<\\e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, <e2>FOXO3a<\\e2>  phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CAPE","object":"FOXO3a","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, <e2>GENE-Y<\\e2>  phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip","sentence":"Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a  phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip"}
{"PMID":23615471,"re_id":11,"annotated sentence":"Treatment with <e1>CAPE<\\e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, <e2>phospho-FOXO1<\\e2> Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CAPE","object":"phospho-FOXO1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, <e2>GENE-Y<\\e2> Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip","sentence":"Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip"}
{"PMID":23615471,"re_id":12,"annotated sentence":"Treatment with <e1>CAPE<\\e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, <e2>phospho-FoxO3a<\\e2> Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CAPE","object":"phospho-FoxO3a","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, <e2>GENE-Y<\\e2> Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip","sentence":"Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip"}
{"PMID":23615471,"re_id":13,"annotated sentence":"Treatment with <e1>CAPE<\\e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, <e2>NF-\u03baB<\\e2>  phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CAPE","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, <e2>GENE-N<\\e2>  phospho-GENE-N Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip","sentence":"Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB  phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip"}
{"PMID":23615471,"re_id":14,"annotated sentence":"Treatment with <e1>CAPE<\\e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, <e2>phospho-NF-\u03baB<\\e2> Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CAPE","object":"phospho-NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, <e2>GENE-N<\\e2> Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip","sentence":"Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip"}
{"PMID":23615471,"re_id":15,"annotated sentence":"Treatment with <e1>CAPE<\\e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, <e2>Rb<\\e2>  phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CAPE","object":"Rb","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, <e2>GENE-Y<\\e2>  phospho-GENE-Y Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip","sentence":"Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb  phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip"}
{"PMID":23615471,"re_id":16,"annotated sentence":"Treatment with <e1>CAPE<\\e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, <e2>phospho-Rb<\\e2> Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CAPE","object":"phospho-Rb","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, <e2>GENE-Y<\\e2> Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip","sentence":"Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip"}
{"PMID":23615471,"re_id":17,"annotated sentence":"Treatment with <e1>CAPE<\\e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, <e2>Skp2<\\e2>  and cyclin D1, but increased cell cycle inhibitor p27Kip","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CAPE","object":"Skp2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, <e2>GENE-Y<\\e2>  and cyclin D1, but increased cell cycle inhibitor p27Kip","sentence":"Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2  and cyclin D1, but increased cell cycle inhibitor p27Kip"}
{"PMID":23615471,"re_id":18,"annotated sentence":"Treatment with <e1>CAPE<\\e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and <e2>cyclin D1<\\e2>  but increased cell cycle inhibitor p27Kip","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CAPE","object":"cyclin D1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and <e2>GENE-Y<\\e2>  but increased cell cycle inhibitor p27Kip","sentence":"Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807\/811, Skp2, and cyclin D1  but increased cell cycle inhibitor p27Kip"}
{"PMID":23618921,"re_id":0,"annotated sentence":"Here we show that <e1>fisetin<\\e1> rapidly increases the levels of both <e2>Nrf2<\\e2> and ATF4 as well as Nrf2- and ATF4-dependent gene transcription via distinct mechanisms","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"fisetin","object":"Nrf2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here we show that <e1>CHEMICAL<\\e1> rapidly increases the levels of both <e2>GENE-Y<\\e2> and ATF4 as well as GENE-Y- and ATF4-dependent gene transcription via distinct mechanisms","sentence":"Here we show that fisetin rapidly increases the levels of both Nrf2 and ATF4 as well as Nrf2- and ATF4-dependent gene transcription via distinct mechanisms"}
{"PMID":23618921,"re_id":1,"annotated sentence":"Here we show that <e1>fisetin<\\e1> rapidly increases the levels of both Nrf2 and <e2>ATF4<\\e2> as well as Nrf2- and ATF4-dependent gene transcription via distinct mechanisms","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"fisetin","object":"ATF4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here we show that <e1>CHEMICAL<\\e1> rapidly increases the levels of both Nrf2 and <e2>GENE-Y<\\e2> as well as Nrf2- and GENE-Y-dependent gene transcription via distinct mechanisms","sentence":"Here we show that fisetin rapidly increases the levels of both Nrf2 and ATF4 as well as Nrf2- and ATF4-dependent gene transcription via distinct mechanisms"}
{"PMID":23618921,"re_id":2,"annotated sentence":"Here we show that <e1>fisetin<\\e1> rapidly increases the levels of both Nrf2 and ATF4 as well as <e2>Nrf2<\\e2>  and ATF4-dependent gene transcription via distinct mechanisms","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"fisetin","object":"Nrf2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here we show that <e1>CHEMICAL<\\e1> rapidly increases the levels of both GENE-Y and ATF4 as well as <e2>GENE-Y<\\e2>  and ATF4-dependent gene transcription via distinct mechanisms","sentence":"Here we show that fisetin rapidly increases the levels of both Nrf2 and ATF4 as well as Nrf2  and ATF4-dependent gene transcription via distinct mechanisms"}
{"PMID":23618921,"re_id":3,"annotated sentence":"Here we show that <e1>fisetin<\\e1> rapidly increases the levels of both Nrf2 and ATF4 as well as Nrf2- and <e2>ATF4<\\e2> dependent gene transcription via distinct mechanisms","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"fisetin","object":"ATF4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here we show that <e1>CHEMICAL<\\e1> rapidly increases the levels of both Nrf2 and GENE-Y as well as Nrf2- and <e2>GENE-Y<\\e2> dependent gene transcription via distinct mechanisms","sentence":"Here we show that fisetin rapidly increases the levels of both Nrf2 and ATF4 as well as Nrf2- and ATF4 dependent gene transcription via distinct mechanisms"}
{"PMID":23618921,"re_id":4,"annotated sentence":"Although <e1>fisetin<\\e1> greatly increases the stability of both <e2>Nrf2<\\e2> and ATF4, only the effect on ATF4 is dependent on protein kinase activity","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"fisetin","object":"Nrf2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although <e1>CHEMICAL<\\e1> greatly increases the stability of both <e2>GENE-Y<\\e2> and ATF4, only the effect on ATF4 is dependent on protein kinase activity","sentence":"Although fisetin greatly increases the stability of both Nrf2 and ATF4, only the effect on ATF4 is dependent on protein kinase activity"}
{"PMID":23618921,"re_id":5,"annotated sentence":"Although <e1>fisetin<\\e1> greatly increases the stability of both Nrf2 and <e2>ATF4<\\e2>  only the effect on ATF4 is dependent on protein kinase activity","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"fisetin","object":"ATF4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although <e1>CHEMICAL<\\e1> greatly increases the stability of both Nrf2 and <e2>GENE-Y<\\e2>  only the effect on GENE-Y is dependent on protein kinase activity","sentence":"Although fisetin greatly increases the stability of both Nrf2 and ATF4  only the effect on ATF4 is dependent on protein kinase activity"}
{"PMID":23623750,"re_id":0,"annotated sentence":"<e2>Cynomolgus FMO1<\\e2>  FMO2, FMO3, and FMO5 metabolized <e1>benzydamine<\\e1>  and FMO1\/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"benzydamine","object":"Cynomolgus FMO1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2>  FMO2, FMO3, and FMO5 metabolized <e1>CHEMICAL<\\e1>  and FMO1\/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively","sentence":"Cynomolgus FMO1  FMO2, FMO3, and FMO5 metabolized benzydamine  and FMO1\/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively"}
{"PMID":23623750,"re_id":1,"annotated sentence":"Cynomolgus FMO1, <e2>FMO2<\\e2>  FMO3, and FMO5 metabolized <e1>benzydamine<\\e1>  and FMO1\/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"benzydamine","object":"FMO2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cynomolgus FMO1, <e2>GENE-Y<\\e2>  FMO3, and FMO5 metabolized <e1>CHEMICAL<\\e1>  and FMO1\/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively","sentence":"Cynomolgus FMO1, FMO2  FMO3, and FMO5 metabolized benzydamine  and FMO1\/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively"}
{"PMID":23623750,"re_id":2,"annotated sentence":"Cynomolgus FMO1, FMO2, <e2>FMO3<\\e2>  and FMO5 metabolized <e1>benzydamine<\\e1>  and FMO1\/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"benzydamine","object":"FMO3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cynomolgus FMO1, FMO2, <e2>GENE-Y<\\e2>  and FMO5 metabolized <e1>CHEMICAL<\\e1>  and FMO1\/GENE-Y and GENE-Y also metabolized methimazole and trimethylamine, respectively","sentence":"Cynomolgus FMO1, FMO2, FMO3  and FMO5 metabolized benzydamine  and FMO1\/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively"}
{"PMID":23623750,"re_id":3,"annotated sentence":"Cynomolgus FMO1, FMO2, FMO3, and <e2>FMO5<\\e2> metabolized <e1>benzydamine<\\e1>  and FMO1\/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"benzydamine","object":"FMO5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cynomolgus FMO1, FMO2, FMO3, and <e2>GENE-Y<\\e2> metabolized <e1>CHEMICAL<\\e1>  and FMO1\/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively","sentence":"Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized benzydamine  and FMO1\/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively"}
{"PMID":23623750,"re_id":4,"annotated sentence":"Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized benzydamine, and <e2>FMO1<\\e2> FMO3 and FMO3 also metabolized <e1>methimazole<\\e1> and trimethylamine, respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"methimazole","object":"FMO1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cynomolgus GENE-Y, FMO2, FMO3, and FMO5 metabolized benzydamine, and <e2>GENE-Y<\\e2> FMO3 and FMO3 also metabolized <e1>CHEMICAL<\\e1> and trimethylamine, respectively","sentence":"Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized benzydamine, and FMO1 FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively"}
{"PMID":23623750,"re_id":5,"annotated sentence":"Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized benzydamine, and FMO1\/<e2>FMO3<\\e2> and FMO3 also metabolized <e1>methimazole<\\e1> and trimethylamine, respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"methimazole","object":"FMO3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cynomolgus FMO1, FMO2, GENE-Y, and FMO5 metabolized benzydamine, and FMO1\/<e2>GENE-Y<\\e2> and GENE-Y also metabolized <e1>CHEMICAL<\\e1> and trimethylamine, respectively","sentence":"Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized benzydamine, and FMO1\/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively"}
{"PMID":23623750,"re_id":6,"annotated sentence":"Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized benzydamine, and FMO1\/FMO3 and <e2>FMO3<\\e2> also metabolized <e1>methimazole<\\e1> and trimethylamine, respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"methimazole","object":"FMO3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cynomolgus FMO1, FMO2, GENE-Y, and FMO5 metabolized benzydamine, and FMO1\/GENE-Y and <e2>GENE-Y<\\e2> also metabolized <e1>CHEMICAL<\\e1> and trimethylamine, respectively","sentence":"Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized benzydamine, and FMO1\/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively"}
{"PMID":23623750,"re_id":7,"annotated sentence":"Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized benzydamine, and <e2>FMO1<\\e2> FMO3 and FMO3 also metabolized methimazole and <e1>trimethylamine<\\e1>  respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"trimethylamine","object":"FMO1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cynomolgus GENE-Y, FMO2, FMO3, and FMO5 metabolized benzydamine, and <e2>GENE-Y<\\e2> FMO3 and FMO3 also metabolized methimazole and <e1>CHEMICAL<\\e1>  respectively","sentence":"Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized benzydamine, and FMO1 FMO3 and FMO3 also metabolized methimazole and trimethylamine  respectively"}
{"PMID":23623750,"re_id":8,"annotated sentence":"Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized benzydamine, and FMO1\/<e2>FMO3<\\e2> and FMO3 also metabolized methimazole and <e1>trimethylamine<\\e1>  respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"trimethylamine","object":"FMO3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cynomolgus FMO1, FMO2, GENE-Y, and FMO5 metabolized benzydamine, and FMO1\/<e2>GENE-Y<\\e2> and GENE-Y also metabolized methimazole and <e1>CHEMICAL<\\e1>  respectively","sentence":"Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized benzydamine, and FMO1\/FMO3 and FMO3 also metabolized methimazole and trimethylamine  respectively"}
{"PMID":23623750,"re_id":9,"annotated sentence":"Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized benzydamine, and FMO1\/FMO3 and <e2>FMO3<\\e2> also metabolized methimazole and <e1>trimethylamine<\\e1>  respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"trimethylamine","object":"FMO3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cynomolgus FMO1, FMO2, GENE-Y, and FMO5 metabolized benzydamine, and FMO1\/GENE-Y and <e2>GENE-Y<\\e2> also metabolized methimazole and <e1>CHEMICAL<\\e1>  respectively","sentence":"Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized benzydamine, and FMO1\/FMO3 and FMO3 also metabolized methimazole and trimethylamine  respectively"}
{"PMID":23623750,"re_id":10,"annotated sentence":"Rates of <e1>benzydamine<\\e1> N-oxygenation (catalyzed by <e2>FMO3<\\e2>  varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in benzydamine N-oxygenation might be partly accounted for by the variable FMO3 expression","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"benzydamine","object":"FMO3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Rates of <e1>CHEMICAL<\\e1> N-oxygenation (catalyzed by <e2>GENE-Y<\\e2>  varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with GENE-Y protein expression, indicating that the inter-animal variations in CHEMICAL N-oxygenation might be partly accounted for by the variable GENE-Y expression","sentence":"Rates of benzydamine N-oxygenation (catalyzed by FMO3  varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in benzydamine N-oxygenation might be partly accounted for by the variable FMO3 expression"}
{"PMID":23623750,"re_id":11,"annotated sentence":"Rates of benzydamine <e1>N<\\e1> oxygenation (catalyzed by <e2>FMO3<\\e2>  varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in benzydamine N-oxygenation might be partly accounted for by the variable FMO3 expression","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"N","object":"FMO3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Rates of benzydamine <e1>CHEMICAL<\\e1> oxygenation (catalyzed by <e2>GENE-Y<\\e2>  varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with GENE-Y protein expression, indicating that the inter-animal variations in benzydamine CHEMICAL-oxygenation might be partly accounted for by the variable GENE-Y expression","sentence":"Rates of benzydamine N oxygenation (catalyzed by FMO3  varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in benzydamine N-oxygenation might be partly accounted for by the variable FMO3 expression"}
{"PMID":23623750,"re_id":12,"annotated sentence":"Rates of benzydamine N-oxygenation (catalyzed by FMO3) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in <e1>benzydamine<\\e1> N-oxygenation might be partly accounted for by the variable <e2>FMO3<\\e2> expression","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"benzydamine","object":"FMO3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Rates of CHEMICAL N-oxygenation (catalyzed by GENE-Y) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with GENE-Y protein expression, indicating that the inter-animal variations in <e1>CHEMICAL<\\e1> N-oxygenation might be partly accounted for by the variable <e2>GENE-Y<\\e2> expression","sentence":"Rates of benzydamine N-oxygenation (catalyzed by FMO3) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in benzydamine N-oxygenation might be partly accounted for by the variable FMO3 expression"}
{"PMID":23623750,"re_id":13,"annotated sentence":"Rates of benzydamine N-oxygenation (catalyzed by FMO3) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in benzydamine <e1>N<\\e1> oxygenation might be partly accounted for by the variable <e2>FMO3<\\e2> expression","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"N","object":"FMO3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Rates of benzydamine CHEMICAL-oxygenation (catalyzed by GENE-Y) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with GENE-Y protein expression, indicating that the inter-animal variations in benzydamine <e1>CHEMICAL<\\e1> oxygenation might be partly accounted for by the variable <e2>GENE-Y<\\e2> expression","sentence":"Rates of benzydamine N-oxygenation (catalyzed by FMO3) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in benzydamine N oxygenation might be partly accounted for by the variable FMO3 expression"}
{"PMID":23623750,"re_id":14,"annotated sentence":"<e2>Cynomolgus FMO6<\\e2> metabolized <e1>benzydamine<\\e1> only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, FMO2, FMO3, and FMO5 which were all functional","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"benzydamine","object":"Cynomolgus FMO6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> metabolized <e1>CHEMICAL<\\e1> only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, FMO2, FMO3, and FMO5 which were all functional","sentence":"Cynomolgus FMO6 metabolized benzydamine only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, FMO2, FMO3, and FMO5 which were all functional"}
{"PMID":23623750,"re_id":15,"annotated sentence":"Cynomolgus FMO6 metabolized <e1>benzydamine<\\e1> only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus <e2>FMO1<\\e2>  FMO2, FMO3, and FMO5 which were all functional","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"benzydamine","object":"FMO1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cynomolgus FMO6 metabolized <e1>CHEMICAL<\\e1> only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus <e2>GENE-Y<\\e2>  FMO2, FMO3, and FMO5 which were all functional","sentence":"Cynomolgus FMO6 metabolized benzydamine only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1  FMO2, FMO3, and FMO5 which were all functional"}
{"PMID":23623750,"re_id":16,"annotated sentence":"Cynomolgus FMO6 metabolized <e1>benzydamine<\\e1> only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, <e2>FMO2<\\e2>  FMO3, and FMO5 which were all functional","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"benzydamine","object":"FMO2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cynomolgus FMO6 metabolized <e1>CHEMICAL<\\e1> only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, <e2>GENE-Y<\\e2>  FMO3, and FMO5 which were all functional","sentence":"Cynomolgus FMO6 metabolized benzydamine only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, FMO2  FMO3, and FMO5 which were all functional"}
{"PMID":23623750,"re_id":17,"annotated sentence":"Cynomolgus FMO6 metabolized <e1>benzydamine<\\e1> only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, FMO2, <e2>FMO3<\\e2>  and FMO5 which were all functional","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"benzydamine","object":"FMO3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cynomolgus FMO6 metabolized <e1>CHEMICAL<\\e1> only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, FMO2, <e2>GENE-Y<\\e2>  and FMO5 which were all functional","sentence":"Cynomolgus FMO6 metabolized benzydamine only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, FMO2, FMO3  and FMO5 which were all functional"}
{"PMID":23623750,"re_id":18,"annotated sentence":"Cynomolgus FMO6 metabolized <e1>benzydamine<\\e1> only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, FMO2, FMO3, and <e2>FMO5<\\e2> which were all functional","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"benzydamine","object":"FMO5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cynomolgus FMO6 metabolized <e1>CHEMICAL<\\e1> only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, FMO2, FMO3, and <e2>GENE-Y<\\e2> which were all functional","sentence":"Cynomolgus FMO6 metabolized benzydamine only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, FMO2, FMO3, and FMO5 which were all functional"}
{"PMID":23625915,"re_id":0,"annotated sentence":"Activation of <e2>AMPK<\\e2> using <e1>AICAR<\\e1> resulted in STIM1 phosphorylation on serine residues and prevented PAR-1-induced Ca2+ entry","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"AICAR","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Activation of <e2>GENE-Y<\\e2> using <e1>CHEMICAL<\\e1> resulted in STIM1 phosphorylation on serine residues and prevented PAR-1-induced Ca2+ entry","sentence":"Activation of AMPK using AICAR resulted in STIM1 phosphorylation on serine residues and prevented PAR-1-induced Ca2+ entry"}
{"PMID":23625915,"re_id":1,"annotated sentence":"Activation of AMPK using <e1>AICAR<\\e1> resulted in <e2>STIM1<\\e2> phosphorylation on serine residues and prevented PAR-1-induced Ca2+ entry","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"AICAR","object":"STIM1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Activation of AMPK using <e1>CHEMICAL<\\e1> resulted in <e2>GENE-Y<\\e2> phosphorylation on serine residues and prevented PAR-1-induced Ca2+ entry","sentence":"Activation of AMPK using AICAR resulted in STIM1 phosphorylation on serine residues and prevented PAR-1-induced Ca2+ entry"}
{"PMID":23625915,"re_id":2,"annotated sentence":"Activation of AMPK using <e1>AICAR<\\e1> resulted in STIM1 phosphorylation on serine residues and prevented <e2>PAR-1<\\e2> induced Ca2+ entry","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"AICAR","object":"PAR-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Activation of AMPK using <e1>CHEMICAL<\\e1> resulted in STIM1 phosphorylation on serine residues and prevented <e2>GENE-Y<\\e2> induced Ca2+ entry","sentence":"Activation of AMPK using AICAR resulted in STIM1 phosphorylation on serine residues and prevented PAR-1 induced Ca2+ entry"}
{"PMID":23625915,"re_id":3,"annotated sentence":"Further, <e1>AICAR<\\e1> pretreatment blocked <e2>PAR-1<\\e2> induced increase in permeability of mouse-lung microvessels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"AICAR","object":"PAR-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Further, <e1>CHEMICAL<\\e1> pretreatment blocked <e2>GENE-Y<\\e2> induced increase in permeability of mouse-lung microvessels","sentence":"Further, AICAR pretreatment blocked PAR-1 induced increase in permeability of mouse-lung microvessels"}
{"PMID":23625915,"re_id":4,"annotated sentence":"Interestingly, <e1>SB203580<\\e1>  a selective inhibitor of <e2>p38<\\e2> MAPK, blocked STIM1 phosphorylation and led to sustained STIM1-puncta formation and Ca2+ entry","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SB203580","object":"p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Interestingly, <e1>CHEMICAL<\\e1>  a selective inhibitor of <e2>GENE-N<\\e2> MAPK, blocked STIM1 phosphorylation and led to sustained STIM1-puncta formation and Ca2+ entry","sentence":"Interestingly, SB203580  a selective inhibitor of p38 MAPK, blocked STIM1 phosphorylation and led to sustained STIM1-puncta formation and Ca2+ entry"}
{"PMID":23625915,"re_id":5,"annotated sentence":"Interestingly, <e1>SB203580<\\e1>  a selective inhibitor of p38 <e2>MAPK<\\e2>  blocked STIM1 phosphorylation and led to sustained STIM1-puncta formation and Ca2+ entry","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SB203580","object":"MAPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Interestingly, <e1>CHEMICAL<\\e1>  a selective inhibitor of p38 <e2>GENE-N<\\e2>  blocked STIM1 phosphorylation and led to sustained STIM1-puncta formation and Ca2+ entry","sentence":"Interestingly, SB203580  a selective inhibitor of p38 MAPK  blocked STIM1 phosphorylation and led to sustained STIM1-puncta formation and Ca2+ entry"}
{"PMID":23625915,"re_id":6,"annotated sentence":"Interestingly, <e1>SB203580<\\e1>  a selective inhibitor of p38 MAPK, blocked <e2>STIM1<\\e2> phosphorylation and led to sustained STIM1-puncta formation and Ca2+ entry","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SB203580","object":"STIM1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, <e1>CHEMICAL<\\e1>  a selective inhibitor of p38 MAPK, blocked <e2>GENE-Y<\\e2> phosphorylation and led to sustained GENE-Y-puncta formation and Ca2+ entry","sentence":"Interestingly, SB203580  a selective inhibitor of p38 MAPK, blocked STIM1 phosphorylation and led to sustained STIM1-puncta formation and Ca2+ entry"}
{"PMID":23628605,"re_id":0,"annotated sentence":"The precise fashion in which these proteins interact and move <e1>cholesterol<\\e1> from the OMM to <e2>P450scc<\\e2>  and the means by which cholesterol is loaded into the OMM, remain unclear","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cholesterol","object":"P450scc","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The precise fashion in which these proteins interact and move <e1>CHEMICAL<\\e1> from the OMM to <e2>GENE-Y<\\e2>  and the means by which CHEMICAL is loaded into the OMM, remain unclear","sentence":"The precise fashion in which these proteins interact and move cholesterol from the OMM to P450scc  and the means by which cholesterol is loaded into the OMM, remain unclear"}
{"PMID":23628605,"re_id":1,"annotated sentence":"Mitochondria in the steroidogenic cells of the adrenal, gonad, placenta and brain contain the <e1>cholesterol<\\e1> side-chain cleavage enzyme, <e2>P450scc<\\e2>  and its two electron-transfer partners, ferredoxin reductase and ferredoxin","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cholesterol","object":"P450scc","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Mitochondria in the steroidogenic cells of the adrenal, gonad, placenta and brain contain the <e1>CHEMICAL<\\e1> side-chain cleavage enzyme, <e2>GENE-Y<\\e2>  and its two electron-transfer partners, ferredoxin reductase and ferredoxin","sentence":"Mitochondria in the steroidogenic cells of the adrenal, gonad, placenta and brain contain the cholesterol side-chain cleavage enzyme, P450scc  and its two electron-transfer partners, ferredoxin reductase and ferredoxin"}
{"PMID":23631440,"re_id":0,"annotated sentence":"New series of <e1>pyrrolidine mercaptosulfide<\\e1>  2-mercaptocyclopentane arylsulfonamide, and 3-mercapto-4-arylsulfonamido pyrrolidine <e2>matrix metalloproteinase<\\e2> inhibitors (MMPIs) were designed, synthesized, and evaluated","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pyrrolidine mercaptosulfide","object":"matrix metalloproteinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"New series of <e1>CHEMICAL<\\e1>  2-mercaptocyclopentane arylsulfonamide, and 3-mercapto-4-arylsulfonamido pyrrolidine <e2>GENE-N<\\e2> inhibitors (MMPIs) were designed, synthesized, and evaluated","sentence":"New series of pyrrolidine mercaptosulfide  2-mercaptocyclopentane arylsulfonamide, and 3-mercapto-4-arylsulfonamido pyrrolidine matrix metalloproteinase inhibitors (MMPIs) were designed, synthesized, and evaluated"}
{"PMID":23631440,"re_id":1,"annotated sentence":"Exhibiting unique properties over other MMPIs (e.g., <e1>hydroxamates<\\e1> , these newly reported compounds are capable of modulating activities of several <e2>MMPs<\\e2> in the low nanomolar range, including MMP-2 (~2 to 50 nM), MMP-13 (~2 to 50 nM), and MMP-14 (~4 to 60 nM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"hydroxamates","object":"MMPs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Exhibiting unique properties over other MMPIs (e.g., <e1>CHEMICAL<\\e1> , these newly reported compounds are capable of modulating activities of several <e2>GENE-N<\\e2> in the low nanomolar range, including MMP-2 (~2 to 50 nM), MMP-13 (~2 to 50 nM), and MMP-14 (~4 to 60 nM)","sentence":"Exhibiting unique properties over other MMPIs (e.g., hydroxamates , these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including MMP-2 (~2 to 50 nM), MMP-13 (~2 to 50 nM), and MMP-14 (~4 to 60 nM)"}
{"PMID":23631440,"re_id":2,"annotated sentence":"Exhibiting unique properties over other MMPIs (e.g., <e1>hydroxamates<\\e1> , these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including <e2>MMP-2<\\e2> (~2 to 50 nM), MMP-13 (~2 to 50 nM), and MMP-14 (~4 to 60 nM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"hydroxamates","object":"MMP-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Exhibiting unique properties over other MMPIs (e.g., <e1>CHEMICAL<\\e1> , these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including <e2>GENE-Y<\\e2> (~2 to 50 nM), MMP-13 (~2 to 50 nM), and MMP-14 (~4 to 60 nM)","sentence":"Exhibiting unique properties over other MMPIs (e.g., hydroxamates , these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including MMP-2 (~2 to 50 nM), MMP-13 (~2 to 50 nM), and MMP-14 (~4 to 60 nM)"}
{"PMID":23631440,"re_id":3,"annotated sentence":"Exhibiting unique properties over other MMPIs (e.g., <e1>hydroxamates<\\e1> , these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including MMP-2 (~2 to 50 nM), <e2>MMP-13<\\e2> (~2 to 50 nM), and MMP-14 (~4 to 60 nM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"hydroxamates","object":"MMP-13","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Exhibiting unique properties over other MMPIs (e.g., <e1>CHEMICAL<\\e1> , these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including MMP-2 (~2 to 50 nM), <e2>GENE-Y<\\e2> (~2 to 50 nM), and MMP-14 (~4 to 60 nM)","sentence":"Exhibiting unique properties over other MMPIs (e.g., hydroxamates , these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including MMP-2 (~2 to 50 nM), MMP-13 (~2 to 50 nM), and MMP-14 (~4 to 60 nM)"}
{"PMID":23631440,"re_id":4,"annotated sentence":"Exhibiting unique properties over other MMPIs (e.g., <e1>hydroxamates<\\e1> , these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including MMP-2 (~2 to 50 nM), MMP-13 (~2 to 50 nM), and <e2>MMP-14<\\e2> (~4 to 60 nM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"hydroxamates","object":"MMP-14","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Exhibiting unique properties over other MMPIs (e.g., <e1>CHEMICAL<\\e1> , these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including MMP-2 (~2 to 50 nM), MMP-13 (~2 to 50 nM), and <e2>GENE-Y<\\e2> (~4 to 60 nM)","sentence":"Exhibiting unique properties over other MMPIs (e.g., hydroxamates , these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including MMP-2 (~2 to 50 nM), MMP-13 (~2 to 50 nM), and MMP-14 (~4 to 60 nM)"}
{"PMID":23631440,"re_id":5,"annotated sentence":"New series of pyrrolidine mercaptosulfide, <e1>2-mercaptocyclopentane arylsulfonamide<\\e1>  and 3-mercapto-4-arylsulfonamido pyrrolidine <e2>matrix metalloproteinase<\\e2> inhibitors (MMPIs) were designed, synthesized, and evaluated","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"2-mercaptocyclopentane arylsulfonamide","object":"matrix metalloproteinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"New series of pyrrolidine mercaptosulfide, <e1>CHEMICAL<\\e1>  and 3-mercapto-4-arylsulfonamido pyrrolidine <e2>GENE-N<\\e2> inhibitors (MMPIs) were designed, synthesized, and evaluated","sentence":"New series of pyrrolidine mercaptosulfide, 2-mercaptocyclopentane arylsulfonamide  and 3-mercapto-4-arylsulfonamido pyrrolidine matrix metalloproteinase inhibitors (MMPIs) were designed, synthesized, and evaluated"}
{"PMID":23631440,"re_id":6,"annotated sentence":"New series of pyrrolidine mercaptosulfide, 2-mercaptocyclopentane arylsulfonamide, and <e1>3-mercapto-4-arylsulfonamido pyrrolidine<\\e1> <e2>matrix metalloproteinase<\\e2> inhibitors (MMPIs) were designed, synthesized, and evaluated","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"3-mercapto-4-arylsulfonamido pyrrolidine","object":"matrix metalloproteinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"New series of pyrrolidine mercaptosulfide, 2-mercaptocyclopentane arylsulfonamide, and <e1>CHEMICAL<\\e1> <e2>GENE-N<\\e2> inhibitors (MMPIs) were designed, synthesized, and evaluated","sentence":"New series of pyrrolidine mercaptosulfide, 2-mercaptocyclopentane arylsulfonamide, and 3-mercapto-4-arylsulfonamido pyrrolidine matrix metalloproteinase inhibitors (MMPIs) were designed, synthesized, and evaluated"}
{"PMID":23631440,"re_id":7,"annotated sentence":"<e2>Matrix Metalloproteinase<\\e2> Inhibitors Based on the <e1>3-Mercaptopyrrolidine<\\e1> Core","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"3-Mercaptopyrrolidine","object":"Matrix Metalloproteinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> Inhibitors Based on the <e1>CHEMICAL<\\e1> Core","sentence":"Matrix Metalloproteinase Inhibitors Based on the 3-Mercaptopyrrolidine Core"}
{"PMID":23638842,"re_id":0,"annotated sentence":"RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive <e1>RS -GRA<\\e1> significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as <e2>interleukin-1\u03b2<\\e2> (IL-1\u03b2), and apoptosis (Bax and caspase 3 expression)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"RS -GRA","object":"interleukin-1\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive <e1>CHEMICAL<\\e1> significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as <e2>GENE-Y<\\e2> (IL-1\u03b2), and apoptosis (Bax and caspase 3 expression)","sentence":"RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive RS -GRA significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as interleukin-1\u03b2 (IL-1\u03b2), and apoptosis (Bax and caspase 3 expression)"}
{"PMID":23638842,"re_id":1,"annotated sentence":"RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive <e1>RS -GRA<\\e1> significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as interleukin-1\u03b2 (<e2>IL-1\u03b2<\\e2> , and apoptosis (Bax and caspase 3 expression)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"RS -GRA","object":"IL-1\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive <e1>CHEMICAL<\\e1> significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as interleukin-1\u03b2 (<e2>GENE-Y<\\e2> , and apoptosis (Bax and caspase 3 expression)","sentence":"RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive RS -GRA significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as interleukin-1\u03b2 (IL-1\u03b2 , and apoptosis (Bax and caspase 3 expression)"}
{"PMID":23638842,"re_id":2,"annotated sentence":"RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive <e1>RS -GRA<\\e1> significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as interleukin-1\u03b2 (IL-1\u03b2), and apoptosis (<e2>Bax<\\e2> and caspase 3 expression)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"RS -GRA","object":"Bax","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive <e1>CHEMICAL<\\e1> significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as interleukin-1\u03b2 (IL-1\u03b2), and apoptosis (<e2>GENE-Y<\\e2> and caspase 3 expression)","sentence":"RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive RS -GRA significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as interleukin-1\u03b2 (IL-1\u03b2), and apoptosis (Bax and caspase 3 expression)"}
{"PMID":23638842,"re_id":3,"annotated sentence":"RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive <e1>RS -GRA<\\e1> significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as interleukin-1\u03b2 (IL-1\u03b2), and apoptosis (Bax and <e2>caspase 3<\\e2> expression)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"RS -GRA","object":"caspase 3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive <e1>CHEMICAL<\\e1> significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as interleukin-1\u03b2 (IL-1\u03b2), and apoptosis (Bax and <e2>GENE-Y<\\e2> expression)","sentence":"RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive RS -GRA significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as interleukin-1\u03b2 (IL-1\u03b2), and apoptosis (Bax and caspase 3 expression)"}
{"PMID":23638842,"re_id":4,"annotated sentence":"RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive <e1>RS -GRA<\\e1> significantly decreased <e2>nuclear factor (NF)-kB<\\e2> translocation, pro-inflammatory cytokine production such as interleukin-1\u03b2 (IL-1\u03b2), and apoptosis (Bax and caspase 3 expression)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"RS -GRA","object":"nuclear factor (NF)-kB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive <e1>CHEMICAL<\\e1> significantly decreased <e2>GENE-N<\\e2> translocation, pro-inflammatory cytokine production such as interleukin-1\u03b2 (IL-1\u03b2), and apoptosis (Bax and caspase 3 expression)","sentence":"RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive RS -GRA significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as interleukin-1\u03b2 (IL-1\u03b2), and apoptosis (Bax and caspase 3 expression)"}
{"PMID":23638842,"re_id":5,"annotated sentence":"RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive <e1>RS -GRA<\\e1> significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory <e2>cytokine<\\e2> production such as interleukin-1\u03b2 (IL-1\u03b2), and apoptosis (Bax and caspase 3 expression)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"RS -GRA","object":"cytokine","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive <e1>CHEMICAL<\\e1> significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory <e2>GENE-N<\\e2> production such as interleukin-1\u03b2 (IL-1\u03b2), and apoptosis (Bax and caspase 3 expression)","sentence":"RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive RS -GRA significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as interleukin-1\u03b2 (IL-1\u03b2), and apoptosis (Bax and caspase 3 expression)"}
{"PMID":23638842,"re_id":6,"annotated sentence":"Recent literature shows that Brassica vegetables (Cruciferae) possess therapeutic effects particularly ascribed due to their content in <e1>glucosinolates<\\e1>  which upon <e2>myrosinase<\\e2> hydrolysis release the corresponding isothiocyanates","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glucosinolates","object":"myrosinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Recent literature shows that Brassica vegetables (Cruciferae) possess therapeutic effects particularly ascribed due to their content in <e1>CHEMICAL<\\e1>  which upon <e2>GENE-N<\\e2> hydrolysis release the corresponding isothiocyanates","sentence":"Recent literature shows that Brassica vegetables (Cruciferae) possess therapeutic effects particularly ascribed due to their content in glucosinolates  which upon myrosinase hydrolysis release the corresponding isothiocyanates"}
{"PMID":23638842,"re_id":7,"annotated sentence":"Recent literature shows that Brassica vegetables (Cruciferae) possess therapeutic effects particularly ascribed due to their content in glucosinolates, which upon <e2>myrosinase<\\e2> hydrolysis release the corresponding <e1>isothiocyanates<\\e1>  This study examines the potential neuroprotective and immunomodulatory effects of (RS )-glucoraphanin from Tuscan black kale (Brassica oleracea L","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"isothiocyanates","object":"myrosinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Recent literature shows that Brassica vegetables (Cruciferae) possess therapeutic effects particularly ascribed due to their content in glucosinolates, which upon <e2>GENE-N<\\e2> hydrolysis release the corresponding <e1>CHEMICAL<\\e1>  This study examines the potential neuroprotective and immunomodulatory effects of (RS )-glucoraphanin from Tuscan black kale (Brassica oleracea L","sentence":"Recent literature shows that Brassica vegetables (Cruciferae) possess therapeutic effects particularly ascribed due to their content in glucosinolates, which upon myrosinase hydrolysis release the corresponding isothiocyanates  This study examines the potential neuroprotective and immunomodulatory effects of (RS )-glucoraphanin from Tuscan black kale (Brassica oleracea L"}
{"PMID":23639191,"re_id":0,"annotated sentence":"There was also an increase in <e2>\u03b3-GCS<\\e2> and HO-1 levels in <e1>calycopterin<\\e1> pretreated cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"calycopterin","object":"\u03b3-GCS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"There was also an increase in <e2>GENE-Y<\\e2> and HO-1 levels in <e1>CHEMICAL<\\e1> pretreated cells","sentence":"There was also an increase in \u03b3-GCS and HO-1 levels in calycopterin pretreated cells"}
{"PMID":23639191,"re_id":1,"annotated sentence":"There was also an increase in \u03b3-GCS and <e2>HO-1<\\e2> levels in <e1>calycopterin<\\e1> pretreated cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"calycopterin","object":"HO-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"There was also an increase in \u03b3-GCS and <e2>GENE-Y<\\e2> levels in <e1>CHEMICAL<\\e1> pretreated cells","sentence":"There was also an increase in \u03b3-GCS and HO-1 levels in calycopterin pretreated cells"}
{"PMID":23639191,"re_id":2,"annotated sentence":"In the presence of H2O2, <e1>calycopterin<\\e1> inhibited decrease in GSH level and <e2>SOD<\\e2> activity","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"calycopterin","object":"SOD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the presence of H2O2, <e1>CHEMICAL<\\e1> inhibited decrease in GSH level and <e2>GENE-N<\\e2> activity","sentence":"In the presence of H2O2, calycopterin inhibited decrease in GSH level and SOD activity"}
{"PMID":23639191,"re_id":3,"annotated sentence":"Moreover, <e1>calycopterin<\\e1>  in presence of H2O2 inhibited the decrease caused by oxidative stress in stress-sensing transcription factors, <e2>CREB<\\e2> and Nrf2, which play an important role in antioxidant capacity of the cell","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"calycopterin","object":"CREB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moreover, <e1>CHEMICAL<\\e1>  in presence of H2O2 inhibited the decrease caused by oxidative stress in stress-sensing transcription factors, <e2>GENE-N<\\e2> and Nrf2, which play an important role in antioxidant capacity of the cell","sentence":"Moreover, calycopterin  in presence of H2O2 inhibited the decrease caused by oxidative stress in stress-sensing transcription factors, CREB and Nrf2, which play an important role in antioxidant capacity of the cell"}
{"PMID":23639191,"re_id":4,"annotated sentence":"Moreover, <e1>calycopterin<\\e1>  in presence of H2O2 inhibited the decrease caused by oxidative stress in stress-sensing transcription factors, CREB and <e2>Nrf2<\\e2>  which play an important role in antioxidant capacity of the cell","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"calycopterin","object":"Nrf2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e1>CHEMICAL<\\e1>  in presence of H2O2 inhibited the decrease caused by oxidative stress in stress-sensing transcription factors, CREB and <e2>GENE-Y<\\e2>  which play an important role in antioxidant capacity of the cell","sentence":"Moreover, calycopterin  in presence of H2O2 inhibited the decrease caused by oxidative stress in stress-sensing transcription factors, CREB and Nrf2  which play an important role in antioxidant capacity of the cell"}
{"PMID":23639191,"re_id":5,"annotated sentence":"Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on <e1>H2O2<\\e1> induced disruption of <e2>phase II detoxifying enzyme<\\e2> system and cAMP response element binding protein (CREB) phosphorylation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"H2O2","object":"phase II detoxifying enzyme","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on <e1>CHEMICAL<\\e1> induced disruption of <e2>GENE-N<\\e2> system and cAMP response element binding protein (CREB) phosphorylation","sentence":"Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on H2O2 induced disruption of phase II detoxifying enzyme system and cAMP response element binding protein (CREB) phosphorylation"}
{"PMID":23639191,"re_id":6,"annotated sentence":"Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on <e1>H2O2<\\e1> induced disruption of phase II detoxifying enzyme system and <e2>cAMP response element binding protein<\\e2> (CREB) phosphorylation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"H2O2","object":"cAMP response element binding protein","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on <e1>CHEMICAL<\\e1> induced disruption of phase II detoxifying enzyme system and <e2>GENE-N<\\e2> (CREB) phosphorylation","sentence":"Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on H2O2 induced disruption of phase II detoxifying enzyme system and cAMP response element binding protein (CREB) phosphorylation"}
{"PMID":23639191,"re_id":7,"annotated sentence":"Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on <e1>H2O2<\\e1> induced disruption of phase II detoxifying enzyme system and cAMP response element binding protein (<e2>CREB<\\e2>  phosphorylation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"H2O2","object":"CREB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on <e1>CHEMICAL<\\e1> induced disruption of phase II detoxifying enzyme system and cAMP response element binding protein (<e2>GENE-N<\\e2>  phosphorylation","sentence":"Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on H2O2 induced disruption of phase II detoxifying enzyme system and cAMP response element binding protein (CREB  phosphorylation"}
{"PMID":23639191,"re_id":8,"annotated sentence":"In H2O2-treated cells, <e1>calycopterin<\\e1> also suppressed <e2>cytochrome C<\\e2> release to cytosol that is necessary for maintaining mitochondrial homeostasis in survived cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"calycopterin","object":"cytochrome C","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In H2O2-treated cells, <e1>CHEMICAL<\\e1> also suppressed <e2>GENE-Y<\\e2> release to cytosol that is necessary for maintaining mitochondrial homeostasis in survived cells","sentence":"In H2O2-treated cells, calycopterin also suppressed cytochrome C release to cytosol that is necessary for maintaining mitochondrial homeostasis in survived cells"}
{"PMID":23639249,"re_id":0,"annotated sentence":"Activation of <e2>STAT3<\\e2>  which is phosphorylated by the IL-6 signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by I3S and <e1>TCDD<\\e1>  Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"STAT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Activation of <e2>GENE-Y<\\e2>  which is phosphorylated by the IL-6 signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by I3S and <e1>CHEMICAL<\\e1>  Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and CHEMICAL, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and GENE-Y, raising a possibility that stimulatory activities of I3S and CHEMICAL on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates GENE-Y activation","sentence":"Activation of STAT3  which is phosphorylated by the IL-6 signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by I3S and TCDD  Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation"}
{"PMID":23639249,"re_id":1,"annotated sentence":"Activation of STAT3, which is phosphorylated by the <e2>IL-6<\\e2> signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by I3S and <e1>TCDD<\\e1>  Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"IL-6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Activation of STAT3, which is phosphorylated by the <e2>GENE-Y<\\e2> signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by I3S and <e1>CHEMICAL<\\e1>  Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and CHEMICAL, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and CHEMICAL on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation","sentence":"Activation of STAT3, which is phosphorylated by the IL-6 signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by I3S and TCDD  Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation"}
{"PMID":23639249,"re_id":2,"annotated sentence":"Phosphorylation of <e2>c-Src<\\e2>  which was shown to be activated by AhR ligands, was also increased by <e1>I3S<\\e1> and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"I3S","object":"c-Src","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Phosphorylation of <e2>GENE-Y<\\e2>  which was shown to be activated by AhR ligands, was also increased by <e1>CHEMICAL<\\e1> and TCDD, and blocking of GENE-Y activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both GENE-Y and STAT3, raising a possibility that stimulatory activities of CHEMICAL and TCDD on Th17 differentiation could be exerted via increased phosphorylation of GENE-Y, which in turn stimulates STAT3 activation","sentence":"Phosphorylation of c-Src  which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation"}
{"PMID":23639249,"re_id":3,"annotated sentence":"Phosphorylation of <e2>c-Src<\\e2>  which was shown to be activated by AhR ligands, was also increased by I3S and <e1>TCDD<\\e1>  and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"c-Src","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Phosphorylation of <e2>GENE-Y<\\e2>  which was shown to be activated by AhR ligands, was also increased by I3S and <e1>CHEMICAL<\\e1>  and blocking of GENE-Y activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both GENE-Y and STAT3, raising a possibility that stimulatory activities of I3S and CHEMICAL on Th17 differentiation could be exerted via increased phosphorylation of GENE-Y, which in turn stimulates STAT3 activation","sentence":"Phosphorylation of c-Src  which was shown to be activated by AhR ligands, was also increased by I3S and TCDD  and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation"}
{"PMID":23639249,"re_id":4,"annotated sentence":"<e1>Indoxyl 3-sulfate<\\e1> stimulates Th17 differentiation enhancing phosphorylation of <e2>c-Src<\\e2> and STAT3 to worsen experimental autoimmune encephalomyelitis","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Indoxyl 3-sulfate","object":"c-Src","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> stimulates Th17 differentiation enhancing phosphorylation of <e2>GENE-Y<\\e2> and STAT3 to worsen experimental autoimmune encephalomyelitis","sentence":"Indoxyl 3-sulfate stimulates Th17 differentiation enhancing phosphorylation of c-Src and STAT3 to worsen experimental autoimmune encephalomyelitis"}
{"PMID":23639249,"re_id":5,"annotated sentence":"<e1>Indoxyl 3-sulfate<\\e1> stimulates Th17 differentiation enhancing phosphorylation of c-Src and <e2>STAT3<\\e2> to worsen experimental autoimmune encephalomyelitis","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Indoxyl 3-sulfate","object":"STAT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> stimulates Th17 differentiation enhancing phosphorylation of c-Src and <e2>GENE-Y<\\e2> to worsen experimental autoimmune encephalomyelitis","sentence":"Indoxyl 3-sulfate stimulates Th17 differentiation enhancing phosphorylation of c-Src and STAT3 to worsen experimental autoimmune encephalomyelitis"}
{"PMID":23639249,"re_id":6,"annotated sentence":"Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of <e1>I3S<\\e1> and TCDD on Th17 differentiation could be exerted via increased phosphorylation of <e2>c-Src<\\e2>  which in turn stimulates STAT3 activation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"I3S","object":"c-Src","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Phosphorylation of GENE-Y, which was shown to be activated by AhR ligands, was also increased by CHEMICAL and TCDD, and blocking of GENE-Y activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both GENE-Y and STAT3, raising a possibility that stimulatory activities of <e1>CHEMICAL<\\e1> and TCDD on Th17 differentiation could be exerted via increased phosphorylation of <e2>GENE-Y<\\e2>  which in turn stimulates STAT3 activation","sentence":"Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src  which in turn stimulates STAT3 activation"}
{"PMID":23639249,"re_id":7,"annotated sentence":"Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of <e1>I3S<\\e1> and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates <e2>STAT3<\\e2> activation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"I3S","object":"STAT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by CHEMICAL and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and GENE-Y, raising a possibility that stimulatory activities of <e1>CHEMICAL<\\e1> and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates <e2>GENE-Y<\\e2> activation","sentence":"Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation"}
{"PMID":23639249,"re_id":8,"annotated sentence":"Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and <e1>TCDD<\\e1> on Th17 differentiation could be exerted via increased phosphorylation of <e2>c-Src<\\e2>  which in turn stimulates STAT3 activation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"c-Src","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Phosphorylation of GENE-Y, which was shown to be activated by AhR ligands, was also increased by I3S and CHEMICAL, and blocking of GENE-Y activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both GENE-Y and STAT3, raising a possibility that stimulatory activities of I3S and <e1>CHEMICAL<\\e1> on Th17 differentiation could be exerted via increased phosphorylation of <e2>GENE-Y<\\e2>  which in turn stimulates STAT3 activation","sentence":"Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src  which in turn stimulates STAT3 activation"}
{"PMID":23639249,"re_id":9,"annotated sentence":"Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and <e1>TCDD<\\e1> on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates <e2>STAT3<\\e2> activation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"STAT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and CHEMICAL, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and GENE-Y, raising a possibility that stimulatory activities of I3S and <e1>CHEMICAL<\\e1> on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates <e2>GENE-Y<\\e2> activation","sentence":"Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation"}
{"PMID":23639249,"re_id":10,"annotated sentence":"Finally, we found that <e1>I3S<\\e1> worsened experimental autoimmune encephalomyelitis (EAE), which is primarily mediated by Th17 cells, enhancing the frequency of <e2>IL-17<\\e2> producing cells in draining lymph nodes.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"I3S","object":"IL-17","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Finally, we found that <e1>CHEMICAL<\\e1> worsened experimental autoimmune encephalomyelitis (EAE), which is primarily mediated by Th17 cells, enhancing the frequency of <e2>GENE-Y<\\e2> producing cells in draining lymph nodes.","sentence":"Finally, we found that I3S worsened experimental autoimmune encephalomyelitis (EAE), which is primarily mediated by Th17 cells, enhancing the frequency of IL-17 producing cells in draining lymph nodes."}
{"PMID":23639249,"re_id":11,"annotated sentence":"In the present study, using in vitro Th17 differentiation model, we examined effects of <e2>AhR<\\e2> activation by <e1>indoxyl 3-sulfate<\\e1> (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"indoxyl 3-sulfate","object":"AhR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the present study, using in vitro Th17 differentiation model, we examined effects of <e2>GENE-Y<\\e2> activation by <e1>CHEMICAL<\\e1> (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms","sentence":"In the present study, using in vitro Th17 differentiation model, we examined effects of AhR activation by indoxyl 3-sulfate (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms"}
{"PMID":23639249,"re_id":12,"annotated sentence":"In the present study, using in vitro Th17 differentiation model, we examined effects of <e2>AhR<\\e2> activation by indoxyl 3-sulfate (<e1>I3S<\\e1> , a uremic toxin, on Th17 differentiation and investigated underlying mechanisms","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"I3S","object":"AhR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the present study, using in vitro Th17 differentiation model, we examined effects of <e2>GENE-Y<\\e2> activation by indoxyl 3-sulfate (<e1>CHEMICAL<\\e1> , a uremic toxin, on Th17 differentiation and investigated underlying mechanisms","sentence":"In the present study, using in vitro Th17 differentiation model, we examined effects of AhR activation by indoxyl 3-sulfate (I3S , a uremic toxin, on Th17 differentiation and investigated underlying mechanisms"}
{"PMID":23639249,"re_id":13,"annotated sentence":"<e1>I3S<\\e1> increased expression of <e2>ROR\u03b3t<\\e2>  the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a prototypical AhR ligand","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"I3S","object":"ROR\u03b3t","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> increased expression of <e2>GENE-Y<\\e2>  the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a prototypical AhR ligand","sentence":"I3S increased expression of ROR\u03b3t  the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a prototypical AhR ligand"}
{"PMID":23639249,"re_id":14,"annotated sentence":"Activation of <e2>STAT3<\\e2>  which is phosphorylated by the IL-6 signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by <e1>I3S<\\e1> and TCDD","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"I3S","object":"STAT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Activation of <e2>GENE-Y<\\e2>  which is phosphorylated by the IL-6 signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by <e1>CHEMICAL<\\e1> and TCDD","sentence":"Activation of STAT3  which is phosphorylated by the IL-6 signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by I3S and TCDD"}
{"PMID":23639249,"re_id":15,"annotated sentence":"Activation of STAT3, which is phosphorylated by the <e2>IL-6<\\e2> signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by <e1>I3S<\\e1> and TCDD","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"I3S","object":"IL-6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Activation of STAT3, which is phosphorylated by the <e2>GENE-Y<\\e2> signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by <e1>CHEMICAL<\\e1> and TCDD","sentence":"Activation of STAT3, which is phosphorylated by the IL-6 signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by I3S and TCDD"}
{"PMID":23639249,"re_id":16,"annotated sentence":"Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of <e2>c-Src<\\e2> activity by <e1>4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine<\\e1> (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine","object":"c-Src","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Phosphorylation of GENE-Y, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of <e2>GENE-Y<\\e2> activity by <e1>CHEMICAL<\\e1> (PP2) inhibited phosphorylation of both GENE-Y and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of GENE-Y, which in turn stimulates STAT3 activation","sentence":"Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation"}
{"PMID":23639249,"re_id":17,"annotated sentence":"Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by <e1>4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine<\\e1> (PP2) inhibited phosphorylation of both <e2>c-Src<\\e2> and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine","object":"c-Src","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Phosphorylation of GENE-Y, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of GENE-Y activity by <e1>CHEMICAL<\\e1> (PP2) inhibited phosphorylation of both <e2>GENE-Y<\\e2> and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of GENE-Y, which in turn stimulates STAT3 activation","sentence":"Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation"}
{"PMID":23639249,"re_id":18,"annotated sentence":"Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by <e1>4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine<\\e1> (PP2) inhibited phosphorylation of both c-Src and <e2>STAT3<\\e2>  raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine","object":"STAT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by <e1>CHEMICAL<\\e1> (PP2) inhibited phosphorylation of both c-Src and <e2>GENE-Y<\\e2>  raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates GENE-Y activation","sentence":"Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3  raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation"}
{"PMID":23639626,"re_id":0,"annotated sentence":"This inhibition was mediated by a <e1>TCDD<\\e1> induced secreted factor which was identified as <e2>insulin-like growth factor binding protein 4<\\e2> (IGFBP-4)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"insulin-like growth factor binding protein 4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This inhibition was mediated by a <e1>CHEMICAL<\\e1> induced secreted factor which was identified as <e2>GENE-Y<\\e2> (IGFBP-4)","sentence":"This inhibition was mediated by a TCDD induced secreted factor which was identified as insulin-like growth factor binding protein 4 (IGFBP-4)"}
{"PMID":23639626,"re_id":1,"annotated sentence":"This inhibition was mediated by a <e1>TCDD<\\e1> induced secreted factor which was identified as insulin-like growth factor binding protein 4 (<e2>IGFBP-4<\\e2> ","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"IGFBP-4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This inhibition was mediated by a <e1>CHEMICAL<\\e1> induced secreted factor which was identified as insulin-like growth factor binding protein 4 (<e2>GENE-Y<\\e2> ","sentence":"This inhibition was mediated by a TCDD induced secreted factor which was identified as insulin-like growth factor binding protein 4 (IGFBP-4 "}
{"PMID":23639626,"re_id":2,"annotated sentence":"<e1>TCDD<\\e1> induces the expression of <e2>insulin-like growth factor binding protein 4<\\e2> in 5L rat hepatoma cells: a cautionary tale of the use of this cell line in studies on dioxin toxicity","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"insulin-like growth factor binding protein 4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induces the expression of <e2>GENE-Y<\\e2> in 5L rat hepatoma cells: a cautionary tale of the use of this cell line in studies on dioxin toxicity","sentence":"TCDD induces the expression of insulin-like growth factor binding protein 4 in 5L rat hepatoma cells: a cautionary tale of the use of this cell line in studies on dioxin toxicity"}
{"PMID":23639626,"re_id":3,"annotated sentence":"The observations suggest that in 5L cells the Igfbp-4 gene may have got under the control of a promoter containing dioxin responsive element(s) leading to the induction of <e2>IGFBP-4<\\e2> by <e1>TCDD<\\e1>  These findings emphasise a particular caution when interpreting and extrapolating results on the action mechanisms of TCDD obtained in studies using 5L cells as a model system.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"IGFBP-4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The observations suggest that in 5L cells the Igfbp-4 gene may have got under the control of a promoter containing dioxin responsive element(s) leading to the induction of <e2>GENE-Y<\\e2> by <e1>CHEMICAL<\\e1>  These findings emphasise a particular caution when interpreting and extrapolating results on the action mechanisms of CHEMICAL obtained in studies using 5L cells as a model system.","sentence":"The observations suggest that in 5L cells the Igfbp-4 gene may have got under the control of a promoter containing dioxin responsive element(s) leading to the induction of IGFBP-4 by TCDD  These findings emphasise a particular caution when interpreting and extrapolating results on the action mechanisms of TCDD obtained in studies using 5L cells as a model system."}
{"PMID":23639626,"re_id":4,"annotated sentence":"By \"working upwards\" from mTOR, we observed that <e1>TCDD<\\e1> inhibited endogenous and <e2>IGF-I<\\e2> induced AKT and ERK activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TCDD","object":"IGF-I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"By \"working upwards\" from mTOR, we observed that <e1>CHEMICAL<\\e1> inhibited endogenous and <e2>GENE-Y<\\e2> induced AKT and ERK activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1","sentence":"By \"working upwards\" from mTOR, we observed that TCDD inhibited endogenous and IGF-I induced AKT and ERK activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1"}
{"PMID":23639626,"re_id":5,"annotated sentence":"By \"working upwards\" from mTOR, we observed that <e1>TCDD<\\e1> inhibited endogenous and IGF-I-induced <e2>AKT<\\e2> and ERK activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TCDD","object":"AKT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"By \"working upwards\" from mTOR, we observed that <e1>CHEMICAL<\\e1> inhibited endogenous and IGF-I-induced <e2>GENE-N<\\e2> and ERK activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1","sentence":"By \"working upwards\" from mTOR, we observed that TCDD inhibited endogenous and IGF-I-induced AKT and ERK activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1"}
{"PMID":23639626,"re_id":6,"annotated sentence":"By \"working upwards\" from mTOR, we observed that <e1>TCDD<\\e1> inhibited endogenous and IGF-I-induced AKT and <e2>ERK<\\e2> activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TCDD","object":"ERK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"By \"working upwards\" from mTOR, we observed that <e1>CHEMICAL<\\e1> inhibited endogenous and IGF-I-induced AKT and <e2>GENE-N<\\e2> activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1","sentence":"By \"working upwards\" from mTOR, we observed that TCDD inhibited endogenous and IGF-I-induced AKT and ERK activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1"}
{"PMID":23639626,"re_id":7,"annotated sentence":"The induction of IGFBP-4 protein was dependent on a functional aryl hydrocarbon receptor and was preceded by a rapid increase in the level of <e2>IGFBP-4<\\e2> mRNA indicating that IGFBP-4 is a previously unknown transcriptional target of <e1>TCDD<\\e1> in 5L cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TCDD","object":"IGFBP-4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The induction of GENE-Y protein was dependent on a functional aryl hydrocarbon receptor and was preceded by a rapid increase in the level of <e2>GENE-Y<\\e2> mRNA indicating that GENE-Y is a previously unknown transcriptional target of <e1>CHEMICAL<\\e1> in 5L cells","sentence":"The induction of IGFBP-4 protein was dependent on a functional aryl hydrocarbon receptor and was preceded by a rapid increase in the level of IGFBP-4 mRNA indicating that IGFBP-4 is a previously unknown transcriptional target of TCDD in 5L cells"}
{"PMID":2386945,"re_id":0,"annotated sentence":"Inhibition of MCF-7 cell growth by the selective calmodulin antagonists W-13 and W-12 is consistent with a role for <e2>calmodulin<\\e2> antagonism in the broad growth-inhibitory properties of <e1>pimozide<\\e1>  We conclude that pimozide and thioridazine may be useful in the control of estradiol- and polypeptide hormone-induced growth of ER-positive and ER-negative human breast tumors.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pimozide","object":"calmodulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of MCF-7 cell growth by the selective GENE-Y antagonists W-13 and W-12 is consistent with a role for <e2>GENE-Y<\\e2> antagonism in the broad growth-inhibitory properties of <e1>CHEMICAL<\\e1>  We conclude that CHEMICAL and thioridazine may be useful in the control of estradiol- and polypeptide hormone-induced growth of ER-positive and ER-negative human breast tumors.","sentence":"Inhibition of MCF-7 cell growth by the selective calmodulin antagonists W-13 and W-12 is consistent with a role for calmodulin antagonism in the broad growth-inhibitory properties of pimozide  We conclude that pimozide and thioridazine may be useful in the control of estradiol- and polypeptide hormone-induced growth of ER-positive and ER-negative human breast tumors."}
{"PMID":2386945,"re_id":1,"annotated sentence":"Inhibition of MCF-7 cell growth by the selective <e2>calmodulin<\\e2> antagonists <e1>W-13<\\e1> and W-12 is consistent with a role for calmodulin antagonism in the broad growth-inhibitory properties of pimozide","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"W-13","object":"calmodulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of MCF-7 cell growth by the selective <e2>GENE-Y<\\e2> antagonists <e1>CHEMICAL<\\e1> and W-12 is consistent with a role for GENE-Y antagonism in the broad growth-inhibitory properties of pimozide","sentence":"Inhibition of MCF-7 cell growth by the selective calmodulin antagonists W-13 and W-12 is consistent with a role for calmodulin antagonism in the broad growth-inhibitory properties of pimozide"}
{"PMID":2386945,"re_id":2,"annotated sentence":"Inhibition of MCF-7 cell growth by the selective <e2>calmodulin<\\e2> antagonists W-13 and <e1>W-12<\\e1> is consistent with a role for calmodulin antagonism in the broad growth-inhibitory properties of pimozide","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"W-12","object":"calmodulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of MCF-7 cell growth by the selective <e2>GENE-Y<\\e2> antagonists W-13 and <e1>CHEMICAL<\\e1> is consistent with a role for GENE-Y antagonism in the broad growth-inhibitory properties of pimozide","sentence":"Inhibition of MCF-7 cell growth by the selective calmodulin antagonists W-13 and W-12 is consistent with a role for calmodulin antagonism in the broad growth-inhibitory properties of pimozide"}
{"PMID":2386945,"re_id":3,"annotated sentence":"Although numerous mechanisms of action of <e1>pimozide<\\e1> and thioridazine have been identified, both drugs are <e2>calmodulin<\\e2> antagonists at drug concentrations that inhibit breast cancer cell growth in vitro","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"pimozide","object":"calmodulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although numerous mechanisms of action of <e1>CHEMICAL<\\e1> and thioridazine have been identified, both drugs are <e2>GENE-Y<\\e2> antagonists at drug concentrations that inhibit breast cancer cell growth in vitro","sentence":"Although numerous mechanisms of action of pimozide and thioridazine have been identified, both drugs are calmodulin antagonists at drug concentrations that inhibit breast cancer cell growth in vitro"}
{"PMID":2386945,"re_id":4,"annotated sentence":"Although numerous mechanisms of action of pimozide and <e1>thioridazine<\\e1> have been identified, both drugs are <e2>calmodulin<\\e2> antagonists at drug concentrations that inhibit breast cancer cell growth in vitro","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"thioridazine","object":"calmodulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although numerous mechanisms of action of pimozide and <e1>CHEMICAL<\\e1> have been identified, both drugs are <e2>GENE-Y<\\e2> antagonists at drug concentrations that inhibit breast cancer cell growth in vitro","sentence":"Although numerous mechanisms of action of pimozide and thioridazine have been identified, both drugs are calmodulin antagonists at drug concentrations that inhibit breast cancer cell growth in vitro"}
{"PMID":2506486,"re_id":0,"annotated sentence":"Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg\/kg i.p.), <e2>MAO-B<\\e2> by <e1>(-)deprenyl<\\e1> (1 mg\/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg\/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg\/kg i.p.)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"(-)deprenyl","object":"MAO-B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg\/kg i.p.), <e2>GENE-Y<\\e2> by <e1>CHEMICAL<\\e1> (1 mg\/kg i.p.), both MAO-A and GENE-Y by nialamide (75 mg\/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg\/kg i.p.)","sentence":"Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg\/kg i.p.), MAO-B by (-)deprenyl (1 mg\/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg\/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg\/kg i.p.)"}
{"PMID":2506486,"re_id":1,"annotated sentence":"Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg\/kg i.p.), MAO-B by (-)deprenyl (1 mg\/kg i.p.), both <e2>MAO-A<\\e2> and MAO-B by <e1>nialamide<\\e1> (75 mg\/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg\/kg i.p.)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"nialamide","object":"MAO-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (GENE-Y) by clorgyline (4 mg\/kg i.p.), MAO-B by (-)deprenyl (1 mg\/kg i.p.), both <e2>GENE-Y<\\e2> and MAO-B by <e1>CHEMICAL<\\e1> (75 mg\/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg\/kg i.p.)","sentence":"Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg\/kg i.p.), MAO-B by (-)deprenyl (1 mg\/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg\/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg\/kg i.p.)"}
{"PMID":2506486,"re_id":2,"annotated sentence":"Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg\/kg i.p.), MAO-B by (-)deprenyl (1 mg\/kg i.p.), both MAO-A and <e2>MAO-B<\\e2> by <e1>nialamide<\\e1> (75 mg\/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg\/kg i.p.)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"nialamide","object":"MAO-B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg\/kg i.p.), GENE-Y by (-)deprenyl (1 mg\/kg i.p.), both MAO-A and <e2>GENE-Y<\\e2> by <e1>CHEMICAL<\\e1> (75 mg\/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg\/kg i.p.)","sentence":"Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg\/kg i.p.), MAO-B by (-)deprenyl (1 mg\/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg\/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg\/kg i.p.)"}
{"PMID":2506486,"re_id":3,"annotated sentence":"Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg\/kg i.p.), MAO-B by (-)deprenyl (1 mg\/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg\/kg i.p.) or peripheral neuronal <e2>MAO<\\e2> by <e1>debrisoquin<\\e1> (40 mg\/kg i.p.)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"debrisoquin","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (GENE-N-A) by clorgyline (4 mg\/kg i.p.), GENE-N-B by (-)deprenyl (1 mg\/kg i.p.), both GENE-N-A and GENE-N-B by nialamide (75 mg\/kg i.p.) or peripheral neuronal <e2>GENE-N<\\e2> by <e1>CHEMICAL<\\e1> (40 mg\/kg i.p.)","sentence":"Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg\/kg i.p.), MAO-B by (-)deprenyl (1 mg\/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg\/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg\/kg i.p.)"}
{"PMID":2506486,"re_id":4,"annotated sentence":"Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of <e2>monoamine oxidase type A<\\e2> (MAO-A) by <e1>clorgyline<\\e1> (4 mg\/kg i.p.), MAO-B by (-)deprenyl (1 mg\/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg\/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg\/kg i.p.)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"clorgyline","object":"monoamine oxidase type A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of <e2>GENE-Y<\\e2> (MAO-A) by <e1>CHEMICAL<\\e1> (4 mg\/kg i.p.), MAO-B by (-)deprenyl (1 mg\/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg\/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg\/kg i.p.)","sentence":"Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg\/kg i.p.), MAO-B by (-)deprenyl (1 mg\/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg\/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg\/kg i.p.)"}
{"PMID":2506486,"re_id":5,"annotated sentence":"Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (<e2>MAO-A<\\e2>  by <e1>clorgyline<\\e1> (4 mg\/kg i.p.), MAO-B by (-)deprenyl (1 mg\/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg\/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg\/kg i.p.)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"clorgyline","object":"MAO-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (<e2>GENE-Y<\\e2>  by <e1>CHEMICAL<\\e1> (4 mg\/kg i.p.), MAO-B by (-)deprenyl (1 mg\/kg i.p.), both GENE-Y and MAO-B by nialamide (75 mg\/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg\/kg i.p.)","sentence":"Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A  by clorgyline (4 mg\/kg i.p.), MAO-B by (-)deprenyl (1 mg\/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg\/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg\/kg i.p.)"}
{"PMID":2506486,"re_id":6,"annotated sentence":"The results suggest that most of the HVA in plasma is derived from deamination of <e1>DA<\\e1> by <e2>MAO-A<\\e2> in peripheral neurons; that DOPAC in plasma is derived from cells outside the central nervous system; that DHPG in plasma is derived virtually exclusively from the metabolism of norepinephrine in sympathetic nerve endings and that residual levels of HVA after treatment with debrisoquin provide an improved but limited indication of central dopaminergic activity.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"DA","object":"MAO-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results suggest that most of the HVA in plasma is derived from deamination of <e1>CHEMICAL<\\e1> by <e2>GENE-Y<\\e2> in peripheral neurons; that DOPAC in plasma is derived from cells outside the central nervous system; that DHPG in plasma is derived virtually exclusively from the metabolism of norepinephrine in sympathetic nerve endings and that residual levels of HVA after treatment with debrisoquin provide an improved but limited indication of central dopaminergic activity.","sentence":"The results suggest that most of the HVA in plasma is derived from deamination of DA by MAO-A in peripheral neurons; that DOPAC in plasma is derived from cells outside the central nervous system; that DHPG in plasma is derived virtually exclusively from the metabolism of norepinephrine in sympathetic nerve endings and that residual levels of HVA after treatment with debrisoquin provide an improved but limited indication of central dopaminergic activity."}
{"PMID":2506486,"re_id":7,"annotated sentence":"The results suggest that most of the <e1>HVA<\\e1> in plasma is derived from deamination of DA by <e2>MAO-A<\\e2> in peripheral neurons; that DOPAC in plasma is derived from cells outside the central nervous system; that DHPG in plasma is derived virtually exclusively from the metabolism of norepinephrine in sympathetic nerve endings and that residual levels of HVA after treatment with debrisoquin provide an improved but limited indication of central dopaminergic activity.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"HVA","object":"MAO-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results suggest that most of the <e1>CHEMICAL<\\e1> in plasma is derived from deamination of DA by <e2>GENE-Y<\\e2> in peripheral neurons; that DOPAC in plasma is derived from cells outside the central nervous system; that DHPG in plasma is derived virtually exclusively from the metabolism of norepinephrine in sympathetic nerve endings and that residual levels of CHEMICAL after treatment with debrisoquin provide an improved but limited indication of central dopaminergic activity.","sentence":"The results suggest that most of the HVA in plasma is derived from deamination of DA by MAO-A in peripheral neurons; that DOPAC in plasma is derived from cells outside the central nervous system; that DHPG in plasma is derived virtually exclusively from the metabolism of norepinephrine in sympathetic nerve endings and that residual levels of HVA after treatment with debrisoquin provide an improved but limited indication of central dopaminergic activity."}
{"PMID":2832297,"re_id":0,"annotated sentence":"After <e1>loperamide<\\e1> administration ACTH levels fell to a nadir of 135 +\/- 76 pg\/ml, and then CRH was still able to induce an <e2>ACTH<\\e2> increase; the pattern of ACTH response to CRH was slightly delayed","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"loperamide","object":"ACTH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"After <e1>CHEMICAL<\\e1> administration GENE-Y levels fell to a nadir of 135 +\/- 76 pg\/ml, and then CRH was still able to induce an <e2>GENE-Y<\\e2> increase; the pattern of GENE-Y response to CRH was slightly delayed","sentence":"After loperamide administration ACTH levels fell to a nadir of 135 +\/- 76 pg\/ml, and then CRH was still able to induce an ACTH increase; the pattern of ACTH response to CRH was slightly delayed"}
{"PMID":2832297,"re_id":1,"annotated sentence":"After <e1>loperamide<\\e1> administration <e2>ACTH<\\e2> levels fell to a nadir of 135 +\/- 76 pg\/ml, and then CRH was still able to induce an ACTH increase; the pattern of ACTH response to CRH was slightly delayed","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"loperamide","object":"ACTH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"After <e1>CHEMICAL<\\e1> administration <e2>GENE-Y<\\e2> levels fell to a nadir of 135 +\/- 76 pg\/ml, and then CRH was still able to induce an GENE-Y increase; the pattern of GENE-Y response to CRH was slightly delayed","sentence":"After loperamide administration ACTH levels fell to a nadir of 135 +\/- 76 pg\/ml, and then CRH was still able to induce an ACTH increase; the pattern of ACTH response to CRH was slightly delayed"}
{"PMID":2857786,"re_id":0,"annotated sentence":"Ambenonium was a less potent antagonist of tissue responses to acetylcholine, and the underestimation in the pKB (as compared to that obtained with bethanechol) could be eliminated by prior treatment of tissues with the <e2>acetylcholinesterase<\\e2> inhibitor <e1>neostigmine<\\e1>  These data suggested that ambenonium had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of acetylcholinesterase and concomitant antagonism by blockade of muscarinic receptors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"neostigmine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ambenonium was a less potent antagonist of tissue responses to acetylcholine, and the underestimation in the pKB (as compared to that obtained with bethanechol) could be eliminated by prior treatment of tissues with the <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1>  These data suggested that ambenonium had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of GENE-Y and concomitant antagonism by blockade of muscarinic receptors","sentence":"Ambenonium was a less potent antagonist of tissue responses to acetylcholine, and the underestimation in the pKB (as compared to that obtained with bethanechol) could be eliminated by prior treatment of tissues with the acetylcholinesterase inhibitor neostigmine  These data suggested that ambenonium had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of acetylcholinesterase and concomitant antagonism by blockade of muscarinic receptors"}
{"PMID":2857786,"re_id":1,"annotated sentence":"These data suggested that <e1>ambenonium<\\e1> had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of <e2>acetylcholinesterase<\\e2> and concomitant antagonism by blockade of muscarinic receptors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ambenonium","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These data suggested that <e1>CHEMICAL<\\e1> had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of <e2>GENE-Y<\\e2> and concomitant antagonism by blockade of muscarinic receptors","sentence":"These data suggested that ambenonium had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of acetylcholinesterase and concomitant antagonism by blockade of muscarinic receptors"}
{"PMID":2857786,"re_id":2,"annotated sentence":"These data suggested that <e1>ambenonium<\\e1> had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of acetylcholinesterase and concomitant antagonism by blockade of <e2>muscarinic receptors<\\e2>  The Schild regressions obtained for ambenonium antagonism of acetylcholine responses formally satisfied criteria for simple competitive antagonism of a homogenous population of receptors (linear regression, slope equal to unity)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ambenonium","object":"muscarinic receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These data suggested that <e1>CHEMICAL<\\e1> had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of acetylcholinesterase and concomitant antagonism by blockade of <e2>GENE-N<\\e2>  The Schild regressions obtained for CHEMICAL antagonism of acetylcholine responses formally satisfied criteria for simple competitive antagonism of a homogenous population of receptors (linear regression, slope equal to unity)","sentence":"These data suggested that ambenonium had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of acetylcholinesterase and concomitant antagonism by blockade of muscarinic receptors  The Schild regressions obtained for ambenonium antagonism of acetylcholine responses formally satisfied criteria for simple competitive antagonism of a homogenous population of receptors (linear regression, slope equal to unity)"}
{"PMID":2857786,"re_id":3,"annotated sentence":"<e1>Ambenonium<\\e1> is known to be an inhibitor of <e2>acetylcholinesterase<\\e2>  and recent data have shown this drug to antagonize muscarinic receptors as well","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Ambenonium","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is known to be an inhibitor of <e2>GENE-Y<\\e2>  and recent data have shown this drug to antagonize muscarinic receptors as well","sentence":"Ambenonium is known to be an inhibitor of acetylcholinesterase  and recent data have shown this drug to antagonize muscarinic receptors as well"}
{"PMID":2857786,"re_id":4,"annotated sentence":"These data suggested that ambenonium had a dual effect on tissue responses to <e1>acetylcholine<\\e1> producing potentiation by blockade of <e2>acetylcholinesterase<\\e2> and concomitant antagonism by blockade of muscarinic receptors","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"acetylcholine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These data suggested that ambenonium had a dual effect on tissue responses to <e1>CHEMICAL<\\e1> producing potentiation by blockade of <e2>CHEMICALsterase<\\e2> and concomitant antagonism by blockade of muscarinic receptors","sentence":"These data suggested that ambenonium had a dual effect on tissue responses to acetylcholine producing potentiation by blockade of acetylcholinesterase and concomitant antagonism by blockade of muscarinic receptors"}
{"PMID":2857786,"re_id":5,"annotated sentence":"These data suggested that <e1>ambenonium<\\e1> had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of acetylcholinesterase and concomitant antagonism by blockade of <e2>muscarinic receptors<\\e2>  The Schild regressions obtained for ambenonium antagonism of acetylcholine responses formally satisfied criteria for simple competitive antagonism of a homogenous population of receptors (linear regression, slope equal to unity)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"ambenonium","object":"muscarinic receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These data suggested that <e1>CHEMICAL<\\e1> had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of acetylcholinesterase and concomitant antagonism by blockade of <e2>GENE-N<\\e2>  The Schild regressions obtained for CHEMICAL antagonism of acetylcholine responses formally satisfied criteria for simple competitive antagonism of a homogenous population of receptors (linear regression, slope equal to unity)","sentence":"These data suggested that ambenonium had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of acetylcholinesterase and concomitant antagonism by blockade of muscarinic receptors  The Schild regressions obtained for ambenonium antagonism of acetylcholine responses formally satisfied criteria for simple competitive antagonism of a homogenous population of receptors (linear regression, slope equal to unity)"}
{"PMID":2857786,"re_id":6,"annotated sentence":"<e1>Ambenonium<\\e1> is known to be an inhibitor of acetylcholinesterase, and recent data have shown this drug to antagonize <e2>muscarinic receptors<\\e2> as well","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Ambenonium","object":"muscarinic receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is known to be an inhibitor of acetylcholinesterase, and recent data have shown this drug to antagonize <e2>GENE-N<\\e2> as well","sentence":"Ambenonium is known to be an inhibitor of acetylcholinesterase, and recent data have shown this drug to antagonize muscarinic receptors as well"}
{"PMID":2891463,"re_id":0,"annotated sentence":"However, <e1>betaxolol<\\e1> produces less systemic beta 2- and possibly <e2>beta 1-adrenergic receptor<\\e2> blockade than either timolol or levobunolol","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"betaxolol","object":"beta 1-adrenergic receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, <e1>CHEMICAL<\\e1> produces less systemic beta 2- and possibly <e2>GENE-Y<\\e2> blockade than either timolol or levobunolol","sentence":"However, betaxolol produces less systemic beta 2- and possibly beta 1-adrenergic receptor blockade than either timolol or levobunolol"}
{"PMID":2891463,"re_id":1,"annotated sentence":"However, betaxolol produces less systemic beta 2- and possibly <e2>beta 1-adrenergic receptor<\\e2> blockade than either <e1>timolol<\\e1> or levobunolol","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"timolol","object":"beta 1-adrenergic receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, betaxolol produces less systemic beta 2- and possibly <e2>GENE-Y<\\e2> blockade than either <e1>CHEMICAL<\\e1> or levobunolol","sentence":"However, betaxolol produces less systemic beta 2- and possibly beta 1-adrenergic receptor blockade than either timolol or levobunolol"}
{"PMID":2891463,"re_id":2,"annotated sentence":"However, betaxolol produces less systemic beta 2- and possibly <e2>beta 1-adrenergic receptor<\\e2> blockade than either timolol or <e1>levobunolol<\\e1>  Betaxolol may be relatively safer to use in patients with reactive airway disease than either timolol or levobunolol","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"levobunolol","object":"beta 1-adrenergic receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, betaxolol produces less systemic beta 2- and possibly <e2>GENE-Y<\\e2> blockade than either timolol or <e1>CHEMICAL<\\e1>  Betaxolol may be relatively safer to use in patients with reactive airway disease than either timolol or CHEMICAL","sentence":"However, betaxolol produces less systemic beta 2- and possibly beta 1-adrenergic receptor blockade than either timolol or levobunolol  Betaxolol may be relatively safer to use in patients with reactive airway disease than either timolol or levobunolol"}
{"PMID":3094574,"re_id":0,"annotated sentence":"<e2>Phenol oxidase<\\e2> inhibitors such as <e1>phenylthiourea<\\e1>  potassium cyanide, and sodium azide inhibited the reaction drastically, suggesting the participation of the active site copper of the enzyme in the catalysis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenylthiourea","object":"Phenol oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> inhibitors such as <e1>CHEMICAL<\\e1>  potassium cyanide, and sodium azide inhibited the reaction drastically, suggesting the participation of the active site copper of the enzyme in the catalysis","sentence":"Phenol oxidase inhibitors such as phenylthiourea  potassium cyanide, and sodium azide inhibited the reaction drastically, suggesting the participation of the active site copper of the enzyme in the catalysis"}
{"PMID":3094574,"re_id":1,"annotated sentence":"<e2>Phenol oxidase<\\e2> inhibitors such as phenylthiourea, <e1>potassium cyanide<\\e1>  and sodium azide inhibited the reaction drastically, suggesting the participation of the active site copper of the enzyme in the catalysis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"potassium cyanide","object":"Phenol oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> inhibitors such as phenylthiourea, <e1>CHEMICAL<\\e1>  and sodium azide inhibited the reaction drastically, suggesting the participation of the active site copper of the enzyme in the catalysis","sentence":"Phenol oxidase inhibitors such as phenylthiourea, potassium cyanide  and sodium azide inhibited the reaction drastically, suggesting the participation of the active site copper of the enzyme in the catalysis"}
{"PMID":3094574,"re_id":2,"annotated sentence":"<e2>Phenol oxidase<\\e2> inhibitors such as phenylthiourea, potassium cyanide, and <e1>sodium azide<\\e1> inhibited the reaction drastically, suggesting the participation of the active site copper of the enzyme in the catalysis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sodium azide","object":"Phenol oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> inhibitors such as phenylthiourea, potassium cyanide, and <e1>CHEMICAL<\\e1> inhibited the reaction drastically, suggesting the participation of the active site copper of the enzyme in the catalysis","sentence":"Phenol oxidase inhibitors such as phenylthiourea, potassium cyanide, and sodium azide inhibited the reaction drastically, suggesting the participation of the active site copper of the enzyme in the catalysis"}
{"PMID":3094574,"re_id":3,"annotated sentence":"<e1>Mimosine<\\e1>  a well-known competitive inhibitor of <e2>tyrosinase<\\e2>  competitively inhibited the new reaction also","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Mimosine","object":"tyrosinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a well-known competitive inhibitor of <e2>GENE-Y<\\e2>  competitively inhibited the new reaction also","sentence":"Mimosine  a well-known competitive inhibitor of tyrosinase  competitively inhibited the new reaction also"}
{"PMID":3094574,"re_id":4,"annotated sentence":"Present studies demonstrate that <e2>mushroom tyrosinase<\\e2> will also catalyze quinone methide production with the same active site copper if a suitable substrate such as <e1>3,4-dihydroxymandelic acid<\\e1> is provided.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"3,4-dihydroxymandelic acid","object":"mushroom tyrosinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Present studies demonstrate that <e2>GENE-N<\\e2> will also catalyze quinone methide production with the same active site copper if a suitable substrate such as <e1>CHEMICAL<\\e1> is provided.","sentence":"Present studies demonstrate that mushroom tyrosinase will also catalyze quinone methide production with the same active site copper if a suitable substrate such as 3,4-dihydroxymandelic acid is provided."}
{"PMID":3094574,"re_id":5,"annotated sentence":"<e2>Tyrosinase<\\e2> usually catalyzes the conversion of <e1>monophenols<\\e1> to o-diphenols and oxidation of diphenols to the corresponding quinones","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"monophenols","object":"Tyrosinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> usually catalyzes the conversion of <e1>CHEMICAL<\\e1> to o-diphenols and oxidation of diphenols to the corresponding quinones","sentence":"Tyrosinase usually catalyzes the conversion of monophenols to o-diphenols and oxidation of diphenols to the corresponding quinones"}
{"PMID":3094574,"re_id":6,"annotated sentence":"<e2>Tyrosinase<\\e2> usually catalyzes the conversion of monophenols to o-diphenols and oxidation of <e1>diphenols<\\e1> to the corresponding quinones","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"diphenols","object":"Tyrosinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> usually catalyzes the conversion of monophenols to o-CHEMICAL and oxidation of <e1>CHEMICAL<\\e1> to the corresponding quinones","sentence":"Tyrosinase usually catalyzes the conversion of monophenols to o-diphenols and oxidation of diphenols to the corresponding quinones"}
{"PMID":3094574,"re_id":7,"annotated sentence":"<e2>Tyrosinase<\\e2> catalyzes an unusual oxidative decarboxylation of <e1>3,4-dihydroxymandelate<\\e1>  Tyrosinase usually catalyzes the conversion of monophenols to o-diphenols and oxidation of diphenols to the corresponding quinones","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"3,4-dihydroxymandelate","object":"Tyrosinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> catalyzes an unusual oxidative decarboxylation of <e1>CHEMICAL<\\e1>  GENE-Y usually catalyzes the conversion of monophenols to o-diphenols and oxidation of diphenols to the corresponding quinones","sentence":"Tyrosinase catalyzes an unusual oxidative decarboxylation of 3,4-dihydroxymandelate  Tyrosinase usually catalyzes the conversion of monophenols to o-diphenols and oxidation of diphenols to the corresponding quinones"}
{"PMID":3094574,"re_id":8,"annotated sentence":"Present studies demonstrate that <e2>mushroom tyrosinase<\\e2> will also catalyze <e1>quinone methide<\\e1> production with the same active site copper if a suitable substrate such as 3,4-dihydroxymandelic acid is provided.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"quinone methide","object":"mushroom tyrosinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Present studies demonstrate that <e2>GENE-N<\\e2> will also catalyze <e1>CHEMICAL<\\e1> production with the same active site copper if a suitable substrate such as 3,4-dihydroxymandelic acid is provided.","sentence":"Present studies demonstrate that mushroom tyrosinase will also catalyze quinone methide production with the same active site copper if a suitable substrate such as 3,4-dihydroxymandelic acid is provided."}
{"PMID":3146348,"re_id":0,"annotated sentence":"The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (<e2>t-PA<\\e2>  is inhibited by Cl-, at physiological concentrations, and stimulated by <e1>epsilon-aminocaproic acid<\\e1> (EACA), as well as fibrin(ogen)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"epsilon-aminocaproic acid","object":"t-PA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (<e2>GENE-Y<\\e2>  is inhibited by Cl-, at physiological concentrations, and stimulated by <e1>CHEMICAL<\\e1> (EACA), as well as fibrin(ogen)","sentence":"The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA  is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen)"}
{"PMID":3146348,"re_id":1,"annotated sentence":"The activation of <e2>human [Glu1]plasminogen<\\e2> [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by <e1>epsilon-aminocaproic acid<\\e1> (EACA), as well as fibrin(ogen)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"epsilon-aminocaproic acid","object":"human [Glu1]plasminogen","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The activation of <e2>GENE-Y<\\e2> [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by <e1>CHEMICAL<\\e1> (EACA), as well as fibrin(ogen)","sentence":"The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen)"}
{"PMID":3146348,"re_id":2,"annotated sentence":"The activation of human [Glu1]plasminogen [<e2>( Glu1]Pg<\\e2>  by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by <e1>epsilon-aminocaproic acid<\\e1> (EACA), as well as fibrin(ogen)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"epsilon-aminocaproic acid","object":"( Glu1]Pg","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The activation of human [Glu1]plasminogen [<e2>GENE-Y<\\e2>  by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by <e1>CHEMICAL<\\e1> (EACA), as well as fibrin(ogen)","sentence":"The activation of human [Glu1]plasminogen [( Glu1]Pg  by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen)"}
{"PMID":3146348,"re_id":3,"annotated sentence":"The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain <e2>tissue plasminogen activator<\\e2> (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by <e1>epsilon-aminocaproic acid<\\e1> (EACA), as well as fibrin(ogen)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"epsilon-aminocaproic acid","object":"tissue plasminogen activator","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain <e2>GENE-Y<\\e2> (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by <e1>CHEMICAL<\\e1> (EACA), as well as fibrin(ogen)","sentence":"The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen)"}
{"PMID":3146348,"re_id":4,"annotated sentence":"The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (<e2>t-PA<\\e2>  is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (<e1>EACA<\\e1> , as well as fibrin(ogen)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"EACA","object":"t-PA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (<e2>GENE-Y<\\e2>  is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (<e1>CHEMICAL<\\e1> , as well as fibrin(ogen)","sentence":"The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA  is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA , as well as fibrin(ogen)"}
{"PMID":3146348,"re_id":5,"annotated sentence":"The activation of <e2>human [Glu1]plasminogen<\\e2> [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (<e1>EACA<\\e1> , as well as fibrin(ogen)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"EACA","object":"human [Glu1]plasminogen","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The activation of <e2>GENE-Y<\\e2> [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (<e1>CHEMICAL<\\e1> , as well as fibrin(ogen)","sentence":"The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA , as well as fibrin(ogen)"}
{"PMID":3146348,"re_id":6,"annotated sentence":"The activation of human [Glu1]plasminogen [<e2>( Glu1]Pg<\\e2>  by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (<e1>EACA<\\e1> , as well as fibrin(ogen)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"EACA","object":"( Glu1]Pg","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The activation of human [Glu1]plasminogen [<e2>GENE-Y<\\e2>  by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (<e1>CHEMICAL<\\e1> , as well as fibrin(ogen)","sentence":"The activation of human [Glu1]plasminogen [( Glu1]Pg  by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA , as well as fibrin(ogen)"}
{"PMID":3146348,"re_id":7,"annotated sentence":"The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain <e2>tissue plasminogen activator<\\e2> (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (<e1>EACA<\\e1> , as well as fibrin(ogen)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"EACA","object":"tissue plasminogen activator","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain <e2>GENE-Y<\\e2> (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (<e1>CHEMICAL<\\e1> , as well as fibrin(ogen)","sentence":"The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA , as well as fibrin(ogen)"}
{"PMID":3146348,"re_id":8,"annotated sentence":"The presence of <e1>Cl-<\\e1> inhibits the stimulation of <e2>[Glu1]Pg<\\e2> activation that would normally occur in the presence of fibrinogen, a result of possible importance to the observation that some degree of systemic fibrinogenolysis accompanies therapeutic use of tissue plasminogen activator.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cl-","object":"[Glu1]Pg","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The presence of <e1>CHEMICAL<\\e1> inhibits the stimulation of <e2>GENE-Y<\\e2> activation that would normally occur in the presence of fibrinogen, a result of possible importance to the observation that some degree of systemic fibrinogenolysis accompanies therapeutic use of tissue plasminogen activator.","sentence":"The presence of Cl- inhibits the stimulation of [Glu1]Pg activation that would normally occur in the presence of fibrinogen, a result of possible importance to the observation that some degree of systemic fibrinogenolysis accompanies therapeutic use of tissue plasminogen activator."}
{"PMID":3146348,"re_id":9,"annotated sentence":"The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (<e2>t-PA<\\e2>  is inhibited by <e1>Cl-<\\e1>  at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cl-","object":"t-PA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (<e2>GENE-Y<\\e2>  is inhibited by <e1>CHEMICAL<\\e1>  at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen)","sentence":"The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA  is inhibited by Cl-  at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen)"}
{"PMID":3146348,"re_id":10,"annotated sentence":"The activation of <e2>human [Glu1]plasminogen<\\e2> [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by <e1>Cl-<\\e1>  at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cl-","object":"human [Glu1]plasminogen","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The activation of <e2>GENE-Y<\\e2> [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by <e1>CHEMICAL<\\e1>  at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen)","sentence":"The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-  at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen)"}
{"PMID":3146348,"re_id":11,"annotated sentence":"The activation of human [Glu1]plasminogen [<e2>( Glu1]Pg<\\e2>  by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by <e1>Cl-<\\e1>  at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cl-","object":"( Glu1]Pg","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The activation of human [Glu1]plasminogen [<e2>GENE-Y<\\e2>  by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by <e1>CHEMICAL<\\e1>  at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen)","sentence":"The activation of human [Glu1]plasminogen [( Glu1]Pg  by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-  at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen)"}
{"PMID":3146348,"re_id":12,"annotated sentence":"The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain <e2>tissue plasminogen activator<\\e2> (t-PA) is inhibited by <e1>Cl-<\\e1>  at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cl-","object":"tissue plasminogen activator","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain <e2>GENE-Y<\\e2> (t-PA) is inhibited by <e1>CHEMICAL<\\e1>  at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen)","sentence":"The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-  at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen)"}
{"PMID":7500004,"re_id":0,"annotated sentence":"Whole-cell voltage-clamp of <e2>hNET<\\e2> 293 cells reveals <e1>NE<\\e1> induced, Na(+)-dependent currents blocked by antidepressants and cocaine that are absent in parental cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"NE","object":"hNET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Whole-cell voltage-clamp of <e2>hCHEMICALT<\\e2> 293 cells reveals <e1>CHEMICAL<\\e1> induced, Na(+)-dependent currents blocked by antidepressants and cocaine that are absent in parental cells","sentence":"Whole-cell voltage-clamp of hNET 293 cells reveals NE induced, Na(+)-dependent currents blocked by antidepressants and cocaine that are absent in parental cells"}
{"PMID":7500004,"re_id":1,"annotated sentence":"Sodium-dependent <e1>norepinephrine<\\e1> induced currents in <e2>norepinephrine-transporter<\\e2> transfected HEK-293 cells blocked by cocaine and antidepressants","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"norepinephrine","object":"norepinephrine-transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Sodium-dependent <e1>CHEMICAL<\\e1> induced currents in <e2>CHEMICAL-transporter<\\e2> transfected HEK-293 cells blocked by cocaine and antidepressants","sentence":"Sodium-dependent norepinephrine induced currents in norepinephrine-transporter transfected HEK-293 cells blocked by cocaine and antidepressants"}
{"PMID":7500004,"re_id":2,"annotated sentence":"Whole-cell voltage-clamp of <e2>hNET<\\e2> 293 cells reveals NE-induced, Na(+)-dependent currents blocked by antidepressants and <e1>cocaine<\\e1> that are absent in parental cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cocaine","object":"hNET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Whole-cell voltage-clamp of <e2>GENE-Y<\\e2> 293 cells reveals NE-induced, Na(+)-dependent currents blocked by antidepressants and <e1>CHEMICAL<\\e1> that are absent in parental cells","sentence":"Whole-cell voltage-clamp of hNET 293 cells reveals NE-induced, Na(+)-dependent currents blocked by antidepressants and cocaine that are absent in parental cells"}
{"PMID":7500004,"re_id":3,"annotated sentence":"Sodium-dependent norepinephrine-induced currents in <e2>norepinephrine-transporter<\\e2> transfected HEK-293 cells blocked by <e1>cocaine<\\e1> and antidepressants","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cocaine","object":"norepinephrine-transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Sodium-dependent norepinephrine-induced currents in <e2>GENE-Y<\\e2> transfected HEK-293 cells blocked by <e1>CHEMICAL<\\e1> and antidepressants","sentence":"Sodium-dependent norepinephrine-induced currents in norepinephrine-transporter transfected HEK-293 cells blocked by cocaine and antidepressants"}
{"PMID":7500004,"re_id":4,"annotated sentence":"To explain our observations, we propose that <e2>hNETs<\\e2> function as ion-gated ligand channels with an indefinite stoichiometry relating ion flux to <e1>NE<\\e1> transport","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"NE","object":"hNETs","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To explain our observations, we propose that <e2>hCHEMICALTs<\\e2> function as ion-gated ligand channels with an indefinite stoichiometry relating ion flux to <e1>CHEMICAL<\\e1> transport","sentence":"To explain our observations, we propose that hNETs function as ion-gated ligand channels with an indefinite stoichiometry relating ion flux to NE transport"}
{"PMID":7554708,"re_id":0,"annotated sentence":"BACKGROUND: The active metabolite of the anti-inflammatory drug <e1>nabumetone<\\e1> has been characterized as a selective inhibitor of the inducible <e2>prostaglandin H synthase<\\e2> (PGHS)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"nabumetone","object":"prostaglandin H synthase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"BACKGROUND: The active metabolite of the anti-inflammatory drug <e1>CHEMICAL<\\e1> has been characterized as a selective inhibitor of the inducible <e2>GENE-N<\\e2> (PGHS)","sentence":"BACKGROUND: The active metabolite of the anti-inflammatory drug nabumetone has been characterized as a selective inhibitor of the inducible prostaglandin H synthase (PGHS)"}
{"PMID":7554708,"re_id":1,"annotated sentence":"BACKGROUND: The active metabolite of the anti-inflammatory drug <e1>nabumetone<\\e1> has been characterized as a selective inhibitor of the inducible prostaglandin H synthase (<e2>PGHS<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"nabumetone","object":"PGHS","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"BACKGROUND: The active metabolite of the anti-inflammatory drug <e1>CHEMICAL<\\e1> has been characterized as a selective inhibitor of the inducible prostaglandin H synthase (<e2>GENE-N<\\e2> ","sentence":"BACKGROUND: The active metabolite of the anti-inflammatory drug nabumetone has been characterized as a selective inhibitor of the inducible prostaglandin H synthase (PGHS "}
{"PMID":7554708,"re_id":2,"annotated sentence":"The daily administration of low-dose <e1>aspirin<\\e1> (40 mg), a selective inhibitor of platelet <e2>PGHS-1<\\e2>  caused a cumulative inhibition of urinary 11-dehydro-TXB2 and whole blood TXB2 production that recovered with a timecourse consistent with platelet turnover","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"aspirin","object":"PGHS-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The daily administration of low-dose <e1>CHEMICAL<\\e1> (40 mg), a selective inhibitor of platelet <e2>GENE-Y<\\e2>  caused a cumulative inhibition of urinary 11-dehydro-TXB2 and whole blood TXB2 production that recovered with a timecourse consistent with platelet turnover","sentence":"The daily administration of low-dose aspirin (40 mg), a selective inhibitor of platelet PGHS-1  caused a cumulative inhibition of urinary 11-dehydro-TXB2 and whole blood TXB2 production that recovered with a timecourse consistent with platelet turnover"}
{"PMID":7554708,"re_id":3,"annotated sentence":"CONCLUSIONS: <e1>Nabumetone<\\e1> does dose-dependently inhibit the <e2>cyclooxygenase<\\e2> activity of platelet PGHS-1 of healthy subjects both in vivo and ex vivo","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Nabumetone","object":"cyclooxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"CONCLUSIONS: <e1>CHEMICAL<\\e1> does dose-dependently inhibit the <e2>GENE-N<\\e2> activity of platelet PGHS-1 of healthy subjects both in vivo and ex vivo","sentence":"CONCLUSIONS: Nabumetone does dose-dependently inhibit the cyclooxygenase activity of platelet PGHS-1 of healthy subjects both in vivo and ex vivo"}
{"PMID":7554708,"re_id":4,"annotated sentence":"CONCLUSIONS: <e1>Nabumetone<\\e1> does dose-dependently inhibit the cyclooxygenase activity of platelet <e2>PGHS-1<\\e2> of healthy subjects both in vivo and ex vivo","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Nabumetone","object":"PGHS-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSIONS: <e1>CHEMICAL<\\e1> does dose-dependently inhibit the cyclooxygenase activity of platelet <e2>GENE-Y<\\e2> of healthy subjects both in vivo and ex vivo","sentence":"CONCLUSIONS: Nabumetone does dose-dependently inhibit the cyclooxygenase activity of platelet PGHS-1 of healthy subjects both in vivo and ex vivo"}
{"PMID":7554708,"re_id":5,"annotated sentence":"Moreover, the production of <e1>TXB2<\\e1> during whole blood clotting was assessed as an index of the <e2>cyclooxygenase<\\e2> activity of platelet PGHS-1 ex vivo","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"TXB2","object":"cyclooxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moreover, the production of <e1>CHEMICAL<\\e1> during whole blood clotting was assessed as an index of the <e2>GENE-N<\\e2> activity of platelet PGHS-1 ex vivo","sentence":"Moreover, the production of TXB2 during whole blood clotting was assessed as an index of the cyclooxygenase activity of platelet PGHS-1 ex vivo"}
{"PMID":7554708,"re_id":6,"annotated sentence":"Moreover, the production of <e1>TXB2<\\e1> during whole blood clotting was assessed as an index of the cyclooxygenase activity of platelet <e2>PGHS-1<\\e2> ex vivo","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"TXB2","object":"PGHS-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, the production of <e1>CHEMICAL<\\e1> during whole blood clotting was assessed as an index of the cyclooxygenase activity of platelet <e2>GENE-Y<\\e2> ex vivo","sentence":"Moreover, the production of TXB2 during whole blood clotting was assessed as an index of the cyclooxygenase activity of platelet PGHS-1 ex vivo"}
{"PMID":7554708,"re_id":7,"annotated sentence":"The daily administration of low-dose aspirin (40 mg), a selective inhibitor of platelet <e2>PGHS-1<\\e2>  caused a cumulative inhibition of urinary <e1>11-dehydro-TXB2<\\e1> and whole blood TXB2 production that recovered with a timecourse consistent with platelet turnover","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"11-dehydro-TXB2","object":"PGHS-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The daily administration of low-dose aspirin (40 mg), a selective inhibitor of platelet <e2>GENE-Y<\\e2>  caused a cumulative inhibition of urinary <e1>CHEMICAL<\\e1> and whole blood TXB2 production that recovered with a timecourse consistent with platelet turnover","sentence":"The daily administration of low-dose aspirin (40 mg), a selective inhibitor of platelet PGHS-1  caused a cumulative inhibition of urinary 11-dehydro-TXB2 and whole blood TXB2 production that recovered with a timecourse consistent with platelet turnover"}
{"PMID":7554708,"re_id":8,"annotated sentence":"The daily administration of low-dose aspirin (40 mg), a selective inhibitor of platelet <e2>PGHS-1<\\e2>  caused a cumulative inhibition of urinary 11-dehydro-TXB2 and whole blood <e1>TXB2<\\e1> production that recovered with a timecourse consistent with platelet turnover","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"TXB2","object":"PGHS-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The daily administration of low-dose aspirin (40 mg), a selective inhibitor of platelet <e2>GENE-Y<\\e2>  caused a cumulative inhibition of urinary 11-dehydro-CHEMICAL and whole blood <e1>CHEMICAL<\\e1> production that recovered with a timecourse consistent with platelet turnover","sentence":"The daily administration of low-dose aspirin (40 mg), a selective inhibitor of platelet PGHS-1  caused a cumulative inhibition of urinary 11-dehydro-TXB2 and whole blood TXB2 production that recovered with a timecourse consistent with platelet turnover"}
{"PMID":7714410,"re_id":0,"annotated sentence":"Preclinical efficacy of <e1>emedastine<\\e1>  a potent, selective <e2>histamine H1<\\e2> antagonist for topical ocular use","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"emedastine","object":"histamine H1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Preclinical efficacy of <e1>CHEMICAL<\\e1>  a potent, selective <e2>GENE-Y<\\e2> antagonist for topical ocular use","sentence":"Preclinical efficacy of emedastine  a potent, selective histamine H1 antagonist for topical ocular use"}
{"PMID":7756657,"re_id":0,"annotated sentence":"(2) Exposure histories vary in secondary 11q23 leukemia, as the only <e2>topoisomerase II<\\e2> inhibitor was <e1>dactinomycin<\\e1> in one case, and, in another case, no topoisomerase II inhibitor was administered","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dactinomycin","object":"topoisomerase II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"(2) Exposure histories vary in secondary 11q23 leukemia, as the only <e2>GENE-Y<\\e2> inhibitor was <e1>CHEMICAL<\\e1> in one case, and, in another case, no GENE-Y inhibitor was administered","sentence":"(2) Exposure histories vary in secondary 11q23 leukemia, as the only topoisomerase II inhibitor was dactinomycin in one case, and, in another case, no topoisomerase II inhibitor was administered"}
{"PMID":7825862,"re_id":0,"annotated sentence":"<e1>Indomethacin<\\e1>  piroxicam, and sulindac sulfide were found to preferentially inhibit <e2>PGHS-1<\\e2>  Ibuprofen and meclofenamate inhibit both enzymes with comparable potencies","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Indomethacin","object":"PGHS-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  piroxicam, and sulindac sulfide were found to preferentially inhibit <e2>GENE-Y<\\e2>  Ibuprofen and meclofenamate inhibit both enzymes with comparable potencies","sentence":"Indomethacin  piroxicam, and sulindac sulfide were found to preferentially inhibit PGHS-1  Ibuprofen and meclofenamate inhibit both enzymes with comparable potencies"}
{"PMID":7825862,"re_id":1,"annotated sentence":"Indomethacin, <e1>piroxicam<\\e1>  and sulindac sulfide were found to preferentially inhibit <e2>PGHS-1<\\e2>  Ibuprofen and meclofenamate inhibit both enzymes with comparable potencies","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"piroxicam","object":"PGHS-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Indomethacin, <e1>CHEMICAL<\\e1>  and sulindac sulfide were found to preferentially inhibit <e2>GENE-Y<\\e2>  Ibuprofen and meclofenamate inhibit both enzymes with comparable potencies","sentence":"Indomethacin, piroxicam  and sulindac sulfide were found to preferentially inhibit PGHS-1  Ibuprofen and meclofenamate inhibit both enzymes with comparable potencies"}
{"PMID":7825862,"re_id":2,"annotated sentence":"Indomethacin, piroxicam, and <e1>sulindac sulfide<\\e1> were found to preferentially inhibit <e2>PGHS-1<\\e2>  Ibuprofen and meclofenamate inhibit both enzymes with comparable potencies","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sulindac sulfide","object":"PGHS-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Indomethacin, piroxicam, and <e1>CHEMICAL<\\e1> were found to preferentially inhibit <e2>GENE-Y<\\e2>  Ibuprofen and meclofenamate inhibit both enzymes with comparable potencies","sentence":"Indomethacin, piroxicam, and sulindac sulfide were found to preferentially inhibit PGHS-1  Ibuprofen and meclofenamate inhibit both enzymes with comparable potencies"}
{"PMID":7825862,"re_id":3,"annotated sentence":"<e1>6-Methoxy-2-naphthylacetic acid<\\e1>  the active metabolite of Relafen, inhibits murine <e2>PGHS-2<\\e2> preferentially","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"6-Methoxy-2-naphthylacetic acid","object":"PGHS-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  the active metabolite of Relafen, inhibits murine <e2>GENE-Y<\\e2> preferentially","sentence":"6-Methoxy-2-naphthylacetic acid  the active metabolite of Relafen, inhibits murine PGHS-2 preferentially"}
{"PMID":7825862,"re_id":4,"annotated sentence":"6-Methoxy-2-naphthylacetic acid, the active metabolite of <e1>Relafen<\\e1>  inhibits murine <e2>PGHS-2<\\e2> preferentially","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Relafen","object":"PGHS-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"6-Methoxy-2-naphthylacetic acid, the active metabolite of <e1>CHEMICAL<\\e1>  inhibits murine <e2>GENE-Y<\\e2> preferentially","sentence":"6-Methoxy-2-naphthylacetic acid, the active metabolite of Relafen  inhibits murine PGHS-2 preferentially"}
{"PMID":7825862,"re_id":5,"annotated sentence":"<e1>Aspirin<\\e1> irreversibly inhibits <e2>PGHS-1<\\e2>  preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of PGHS-2 causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (15-HETE) instead of PGH2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Aspirin","object":"PGHS-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> irreversibly inhibits <e2>GENE-Y<\\e2>  preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of PGHS-2 causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (15-HETE) instead of PGH2","sentence":"Aspirin irreversibly inhibits PGHS-1  preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of PGHS-2 causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (15-HETE) instead of PGH2"}
{"PMID":7825862,"re_id":6,"annotated sentence":"Aspirin irreversibly inhibits PGHS-1, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of <e2>PGHS-2<\\e2> causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (<e1>15-HETE<\\e1>  instead of PGH2","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"15-HETE","object":"PGHS-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Aspirin irreversibly inhibits PGHS-1, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of <e2>GENE-Y<\\e2> causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (<e1>CHEMICAL<\\e1>  instead of PGH2","sentence":"Aspirin irreversibly inhibits PGHS-1, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of PGHS-2 causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (15-HETE  instead of PGH2"}
{"PMID":7825862,"re_id":7,"annotated sentence":"Aspirin irreversibly inhibits PGHS-1, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of <e2>PGHS-2<\\e2> causes this enzyme to form <e1>15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid<\\e1> (15-HETE) instead of PGH2","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid","object":"PGHS-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Aspirin irreversibly inhibits PGHS-1, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of <e2>GENE-Y<\\e2> causes this enzyme to form <e1>CHEMICAL<\\e1> (15-HETE) instead of PGH2","sentence":"Aspirin irreversibly inhibits PGHS-1, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of PGHS-2 causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (15-HETE) instead of PGH2"}
{"PMID":7902561,"re_id":0,"annotated sentence":"Anorexia induced by (+)-amphetamine, phentermine, diethylpropion and phenylpropanolamine seems to be the result of their ability to increase the release of noradrenaline and\/or dopamine from nerve terminals and inhibit their reuptake or, in the case of <e1>phenylpropanolamine<\\e1>  to stimulate directly <e2>alpha 1-adrenoceptors<\\e2>  It has been suggested that beta- and alpha 1-adrenoceptors and D1 dopamine receptors are involved in their effect on food intake","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"phenylpropanolamine","object":"alpha 1-adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Anorexia induced by (+)-amphetamine, phentermine, diethylpropion and CHEMICAL seems to be the result of their ability to increase the release of noradrenaline and\/or dopamine from nerve terminals and inhibit their reuptake or, in the case of <e1>CHEMICAL<\\e1>  to stimulate directly <e2>GENE-N<\\e2>  It has been suggested that beta- and GENE-N and D1 dopamine receptors are involved in their effect on food intake","sentence":"Anorexia induced by (+)-amphetamine, phentermine, diethylpropion and phenylpropanolamine seems to be the result of their ability to increase the release of noradrenaline and\/or dopamine from nerve terminals and inhibit their reuptake or, in the case of phenylpropanolamine  to stimulate directly alpha 1-adrenoceptors  It has been suggested that beta- and alpha 1-adrenoceptors and D1 dopamine receptors are involved in their effect on food intake"}
{"PMID":8032658,"re_id":0,"annotated sentence":"Under these conditions, blockade of <e2>monoamine oxidase<\\e2> with <e1>pargyline<\\e1> (100 microM for 15 min) caused a leftward displacement of concentration-effect curves for both 5-methoxytryptamine (5-MeO-T) and tryptamine","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pargyline","object":"monoamine oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Under these conditions, blockade of <e2>GENE-N<\\e2> with <e1>CHEMICAL<\\e1> (100 microM for 15 min) caused a leftward displacement of concentration-effect curves for both 5-methoxytryptamine (5-MeO-T) and tryptamine","sentence":"Under these conditions, blockade of monoamine oxidase with pargyline (100 microM for 15 min) caused a leftward displacement of concentration-effect curves for both 5-methoxytryptamine (5-MeO-T) and tryptamine"}
{"PMID":8032658,"re_id":1,"annotated sentence":"In addition several ligands known to act as agonists at either <e2>5-HT2A<\\e2> or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), <e1>Ru 24969<\\e1>  MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"Ru 24969","object":"5-HT2A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition several ligands known to act as agonists at either <e2>GENE-Y<\\e2> or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), <e1>CHEMICAL<\\e1>  MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive","sentence":"In addition several ligands known to act as agonists at either 5-HT2A or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969  MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive"}
{"PMID":8032658,"re_id":2,"annotated sentence":"In addition several ligands known to act as agonists at either 5-HT2A or <e2>5-HT2C<\\e2> receptors including 1-m-chlorophenylpiperazine (m-CPP), <e1>Ru 24969<\\e1>  MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"Ru 24969","object":"5-HT2C","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition several ligands known to act as agonists at either 5-HT2A or <e2>GENE-Y<\\e2> receptors including 1-m-chlorophenylpiperazine (m-CPP), <e1>CHEMICAL<\\e1>  MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive","sentence":"In addition several ligands known to act as agonists at either 5-HT2A or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969  MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive"}
{"PMID":8032658,"re_id":3,"annotated sentence":"In addition several ligands known to act as agonists at either <e2>5-HT2A<\\e2> or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, <e1>MK 212<\\e1> and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"MK 212","object":"5-HT2A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition several ligands known to act as agonists at either <e2>GENE-Y<\\e2> or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, <e1>CHEMICAL<\\e1> and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive","sentence":"In addition several ligands known to act as agonists at either 5-HT2A or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive"}
{"PMID":8032658,"re_id":4,"annotated sentence":"In addition several ligands known to act as agonists at either 5-HT2A or <e2>5-HT2C<\\e2> receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, <e1>MK 212<\\e1> and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"MK 212","object":"5-HT2C","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition several ligands known to act as agonists at either 5-HT2A or <e2>GENE-Y<\\e2> receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, <e1>CHEMICAL<\\e1> and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive","sentence":"In addition several ligands known to act as agonists at either 5-HT2A or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive"}
{"PMID":8032658,"re_id":5,"annotated sentence":"In addition several ligands known to act as agonists at either <e2>5-HT2A<\\e2> or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and <e1>SCH 23390<\\e1> were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"SCH 23390","object":"5-HT2A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition several ligands known to act as agonists at either <e2>GENE-Y<\\e2> or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and <e1>CHEMICAL<\\e1> were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive","sentence":"In addition several ligands known to act as agonists at either 5-HT2A or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive"}
{"PMID":8032658,"re_id":6,"annotated sentence":"In addition several ligands known to act as agonists at either 5-HT2A or <e2>5-HT2C<\\e2> receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and <e1>SCH 23390<\\e1> were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"SCH 23390","object":"5-HT2C","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition several ligands known to act as agonists at either 5-HT2A or <e2>GENE-Y<\\e2> receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and <e1>CHEMICAL<\\e1> were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive","sentence":"In addition several ligands known to act as agonists at either 5-HT2A or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive"}
{"PMID":8032658,"re_id":7,"annotated sentence":"In addition several ligands known to act as agonists at either <e2>5-HT2A<\\e2> or 5-HT2C receptors including <e1>1-m-chlorophenylpiperazine<\\e1> (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"1-m-chlorophenylpiperazine","object":"5-HT2A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition several ligands known to act as agonists at either <e2>GENE-Y<\\e2> or 5-HT2C receptors including <e1>CHEMICAL<\\e1> (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive","sentence":"In addition several ligands known to act as agonists at either 5-HT2A or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive"}
{"PMID":8032658,"re_id":8,"annotated sentence":"In addition several ligands known to act as agonists at either 5-HT2A or <e2>5-HT2C<\\e2> receptors including <e1>1-m-chlorophenylpiperazine<\\e1> (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"1-m-chlorophenylpiperazine","object":"5-HT2C","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition several ligands known to act as agonists at either 5-HT2A or <e2>GENE-Y<\\e2> receptors including <e1>CHEMICAL<\\e1> (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive","sentence":"In addition several ligands known to act as agonists at either 5-HT2A or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive"}
{"PMID":8032658,"re_id":9,"annotated sentence":"In addition several ligands known to act as agonists at either <e2>5-HT2A<\\e2> or 5-HT2C receptors including 1-m-chlorophenylpiperazine (<e1>m-CPP<\\e1> , Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"m-CPP","object":"5-HT2A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition several ligands known to act as agonists at either <e2>GENE-Y<\\e2> or 5-HT2C receptors including 1-m-chlorophenylpiperazine (<e1>CHEMICAL<\\e1> , Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive","sentence":"In addition several ligands known to act as agonists at either 5-HT2A or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP , Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive"}
{"PMID":8032658,"re_id":10,"annotated sentence":"In addition several ligands known to act as agonists at either 5-HT2A or <e2>5-HT2C<\\e2> receptors including 1-m-chlorophenylpiperazine (<e1>m-CPP<\\e1> , Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"m-CPP","object":"5-HT2C","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition several ligands known to act as agonists at either 5-HT2A or <e2>GENE-Y<\\e2> receptors including 1-m-chlorophenylpiperazine (<e1>CHEMICAL<\\e1> , Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive","sentence":"In addition several ligands known to act as agonists at either 5-HT2A or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP , Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive"}
{"PMID":8294418,"re_id":0,"annotated sentence":"Neither ryanodine nor <e1>EGTA<\\e1> inhibited down-regulation of <e2>alpha-AR<\\e2> mRNA by NE","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"EGTA","object":"alpha-AR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Neither ryanodine nor <e1>CHEMICAL<\\e1> inhibited down-regulation of <e2>GENE-N<\\e2> mRNA by NE","sentence":"Neither ryanodine nor EGTA inhibited down-regulation of alpha-AR mRNA by NE"}
{"PMID":8294418,"re_id":1,"annotated sentence":"Neither <e1>ryanodine<\\e1> nor EGTA inhibited down-regulation of <e2>alpha-AR<\\e2> mRNA by NE","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ryanodine","object":"alpha-AR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Neither <e1>CHEMICAL<\\e1> nor EGTA inhibited down-regulation of <e2>GENE-N<\\e2> mRNA by NE","sentence":"Neither ryanodine nor EGTA inhibited down-regulation of alpha-AR mRNA by NE"}
{"PMID":8294418,"re_id":2,"annotated sentence":"Neither ryanodine nor EGTA inhibited down-regulation of <e2>alpha-AR<\\e2> mRNA by <e1>NE<\\e1>  Actinomycin D caused alpha-AR mRNA level to decrease with a half-life of 3.2 +\/- 0.4 h and blocked the effect of H-7 to decrease basal alpha-AR mRNA level","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NE","object":"alpha-AR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Neither ryanodine nor EGTA inhibited down-regulation of <e2>GENE-N<\\e2> mRNA by <e1>CHEMICAL<\\e1>  Actinomycin D caused GENE-N mRNA level to decrease with a half-life of 3.2 +\/- 0.4 h and blocked the effect of H-7 to decrease basal GENE-N mRNA level","sentence":"Neither ryanodine nor EGTA inhibited down-regulation of alpha-AR mRNA by NE  Actinomycin D caused alpha-AR mRNA level to decrease with a half-life of 3.2 +\/- 0.4 h and blocked the effect of H-7 to decrease basal alpha-AR mRNA level"}
{"PMID":8294418,"re_id":3,"annotated sentence":"<e1>Actinomycin D<\\e1> caused <e2>alpha-AR<\\e2> mRNA level to decrease with a half-life of 3.2 +\/- 0.4 h and blocked the effect of H-7 to decrease basal alpha-AR mRNA level","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Actinomycin D","object":"alpha-AR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> caused <e2>GENE-N<\\e2> mRNA level to decrease with a half-life of 3.2 +\/- 0.4 h and blocked the effect of H-7 to decrease basal GENE-N mRNA level","sentence":"Actinomycin D caused alpha-AR mRNA level to decrease with a half-life of 3.2 +\/- 0.4 h and blocked the effect of H-7 to decrease basal alpha-AR mRNA level"}
{"PMID":8294418,"re_id":4,"annotated sentence":"<e1>Actinomycin D<\\e1> caused alpha-AR mRNA level to decrease with a half-life of 3.2 +\/- 0.4 h and blocked the effect of H-7 to decrease basal <e2>alpha-AR<\\e2> mRNA level","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Actinomycin D","object":"alpha-AR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> caused GENE-N mRNA level to decrease with a half-life of 3.2 +\/- 0.4 h and blocked the effect of H-7 to decrease basal <e2>GENE-N<\\e2> mRNA level","sentence":"Actinomycin D caused alpha-AR mRNA level to decrease with a half-life of 3.2 +\/- 0.4 h and blocked the effect of H-7 to decrease basal alpha-AR mRNA level"}
{"PMID":8294418,"re_id":5,"annotated sentence":"Both <e1>NE<\\e1> and phorbol esters increased the rate of <e2>alpha-AR<\\e2> mRNA degradation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NE","object":"alpha-AR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Both <e1>CHEMICAL<\\e1> and phorbol esters increased the rate of <e2>GENE-N<\\e2> mRNA degradation","sentence":"Both NE and phorbol esters increased the rate of alpha-AR mRNA degradation"}
{"PMID":8294418,"re_id":6,"annotated sentence":"Both NE and <e1>phorbol esters<\\e1> increased the rate of <e2>alpha-AR<\\e2> mRNA degradation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phorbol esters","object":"alpha-AR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Both NE and <e1>CHEMICAL<\\e1> increased the rate of <e2>GENE-N<\\e2> mRNA degradation","sentence":"Both NE and phorbol esters increased the rate of alpha-AR mRNA degradation"}
{"PMID":8294418,"re_id":7,"annotated sentence":"In <e1>NE<\\e1> desensitized cells, phorbol esters and bradykinin each caused the expected down-regulation of <e2>alpha-AR<\\e2> mRNA","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NE","object":"alpha-AR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In <e1>CHEMICAL<\\e1> desensitized cells, phorbol esters and bradykinin each caused the expected down-regulation of <e2>GENE-N<\\e2> mRNA","sentence":"In NE desensitized cells, phorbol esters and bradykinin each caused the expected down-regulation of alpha-AR mRNA"}
{"PMID":8294418,"re_id":8,"annotated sentence":"In NE-desensitized cells, <e1>phorbol esters<\\e1> and bradykinin each caused the expected down-regulation of <e2>alpha-AR<\\e2> mRNA","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phorbol esters","object":"alpha-AR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In NE-desensitized cells, <e1>CHEMICAL<\\e1> and bradykinin each caused the expected down-regulation of <e2>GENE-N<\\e2> mRNA","sentence":"In NE-desensitized cells, phorbol esters and bradykinin each caused the expected down-regulation of alpha-AR mRNA"}
{"PMID":8294418,"re_id":9,"annotated sentence":"The <e2>protein phosphatase<\\e2> inhibitor <e1>okadaic acid<\\e1> prolonged the normally transient effect of NE for at least 24 h","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"okadaic acid","object":"protein phosphatase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1> prolonged the normally transient effect of NE for at least 24 h","sentence":"The protein phosphatase inhibitor okadaic acid prolonged the normally transient effect of NE for at least 24 h"}
{"PMID":8294418,"re_id":10,"annotated sentence":"<e1>NE<\\e1>  phorbol esters, and bradykinin each decreased <e2>alpha-AR<\\e2> mRNA levels by 70-80%","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NE","object":"alpha-AR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  phorbol esters, and bradykinin each decreased <e2>GENE-N<\\e2> mRNA levels by 70-80%","sentence":"NE  phorbol esters, and bradykinin each decreased alpha-AR mRNA levels by 70-80%"}
{"PMID":8294418,"re_id":11,"annotated sentence":"Phorbol esters and <e1>norepinephrine<\\e1> destabilize <e2>alpha 1B-adrenergic receptor<\\e2> mRNA in vascular smooth muscle cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"norepinephrine","object":"alpha 1B-adrenergic receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Phorbol esters and <e1>CHEMICAL<\\e1> destabilize <e2>GENE-Y<\\e2> mRNA in vascular smooth muscle cells","sentence":"Phorbol esters and norepinephrine destabilize alpha 1B-adrenergic receptor mRNA in vascular smooth muscle cells"}
{"PMID":8294418,"re_id":12,"annotated sentence":"NE, <e1>phorbol esters<\\e1>  and bradykinin each decreased <e2>alpha-AR<\\e2> mRNA levels by 70-80%","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phorbol esters","object":"alpha-AR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"NE, <e1>CHEMICAL<\\e1>  and bradykinin each decreased <e2>GENE-N<\\e2> mRNA levels by 70-80%","sentence":"NE, phorbol esters  and bradykinin each decreased alpha-AR mRNA levels by 70-80%"}
{"PMID":8294418,"re_id":13,"annotated sentence":"The mechanism by which <e1>norepinephrine<\\e1> (NE) down-regulates <e2>alpha 1B-adrenergic receptor<\\e2> (alpha-AR) mRNA was studied in rabbit aortic smooth muscle cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"norepinephrine","object":"alpha 1B-adrenergic receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mechanism by which <e1>CHEMICAL<\\e1> (NE) down-regulates <e2>GENE-Y<\\e2> (alpha-AR) mRNA was studied in rabbit aortic smooth muscle cells","sentence":"The mechanism by which norepinephrine (NE) down-regulates alpha 1B-adrenergic receptor (alpha-AR) mRNA was studied in rabbit aortic smooth muscle cells"}
{"PMID":8294418,"re_id":14,"annotated sentence":"The mechanism by which <e1>norepinephrine<\\e1> (NE) down-regulates alpha 1B-adrenergic receptor (<e2>alpha-AR<\\e2>  mRNA was studied in rabbit aortic smooth muscle cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"norepinephrine","object":"alpha-AR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The mechanism by which <e1>CHEMICAL<\\e1> (NE) down-regulates alpha 1B-adrenergic receptor (<e2>GENE-N<\\e2>  mRNA was studied in rabbit aortic smooth muscle cells","sentence":"The mechanism by which norepinephrine (NE) down-regulates alpha 1B-adrenergic receptor (alpha-AR  mRNA was studied in rabbit aortic smooth muscle cells"}
{"PMID":8294418,"re_id":15,"annotated sentence":"The <e2>protein kinase C<\\e2> inhibitor <e1>(+)-1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride<\\e1> (H-7) abolished the effects of phorbol esters and NE and decreased basal mRNA levels by 52 +\/- 3%","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"(+)-1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride","object":"protein kinase C","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1> (H-7) abolished the effects of phorbol esters and NE and decreased basal mRNA levels by 52 +\/- 3%","sentence":"The protein kinase C inhibitor (+)-1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride (H-7) abolished the effects of phorbol esters and NE and decreased basal mRNA levels by 52 +\/- 3%"}
{"PMID":8294418,"re_id":16,"annotated sentence":"The <e2>protein kinase C<\\e2> inhibitor (+)-1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride (<e1>H-7<\\e1>  abolished the effects of phorbol esters and NE and decreased basal mRNA levels by 52 +\/- 3%","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"H-7","object":"protein kinase C","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e2>GENE-N<\\e2> inhibitor (+)-1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride (<e1>CHEMICAL<\\e1>  abolished the effects of phorbol esters and NE and decreased basal mRNA levels by 52 +\/- 3%","sentence":"The protein kinase C inhibitor (+)-1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride (H-7  abolished the effects of phorbol esters and NE and decreased basal mRNA levels by 52 +\/- 3%"}
{"PMID":8294418,"re_id":17,"annotated sentence":"The mechanism by which norepinephrine (<e1>NE<\\e1>  down-regulates <e2>alpha 1B-adrenergic receptor<\\e2> (alpha-AR) mRNA was studied in rabbit aortic smooth muscle cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NE","object":"alpha 1B-adrenergic receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mechanism by which norepinephrine (<e1>CHEMICAL<\\e1>  down-regulates <e2>GENE-Y<\\e2> (alpha-AR) mRNA was studied in rabbit aortic smooth muscle cells","sentence":"The mechanism by which norepinephrine (NE  down-regulates alpha 1B-adrenergic receptor (alpha-AR) mRNA was studied in rabbit aortic smooth muscle cells"}
{"PMID":8294418,"re_id":18,"annotated sentence":"The mechanism by which norepinephrine (<e1>NE<\\e1>  down-regulates alpha 1B-adrenergic receptor (<e2>alpha-AR<\\e2>  mRNA was studied in rabbit aortic smooth muscle cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NE","object":"alpha-AR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The mechanism by which norepinephrine (<e1>CHEMICAL<\\e1>  down-regulates alpha 1B-adrenergic receptor (<e2>GENE-N<\\e2>  mRNA was studied in rabbit aortic smooth muscle cells","sentence":"The mechanism by which norepinephrine (NE  down-regulates alpha 1B-adrenergic receptor (alpha-AR  mRNA was studied in rabbit aortic smooth muscle cells"}
{"PMID":8384716,"re_id":0,"annotated sentence":"HeLa cells transfected with the MR77 gene exhibited inhibition of <e2>adenylate cyclase<\\e2> in response to <e1>serotonin<\\e1>  MR77 is expressed at low levels throughout the brain, with the greatest expression in the cortex, hippocampus, and striatum","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"serotonin","object":"adenylate cyclase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"HeLa cells transfected with the MR77 gene exhibited inhibition of <e2>GENE-N<\\e2> in response to <e1>CHEMICAL<\\e1>  MR77 is expressed at low levels throughout the brain, with the greatest expression in the cortex, hippocampus, and striatum","sentence":"HeLa cells transfected with the MR77 gene exhibited inhibition of adenylate cyclase in response to serotonin  MR77 is expressed at low levels throughout the brain, with the greatest expression in the cortex, hippocampus, and striatum"}
{"PMID":8384716,"re_id":1,"annotated sentence":"The specific binding is displaced by the selective <e2>5-HT1D<\\e2> agonist <e1>sumatriptan<\\e1> but not by the mixed 5-HT1A\/1D agonist 5-carboxyamidotryptamine","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"sumatriptan","object":"5-HT1D","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The specific binding is displaced by the selective <e2>GENE-Y<\\e2> agonist <e1>CHEMICAL<\\e1> but not by the mixed 5-HT1A\/1D agonist 5-carboxyamidotryptamine","sentence":"The specific binding is displaced by the selective 5-HT1D agonist sumatriptan but not by the mixed 5-HT1A\/1D agonist 5-carboxyamidotryptamine"}
{"PMID":8425287,"re_id":0,"annotated sentence":"The antiarrhythmic effects of exogenous adenosine and Valsalva on this form of VT may be due to receptor-mediated inhibition of adenylate cyclase or to noncardiac receptor-mediated effects, i.e., exogenous <e1>adenosine<\\e1> may modulate VT through alterations in autonomic tone by activation of arterial <e2>chemoreceptors<\\e2>  and Valsalva has been shown to decrease venous return, resulting in a reduction in cardiac dimensions and myocardial stretch","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"adenosine","object":"chemoreceptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The antiarrhythmic effects of exogenous CHEMICAL and Valsalva on this form of VT may be due to receptor-mediated inhibition of adenylate cyclase or to noncardiac receptor-mediated effects, i.e., exogenous <e1>CHEMICAL<\\e1> may modulate VT through alterations in autonomic tone by activation of arterial <e2>GENE-N<\\e2>  and Valsalva has been shown to decrease venous return, resulting in a reduction in cardiac dimensions and myocardial stretch","sentence":"The antiarrhythmic effects of exogenous adenosine and Valsalva on this form of VT may be due to receptor-mediated inhibition of adenylate cyclase or to noncardiac receptor-mediated effects, i.e., exogenous adenosine may modulate VT through alterations in autonomic tone by activation of arterial chemoreceptors  and Valsalva has been shown to decrease venous return, resulting in a reduction in cardiac dimensions and myocardial stretch"}
{"PMID":8425287,"re_id":1,"annotated sentence":"<e1>Edrophonium<\\e1> (10 mg i.v.), a <e2>cholinesterase<\\e2> inhibitor that potentiates the effects of acetylcholine at the muscarinic cholinergic receptor, terminated VT in four of four patients, an effect that was reversed by atropine","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Edrophonium","object":"cholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (10 mg i.v.), a <e2>GENE-Y<\\e2> inhibitor that potentiates the effects of acetylcholine at the muscarinic cholinergic receptor, terminated VT in four of four patients, an effect that was reversed by atropine","sentence":"Edrophonium (10 mg i.v.), a cholinesterase inhibitor that potentiates the effects of acetylcholine at the muscarinic cholinergic receptor, terminated VT in four of four patients, an effect that was reversed by atropine"}
{"PMID":8425287,"re_id":2,"annotated sentence":"Edrophonium (10 mg i.v.), a cholinesterase inhibitor that potentiates the effects of acetylcholine at the <e2>muscarinic cholinergic receptor<\\e2>  terminated VT in four of four patients, an effect that was reversed by <e1>atropine<\\e1>  Group 2 (n = 6): In patients with reentrant VT, dipyridamole and edrophonium had no effect on VT cycle length or duration","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"atropine","object":"muscarinic cholinergic receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Edrophonium (10 mg i.v.), a cholinesterase inhibitor that potentiates the effects of acetylcholine at the <e2>GENE-N<\\e2>  terminated VT in four of four patients, an effect that was reversed by <e1>CHEMICAL<\\e1>  Group 2 (n = 6): In patients with reentrant VT, dipyridamole and edrophonium had no effect on VT cycle length or duration","sentence":"Edrophonium (10 mg i.v.), a cholinesterase inhibitor that potentiates the effects of acetylcholine at the muscarinic cholinergic receptor  terminated VT in four of four patients, an effect that was reversed by atropine  Group 2 (n = 6): In patients with reentrant VT, dipyridamole and edrophonium had no effect on VT cycle length or duration"}
{"PMID":8425287,"re_id":3,"annotated sentence":"VT recurred with the addition of <e1>aminophylline<\\e1>  a competitive <e2>adenosine A1-receptor<\\e2> antagonist","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"aminophylline","object":"adenosine A1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"VT recurred with the addition of <e1>CHEMICAL<\\e1>  a competitive <e2>GENE-Y<\\e2> antagonist","sentence":"VT recurred with the addition of aminophylline  a competitive adenosine A1-receptor antagonist"}
{"PMID":8566141,"re_id":0,"annotated sentence":"Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the NMDA receptor antagonist, MK-801, blocked <e1>amantadine<\\e1> induction of <e2>Fos<\\e2> in the striatum","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"amantadine","object":"Fos","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the NMDA receptor antagonist, MK-801, blocked <e1>CHEMICAL<\\e1> induction of <e2>GENE-Y<\\e2> in the striatum","sentence":"Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the NMDA receptor antagonist, MK-801, blocked amantadine induction of Fos in the striatum"}
{"PMID":8566141,"re_id":1,"annotated sentence":"However, <e1>amantadine<\\e1> induction of <e2>Fos<\\e2> in the striatum was unaffected by the dopamine D2 receptor antagonist, sulpiride","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"amantadine","object":"Fos","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, <e1>CHEMICAL<\\e1> induction of <e2>GENE-Y<\\e2> in the striatum was unaffected by the dopamine D2 receptor antagonist, sulpiride","sentence":"However, amantadine induction of Fos in the striatum was unaffected by the dopamine D2 receptor antagonist, sulpiride"}
{"PMID":8566141,"re_id":2,"annotated sentence":"These results suggest that <e1>amantadine<\\e1> induction of <e2>Fos<\\e2> in the rat striatum is related to dopamine D1 and NMDA receptors.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"amantadine","object":"Fos","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that <e1>CHEMICAL<\\e1> induction of <e2>GENE-Y<\\e2> in the rat striatum is related to dopamine D1 and NMDA receptors.","sentence":"These results suggest that amantadine induction of Fos in the rat striatum is related to dopamine D1 and NMDA receptors."}
{"PMID":8566141,"re_id":3,"annotated sentence":"<e1>Amantadine<\\e1> induces <e2>c-fos<\\e2> in rat striatum: reversal with dopamine D1 and NMDA receptor antagonists","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Amantadine","object":"c-fos","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induces <e2>GENE-Y<\\e2> in rat striatum: reversal with dopamine D1 and NMDA receptor antagonists","sentence":"Amantadine induces c-fos in rat striatum: reversal with dopamine D1 and NMDA receptor antagonists"}
{"PMID":8566141,"re_id":4,"annotated sentence":"<e1>Amantadine<\\e1> (1-aminoadamantane) induced <e2>Fos<\\e2> expression in the central, dorsal-medial and ventral-medial part of the striatum","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Amantadine","object":"Fos","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (1-aminoadamantane) induced <e2>GENE-Y<\\e2> expression in the central, dorsal-medial and ventral-medial part of the striatum","sentence":"Amantadine (1-aminoadamantane) induced Fos expression in the central, dorsal-medial and ventral-medial part of the striatum"}
{"PMID":8566141,"re_id":5,"annotated sentence":"Amantadine (<e1>1-aminoadamantane<\\e1>  induced <e2>Fos<\\e2> expression in the central, dorsal-medial and ventral-medial part of the striatum","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"1-aminoadamantane","object":"Fos","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Amantadine (<e1>CHEMICAL<\\e1>  induced <e2>GENE-Y<\\e2> expression in the central, dorsal-medial and ventral-medial part of the striatum","sentence":"Amantadine (1-aminoadamantane  induced Fos expression in the central, dorsal-medial and ventral-medial part of the striatum"}
{"PMID":8566141,"re_id":6,"annotated sentence":"The distribution pattern of <e2>Fos<\\e2> induced by <e1>amantadine<\\e1> was more similar to those seen with dopaminomimetics than with N-methyl-D-aspartate (NMDA) receptor antagonists","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"amantadine","object":"Fos","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The distribution pattern of <e2>GENE-Y<\\e2> induced by <e1>CHEMICAL<\\e1> was more similar to those seen with dopaminomimetics than with N-methyl-D-aspartate (NMDA) receptor antagonists","sentence":"The distribution pattern of Fos induced by amantadine was more similar to those seen with dopaminomimetics than with N-methyl-D-aspartate (NMDA) receptor antagonists"}
{"PMID":8566141,"re_id":7,"annotated sentence":"Pretreatment with the dopamine D1 receptor antagonist, <e1>SCH23390<\\e1>  and the NMDA receptor antagonist, MK-801, blocked amantadine induction of <e2>Fos<\\e2> in the striatum","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SCH23390","object":"Fos","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pretreatment with the dopamine D1 receptor antagonist, <e1>CHEMICAL<\\e1>  and the NMDA receptor antagonist, MK-801, blocked amantadine induction of <e2>GENE-Y<\\e2> in the striatum","sentence":"Pretreatment with the dopamine D1 receptor antagonist, SCH23390  and the NMDA receptor antagonist, MK-801, blocked amantadine induction of Fos in the striatum"}
{"PMID":8566141,"re_id":8,"annotated sentence":"Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the NMDA receptor antagonist, <e1>MK-801<\\e1>  blocked amantadine induction of <e2>Fos<\\e2> in the striatum","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MK-801","object":"Fos","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the NMDA receptor antagonist, <e1>CHEMICAL<\\e1>  blocked amantadine induction of <e2>GENE-Y<\\e2> in the striatum","sentence":"Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the NMDA receptor antagonist, MK-801  blocked amantadine induction of Fos in the striatum"}
{"PMID":8566141,"re_id":9,"annotated sentence":"However, amantadine induction of Fos in the striatum was unaffected by the <e2>dopamine D2 receptor<\\e2> antagonist, <e1>sulpiride<\\e1>  These results suggest that amantadine induction of Fos in the rat striatum is related to dopamine D1 and NMDA receptors.","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"sulpiride","object":"dopamine D2 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, amantadine induction of Fos in the striatum was unaffected by the <e2>GENE-Y<\\e2> antagonist, <e1>CHEMICAL<\\e1>  These results suggest that amantadine induction of Fos in the rat striatum is related to dopamine D1 and NMDA receptors.","sentence":"However, amantadine induction of Fos in the striatum was unaffected by the dopamine D2 receptor antagonist, sulpiride  These results suggest that amantadine induction of Fos in the rat striatum is related to dopamine D1 and NMDA receptors."}
{"PMID":8566141,"re_id":10,"annotated sentence":"Pretreatment with the <e2>dopamine D1 receptor<\\e2> antagonist, <e1>SCH23390<\\e1>  and the NMDA receptor antagonist, MK-801, blocked amantadine induction of Fos in the striatum","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"SCH23390","object":"dopamine D1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pretreatment with the <e2>GENE-Y<\\e2> antagonist, <e1>CHEMICAL<\\e1>  and the NMDA receptor antagonist, MK-801, blocked amantadine induction of Fos in the striatum","sentence":"Pretreatment with the dopamine D1 receptor antagonist, SCH23390  and the NMDA receptor antagonist, MK-801, blocked amantadine induction of Fos in the striatum"}
{"PMID":8566141,"re_id":11,"annotated sentence":"Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the <e2>NMDA receptor<\\e2> antagonist, <e1>MK-801<\\e1>  blocked amantadine induction of Fos in the striatum","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"MK-801","object":"NMDA receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the <e2>GENE-N<\\e2> antagonist, <e1>CHEMICAL<\\e1>  blocked amantadine induction of Fos in the striatum","sentence":"Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the NMDA receptor antagonist, MK-801  blocked amantadine induction of Fos in the striatum"}
{"PMID":8697470,"re_id":0,"annotated sentence":"bolus); finally, 8 rabbits received <e1>aurintrycarboxilic acid<\\e1> (ATA), an inhibitor of platelet <e2>glycoprotein Ib<\\e2> von Willebrand factor interaction (10 mg\/kg i.v","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"aurintrycarboxilic acid","object":"glycoprotein Ib","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"bolus); finally, 8 rabbits received <e1>CHEMICAL<\\e1> (ATA), an inhibitor of platelet <e2>GENE-N<\\e2> von Willebrand factor interaction (10 mg\/kg i.v","sentence":"bolus); finally, 8 rabbits received aurintrycarboxilic acid (ATA), an inhibitor of platelet glycoprotein Ib von Willebrand factor interaction (10 mg\/kg i.v"}
{"PMID":8697470,"re_id":1,"annotated sentence":"bolus); finally, 8 rabbits received <e1>aurintrycarboxilic acid<\\e1> (ATA), an inhibitor of platelet glycoprotein Ib\/<e2>von Willebrand factor<\\e2> interaction (10 mg\/kg i.v","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"aurintrycarboxilic acid","object":"von Willebrand factor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"bolus); finally, 8 rabbits received <e1>CHEMICAL<\\e1> (ATA), an inhibitor of platelet glycoprotein Ib\/<e2>GENE-Y<\\e2> interaction (10 mg\/kg i.v","sentence":"bolus); finally, 8 rabbits received aurintrycarboxilic acid (ATA), an inhibitor of platelet glycoprotein Ib\/von Willebrand factor interaction (10 mg\/kg i.v"}
{"PMID":8697470,"re_id":2,"annotated sentence":"bolus); finally, 8 rabbits received aurintrycarboxilic acid (<e1>ATA<\\e1> , an inhibitor of platelet <e2>glycoprotein Ib<\\e2> von Willebrand factor interaction (10 mg\/kg i.v","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ATA","object":"glycoprotein Ib","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"bolus); finally, 8 rabbits received aurintrycarboxilic acid (<e1>CHEMICAL<\\e1> , an inhibitor of platelet <e2>GENE-N<\\e2> von Willebrand factor interaction (10 mg\/kg i.v","sentence":"bolus); finally, 8 rabbits received aurintrycarboxilic acid (ATA , an inhibitor of platelet glycoprotein Ib von Willebrand factor interaction (10 mg\/kg i.v"}
{"PMID":8697470,"re_id":3,"annotated sentence":"bolus); finally, 8 rabbits received aurintrycarboxilic acid (<e1>ATA<\\e1> , an inhibitor of platelet glycoprotein Ib\/<e2>von Willebrand factor<\\e2> interaction (10 mg\/kg i.v","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ATA","object":"von Willebrand factor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"bolus); finally, 8 rabbits received aurintrycarboxilic acid (<e1>CHEMICAL<\\e1> , an inhibitor of platelet glycoprotein Ib\/<e2>GENE-Y<\\e2> interaction (10 mg\/kg i.v","sentence":"bolus); finally, 8 rabbits received aurintrycarboxilic acid (ATA , an inhibitor of platelet glycoprotein Ib\/von Willebrand factor interaction (10 mg\/kg i.v"}
{"PMID":8710929,"re_id":0,"annotated sentence":"These events are stimulated by NE and by guanethidine, an <e2>hNET<\\e2> substrate, and they are blocked by <e1>cocaine<\\e1> and the antidepressant desipramine","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cocaine","object":"hNET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These events are stimulated by NE and by guanethidine, an <e2>GENE-Y<\\e2> substrate, and they are blocked by <e1>CHEMICAL<\\e1> and the antidepressant desipramine","sentence":"These events are stimulated by NE and by guanethidine, an hNET substrate, and they are blocked by cocaine and the antidepressant desipramine"}
{"PMID":8710929,"re_id":1,"annotated sentence":"These events are stimulated by NE and by guanethidine, an <e2>hNET<\\e2> substrate, and they are blocked by cocaine and the antidepressant <e1>desipramine<\\e1>  Voltage-clamp data combined with NE uptake data from these same cells indicate that hNETs have two functional modes of conduction: a classical transporter mode (T-mode) and a novel channel mode (C-mode)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"desipramine","object":"hNET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These events are stimulated by NE and by guanethidine, an <e2>GENE-Y<\\e2> substrate, and they are blocked by cocaine and the antidepressant <e1>CHEMICAL<\\e1>  Voltage-clamp data combined with NE uptake data from these same cells indicate that GENE-Ys have two functional modes of conduction: a classical transporter mode (T-mode) and a novel channel mode (C-mode)","sentence":"These events are stimulated by NE and by guanethidine, an hNET substrate, and they are blocked by cocaine and the antidepressant desipramine  Voltage-clamp data combined with NE uptake data from these same cells indicate that hNETs have two functional modes of conduction: a classical transporter mode (T-mode) and a novel channel mode (C-mode)"}
{"PMID":8710929,"re_id":2,"annotated sentence":"Voltage-clamp data combined with <e1>NE<\\e1> uptake data from these same cells indicate that <e2>hNETs<\\e2> have two functional modes of conduction: a classical transporter mode (T-mode) and a novel channel mode (C-mode)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"NE","object":"hNETs","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Voltage-clamp data combined with <e1>CHEMICAL<\\e1> uptake data from these same cells indicate that <e2>hCHEMICALTs<\\e2> have two functional modes of conduction: a classical transporter mode (T-mode) and a novel channel mode (C-mode)","sentence":"Voltage-clamp data combined with NE uptake data from these same cells indicate that hNETs have two functional modes of conduction: a classical transporter mode (T-mode) and a novel channel mode (C-mode)"}
{"PMID":8710929,"re_id":3,"annotated sentence":"These events are stimulated by <e1>NE<\\e1> and by guanethidine, an <e2>hNET<\\e2> substrate, and they are blocked by cocaine and the antidepressant desipramine","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"NE","object":"hNET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These events are stimulated by <e1>CHEMICAL<\\e1> and by guanethidine, an <e2>hCHEMICALT<\\e2> substrate, and they are blocked by cocaine and the antidepressant desipramine","sentence":"These events are stimulated by NE and by guanethidine, an hNET substrate, and they are blocked by cocaine and the antidepressant desipramine"}
{"PMID":8710929,"re_id":4,"annotated sentence":"These events are stimulated by NE and by <e1>guanethidine<\\e1>  an <e2>hNET<\\e2> substrate, and they are blocked by cocaine and the antidepressant desipramine","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"guanethidine","object":"hNET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These events are stimulated by NE and by <e1>CHEMICAL<\\e1>  an <e2>GENE-Y<\\e2> substrate, and they are blocked by cocaine and the antidepressant desipramine","sentence":"These events are stimulated by NE and by guanethidine  an hNET substrate, and they are blocked by cocaine and the antidepressant desipramine"}
{"PMID":8733007,"re_id":0,"annotated sentence":"In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the <e2>mineralocorticoid receptor<\\e2> (MR) antagonist <e1>RU28318<\\e1>  (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"RU28318","object":"mineralocorticoid receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the <e2>GENE-Y<\\e2> (MR) antagonist <e1>CHEMICAL<\\e1>  (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting","sentence":"In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318  (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting"}
{"PMID":8733007,"re_id":1,"annotated sentence":"In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (<e2>MR<\\e2>  antagonist <e1>RU28318<\\e1>  (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"RU28318","object":"MR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (<e2>GENE-Y<\\e2>  antagonist <e1>CHEMICAL<\\e1>  (v) is via classical GENE-Y, in that it is blocked by concurrent administration of the GENE-Y antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting","sentence":"In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR  antagonist RU28318  (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting"}
{"PMID":8733007,"re_id":2,"annotated sentence":"In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical <e2>MR<\\e2>  in that it is blocked by concurrent administration of the MR antagonist <e1>potassium canrenoate<\\e1>  and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"potassium canrenoate","object":"MR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (GENE-Y) antagonist RU28318; (v) is via classical <e2>GENE-Y<\\e2>  in that it is blocked by concurrent administration of the GENE-Y antagonist <e1>CHEMICAL<\\e1>  and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting","sentence":"In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR  in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate  and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting"}
{"PMID":8733007,"re_id":3,"annotated sentence":"In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the <e2>MR<\\e2> antagonist <e1>potassium canrenoate<\\e1>  and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"potassium canrenoate","object":"MR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (GENE-Y) antagonist RU28318; (v) is via classical GENE-Y, in that it is blocked by concurrent administration of the <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1>  and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting","sentence":"In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate  and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting"}
{"PMID":8740147,"re_id":0,"annotated sentence":"The results when considered with previous reports in the literature show that <e1>amezinium<\\e1> is about 1000 times more potent and debrisoquine is about 20 times more potent for <e2>MAO<\\e2> inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by uptake1","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"amezinium","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The results when considered with previous reports in the literature show that <e1>CHEMICAL<\\e1> is about 1000 times more potent and debrisoquine is about 20 times more potent for <e2>GENE-N<\\e2> inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by uptake1","sentence":"The results when considered with previous reports in the literature show that amezinium is about 1000 times more potent and debrisoquine is about 20 times more potent for MAO inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by uptake1"}
{"PMID":8740147,"re_id":1,"annotated sentence":"The results when considered with previous reports in the literature show that amezinium is about 1000 times more potent and <e1>debrisoquine<\\e1> is about 20 times more potent for <e2>MAO<\\e2> inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by uptake1","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"debrisoquine","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The results when considered with previous reports in the literature show that amezinium is about 1000 times more potent and <e1>CHEMICAL<\\e1> is about 20 times more potent for <e2>GENE-N<\\e2> inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by uptake1","sentence":"The results when considered with previous reports in the literature show that amezinium is about 1000 times more potent and debrisoquine is about 20 times more potent for MAO inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by uptake1"}
{"PMID":8740147,"re_id":2,"annotated sentence":"<e1>Amezinium<\\e1> is much less potent as a <e2>MAO<\\e2> inhibitor in cells with the uptake2 transporter, such as the myocardial cells of the heart","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Amezinium","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is much less potent as a <e2>GENE-N<\\e2> inhibitor in cells with the uptake2 transporter, such as the myocardial cells of the heart","sentence":"Amezinium is much less potent as a MAO inhibitor in cells with the uptake2 transporter, such as the myocardial cells of the heart"}
{"PMID":8740147,"re_id":3,"annotated sentence":"The results also confirmed previous reports that <e1>amezinium<\\e1> is highly selective for <e2>MAO-A<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"amezinium","object":"MAO-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results also confirmed previous reports that <e1>CHEMICAL<\\e1> is highly selective for <e2>GENE-Y<\\e2> ","sentence":"The results also confirmed previous reports that amezinium is highly selective for MAO-A "}
{"PMID":8740147,"re_id":4,"annotated sentence":"Previous studies have resulted in the classification of <e1>amezinium<\\e1> as a selective inhibitor of neuronal <e2>monoamine oxidase<\\e2> (MAO), because it is a much more potent MAO inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"amezinium","object":"monoamine oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Previous studies have resulted in the classification of <e1>CHEMICAL<\\e1> as a selective inhibitor of neuronal <e2>GENE-N<\\e2> (MAO), because it is a much more potent MAO inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates","sentence":"Previous studies have resulted in the classification of amezinium as a selective inhibitor of neuronal monoamine oxidase (MAO), because it is a much more potent MAO inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates"}
{"PMID":8740147,"re_id":5,"annotated sentence":"Previous studies have resulted in the classification of <e1>amezinium<\\e1> as a selective inhibitor of neuronal monoamine oxidase (<e2>MAO<\\e2> , because it is a much more potent MAO inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"amezinium","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Previous studies have resulted in the classification of <e1>CHEMICAL<\\e1> as a selective inhibitor of neuronal monoamine oxidase (<e2>GENE-N<\\e2> , because it is a much more potent GENE-N inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates","sentence":"Previous studies have resulted in the classification of amezinium as a selective inhibitor of neuronal monoamine oxidase (MAO , because it is a much more potent MAO inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates"}
{"PMID":8740147,"re_id":6,"annotated sentence":"Previous studies have resulted in the classification of <e1>amezinium<\\e1> as a selective inhibitor of neuronal monoamine oxidase (MAO), because it is a much more potent <e2>MAO<\\e2> inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"amezinium","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Previous studies have resulted in the classification of <e1>CHEMICAL<\\e1> as a selective inhibitor of neuronal monoamine oxidase (GENE-N), because it is a much more potent <e2>GENE-N<\\e2> inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates","sentence":"Previous studies have resulted in the classification of amezinium as a selective inhibitor of neuronal monoamine oxidase (MAO), because it is a much more potent MAO inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates"}
{"PMID":8740147,"re_id":7,"annotated sentence":"In addition, another drug that is both a substrate of uptake1 and a <e2>MAO<\\e2> inhibitor, <e1>debrisoquine<\\e1>  was investigated in the study","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"debrisoquine","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition, another drug that is both a substrate of uptake1 and a <e2>GENE-N<\\e2> inhibitor, <e1>CHEMICAL<\\e1>  was investigated in the study","sentence":"In addition, another drug that is both a substrate of uptake1 and a MAO inhibitor, debrisoquine  was investigated in the study"}
{"PMID":8740147,"re_id":8,"annotated sentence":"<e1>Amezinium<\\e1> and debrisoquine are substrates of uptake1 and potent inhibitors of <e2>monoamine oxidase<\\e2> in perfused lungs of rats","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Amezinium","object":"monoamine oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> and debrisoquine are substrates of uptake1 and potent inhibitors of <e2>GENE-N<\\e2> in perfused lungs of rats","sentence":"Amezinium and debrisoquine are substrates of uptake1 and potent inhibitors of monoamine oxidase in perfused lungs of rats"}
{"PMID":8740147,"re_id":9,"annotated sentence":"Amezinium and <e1>debrisoquine<\\e1> are substrates of uptake1 and potent inhibitors of <e2>monoamine oxidase<\\e2> in perfused lungs of rats","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"debrisoquine","object":"monoamine oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Amezinium and <e1>CHEMICAL<\\e1> are substrates of uptake1 and potent inhibitors of <e2>GENE-N<\\e2> in perfused lungs of rats","sentence":"Amezinium and debrisoquine are substrates of uptake1 and potent inhibitors of monoamine oxidase in perfused lungs of rats"}
{"PMID":8740147,"re_id":10,"annotated sentence":"When MAO-B was also inhibited, 10 nmol\/l <e1>amezinium<\\e1> caused 84% inhibition of the deamination of noradrenaline by <e2>MAO-A<\\e2> in the lungs","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"amezinium","object":"MAO-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"When MAO-B was also inhibited, 10 nmol\/l <e1>CHEMICAL<\\e1> caused 84% inhibition of the deamination of noradrenaline by <e2>GENE-Y<\\e2> in the lungs","sentence":"When MAO-B was also inhibited, 10 nmol\/l amezinium caused 84% inhibition of the deamination of noradrenaline by MAO-A in the lungs"}
{"PMID":8740147,"re_id":11,"annotated sentence":"The results when considered with previous reports in the literature show that <e1>amezinium<\\e1> is about 1000 times more potent and debrisoquine is about 20 times more potent for MAO inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by <e2>uptake1<\\e2>  Amezinium is much less potent as a MAO inhibitor in cells with the uptake2 transporter, such as the myocardial cells of the heart","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"amezinium","object":"uptake1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The results when considered with previous reports in the literature show that <e1>CHEMICAL<\\e1> is about 1000 times more potent and debrisoquine is about 20 times more potent for MAO inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by <e2>GENE-N<\\e2>  Amezinium is much less potent as a MAO inhibitor in cells with the uptake2 transporter, such as the myocardial cells of the heart","sentence":"The results when considered with previous reports in the literature show that amezinium is about 1000 times more potent and debrisoquine is about 20 times more potent for MAO inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by uptake1  Amezinium is much less potent as a MAO inhibitor in cells with the uptake2 transporter, such as the myocardial cells of the heart"}
{"PMID":8740147,"re_id":12,"annotated sentence":"The results when considered with previous reports in the literature show that amezinium is about 1000 times more potent and <e1>debrisoquine<\\e1> is about 20 times more potent for MAO inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by <e2>uptake1<\\e2>  Amezinium is much less potent as a MAO inhibitor in cells with the uptake2 transporter, such as the myocardial cells of the heart","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"debrisoquine","object":"uptake1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The results when considered with previous reports in the literature show that amezinium is about 1000 times more potent and <e1>CHEMICAL<\\e1> is about 20 times more potent for MAO inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by <e2>GENE-N<\\e2>  Amezinium is much less potent as a MAO inhibitor in cells with the uptake2 transporter, such as the myocardial cells of the heart","sentence":"The results when considered with previous reports in the literature show that amezinium is about 1000 times more potent and debrisoquine is about 20 times more potent for MAO inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by uptake1  Amezinium is much less potent as a MAO inhibitor in cells with the uptake2 transporter, such as the myocardial cells of the heart"}
{"PMID":8740147,"re_id":13,"annotated sentence":"<e1>Amezinium<\\e1> is much less potent as a MAO inhibitor in cells with the <e2>uptake2 transporter<\\e2>  such as the myocardial cells of the heart","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Amezinium","object":"uptake2 transporter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is much less potent as a MAO inhibitor in cells with the <e2>GENE-N<\\e2>  such as the myocardial cells of the heart","sentence":"Amezinium is much less potent as a MAO inhibitor in cells with the uptake2 transporter  such as the myocardial cells of the heart"}
{"PMID":8740147,"re_id":14,"annotated sentence":"In addition, another drug that is both a substrate of <e2>uptake1<\\e2> and a MAO inhibitor, <e1>debrisoquine<\\e1>  was investigated in the study","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"debrisoquine","object":"uptake1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition, another drug that is both a substrate of <e2>GENE-N<\\e2> and a MAO inhibitor, <e1>CHEMICAL<\\e1>  was investigated in the study","sentence":"In addition, another drug that is both a substrate of uptake1 and a MAO inhibitor, debrisoquine  was investigated in the study"}
{"PMID":8740147,"re_id":15,"annotated sentence":"<e1>Amezinium<\\e1> and debrisoquine are substrates of <e2>uptake1<\\e2> and potent inhibitors of monoamine oxidase in perfused lungs of rats","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Amezinium","object":"uptake1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> and debrisoquine are substrates of <e2>GENE-N<\\e2> and potent inhibitors of monoamine oxidase in perfused lungs of rats","sentence":"Amezinium and debrisoquine are substrates of uptake1 and potent inhibitors of monoamine oxidase in perfused lungs of rats"}
{"PMID":8740147,"re_id":16,"annotated sentence":"Amezinium and <e1>debrisoquine<\\e1> are substrates of <e2>uptake1<\\e2> and potent inhibitors of monoamine oxidase in perfused lungs of rats","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"debrisoquine","object":"uptake1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Amezinium and <e1>CHEMICAL<\\e1> are substrates of <e2>GENE-N<\\e2> and potent inhibitors of monoamine oxidase in perfused lungs of rats","sentence":"Amezinium and debrisoquine are substrates of uptake1 and potent inhibitors of monoamine oxidase in perfused lungs of rats"}
{"PMID":8836617,"re_id":0,"annotated sentence":"We have investigated the effects of <e1>CP-99,994<\\e1> [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a <e2>tachykinin NK1 receptor<\\e2> antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"CP-99,994","object":"tachykinin NK1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We have investigated the effects of <e1>CHEMICAL<\\e1> [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a <e2>GENE-Y<\\e2> antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde","sentence":"We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde"}
{"PMID":8836617,"re_id":1,"annotated sentence":"We have investigated the effects of CP-99,994 <e1>[(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine]<\\e1>  a <e2>tachykinin NK1 receptor<\\e2> antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"[(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine]","object":"tachykinin NK1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We have investigated the effects of CP-99,994 <e1>CHEMICAL<\\e1>  a <e2>GENE-Y<\\e2> antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde","sentence":"We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine]  a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde"}
{"PMID":8836617,"re_id":2,"annotated sentence":"We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, <e1>HOE 140<\\e1> (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a <e2>bradykinin B2 receptor<\\e2> antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"HOE 140","object":"bradykinin B2 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, <e1>CHEMICAL<\\e1> (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a <e2>GENE-Y<\\e2> antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde","sentence":"We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde"}
{"PMID":8836617,"re_id":3,"annotated sentence":"We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 <e1>(D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin)<\\e1>  a <e2>bradykinin B2 receptor<\\e2> antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"(D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin)","object":"bradykinin B2 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 <e1>CHEMICAL<\\e1>  a <e2>GENE-Y<\\e2> antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde","sentence":"We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin)  a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde"}
{"PMID":8836617,"re_id":4,"annotated sentence":"We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and <e1>ketotifen<\\e1> (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a <e2>histamine H1 receptor<\\e2> antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"ketotifen","object":"histamine H1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and <e1>CHEMICAL<\\e1> (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a <e2>GENE-Y<\\e2> antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde","sentence":"We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde"}
{"PMID":8836617,"re_id":5,"annotated sentence":"We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen <e1>(4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate)<\\e1>  a <e2>histamine H1 receptor<\\e2> antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"(4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate)","object":"histamine H1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen <e1>CHEMICAL<\\e1>  a <e2>GENE-Y<\\e2> antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde","sentence":"We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate)  a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde"}
{"PMID":9486667,"re_id":0,"annotated sentence":"<e2>HERG<\\e2> IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, <e1>E4031<\\e1>  and MK-499, at submicromolar concentrations","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"E4031","object":"HERG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, <e1>CHEMICAL<\\e1>  and MK-499, at submicromolar concentrations","sentence":"HERG IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, E4031  and MK-499, at submicromolar concentrations"}
{"PMID":9486667,"re_id":1,"annotated sentence":"HERG\/<e2>IKr<\\e2> channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, <e1>E4031<\\e1>  and MK-499, at submicromolar concentrations","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"E4031","object":"IKr","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"HERG\/<e2>GENE-N<\\e2> channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, <e1>CHEMICAL<\\e1>  and MK-499, at submicromolar concentrations","sentence":"HERG\/IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, E4031  and MK-499, at submicromolar concentrations"}
{"PMID":9486667,"re_id":2,"annotated sentence":"<e2>HERG<\\e2> IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, E4031, and <e1>MK-499<\\e1>  at submicromolar concentrations","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MK-499","object":"HERG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, E4031, and <e1>CHEMICAL<\\e1>  at submicromolar concentrations","sentence":"HERG IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, E4031, and MK-499  at submicromolar concentrations"}
{"PMID":9486667,"re_id":3,"annotated sentence":"HERG\/<e2>IKr<\\e2> channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, E4031, and <e1>MK-499<\\e1>  at submicromolar concentrations","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MK-499","object":"IKr","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"HERG\/<e2>GENE-N<\\e2> channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, E4031, and <e1>CHEMICAL<\\e1>  at submicromolar concentrations","sentence":"HERG\/IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, E4031, and MK-499  at submicromolar concentrations"}
{"PMID":9486667,"re_id":4,"annotated sentence":"Molecular determinants of <e1>dofetilide<\\e1> block of <e2>HERG<\\e2> K+ channels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dofetilide","object":"HERG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Molecular determinants of <e1>CHEMICAL<\\e1> block of <e2>GENE-Y<\\e2> K+ channels","sentence":"Molecular determinants of dofetilide block of HERG K+ channels"}
{"PMID":9486667,"re_id":5,"annotated sentence":"Molecular determinants of <e1>dofetilide<\\e1> block of HERG <e2>K+ channels<\\e2>  The human ether-a-go-go-related gene (HERG) encodes a K+ channel with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier K+ current (IKr)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dofetilide","object":"K+ channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Molecular determinants of <e1>CHEMICAL<\\e1> block of HERG <e2>GENE-N<\\e2>  The human ether-a-go-go-related gene (HERG) encodes a K+ channel with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier K+ current (IKr)","sentence":"Molecular determinants of dofetilide block of HERG K+ channels  The human ether-a-go-go-related gene (HERG) encodes a K+ channel with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier K+ current (IKr)"}
{"PMID":9486667,"re_id":6,"annotated sentence":"<e2>HERG<\\e2> IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic <e1>methanesulfonanilide<\\e1> drugs, such as dofetilide, E4031, and MK-499, at submicromolar concentrations","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"methanesulfonanilide","object":"HERG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic <e1>CHEMICAL<\\e1> drugs, such as dofetilide, E4031, and MK-499, at submicromolar concentrations","sentence":"HERG IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, E4031, and MK-499, at submicromolar concentrations"}
{"PMID":9486667,"re_id":7,"annotated sentence":"HERG\/<e2>IKr<\\e2> channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic <e1>methanesulfonanilide<\\e1> drugs, such as dofetilide, E4031, and MK-499, at submicromolar concentrations","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"methanesulfonanilide","object":"IKr","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"HERG\/<e2>GENE-N<\\e2> channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic <e1>CHEMICAL<\\e1> drugs, such as dofetilide, E4031, and MK-499, at submicromolar concentrations","sentence":"HERG\/IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, E4031, and MK-499, at submicromolar concentrations"}
{"PMID":9486667,"re_id":8,"annotated sentence":"<e2>HERG<\\e2> IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as <e1>dofetilide<\\e1>  E4031, and MK-499, at submicromolar concentrations","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dofetilide","object":"HERG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as <e1>CHEMICAL<\\e1>  E4031, and MK-499, at submicromolar concentrations","sentence":"HERG IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide  E4031, and MK-499, at submicromolar concentrations"}
{"PMID":9486667,"re_id":9,"annotated sentence":"HERG\/<e2>IKr<\\e2> channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as <e1>dofetilide<\\e1>  E4031, and MK-499, at submicromolar concentrations","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dofetilide","object":"IKr","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"HERG\/<e2>GENE-N<\\e2> channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as <e1>CHEMICAL<\\e1>  E4031, and MK-499, at submicromolar concentrations","sentence":"HERG\/IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide  E4031, and MK-499, at submicromolar concentrations"}
{"PMID":9521275,"re_id":0,"annotated sentence":"Treatment using a combination of testosterone and the <e2>aromatase<\\e2> inhibitor <e1>testolactone<\\e1> may have significantly better effects on sexual function and also seizure frequency than testosterone alone.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"testolactone","object":"aromatase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment using a combination of testosterone and the <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1> may have significantly better effects on sexual function and also seizure frequency than testosterone alone.","sentence":"Treatment using a combination of testosterone and the aromatase inhibitor testolactone may have significantly better effects on sexual function and also seizure frequency than testosterone alone."}
{"PMID":9631585,"re_id":0,"annotated sentence":"A 59-year-old female suffering from malignant lymphoma developed therapy-related acute myeloblastic leukemia (t-AML) after chemotherapy consisting of treatment with <e2>DNA-topoisomerase II<\\e2> inhibitors, <e1>etoposide<\\e1> and mitoxantrone, and an alkylating agent, cyclophosphamide","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"etoposide","object":"DNA-topoisomerase II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A 59-year-old female suffering from malignant lymphoma developed therapy-related acute myeloblastic leukemia (t-AML) after chemotherapy consisting of treatment with <e2>GENE-Y<\\e2> inhibitors, <e1>CHEMICAL<\\e1> and mitoxantrone, and an alkylating agent, cyclophosphamide","sentence":"A 59-year-old female suffering from malignant lymphoma developed therapy-related acute myeloblastic leukemia (t-AML) after chemotherapy consisting of treatment with DNA-topoisomerase II inhibitors, etoposide and mitoxantrone, and an alkylating agent, cyclophosphamide"}
{"PMID":9631585,"re_id":1,"annotated sentence":"A 59-year-old female suffering from malignant lymphoma developed therapy-related acute myeloblastic leukemia (t-AML) after chemotherapy consisting of treatment with <e2>DNA-topoisomerase II<\\e2> inhibitors, etoposide and <e1>mitoxantrone<\\e1>  and an alkylating agent, cyclophosphamide","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"mitoxantrone","object":"DNA-topoisomerase II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A 59-year-old female suffering from malignant lymphoma developed therapy-related acute myeloblastic leukemia (t-AML) after chemotherapy consisting of treatment with <e2>GENE-Y<\\e2> inhibitors, etoposide and <e1>CHEMICAL<\\e1>  and an alkylating agent, cyclophosphamide","sentence":"A 59-year-old female suffering from malignant lymphoma developed therapy-related acute myeloblastic leukemia (t-AML) after chemotherapy consisting of treatment with DNA-topoisomerase II inhibitors, etoposide and mitoxantrone  and an alkylating agent, cyclophosphamide"}
{"PMID":9631585,"re_id":2,"annotated sentence":"A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with <e2>DNA-topoisomerase II<\\e2> inhibitors, <e1>etoposide<\\e1> and mitoxantrone, and the alkylating agent, cyclophosphamide","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"etoposide","object":"DNA-topoisomerase II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with <e2>GENE-Y<\\e2> inhibitors, <e1>CHEMICAL<\\e1> and mitoxantrone, and the alkylating agent, cyclophosphamide","sentence":"A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with DNA-topoisomerase II inhibitors, etoposide and mitoxantrone, and the alkylating agent, cyclophosphamide"}
{"PMID":9631585,"re_id":3,"annotated sentence":"A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with <e2>DNA-topoisomerase II<\\e2> inhibitors, etoposide and <e1>mitoxantrone<\\e1>  and the alkylating agent, cyclophosphamide","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"mitoxantrone","object":"DNA-topoisomerase II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with <e2>GENE-Y<\\e2> inhibitors, etoposide and <e1>CHEMICAL<\\e1>  and the alkylating agent, cyclophosphamide","sentence":"A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with DNA-topoisomerase II inhibitors, etoposide and mitoxantrone  and the alkylating agent, cyclophosphamide"}
{"PMID":9673855,"re_id":0,"annotated sentence":"A low tyramine diet is recommended if <e1>selegiline<\\e1> is used together with nonselective <e2>MAO<\\e2> inhibitors or the selective, reversible MAO-A inhibitor, moclobemide","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"selegiline","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A low tyramine diet is recommended if <e1>CHEMICAL<\\e1> is used together with nonselective <e2>GENE-N<\\e2> inhibitors or the selective, reversible GENE-N-A inhibitor, moclobemide","sentence":"A low tyramine diet is recommended if selegiline is used together with nonselective MAO inhibitors or the selective, reversible MAO-A inhibitor, moclobemide"}
{"PMID":9673855,"re_id":1,"annotated sentence":"A low tyramine diet is recommended if selegiline is used together with nonselective MAO inhibitors or the selective, reversible <e2>MAO-A<\\e2> inhibitor, <e1>moclobemide<\\e1>  Several adverse effects have been reported when fluoxetine and selegiline have been used together","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"moclobemide","object":"MAO-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A low tyramine diet is recommended if selegiline is used together with nonselective MAO inhibitors or the selective, reversible <e2>GENE-Y<\\e2> inhibitor, <e1>CHEMICAL<\\e1>  Several adverse effects have been reported when fluoxetine and selegiline have been used together","sentence":"A low tyramine diet is recommended if selegiline is used together with nonselective MAO inhibitors or the selective, reversible MAO-A inhibitor, moclobemide  Several adverse effects have been reported when fluoxetine and selegiline have been used together"}
{"PMID":9673855,"re_id":2,"annotated sentence":"<e1>Selegiline<\\e1> (deprenyl), a selective, irreversible inhibitor of <e2>monoamine oxidase type B<\\e2> (MAO-B) is widely used in the treatment of Parkinson's disease","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Selegiline","object":"monoamine oxidase type B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (deprenyl), a selective, irreversible inhibitor of <e2>GENE-Y<\\e2> (MAO-B) is widely used in the treatment of Parkinson's disease","sentence":"Selegiline (deprenyl), a selective, irreversible inhibitor of monoamine oxidase type B (MAO-B) is widely used in the treatment of Parkinson's disease"}
{"PMID":9673855,"re_id":3,"annotated sentence":"<e1>Selegiline<\\e1> (deprenyl), a selective, irreversible inhibitor of monoamine oxidase type B (<e2>MAO-B<\\e2>  is widely used in the treatment of Parkinson's disease","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Selegiline","object":"MAO-B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (deprenyl), a selective, irreversible inhibitor of monoamine oxidase type B (<e2>GENE-Y<\\e2>  is widely used in the treatment of Parkinson's disease","sentence":"Selegiline (deprenyl), a selective, irreversible inhibitor of monoamine oxidase type B (MAO-B  is widely used in the treatment of Parkinson's disease"}
{"PMID":9673855,"re_id":4,"annotated sentence":"Unlike the nonselective <e2>MAO<\\e2> inhibitors, <e1>selegiline<\\e1> does not significantly potentiate tyramine-induced hypertension (the 'cheese effect') at the dosages (5 to 10 mg daily) used for the treatment of Parkinson's disease","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"selegiline","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Unlike the nonselective <e2>GENE-N<\\e2> inhibitors, <e1>CHEMICAL<\\e1> does not significantly potentiate tyramine-induced hypertension (the 'cheese effect') at the dosages (5 to 10 mg daily) used for the treatment of Parkinson's disease","sentence":"Unlike the nonselective MAO inhibitors, selegiline does not significantly potentiate tyramine-induced hypertension (the 'cheese effect') at the dosages (5 to 10 mg daily) used for the treatment of Parkinson's disease"}
{"PMID":9673855,"re_id":5,"annotated sentence":"Selegiline (<e1>deprenyl<\\e1> , a selective, irreversible inhibitor of <e2>monoamine oxidase type B<\\e2> (MAO-B) is widely used in the treatment of Parkinson's disease","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"deprenyl","object":"monoamine oxidase type B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Selegiline (<e1>CHEMICAL<\\e1> , a selective, irreversible inhibitor of <e2>GENE-Y<\\e2> (MAO-B) is widely used in the treatment of Parkinson's disease","sentence":"Selegiline (deprenyl , a selective, irreversible inhibitor of monoamine oxidase type B (MAO-B) is widely used in the treatment of Parkinson's disease"}
{"PMID":9673855,"re_id":6,"annotated sentence":"Selegiline (<e1>deprenyl<\\e1> , a selective, irreversible inhibitor of monoamine oxidase type B (<e2>MAO-B<\\e2>  is widely used in the treatment of Parkinson's disease","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"deprenyl","object":"MAO-B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Selegiline (<e1>CHEMICAL<\\e1> , a selective, irreversible inhibitor of monoamine oxidase type B (<e2>GENE-Y<\\e2>  is widely used in the treatment of Parkinson's disease","sentence":"Selegiline (deprenyl , a selective, irreversible inhibitor of monoamine oxidase type B (MAO-B  is widely used in the treatment of Parkinson's disease"}
{"PMID":9710435,"re_id":0,"annotated sentence":"<e1>Ibuprofen<\\e1> inhibits <e2>cystic fibrosis transmembrane conductance regulator<\\e2> mediated Cl- secretion","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Ibuprofen","object":"cystic fibrosis transmembrane conductance regulator","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits <e2>GENE-Y<\\e2> mediated Cl- secretion","sentence":"Ibuprofen inhibits cystic fibrosis transmembrane conductance regulator mediated Cl- secretion"}
{"PMID":9710435,"re_id":1,"annotated sentence":"<e1>Ibuprofen<\\e1> (300 microM) reduced <e2>CFTR<\\e2> Cl- current by 60+\/-16% and this was explained by a short-lived block (approximately 1.2 ms) which causes an apparent reduction in single channel amplitude from 1.07+\/-0.04 pA to 0.59+\/-0.04 pA (n = 3)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Ibuprofen","object":"CFTR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (300 microM) reduced <e2>GENE-Y<\\e2> Cl- current by 60+\/-16% and this was explained by a short-lived block (approximately 1.2 ms) which causes an apparent reduction in single channel amplitude from 1.07+\/-0.04 pA to 0.59+\/-0.04 pA (n = 3)","sentence":"Ibuprofen (300 microM) reduced CFTR Cl- current by 60+\/-16% and this was explained by a short-lived block (approximately 1.2 ms) which causes an apparent reduction in single channel amplitude from 1.07+\/-0.04 pA to 0.59+\/-0.04 pA (n = 3)"}
{"PMID":9710435,"re_id":2,"annotated sentence":"Similarly, <e1>salicylic acid<\\e1> (3 mM) reduced <e2>CFTR<\\e2> Cl- current by 50+\/-8% with an apparent reduction in single channel amplitude from 1.08+\/-0.03 pA to 0.48+\/-0.06 pA (n = 4)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"salicylic acid","object":"CFTR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Similarly, <e1>CHEMICAL<\\e1> (3 mM) reduced <e2>GENE-Y<\\e2> Cl- current by 50+\/-8% with an apparent reduction in single channel amplitude from 1.08+\/-0.03 pA to 0.48+\/-0.06 pA (n = 4)","sentence":"Similarly, salicylic acid (3 mM) reduced CFTR Cl- current by 50+\/-8% with an apparent reduction in single channel amplitude from 1.08+\/-0.03 pA to 0.48+\/-0.06 pA (n = 4)"}
{"PMID":9710435,"re_id":3,"annotated sentence":"Based on these results, we conclude that the NSAIDs <e1>ibuprofen<\\e1> and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of <e2>CFTR<\\e2> Cl- channels as well as basolateral membrane K+ channels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ibuprofen","object":"CFTR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Based on these results, we conclude that the NSAIDs <e1>CHEMICAL<\\e1> and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of <e2>GENE-Y<\\e2> Cl- channels as well as basolateral membrane K+ channels","sentence":"Based on these results, we conclude that the NSAIDs ibuprofen and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR Cl- channels as well as basolateral membrane K+ channels"}
{"PMID":9710435,"re_id":4,"annotated sentence":"Based on these results, we conclude that the NSAIDs <e1>ibuprofen<\\e1> and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR <e2>Cl- channels<\\e2> as well as basolateral membrane K+ channels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ibuprofen","object":"Cl- channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Based on these results, we conclude that the NSAIDs <e1>CHEMICAL<\\e1> and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR <e2>GENE-N<\\e2> as well as basolateral membrane K+ channels","sentence":"Based on these results, we conclude that the NSAIDs ibuprofen and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR Cl- channels as well as basolateral membrane K+ channels"}
{"PMID":9710435,"re_id":5,"annotated sentence":"Based on these results, we conclude that the NSAIDs <e1>ibuprofen<\\e1> and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR Cl- channels as well as basolateral membrane <e2>K+ channels<\\e2>  This may reduce their efficacy in conjunction with other therapeutic strategies designed to increase CFTR expression and\/or function in secretory epithelia.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ibuprofen","object":"K+ channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Based on these results, we conclude that the NSAIDs <e1>CHEMICAL<\\e1> and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR Cl- channels as well as basolateral membrane <e2>GENE-N<\\e2>  This may reduce their efficacy in conjunction with other therapeutic strategies designed to increase CFTR expression and\/or function in secretory epithelia.","sentence":"Based on these results, we conclude that the NSAIDs ibuprofen and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR Cl- channels as well as basolateral membrane K+ channels  This may reduce their efficacy in conjunction with other therapeutic strategies designed to increase CFTR expression and\/or function in secretory epithelia."}
{"PMID":9710435,"re_id":6,"annotated sentence":"Based on these results, we conclude that the NSAIDs ibuprofen and <e1>salicylic acid<\\e1> inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of <e2>CFTR<\\e2> Cl- channels as well as basolateral membrane K+ channels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"salicylic acid","object":"CFTR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Based on these results, we conclude that the NSAIDs ibuprofen and <e1>CHEMICAL<\\e1> inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of <e2>GENE-Y<\\e2> Cl- channels as well as basolateral membrane K+ channels","sentence":"Based on these results, we conclude that the NSAIDs ibuprofen and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR Cl- channels as well as basolateral membrane K+ channels"}
{"PMID":9710435,"re_id":7,"annotated sentence":"Based on these results, we conclude that the NSAIDs ibuprofen and <e1>salicylic acid<\\e1> inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR <e2>Cl- channels<\\e2> as well as basolateral membrane K+ channels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"salicylic acid","object":"Cl- channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Based on these results, we conclude that the NSAIDs ibuprofen and <e1>CHEMICAL<\\e1> inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR <e2>GENE-N<\\e2> as well as basolateral membrane K+ channels","sentence":"Based on these results, we conclude that the NSAIDs ibuprofen and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR Cl- channels as well as basolateral membrane K+ channels"}
{"PMID":9710435,"re_id":8,"annotated sentence":"Based on these results, we conclude that the NSAIDs ibuprofen and <e1>salicylic acid<\\e1> inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR Cl- channels as well as basolateral membrane <e2>K+ channels<\\e2>  This may reduce their efficacy in conjunction with other therapeutic strategies designed to increase CFTR expression and\/or function in secretory epithelia.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"salicylic acid","object":"K+ channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Based on these results, we conclude that the NSAIDs ibuprofen and <e1>CHEMICAL<\\e1> inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR Cl- channels as well as basolateral membrane <e2>GENE-N<\\e2>  This may reduce their efficacy in conjunction with other therapeutic strategies designed to increase CFTR expression and\/or function in secretory epithelia.","sentence":"Based on these results, we conclude that the NSAIDs ibuprofen and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR Cl- channels as well as basolateral membrane K+ channels  This may reduce their efficacy in conjunction with other therapeutic strategies designed to increase CFTR expression and\/or function in secretory epithelia."}
{"PMID":9832994,"re_id":0,"annotated sentence":"none","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"mCPP","object":"plasma prolactin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":9832994,"re_id":1,"annotated sentence":"none","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"mCPP","object":"ACTH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":9832994,"re_id":2,"annotated sentence":"These data indicate that mixed 5-HT1\/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective <e2>5-HT2A<\\e2> 5-HT2C antagonist <e1>ritanserin<\\e1> ","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"ritanserin","object":"5-HT2A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These data indicate that mixed 5-HT1\/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective <e2>GENE-Y<\\e2> 5-HT2C antagonist <e1>CHEMICAL<\\e1> ","sentence":"These data indicate that mixed 5-HT1\/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A 5-HT2C antagonist ritanserin "}
{"PMID":9832994,"re_id":3,"annotated sentence":"These data indicate that mixed 5-HT1\/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A\/<e2>5-HT2C<\\e2> antagonist <e1>ritanserin<\\e1> ","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"ritanserin","object":"5-HT2C","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These data indicate that mixed 5-HT1\/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A\/<e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> ","sentence":"These data indicate that mixed 5-HT1\/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A\/5-HT2C antagonist ritanserin "}
{"PMID":9832994,"re_id":4,"annotated sentence":"These data indicate that mixed <e2>5-HT1<\\e2> 5-HT2 receptor antagonists such as <e1>pizotifen<\\e1> and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A\/5-HT2C antagonist ritanserin.","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"pizotifen","object":"5-HT1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These data indicate that mixed <e2>GENE-N<\\e2> 5-HT2 receptor antagonists such as <e1>CHEMICAL<\\e1> and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A\/5-HT2C antagonist ritanserin.","sentence":"These data indicate that mixed 5-HT1 5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A\/5-HT2C antagonist ritanserin."}
{"PMID":9832994,"re_id":5,"annotated sentence":"These data indicate that mixed 5-HT1\/<e2>5-HT2<\\e2> receptor antagonists such as <e1>pizotifen<\\e1> and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A\/5-HT2C antagonist ritanserin.","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"pizotifen","object":"5-HT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These data indicate that mixed 5-HT1\/<e2>GENE-Y<\\e2> receptor antagonists such as <e1>CHEMICAL<\\e1> and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective GENE-YA\/GENE-YC antagonist ritanserin.","sentence":"These data indicate that mixed 5-HT1\/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A\/5-HT2C antagonist ritanserin."}
{"PMID":9832994,"re_id":6,"annotated sentence":"These data indicate that mixed <e2>5-HT1<\\e2> 5-HT2 receptor antagonists such as pizotifen and <e1>methysergide<\\e1>  and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A\/5-HT2C antagonist ritanserin.","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"methysergide","object":"5-HT1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These data indicate that mixed <e2>GENE-N<\\e2> 5-HT2 receptor antagonists such as pizotifen and <e1>CHEMICAL<\\e1>  and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A\/5-HT2C antagonist ritanserin.","sentence":"These data indicate that mixed 5-HT1 5-HT2 receptor antagonists such as pizotifen and methysergide  and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A\/5-HT2C antagonist ritanserin."}
{"PMID":9832994,"re_id":7,"annotated sentence":"These data indicate that mixed 5-HT1\/<e2>5-HT2<\\e2> receptor antagonists such as pizotifen and <e1>methysergide<\\e1>  and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A\/5-HT2C antagonist ritanserin.","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"methysergide","object":"5-HT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These data indicate that mixed 5-HT1\/<e2>GENE-Y<\\e2> receptor antagonists such as pizotifen and <e1>CHEMICAL<\\e1>  and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective GENE-YA\/GENE-YC antagonist ritanserin.","sentence":"These data indicate that mixed 5-HT1\/5-HT2 receptor antagonists such as pizotifen and methysergide  and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A\/5-HT2C antagonist ritanserin."}
{"PMID":9851542,"re_id":0,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Tacrine","object":"cholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":9851542,"re_id":1,"annotated sentence":"The cardiovascular effects of three different <e2>acetylcholinesterase<\\e2> inhibitors: <e1>physostigmine<\\e1>  tacrine and rivastigmine injected by intravenous (i.v.) route were compared in freely moving Wistar rats","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"physostigmine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The cardiovascular effects of three different <e2>GENE-Y<\\e2> inhibitors: <e1>CHEMICAL<\\e1>  tacrine and rivastigmine injected by intravenous (i.v.) route were compared in freely moving Wistar rats","sentence":"The cardiovascular effects of three different acetylcholinesterase inhibitors: physostigmine  tacrine and rivastigmine injected by intravenous (i.v.) route were compared in freely moving Wistar rats"}
{"PMID":9851542,"re_id":2,"annotated sentence":"The cardiovascular effects of three different <e2>acetylcholinesterase<\\e2> inhibitors: physostigmine, <e1>tacrine<\\e1> and rivastigmine injected by intravenous (i.v.) route were compared in freely moving Wistar rats","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tacrine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The cardiovascular effects of three different <e2>GENE-Y<\\e2> inhibitors: physostigmine, <e1>CHEMICAL<\\e1> and rivastigmine injected by intravenous (i.v.) route were compared in freely moving Wistar rats","sentence":"The cardiovascular effects of three different acetylcholinesterase inhibitors: physostigmine, tacrine and rivastigmine injected by intravenous (i.v.) route were compared in freely moving Wistar rats"}
{"PMID":9851542,"re_id":3,"annotated sentence":"The cardiovascular effects of three different <e2>acetylcholinesterase<\\e2> inhibitors: physostigmine, tacrine and <e1>rivastigmine<\\e1> injected by intravenous (i.v.) route were compared in freely moving Wistar rats","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"rivastigmine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The cardiovascular effects of three different <e2>GENE-Y<\\e2> inhibitors: physostigmine, tacrine and <e1>CHEMICAL<\\e1> injected by intravenous (i.v.) route were compared in freely moving Wistar rats","sentence":"The cardiovascular effects of three different acetylcholinesterase inhibitors: physostigmine, tacrine and rivastigmine injected by intravenous (i.v.) route were compared in freely moving Wistar rats"}
{"PMID":9851542,"re_id":4,"annotated sentence":"The <e2>alpha1-adrenoceptor<\\e2> antagonist <e1>prazosin<\\e1> or the vasopressin V1 receptor antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"prazosin","object":"alpha1-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e2>GENE-N<\\e2> antagonist <e1>CHEMICAL<\\e1> or the vasopressin V1 receptor antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly","sentence":"The alpha1-adrenoceptor antagonist prazosin or the vasopressin V1 receptor antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly"}
{"PMID":9851542,"re_id":5,"annotated sentence":"The alpha1-adrenoceptor antagonist prazosin or the <e2>vasopressin V1 receptor<\\e2> antagonist, <e1>[beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin<\\e1> partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"[beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin","object":"vasopressin V1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The alpha1-adrenoceptor antagonist prazosin or the <e2>GENE-N<\\e2> antagonist, <e1>CHEMICAL<\\e1> partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly","sentence":"The alpha1-adrenoceptor antagonist prazosin or the vasopressin V1 receptor antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly"}
{"PMID":9851542,"re_id":6,"annotated sentence":"administration of the non-selective <e2>muscarinic receptor<\\e2> antagonist <e1>atropine<\\e1> (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"atropine","object":"muscarinic receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"administration of the non-selective <e2>GENE-N<\\e2> antagonist <e1>CHEMICAL<\\e1> (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg)","sentence":"administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg)"}
{"PMID":9851542,"re_id":7,"annotated sentence":"administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the <e2>muscarinic M1 receptor<\\e2> antagonist <e1>pirenzepine<\\e1> (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"pirenzepine","object":"muscarinic M1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg)","sentence":"administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg)"}
{"PMID":9851542,"re_id":8,"annotated sentence":"administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the <e2>muscarinic M2 receptor<\\e2> antagonist <e1>methoctramine<\\e1> (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"methoctramine","object":"muscarinic M2 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg)","sentence":"administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg)"}
{"PMID":9851542,"re_id":9,"annotated sentence":"administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the <e2>muscarinic M3 receptor<\\e2> antagonist <e1>para-fluoro-hexahydro-sila-difenidol<\\e1> (ID50 = 31.19 microg)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"para-fluoro-hexahydro-sila-difenidol","object":"muscarinic M3 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> (ID50 = 31.19 microg)","sentence":"administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg)"}
{"PMID":9876137,"re_id":0,"annotated sentence":"<e1>Cocaine<\\e1> block of <e2>human cardiac (hH1)<\\e2> and rat skeletal (mu1) muscle sodium channels was examined under whole-cell voltage clamp in transiently transfected HEK293t cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cocaine","object":"human cardiac (hH1)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> block of <e2>GENE-Y<\\e2> and rat skeletal (mu1) muscle sodium channels was examined under whole-cell voltage clamp in transiently transfected HEK293t cells","sentence":"Cocaine block of human cardiac (hH1) and rat skeletal (mu1) muscle sodium channels was examined under whole-cell voltage clamp in transiently transfected HEK293t cells"}
{"PMID":9876137,"re_id":1,"annotated sentence":"<e1>Cocaine<\\e1> block of human cardiac (hH1) and <e2>rat skeletal (mu1) muscle sodium channels<\\e2> was examined under whole-cell voltage clamp in transiently transfected HEK293t cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cocaine","object":"rat skeletal (mu1) muscle sodium channels","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> block of human cardiac (hH1) and <e2>GENE-Y<\\e2> was examined under whole-cell voltage clamp in transiently transfected HEK293t cells","sentence":"Cocaine block of human cardiac (hH1) and rat skeletal (mu1) muscle sodium channels was examined under whole-cell voltage clamp in transiently transfected HEK293t cells"}
{"PMID":9876137,"re_id":2,"annotated sentence":"<e1>Cocaine<\\e1> block of <e2>hH1 channels<\\e2> was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of hH1 channels in this voltage range makes them more susceptible to cocaine block","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cocaine","object":"hH1 channels","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> block of <e2>GENE-Y<\\e2> was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of GENE-Y in this voltage range makes them more susceptible to cocaine block","sentence":"Cocaine block of hH1 channels was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of hH1 channels in this voltage range makes them more susceptible to cocaine block"}
{"PMID":9876137,"re_id":3,"annotated sentence":"<e1>Cocaine<\\e1> block of hH1 channels was greater than block of <e2>mu1 channels<\\e2> at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of hH1 channels in this voltage range makes them more susceptible to cocaine block","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cocaine","object":"mu1 channels","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> block of hH1 channels was greater than block of <e2>GENE-Y<\\e2> at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of hH1 channels in this voltage range makes them more susceptible to cocaine block","sentence":"Cocaine block of hH1 channels was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of hH1 channels in this voltage range makes them more susceptible to cocaine block"}
{"PMID":9876137,"re_id":4,"annotated sentence":"<e1>Cocaine<\\e1> block of hH1 channels was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of <e2>hH1 channels<\\e2> in this voltage range makes them more susceptible to cocaine block","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cocaine","object":"hH1 channels","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> block of GENE-Y was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of <e2>GENE-Y<\\e2> in this voltage range makes them more susceptible to cocaine block","sentence":"Cocaine block of hH1 channels was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of hH1 channels in this voltage range makes them more susceptible to cocaine block"}
{"PMID":9876137,"re_id":5,"annotated sentence":"Cocaine block of hH1 channels was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of <e2>hH1 channels<\\e2> in this voltage range makes them more susceptible to <e1>cocaine<\\e1> block","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cocaine","object":"hH1 channels","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cocaine block of GENE-Y was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of <e2>GENE-Y<\\e2> in this voltage range makes them more susceptible to <e1>CHEMICAL<\\e1> block","sentence":"Cocaine block of hH1 channels was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of hH1 channels in this voltage range makes them more susceptible to cocaine block"}
{"PMID":9876137,"re_id":6,"annotated sentence":"State-dependent <e1>cocaine<\\e1> block of <e2>sodium channel<\\e2> isoforms, chimeras, and channels coexpressed with the beta1 subunit","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cocaine","object":"sodium channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"State-dependent <e1>CHEMICAL<\\e1> block of <e2>GENE-N<\\e2> isoforms, chimeras, and channels coexpressed with the beta1 subunit","sentence":"State-dependent cocaine block of sodium channel isoforms, chimeras, and channels coexpressed with the beta1 subunit"}